<SEC-DOCUMENT>0001725160-23-000113.txt : 20230510
<SEC-HEADER>0001725160-23-000113.hdr.sgml : 20230510
<ACCEPTANCE-DATETIME>20230510070626
ACCESSION NUMBER:		0001725160-23-000113
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		70
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230510
DATE AS OF CHANGE:		20230510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Zentalis Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001725160
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				823607803
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39263
		FILM NUMBER:		23904295

	BUSINESS ADDRESS:	
		STREET 1:		1359 BROADWAY, SUITE 801
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10018
		BUSINESS PHONE:		(212) 433-3791

	MAIL ADDRESS:	
		STREET 1:		1359 BROADWAY, SUITE 801
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10018

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Zentalis Pharmaceuticals, LLC
		DATE OF NAME CHANGE:	20200107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Zeno Pharma, LLC
		DATE OF NAME CHANGE:	20171212
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>zntl-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:b3a2bb04-db5e-4a01-a061-9002e22e0a2d,g:6cdaa420-7596-4787-9871-3e57ed815727,d:ede2e4c8548c40d4910b7a838a08d814--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:zntl="http://www.zentalis.com/20230331" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>zntl-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80L2ZyYWc6NWU1MWM3Zjg2ODlkNGUxYThlMDQyYjc5NDI0MjM1ODIvdGFibGU6MDQ4YTgyMzMzMzMzNGY4ZDhkNWFhMjg1YzMxYjk5ZTMvdGFibGVyYW5nZTowNDhhODIzMzMzMzM0ZjhkOGQ1YWEyODVjMzFiOTllM18wLTEtMS0xLTc5Mjgz_6d001a30-fc95-41c3-ad47-c5d1c113d98b">0001725160</ix:nonNumeric><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80L2ZyYWc6NWU1MWM3Zjg2ODlkNGUxYThlMDQyYjc5NDI0MjM1ODIvdGFibGU6MDQ4YTgyMzMzMzMzNGY4ZDhkNWFhMjg1YzMxYjk5ZTMvdGFibGVyYW5nZTowNDhhODIzMzMzMzM0ZjhkOGQ1YWEyODVjMzFiOTllM18xLTEtMS0xLTc5Mjgz_dc006dea-f4cb-4c64-9641-5fd3cda74982">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80L2ZyYWc6NWU1MWM3Zjg2ODlkNGUxYThlMDQyYjc5NDI0MjM1ODIvdGFibGU6MDQ4YTgyMzMzMzMzNGY4ZDhkNWFhMjg1YzMxYjk5ZTMvdGFibGVyYW5nZTowNDhhODIzMzMzMzM0ZjhkOGQ1YWEyODVjMzFiOTllM18yLTEtMS0xLTc5Mjgz_fb6a5c5a-dc58-4d29-827e-7afdac717cab">Q1</ix:nonNumeric><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80L2ZyYWc6NWU1MWM3Zjg2ODlkNGUxYThlMDQyYjc5NDI0MjM1ODIvdGFibGU6MDQ4YTgyMzMzMzMzNGY4ZDhkNWFhMjg1YzMxYjk5ZTMvdGFibGVyYW5nZTowNDhhODIzMzMzMzM0ZjhkOGQ1YWEyODVjMzFiOTllM18zLTEtMS0xLTc5Mjgz_b8cc2a97-3c76-4e09-b18f-f343d922a6a8">12/31</ix:nonNumeric><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80L2ZyYWc6NWU1MWM3Zjg2ODlkNGUxYThlMDQyYjc5NDI0MjM1ODIvdGFibGU6MDQ4YTgyMzMzMzMzNGY4ZDhkNWFhMjg1YzMxYjk5ZTMvdGFibGVyYW5nZTowNDhhODIzMzMzMzM0ZjhkOGQ1YWEyODVjMzFiOTllM180LTEtMS0xLTc5Mjgz_118fbb5d-9905-4bcb-b11e-934edee06b2b">2023</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i8d0fc8e3ccd3496085dc4e71a7cfa31e_I20220331" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNjIvZnJhZzpjYzk2NDhkNTc3MDI0Nzc0YTBlOGEzZjNjZTUyNTNjZi90ZXh0cmVnaW9uOmNjOTY0OGQ1NzcwMjQ3NzRhMGU4YTNmM2NlNTI1M2NmXzE2NDkyNjc0NDE2ODI_12403860-2023-49c6-b915-c77ce1a11a7c">0</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="zntl-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia48f187fdc694ec0a436fbbe630672db_I20230508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i3e95cef051ea47c385703716fa2a0497_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i952b505edf2c4ed8969edcd9dd637d0b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94cbb15018ea46098ad9249cb81ecbd5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7e45d5095eb4183b28589ea3d638b55_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45b55ea2c54349ec90158494f177ec3d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7921e87cee7146e4aaa27c62453d6118_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id87bc3ab81a548e8accd9e1b819b5bf8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5aa6d947913f4a7d8075467238402e4b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7baae8bf509c4eea871e58fce347a357_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaab72f9bd1f4b3497c269553c88fda8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia44df45deeac4a16be141cf7af1287d1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i395ba3df136f49c6a25790e6923789ec_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ea4061b88a64ee98000673bd1783d8b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2e8bcaca2ae474db63161b8e88a7c52_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i610df3d7d3254dbeab79d57a582a4636_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iace7d762ee1c45ad98a341537427e32e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94f3732fa0324bb6bf7f1984084ff4ef_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa0fa90a552e423ba8d1643810caf083_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fd115a5bb984e3b9b063c8e4aa9ff7a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i695f99adc41f4c8999aa3b6012882f02_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9fbed8715344dabb36930b6006326a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id75a0e799fe54633ad1d1d401d14de96_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafaecb2d14b0479c99a524aaae490852_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64968b563eff48948e2e24b37867c00a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic40194aeff86496eb4c5f12057c31115_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47afaacc781e4b58940615c4b23bc5c2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i545b3742a8c44d08a0306fb64b39b848_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bb99470d90047cd99a51fc8bee670ee_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9d78fa526224fafa319798fa29dbe0c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c97f79d62ab413ba0fa4b3ab5ea6198_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cbaa2e908e04b1f879853beb7b39556_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8e9a378813b4bcc9f882c0a7318ebe1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic86274b750794080aa0a3b9b4a40044d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4df1e7317eb24fb4960e2db40e43b0ae_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">zntl:ZenteraTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if503536b265745f78bee8b2c10f7dd63_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">zntl:ZenteraTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c81d5274f084d8ca588db925f2f294d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">zntl:ZenteraTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a32b2ade07d41f4b1cad2d93ca61367_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">zntl:ZenteraTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4817ffa176c043dcaa4bcc0e640d9ac8_D20171221-20171221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">zntl:KalyraPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-21</xbrli:startDate><xbrli:endDate>2017-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ff9bd8c8cc546c2bfa853ff3951cad7_I20171221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">zntl:KalyraPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i56332e226885432ebe62ee97b3aa1f96_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e5d1442f22141d2ad21e2f741cecbe5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6809bcb1666148168afab58d0ffe577e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d2a23e4bb2343d588f6a5d196d2a18b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52d0e027780241b79c9c17cfcdd13982_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c2420fac1a84e158a6092ec05ed0417_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fdc062e1b6242f3bfa7722f537c5cc0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i410ff4f16a8040efb58e3e8e477cb639_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84739e60c7164232abd1054fd4938e36_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fcb530524114c769687f7c9f1fb749a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5fcea6723664d4697c80360ebeed61d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1b64d6100e743e984f7d8b3995bd09b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32d2e7ccd63b4e078ab5c066f13b44d2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>zntl:security</xbrli:measure></xbrli:unit><xbrli:context id="i49f1fa2e5d5d4f479e5668a21e82148b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia30f21df13f94f9ebd972a8a09ca6fac_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf38ee1491e140b8adacc29d8bb9760f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74f300d2e9d948a683e65b0cdc3aa411_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i380c135ffd6844f7997d78a2b67138ec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48ff0df351ef40fe8a05cd86f1008d36_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i101ae399b06242f49e876e6d8e25a264_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c6f54b010c64504bbd0705c0ac17af0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd6ec7e59ffb4b9eb4453d5218e35173_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9c408849fc84006b3a025992352774f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3150edba5268450db0756b69a3a1addf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d89135319bc455fa6a091097227fc6e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i512ef6b869c04c8a878f93105c57c41a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i598f17c497e545c58b325723fdc76f66_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71a8b179af364abb8287fabef06e5efe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i617ebbcc5095463d8013bb0f56fc9a65_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0843a9ee0f4743b7b17b8de5c7778791_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadc356695ac24c8cb111a3afaaa7ff8c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b730087c46740158ea57877aa0ae9a6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4459dcf3fc2c4ce79822c49134d753a4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcf1f1860f224f7783c2b7814b873ab3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i128d0fd7cbbf49d2b23f8f6ed5e8b638_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica67869b706548afa466add7912fddd6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c53bb5c6ef84b26a856ac6cf9e2e408_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b44713e1e994101839f64aec91e45b1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5c6ab2386b6421d83ee4eb9753b73cd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94ff901c1e7144e985fe76366d30065a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3727eb6a2b984c7ca52fc3f51b6afa97_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e83e26bd72349338171ae705edbe7f0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a2cf14e1f2448cdbc8fb71792150777_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadaa692c5c72427cbb64934ad0fa3730_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a695ef0eca441ed8cac49e237e173fa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i073dd536aa7f4e92a0c00f9b8001ea13_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">zntl:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i846b0f7b2bec4d4e9f5a806b4294790a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">zntl:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaecf109643ad41c2acacd554e5a7f04a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9990e1c841ed44748d68c3e408a17ce7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65c0b3ee517a4e78a0b1cf3438d6c138_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">zntl:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd91a2b14d264c7f801b908e210ab0e1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">zntl:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19492fb07b694a8f831a804dd56146ac_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i716b7da8349e417aab51c34f8ddc80f4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea20b17bd4be4aaeac426373ae7aa5ca_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i313676da216b4874b3024ccf5d0337d9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i107f398d916b45ab840efc6b49511a32_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:A2020IncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b8527f1b94449b499e8720cddbb6d40_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:A2020IncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a9d42e696914ee6ac56aebc0b0ccdf1_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:A2020IncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i892983c302494b99a210a868ff39cecd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:A2020IncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91b8baeaf3fd40eea9dc65835916019a_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:A2022EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9548270e5788494cb09db3f66fae3c93_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:A2022EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc1a500ef2574f02955ba6e37b2c81ac_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie297eca60e624e8d93b5c2d311094db0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f732ecb401746458a388bfa07d3afc2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f721a2929d54ac5ba6903405fe9cba7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i037f9049a8294a5c99bf21de04775e11_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32bfab5a7c4d46cbb67792b462367d55_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45742a89bf3246eb9070cc158debe73f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic196aacc6ecf4e049fc4defb2ff097a4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied35ca1f9fa14bff85ddf36999e934ec_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">zntl:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95aef8aaac164782aafe41f536dfd292_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">zntl:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i011753e6eaf2413a911eecf0b87cca62_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfa47905419248b98bc84b2436b91faf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae4fb48df2fa4ca3ab3a8ec68fdbb56b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2547f09e3d334b9e9a5869e04478bfe6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib06002bdaeab4e58a39c96013dac6a87_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9df9a5968b2476b88207ca1aa4feb7a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ae26c0f79da45b29f5451ae2499e17f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2487cf2d4d34a84be4fe6513ad27639_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2b9ea7d02e840689c4b7f3112d26cf8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4fa1db40e4948c89927ea38cf78d599_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9be73cf481a40aaba4c6cc6e675a708_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7a5cbabc41941ada32f7ae938592fa6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37ef16e02d7e43ba862a5c169d0332ea_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fb0cb9f5b6a4708aab9cfcff606daf7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e96002c4838463f94c1dab336a29f92_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d916b6b431a4bb1b63b1b45fcaf58c3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4be5fa9930e7403c9c0f8ba0f46352fe_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">zntl:MasterServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d0fc8e3ccd3496085dc4e71a7cfa31e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001725160</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">zntl:MasterServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iede2e4c8548c40d4910b7a838a08d814_1"></div><div style="min-height:0pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.250%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjg4_4aaf24c0-0d00-4a88-b6f3-eda2cf4eb3e5">10-Q</ix:nonNumeric></span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.250%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjg0_66e8165e-38a6-47d2-9fc3-02ad23f6f90d">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjQ_8d491b0f-d30a-4ce9-9dea-b6a9e5631491">March&#160;31, 2023</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjg1_1573c380-7ae7-4c5a-9461-41eae0f0fce7">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from ___________________ to ___________________</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjg2_d53eea4a-6296-4bea-8085-7d94b7f2fabd">001-39263</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.250%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjky_d0ddd708-9035-41fd-8150-1d57ea6867d6">Zentalis Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.250%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6OTlhZmViODU2YjRlNDE4ZDllN2E2YjYyZTg0NzRlMDYvdGFibGVyYW5nZTo5OWFmZWI4NTZiNGU0MThkOWU3YTZiNjJlODQ3NGUwNl8wLTAtMS0xLTc5Mjgz_ca517937-b12c-40ad-8398-9ec89c8ee204">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6OTlhZmViODU2YjRlNDE4ZDllN2E2YjYyZTg0NzRlMDYvdGFibGVyYW5nZTo5OWFmZWI4NTZiNGU0MThkOWU3YTZiNjJlODQ3NGUwNl8wLTEtMS0xLTc5Mjgz_7d771d7a-5935-4d3d-b627-1a5716ad7ade">82-3607803</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6OTlhZmViODU2YjRlNDE4ZDllN2E2YjYyZTg0NzRlMDYvdGFibGVyYW5nZTo5OWFmZWI4NTZiNGU0MThkOWU3YTZiNjJlODQ3NGUwNl8zLTAtMS0xLTc5MjgzL3RleHRyZWdpb246Njk2MTgyZGI1Mzg1NGFmOTliYTJlNTFlNmZkNzEwYWRfNA_80a7ada8-9a9b-4594-96a4-592af9260854">1359 Broadway</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6OTlhZmViODU2YjRlNDE4ZDllN2E2YjYyZTg0NzRlMDYvdGFibGVyYW5nZTo5OWFmZWI4NTZiNGU0MThkOWU3YTZiNjJlODQ3NGUwNl8zLTAtMS0xLTc5MjgzL3RleHRyZWdpb246Njk2MTgyZGI1Mzg1NGFmOTliYTJlNTFlNmZkNzEwYWRfOA_62cb3613-1d30-424c-a083-cb4f91b7f64b">Suite 801</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6OTlhZmViODU2YjRlNDE4ZDllN2E2YjYyZTg0NzRlMDYvdGFibGVyYW5nZTo5OWFmZWI4NTZiNGU0MThkOWU3YTZiNjJlODQ3NGUwNl81LTAtMS0xLTc5Mjgz_57391e08-8021-4354-897a-054555d3987e">New York,</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;<ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6OTlhZmViODU2YjRlNDE4ZDllN2E2YjYyZTg0NzRlMDYvdGFibGVyYW5nZTo5OWFmZWI4NTZiNGU0MThkOWU3YTZiNjJlODQ3NGUwNl82LTAtMS0xLTc5Mjgz_9e5a542e-a03e-46ce-8cbb-048b5d005bb3">New York</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6OTlhZmViODU2YjRlNDE4ZDllN2E2YjYyZTg0NzRlMDYvdGFibGVyYW5nZTo5OWFmZWI4NTZiNGU0MThkOWU3YTZiNjJlODQ3NGUwNl82LTEtMS0xLTc5Mjgz_4728392a-5f56-4653-85c4-36c61626706b">10018</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjgy_cb1398ec-2a3f-4cc9-afa1-0ee7515b01d1">212</ix:nonNumeric>) <ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjk0_2104507f-1fbc-457e-abd9-19a2fe3d98e2">433-3791</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.250%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6ZmEzNTBiZTJlNjVhNDI1NDkwZmNkZDJjNjc4ZmUyMDQvdGFibGVyYW5nZTpmYTM1MGJlMmU2NWE0MjU0OTBmY2RkMmM2NzhmZTIwNF8xLTAtMS0xLTc5Mjgz_2800914a-2040-47b2-87f7-94b7470c4f2f"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common Stock,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$0.001 par value per share</span></div></ix:nonNumeric></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6ZmEzNTBiZTJlNjVhNDI1NDkwZmNkZDJjNjc4ZmUyMDQvdGFibGVyYW5nZTpmYTM1MGJlMmU2NWE0MjU0OTBmY2RkMmM2NzhmZTIwNF8xLTEtMS0xLTc5Mjgz_48e041dc-9fc6-4336-9ff9-b20620da229d">ZNTL</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6ZmEzNTBiZTJlNjVhNDI1NDkwZmNkZDJjNjc4ZmUyMDQvdGFibGVyYW5nZTpmYTM1MGJlMmU2NWE0MjU0OTBmY2RkMmM2NzhmZTIwNF8xLTItMS0xLTc5MjgzL3RleHRyZWdpb246NGQ4ZGE2OWJhNjc0NDNhMmJhMzFjMzMxOTkzNTYyNTRfNA_2c273c0b-b707-4458-be92-ab82393894e8">The Nasdaq Stock Market LLC</ix:nonNumeric> (The Nasdaq Global Market)</span></div></td></tr></table></div><div style="margin-bottom:6pt;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjkw_c8f50a07-db02-4045-a100-456a30e67858">Yes</ix:nonNumeric> &#9746;  &#160;No  &#9744;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjkz_4f776ba0-8df0-4ded-ac8b-773ad4e69e28">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-bottom:3pt;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.722%"><tr><td style="width:1.0%"></td><td style="width:34.968%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.968%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6NGVlNTM2NzE0MzJlNDlhOWE2NWZlYTAzZjYyZjcxODUvdGFibGVyYW5nZTo0ZWU1MzY3MTQzMmU0OWE5YTY1ZmVhMDNmNjJmNzE4NV8wLTAtMS0xLTc5Mjgz_ebf8a40e-1a58-48e2-8e52-c33cfb5576b3">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6NGVlNTM2NzE0MzJlNDlhOWE2NWZlYTAzZjYyZjcxODUvdGFibGVyYW5nZTo0ZWU1MzY3MTQzMmU0OWE5YTY1ZmVhMDNmNjJmNzE4NV8xLTQtMS0xLTc5Mjgz_98ebb5af-469b-49c0-8632-9b03498a5283">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6NGVlNTM2NzE0MzJlNDlhOWE2NWZlYTAzZjYyZjcxODUvdGFibGVyYW5nZTo0ZWU1MzY3MTQzMmU0OWE5YTY1ZmVhMDNmNjJmNzE4NV8yLTQtMS0xLTc5Mjgz_9b52efdb-4fb8-4ab2-9212-d8ffc1a0052d">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div style="margin-bottom:6pt;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjgz_93e53e11-93ef-4b82-b4b1-7968a217176b">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="margin-bottom:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of May 8, 2023, the registrant had <ix:nonFraction unitRef="shares" contextRef="ia48f187fdc694ec0a436fbbe630672db_I20230508" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjE0_71e843e5-7f1e-4b6a-beac-1e7c551b3afb">59,477,824</ix:nonFraction> shares of common stock, $0.001 par value per share, outstanding.</span></div><div style="text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:0pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><div id="iede2e4c8548c40d4910b7a838a08d814_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_16">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_16">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_19">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_19">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_22">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_22">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_25">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_25">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_28">Condensed Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_28">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_31">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_31">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_34">Condensed Consolidated Statement of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_34">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_37">Notes to Condensed Consolidated Financial Statements </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_37">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_76">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_76">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_79">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_79">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_82">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_82">35</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_85">OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_85">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_88">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_88">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_91">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_91">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_94">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_94">93</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_97">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_97">93</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_100">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_100">93</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_103">Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_103">93</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_106">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_106">94</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_109">Signatures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iede2e4c8548c40d4910b7a838a08d814_109">96</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="iede2e4c8548c40d4910b7a838a08d814_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements within the meaning of the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;design,&#8221;  &#8220;support&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements contained in this Quarterly Report include, but are not limited to, statements about: </span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our competitive position, including estimates and other information relating to our competitors and their products and product candidates, and our industry;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our expectations, projections and estimates regarding our capital requirements, need for additional capital, financing our future cash needs, costs, expenses, revenues, capital resources, cash flows, financial performance, profitability, tax obligations, liquidity, growth, contractual obligations, the period of time our cash resources will fund our current operating plan, our internal control over financial reporting and disclosure controls and procedures;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">U.S. and global economic issues, global supply chain issues and increased inflation and interest rates; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing and focus of our ongoing and future preclinical studies and clinical trials, including the reporting of data from those studies and trials and the timing thereof and the timing of initiation of enrollment in our clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our estimates of the number of patients that we will enroll in our clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans relating to disclosing a monotherapy dose for our product candidates, dose optimization activities and the timing thereof;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our and our collaborators' strategy, plans and expectations with respect to the development, manufacturing, supply, approval and commercialization of our product candidates and the timing thereof;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the designs of our studies and the type of information and data expected from our studies and the expected benefits thereof;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to obtain and maintain any marketing authorizations and our ability to complete post-marketing requirements with respect thereto;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing and amounts of payments from or to our collaborators and licensees, and the anticipated arrangements and benefits under our collaboration and license agreements, including with respect to milestones and royalties;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our pipeline, including its potential, and our related research and development activities;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans relating to our Cyclin E1 patient enrichment strategy and the timing of milestones related thereto;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans relating to the further development of our product candidates, including program timelines, potential paths to registration, and additional indications we may pursue;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to negotiate, secure and maintain adequate pricing, coverage and reimbursement terms and processes on a timely basis, or at all, with third-party payors for our product candidates, if approved;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans, including the costs thereof, of development of any diagnostic tools;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans to evaluate additional strategic opportunities to maximize the value of our pipeline;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans to advance our ongoing research on protein degrader programs;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans to advance IND-enabling studies for our product candidates, including our BCL-xL protein degrader product candidate;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans to develop our product candidates in combination with other therapies;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our existing collaborations and our ability to obtain, and negotiate favorable terms of, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">timing and likelihood of success of our research, development and commercialization efforts;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">timing of expected milestones and the announcement thereof;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the size of the market opportunity for our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our expectations regarding the approval and use of our product candidates as first, second or subsequent lines of therapy or in combination with other drugs;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing or likelihood of regulatory filings and approvals, including our expectation to seek an accelerated approval pathway and special designations for our product candidates for various diseases;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to obtain and maintain regulatory approval of our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">existing regulations and regulatory developments in the United States, the European Union and other jurisdictions;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our intellectual property position, including obtaining and maintaining patents, and the timing, outcome and impact of administrative, regulatory, legal and other proceedings relating to our patents and other proprietary and intellectual property rights, and the timing and resolution thereof;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our facilities, lease commitments, and future availability of facilities;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">accounting standards and estimates, their impact, and their expected timing of completion;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">cybersecurity and information security;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expected ongoing reliance on third parties, including with respect to the development, manufacturing, supply and commercialization of our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">insurance coverage;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">estimated periods of performance of key contracts;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the need to hire additional personnel and our ability to attract and retain personnel, and our ability to provide competitive compensation and benefits; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of the COVID-19 pandemic on our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Quarterly Report are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of known and unknown risks, uncertainties, assumptions and other important factors, including those described under &#8220;Summary Risk Factors&#8221; below and in the sections in this Quarterly Report entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Quarterly Report.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, they may turn out to be inaccurate and you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results, financial condition, performance or achievements could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ZENTALIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and its associated logo are trademarks of Zentalis.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> All other trademarks, trade names and service marks appearing in this Quarterly Report are the property of their respective owners. All website addresses given in this Quarterly Report are for information only and are not intended to be an active link or to incorporate any website information into this document.</span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY RISK FACTORS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks and uncertainties, including those described in Part II, Item 1A, &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include the following:</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We have a limited operating history and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We are substantially dependent on the success of our lead product candidates, azenosertib (ZN-c3) and/or ZN-d5, which are currently in clinical trials. If we are unable to complete development of, obtain approval for and commercialize these product candidates in a timely manner, our business will be harmed.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The clinical trials of our product candidates may not demonstrate safety and efficacy to the satisfaction of the U.S. Food and Drug Administration, or FDA, or other comparable ex-U.S. regulatory authorities or otherwise produce positive results.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to successfully develop diagnostic tools for biomarkers that enable patient selection, or experience significant delays in doing so, we may not realize the full commercial potential of our product candidates.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We are developing our product candidates in combination with other therapies, which exposes us to additional risks.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The regulatory approval processes of the FDA and other comparable ex-U.S. regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We face significant competition. and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our success depends on our ability to protect our intellectual property and our proprietary platform. If we are unable to adequately protect our intellectual property and our proprietary platform, or to obtain and  maintain issued patents which are sufficient to protect our product candidates, then others could compete against us more directly, which would negatively impact our business.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our existing collaborations are important to our business and future licenses may also be important to us and, if we are unable to maintain any of these collaborations, or if these arrangements are not successful, our business could be adversely affected.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct certain aspects of our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The competition for qualified personnel is particularly intense in our industry. If we are unable to retain or hire key personnel, then we may not be able to sustain or grow our business.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The COVID-19 pandemic has adversely impacted, and may continue to adversely impact, our business, including our preclinical studies and clinical trials. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Unfavorable U.S., global, political or economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv</span></div></div></div><div id="iede2e4c8548c40d4910b7a838a08d814_16"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="iede2e4c8548c40d4910b7a838a08d814_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="iede2e4c8548c40d4910b7a838a08d814_22"></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zentalis Pharmaceuticals, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share amounts and par value)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfNC0xLTEtMS03OTI4Mw_446576aa-a79e-44ce-b443-ce7724f7f7bc">36,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfNC0zLTEtMS03OTI4Mw_11b9249b-2cbf-46d7-9a8d-5c6da2f641bb">43,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities, available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfNS0xLTEtMS03OTI4Mw_de04d5ef-04b4-4cc7-b419-1c76fbb5dbb6">356,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfNS0zLTEtMS03OTI4Mw_add160a7-1254-4513-b0e7-f67b46f26d3b">394,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfNy0xLTEtMS03OTI4Mw_2aa59922-c4e0-4125-8b31-42e9f4b61741">17,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfNy0zLTEtMS03OTI4Mw_9468ca43-11a6-4583-9646-d23e7b18d155">14,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfOS0xLTEtMS03OTI4Mw_51138908-e10a-4b15-9b6f-91e64d0f192d">410,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfOS0zLTEtMS03OTI4Mw_31699c1f-c6d0-4adc-aadb-7dc90f61ea06">451,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTAtMS0xLTEtNzkyODM_3bf927b0-1250-4410-8b36-57e1c92187c4">6,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTAtMy0xLTEtNzkyODM_7ea8e684-b762-47f1-a664-d578be89d412">7,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease&#160;right-of-use&#160;assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTEtMS0xLTEtNzkyODM_f840d1f3-133d-4142-9a3a-9e704b110152">37,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTEtMy0xLTEtNzkyODM_f4d67c72-78f5-4c87-b7da-6d20c72624d6">42,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTItMS0xLTEtNzkyODM_6886f5a2-76f8-4232-af4a-f2f02138cfbf">9,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTItMy0xLTEtNzkyODM_aba921ad-2ee3-4225-8f87-165060564e48">9,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTMtMS0xLTEtNzkyODM_b4db6484-069d-4cbf-aefe-8a7d828f6394">3,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTMtMy0xLTEtNzkyODM_43c48609-e5a1-4dac-b009-25a6c743d638">3,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in Zentera Therapeutics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTUtMS0xLTEtNzkyODM_dd08cb9d-b839-4593-98c4-94839f869a51">18,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTUtMy0xLTEtNzkyODM_635ec20e-c6b0-4a4b-a458-5f45aafe5a66">21,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTYtMS0xLTEtNzkyODM_605bffca-8186-4be4-94a3-617da759fa3a">2,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTYtMy0xLTEtNzkyODM_2c04d82c-2d09-42a8-b93f-960335386c5f">2,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTctMS0xLTEtNzkyODM_be321f87-8a1b-48d6-a8d4-9915ca4ab691">489,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTctMy0xLTEtNzkyODM_720b4afd-6464-4ff3-b944-808f62449f99">539,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES&#160;AND&#160;STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjAtMS0xLTEtNzkyODM_49be8359-8b34-4597-a68f-672758694b16">12,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjAtMy0xLTEtNzkyODM_46a1f4b4-e170-4af0-945c-42cfcd2d7776">11,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjEtMS0xLTEtNzkyODM_cb56cf76-7548-40c1-8dde-2dd56c3556b3">43,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjEtMy0xLTEtNzkyODM_daf49620-4bb4-47af-be1c-5771a08e7da6">45,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjItMS0xLTEtNzkyODM_2027cd53-6ebb-4272-9a66-226411828874">56,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjItMy0xLTEtNzkyODM_73b84e18-88b3-45fd-b7c8-4e2e975fa33a">56,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjMtMS0xLTEtNzkyODM_5836646a-23ab-4837-93d2-713a5784240e">756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjMtMy0xLTEtNzkyODM_32d26dab-7221-4c7c-a81c-1498cc8ea31c">853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjQtMS0xLTEtNzkzNTM_7159c60d-4880-49a6-9242-1515cbb4b838">44,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjQtMy0xLTEtNzkzNTM_5faff354-3edd-44d4-9aa6-c50641a623e2">45,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjQtMS0xLTEtNzkyODM_53942095-2459-4a9c-b704-fff94594cad2">1,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjQtMy0xLTEtNzkyODM_22d8a3d9-6ee0-45e9-9187-51a3f20c7b39">2,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjUtMS0xLTEtNzkyODM_ffcc9756-bc7e-4720-819c-0aab9f55cea1">103,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjUtMy0xLTEtNzkyODM_895c1077-92e9-45a5-99e3-305fda3b8037">105,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjYtMS0xLTEtNzkyODM_03a34e9e-406f-4988-b815-ec395e50bfc4"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjYtMy0xLTEtNzkyODM_e312d495-96eb-478e-a796-b4f9975fdf02"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzEtMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjowYjJkN2JjNzI3MWY0YjIxOWY1Y2EyODczNTM3NmQ2Nl8yMQ_41e4ddb2-6d1c-47da-b496-924ceb08495a"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzEtMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjowYjJkN2JjNzI3MWY0YjIxOWY1Y2EyODczNTM3NmQ2Nl8yMQ_df5fa202-d45d-480d-a2af-13f90c9f3c60">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzEtMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjowYjJkN2JjNzI3MWY0YjIxOWY1Y2EyODczNTM3NmQ2Nl8zNQ_54d67a79-ea8f-4002-a5f1-d7513119f389"><ix:nonFraction unitRef="shares" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzEtMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjowYjJkN2JjNzI3MWY0YjIxOWY1Y2EyODczNTM3NmQ2Nl8zNQ_70dee25d-104e-42fe-923e-bcf06480f25f">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzEtMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjowYjJkN2JjNzI3MWY0YjIxOWY1Y2EyODczNTM3NmQ2Nl81Nw_6a9b1e52-9331-43f4-96de-0dd76142c7b4"><ix:nonFraction unitRef="shares" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzEtMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjowYjJkN2JjNzI3MWY0YjIxOWY1Y2EyODczNTM3NmQ2Nl81Nw_6f24f0e6-a895-455c-aeca-841679f9e984"><ix:nonFraction unitRef="shares" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzEtMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjowYjJkN2JjNzI3MWY0YjIxOWY1Y2EyODczNTM3NmQ2Nl81Nw_b1f6d536-a425-471b-826d-6361252e71f7"><ix:nonFraction unitRef="shares" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzEtMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjowYjJkN2JjNzI3MWY0YjIxOWY1Y2EyODczNTM3NmQ2Nl81Nw_d26b767d-3226-4724-ae0b-7b4a13f3423a">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2023 and December 31, 2022 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzEtMS0xLTEtNzkyODM_b97558cd-3488-44fc-81ca-333bc47d891f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzEtMy0xLTEtNzkyODM_f026cd4b-82c5-4b71-95ee-ee7cf059bb8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzItMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjpjZTM2ZTIwMGY3OTA0ODI0ODk2Y2E0MTU1MTEwOGNhZF8xOA_bbcfe703-8340-479f-b644-df56e3053e8d"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzItMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjpjZTM2ZTIwMGY3OTA0ODI0ODk2Y2E0MTU1MTEwOGNhZF8xOA_d1d568cf-67e9-46fe-83c6-b821d14efc8d">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzItMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjpjZTM2ZTIwMGY3OTA0ODI0ODk2Y2E0MTU1MTEwOGNhZF8zMg_0d5800cd-d0d7-4127-b8ef-751c18d4d33a"><ix:nonFraction unitRef="shares" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzItMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjpjZTM2ZTIwMGY3OTA0ODI0ODk2Y2E0MTU1MTEwOGNhZF8zMg_a7d3e378-f685-48d4-b921-3cad717c77f8">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzItMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjpjZTM2ZTIwMGY3OTA0ODI0ODk2Y2E0MTU1MTEwOGNhZF81NA_3b36ec2f-fde2-4051-babe-9a1cdecf0b0f"><ix:nonFraction unitRef="shares" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzItMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjpjZTM2ZTIwMGY3OTA0ODI0ODk2Y2E0MTU1MTEwOGNhZF81NA_a844b3e4-a70a-4d71-959e-ccd31e188df1">59,442,342</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzItMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjpjZTM2ZTIwMGY3OTA0ODI0ODk2Y2E0MTU1MTEwOGNhZF82MQ_40aeafa6-c631-474c-aad9-b110b084d1c0"><ix:nonFraction unitRef="shares" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzItMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjpjZTM2ZTIwMGY3OTA0ODI0ODk2Y2E0MTU1MTEwOGNhZF82MQ_bbf6b591-1a68-4927-bfde-98e247184b1c">59,280,247</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2023 and December 31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzItMS0xLTEtNzkyODM_6eebf656-f7fe-4758-96ae-d3ae2c5d65b3">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzItMy0xLTEtNzkyODM_5d8c1386-82a5-4823-9d56-885a2fe08670">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzMtMS0xLTEtNzkyODM_33a201ef-a720-4a8f-b7bc-97f0cad8f01f">1,045,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzMtMy0xLTEtNzkyODM_628cbc57-eaba-4069-8d0e-d9cfed24100a">1,031,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzQtMS0xLTEtNzkyODM_41aeeefa-b57c-45c6-b6cf-271c74fe8d0f">556</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzQtMy0xLTEtNzkyODM_57a9eb80-97d0-4a66-a6c4-0af28c7651ee">1,353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzUtMS0xLTEtNzkyODM_41b9728f-feac-4a9f-b5e6-5713981fdcaa">659,584</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzUtMy0xLTEtNzkyODM_80d8c88c-cc7d-40d9-b9c5-c0dfa70241f8">596,365</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzYtMS0xLTEtNzkyODM_dbfd49e2-09fd-49a4-a3be-1600edff4515">385,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzYtMy0xLTEtNzkyODM_e07e2fb0-cfce-4c33-bcdb-ee479bb9db22">433,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzctMS0xLTEtNzkyODM_66d3cf56-c67d-4a09-a109-7f22d4a73c4c">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzctMy0xLTEtNzkyODM_ac83834c-205e-4142-ba34-c90b39b1bfe4">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzgtMS0xLTEtNzkyODM_0daefcb4-336e-4a39-9bb0-a64be3891d5a">385,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzgtMy0xLTEtNzkyODM_823de688-a4c7-449c-986f-97dace42c770">434,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzktMS0xLTEtNzkyODM_054ca176-99f3-4bbc-b5b1-99ee902499da">489,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzktMy0xLTEtNzkyODM_e69b21af-7771-488f-a527-ae9a647bbaf9">539,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements. </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="iede2e4c8548c40d4910b7a838a08d814_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zentalis Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"></td><td style="width:48.569%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.159%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMy01LTEtMS03OTI4Mw_682e9064-e372-40e1-81f8-87635cd41273">48,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMy03LTEtMS03OTI4Mw_1a3a932c-6905-46f5-ba80-400cfb235fb4">46,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfNC01LTEtMS03OTI4Mw_0f6da4d3-40ee-4706-a88d-d9946198b1da">16,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfNC03LTEtMS03OTI4Mw_371b682e-b77c-474b-b6de-1669e338ebca">11,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfNS01LTEtMS03OTI4Mw_a852cf1f-9f31-4010-8ec4-06884baa59c6">64,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfNS03LTEtMS03OTI4Mw_8ba223ac-6314-45cc-bf65-33b945ed01e7">57,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfNi01LTEtMS03OTI4Mw_5e7d9b92-8c7b-48cc-982b-382f1c63bb0a">64,953</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfNi03LTEtMS03OTI4Mw_06ad06f3-d7fb-4599-9cbf-1c0968311d15">57,879</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Income (Expense)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment and other income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="zntl:InvestmentAndOtherIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfOC01LTEtMS03OTI4Mw_1e9c94a2-51aa-4179-9701-4a81d5b091d8">4,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="zntl:InvestmentAndOtherIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfOC03LTEtMS03OTI4Mw_2b683fff-2b36-4ed1-88ac-1f9bef9b8335">426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTEtNS0xLTEtNzkyODM_5866f0e8-8190-4665-b943-e1fc66e5d524">60,844</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTEtNy0xLTEtNzkyODM_0d41cf32-bc83-4791-a1f7-b0187e144394">57,453</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTItNS0xLTEtNzkyODM_41a97563-9d4f-40b0-b398-37549091f421">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTItNy0xLTEtNzkyODM_af36cbdb-32ba-4bc3-a467-83c13df504ef">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on equity method investment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTMtNS0xLTEtNzkyODM_10220cb6-06e8-417d-a3a4-8da944197601">2,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTMtNy0xLTEtNzkyODM_9b73d9b8-9ac7-4b82-81de-6a35ca884969">1,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTQtNS0xLTEtNzkyODM_1dcd9a13-2d83-441a-8465-0c718a93bce1">63,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTQtNy0xLTEtNzkyODM_ab85f3b0-e9f8-413e-9aaa-554f8437563e">59,237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTUtNS0xLTEtNzkyODM_cba9625a-ac71-4e80-bbea-84493583aab2">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTUtNy0xLTEtNzkyODM_7b363f1e-4b37-4538-ac27-67a458196feb">160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Zentalis </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTYtNS0xLTEtNzkyODM_729a7073-efbe-474c-a4dd-8615bb16eae0">63,219</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTYtNy0xLTEtNzkyODM_bbcf9612-27af-4bf7-be82-68105c62a851">59,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share outstanding, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTctNS0xLTEtNzkyODM_0abed70d-55f7-4c65-b5b1-c5f419c55407"><ix:nonFraction unitRef="usdPerShare" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTctNS0xLTEtNzkyODM_b31ed39d-5b14-401b-94fb-92936d3132d6">1.07</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTctNy0xLTEtNzkyODM_7e24d30b-38f8-4ca8-ad4f-51a440397d3c"><ix:nonFraction unitRef="usdPerShare" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTctNy0xLTEtNzkyODM_98fc2b24-f27a-4351-b1cc-7a5e3cfe4fa8">1.31</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares used in computing net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTktNS0xLTEtNzkyODM_940e4707-2d41-4943-877a-b749dfb9146c"><ix:nonFraction unitRef="shares" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTktNS0xLTEtNzkyODM_dd940558-eaa1-4a94-88fd-a94b5197df6a">59,277</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTktNy0xLTEtNzkyODM_bf540d4c-f842-4192-b41b-206916468515"><ix:nonFraction unitRef="shares" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTktNy0xLTEtNzkyODM_dff258d7-5492-4ccc-b037-6c638f9e43aa">45,244</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="iede2e4c8548c40d4910b7a838a08d814_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zentalis Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.500%"><tr><td style="width:1.0%"></td><td style="width:50.182%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:23.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yOC9mcmFnOjBiNjE5Y2NmZDA5NTQ1N2Y5NTRkMzE5ZWEyOTUxZjc4L3RhYmxlOjUzMDkxMzc5ZmE1MTQ0N2Q4YWVjOTgwZmYxZGNhODExL3RhYmxlcmFuZ2U6NTMwOTEzNzlmYTUxNDQ3ZDhhZWM5ODBmZjFkY2E4MTFfMi0zLTEtMS03OTI4Mw_1dcd9a13-2d83-441a-8465-0c718a93bce1">63,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yOC9mcmFnOjBiNjE5Y2NmZDA5NTQ1N2Y5NTRkMzE5ZWEyOTUxZjc4L3RhYmxlOjUzMDkxMzc5ZmE1MTQ0N2Q4YWVjOTgwZmYxZGNhODExL3RhYmxlcmFuZ2U6NTMwOTEzNzlmYTUxNDQ3ZDhhZWM5ODBmZjFkY2E4MTFfMi00LTEtMS03OTI4Mw_ab85f3b0-e9f8-413e-9aaa-554f8437563e">59,237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on marketable securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yOC9mcmFnOjBiNjE5Y2NmZDA5NTQ1N2Y5NTRkMzE5ZWEyOTUxZjc4L3RhYmxlOjUzMDkxMzc5ZmE1MTQ0N2Q4YWVjOTgwZmYxZGNhODExL3RhYmxlcmFuZ2U6NTMwOTEzNzlmYTUxNDQ3ZDhhZWM5ODBmZjFkY2E4MTFfNS0zLTEtMS03OTI4Mw_e0ef115a-c92b-43ea-ba4f-84b09b934f82">797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yOC9mcmFnOjBiNjE5Y2NmZDA5NTQ1N2Y5NTRkMzE5ZWEyOTUxZjc4L3RhYmxlOjUzMDkxMzc5ZmE1MTQ0N2Q4YWVjOTgwZmYxZGNhODExL3RhYmxlcmFuZ2U6NTMwOTEzNzlmYTUxNDQ3ZDhhZWM5ODBmZjFkY2E4MTFfNS00LTEtMS03OTI4Mw_1a4143bd-b2bf-4ae6-a513-ef880205ba12">984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yOC9mcmFnOjBiNjE5Y2NmZDA5NTQ1N2Y5NTRkMzE5ZWEyOTUxZjc4L3RhYmxlOjUzMDkxMzc5ZmE1MTQ0N2Q4YWVjOTgwZmYxZGNhODExL3RhYmxlcmFuZ2U6NTMwOTEzNzlmYTUxNDQ3ZDhhZWM5ODBmZjFkY2E4MTFfNi0zLTEtMS03OTI4Mw_b8d008f1-fdfe-4e3c-8fa0-d3a90ac6e71b">62,465</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yOC9mcmFnOjBiNjE5Y2NmZDA5NTQ1N2Y5NTRkMzE5ZWEyOTUxZjc4L3RhYmxlOjUzMDkxMzc5ZmE1MTQ0N2Q4YWVjOTgwZmYxZGNhODExL3RhYmxlcmFuZ2U6NTMwOTEzNzlmYTUxNDQ3ZDhhZWM5ODBmZjFkY2E4MTFfNi00LTEtMS03OTI4Mw_608699f4-727f-4d85-a429-eb747d7336a6">60,221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yOC9mcmFnOjBiNjE5Y2NmZDA5NTQ1N2Y5NTRkMzE5ZWEyOTUxZjc4L3RhYmxlOjUzMDkxMzc5ZmE1MTQ0N2Q4YWVjOTgwZmYxZGNhODExL3RhYmxlcmFuZ2U6NTMwOTEzNzlmYTUxNDQ3ZDhhZWM5ODBmZjFkY2E4MTFfNy0zLTEtMS03OTI4Mw_3563dcde-10a0-48c1-bb15-ca7a45b5c30e">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yOC9mcmFnOjBiNjE5Y2NmZDA5NTQ1N2Y5NTRkMzE5ZWEyOTUxZjc4L3RhYmxlOjUzMDkxMzc5ZmE1MTQ0N2Q4YWVjOTgwZmYxZGNhODExL3RhYmxlcmFuZ2U6NTMwOTEzNzlmYTUxNDQ3ZDhhZWM5ODBmZjFkY2E4MTFfNy00LTEtMS03OTI4Mw_07427fc6-212b-4075-8da8-d6ef66760bed">160</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to Zentalis</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yOC9mcmFnOjBiNjE5Y2NmZDA5NTQ1N2Y5NTRkMzE5ZWEyOTUxZjc4L3RhYmxlOjUzMDkxMzc5ZmE1MTQ0N2Q4YWVjOTgwZmYxZGNhODExL3RhYmxlcmFuZ2U6NTMwOTEzNzlmYTUxNDQ3ZDhhZWM5ODBmZjFkY2E4MTFfOC0zLTEtMS03OTI4Mw_38dd7ca7-2fd0-4373-9e75-1fd3ca89dfba">62,422</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yOC9mcmFnOjBiNjE5Y2NmZDA5NTQ1N2Y5NTRkMzE5ZWEyOTUxZjc4L3RhYmxlOjUzMDkxMzc5ZmE1MTQ0N2Q4YWVjOTgwZmYxZGNhODExL3RhYmxlcmFuZ2U6NTMwOTEzNzlmYTUxNDQ3ZDhhZWM5ODBmZjFkY2E4MTFfOC00LTEtMS03OTI4Mw_9289c225-95b6-48a2-8387-4a2056898894">60,061</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="iede2e4c8548c40d4910b7a838a08d814_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zentalis Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:1pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMy0xLTEtMS03OTI4Mw_8a322ce0-88fb-4110-8ce2-851e81225b55">63,262</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMy0zLTEtMS03OTI4Mw_b4d8e686-77b4-4026-b69f-3a773c0effc5">59,237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfNS0xLTEtMS03OTI4Mw_1831b7e9-5fa3-4ef7-9e21-ee3775e97586">360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfNS0zLTEtMS03OTI4Mw_1af148a9-7711-4b55-9574-fc29cf5ec9b8">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset and fixed asset impairment </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfNi0xLTEtMS05NzE0NA_882ef0d9-a68f-4f8f-9807-1964de56f590">4,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfNi0zLTEtMS05NzE1Mg_bda14b87-6298-4a62-aa26-2b5cb3039464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfOS0xLTEtMS03OTI4Mw_0b96707c-6e2f-4e28-8468-10098c022827">13,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfOS0zLTEtMS03OTI4Mw_140414f7-ccef-45bc-984a-9618b924cf4b">10,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Accretion of discounts)/amortization of premiums on marketable securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTEtMS0xLTEtNzkyODM_f0437820-3c06-41f2-a271-a1a44c5a93fc">3,261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTEtMy0xLTEtNzkyODM_7888cf90-6e00-4290-b34e-46ab454f2aa6">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTItMS0xLTEtNzkyODM_87282eea-236b-48c9-be44-dd18ec65ae09">2,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTItMy0xLTEtNzkyODM_3b68b422-2f34-4495-b97d-2e48841e86d0">1,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTMtMS0xLTEtOTUxNzA_8f0435ea-b19e-4392-a9e2-d13dc10c4e75">97</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTMtMy0xLTEtOTUxNzA_d59ddb3c-089f-4de4-affe-138684f177f3">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTUtMS0xLTEtNzkyODM_58f90e1f-9d82-4891-8081-66aa9e3e0ed0">2,917</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTUtMy0xLTEtNzkyODM_d5b7ded5-c8d9-49c8-a916-029ae26dd67c">4,154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTYtMS0xLTEtNzkyODM_9ec5a93e-f34b-4fa9-8f04-a00d08ed2010">1,411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTYtMy0xLTEtNzkyODM_df247ad2-3d22-4b15-b62d-124d81acd09f">500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="zntl:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTctMS0xLTEtNzkyODM_e068c9f8-fe0a-420b-a8b9-51ad1e4a0cc1">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="zntl:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTctMy0xLTEtNzkyODM_c2b69d51-a628-4bd8-adde-221bbe81a97e">1,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTgtMS0xLTEtNzkyODM_70a6422d-c64e-47e1-88e7-4d35fa908f19">49,283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTgtMy0xLTEtNzkyODM_48d987eb-bf0d-4d40-8bbf-40733238dc7e">50,196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMjAtMS0xLTEtNzkyODM_122c7882-03ec-4307-8b5b-1c977579ab0a">63,879</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMjAtMy0xLTEtNzkyODM_a875ccbd-2f95-47d4-be11-642e7c0c655e">79,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMjEtMS0xLTEtNzkyODM_ac9237b5-3a79-48dd-99d3-00ae7b46885a">106,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMjEtMy0xLTEtNzkyODM_e6d745b9-aa09-42ab-854e-848388502ff9">99,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMjMtMS0xLTEtNzkyODM_b55ec276-e4a6-4743-99fb-601684384ac9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMjMtMy0xLTEtNzkyODM_6ad487cf-4e9c-4e9e-a82a-1ca15898d839">450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMjQtMS0xLTEtNzkyODM_5b33b345-884c-44c0-a833-141481b5e000">42,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMjQtMy0xLTEtNzkyODM_429c735d-ad3b-41a7-924f-46cd1369f1ba">19,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMjgtMS0xLTEtNzkyODM_233fa620-c28c-4224-8e0d-a4cef7787a2b">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMjgtMy0xLTEtNzkyODM_22c98957-93b8-4085-8b8b-1981a0360409">1,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMzMtMS0xLTEtNzkyODM_1f785ed6-ef92-4d52-b793-d8070163a43b">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMzMtMy0xLTEtNzkyODM_55de1dd6-4385-4646-90d9-702b50287a98">1,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMzQtMS0xLTEtNzkyODM_2bcb7a9d-5bf6-4357-a866-b6d15f50e5e1">6,789</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMzQtMy0xLTEtNzkyODM_6cde5394-8442-497b-ae41-f008cc2baf86">29,142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMzUtMS0xLTEtNzkyODM_e0615932-7e2d-472c-9793-3734538f9db7">45,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i952b505edf2c4ed8969edcd9dd637d0b_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMzUtMy0xLTEtNzkyODM_57f69c6b-26d9-45fd-a3f2-0f11b7f8cb39">62,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMzYtMS0xLTEtNzkyODM_0a85e626-4b3d-4ab9-b15f-b14da2291849">38,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94cbb15018ea46098ad9249cb81ecbd5_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMzYtMy0xLTEtNzkyODM_7bfd0abe-ffec-4233-8071-2242b05a683a">33,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of&#160;non-cash&#160;investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued capital expenditures</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMzgtMS0xLTEtNzkyODM_bbcb0f27-8197-4bd8-a8f6-06ff33fb4d9e">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMzgtMy0xLTEtNzkyODM_f588b2b4-d4ee-45bc-96fb-7bbb6f21b83e">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-top:7pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the Consolidated Statements of Cash Flows for the periods presented:</span></div><div style="margin-bottom:1pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOmRjMTUyOGU4MTQ3MTQzODg5MWIyMGQyZGE5MzFlOGRiL3RhYmxlcmFuZ2U6ZGMxNTI4ZTgxNDcxNDM4ODkxYjIwZDJkYTkzMWU4ZGJfMi0xLTEtMS03OTI4Mw_7c0f413b-65c6-463a-ba0e-23f5fa52d35a">36,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94cbb15018ea46098ad9249cb81ecbd5_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOmRjMTUyOGU4MTQ3MTQzODg5MWIyMGQyZGE5MzFlOGRiL3RhYmxlcmFuZ2U6ZGMxNTI4ZTgxNDcxNDM4ODkxYjIwZDJkYTkzMWU4ZGJfMi0zLTEtMS03OTI4Mw_ced14540-de30-430d-88e8-861ae6ab1c06">30,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOmRjMTUyOGU4MTQ3MTQzODg5MWIyMGQyZGE5MzFlOGRiL3RhYmxlcmFuZ2U6ZGMxNTI4ZTgxNDcxNDM4ODkxYjIwZDJkYTkzMWU4ZGJfMy0xLTEtMS03OTI4Mw_7bfd63a3-18b8-46f6-8f50-cbde3cbfd396">2,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94cbb15018ea46098ad9249cb81ecbd5_I20220331" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOmRjMTUyOGU4MTQ3MTQzODg5MWIyMGQyZGE5MzFlOGRiL3RhYmxlcmFuZ2U6ZGMxNTI4ZTgxNDcxNDM4ODkxYjIwZDJkYTkzMWU4ZGJfMy0zLTEtMS03OTI4Mw_24ff1d8b-ada2-4c99-9d75-200205435572">2,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash reported in the Condensed Consolidated Statement of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOmRjMTUyOGU4MTQ3MTQzODg5MWIyMGQyZGE5MzFlOGRiL3RhYmxlcmFuZ2U6ZGMxNTI4ZTgxNDcxNDM4ODkxYjIwZDJkYTkzMWU4ZGJfNC0xLTEtMS03OTI4Mw_d6722527-ade0-4c08-9dc8-6dbb89b05fbb">38,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94cbb15018ea46098ad9249cb81ecbd5_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOmRjMTUyOGU4MTQ3MTQzODg5MWIyMGQyZGE5MzFlOGRiL3RhYmxlcmFuZ2U6ZGMxNTI4ZTgxNDcxNDM4ODkxYjIwZDJkYTkzMWU4ZGJfNC0zLTEtMS03OTI4Mw_d77b4f3b-b182-435f-ad2e-1372c8874e47">33,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="iede2e4c8548c40d4910b7a838a08d814_34"></div><hr style="page-break-after:always"/><div style="min-height:0pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zentalis Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.230%"><tr><td style="width:1.0%"></td><td style="width:34.071%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.606%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Noncontrolling</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Interests</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7e45d5095eb4183b28589ea3d638b55_I20221231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfNC0xLTEtMS03OTI4Mw_9eec6cc8-0e6a-4687-9f14-7fd884531a34">59,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e45d5095eb4183b28589ea3d638b55_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfNC0zLTEtMS03OTI4Mw_3fd555c9-39e8-43d2-a21c-4c8985951081">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b55ea2c54349ec90158494f177ec3d_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfNC01LTEtMS03OTI4Mw_8558e57c-ab56-465b-8623-432cf9235132">1,031,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7921e87cee7146e4aaa27c62453d6118_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfNC03LTEtMS03OTI4Mw_b059d580-a8da-458b-a14b-a79351721612">1,353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id87bc3ab81a548e8accd9e1b819b5bf8_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfNC05LTEtMS03OTI4Mw_03ed9791-2e11-44cd-922b-fa077c574394">596,365</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aa6d947913f4a7d8075467238402e4b_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfNC0xMS0xLTEtNzkyODM_4ba26c5b-3f81-4f0c-8e55-38b382bd3aca">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfNC0xMy0xLTEtNzkyODM_10baf0dd-b564-4748-bc38-75ad28a60abb">434,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7baae8bf509c4eea871e58fce347a357_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfNS01LTEtMS03OTI4Mw_07d1fc78-03a1-43bf-a54f-92c41c472903">13,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfNS0xMy0xLTEtNzkyODM_60b83f53-61f4-47b6-89cb-68314d2a4652">13,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaab72f9bd1f4b3497c269553c88fda8_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfNi03LTEtMS03OTI4Mw_99a4f9fe-1748-417e-a5ad-4bac3ae19a4b">797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfNi0xMy0xLTEtNzkyODM_3eb9ed1d-3bca-40cc-89cc-e6b3f461cf12">797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with restricted stock unit vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia44df45deeac4a16be141cf7af1287d1_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfOC0xLTEtMS03OTI4Mw_e425aace-a9de-403e-9802-4aaefa0ac2b3">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia44df45deeac4a16be141cf7af1287d1_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTEtMS0xLTEtNzkyODM_924abd44-14b0-4486-938b-fb858b7942d6">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7baae8bf509c4eea871e58fce347a357_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTEtNS0xLTEtNzkyODM_fabca4c1-77aa-4961-84dd-23944b6e8c9d">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTEtMTMtMS0xLTc5Mjgz_f7d6adad-51b7-4acb-b92a-09718c898f8e">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia44df45deeac4a16be141cf7af1287d1_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTItMS0xLTEtNzkyODM_c1aa915c-1a2c-4aec-bb68-a058df52d6ba">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i395ba3df136f49c6a25790e6923789ec_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTMtMTEtMS0xLTc5Mjgz_8b66afc3-4bbe-4d8c-96c7-6ff7b3506f30">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTMtMTMtMS0xLTc5Mjgz_a978ddb8-983a-46b8-a752-09202386acef">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to Zentalis </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ea4061b88a64ee98000673bd1783d8b_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTQtOS0xLTEtNzkyODM_4e388cdb-860a-4842-83c4-e9fd97639ca7">63,219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTQtMTMtMS0xLTc5Mjgz_44d94728-6711-4195-b0d5-f50bc9148f17">63,219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2e8bcaca2ae474db63161b8e88a7c52_I20230331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTUtMS0xLTEtNzkyODM_55f0f574-e3d2-4737-896a-08d83fe21231">59,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e8bcaca2ae474db63161b8e88a7c52_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTUtMy0xLTEtNzkyODM_f8336319-5d21-4a80-bf3c-dc78052098b5">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i610df3d7d3254dbeab79d57a582a4636_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTUtNS0xLTEtNzkyODM_bdeb32f8-bbbd-420d-8bbd-6601416b81f1">1,045,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iace7d762ee1c45ad98a341537427e32e_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTUtNy0xLTEtNzkyODM_cc634b58-c8d0-4e3d-903b-4ae300ddd9fb">556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94f3732fa0324bb6bf7f1984084ff4ef_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTUtOS0xLTEtNzkyODM_458075c6-549c-4655-8897-c473f8e5d821">659,584</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa0fa90a552e423ba8d1643810caf083_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTUtMTEtMS0xLTc5Mjgz_0ab70a97-94fa-4017-b623-777921694844">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTUtMTMtMS0xLTc5Mjgz_52cf2e37-36e4-4f4b-be0a-b392bfadcd43">385,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.171%"><tr><td style="width:1.0%"></td><td style="width:33.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Noncontrolling</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Interests</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fd115a5bb984e3b9b063c8e4aa9ff7a_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfNC0xLTEtMS03OTI4Mw_56cbae90-dcca-4fe1-8833-299c633d2a6f">45,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd115a5bb984e3b9b063c8e4aa9ff7a_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfNC0zLTEtMS03OTI4Mw_00a067c7-9f74-41a9-856d-1b3849a9176e">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i695f99adc41f4c8999aa3b6012882f02_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfNC01LTEtMS03OTI4Mw_39971fc7-e6f5-4141-91f2-0351ded7a237">723,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9fbed8715344dabb36930b6006326a2_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfNC03LTEtMS03OTI4Mw_473ae60d-97c9-4fd9-8a1e-71f1da8385a9">125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id75a0e799fe54633ad1d1d401d14de96_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfNC05LTEtMS03OTI4Mw_ca20dc01-75b9-4a8c-8d6a-d60b1114d8d2">359,559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafaecb2d14b0479c99a524aaae490852_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfNC0xMS0xLTEtNzkyODM_2322e555-bf12-4e99-a208-d7111050f154">528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i952b505edf2c4ed8969edcd9dd637d0b_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfNC0xMy0xLTEtNzkyODM_d4df9dd2-e01e-4075-ab69-6645ddc76d2f">364,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64968b563eff48948e2e24b37867c00a_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfNS01LTEtMS03OTI4Mw_6c5064d2-db51-40ba-a157-692b53998e3b">10,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfNS0xMy0xLTEtNzkyODM_83b1aa8b-1522-473d-9545-477f91794098">10,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic40194aeff86496eb4c5f12057c31115_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfNi03LTEtMS03OTI4Mw_0921d9fc-1ca3-49c4-a7d0-57ebaff1d4bf">984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfNi0xMy0xLTEtNzkyODM_2e700c47-cbe1-4be3-a506-c6a3457b750a">984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with restricted stock unit vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47afaacc781e4b58940615c4b23bc5c2_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfOC0xLTEtMS03OTI4Mw_77574df5-7280-416f-a1ff-bfc8aabdea61">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47afaacc781e4b58940615c4b23bc5c2_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfOC0zLTEtMS03OTI4Mw_4d865278-b9bd-4678-9e26-ee2ae34cd635">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfOC0xMy0xLTEtNzkyODM_6e6945bd-2690-46a1-b39c-27cdd2508b0c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47afaacc781e4b58940615c4b23bc5c2_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTAtMS0xLTEtNzkyODM_16a79b6b-212c-426e-9be7-aaaf13017ecb">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64968b563eff48948e2e24b37867c00a_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTAtNS0xLTEtNzkyODM_0e378538-185f-430c-a992-565ea75cd4a2">645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTAtMTMtMS0xLTc5Mjgz_7ff9286b-26d9-4460-a861-a0eacf12a18b">645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47afaacc781e4b58940615c4b23bc5c2_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTEtMS0xLTEtNzkyODM_7dbd1d9c-0874-4a34-a03c-838f4a7a1e2a">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64968b563eff48948e2e24b37867c00a_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTEtNS0xLTEtNzkyODM_3f5770b9-121f-42e6-b06b-2b8fc72e35e5">612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTEtMTMtMS0xLTc5Mjgz_2583c7bf-7d88-4ee9-8391-32fbb3e80a63">612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i47afaacc781e4b58940615c4b23bc5c2_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTItMS0xLTEtNzkyODM_9bbe8b8f-58a3-428b-b888-38e291713f08">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i545b3742a8c44d08a0306fb64b39b848_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTMtMTEtMS0xLTc5Mjgz_09357836-f464-4723-b7d1-96d2cf6f9710">160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTMtMTMtMS0xLTc5Mjgz_bbaf6594-dd81-4ec1-9ec6-5759238eefb9">160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to Zentalis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1bb99470d90047cd99a51fc8bee670ee_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTQtOS0xLTEtNzkyODM_6d15ec12-bc4b-4105-bf09-64999b6cf96b">59,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTQtMTMtMS0xLTc5Mjgz_0500ee43-464f-4fca-9c64-1acee3b83a64">59,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9d78fa526224fafa319798fa29dbe0c_I20220331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTUtMS0xLTEtNzkyODM_ffe744ff-248e-467c-9a04-c18ecd44e970">45,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9d78fa526224fafa319798fa29dbe0c_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTUtMy0xLTEtNzkyODM_17105041-ec67-4209-8008-7d98b77325ea">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c97f79d62ab413ba0fa4b3ab5ea6198_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTUtNS0xLTEtNzkyODM_83bc8d4f-f5ee-484d-9def-849d4ee1f47c">734,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cbaa2e908e04b1f879853beb7b39556_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTUtNy0xLTEtNzkyODM_364d15dd-066a-4657-8699-f9465567e9eb">1,109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8e9a378813b4bcc9f882c0a7318ebe1_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTUtOS0xLTEtNzkyODM_1c962946-db9b-45bc-85f1-9937cbcfda4e">418,636</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic86274b750794080aa0a3b9b4a40044d_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTUtMTEtMS0xLTc5Mjgz_1a849401-985b-448e-88a3-1dccde6ce2df">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94cbb15018ea46098ad9249cb81ecbd5_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTUtMTMtMS0xLTc5Mjgz_dcaf2200-842a-47ea-8a9b-15557415f216">315,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:0pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="iede2e4c8548c40d4910b7a838a08d814_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="iede2e4c8548c40d4910b7a838a08d814_40"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80MC9mcmFnOjQ5ZTZjMjIwMDQzMTQ3ZGE4M2ViMjdkMDIwMzMyODRjL3RleHRyZWdpb246NDllNmMyMjAwNDMxNDdkYTgzZWIyN2QwMjAzMzI4NGNfMTEwNQ_97ecf856-31e0-4b0f-8357-41fdc1e43888" continuedAt="ie82530be0a684da3814d5b2a99fef7a6" escape="true">Organization and Business</ix:nonNumeric></span></div><ix:continuation id="ie82530be0a684da3814d5b2a99fef7a6" continuedAt="i6b338a912a3e4cf0a9e197f752118380"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zentalis Pharmaceuticals, Inc. (&#8220;Zentalis&#8221;, &#8220;We&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancer. The Company is developing a focused pipeline of potentially best-in-class oncology candidates. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. All of the Company&#8217;s tangible assets are held in the United States.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div></ix:continuation><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6b338a912a3e4cf0a9e197f752118380">Substantial doubt about an entity&#8217;s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year from the financial statement issuance date. The Company determined that there are no conditions or events that raise substantial doubt about its ability to continue as a going concern within one year after the date that the interim unaudited condensed consolidated financial statements for the quarter ended March&#160;31, 2023 are issued.</ix:continuation> </span></div><div id="iede2e4c8548c40d4910b7a838a08d814_43"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80My9mcmFnOjAzNjU0ZmMwYjVhYjRkZGJiMWExYjg5NmEzNTIwMTUwL3RleHRyZWdpb246MDM2NTRmYzBiNWFiNGRkYmIxYTFiODk2YTM1MjAxNTBfNDAzNw_d8505ae3-8678-4a56-b948-768369f722a3" continuedAt="i3f105845937c4a1cb6761d48686c42a4" escape="true">Interim Unaudited Financial Statements </ix:nonNumeric></span></div><ix:continuation id="i3f105845937c4a1cb6761d48686c42a4" continuedAt="ib545628874a44a2ea37153483772b93f"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80My9mcmFnOjAzNjU0ZmMwYjVhYjRkZGJiMWExYjg5NmEzNTIwMTUwL3RleHRyZWdpb246MDM2NTRmYzBiNWFiNGRkYmIxYTFiODk2YTM1MjAxNTBfNDAzOA_d7564d15-f0d8-489a-bc10-fd2af0f94095" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form 10-Q. The year-end condensed consolidated balance sheet data was derived from the Company&#8217;s audited financial statements but do not include all disclosures required by U.S. GAAP. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on March 1, 2023. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operation for the periods presented, with such adjustments consisting only of normal recurring adjustments. Certain reclassifications have been made to the prior period condensed consolidated balance sheet to conform to the current period presentation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80My9mcmFnOjAzNjU0ZmMwYjVhYjRkZGJiMWExYjg5NmEzNTIwMTUwL3RleHRyZWdpb246MDM2NTRmYzBiNWFiNGRkYmIxYTFiODk2YTM1MjAxNTBfNDA0MA_2b0d29dc-f87a-4ed4-80f0-dab9bf415764" continuedAt="ibab7f756fa7d4e3aac9453c851da8f97" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements include our wholly-owned subsidiaries and variable interest entity (&#8220;VIE&#8221;), for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether we are the primary beneficiary of the VIE. In determining whether we are the primary beneficiary of a VIE and therefore required to consolidate the VIE, we apply a qualitative approach that determines whether we have both (1)&#160;the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2)&#160;the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continuously assess whether we are the primary beneficiary of a VIE, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of such VIE. During the </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="ib545628874a44a2ea37153483772b93f"><ix:continuation id="ibab7f756fa7d4e3aac9453c851da8f97"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periods presented, we have not provided any other material financial or other support to our VIEs that we were not contractually required to provide.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The equity method is used to account for investments in which we have the ability to exercise significant influence, but not control, over the investee. Such investments are recorded on the balance sheet, and the share of net income or losses of equity investments is recognized on a one quarter lag in investment and other income (expense), net.</span></div></ix:continuation><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80My9mcmFnOjAzNjU0ZmMwYjVhYjRkZGJiMWExYjg5NmEzNTIwMTUwL3RleHRyZWdpb246MDM2NTRmYzBiNWFiNGRkYmIxYTFiODk2YTM1MjAxNTBfNDAzNA_e248ab14-dff7-4cde-ae38-32c76668aa05" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#8217;s estimates.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.</span></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, there have been no changes to the Company&#8217;s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December 31, 2022.</span></div></ix:continuation><div id="iede2e4c8548c40d4910b7a838a08d814_46"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80Ni9mcmFnOjk4ODg0OWNkYWYyNjQxMzFhNzFmNTAxNzk3OTdjZTZmL3RleHRyZWdpb246OTg4ODQ5Y2RhZjI2NDEzMWE3MWY1MDE3OTc5N2NlNmZfNDQ2OA_0b5ff854-002d-47af-bf02-33101018ff6a" continuedAt="i40cc2e95cb1940f5a499e7c92464736a" escape="true">Significant Transactions</ix:nonNumeric></span></div><ix:continuation id="i40cc2e95cb1940f5a499e7c92464736a" continuedAt="i12664f6b5e764d539f8b3358a7363636"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zentera Therapeutics</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we became a majority common shareholder of Zentera Therapeutics, a Shanghai-based clinical-stage biopharmaceutical company focused on developing cancer therapeutics (&#8220;Zentera&#8221;), concurrent with its Series A convertible preferred stock offering. The financial position and results of operations of Zentera were included in our consolidated financial statements from the date of the initial investment as a result of our control of the entity and our determination that we were the primary beneficiary of Zentera. In July 2021, Zentera completed a Series B convertible preferred stock offering which diluted our investment to a position of less than majority owned. Upon review of the facts and circumstances, together with the authoritative accounting literature, we determined that while Zentera is a VIE, consolidation of Zentera is no longer appropriate. After the July 2021 Series B convertible preferred offering in which we did not participate, our review concluded that we ceased to be the primary beneficiary of Zentera as our equity ownership was reduced and changes were made to the corporate governance of Zentera. As a result, we no longer individually have the ability to direct the activities that most significantly impact Zentera's economic performance. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in July 2021, the financial position and results of operations of Zentera were no longer included in our consolidated financial statements. During the period of deconsolidation we measured the fair value of our retained investment in Zentera using the backsolve method with consideration for a lack of marketability. An equity method investment of $<ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-5" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80Ni9mcmFnOjk4ODg0OWNkYWYyNjQxMzFhNzFmNTAxNzk3OTdjZTZmL3RleHRyZWdpb246OTg4ODQ5Y2RhZjI2NDEzMWE3MWY1MDE3OTc5N2NlNmZfMTcwMQ_ab43214d-f510-4777-b86c-6b68877c9ba7">18.9</ix:nonFraction> million is recorded on our balance sheet at March&#160;31, 2023. This amount represents our maximum exposure to loss as a result of our involvement with Zentera. A deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="i4df1e7317eb24fb4960e2db40e43b0ae_I20230331" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80Ni9mcmFnOjk4ODg0OWNkYWYyNjQxMzFhNzFmNTAxNzk3OTdjZTZmL3RleHRyZWdpb246OTg4ODQ5Y2RhZjI2NDEzMWE3MWY1MDE3OTc5N2NlNmZfMTg3Nw_444f0a57-f405-41c4-abb9-cf7ae3736360">4.0</ix:nonFraction> million representing the tax impact of the unrealized gain on deconsolidation is recorded on our balance sheet at March&#160;31, 2023. A gain of $<ix:nonFraction unitRef="usd" contextRef="if503536b265745f78bee8b2c10f7dd63_D20210101-20211231" decimals="-5" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80Ni9mcmFnOjk4ODg0OWNkYWYyNjQxMzFhNzFmNTAxNzk3OTdjZTZmL3RleHRyZWdpb246OTg4ODQ5Y2RhZjI2NDEzMWE3MWY1MDE3OTc5N2NlNmZfMjAwOA_11754f72-0bd5-40b3-9acc-eda6482ea516">51.6</ix:nonFraction>&#160;million, measured as the difference between the fair value of our retained noncontrolling interest together with the carrying amount of the Zentera noncontrolling interest, and the carrying amount of Zentera&#8217;s assets and liabilities was recognized during the year ended December 31, 2021. The difference between the carrying amount of our investment in Zentera and our portion of the Zentera net assets was $<ix:nonFraction unitRef="usd" contextRef="i4df1e7317eb24fb4960e2db40e43b0ae_I20230331" decimals="-5" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80Ni9mcmFnOjk4ODg0OWNkYWYyNjQxMzFhNzFmNTAxNzk3OTdjZTZmL3RleHRyZWdpb246OTg4ODQ5Y2RhZjI2NDEzMWE3MWY1MDE3OTc5N2NlNmZfMjQxMA_61af6e02-9c31-40ec-bb3a-c68addb89db3">5.5</ix:nonFraction> million as of </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="i12664f6b5e764d539f8b3358a7363636"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023. This difference is accounted for in our equity method investment analogous to in-process research and development. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2020, each of our subsidiaries Zeno Alpha, Inc., K-Group Alpha, Inc., and K-Group Beta, Inc. entered into a collaboration and royalty-bearing license agreement with Zentera, which we refer to as the &#8220;Zentera Sublicenses,&#8221; pursuant to which we collaborate with Zentera on the development and commercialization of ZN-c5, ZN-d5 and azenosertib, respectively, collectively referred to as the &#8220;Collaboration Products,&#8221; respectively, in the People&#8217;s Republic of China, Macau, Hong Kong and Taiwan, which is referred to as the &#8220;Zentera Collaboration Territory.&#8221; Under each Zentera Sublicense, Zentera will lead development, and upon regulatory approval, the commercialization, of the Collaboration Products in the Zentera Collaboration Territory.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Zentera Sublicenses, Zentera is generally responsible for the costs of developing the Collaboration Products in the Zentera Collaboration Territory, and we are generally responsible for the costs of developing the Collaboration Products outside the Zentera Collaboration Territory, provided that Zentera will reimburse us for a portion of the costs for global data management, pharmacovigilance, safety database management, and chemistry, manufacturing and controls activities with respect to each Collaboration Product. Prior to the deconsolidation of Zentera in July 2021, these costs were eliminated in consolidation. For the three months ended March&#160;31, 2023 and 2022 the amounts incurred under this arrangement totaled $<ix:nonFraction unitRef="usd" contextRef="i7c81d5274f084d8ca588db925f2f294d_D20230101-20230331" decimals="-5" name="zntl:ResearchAndDevelopmentExpenseReimbursements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80Ni9mcmFnOjk4ODg0OWNkYWYyNjQxMzFhNzFmNTAxNzk3OTdjZTZmL3RleHRyZWdpb246OTg4ODQ5Y2RhZjI2NDEzMWE3MWY1MDE3OTc5N2NlNmZfNDAwNw_d5423e18-5f8d-4317-913a-42dc00fdc021">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4a32b2ade07d41f4b1cad2d93ca61367_D20220101-20220331" decimals="-5" name="zntl:ResearchAndDevelopmentExpenseReimbursements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80Ni9mcmFnOjk4ODg0OWNkYWYyNjQxMzFhNzFmNTAxNzk3OTdjZTZmL3RleHRyZWdpb246OTg4ODQ5Y2RhZjI2NDEzMWE3MWY1MDE3OTc5N2NlNmZfNDAyMg_e1d15803-d254-48de-8099-646e34cf6cb1">2.1</ix:nonFraction> million, respectively, and are presented as contra-research and development expense in the unaudited condensed consolidated statement of operations. A corresponding receivable is recorded within prepaid expenses and other current assets on the unaudited condensed consolidated balance sheet. We have not provided material financial or other support to Zentera during the periods ended March&#160;31, 2023 and 2022 that was not  contractually required.</span></div></ix:continuation><div id="iede2e4c8548c40d4910b7a838a08d814_49"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80OS9mcmFnOjQ4OWNkNTA5ZWUyNjRjZGFhY2JjOWM3NTY3MWU0NzFjL3RleHRyZWdpb246NDg5Y2Q1MDllZTI2NGNkYWFjYmM5Yzc1NjcxZTQ3MWNfMTgyMg_2da7e2bf-fc3e-431c-b818-a09ed0bea8a9" continuedAt="i09e4a767031c45a88d740ba5b972cff7" escape="true">Business Combinations</ix:nonNumeric></span></div><ix:continuation id="i09e4a767031c45a88d740ba5b972cff7"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Kalyra Pharmaceuticals, Inc.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;21, 2017, we acquired $<ix:nonFraction unitRef="usd" contextRef="i4817ffa176c043dcaa4bcc0e640d9ac8_D20171221-20171221" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80OS9mcmFnOjQ4OWNkNTA5ZWUyNjRjZGFhY2JjOWM3NTY3MWU0NzFjL3RleHRyZWdpb246NDg5Y2Q1MDllZTI2NGNkYWFjYmM5Yzc1NjcxZTQ3MWNfOTQ_d9c8ef4b-e68a-4136-94d0-a141c127759a">4.5</ix:nonFraction>&#160;million of Kalyra Pharmaceuticals, Inc.&#8217;s (&#8220;Kalyra&#8221;) Series B Preferred Stock representing a <ix:nonFraction unitRef="number" contextRef="i9ff9bd8c8cc546c2bfa853ff3951cad7_I20171221" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80OS9mcmFnOjQ4OWNkNTA5ZWUyNjRjZGFhY2JjOWM3NTY3MWU0NzFjL3RleHRyZWdpb246NDg5Y2Q1MDllZTI2NGNkYWFjYmM5Yzc1NjcxZTQ3MWNfMTgy_a33c530d-6721-4d80-9389-1e59a4e37ee3">25</ix:nonFraction>% equity interest in Kalyra for purposes of entering the analgesics therapeutic research space. The acquisition price was paid entirely in cash.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the authoritative guidance, we concluded that Kalyra is a business consisting of inputs, employees, intellectual property and processes capable of producing outputs. Additionally, we have concluded that Kalyra is a VIE, we are the primary beneficiary and have the power to direct the activities that most significantly affect Kalyra&#8217;s economic performance through common management and our board representation. Prior to December 21, 2017, the Company and Kalyra transacted for the delivery of research and development services and support. The financial position and results of operations of Kalyra have been included in our consolidated financial statements from the date of the initial investment.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant with authoritative guidance, we have recorded the identifiable assets, liabilities and noncontrolling interests in the VIE at their fair value upon initial consolidation. The identified goodwill is comprised of the workforce and expected synergies from combining the entities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">otal assets and liabilities of Kalyra as of March&#160;31, 2023 and December&#160;31, 2022 are immaterial. The liabilities recognized as a result of consolidating Kalyra do not represent additional claims on our general assets. Pursuant to the authoritative guidance, the equity interest in Kalyra not owned by Zentalis is reported as a noncontrolling interest on our condensed consolidated balance sheets.</span></div><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="zntl:ReconciliationOfNoncontrollingInterestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80OS9mcmFnOjQ4OWNkNTA5ZWUyNjRjZGFhY2JjOWM3NTY3MWU0NzFjL3RleHRyZWdpb246NDg5Y2Q1MDllZTI2NGNkYWFjYmM5Yzc1NjcxZTQ3MWNfMTgyMw_3969a824-3217-49a0-aea8-9c6ee188126b" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of equity (net assets) attributable to the noncontrolling interest (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56332e226885432ebe62ee97b3aa1f96_I20221231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80OS9mcmFnOjQ4OWNkNTA5ZWUyNjRjZGFhY2JjOWM3NTY3MWU0NzFjL3RhYmxlOjBhZmU1YmVkOTRhYzQ0YzFhOTY3NDY2NzI2ZGM4M2VkL3RhYmxlcmFuZ2U6MGFmZTViZWQ5NGFjNDRjMWE5Njc0NjY3MjZkYzgzZWRfMi0xLTEtMS03OTI4Mw_9fcc66aa-7dfd-47d6-9b63-876de3055876">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e5d1442f22141d2ad21e2f741cecbe5_I20211231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80OS9mcmFnOjQ4OWNkNTA5ZWUyNjRjZGFhY2JjOWM3NTY3MWU0NzFjL3RhYmxlOjBhZmU1YmVkOTRhYzQ0YzFhOTY3NDY2NzI2ZGM4M2VkL3RhYmxlcmFuZ2U6MGFmZTViZWQ5NGFjNDRjMWE5Njc0NjY3MjZkYzgzZWRfMi0zLTEtMS03OTI4Mw_6c7b9aea-4508-4f19-b1b4-611589b909bd">528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6809bcb1666148168afab58d0ffe577e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80OS9mcmFnOjQ4OWNkNTA5ZWUyNjRjZGFhY2JjOWM3NTY3MWU0NzFjL3RhYmxlOjBhZmU1YmVkOTRhYzQ0YzFhOTY3NDY2NzI2ZGM4M2VkL3RhYmxlcmFuZ2U6MGFmZTViZWQ5NGFjNDRjMWE5Njc0NjY3MjZkYzgzZWRfMy0xLTEtMS03OTI4Mw_bc6d2def-8766-46bc-a3bb-083a89a89c4d">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d2a23e4bb2343d588f6a5d196d2a18b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80OS9mcmFnOjQ4OWNkNTA5ZWUyNjRjZGFhY2JjOWM3NTY3MWU0NzFjL3RhYmxlOjBhZmU1YmVkOTRhYzQ0YzFhOTY3NDY2NzI2ZGM4M2VkL3RhYmxlcmFuZ2U6MGFmZTViZWQ5NGFjNDRjMWE5Njc0NjY3MjZkYzgzZWRfMy0zLTEtMS03OTI4Mw_9f43f497-2d8f-4d8a-a7cf-2ee79bd8ed88">307</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d0e027780241b79c9c17cfcdd13982_I20230331" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80OS9mcmFnOjQ4OWNkNTA5ZWUyNjRjZGFhY2JjOWM3NTY3MWU0NzFjL3RhYmxlOjBhZmU1YmVkOTRhYzQ0YzFhOTY3NDY2NzI2ZGM4M2VkL3RhYmxlcmFuZ2U6MGFmZTViZWQ5NGFjNDRjMWE5Njc0NjY3MjZkYzgzZWRfNy0xLTEtMS03OTI4Mw_330ad2d4-476e-417a-b896-202db4f8c4f3">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56332e226885432ebe62ee97b3aa1f96_I20221231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80OS9mcmFnOjQ4OWNkNTA5ZWUyNjRjZGFhY2JjOWM3NTY3MWU0NzFjL3RhYmxlOjBhZmU1YmVkOTRhYzQ0YzFhOTY3NDY2NzI2ZGM4M2VkL3RhYmxlcmFuZ2U6MGFmZTViZWQ5NGFjNDRjMWE5Njc0NjY3MjZkYzgzZWRfNy0zLTEtMS03OTI4Mw_6337e674-a8d0-4b70-ae08-07b642b782e9">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="iede2e4c8548c40d4910b7a838a08d814_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RleHRyZWdpb246Y2EzYzFlNWI5YmVjNDQ2Nzg3M2I2YWUzNzZiNWRkNTZfMTQ4OQ_28613736-5f3f-4f0d-95a6-500e71dea77f" continuedAt="id0343435582c4c7d979e6cc3998ee191" escape="true">Fair Value Measurement</ix:nonNumeric></span></div><ix:continuation id="id0343435582c4c7d979e6cc3998ee191" continuedAt="ie63a7ccbecf545af8d7ff4279c3fefec"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RleHRyZWdpb246Y2EzYzFlNWI5YmVjNDQ2Nzg3M2I2YWUzNzZiNWRkNTZfMTQ5MA_2e154df2-a076-41c9-a0be-5b7a94c559b7" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2420fac1a84e158a6092ec05ed0417_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfMi0xLTEtMS03OTI4Mw_5b1a2008-7733-4f18-bce8-c8c38311bce6">281,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2420fac1a84e158a6092ec05ed0417_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfMi0zLTEtMS03OTI4Mw_cfe95026-93c4-466a-936c-9e7afc319748">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c2420fac1a84e158a6092ec05ed0417_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfMi01LTEtMS03OTI4Mw_26665c8a-f168-45fb-aaec-8a67acf2c9e0">286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2420fac1a84e158a6092ec05ed0417_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfMi03LTEtMS03OTI4Mw_1992e56b-4269-4bc5-bff5-53cce83ed1ca">281,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fdc062e1b6242f3bfa7722f537c5cc0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfMy0xLTEtMS03OTI4Mw_15717981-fb97-41cd-a63c-3ea8bf78bdc3">2,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fdc062e1b6242f3bfa7722f537c5cc0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfMy0zLTEtMS03OTI4Mw_32de54f8-a398-4757-a6e2-4a5cd6f0051a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fdc062e1b6242f3bfa7722f537c5cc0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfMy01LTEtMS03OTI4Mw_94d776f3-3540-4b43-913b-c4208feeccc8">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fdc062e1b6242f3bfa7722f537c5cc0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfMy03LTEtMS03OTI4Mw_ab2004c3-da8d-4e11-b83a-1d5ee4f587fb">2,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Government Agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i410ff4f16a8040efb58e3e8e477cb639_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNC0xLTEtMS03OTI4Mw_885d9942-5d9f-40cf-b0fb-cc6a506aa511">21,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i410ff4f16a8040efb58e3e8e477cb639_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNC0zLTEtMS03OTI4Mw_f3a06828-037a-4b9f-a903-6dd6c57e26c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i410ff4f16a8040efb58e3e8e477cb639_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNC01LTEtMS03OTI4Mw_4d7c7204-5e36-406a-b85d-d18c6b0d5120">98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i410ff4f16a8040efb58e3e8e477cb639_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNC03LTEtMS03OTI4Mw_d1f3733b-e627-4cbf-be1c-4ff1141dd3b1">21,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84739e60c7164232abd1054fd4938e36_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNS0xLTEtMS03OTI4Mw_2ede1de8-ea5b-46f3-8949-51710200b5eb">50,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84739e60c7164232abd1054fd4938e36_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNS0zLTEtMS03OTI4Mw_0830cfce-720b-49eb-94bb-74eeb5ca1172">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84739e60c7164232abd1054fd4938e36_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNS01LTEtMS03OTI4Mw_ba07f945-51b6-41a5-91a1-092da474262f">223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84739e60c7164232abd1054fd4938e36_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNS03LTEtMS03OTI4Mw_94b23a39-37ea-4d0f-9c45-d11816513f31">50,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNi0xLTEtMS03OTI4Mw_9758828c-4776-4423-9020-8ede31ebd1b0">356,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNi0zLTEtMS03OTI4Mw_fd5a1c11-60ce-41ee-91b5-5e7655683860">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNi01LTEtMS03OTI4Mw_723db981-8222-4d5a-9494-63978fa9f919">613</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNi03LTEtMS03OTI4Mw_eb37ae47-2f7f-4013-8f77-4ac12400ab4a">356,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcb530524114c769687f7c9f1fb749a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfMi0xLTEtMS03OTI4Mw_e410de22-bc21-4823-b0cb-0fc35d7c37bd">296,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcb530524114c769687f7c9f1fb749a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfMi0zLTEtMS03OTI4Mw_8d3dee48-a3de-4d84-a469-7d77576cb4b2">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcb530524114c769687f7c9f1fb749a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfMi01LTEtMS03OTI4Mw_034e5cd9-9eab-4c29-87af-958f8f65ba55">587</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcb530524114c769687f7c9f1fb749a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfMi03LTEtMS03OTI4Mw_054a1686-e9a9-4a83-9fca-49e1a2d92fa9">295,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5fcea6723664d4697c80360ebeed61d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfMy0xLTEtMS03OTI4Mw_6b2ac4ca-4733-4b98-bcb7-2948c9547555">7,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5fcea6723664d4697c80360ebeed61d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfMy0zLTEtMS03OTI4Mw_ccc1e2de-a2d8-4844-8772-acfc49973a1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5fcea6723664d4697c80360ebeed61d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfMy01LTEtMS03OTI4Mw_1f672ffc-c5ba-4a59-98e0-29872de4d9ff">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5fcea6723664d4697c80360ebeed61d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfMy03LTEtMS03OTI4Mw_eb031c48-8a18-471c-8347-35a30e45bad1">7,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Government Agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b64d6100e743e984f7d8b3995bd09b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNC0xLTEtMS03OTI4Mw_03699d88-daf4-4eb2-b50f-66f94e1c13a6">23,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b64d6100e743e984f7d8b3995bd09b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNC0zLTEtMS03OTI4Mw_457aad71-3a20-404b-9798-beb3d55b4ec1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1b64d6100e743e984f7d8b3995bd09b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNC01LTEtMS03OTI4Mw_4d02dc14-4614-4984-8a2f-49f6177c70c2">182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b64d6100e743e984f7d8b3995bd09b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNC03LTEtMS03OTI4Mw_97f30cc8-b83d-417c-b678-fb935f46ed32">23,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32d2e7ccd63b4e078ab5c066f13b44d2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNS0xLTEtMS03OTI4Mw_3590c5ab-d0df-4b85-bce4-b5a4d7f56c65">67,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32d2e7ccd63b4e078ab5c066f13b44d2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNS0zLTEtMS03OTI4Mw_37d46b1e-a5f7-452e-8328-96553a189b8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32d2e7ccd63b4e078ab5c066f13b44d2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNS01LTEtMS03OTI4Mw_243e3977-6bcb-488d-b131-1cb497bf1319">629</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32d2e7ccd63b4e078ab5c066f13b44d2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNS03LTEtMS03OTI4Mw_cfe24660-0062-401a-8d06-60c486a83f63">67,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNi0xLTEtMS03OTI4Mw_67a98d4c-65ec-4a29-8d34-67dec37f0c49">395,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNi0zLTEtMS03OTI4Mw_bbf22ed9-b73e-4610-b58d-2ea222b54f48">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNi01LTEtMS03OTI4Mw_d8876da2-2a6c-41e2-9b7b-de860ad74f42">1,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNi03LTEtMS03OTI4Mw_4efc4a37-958a-4a2a-b1e0-f598502a7081">394,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="security" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RleHRyZWdpb246Y2EzYzFlNWI5YmVjNDQ2Nzg3M2I2YWUzNzZiNWRkNTZfMTI5_5cdda0d7-ed94-49c1-ad43-eb52ba6b9076">fifty</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of our available-for-sale debt securities with a fair market value of $<ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-5" name="us-gaap:TradingSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RleHRyZWdpb246Y2EzYzFlNWI5YmVjNDQ2Nzg3M2I2YWUzNzZiNWRkNTZfMjAy_92547de4-1c2e-4577-bdfa-ec1faff295c2">268.0</ix:nonFraction> million were in a gross unrealized loss position of $<ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RleHRyZWdpb246Y2EzYzFlNWI5YmVjNDQ2Nzg3M2I2YWUzNzZiNWRkNTZfMjU3_19c72843-fcea-4ed0-9ef2-5f0d783f228d">0.6</ix:nonFraction> million. Of those, <ix:nonFraction unitRef="security" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RleHRyZWdpb246Y2EzYzFlNWI5YmVjNDQ2Nzg3M2I2YWUzNzZiNWRkNTZfNTQ5NzU1ODE1NDA3_9493596e-5017-4dc4-a4d1-75d95b26c2cc">forty-seven</ix:nonFraction> have been in a gross unrealized loss position of $<ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RleHRyZWdpb246Y2EzYzFlNWI5YmVjNDQ2Nzg3M2I2YWUzNzZiNWRkNTZfNTQ5NzU1ODE1NTky_4ee18ea9-6347-41de-999a-6dcc92afd4f6">0.5</ix:nonFraction> million for less than one year and <ix:nonFraction unitRef="security" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RleHRyZWdpb246Y2EzYzFlNWI5YmVjNDQ2Nzg3M2I2YWUzNzZiNWRkNTZfNTQ5NzU1ODE1NjQ0_cb4a71ab-ae36-419b-b223-af141b9b0c33">three</ix:nonFraction> have been in a gross unrealized loss position of $<ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RleHRyZWdpb246Y2EzYzFlNWI5YmVjNDQ2Nzg3M2I2YWUzNzZiNWRkNTZfNTQ5NzU1ODE1NzAx_c004b869-8637-4cc3-af55-3b2a9695c006">0.1</ix:nonFraction> million for more than one year. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">When evaluating an investment for impairment, we review factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, our intent to sell or the likelihood that we would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. Based on our review of these marketable securities, we believe none of the unrealized loss is as a result of a credit loss as of March&#160;31, 2023, because we do not intend to sell these securities, and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis. </span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RleHRyZWdpb246Y2EzYzFlNWI5YmVjNDQ2Nzg3M2I2YWUzNzZiNWRkNTZfMTQ5MQ_d0247bb4-b4f2-408e-942b-eaed22f8ab3e" continuedAt="i2dd53975859f440d89edafa83d973f5d" escape="true">Contractual maturities of available-for-sale debt securities are as follows (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="ie63a7ccbecf545af8d7ff4279c3fefec"><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><ix:continuation id="i2dd53975859f440d89edafa83d973f5d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.044%"><tr><td style="width:1.0%"></td><td style="width:51.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.362%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.256%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOjg5YzQzYmMyOWM0NTQzYWZhNWNlNDQ5MDQxN2FmYmM1L3RhYmxlcmFuZ2U6ODljNDNiYzI5YzQ1NDNhZmE1Y2U0NDkwNDE3YWZiYzVfMy0xLTEtMS03OTI4Mw_468aa8d0-7fe9-47ac-9773-05c9bd641d25">356,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOjg5YzQzYmMyOWM0NTQzYWZhNWNlNDQ5MDQxN2FmYmM1L3RhYmxlcmFuZ2U6ODljNDNiYzI5YzQ1NDNhZmE1Y2U0NDkwNDE3YWZiYzVfMy0zLTEtMS03OTI4Mw_5ee7a157-20bd-43e6-a9b0-17a49dc7d332">394,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOjg5YzQzYmMyOWM0NTQzYWZhNWNlNDQ5MDQxN2FmYmM1L3RhYmxlcmFuZ2U6ODljNDNiYzI5YzQ1NDNhZmE1Y2U0NDkwNDE3YWZiYzVfNS0xLTEtMS03OTI4Mw_17005b6e-ce42-4cfe-9c85-88ed8f4cac74">356,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOjg5YzQzYmMyOWM0NTQzYWZhNWNlNDQ5MDQxN2FmYmM1L3RhYmxlcmFuZ2U6ODljNDNiYzI5YzQ1NDNhZmE1Y2U0NDkwNDE3YWZiYzVfNS0zLTEtMS03OTI4Mw_0f599769-f9e0-4443-9dc5-858a6ecb151d">394,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RleHRyZWdpb246Y2EzYzFlNWI5YmVjNDQ2Nzg3M2I2YWUzNzZiNWRkNTZfMTQ5Mg_4f74949f-d940-413b-bff2-f8e43cae35d9" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:19.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.357%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.247%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total estimated fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49f1fa2e5d5d4f479e5668a21e82148b_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMy0xLTEtMS03OTI4Mw_b3296add-cede-4826-9272-062dacaa965d">33,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia30f21df13f94f9ebd972a8a09ca6fac_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMy0zLTEtMS03OTI4Mw_d3d9d2af-d028-4ff1-984b-e373d478f75e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf38ee1491e140b8adacc29d8bb9760f_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMy01LTEtMS03OTI4Mw_dff07e7a-d379-4e3f-b26b-deba13987a10">33,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f300d2e9d948a683e65b0cdc3aa411_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMy03LTEtMS03OTI4Mw_580f5af1-f9bd-4c2a-8990-60af9300dff5">26,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i380c135ffd6844f7997d78a2b67138ec_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMy05LTEtMS03OTI4Mw_af560f7e-c700-4d70-84f2-2e1c0e72bdfd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48ff0df351ef40fe8a05cd86f1008d36_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMy0xMS0xLTEtNzkyODM_be628eef-1fa3-4248-9d39-0556acbd32d3">26,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101ae399b06242f49e876e6d8e25a264_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNC0xLTEtMS03OTI4Mw_327b2c23-7140-4835-8cdf-bc54bedb3f88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6f54b010c64504bbd0705c0ac17af0_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNC0zLTEtMS03OTI4Mw_83f22675-4dea-4671-8d75-13b6fc0e9185">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd6ec7e59ffb4b9eb4453d5218e35173_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNC01LTEtMS03OTI4Mw_2c6355bf-7ec2-4985-9bda-8093448ed318">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9c408849fc84006b3a025992352774f_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNC03LTEtMS03OTI4Mw_0ef27e77-1767-4ebd-a757-1632a6eee85c">1,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3150edba5268450db0756b69a3a1addf_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNC05LTEtMS03OTI4Mw_c74cef7a-eae5-43a9-9cec-9ae6191e935c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d89135319bc455fa6a091097227fc6e_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNC0xMS0xLTEtNzkyODM_92619e13-791d-4e20-9853-a22ad6dc64db">1,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents:</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i512ef6b869c04c8a878f93105c57c41a_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNS0xLTEtMS03OTI4Mw_b7be0205-00d2-45ca-acec-21c1d014168f">33,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i598f17c497e545c58b325723fdc76f66_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNS0zLTEtMS03OTI4Mw_e6af028b-02e8-4d30-8c77-5b8abef1316d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNS01LTEtMS03OTI4Mw_56320b14-616b-406a-8e17-5599e8fb811a">33,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a8b179af364abb8287fabef06e5efe_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNS03LTEtMS03OTI4Mw_6a7ada94-0761-4959-9eed-02f656c374e2">28,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i617ebbcc5095463d8013bb0f56fc9a65_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNS05LTEtMS03OTI4Mw_6b333428-1d3c-41f7-98cf-a1fd2518de52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNS0xMS0xLTEtNzkyODM_91edd335-2d40-470e-8af2-04020dd6667d">28,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0843a9ee0f4743b7b17b8de5c7778791_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOC0xLTEtMS03OTI4Mw_9aa1bbea-f666-4cd3-a46d-b90123a9ce10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc356695ac24c8cb111a3afaaa7ff8c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOC0zLTEtMS03OTI4Mw_4d94574f-4306-41f1-9b04-941d76461886">281,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2420fac1a84e158a6092ec05ed0417_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOC01LTEtMS03OTI4Mw_54d0b36b-f34f-44de-a1ec-827d052b57ed">281,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b730087c46740158ea57877aa0ae9a6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOC03LTEtMS03OTI4Mw_bb33b158-5e44-42ae-b531-15a5395d403a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4459dcf3fc2c4ce79822c49134d753a4_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOC05LTEtMS03OTI4Mw_4f68762d-aa53-4f30-a904-8d6d695650eb">295,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcb530524114c769687f7c9f1fb749a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOC0xMS0xLTEtNzkyODM_f67e1eba-8dbc-4861-8d92-2c6b8dd7d5cf">295,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcf1f1860f224f7783c2b7814b873ab3_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOS0xLTEtMS03OTI4Mw_313f65f4-7067-4109-a753-cf7cfc375b38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i128d0fd7cbbf49d2b23f8f6ed5e8b638_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOS0zLTEtMS03OTI4Mw_615c0ad5-a999-4ca8-8279-cb51221be98d">2,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fdc062e1b6242f3bfa7722f537c5cc0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOS01LTEtMS03OTI4Mw_4af91fc7-f07e-47d0-9149-ea0e86995316">2,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica67869b706548afa466add7912fddd6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOS03LTEtMS03OTI4Mw_83d7b7b8-32d4-40f9-b5d0-7b631be7da7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c53bb5c6ef84b26a856ac6cf9e2e408_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOS05LTEtMS03OTI4Mw_aa8e0ecf-42dd-491c-bf17-e710aa6665e8">7,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5fcea6723664d4697c80360ebeed61d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOS0xMS0xLTEtNzkyODM_f2d64856-ae0d-44ea-a410-c3bf81e0398c">7,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Government Agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b44713e1e994101839f64aec91e45b1_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTAtMS0xLTEtNzkyODM_2e40a1b2-393f-49c2-bcd1-c8cf5cbacb2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5c6ab2386b6421d83ee4eb9753b73cd_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTAtMy0xLTEtNzkyODM_ad11ddcb-117e-4278-b909-a16fb3199f26">21,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i410ff4f16a8040efb58e3e8e477cb639_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTAtNS0xLTEtNzkyODM_62dd8ba5-1090-473f-a3e3-afea6151c52a">21,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94ff901c1e7144e985fe76366d30065a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTAtNy0xLTEtNzkyODM_df133759-7031-4ca1-9986-4b5494a55ffb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3727eb6a2b984c7ca52fc3f51b6afa97_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTAtOS0xLTEtNzkyODM_1549cde1-5229-4b8c-b267-0d4b7b65d9d3">23,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b64d6100e743e984f7d8b3995bd09b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTAtMTEtMS0xLTc5Mjgz_32226697-5988-44c3-9494-2e220924d669">23,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e83e26bd72349338171ae705edbe7f0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTEtMS0xLTEtNzkyODM_43b754f0-9c4d-45ed-b296-64627716a36d">50,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a2cf14e1f2448cdbc8fb71792150777_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTEtMy0xLTEtNzkyODM_efae90c5-7099-4f65-81e3-7399388d732b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84739e60c7164232abd1054fd4938e36_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTEtNS0xLTEtNzkyODM_99501b05-888e-40d5-b19d-ab498e7773bd">50,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadaa692c5c72427cbb64934ad0fa3730_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTEtNy0xLTEtNzkyODM_3765ed08-72ef-4550-824b-82f1b9b08571">67,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a695ef0eca441ed8cac49e237e173fa_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTEtOS0xLTEtNzkyODM_f5489a32-5272-4c45-9844-3e1bd7b65ceb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32d2e7ccd63b4e078ab5c066f13b44d2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTEtMTEtMS0xLTc5Mjgz_96c76449-eacb-429b-95e7-001040023731">67,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale marketable securities:</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i512ef6b869c04c8a878f93105c57c41a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTItMS0xLTEtNzkyODM_f54d0061-2404-4385-92b0-34f2fb3bffdf">50,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i598f17c497e545c58b325723fdc76f66_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTItMy0xLTEtNzkyODM_102f47e4-eba1-43b9-b37c-3104bdc764ba">305,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTItNS0xLTEtNzkyODM_428660e7-a3e4-4323-afac-c5eea3676a31">356,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a8b179af364abb8287fabef06e5efe_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTItNy0xLTEtNzkyODM_3775a31c-b8e5-44c6-84a6-c14a1129fcae">67,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i617ebbcc5095463d8013bb0f56fc9a65_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTItOS0xLTEtNzkyODM_3742de71-4044-4b4c-9532-31678ce2e0db">327,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTItMTEtMS0xLTc5Mjgz_90bb2153-ff1e-44b4-b356-4b585a7b9907">394,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value<br/></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i512ef6b869c04c8a878f93105c57c41a_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTQtMS0xLTEtNzkyODM_93ee0831-d48b-49c9-a833-7252f411d6e7">84,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i598f17c497e545c58b325723fdc76f66_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTQtMy0xLTEtNzkyODM_ffd6c77a-f85e-4d48-a910-cf93a3cb9807">305,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTQtNS0xLTEtNzkyODM_9048acd0-195d-49ef-b1d6-0f67b7cde8b7">389,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a8b179af364abb8287fabef06e5efe_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTQtNy0xLTEtNzkyODM_830e0736-6e38-452b-99d7-62326e97704d">96,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i617ebbcc5095463d8013bb0f56fc9a65_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTQtOS0xLTEtNzkyODM_11e2e6f7-cb45-4afb-9c42-3187765b0aec">327,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTQtMTEtMS0xLTc5Mjgz_f365abc5-1e6b-41a0-a2bc-0638b0ebb85e">423,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level&#160;1 and Level&#160;2 of the fair value hierarchy during the three months ended March&#160;31, 2023. We had no instruments that were classified within Level&#160;3 as of March&#160;31, 2023 or December&#160;31, 2022.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="iede2e4c8548c40d4910b7a838a08d814_55"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:OtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RleHRyZWdpb246MDdlMzMxYTdhNGI2NGRhNGIxYTUxYWMyZDhlNjVlOWJfMTIw_3a7b3a46-b010-4ba1-9dcd-c096988b72bb" continuedAt="i51c2f980996c453f8a92d72959ee167b" escape="true">Prepaid Expenses and Other Assets</ix:nonNumeric></span></div><ix:continuation id="i51c2f980996c453f8a92d72959ee167b"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RleHRyZWdpb246MDdlMzMxYTdhNGI2NGRhNGIxYTUxYWMyZDhlNjVlOWJfMTIx_cb3b8a3b-784e-4b09-ae0a-4b720c59d1f2" escape="true"><div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfMi0xLTEtMS03OTI4Mw_08b4a189-625d-49f8-ae87-2020aba8c7a1">523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfMi0zLTEtMS03OTI4Mw_2dcffd43-2e0c-4a01-9018-d3235c7a4888">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid software licenses and maintenance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="zntl:PrepaidSoftwareLicenseAndMaintenance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfMy0xLTEtMS03OTI4Mw_758e2aa8-5826-48e8-939c-81c2da52003d">870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="zntl:PrepaidSoftwareLicenseAndMaintenance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfMy0zLTEtMS03OTI4Mw_8f2cc97c-f5b2-4a4a-b888-7277173c8a6e">958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign R&amp;D credit refund</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="zntl:ForeignResearchAndDevelopmentCreditRefund" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfNC0xLTEtMS03OTI4Mw_d1a53754-a04d-48f0-aad0-8317362336a6">940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="zntl:ForeignResearchAndDevelopmentCreditRefund" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfNC0zLTEtMS03OTI4Mw_91d4d81a-ea91-4db8-ba6e-11b740af01ed">659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="zntl:PrepaidResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfNS0xLTEtMS03OTI4Mw_05e87ca1-5ba8-4415-9c06-30ac9d0e8f7b">16,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="zntl:PrepaidResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfNS0zLTEtMS03OTI4Mw_a6f4c580-b0d2-46d8-835b-6284402aa29f">15,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:InterestReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfNi0xLTEtMS03OTI4Mw_4cbf2348-4ece-4f56-ae90-e49340446be7">385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:InterestReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfNi0zLTEtMS03OTI4Mw_3e217170-e288-4914-a6e2-366b310679c2">508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zentera receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:DueFromRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfNy0xLTEtMS03OTI4Mw_6b8e64c5-d458-4f7f-8d1c-60bf38c3d0ac">7,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:DueFromRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfNy0zLTEtMS03OTI4Mw_928fef0e-b788-4dd1-b21f-3c9896a0f861">5,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="zntl:OtherPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfOC0xLTEtMS03OTI4Mw_2162a29d-1047-4034-afa5-11619a340f93">422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="zntl:OtherPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfOC0zLTEtMS03OTI4Mw_0b8d2553-852d-4a49-ae10-ada5c913c972">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfOS0xLTEtMS03OTI4Mw_157922de-20d2-47e9-8c80-563fd1357ae9">27,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfOS0zLTEtMS03OTI4Mw_68ca4646-6420-4013-a75b-823e2f86124a">24,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfMTAtMS0xLTEtNzkyODM_061437ba-8956-41bd-aec2-f1fd03261d19">9,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfMTAtMy0xLTEtNzkyODM_e4e64edf-a061-4e7c-9eea-bacd15c3e594">9,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other assets, current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfMTEtMS0xLTEtNzkyODM_e3810f88-1645-4a56-a387-88f63f91c181">17,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfMTEtMy0xLTEtNzkyODM_aa9ce420-4c68-4557-83ce-00b3f87bee2e">14,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="iede2e4c8548c40d4910b7a838a08d814_58"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RleHRyZWdpb246M2QwODgyMzc4YmZiNDI4Y2FjM2IxZDc5MjZiZDJjMWZfMzcz_381ad0c4-82d9-4889-83ea-6cc5814b14a5" continuedAt="ie5d9608cfc3546f7a67c20f0a4103421" escape="true">Property and Equipment, net</ix:nonNumeric></span></div><ix:continuation id="ie5d9608cfc3546f7a67c20f0a4103421" continuedAt="i3276d5db3ae046118239d864f50c05d7"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RleHRyZWdpb246M2QwODgyMzc4YmZiNDI4Y2FjM2IxZDc5MjZiZDJjMWZfMzc0_4b149287-4373-4fa7-b18f-6c6038e50049" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i073dd536aa7f4e92a0c00f9b8001ea13_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfMy0xLTEtMS03OTI4Mw_45a0fe29-8f64-45ad-9743-6afb4a4f9d53">2,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i846b0f7b2bec4d4e9f5a806b4294790a_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfMy0zLTEtMS03OTI4Mw_011fbf3b-db76-4a7c-9cd6-25d5dba7b95e">2,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaecf109643ad41c2acacd554e5a7f04a_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfNC0xLTEtMS03OTI4Mw_baf13d2d-c1f8-40f7-855e-9dda94f9aea5">4,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9990e1c841ed44748d68c3e408a17ce7_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfNC0zLTEtMS03OTI4Mw_a6d87ce5-dbd1-4879-a742-34e2cf97a405">4,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c0b3ee517a4e78a0b1cf3438d6c138_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfNS0xLTEtMS03OTI4Mw_71650114-4d2d-4e86-a1f6-377b6cbff2e9">2,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd91a2b14d264c7f801b908e210ab0e1_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfNS0zLTEtMS03OTI4Mw_af693944-41dd-46ef-8948-1fe9f136218c">2,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19492fb07b694a8f831a804dd56146ac_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfNi0xLTEtMS03OTI4Mw_fb70b36a-1122-4195-b8fe-9c6e77582d86">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716b7da8349e417aab51c34f8ddc80f4_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfNi0zLTEtMS03OTI4Mw_1c6ffd5c-3ad2-4c88-a07a-ca7a26eaa4af">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea20b17bd4be4aaeac426373ae7aa5ca_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfNy0xLTEtMS03OTI4Mw_f9aa962b-a48e-4084-9fde-e72bfb28af38">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313676da216b4874b3024ccf5d0337d9_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfNy0zLTEtMS03OTI4Mw_7d0292f8-5b35-42ab-b57c-1f6295f4d5ba">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfOC0xLTEtMS03OTI4Mw_4c14f1e3-8d29-4861-b3c6-b7b926fb4f68">9,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfOC0zLTEtMS03OTI4Mw_a4798c03-c4cc-437c-8993-000b95e77b5a">9,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfOS0xLTEtMS03OTI4Mw_655e20af-9573-410c-89cc-c026b67ae005">3,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfOS0zLTEtMS03OTI4Mw_1068b43b-287f-4099-9bec-2699839169cf">2,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfMTAtMS0xLTEtNzkyODM_c975f10e-ec6e-4310-ae1a-c9383c33e7ec">6,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfMTAtMy0xLTEtNzkyODM_ffe625af-f5f7-4d01-8ba6-c90de1db64b9">7,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;text-indent:18pt"><ix:continuation id="i3276d5db3ae046118239d864f50c05d7" continuedAt="ic4bb2627f33945db84fd8b6853f046d2"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the three months ended March&#160;31, 2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic4bb2627f33945db84fd8b6853f046d2"> was approximately $<ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RleHRyZWdpb246M2QwODgyMzc4YmZiNDI4Y2FjM2IxZDc5MjZiZDJjMWZfMjAy_eff615c7-ca1d-4b7d-8388-8ead63547781">360</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RleHRyZWdpb246M2QwODgyMzc4YmZiNDI4Y2FjM2IxZDc5MjZiZDJjMWZfMjE5_d13e365f-ed99-4e0b-b642-cd2923ecf58b">344</ix:nonFraction> thousand, respectively.</ix:continuation> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="iede2e4c8548c40d4910b7a838a08d814_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RleHRyZWdpb246ZmEyMmI0NWMwYjM0NGIxZjg3YmY5YTMzYzBiM2Q0MDlfODM_2bdd54b1-7998-431e-805c-cf3398d1b59b" continuedAt="i692dd67084de456a835ca774b9ea4ab8" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="i692dd67084de456a835ca774b9ea4ab8"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RleHRyZWdpb246ZmEyMmI0NWMwYjM0NGIxZjg3YmY5YTMzYzBiM2Q0MDlfODQ_a6a15476-6720-4ab6-87c8-396bdd90c8bb" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="zntl:AccruedResearchAndDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfMi0xLTEtMS03OTI4Mw_1ea0f09d-e563-4876-8ceb-f927df5b8077">34,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="zntl:AccruedResearchAndDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfMi0zLTEtMS03OTI4Mw_74c09848-012f-47f7-836b-b5d7da0b8a55">32,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfMy0xLTEtMS03OTI4Mw_0fa1f7c7-0ff7-4219-8a93-3915017fb2f1">6,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfMy0zLTEtMS03OTI4Mw_80e5f274-affb-4dba-a87f-b2832f1f276c">11,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfNC0xLTEtMS03OTI4Mw_4e2ea4c1-e40a-4d4e-835e-d51e55fa8fc7">828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfNC0zLTEtMS03OTI4Mw_d05dd22f-71cb-42ba-8736-fc81c23eee74">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="zntl:AccruedGeneralAndAdministrativeCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfNS0xLTEtMS03OTI4Mw_e530641f-dfdd-45c7-8057-21ed88ead7a1">726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="zntl:AccruedGeneralAndAdministrativeCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfNS0zLTEtMS03OTI4Mw_c495554a-185c-41c4-b9a1-6487da3c4b87">662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfNi0xLTEtMS03OTI4Mw_9f3dec3c-7f5f-4dac-a092-72c4e6a0499f">2,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfNi0zLTEtMS03OTI4Mw_7c757ae2-5c66-4cfe-b19c-ee89ff6b8ae7">2,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfNy0xLTEtMS03OTI4Mw_07d584be-da08-41cd-98c0-1598c69eff21">425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfNy0zLTEtMS03OTI4Mw_4df48ee5-f19e-42dc-91ff-498277eefc4c">384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfOC0xLTEtMS04ODExOA_b2bb31d5-8489-4745-a689-57de1c5879c1">45,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfOC0zLTEtMS04ODExOA_9cdddf89-9159-43c2-8a69-25d4972f87cc">48,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfMTAtMS0xLTEtODgxMjk_73b67154-e759-47aa-977c-0f1841653aee">1,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfMTAtMy0xLTEtODgxMjk_a7ee9602-4516-4541-b52e-555e3aa4f9a9">2,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfOS0xLTEtMS03OTI4Mw_ecd25b68-39fa-4d6f-a6b6-4f9aec28f312">43,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfOS0zLTEtMS03OTI4Mw_e604461d-ac50-459b-9ccc-b61201fa157a">45,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="iede2e4c8548c40d4910b7a838a08d814_64"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjk3Mw_38e43e7c-668e-4b9b-a43a-de27423a6833" continuedAt="i27b345010de34e41b9c9db4f16c6b512" escape="true">Stockholders&#8217; Equity </ix:nonNumeric></span></div><ix:continuation id="i27b345010de34e41b9c9db4f16c6b512" continuedAt="i6afb497fc1414f9fbab0f66c78a67408"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2020, the Company&#8217;s Board of Directors adopted, and the Company&#8217;s stockholders approved, the 2020 Incentive Award Plan (the &#8220;2020 Plan&#8221;), which allows for grants to selected employees, consultants and non-employee members of the Board of Directors. We currently grant stock options and restricted stock units (&#8220;RSUs&#8221;), under the 2020 Plan. Awards may be made under the 2020 Plan covering up to the sum of (1) <ix:nonFraction unitRef="shares" contextRef="i107f398d916b45ab840efc6b49511a32_I20200430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfMTk3Ng_5e615fdd-ab83-471d-a9f9-90c34785caff">5,600,000</ix:nonFraction> shares of common stock; plus (2) any shares forfeited from the unvested restricted shares of our common stock issued upon conversion of unvested Class B common units (up to <ix:nonFraction unitRef="shares" contextRef="i2b8527f1b94449b499e8720cddbb6d40_I20200430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfMjE1Mg_a6ae1cd1-05c6-4977-9f9b-1dc2249d9d1d">1,250,000</ix:nonFraction> shares); plus (3) an annual increase on the first day of each fiscal year beginning with the fiscal year ending December 31, 2021 and continuing to, and including, the fiscal year ending December 31, 2030, equal to the lesser of (a) <ix:nonFraction unitRef="number" contextRef="i0a9d42e696914ee6ac56aebc0b0ccdf1_D20200401-20200430" decimals="INF" name="zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfMjM4OA_12c9f520-140d-43f1-a057-f26b3a0445be">5</ix:nonFraction>% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by our Board of Directors. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="i892983c302494b99a210a868ff39cecd_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfMjU4MQ_b483a64b-a3e3-4d80-a19c-c4f5ff15284c">9,975,086</ix:nonFraction> shares were subject to outstanding awards under the 2020 Plan and <ix:nonFraction unitRef="shares" contextRef="i892983c302494b99a210a868ff39cecd_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfMjY1MA_126e4375-d904-49f7-8a18-3a8fa82e9038">1,350,490</ix:nonFraction> shares were available for future grants of share-based awards under the 2020 Plan.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, the Company&#8217;s Board of Directors approved the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (the &#8220;2022 Inducement Plan&#8221;), which is used exclusively for the grant of equity awards to new employees as an inducement material to the employees&#8217; entering into employment with the </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="i6afb497fc1414f9fbab0f66c78a67408" continuedAt="i21ac73318db148088b01fee9c6198bac"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company. The Board of Directors has initially reserved <ix:nonFraction unitRef="shares" contextRef="i91b8baeaf3fd40eea9dc65835916019a_I20220731" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfMzExMg_97ad46a3-086e-4035-acab-bd5ffee681a9">1,500,000</ix:nonFraction> shares of the Company&#8217;s common stock for issuance pursuant to awards granted under the 2022 Inducement Plan. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="i9548270e5788494cb09db3f66fae3c93_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfMzIzMg_191a916c-1355-4fc6-9040-a455264936ae">1,485,975</ix:nonFraction> shares were subject to outstanding awards under the 2022 Inducement Plan and <ix:nonFraction unitRef="shares" contextRef="i9548270e5788494cb09db3f66fae3c93_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfMzMxMg_3bfc5277-d574-4164-ae4a-256d2b131807">14,025</ix:nonFraction> shares were available for future grants of share-based awards under the 2022 Inducement Plan. </span></div><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjk3NA_d3fb8851-7a81-4b03-a062-b33a3c3a95d4" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense related to share based awards was comprised of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.570%"><tr><td style="width:1.0%"></td><td style="width:53.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.100%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.102%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc1a500ef2574f02955ba6e37b2c81ac_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmQxMjA5ZmNhY2U2MjRhY2U4ZjBlNmFkZWUwOTlhY2I1L3RhYmxlcmFuZ2U6ZDEyMDlmY2FjZTYyNGFjZThmMGU2YWRlZTA5OWFjYjVfMi0xLTEtMS03OTI4Mw_1ea56a97-8130-4288-aebe-ef6b97261967">5,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie297eca60e624e8d93b5c2d311094db0_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmQxMjA5ZmNhY2U2MjRhY2U4ZjBlNmFkZWUwOTlhY2I1L3RhYmxlcmFuZ2U6ZDEyMDlmY2FjZTYyNGFjZThmMGU2YWRlZTA5OWFjYjVfMi0zLTEtMS03OTI4Mw_c1c4669c-52b8-4268-8637-ec6924cf0361">5,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f732ecb401746458a388bfa07d3afc2_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmQxMjA5ZmNhY2U2MjRhY2U4ZjBlNmFkZWUwOTlhY2I1L3RhYmxlcmFuZ2U6ZDEyMDlmY2FjZTYyNGFjZThmMGU2YWRlZTA5OWFjYjVfMy0xLTEtMS03OTI4Mw_a6192fb3-76f2-4f5c-8ab5-f9f30e39e42e">7,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f721a2929d54ac5ba6903405fe9cba7_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmQxMjA5ZmNhY2U2MjRhY2U4ZjBlNmFkZWUwOTlhY2I1L3RhYmxlcmFuZ2U6ZDEyMDlmY2FjZTYyNGFjZThmMGU2YWRlZTA5OWFjYjVfMy0zLTEtMS03OTI4Mw_9bb5bedd-6c8f-42c4-9e68-570b1a4ac5ec">5,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmQxMjA5ZmNhY2U2MjRhY2U4ZjBlNmFkZWUwOTlhY2I1L3RhYmxlcmFuZ2U6ZDEyMDlmY2FjZTYyNGFjZThmMGU2YWRlZTA5OWFjYjVfNC0xLTEtMS03OTI4Mw_07cfcca2-bca0-4309-ac41-7bde0a37802d">13,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmQxMjA5ZmNhY2U2MjRhY2U4ZjBlNmFkZWUwOTlhY2I1L3RhYmxlcmFuZ2U6ZDEyMDlmY2FjZTYyNGFjZThmMGU2YWRlZTA5OWFjYjVfNC0zLTEtMS03OTI4Mw_6ad22535-940e-4526-8027-7d7a9c29dd4d">10,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by type of share-based award (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.211%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.929%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i037f9049a8294a5c99bf21de04775e11_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmY5NTM2YjFlYTAxNjQyNTk5ZGQ5MjkxYWFlMGQyNWZmL3RhYmxlcmFuZ2U6Zjk1MzZiMWVhMDE2NDI1OTlkZDkyOTFhYWUwZDI1ZmZfMy0xLTEtMS03OTI4Mw_36e428d3-c18b-4b73-87fe-9e9fdd311431">10,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32bfab5a7c4d46cbb67792b462367d55_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmY5NTM2YjFlYTAxNjQyNTk5ZGQ5MjkxYWFlMGQyNWZmL3RhYmxlcmFuZ2U6Zjk1MzZiMWVhMDE2NDI1OTlkZDkyOTFhYWUwZDI1ZmZfMy0zLTEtMS03OTI4Mw_bedc85e3-bb18-4a62-bdf9-2b9750ea257c">7,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45742a89bf3246eb9070cc158debe73f_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmY5NTM2YjFlYTAxNjQyNTk5ZGQ5MjkxYWFlMGQyNWZmL3RhYmxlcmFuZ2U6Zjk1MzZiMWVhMDE2NDI1OTlkZDkyOTFhYWUwZDI1ZmZfNC0xLTEtMS03OTI4Mw_3c077298-b222-4e6b-8a0d-2d81135854fa">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic196aacc6ecf4e049fc4defb2ff097a4_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmY5NTM2YjFlYTAxNjQyNTk5ZGQ5MjkxYWFlMGQyNWZmL3RhYmxlcmFuZ2U6Zjk1MzZiMWVhMDE2NDI1OTlkZDkyOTFhYWUwZDI1ZmZfNC0zLTEtMS03OTI4Mw_c59e3d6c-1cc7-4504-9509-cb32226ad4e4">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied35ca1f9fa14bff85ddf36999e934ec_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmY5NTM2YjFlYTAxNjQyNTk5ZGQ5MjkxYWFlMGQyNWZmL3RhYmxlcmFuZ2U6Zjk1MzZiMWVhMDE2NDI1OTlkZDkyOTFhYWUwZDI1ZmZfNS0xLTEtMS03OTI4Mw_84a29685-431c-46f9-a6f0-01c9511b9fe5">3,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95aef8aaac164782aafe41f536dfd292_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmY5NTM2YjFlYTAxNjQyNTk5ZGQ5MjkxYWFlMGQyNWZmL3RhYmxlcmFuZ2U6Zjk1MzZiMWVhMDE2NDI1OTlkZDkyOTFhYWUwZDI1ZmZfNS0zLTEtMS03OTI4Mw_515aa008-7ffd-45e3-8856-0a4dfea8a08b">2,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmY5NTM2YjFlYTAxNjQyNTk5ZGQ5MjkxYWFlMGQyNWZmL3RhYmxlcmFuZ2U6Zjk1MzZiMWVhMDE2NDI1OTlkZDkyOTFhYWUwZDI1ZmZfNi0xLTEtMS03OTI4Mw_9661150d-e4e4-49d3-ad77-5bf93c8f9ffd">13,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmY5NTM2YjFlYTAxNjQyNTk5ZGQ5MjkxYWFlMGQyNWZmL3RhYmxlcmFuZ2U6Zjk1MzZiMWVhMDE2NDI1OTlkZDkyOTFhYWUwZDI1ZmZfNi0zLTEtMS03OTI4Mw_b320f47e-bc91-4fb3-a113-941373a73d95">10,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjk4MA_2db4c632-3baa-41d6-b3d9-c6903d2abb4b" continuedAt="if6e14dbd430a454d972f52ce7fe45e7c" escape="true"></ix:nonNumeric>Stock Options and Restricted Stock Units</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options granted is equal to the closing price of the Company&#8217;s common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes model. Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of a group of similar companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards. The Company uses the &#8220;simplified method&#8221; for estimating the expected term of employee options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option (generally <ix:nonNumeric contextRef="i037f9049a8294a5c99bf21de04775e11_D20230101-20230331" name="zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNDc0Mw_e2d01c74-16b9-4baf-ba20-837881df2f0c">10</ix:nonNumeric> years). The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be <ix:nonFraction unitRef="number" contextRef="i037f9049a8294a5c99bf21de04775e11_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNTA4Mw_0cc20a65-1b84-498f-b788-54539b59b752">zero</ix:nonFraction>. <ix:continuation id="if6e14dbd430a454d972f52ce7fe45e7c" continuedAt="i24ec5b7e1b0045339b95ae2217e776a7">The fair value of the stock options granted during the three months ended March&#160;31, 2023 and March&#160;31, 2022 was determined with the following assumptions:</ix:continuation></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><ix:continuation id="i21ac73318db148088b01fee9c6198bac" continuedAt="iea85d75ca15649b1a72fcf97b54a581e"><div style="margin-bottom:12pt;text-indent:18pt"><ix:continuation id="i24ec5b7e1b0045339b95ae2217e776a7"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.839%"><tr><td style="width:1.0%"></td><td style="width:44.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i037f9049a8294a5c99bf21de04775e11_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMS0xLTEtMS03OTI4My90ZXh0cmVnaW9uOjZiYTM0M2ZkZDI5ZjRiZTQ5MWY1ZWY0ZWJkZjNlNmQ0XzQ_e0ad6d8e-4e18-4926-bfd1-294be15008c7">79.0</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i037f9049a8294a5c99bf21de04775e11_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMS0xLTEtMS03OTI4My90ZXh0cmVnaW9uOjZiYTM0M2ZkZDI5ZjRiZTQ5MWY1ZWY0ZWJkZjNlNmQ0Xzk_b3fba750-c209-4edb-a69f-7f2ede845f12">80.8</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i32bfab5a7c4d46cbb67792b462367d55_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMS0zLTEtMS03OTI4My90ZXh0cmVnaW9uOjhjMTUxZjQ2MmNlNDQ1NWNhZTcwMGFkYmM3YjMzODVmXzQ_1b3f8b92-5350-4bb1-a9c9-4b00bcc9aa26">73.6</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i32bfab5a7c4d46cbb67792b462367d55_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMS0zLTEtMS03OTI4My90ZXh0cmVnaW9uOjhjMTUxZjQ2MmNlNDQ1NWNhZTcwMGFkYmM3YjMzODVmXzk_2435d0a2-ea4b-4071-8140-c569deea906f">74.3</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i011753e6eaf2413a911eecf0b87cca62_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMi0xLTEtMS03OTI4My90ZXh0cmVnaW9uOmQ3ZjcxNjlmZDg1ZTQzMWViNmZlNGU1ZWEzZDEzMjg4XzQ_9b814873-d9a2-4d33-b966-b05cb7c5f96f">5.5</ix:nonNumeric> - <ix:nonNumeric contextRef="ibfa47905419248b98bc84b2436b91faf_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMi0xLTEtMS03OTI4My90ZXh0cmVnaW9uOmQ3ZjcxNjlmZDg1ZTQzMWViNmZlNGU1ZWEzZDEzMjg4Xzk_080e6c66-b39e-4121-ab1e-7f9306353bd0">6.1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iae4fb48df2fa4ca3ab3a8ec68fdbb56b_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMi0zLTEtMS03OTI4My90ZXh0cmVnaW9uOjZhNjFiNzc0NmQxNzQ2YWU5M2E3NjUxNDliNTYwMzAwXzQ_1e2e9c37-7220-415c-b409-8275f64fe6f6">6.0</ix:nonNumeric> - <ix:nonNumeric contextRef="i2547f09e3d334b9e9a5869e04478bfe6_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMi0zLTEtMS03OTI4My90ZXh0cmVnaW9uOjZhNjFiNzc0NmQxNzQ2YWU5M2E3NjUxNDliNTYwMzAwXzk_b0404b0e-746f-4845-be6c-96535b42e697">6.1</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i037f9049a8294a5c99bf21de04775e11_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMy0xLTEtMS03OTI4My90ZXh0cmVnaW9uOjM3NjAxMzlhM2ZhMzQ0ZjM4MjJjOWRmOWM5ZmM0YTBjXzQ_59584149-6d7c-46e9-8aa3-5095b76f5f8d">3.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i037f9049a8294a5c99bf21de04775e11_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMy0xLTEtMS03OTI4My90ZXh0cmVnaW9uOjM3NjAxMzlhM2ZhMzQ0ZjM4MjJjOWRmOWM5ZmM0YTBjXzk_2481a983-8b0e-4fba-a16b-a1e1129e3b9d">4.2</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i32bfab5a7c4d46cbb67792b462367d55_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMy0zLTEtMS03OTI4My90ZXh0cmVnaW9uOjE1YjMxN2NkNDhjODQ4MGQ4OGU0Zjk3ZjMyMDY1NWExXzQ_2a1f04e4-006b-4f07-92ad-fc28109c73d6">1.5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i32bfab5a7c4d46cbb67792b462367d55_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMy0zLTEtMS03OTI4My90ZXh0cmVnaW9uOjE1YjMxN2NkNDhjODQ4MGQ4OGU0Zjk3ZjMyMDY1NWExXzk_3de7de37-bf2d-4727-b1de-b74fd91ef027">2.3</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i037f9049a8294a5c99bf21de04775e11_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfNC0xLTEtMS03OTI4Mw_f31ae8c6-eb54-400e-8cf8-9043c7a1f679">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i32bfab5a7c4d46cbb67792b462367d55_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfNC0zLTEtMS03OTI4Mw_710b956b-5a65-4586-856b-acdbe686f7be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2020, the Company&#8217;s Board of Directors adopted, and the Company&#8217;s stockholders approved the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which was subsequently amended and restated effective March 15, 2021. The maximum aggregate number of shares of the Company&#8217;s common stock available for issuance under the ESPP at March 31, 2023 was <ix:nonFraction unitRef="shares" contextRef="ib06002bdaeab4e58a39c96013dac6a87_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNTYzMQ_7fb4a99e-6374-41bd-ae3c-39afd0cdfd6c">1,929,891</ix:nonFraction>. Under the terms of the ESPP, the Company&#8217;s employees may elect to have up to <ix:nonFraction unitRef="number" contextRef="ib06002bdaeab4e58a39c96013dac6a87_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNTcxMg_e9020ee9-8525-4cd0-b503-2e8629d1ccad">20</ix:nonFraction>% of their compensation, up to a maximum value of $<ix:nonFraction unitRef="usd" contextRef="i45742a89bf3246eb9070cc158debe73f_D20230101-20230331" decimals="INF" name="zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNTc2Mw_061230c6-6257-40da-9506-e421fd3e39ee">25,000</ix:nonFraction> per calendar year, withheld to purchase shares of the Company&#8217;s common stock for a purchase price equal to <ix:nonFraction unitRef="number" contextRef="i45742a89bf3246eb9070cc158debe73f_D20230101-20230331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNTg3Mw_fe244901-d0a4-48d0-b551-f51ad91dbc1d">85</ix:nonFraction>% of the lower of the fair market value per share (at closing) of the Company&#8217;s common stock on (i) the first trading day of a <ix:nonNumeric contextRef="i45742a89bf3246eb9070cc158debe73f_D20230101-20230331" name="zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjk3NQ_7b26bb6f-74a0-4b77-9a99-5e3a17f07b70">six-month</ix:nonNumeric> offering period, or (ii) the applicable purchase date, defined as the last trading day of the <ix:nonNumeric contextRef="i45742a89bf3246eb9070cc158debe73f_D20230101-20230331" name="zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjk4MQ_16a2b472-2f95-4728-8ef6-87704698f070">six-month</ix:nonNumeric> offering period. <ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjk3OA_9da337b0-8d17-4bce-8389-38d2dd8b3f99" continuedAt="ib7b275f61851413cbee1c191a2e8483b" escape="true">The weighted average assumptions used to estimate the fair value of stock purchase rights under the ESPP during the period ended March 31, 2023 are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><ix:continuation id="ib7b275f61851413cbee1c191a2e8483b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.846%"><tr><td style="width:1.0%"></td><td style="width:48.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.652%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i45742a89bf3246eb9070cc158debe73f_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjAyNmMzODg1ZWUzNzRiNjBhNjI5YWYxMzc5MjEwNTliL3RhYmxlcmFuZ2U6MDI2YzM4ODVlZTM3NGI2MGE2MjlhZjEzNzkyMTA1OWJfMy0zLTEtMS03OTI4Mw_d23a724d-db57-46a3-90a2-c2905f1e702f">101.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i45742a89bf3246eb9070cc158debe73f_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjAyNmMzODg1ZWUzNzRiNjBhNjI5YWYxMzc5MjEwNTliL3RhYmxlcmFuZ2U6MDI2YzM4ODVlZTM3NGI2MGE2MjlhZjEzNzkyMTA1OWJfNC0zLTEtMS03OTI4Mw_f5ee70aa-3906-4b21-869e-c3822597ae61">0.5</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i45742a89bf3246eb9070cc158debe73f_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjAyNmMzODg1ZWUzNzRiNjBhNjI5YWYxMzc5MjEwNTliL3RhYmxlcmFuZ2U6MDI2YzM4ODVlZTM3NGI2MGE2MjlhZjEzNzkyMTA1OWJfNS0zLTEtMS03OTI4Mw_1b346ca8-7e80-499e-ac6e-9151bc3434ae">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i45742a89bf3246eb9070cc158debe73f_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjAyNmMzODg1ZWUzNzRiNjBhNjI5YWYxMzc5MjEwNTliL3RhYmxlcmFuZ2U6MDI2YzM4ODVlZTM3NGI2MGE2MjlhZjEzNzkyMTA1OWJfNi0zLTEtMS03OTI4Mw_24024855-c9fd-4323-a952-0b03771eb101">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense Summary</span></div><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjk3Nw_56cdffd6-9531-4730-a77a-881fba167c2f" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized estimated compensation cost by type of award and the weighted average requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.256%"><tr><td style="width:1.0%"></td><td style="width:31.878%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.878%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.881%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized <br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining <br/>Weighted-Average Recognition Period <br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9df9a5968b2476b88207ca1aa4feb7a_I20230331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjU0ZjQ2Y2JkNTg1YTRiYTNhMGZlYjYwMGE0OGU2ZDBhL3RhYmxlcmFuZ2U6NTRmNDZjYmQ1ODVhNGJhM2EwZmViNjAwYTQ4ZTZkMGFfMi0xLTEtMS03OTI4Mw_612aa336-4ceb-4bb1-b053-4f86d20ff09e">119,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i037f9049a8294a5c99bf21de04775e11_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjU0ZjQ2Y2JkNTg1YTRiYTNhMGZlYjYwMGE0OGU2ZDBhL3RhYmxlcmFuZ2U6NTRmNDZjYmQ1ODVhNGJhM2EwZmViNjAwYTQ4ZTZkMGFfMi0zLTEtMS03OTI4Mw_7c348bb2-2f18-4414-836f-2d2ac70d3915">3.15</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae26c0f79da45b29f5451ae2499e17f_I20230331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjU0ZjQ2Y2JkNTg1YTRiYTNhMGZlYjYwMGE0OGU2ZDBhL3RhYmxlcmFuZ2U6NTRmNDZjYmQ1ODVhNGJhM2EwZmViNjAwYTQ4ZTZkMGFfMy0xLTEtMS03OTI4Mw_c0e02084-1fe9-4c4e-8a08-05fa18330fb5">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib2487cf2d4d34a84be4fe6513ad27639_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjU0ZjQ2Y2JkNTg1YTRiYTNhMGZlYjYwMGE0OGU2ZDBhL3RhYmxlcmFuZ2U6NTRmNDZjYmQ1ODVhNGJhM2EwZmViNjAwYTQ4ZTZkMGFfMy0zLTEtMS03OTI4Mw_72e65623-46da-4000-a56e-9bce56b67479">0.50</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2b9ea7d02e840689c4b7f3112d26cf8_I20230331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjU0ZjQ2Y2JkNTg1YTRiYTNhMGZlYjYwMGE0OGU2ZDBhL3RhYmxlcmFuZ2U6NTRmNDZjYmQ1ODVhNGJhM2EwZmViNjAwYTQ4ZTZkMGFfNC0xLTEtMS03OTI4Mw_90c6755d-b4a5-47d3-837b-634c563cd2d3">34,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if4fa1db40e4948c89927ea38cf78d599_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjU0ZjQ2Y2JkNTg1YTRiYTNhMGZlYjYwMGE0OGU2ZDBhL3RhYmxlcmFuZ2U6NTRmNDZjYmQ1ODVhNGJhM2EwZmViNjAwYTQ4ZTZkMGFfNC0zLTEtMS03OTI4Mw_7bfc1a79-9407-45ae-91b3-1e862ca49a34">3.16</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib06002bdaeab4e58a39c96013dac6a87_I20230331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjU0ZjQ2Y2JkNTg1YTRiYTNhMGZlYjYwMGE0OGU2ZDBhL3RhYmxlcmFuZ2U6NTRmNDZjYmQ1ODVhNGJhM2EwZmViNjAwYTQ4ZTZkMGFfNS0xLTEtMS03OTI4Mw_20e6b1a8-7d6e-4181-9181-1c1d7c0da3ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i45742a89bf3246eb9070cc158debe73f_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjU0ZjQ2Y2JkNTg1YTRiYTNhMGZlYjYwMGE0OGU2ZDBhL3RhYmxlcmFuZ2U6NTRmNDZjYmQ1ODVhNGJhM2EwZmViNjAwYTQ4ZTZkMGFfNS0zLTEtMS03OTI4Mw_ea313e20-9f2e-4c9b-b9e1-1430c340136e">0</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we issued <ix:nonFraction unitRef="shares" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-2" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjU3Nw_a3afc7a5-a25b-43f8-9c77-e7051e70ffd5">zero</ix:nonFraction> shares of common stock in connection with the exercises of stock options. For the three months ended March&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-2" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjY4Mg_9ba0ea2f-811a-4516-ba1b-1489dd25b9c2">41.1</ix:nonFraction> thousand shares of common stock </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iea85d75ca15649b1a72fcf97b54a581e">issued in conjunction with certain restricted stock awards (&#8220;RSAs&#8221;), vested. Outstanding stock options, unvested RSAs, and unvested RSUs totaling approximately <ix:nonFraction unitRef="shares" contextRef="ia9df9a5968b2476b88207ca1aa4feb7a_I20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjg3Ng_1bcef152-1fcd-48e4-b6d1-09724082ea8c">9.9</ix:nonFraction>&#160;million shares, <ix:nonFraction unitRef="shares" contextRef="i1ae26c0f79da45b29f5451ae2499e17f_I20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjg4Nw_dadbaf0b-975b-4503-88b6-87efd2dc7f82">0.1</ix:nonFraction>&#160;million shares and <ix:nonFraction unitRef="shares" contextRef="ie2b9ea7d02e840689c4b7f3112d26cf8_I20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjkwMQ_ad00ce5f-043f-4a25-bf99-32c3eed5eb35">1.6</ix:nonFraction>&#160;million shares of our common stock, respectively, were outstanding as of March&#160;31, 2023.</ix:continuation> </span></div><div id="iede2e4c8548c40d4910b7a838a08d814_67"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RleHRyZWdpb246OTlhY2ZmMjliMGJlNGU5Nzg4ZDE2ODI0MmU1Yzg0NTBfMTkyNg_ad616d2c-b3ba-4f47-b152-562c6cc2e5f1" continuedAt="ie2c7c2e6f6b24d1fb22995a6a8371774" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ie2c7c2e6f6b24d1fb22995a6a8371774" continuedAt="i1994648c2d8a432ab953cd36a2f1c2a7"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Contingencies </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, we may be involved in various disputes, including lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters. Any of these claims could subject us to costly legal expenses. The Company records a liability in its consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amounts of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary to make the consolidated financial statements not misleading. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in our consolidated financial statements. While we do generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage, or our policy limits may be inadequate to fully satisfy any damage awards or settlement. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We are currently not a party to any legal proceedings that require a loss liability to be recorded.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitments include payments related to operating leases. <ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RleHRyZWdpb246OTlhY2ZmMjliMGJlNGU5Nzg4ZDE2ODI0MmU1Yzg0NTBfMTkyNw_9689e997-6d97-4cd2-b922-a1ad4cb577ca" continuedAt="i4841abd0fa4644c6b0aa9f1d3461e064" escape="true">Approximate annual future minimum operating lease payments as of March&#160;31, 2023 are as follows (in thousands): </ix:nonNumeric></span></div><div style="margin-bottom:12pt"><ix:continuation id="i4841abd0fa4644c6b0aa9f1d3461e064"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RhYmxlOmQ1NTM5NDNlNWRiYjQ1M2ZhNmNkNjRmYzA0MzU0MzRmL3RhYmxlcmFuZ2U6ZDU1Mzk0M2U1ZGJiNDUzZmE2Y2Q2NGZjMDQzNTQzNGZfMi0yLTEtMS03OTI4Mw_71b3acea-82a3-4c35-8203-9a1b75712b8d">4,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RhYmxlOmQ1NTM5NDNlNWRiYjQ1M2ZhNmNkNjRmYzA0MzU0MzRmL3RhYmxlcmFuZ2U6ZDU1Mzk0M2U1ZGJiNDUzZmE2Y2Q2NGZjMDQzNTQzNGZfMy0yLTEtMS03OTI4Mw_9002d604-de40-490a-a200-84d21fb385fc">6,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RhYmxlOmQ1NTM5NDNlNWRiYjQ1M2ZhNmNkNjRmYzA0MzU0MzRmL3RhYmxlcmFuZ2U6ZDU1Mzk0M2U1ZGJiNDUzZmE2Y2Q2NGZjMDQzNTQzNGZfNC0yLTEtMS03OTI4Mw_bcffedc3-a5cd-4eb2-a985-7934728229e8">6,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RhYmxlOmQ1NTM5NDNlNWRiYjQ1M2ZhNmNkNjRmYzA0MzU0MzRmL3RhYmxlcmFuZ2U6ZDU1Mzk0M2U1ZGJiNDUzZmE2Y2Q2NGZjMDQzNTQzNGZfNS0yLTEtMS03OTI4Mw_6df65400-8cc8-4fc1-ab5e-14943f495685">7,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RhYmxlOmQ1NTM5NDNlNWRiYjQ1M2ZhNmNkNjRmYzA0MzU0MzRmL3RhYmxlcmFuZ2U6ZDU1Mzk0M2U1ZGJiNDUzZmE2Y2Q2NGZjMDQzNTQzNGZfNi0yLTEtMS05MTk0OA_4141fb45-b600-4a6d-9b73-5bcbc417adda">7,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="zntl:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RhYmxlOmQ1NTM5NDNlNWRiYjQ1M2ZhNmNkNjRmYzA0MzU0MzRmL3RhYmxlcmFuZ2U6ZDU1Mzk0M2U1ZGJiNDUzZmE2Y2Q2NGZjMDQzNTQzNGZfNi0yLTEtMS03OTI4Mw_e3aed668-897e-40ec-b21e-3ade55aad458">38,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RhYmxlOmQ1NTM5NDNlNWRiYjQ1M2ZhNmNkNjRmYzA0MzU0MzRmL3RhYmxlcmFuZ2U6ZDU1Mzk0M2U1ZGJiNDUzZmE2Y2Q2NGZjMDQzNTQzNGZfNy0yLTEtMS03OTI4Mw_f030ce02-a009-4e60-9036-175f6a6585cd">71,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: imputed interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RhYmxlOmQ1NTM5NDNlNWRiYjQ1M2ZhNmNkNjRmYzA0MzU0MzRmL3RhYmxlcmFuZ2U6ZDU1Mzk0M2U1ZGJiNDUzZmE2Y2Q2NGZjMDQzNTQzNGZfOC0yLTEtMS03OTI4Mw_2e93f725-e11c-478e-8a81-601053008e6d">24,740</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RhYmxlOmQ1NTM5NDNlNWRiYjQ1M2ZhNmNkNjRmYzA0MzU0MzRmL3RhYmxlcmFuZ2U6ZDU1Mzk0M2U1ZGJiNDUzZmE2Y2Q2NGZjMDQzNTQzNGZfOS0yLTEtMS03OTI4Mw_7a191104-80eb-435b-bcb4-724cd90a5fd1">47,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: current portion</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RhYmxlOmQ1NTM5NDNlNWRiYjQ1M2ZhNmNkNjRmYzA0MzU0MzRmL3RhYmxlcmFuZ2U6ZDU1Mzk0M2U1ZGJiNDUzZmE2Y2Q2NGZjMDQzNTQzNGZfMTAtMi0xLTEtNzkyODM_1cc15087-6f8f-4f09-b66e-b4ca273207e6">2,247</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, net of current portion</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RhYmxlOmQ1NTM5NDNlNWRiYjQ1M2ZhNmNkNjRmYzA0MzU0MzRmL3RhYmxlcmFuZ2U6ZDU1Mzk0M2U1ZGJiNDUzZmE2Y2Q2NGZjMDQzNTQzNGZfMTEtMi0xLTEtNzkyODM_22e2d77e-3bbd-4516-8651-5bfcb59aa888">44,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease term of our operating leases is approximately <ix:nonNumeric contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RleHRyZWdpb246OTlhY2ZmMjliMGJlNGU5Nzg4ZDE2ODI0MmU1Yzg0NTBfMTkyMQ_0e4adb80-141f-4f87-a688-b2bcac1d7f19">9.5</ix:nonNumeric> years. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 6, 2023, we entered into a sublease agreement pursuant to which we will sublease the office space located at 1359 Broadway, Suites 1710 and 1800 in New York, New York to a subtenant. As a result of certain triggering events, we performed an interim impairment test by comparing the carrying value of the long-lived asset group to its estimated fair value, which was determined based on the income approach using a discounted cash flow model. Estimates and assumptions used in the model included projected cash flows and a discount rate. As a result, </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1994648c2d8a432ab953cd36a2f1c2a7">we recorded an impairment expense of $<ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RleHRyZWdpb246OTlhY2ZmMjliMGJlNGU5Nzg4ZDE2ODI0MmU1Yzg0NTBfNTQ5NzU1ODE2MDA1_da39ad32-385e-4f6e-b61c-2af1f6f27ab1">5.0</ix:nonFraction> million within our operating expenses against our operating lease right-of-use asset and fixed assets associated with our New York lease during the three months ended March 31, 2023.</ix:continuation> </span></div><div id="iede2e4c8548c40d4910b7a838a08d814_70"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RleHRyZWdpb246N2Q5MTA5OTUzMjUwNDI1MzkxMWQ3ZWMwNjZlOTlhOTJfNTYx_c7adbb74-a6aa-4d9c-86b6-69c96172e08b" continuedAt="ibaa3e221805243ba995800f3651663c6" escape="true">Net Loss Per Common Share </ix:nonNumeric></span></div><ix:continuation id="ibaa3e221805243ba995800f3651663c6"><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RleHRyZWdpb246N2Q5MTA5OTUzMjUwNDI1MzkxMWQ3ZWMwNjZlOTlhOTJfNTU4_cec49798-b3db-4cb3-95fc-3cfa33da0274" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share were calculated as follows (in thousands except per share amounts):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.967%"><tr><td style="width:1.0%"></td><td style="width:50.002%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:22.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Zentalis</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjE1ZmY2ZTU3MjFmZjQyYzBhN2IzZDI3ODQ0NzFjZWZjL3RhYmxlcmFuZ2U6MTVmZjZlNTcyMWZmNDJjMGE3YjNkMjc4NDQ3MWNlZmNfMy0xMC0xLTEtNzkyODM_729a7073-efbe-474c-a4dd-8615bb16eae0">63,219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjE1ZmY2ZTU3MjFmZjQyYzBhN2IzZDI3ODQ0NzFjZWZjL3RhYmxlcmFuZ2U6MTVmZjZlNTcyMWZmNDJjMGE3YjNkMjc4NDQ3MWNlZmNfMy0xMi0xLTEtNzkyODM_bbcf9612-27af-4bf7-be82-68105c62a851">59,077</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjE1ZmY2ZTU3MjFmZjQyYzBhN2IzZDI3ODQ0NzFjZWZjL3RhYmxlcmFuZ2U6MTVmZjZlNTcyMWZmNDJjMGE3YjNkMjc4NDQ3MWNlZmNfNS0xMC0xLTEtNzkyODM_940e4707-2d41-4943-877a-b749dfb9146c"><ix:nonFraction unitRef="shares" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjE1ZmY2ZTU3MjFmZjQyYzBhN2IzZDI3ODQ0NzFjZWZjL3RhYmxlcmFuZ2U6MTVmZjZlNTcyMWZmNDJjMGE3YjNkMjc4NDQ3MWNlZmNfNS0xMC0xLTEtNzkyODM_dd940558-eaa1-4a94-88fd-a94b5197df6a">59,277</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjE1ZmY2ZTU3MjFmZjQyYzBhN2IzZDI3ODQ0NzFjZWZjL3RhYmxlcmFuZ2U6MTVmZjZlNTcyMWZmNDJjMGE3YjNkMjc4NDQ3MWNlZmNfNS0xMi0xLTEtNzkyODM_bf540d4c-f842-4192-b41b-206916468515"><ix:nonFraction unitRef="shares" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjE1ZmY2ZTU3MjFmZjQyYzBhN2IzZDI3ODQ0NzFjZWZjL3RhYmxlcmFuZ2U6MTVmZjZlNTcyMWZmNDJjMGE3YjNkMjc4NDQ3MWNlZmNfNS0xMi0xLTEtNzkyODM_dff258d7-5492-4ccc-b037-6c638f9e43aa">45,244</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjE1ZmY2ZTU3MjFmZjQyYzBhN2IzZDI3ODQ0NzFjZWZjL3RhYmxlcmFuZ2U6MTVmZjZlNTcyMWZmNDJjMGE3YjNkMjc4NDQ3MWNlZmNfNi0xMC0xLTEtNzkyODM_572eab0c-3e1a-4388-b5e1-84493c607411"><ix:nonFraction unitRef="usdPerShare" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjE1ZmY2ZTU3MjFmZjQyYzBhN2IzZDI3ODQ0NzFjZWZjL3RhYmxlcmFuZ2U6MTVmZjZlNTcyMWZmNDJjMGE3YjNkMjc4NDQ3MWNlZmNfNi0xMC0xLTEtNzkyODM_e3677941-74be-48fc-956d-ba9a8d8c611c">1.07</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjE1ZmY2ZTU3MjFmZjQyYzBhN2IzZDI3ODQ0NzFjZWZjL3RhYmxlcmFuZ2U6MTVmZjZlNTcyMWZmNDJjMGE3YjNkMjc4NDQ3MWNlZmNfNi0xMi0xLTEtNzkyODM_5a572ea5-8bf8-4309-829b-264d285fae87"><ix:nonFraction unitRef="usdPerShare" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjE1ZmY2ZTU3MjFmZjQyYzBhN2IzZDI3ODQ0NzFjZWZjL3RhYmxlcmFuZ2U6MTVmZjZlNTcyMWZmNDJjMGE3YjNkMjc4NDQ3MWNlZmNfNi0xMi0xLTEtNzkyODM_70341e37-30d1-41f8-988b-48fbc01d3f21">1.31</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential and dilutive securities, which include outstanding stock options, unvested RSAs and unvested RSUs have been excluded from the computation of diluted net loss per common share as the effect would be anti-dilutive. </span></div><ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RleHRyZWdpb246N2Q5MTA5OTUzMjUwNDI1MzkxMWQ3ZWMwNjZlOTlhOTJfNTYw_a86fbc07-85ac-470c-8cab-02bda7009d77" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents have been excluded from the calculations of diluted net loss per common share because their inclusion would be antidilutive (in thousands).</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.166%"><tr><td style="width:1.0%"></td><td style="width:52.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.776%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia9be73cf481a40aaba4c6cc6e675a708_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjY3MTc4MGQ0MzUzODQxYThhYmZlODQ1ZmI3NmZkZDlmL3RhYmxlcmFuZ2U6NjcxNzgwZDQzNTM4NDFhOGFiZmU4NDVmYjc2ZmRkOWZfMi0xLTEtMS03OTI4Mw_9905209c-4e18-4a3a-9286-d18cfead88b4">9,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7a5cbabc41941ada32f7ae938592fa6_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjY3MTc4MGQ0MzUzODQxYThhYmZlODQ1ZmI3NmZkZDlmL3RhYmxlcmFuZ2U6NjcxNzgwZDQzNTM4NDFhOGFiZmU4NDVmYjc2ZmRkOWZfMi0zLTEtMS03OTI4Mw_5913e5f4-87a7-487e-b3a1-cab4be1c087f">5,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSAs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i37ef16e02d7e43ba862a5c169d0332ea_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjY3MTc4MGQ0MzUzODQxYThhYmZlODQ1ZmI3NmZkZDlmL3RhYmxlcmFuZ2U6NjcxNzgwZDQzNTM4NDFhOGFiZmU4NDVmYjc2ZmRkOWZfMy0xLTEtMS03OTI4Mw_b3f20311-67ae-47da-b78c-0f42df154a20">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6fb0cb9f5b6a4708aab9cfcff606daf7_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjY3MTc4MGQ0MzUzODQxYThhYmZlODQ1ZmI3NmZkZDlmL3RhYmxlcmFuZ2U6NjcxNzgwZDQzNTM4NDFhOGFiZmU4NDVmYjc2ZmRkOWZfMy0zLTEtMS03OTI4Mw_51650912-a925-4ee4-ad1c-ecfff6fe42d4">287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e96002c4838463f94c1dab336a29f92_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjY3MTc4MGQ0MzUzODQxYThhYmZlODQ1ZmI3NmZkZDlmL3RhYmxlcmFuZ2U6NjcxNzgwZDQzNTM4NDFhOGFiZmU4NDVmYjc2ZmRkOWZfNC0xLTEtMS03OTI4Mw_b380f22e-7210-407b-9379-8d940ad7cdb9">1,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d916b6b431a4bb1b63b1b45fcaf58c3_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjY3MTc4MGQ0MzUzODQxYThhYmZlODQ1ZmI3NmZkZDlmL3RhYmxlcmFuZ2U6NjcxNzgwZDQzNTM4NDFhOGFiZmU4NDVmYjc2ZmRkOWZfNC0zLTEtMS03OTI4Mw_1206172c-59d9-4191-bca9-77458d2f07be">433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjY3MTc4MGQ0MzUzODQxYThhYmZlODQ1ZmI3NmZkZDlmL3RhYmxlcmFuZ2U6NjcxNzgwZDQzNTM4NDFhOGFiZmU4NDVmYjc2ZmRkOWZfNS0xLTEtMS03OTI4Mw_8242b8fa-3aca-4823-9a1e-b01f92b4c518">11,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjY3MTc4MGQ0MzUzODQxYThhYmZlODQ1ZmI3NmZkZDlmL3RhYmxlcmFuZ2U6NjcxNzgwZDQzNTM4NDFhOGFiZmU4NDVmYjc2ZmRkOWZfNS0zLTEtMS03OTI4Mw_1d7776ec-754b-4c07-9671-418112aa6ca7">6,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="iede2e4c8548c40d4910b7a838a08d814_73"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83My9mcmFnOmFjY2ZkMjU2OTE3NTRiYTJhYWE2YWU5YmM0MTE1ODM1L3RleHRyZWdpb246YWNjZmQyNTY5MTc1NGJhMmFhYTZhZTliYzQxMTU4MzVfMTg0Mw_1a75d528-12e0-45ba-a348-c3835c395649" continuedAt="i3f0d45e5edc7491281f3b8bd35dd20af" escape="true">Related Party Disclosures</ix:nonNumeric></span></div><ix:continuation id="i3f0d45e5edc7491281f3b8bd35dd20af" continuedAt="i3939c38ee58144bfb86dbd456c010ee8"><div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tempus</span></div><div style="text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kimberly Blackwell, M.D., our Chief Executive Officer and a member of our Board of Directors, was previously employed by Tempus Labs, Inc. ("Tempus") and now serves as an advisor of Tempus. The Company entered into a Master Services Agreement with Tempus in December 2020 to provide data licensing and research services. There were $<ix:nonFraction unitRef="usd" contextRef="i4be5fa9930e7403c9c0f8ba0f46352fe_I20230331" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83My9mcmFnOmFjY2ZkMjU2OTE3NTRiYTJhYWE2YWU5YmM0MTE1ODM1L3RleHRyZWdpb246YWNjZmQyNTY5MTc1NGJhMmFhYTZhZTliYzQxMTU4MzVfMzc0_a67a924f-dbae-4f40-9a0f-f74a42d44298">0.4</ix:nonFraction> million and immaterial fees incurred for services performed by Tempus for the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zentera</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kevin D. Bunker, Ph.D., our Chief Scientific Officer, serves as a member of the Board of Directors of Zentera. Accordingly, the Company identifies Zentera as a related party.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3939c38ee58144bfb86dbd456c010ee8" continuedAt="ie2f8100998084c6c820f3770b911ac43">In May 2020, each of our wholly owned subsidiaries, Zeno Alpha, Inc., K-Group Alpha, Inc. and K-Group Beta, Inc., entered into the Zentera Sublicenses, pursuant to which we collaborate with Zentera on the development and comm</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie2f8100998084c6c820f3770b911ac43">ercialization of the Collaboration Products in the Zentera Collaboration Territory. Under the terms of the Zentera Sublicenses, Zentera is responsible for the costs of developing the Collaboration Products in the Zentera Collaboration Territory, and we are responsible for the costs of developing the Collaboration Products outside the Zentera Collaboration Territory, provided that Zentera will reimburse us for a portion of its costs for global data management, pharmacovigilance, safety database management, and chemistry, manufacturing and controls activities with respect to each Collaboration Product. For the three months ended March 31, 2023 and 2022, the amounts incurred under this arrangement totaled $<ix:nonFraction unitRef="usd" contextRef="i7c81d5274f084d8ca588db925f2f294d_D20230101-20230331" decimals="-5" name="zntl:ResearchAndDevelopmentExpenseReimbursements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83My9mcmFnOmFjY2ZkMjU2OTE3NTRiYTJhYWE2YWU5YmM0MTE1ODM1L3RleHRyZWdpb246YWNjZmQyNTY5MTc1NGJhMmFhYTZhZTliYzQxMTU4MzVfNjU5NzA2OTc2ODg2MA_d5423e18-5f8d-4317-913a-42dc00fdc021">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4a32b2ade07d41f4b1cad2d93ca61367_D20220101-20220331" decimals="-5" name="zntl:ResearchAndDevelopmentExpenseReimbursements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83My9mcmFnOmFjY2ZkMjU2OTE3NTRiYTJhYWE2YWU5YmM0MTE1ODM1L3RleHRyZWdpb246YWNjZmQyNTY5MTc1NGJhMmFhYTZhZTliYzQxMTU4MzVfMTY0OTI2NzQ0Mzg0Nw_9e1a7d51-45ce-468a-9a7e-6df46e864aa7">2.1</ix:nonFraction>&#160;million, respectively, and are presented as contra-research and development expense in the consolidated statement of operations.</ix:continuation> </span></div><div id="iede2e4c8548c40d4910b7a838a08d814_76"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of financial condition and operating results should be read together with our interim unaudited condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and the related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q contains forward-looking statements that involve significant risks and uncertainties. As a result of many important factors, such as those set forth in the &#8220;Risk Factors&#8221; section of this Quarterly Report on Form 10-Q, our actual results may differ materially from those anticipated in these forward-looking statements. For convenience of presentation some of the numbers have been rounded in the text below.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. We are developing a focused pipeline of potentially best-in-class oncology candidates. Our product candidates are:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor for advanced solid tumors and hematological malignancies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ZN-d5, a B-cell lymphoma 2, or BCL-2, inhibitor for hematological malignancies and related disorders; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A heterobifunctional degrader of BCL-xL, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently evaluating azenosertib and ZN-d5 in multiple ongoing clinical trials and conducting studies to enable an Investigational New Drug, or IND, application for our BCL-xL product candidate. We also continue to use our extensive drug discovery experience and capabilities across cancer biology and medicinal chemistry, which we refer to as our Integrated Discovery Engine, to advance our ongoing research on protein degraders of undisclosed targets. We believe our product candidates are differentiated from current programs targeting similar pathways and, if approved, have the potential to significantly impact clinical outcomes of patients with cancer.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our Pipeline</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We are developing a focused pipeline of oncology product candidates with the potential to address significant unmet medical need for cancer patients. Two of our product candidates are currently in multiple ongoing clinical trials: azenosertib, an inhibitor of WEE1, a protein tyrosine kinase, and ZN-d5, a selective inhibitor of BCL-2. To date, azenosertib has been well tolerated and has demonstrated monotherapy anti-tumor activity across multiple tumor types in clinical trials. In addition, ZN-d5 has been well tolerated in clinical trials to date. We have also declared a development candidate for our BCL-xL degrader program, for which we are conducting IND-enabling studies.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We currently exclusively in-license worldwide development and commercialization rights to azenosertib, ZN-d5, and our BCL-xL product candidate. We out-licensed azenosertib and ZN-d5 development and commercialization rights in select Asian countries, including China, to our joint venture, Zentera Therapeutics, or Zentera. As of March 31, 2023, we held a 40.3% equity interest in Zentera. For more information about our joint venture with Zentera, see below under &#8220;License Agreements and Strategic Collaborations&#8221; and Note 3 to our interim unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><br/>The following table summarizes our product candidate pipeline:</span></div><div style="margin-bottom:12pt;text-align:center"><img src="zntl-20230331_g1.jpg" alt="Pipeline.jpg" style="height:430px;margin-bottom:5pt;vertical-align:text-bottom;width:820px"/></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Our Development Programs</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Azenosertib (WEE1 Inhibitor)</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Azenosertib is a potentially best-in-class and first-in-class oral, small molecule WEE1 inhibitor. As illustrated in the figure below, the inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and thereby preventing tumor growth and potentially causing tumor regression. Currently, there are no WEE1 inhibitors approved by the U.S. Food and Drug Administration, or FDA. We have designed azenosertib to have advantages over other investigational therapies targeting WEE1, including superior selectivity and pharmacokinetic, or PK, properties. Azenosertib is currently being evaluated in the clinic for advanced solid tumors and hematological malignancies in the following three therapeutic settings of high unmet medical need: </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">as a monotherapy, </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in combination with traditional chemotherapy and DNA damaging agents, and </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in combination with molecularly targeted agents.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Two key components of our azenosertib clinical development strategy are our dose optimization activities and our pursuit of Cyclin E1 as a patient enrichment strategy.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Azenosertib is being evaluated in multiple current or planned clinical trials, including the following: </span></div><div><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Monotherapy - Phase 2 Clinical Trial in Cyclin E1 Driven High-Grade Serous Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC) (ZN-c3-005). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are evaluating azenosertib as a monotherapy in a Phase 2 clinical trial in patients with Cyclin E1 driven HGSOC. Our Cyclin E1 enrichment strategy is supported by preclinical data that showed that high Cyclin E1 protein expression sensitized cancer cells to the anti-tumor effects of azenosertib as well as preliminary retrospective clinical data that Cyclin E1 protein levels may be associated with clinical benefit from WEE1 inhibition. In addition, in April 2023, we announced preclinical data at the 2023 American Association for Cancer Research, or AACR, Annual Meeting that demonstrated that azenosertib drove cancer cell death in Cyclin E1-high tumor cells </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and substantially inhibited growth of Cyclin E1-high, patient derived, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tumor models.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Monotherapy - Phase 2 Clinical Trial in Recurrent or Persistent Uterine Serous Carcinoma (USC) (ZN-c3-004). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Azenosertib is currently being evaluated as a monotherapy in a Phase 2 clinical trial in adult women with USC. As of a September 14, 2022 data cutoff, a total of 43 patients were enrolled and dosed. Azenosertib was well tolerated. The most common treatment related adverse events, or AEs, were nausea (60.5% all grades/9.3% grade 3 or higher), fatigue (46.5% all grades/9.3% grade 3 or higher), diarrhea (37.2% all grades/7.0% grade 3 or higher) and vomiting (32.6% all grades/7.0% grade 3 or higher). We anticipate that we will disclose the monotherapy dose for azenosertib in the first half of 2023, and we plan to update the timeline of this USC study thereafter. The FDA granted Fast Track designation in November 2021 to azenosertib in patients with advanced or metastatic USC who have received at least one prior platinum-based chemotherapy regimen for management of advanced or metastatic disease. We believe that the study design in this patient population has the potential to support registration in the United States.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Combination - Phase 1/2 Clinical Trial of Azenosertib and PARPi in Platinum-Resistant Ovarian Cancer (ZN-c3-006). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are evaluating azenosertib in combination with GSK's PARP inhibitor, niraparib (ZEJULA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">), in a Phase 1/2 clinical trial in platinum-resistant ovarian cancer patients who have failed PARP inhibitor, or PARPi, maintenance treatment as part of a clinical collaboration with GSK. This study is currently enrolling two cohorts &#8212; one with concurrent dosing of the two drugs, and one with azenosertib and niraparib administered on a dose escalating, alternating schedule of one week of azenosertib followed by one week of niraparib. This clinical study is supported by preclinical data that showed that combining azenosertib and niraparib resulted in synergistic cell killing in ovarian </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> models.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Combination - Phase 1b Clinical Trial of Azenosertib and Chemotherapy in Platinum-Resistant Ovarian, Peritoneal or Fallopian Tube Cancer (ZN-c3-002). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Azenosertib is currently being evaluated in combination with each of paclitaxel, carboplatin, pegylated liposomal doxorubicin (PLD) and gemcitabine in four separate cohorts in a Phase 1b clinical trial in patients with platinum-resistant ovarian, peritoneal or fallopian tube cancer. We provided a preliminary efficacy and safety update at the 2022 AACR Annual Meeting in April 2022, highlighting that azenosertib in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population and was well tolerated. As of the January 28, 2022 data cutoff, there were 43 evaluable patients for efficacy, with an ORR of 30.2% across all evaluable chemotherapy cohorts (paclitaxel, carboplatin and PLD). In the paclitaxel cohort, there were 8 evaluable patients and an ORR of 62.5%; in the carboplatin cohort, there were 11 evaluable patients and an ORR of 45.5%; and in the PLD cohort, there were 24 evaluable patients and an ORR of 12.5%. As of the January 28, 2022 data cutoff, there were 56 evaluable patients for safety. The most common treatment related AEs were nausea (48.2% all grades/5.4% grade 3 or higher), neutropenia (41.1% all grades/32.1% grade 3 or higher), thrombocytopenia (37.5% all grades/17.9% grade 3 or higher), vomiting (30.4% all grades/7.1% grade 3 or higher) and anemia (26.8 all grades/7.1% grade 3 or higher). In April 2023, we announced that we are scheduled to present positive clinical data from this trial at the American Society of Clinical Oncology Meeting on June 5, 2023.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Monotherapy - Phase 1 Dose Optimization Clinical Trial in Solid Tumors (ZN-c3-001). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are currently evaluating azenosertib as a monotherapy in a Phase 1 dose optimization clinical trial for the treatment of solid tumors. We announced preliminary efficacy data from this trial with a data cutoff of May 15, 2021 from 34 patients, where we showed five confirmed partial responses, or cPRs, to azenosertib in monotherapy across several tumor types, including ovarian cancer (-69% cPR), colorectal cancer (-51% cPR), NSCLC (-49% cPR), and USC (-49% cPR) and (-43% cPR). We announced preliminary safety data from this trial at the 2022 AACR Annual Meeting in April 2022. As of a January 21, 2022 data cutoff, there were 32 patients evaluated for safety and azenosertib was well tolerated. The most common treatment related AEs were nausea (71.9% all grades/3.1% grade 3 or higher), fatigue (53.1% all grades/18.8% grade 3 or higher), diarrhea (46.9% all grades/6.3% grade 3 or higher) and vomiting (46.9% all grades/0% grade 3 or higher). We also announced preliminary efficacy data from the Phase 1 monotherapy expansion cohort in USC from this trial at the 2022 AACR Annual Meeting. As of a January 21, 2022 data cutoff, there were 11 evaluable patients in the USC cohort, with 27.3% demonstrating an objective response rate, or ORR, and 90.9% demonstrating a disease control rate, or DCR.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Combination - Phase 1/2 Clinical Trial of Azenosertib and Chemotherapy in Relapsed or Refractory Osteosarcoma (ZN-c3-003). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Azenosertib is currently being evaluated in combination with gemcitabine, in a Phase 1/2 clinical trial in adult and pediatric patients with R/R osteosarcoma. We reported initial results from this trial at the 2022 Connective Tissue Oncology Society, or CTOS, Annual Meeting in November 2022. As of a October 24, 2022 data cutoff, there were 12 patients evaluable for efficacy, with approximately 33% of patients demonstrating event-free survival, or EFS, at 18 weeks (compared to approximately 12% at 18 weeks for this indication historically). As of the October 24, 2022 data cutoff, there were 17 patients evaluable for safety. Azenosertib demonstrated a manageable safety profile with 82.4% experiencing treatment related AEs of which 52.9% were grade 3 or higher. The most common treatment related AEs were platelet count decreased/thrombocytopenia (47.1% all grades/35.3% grade 3 or higher), fatigue (29.4% all grades/5.9% grade 3 or higher), nausea (29.4% all grades/0% grade 3 or higher) and rash (29.4% all grades/5.9% grade 3 or higher). We received orphan drug designation and rare pediatric disease designation from the FDA for azenosertib in osteosarcoma.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Combination - Phase 1/2 Clinical Trial of Azenosertib with Encorafenib and Cetuximab (BEACON Regimen) in BRAF V600E Mutant Metastatic Colorectal Cancer (mCRC) (ZN-c3-016). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are collaborating with Pfizer to evaluate azenosertib in combination with encorafenib and cetuximab, an FDA-approved standard of care known as the BEACON regimen, in patients with BRAF V600E mutant mCRC in a Phase 1/2 clinical trial. In preclinical studies, WEE1 inhibition has shown synergy with many targeted agents in mutationally driven cancers, and the addition of azenosertib to the BEACON regimen enhanced anti-tumor activity in a cell-line-derived xenograft model. We initiated enrollment in this clinical trial in the first quarter of 2023.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Combination - Phase 1/2 Clinical Trial of Azenosertib and Chemotherapy in Pancreatic Cancer. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also agreed to support the Dana Farber-sponsored Phase 1/2 clinical trial evaluating azenosertib and chemotherapy, gemcitabine, in platinum-resistant pancreatic cancer patients.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ZN-d5 (BCL-2 Inhibitor)</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ZN-d5 is a potentially best-in-class, selective, oral small molecule inhibitor of BCL-2. BCL-2 is a protein that plays a critical role in the regulation of cell death, known as apoptosis. The overexpression of BCL-2 is frequently detected in numerous cancer types, which prevents apoptosis of cancer cells. Utilizing our medicinal chemistry expertise, we have designed ZN-d5 to have best-in-class potency, selectivity and PK properties. ZN-d5 is currently being evaluated in the clinic in patients with hematological malignancies in both the monotherapy and combination settings.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZN-d5 is being evaluated in the following monotherapy and combination clinical trials:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Monotherapy - Phase 1/2 Clinical Trial in Relapsed or Refractory Light Chain Amyloidosis (R/R AL Amyloidosis) (ZN-d5-003). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ZN-d5 is being evaluated as a monotherapy in a Phase 1/2 clinical trial in R/R AL amyloidosis. BCL-2 inhibition has demonstrated clinical activity in R/R AL amyloidosis; however, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">there are currently no FDA-approved BCL-2 inhibitors for the treatment of R/R AL amyloidosis. This Phase 1/2 study in patients with R/R AL amyloidosis consists of a dose escalation phase to establish the monotherapy dose in this setting, and an expansion phase to further assess the safety and efficacy of ZN-d5 in this population. The study is expected to enroll up to approximately 140 patients.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Monotherapy - Phase 1 Clinical Trial in Non-Hodgkin Lymphoma (NHL) (ZN-d5-001). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are evaluating ZN-d5 as a monotherapy in a Phase 1 dose escalation clinical trial in patients with NHL. As of the database cutoff date of November 3, 2021, 23 patients with NHL were evaluable for safety. At our R&amp;D Day in December 2021, we reported preliminary interim data from the NHL patients in this study. As of the November 3, 2021 database cutoff date, ZN-d5 was well tolerated, with 73.9% of the NHL patients having experienced AEs (30.4% grade 3 or higher), not all of which were related ZN-d5. Anemia (21.7% all grades/8.7% grade 3 or higher), diarrhea (13.0% all grades/4.3% grade 3 or higher), and nausea and vomiting (8.7% each all grades/0% grade 3 or higher) comprise the most commonly experienced AEs. Investigator-reported responses using the Lugano 2014 classification among 11 patients with diffuse large B-cell lymphoma included a complete response, an unconfirmed PR, and two subjects with stable disease, as of the database cutoff date of November 3, 2021.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Combination - Phase 1/2 Clinical Trial of ZN-d5 and Azenosertib in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) (ZN-d5-004C). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ZN-d5 is being evaluated in combination with azenosertib in a Phase 1/2 dose escalation clinical trial in patients with  R/R AML. The Phase 1 portion of this trial will escalate the doses of both drugs to identify the dose for the combination, which will be assessed in Phase 2 expansion cohort(s). This study is expected to enroll up to approximately 100 patients. This clinical trial is supported by preclinical models that showed that the combination of ZN-d5 with azenosertib yielded a significant enhancement of activity in several indications, including R/R AML, as compared to activity shown with either of these product candidates as a single agent. Preclinical models also showed that the combination of ZN-d5 with azenosertib was well tolerated in mice. We believe we are the only company to have both a WEE1 inhibitor and a BCL-2 inhibitor in clinical development.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">BCL-xL Heterobifunctional Degrader</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2022, we announced that we identified a BCL-xL protein degrader candidate and initiated IND-enabling studies. We are developing a BCL-xL heterobifunctional degrader based on non-functional or dysfunctional E3 ubiquitin ligase complex in platelets, allowing for the potential mitigation of dose-limiting thrombocytopenia historically associated with BCL-xL inhibitors.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liquidity Overview</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, our operations have been limited to organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio and performing research and development of our product pipeline. We do not have any products approved for commercial sale and have not generated any revenues from product sales. We will not generate revenue from product sales unless and until we successfully complete clinical development, obtain regulatory approval for and commercialize one or more of our product candidates. We will need to raise substantial additional capital to support our continuing operations and pursue our growth strategy. </span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant operating losses. Our net losses were $237.1 million for the year ended December 31, 2022, and $63.3 million and $59.2 million for the three months ended March&#160;31, 2023 and March&#160;31, 2022, respectively. We had an accumulated deficit of $659.6 million as of March&#160;31, 2023. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We had cash, cash equivalents and marketable securities of $392.5 million as of March&#160;31, 2023. We believe that our existing cash, cash equivalents and marketable securities as of March&#160;31, 2023 will be sufficient to fund our operating expenses and capital expenditure requirements into the second quarter of 2025. We have based these estimates on assumptions that may prove to be imprecise, and we could utilize our available capital resources sooner than we expect. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19 Pandemic and Global Macroeconomic Environment</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor how the COVID-19 pandemic is affecting our employees, business, preclinical studies and clinical trials. At this time, there is continuing uncertainty relating to the trajectory of the COVID-19 pandemic and impact of related responses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of COVID-19 on our future results will largely depend on future developments, which are highly uncertain and cannot be predicted with confidence. See &#8220;Risk Factors&#8212;The COVID-19 pandemic has adversely impacted and we expect will continue to adversely impact our business, including our preclinical studies and clinical trials.&#8221; in Part II, Item 1A. of this Quarterly Report on Form 10-Q. Further, the global economy, including credit and financial markets, has recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, rising interest and inflation rates, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. All of these factors could impact our liquidity and future funding requirements, including but not limited to, our ability to raise additional capital when needed on acceptable terms, if at all. The duration of this economic slowdown is uncertain and the impact on our business is difficult to predict. See &#8220;Risk Factors&#8212;Unfavorable U.S., global, political or economic conditions could adversely affect our business, financial condition or results of operations.&#8221; in Part II, Item 1A. of this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreements and Strategic Collaborations</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recurium IP Holdings, LLC License Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2014, our wholly owned subsidiary, Zeno Pharmaceuticals, Inc., entered into the Recurium Agreement with Recurium IP, which was subsequently amended, under which Zeno Pharmaceuticals, Inc. was granted an exclusive worldwide license to certain intellectual property rights owned or controlled by Recurium IP to develop and commercialize pharmaceutical products for the treatment or prevention of disease, other than for providing pain relief. Following certain corporate restructuring disclosed elsewhere in this Annual Report on 10-K, our wholly owned subsidiary, ZMI, became the Zentalis contracting party to the Recurium Agreement. The intellectual property rights exclusively licensed by ZMI under the Recurium Agreement include certain intellectual property covering azenosertib, ZN-d5 and our BCL-xL product candidate. ZMI has the right to sublicense its rights under the Recurium Agreement, subject to certain conditions. ZMI is required to use commercially reasonable efforts to develop and commercialize at least one product that comprises or contains a compound modulating one of ten specific biological targets and to execute certain development activities. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Recurium Agreement, ZMI is obligated to make development and regulatory milestone payments, pay royalties on net sales, and make certain sublicensing payments with respect to products that comprise or contain a compound modulating one of ten specific biological targets, including azenosertib, ZN-d5, our BCL-xL product candidate and two licensed products for which we discontinued clinical development in 2022, ZN-c5 and ZN-e4. ZMI is obligated to make development and regulatory milestone payments for each such licensed product of up to $44.5 million. In addition, ZMI is obligated to make milestone payments up to $150,000 for certain licensed products used in animals. ZMI is also obligated to pay royalties on sales of such licensed products at a mid- to high-single digit percentage. In addition, if ZMI chooses to sublicense or assign to any third parties its rights under certain patents exclusively in-licensed under the Recurium Agreement, ZMI must pay to Recurium IP 20% of certain sublicensing income received in connection with such transaction.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Recurium Agreement will expire on the later of December 21, 2032 and, on a country-by-country basis, on the date of expiration of the last-to-expire royalty term for all licensed products in such country, unless earlier terminated by either party for cause or a bankruptcy event. </span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Development Agreement </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we entered into a development agreement with Pfizer to collaborate to advance the clinical development of azenosertib. We did not grant Pfizer any economic ownership or control of azenosertib or the rest of our pipeline. In October 2022, we announced our first clinical development collaboration with Pfizer to initiate a </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1/2 dose escalation study of azenosertib, in combination with encorafenib and cetuximab (an FDA-approved standard of care known as the BEACON regimen) in patients with BRAF V600E-mutant mCRC. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">GlaxoSmithKline Clinical Trial Collaboration and Supply Agreement</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, we entered into a clinical trial collaboration and supply agreement with GSK under which we are evaluating the combination of azenosertib and niraparib, GSK&#8217;s poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with platinum-resistant ovarian cancer. Pursuant to this agreement, we are responsible for the conduct and cost of the relevant studies, under the supervision of a joint development committee made up of our representatives and representatives of GSK that meets quarterly. GSK is supplying niraparib for use in the collaboration, at no cost to us. We are required to provide to GSK clinical data and other reports upon completion of the study. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This agreement does not grant any right of first negotiation to participate in future clinical trials, and neither party granted the other any additional right or ability to evaluate their respective compounds in any other clinical studies, either as monotherapy or in combination with any other product or compound, in any therapeutic area. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The agreement with GSK will expire upon completion of all obligations of the parties thereunder or upon termination by either party. We and GSK each have the right to terminate the agreement for material breach by the other party. In addition, the agreement may be terminated by either party due to safety considerations or if either party decides to discontinue development of its own compound for medical, scientific, legal or other reasons or if a regulatory authority takes any action preventing that party from supplying its compound for the study or in the event the other party is subject to specified bankruptcy, insolvency or similar circumstances. GSK also has the right to terminate this agreement if it notifies us in writing that it reasonably and in good faith believes that niraparib is being used in an unsafe manner, and we fail to incorporate changes to address such issue, and the issue is unable to be resolved following elevation to appropriate parties. </span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zentera Therapeutics</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, each of our wholly owned subsidiaries Zeno Alpha, Inc., K-Group Alpha, Inc. and K-Group Beta, Inc. entered into a collaboration and license agreement with our joint venture, Zentera, which we refer to as the &#8220;Zentera Sublicenses&#8221;, pursuant to which we collaborate with Zentera on the development and commercialization of ZN-c5, ZN-d5 and azenosertib, respectively, whether alone or in a licensed product, which we collectively refer to as the "Collaboration Products", in each case for the treatment or prevention of disease, other than for pain, which is referred to as the "Zentera Field", in the People&#8217;s Republic of China, Macau, Hong Kong and Taiwan, which is referred to as the &#8220;Zentera Collaboration Territory&#8221;. As disclosed in August 2022, we have discontinued clinical development of ZN-c5. Under each Zentera Sublicense, Zentera will lead development, and upon regulatory approval, the commercialization, of the Collaboration Products in the Zentera Collaboration Territory. On May 19, 2020, Zentera issued an aggregate of 60.2% of its issued shares of common stock to Zeno Alpha, Inc., K-Group Alpha, Inc., K-Group Beta, Inc., Zeno Management, Inc. and Zeno Beta, Inc. In July 2021, Zentera entered into a Series B Preference Shares Purchase Agreement, pursuant to which it raised $75.0 million in gross proceeds. As of March&#160;31, 2023, we hold a 40.3% equity interest in Zentera. Kevin D. Bunker, Ph.D., our Chief Scientific Officer, serves as a member of the Board of Directors of Zentera. </span></div><div style="margin-bottom:12pt;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under each Zentera Sublicense, we granted Zentera an exclusive, royalty-bearing license under certain of our technology, including technology licensed from Recurium IP under the Recurium Agreement, to develop and commercialize the Collaboration Products in the Zentera Field  in the Zentera Collaboration Territory, subject to certain rights that we retain, and upon a successful manufacturing transfer, a non-exclusive license under certain of our manufacturing technology to manufacture Collaboration Products in the Zentera Field  in the Zentera Collaboration Territory. Zentera has the right to sublicense its rights under the Zentera Sublicenses subject to certain conditions.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Zentera Sublicenses, Zentera is generally responsible for the costs of developing the Collaboration Products in the Zentera Collaboration Territory, and we are generally responsible for the costs of developing the Collaboration Products outside the Zentera Collaboration Territory, provided that Zentera will reimburse us for a portion of its costs for global data management, pharmacovigilance, safety database management, and chemistry, manufacturing and controls activities with respect to each Collaboration Product. Under the Zentera Sublicenses, we will be eligible to receive future development and regulatory milestones of up to $4.45 million per Collaboration Product. Zentera will pay us royalties on net sales of Collaboration Products in the Zentera Collaboration Territory at a mid- to high-single digit percentage, subject to certain reductions. In addition, if Zentera or its affiliate chooses to sublicense or assign to any third parties its rights under the Zentera Sublicenses with respect to any Collaboration Product, Zentera must pay to us 20% of certain sublicensing income received by Zentera or its affiliates in connection with such transaction.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zentera&#8217;s royalty obligations will expire on a Collaboration Product-by-Collaboration Product and region-by-region basis upon the later of the date on which such product is no longer covered by a valid claim of a licensed patent and the 15th anniversary of the first commercial sale of such product in such region.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Results of Operations</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue, and we do not expect to generate any revenue in the foreseeable future from product sales. We have generated, and may in the future generate, revenue from payments received under our collaboration agreements, which includes payments of upfront fees, license fees, milestone-based payments and reimbursements for research and development efforts. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the development of our product candidates, and include: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expenses incurred under agreements with third parties, including contract research organizations, or CROs, and other third parties that conduct research, preclinical activities and clinical trials on our behalf as well as contract manufacturing organizations, or CMOs, that manufacture drug material for use in our preclinical studies and clinical trials; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">costs of outside consultants, including their fees, stock-based compensation and related travel expenses; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">license payments made for intellectual property used in research and development activities; and </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">allocated expenses for rent and maintenance of facilities and other operating costs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. Reimbursed research and development costs under government grants and certain collaborative arrangements are recorded as a reduction to research and development expenses and are recognized in the period in which the related costs are incurred. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We track external development costs by product candidate or development program, but we do not allocate personnel costs, general license payments made under our licensing arrangements or other internal costs to specific </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development programs or product candidates. These costs are included in unallocated research and development expenses in the table below. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses by product candidate or development program:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.897%"><tr><td style="width:1.0%"></td><td style="width:48.713%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.289%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="12" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Azenosertib</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZN-d5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZN-c5<span style="font-size:6.5pt;position:relative;top:-3.5pt;vertical-align:baseline">1</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZN-e4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,584&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,112&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have a higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will continue to increase substantially for the foreseeable future and will comprise a larger percentage of our total expenses as we complete our ongoing clinical trials, initiate new clinical trials, continue to discover and develop additional product candidates and prepare regulatory filings for any product candidates that successfully complete clinical development. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development of our product candidates is highly uncertain. At this time, we cannot determine with certainty the duration and costs of our existing and future clinical trials of our product candidates or any other product candidate we may develop or if, when, or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. We may never succeed in obtaining marketing approval for any product candidate. The duration, costs and timing of clinical trials and development of our product candidates and any other product candidate we may develop in the future will depend on a variety of factors, including:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">per patient trial costs; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of patients who enroll in each trial; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of trials required for approval; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of sites included in the trials; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the countries in which the trials are conducted; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the length of time required to enroll eligible patients; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the drop-out or discontinuation rates of patients; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any delays in clinical trials as a result of the COVID-19 pandemic;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">potential additional safety monitoring requested by regulatory agencies; </span></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As disclosed previously, in August 2022, we announced that we were discontinuing the clinical development of ZN-c5 and ZN-e4.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the duration of patient participation in the trials and follow-up; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the phase of development of the product candidate; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the efficacy and safety profile of the product candidate. </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">uncertainties in clinical trial design and patient enrollment rates; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the actual probability of success for our product candidates, including the safety and efficacy, early clinical data, competition, manufacturing capability and commercial viability; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">significant and changing government regulation and regulatory guidance; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing and receipt of any marketing approvals; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to attract and retain skilled personnel.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, business development and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support research and development activities relating to our clinical stage programs, and any other product candidate we may develop. We also expect to incur increased expenses associated with being a public company, particularly now that we are no longer an emerging growth company, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with Nasdaq and SEC requirements; director and officer insurance costs; and investor and public relations costs. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on cash, cash equivalents and available-for-sale marketable securities.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we and our corporate subsidiaries have generated cumulative federal, state and foreign net operating loss in certain jurisdictions for which we have not recorded any net tax benefit due to uncertainty around utilizing these tax attributes within their respective carryforward periods.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Three Months Ended March 31, 2023 to Three Months Ended March 31, 2022 </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the periods indicated, together with the changes in those items in dollars:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.442%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="6" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase<br/>(Decrease)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="24" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,953&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,879&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,074&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,953)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,879)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,074)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment and other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,844)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,453)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,391)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on equity method investment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,262)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,237)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,025)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Zentalis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,219)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,077)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,142)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Research and development, or R&amp;D, expenses for the three months ended March&#160;31, 2023 were $48.6 million, compared to $46.1 million for the three months ended March&#160;31, 2022. The increase of $2.5 million was primarily due to a $3.2 million increase in overhead allocations driven by an operating lease impairment charge, and an increase of $1.9 million in personnel costs. These increases were partially offset by a $1.8 million decrease in clinical trial-related costs and $0.8 million in decreased collaboration costs. </span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">General and administrative expenses for the three months ended March&#160;31, 2023 were $16.4 million, compared to $11.8 million during the three months ended March&#160;31, 2022. This increase of $4.6 million was primarily attributable to a $5.0 million operating lease impairment charge and a $3.0 million increase in personnel costs, of which $2.7 million was non-cash stock-based compensation. These increases were partially offset by $3.1 million related to the allocation of overhead expenditures, and net reductions in outside services and supplies of $0.3 million.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment and Other Income, Net </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment and other income, net was $4.1 million for the three months ended March&#160;31, 2023, compared to $0.4 million for the three months ended March&#160;31, 2022. The increase of $3.7 million was primarily driven by returns on an increase of invested cash and marketable securities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, our operations have been limited to organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio and performing research and development of our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product pipeline. We do not have any products approved for commercial sale and have not generated any revenues from product sales and we have incurred significant operating losses. We expect to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical and clinical development of our research programs and product candidates. We expect that our research and development and general and administrative costs will increase in connection with conducting additional preclinical studies and clinical trials for our current and future research programs and product candidates, contracting with CMOs to support preclinical studies and clinical trials, expanding our intellectual property portfolio, and providing general and administrative support for our operations. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we will need to raise substantial additional capital to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we plan to finance our operations through the sale of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. There are no assurances that we will be successful in obtaining an adequate level of financing as and when needed to finance our operations on terms acceptable to us or at all, particularly in light of the economic downturn and ongoing uncertainty related to the evolving COVID-19 pandemic, the conflict in Ukraine, ongoing global supply chain issues and increased inflation and interest rates. The COVID-19 pandemic and related global events have resulted in an economic downturn that could adversely affect our operations, our ability to conduct our clinical trials, our ability to raise additional funds through public offerings and the volatility of our stock price and trading in our stock. Even after the effects of the COVID-19 pandemic have subsided, we expect we will continue to experience adverse impacts to our business as a result of any economic recession or depression that has occurred or may occur in the future. If we are unable to secure adequate additional funding as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more product candidates or delay our pursuit of potential in-licenses or acquisitions. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with developing and commercializing therapeutics, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any approved products and have never generated any revenue from product sales. To date, we have financed our operations primarily through the sale of equity securities. From inception through March&#160;31, 2023, we raised a total of $975.9 million in gross proceeds from the sale of our common stock and Series A, B and C convertible preferred units. As of March&#160;31, 2023, we had cash, cash equivalents, and marketable securities of $392.5 million, and an accumulated deficit of $659.6 million. We maintain the majority of our cash and cash equivalents in accounts with major financial institutions, and our deposits at these institutions exceed insured limits.  Market conditions can impact the viability of these institutions.  In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all.  Any inability to access or delay in accessing these funds could adversely affect our business and financial position. We had no indebtedness as of March&#160;31, 2023. </span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM Program</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we entered into a sales agreement, or the Sales Agreement, with SVB Leerink LLC, or SVB Leerink, as sales agent, pursuant to which we may, from time to time, issue and sell common stock with an aggregate value of up to $200.0 million in &#8220;at-the-market&#8221; offerings, or the ATM, under our Registration Statement on Form S-3 (File No. 333-255769) filed with the U.S. Securities and Exchange Commission, or the SEC, on May 4, 2021. Sales of common stock, if any, pursuant to the Sales Agreement, may be made in sales deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a) of the Securities Act of 1933, as amended, or the Securities Act, including sales made directly through The Nasdaq Global Market or any other existing trading market for our common stock. During the quarter ended March&#160;31, 2023, we did not sell any shares of common stock under the Sales Agreement. As of March&#160;31, 2023, there was $140.3 million of common stock remaining available for sale under the Sales Agreement. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Cash Flows </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our sources and uses of cash for the period presented: </span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.441%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,283)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,789)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,142)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred losses since inception. Net cash used in operating activities for the three months ended March&#160;31, 2023 was $49.3 million, consisting primarily of our net loss of $63.3 million as we incurred expenses associated with research and development activities for our product candidates and incurred general and administrative expenses, and offset by non-cash adjustments of $18.0 million and changes in operating assets and liabilities of $4.0 million.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the three months ended March&#160;31, 2023 of $42.1 million was attributable to the proceeds from maturities of marketable securities of $106.0 million, offset by net investment of excess cash of $63.9 million.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March&#160;31, 2023 of $0.4 million was provided from the issuance of common stock under equity incentive plans.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses increased in 2022 and are expected to increase substantially in the future in connection with our ongoing activities. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, our expenses will increase as we:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">advance the clinical development of azenosertib and ZN-d5 for the treatment of oncology indications; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">pursue the preclinical and clinical development of other current and future research programs and product candidates and, if applicable, diagnostics tools for biomarkers associated with our product candidates and future product candidates;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">in-license or acquire the rights to other products, product candidates or technologies; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">maintain, expand and protect our intellectual property portfolio; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">hire additional personnel, including in research, manufacturing and regulatory and clinical development, as well as management personnel; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">seek regulatory approval for any product candidates and, if needed, diagnostic tools for biomarkers associated with such product candidates, that successfully complete clinical development; and </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expand our operational, financial and management systems and increase personnel, including personnel to support our operations as a public company.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing cash, cash equivalents and marketable securities as of March&#160;31, 2023 will be sufficient to fund our operating expenses and capital expenditure requirements into the second quarter of 2025.  We have based these estimates on assumptions that may prove to be imprecise, and we could utilize our available capital resources sooner than we expect. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical drugs, it is difficult to estimate with certainty the amount of our working capital requirements. Our future funding requirements will depend on many factors, including:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the progress, costs and results of our clinical trials for our programs for azenosertib and ZN-d5;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the progress, costs and results of additional research and preclinical studies in other research programs we initiate in the future and, if needed, of diagnostic tools for biomarkers associated with our product candidates and future product candidates; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs and timing of process development and manufacturing scale-up activities associated with our product candidates and other programs as we advance them through preclinical and clinical development; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to establish and maintain strategic collaborations, licensing or other agreements and the financial terms of such agreements; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the extent to which we in-license or acquire rights to other products, product candidates or technologies;  </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against any intellectual property-related claims; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to attract and retain skilled personnel.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the magnitude and duration of the COVID-19 pandemic and its impact on our liquidity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and future funding requirements is uncertain as of the filing date of this Quarterly Report on Form 10-Q, as the pandemic continues to evolve globally. See &#8220;Impact of COVID-19 Pandemic&#8221; and &#8220;Risk Factors&#8212;The COVID-19 pandemic has adversely impacted and we expect will continue to adversely impact our business, including our preclinical studies and clinical trials&#8221;. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, our operating results may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time as we can generate significant revenue from product sales, if ever, we plan to finance our operations through the sale of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no credit facility or committed sources of capital. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through other third-party funding, collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to our critical accounting estimates from our disclosure reported in &#8220;Critical Accounting Estimates&#8221; in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not entered into any off-balance sheet arrangements.</span></div><div id="iede2e4c8548c40d4910b7a838a08d814_79"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="iede2e4c8548c40d4910b7a838a08d814_82"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls and Procedures</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March&#160;31, 2023.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) identified in management&#8217;s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act that occurred during the quarter ended March&#160;31, 2023 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="iede2e4c8548c40d4910b7a838a08d814_85"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="iede2e4c8548c40d4910b7a838a08d814_88"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to any material legal proceedings.</span></div><div id="iede2e4c8548c40d4910b7a838a08d814_91"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the risks and uncertainties described below and the other information in this Quarterly Report on Form 10-Q, including our interim unaudited condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. Our business, financial condition, results of operations or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our common stock could decline and you could lose all or part of your investment. This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. See &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221; Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain important factors, including those set forth below. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. We have no products approved for commercial sale and have not generated any revenue from product sales. To date, we have devoted substantially all of our resources and efforts to organizing and staffing our company, business planning, executing partnerships, raising capital, discovering, identifying and developing potential product candidates, securing related intellectual property rights and conducting preclinical studies and clinical trials of our product candidates, including the ongoing clinical trials of azenosertib and ZN-d5. We have not yet demonstrated our ability to obtain marketing approvals, manufacture a product at commercial scale or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. As a result, it may be more difficult for you to accurately predict our future success or viability than it could be if we had a longer operating history. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by clinical stage biopharmaceutical companies in rapidly evolving fields. We also may need to transition from a company with a research and development focus to a company capable of supporting commercial activities. If we do not adequately address these risks and difficulties or successfully make such a transition, our business will suffer. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have incurred net losses in each reporting period since our inception, we have not generated any revenue from product sales to date, and we have financed our operations principally through private financings, our initial public offering, or IPO, and follow-on public offerings of our common stock. We have incurred net losses of $237.1 million for the year ended December&#160;31, 2022, and $63.3 million and $59.2 million for the three months ended March&#160;31, 2023 and March&#160;31, 2022, respectively. As of March&#160;31, 2023, we had an accumulated deficit of $659.6 million. Our losses have resulted principally from expenses incurred in research and development of our product candidates and from management and administrative costs and other expenses that we have incurred while building our business infrastructure. We expect that it will be several years, if ever, before we have a commercialized product and generate revenue from product sales. Even if we succeed in receiving marketing approval for and commercializing one or more of our product candidates, we expect that we will continue to incur substantial research and development and other expenses as we discover, develop and market additional potential products. </span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we continue our research and development efforts and seek to obtain regulatory approval and commercialization of our product candidates. The net losses we incur may fluctuate significantly from quarter to quarter such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our working capital and our ability to achieve and maintain profitability. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve a number of objectives. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends entirely on the successful discovery, development and commercialization of our product candidates. We currently generate no revenues from sales of any products. We have no products approved for commercial sale and do not anticipate generating any revenue from product sales for the next several years, if ever. Our ability to generate revenue and achieve profitability depends significantly on our ability, or any future collaborator&#8217;s ability, to achieve a number of objectives, including: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">successful and timely completion of preclinical and clinical development of our product candidates, including azenosertib and ZN-d5 and any other future product candidates, as well as the associated costs, including any unforeseen costs we have incurred and may continue to incur as a result of preclinical study or clinical trial delays due to public health emergencies, including the COVID-19 pandemic, U.S. and global economic issues, including rising inflation and interest rates, or the ongoing military conflict in Ukraine, among other causes; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if applicable, the availability or successful development of diagnostic tools for biomarkers associated with our product candidates or any other future product candidates;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establishing and maintaining relationships with CROs and clinical sites for the clinical development, both in the United States and internationally, of our product candidates, including azenosertib and ZN-d5, and any other future product candidates; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">timely receipt of marketing approvals from applicable regulatory authorities for any product candidates for which we successfully complete clinical development; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">maintaining marketing approvals, including making any required post-marketing approval commitments to applicable regulatory authorities; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developing an efficient and scalable manufacturing process for our product candidates, including obtaining finished products that are appropriately packaged for sale; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establishing and maintaining commercially viable supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and meet the market demand for product candidates that we develop, if approved; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">successful commercial launch following any marketing approval, including the development of a commercial infrastructure, whether in-house or with one or more collaborators; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a continued acceptable safety profile following any marketing approval of our product candidates; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">commercial acceptance of our product candidates by patients, the medical community and third-party payors; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">identifying, assessing and developing new product candidates; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining, maintaining and expanding our intellectual property rights, including patents, trade secrets and know how, and regulatory exclusivity, both in the United States and internationally; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">protecting our rights in our intellectual property portfolio; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">defending against third-party interference or infringement claims, if any; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">negotiating favorable terms in any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining adequate pricing, coverage and reimbursement by hospitals, government and third-party payors for product candidates that we develop; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">addressing any competing therapies and technological and market developments; and </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">attracting, hiring and retaining qualified personnel, especially in the current labor market.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may never be successful in achieving our objectives and, even if we do, may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to maintain or further our research and development efforts, raise additional necessary capital, grow our business and continue our operations. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase in connection with our ongoing activities, particularly as we initiate and conduct clinical trials of, and seek marketing approval for, azenosertib, ZN-d5 and our other product candidates. Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond our expectations if we are required by the FDA, the European Medicines Agency, or the EMA, or other regulatory agencies to perform clinical trials or preclinical studies in addition to those that we currently anticipate. We may also incur costs related to collaborating with certain diagnostic companies for the development, manufacturing and supply of diagnostic tools for biomarkers associated with our product candidates and any future product candidates. Other unanticipated costs may also arise. In addition, if we obtain marketing approval for any of our product candidates, including azenosertib and ZN-d5, we expect to incur significant commercialization expenses related to drug sales, marketing, manufacturing and distribution. Because the design and outcome of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any product candidate we develop. We have also incurred, and expect to continue to incur, additional costs associated with operating as a public company, particularly now that we are no longer an emerging growth company. Accordingly, we will need to obtain substantial additional funding in order to maintain our continuing operations. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had cash and cash equivalents and marketable securities of $392.5 million. Based on current business plans, we believe that our existing cash, cash equivalents and marketable securities as of March&#160;31, 2023 will be sufficient to fund our operating expenses and capital expenditure requirements into the second quarter of 2025, but will not be sufficient to fund all of the activities that are necessary to complete the development of our product candidates. This estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain the majority of our cash and cash equivalents in accounts with major U.S. and multi-national financial institutions, and our deposits at certain of these institutions exceed insured limits. Market conditions can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources, which may dilute our stockholders or restrict our operating activities. We do not have any committed external source of funds. Adequate additional financing may not be available to us on acceptable terms, or at all. Market volatility resulting from public health emergencies such as the COVID-19 pandemic, U.S. and global economic issues, global supply chain disruptions, international political instability, rising inflation and interest rates or other factors could also adversely impact our ability to access capital as and when needed. Our failure to raise capital as and when needed or on acceptable terms would have a negative impact on our financial condition and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our research-stage programs, clinical trials or future commercialization efforts. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery, Development and Commercialization of Our Product Candidates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on the success of our lead product candidates, azenosertib and/or ZN-d5, which are currently in clinical trials. If we are unable to complete development of, obtain approval for and commercialize these product candidates in a timely manner, our business will be harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is dependent on our ability to timely complete clinical trials, obtain marketing approval for and successfully commercialize our lead product candidates. We are investing significant efforts and financial resources in the research and development of our product candidates, which will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, marketing approval from government regulators, substantial investment and significant marketing efforts before we can generate any revenues from product sales. We are not permitted to market or promote any other product candidate before we receive marketing approval from the FDA and comparable ex-U.S. regulatory authorities, and we may never receive such marketing approvals. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our lead product candidates will depend on several factors, including the following: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the successful and timely completion of our ongoing and planned clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">maintaining and establishing relationships with CROs and clinical sites for the clinical development of our product candidates both in the United States and internationally; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the frequency and severity of AEs observed in clinical trials; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">efficacy, safety and tolerability profiles that are satisfactory to the FDA or any comparable ex-U.S. regulatory authority for marketing approval; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timely receipt of marketing approvals from applicable regulatory authorities; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the extent of any required post-marketing approval commitments to applicable regulatory authorities; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if applicable, the availability or successful development of diagnostic tools for biomarkers associated with our product candidates or any other future product candidates;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the maintenance of existing or the establishment of new supply arrangements with third-party drug substance and drug product suppliers and manufacturers for clinical development of our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the maintenance of existing, or the establishment of new, scaled production arrangements with third-party manufacturers to obtain finished products that are appropriate for commercial sale of our product candidates if approved, including for supplies of drugs that we are testing in combination with our product candidates; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining and maintaining our intellectual property rights, including patents, trade secrets and know how, and regulatory exclusivity, both in the United States and internationally; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the protection of our rights in our intellectual property portfolio; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the successful launch of commercial sales following any marketing approval; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a continued acceptable safety profile following any marketing approval; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">commercial acceptance by patients, the medical community and third-party payors; and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to compete with other therapies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business. If we do not receive marketing approvals for our product candidates, we may not be able to continue our operations. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have and in the future may enter into collaborations with third parties for the research, development and commercialization of certain of the product candidates we may develop. If any of these collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have and in the future may seek third-party collaborators for the research, development and commercialization of one or more of our product candidates. For example, we are collaborating with Pfizer on development of azenosertib, GSK on development of azenosertib, Dana Farber on development of azenosertib, and Zentera on development of certain of our product candidates, including azenosertib and ZN-d5, in certain Asian jurisdictions including China. Our likely collaborators in any future collaboration arrangements we may enter into include large and mid-size pharmaceutical companies and biotechnology companies. If we were to enter into any collaboration arrangements with third parties, those agreements may limit our control over the amount and timing of resources that our collaborators dedicate to the development and commercialization of any product candidates we may seek to develop with them. We cannot predict the success of any collaboration in which we have entered or may enter. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations involving our research programs, our product candidates and any future research programs or product candidates we may develop pose the following risks to us: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations. </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Collaborators may not pursue development and commercialization of any product candidates we may develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator's strategic focus or market considerations, including as a result of a sale or disposition of a business unit or development function, or available funding or external factors such as an acquisition or business combination that diverts resources or creates competing priorities. If this were to happen, we may need additional capital to pursue further development or commercialization of the applicable product candidates. </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, use our product candidates in clinical trials in an unsafe manner, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing. </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours. </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Subject to certain diligence obligations, collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Collaborators may not properly obtain, maintain, enforce or defend our intellectual property or proprietary rights or may use proprietary information in a way that could jeopardize or invalidate our proprietary information or expose us to potential litigation. </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in cases where that applies, we would not have the exclusive right to commercialize the collaboration intellectual property. </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Disputes may arise between our collaborators and us that result in the delay or termination of the research, development or commercialization of our products or product candidates or that result in costly litigation or arbitration that diverts management attention and resources. </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We may lose certain rights under circumstances identified in our collaborations, including if we undergo a change of control. </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates. </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated. </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Collaborators may be unable to maintain compliance with applicable laws, regulations and guidance, including good practice quality guidelines and regulations, including good laboratory practice, or GLP, good clinical practice, or GCP, and current good manufacturing practice, or cGMP, or to secure approval for clinical development plans from the FDA or comparable ex-U.S. regulatory authorities.</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We may require certain regulatory, clinical, manufacturing, financial and other information from our collaborators, which, if not provided in a timely manner or at all, could affect our ability to meet our business objectives and/or comply with applicable laws, regulations and guidance. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not receive the funding we expect under these agreements, our development of product candidates could be delayed and we may need additional resources to develop our product candidates. In addition, if one of our collaborators terminates its agreement with us, we may find it more difficult to find a suitable replacement collaborator or attract new collaborators and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, marketing approval and commercialization described in this report apply to the activities of our collaborators. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of any product candidates we may develop. These and other similar relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we could face significant competition in seeking appropriate collaborators and the negotiation process is time-consuming and complex. Our ability to reach a definitive collaboration agreement will depend, among other things, upon our assessment of the collaborator's resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator's evaluation of several factors. If we license rights to any product candidates we or our collaborators may develop, we may not be able to realize the benefit of those transactions if we are unable to successfully integrate them with our existing operations and company culture. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our long-term prospects depend in part upon discovering, developing and commercializing additional product candidates, which may fail in development or suffer delays that adversely affect their commercial viability.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future operating results are dependent on our ability to successfully discover, develop, obtain regulatory approval for and commercialize product candidates beyond those we currently have in clinical development. A product candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for product candidates is high due to risks relating to safety, efficacy, clinical execution, changing standards of medical care and other unpredictable variables. The results from preclinical testing or early clinical trials of a product candidate may not be predictive of the results that will be obtained in later stage clinical trials of the product candidate.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of other product candidates we may develop will depend on many factors, including the following:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">generating sufficient data to support the initiation or continuation of clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining regulatory permission to initiate clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">contracting with the necessary parties to conduct clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">successful enrollment of patients in, and the completion of, clinical trials on a timely basis;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timely manufacture of sufficient quantities of the product candidate for use in clinical trials; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">AEs in the clinical trials.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we successfully advance any other product candidates into clinical development, their success will be subject to all of the clinical, regulatory and commercial risks described elsewhere in this &#8220;Risk Factors&#8221; section. Accordingly, we cannot assure you that we will ever be able to discover, develop, obtain regulatory approval of, commercialize or generate significant revenue from our other product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and other comparable ex-U.S. regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Ex-U.S. regulatory authorities impose similar requirements. The time required to obtain approval by the FDA and other comparable ex-U.S. regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Even if we eventually complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA and other comparable ex-U.S. regulatory authorities may approve our product candidates for a more limited indication or a narrower patient population than we originally requested. We have not submitted for, or obtained, regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applications for our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA or other comparable ex-U.S. regulatory authorities may disagree with the design, implementation or results of our clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA or other comparable ex-U.S. regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA or other comparable ex-U.S. regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a New Drug Application, or NDA, or other submission or to obtain regulatory approval in the United States or elsewhere;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be unable to demonstrate to the FDA or other comparable ex-U.S. regulatory authorities that a product candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA or other comparable ex-U.S. regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if the FDA or comparable regulatory authority requires approval or clearance of a companion diagnostic for a particular product candidate, and the FDA or comparable regulatory authority does not provide such approval or clearance, then the product candidate may not be approved for marketing; and/or</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the approval policies or regulations of the FDA or other comparable ex-U.S. regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the policies and practices of the FDA and other regulatory authorities' with respect to clinical trials may change and additional government regulations may be enacted. For example, in recent years the FDA has issued draft guidance and launched programs aiming to reform and modernize the dose optimization procedures used by clinical trial sponsors during the development of oncology drugs. Although these efforts have not yet resulted in any formal changes to the FDA&#8217;s regulations or policies, changes in the FDA&#8217;s thinking with respect to dose selection and optimization could require us to change the design of our planned or ongoing clinical trials or otherwise conduct additional preclinical, clinical or manufacturing studies beyond those we currently anticipate, which could increase our costs and/or delay the development of our product candidates. The FDA has also issued a draft guidance regarding diversity in clinical trials. The purpose of this guidance is to provide recommendations to sponsors developing medical products on the approach for developing a Race and Ethnicity Diversity Plan to enroll representative numbers of participants from underrepresented racial and ethnic populations in the United States. If implemented, the FDA will evaluate the Race and Ethnicity Diversity Plan as an important part of the sponsor&#8217;s development program. This could require us to change the way we enroll our planned clinical trials, which could increase our costs and/or delay the development of our product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the regulatory landscape related to clinical trials in the European Union, or EU, recently evolved. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the Clinical Trials Directive required a separate clinical trial application, or CTA, to be submitted in each member state, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single submission to both the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. Clinical trials for which an application was submitted (i) prior to January 31, 2022 under the Clinical Trials Directive, or (ii) between January 31, 2022 and January 31, 2023 and for which the sponsor has opted for the application of the Clinical Trials Directive remain governed by said Directive until January 31, 2025. After this date, all clinical trials, including those that are ongoing, will become subject to the provisions of the CTR. Compliance with the CTR requirements by us, our collaborators and third-party service providers, such as CROs, may impact our development plans.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we obtain approval of our product candidates, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may impose significant limitations in the form of narrow indications, warnings, or a Risk Evaluation and Mitigation Strategy, or REMS, or similar risk management measures. Regulatory authorities may not approve the price we intend to charge for products we may develop, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could seriously harm our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The clinical trials of our product candidates may not demonstrate safety and efficacy to the satisfaction of the FDA or other comparable ex-U.S. regulatory authorities or otherwise produce positive results.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining marketing approval from the FDA or other comparable ex-U.S. regulatory authorities for the sale of our product candidates, we must complete preclinical development and extensive clinical trials to demonstrate the safety and efficacy of our product candidates. Clinical testing is expensive, difficult to design and implement, can take many years to complete and its ultimate outcome is uncertain. A failure of one or more clinical trials can occur at any stage of the process. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials, including that potential biomarkers, even if validated preclinically, may not be functionally validated in clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs. We cannot guarantee that the FDA or comparable ex-U.S. regulatory authorities will interpret trial results as we do, and more trials could be required before we are able to submit applications seeking approval of our product candidates, which may require us to expend significant resources that may not be available to us. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may rely in part on preclinical, clinical and quality data generated by CROs, our collaborators and other third parties for regulatory submissions for our product candidates. While we have or will have agreements governing our relationships with these third parties, we have limited influence over their actual performance. If these third parties do not make data available to us, or, if applicable, make regulatory submissions in a timely manner, in each case pursuant to our agreements with them, our development programs may be significantly delayed, and we may need to conduct additional studies or collect additional data independently. In either case, our development costs would increase.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not know whether our future clinical trials will begin on time or enroll patients on time, or whether our ongoing and/or future clinical trials will be completed on schedule or at all. Clinical trials can be delayed for a variety of reasons, including delays related to:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA or comparable ex-U.S. regulatory authorities disagreeing as to the design or implementation of our clinical studies;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining regulatory authorizations to commence a trial or reaching a consensus with regulatory authorities on trial design;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining approval from one or more institutional review boards, or IRBs, or ethics committees;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">IRBs or ethics committees refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes to clinical trial protocol;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical sites deviating from trial protocol or dropping out of a trial;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">manufacturing sufficient quantities of product candidate or obtaining sufficient quantities of combination therapies for use in clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subjects failing to enroll or remain in our trial at the rate we expect, or failing to return for post-treatment follow-up;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subjects choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">lack of adequate funding to continue the clinical trial;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subjects experiencing severe or unexpected drug-related AEs;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">occurrence of serious AEs in trials of the same class of agents conducted by other companies;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">selection of clinical end points that require prolonged periods of clinical observation or analysis of the resulting data;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a facility manufacturing our product candidates or any of their components being ordered by the FDA or comparable ex-U.S.regulatory authorities to temporarily or permanently shut down due to violations of cGMP regulations or similar ex-U.S. requirements or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any changes to our manufacturing process that may be necessary or desired;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, GCP, or other regulatory requirements;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">third-party contractors not performing data collection or analysis in a timely or accurate manner; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications; and/or</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if we are collaborating with a third party on a clinical trial, our collaborator may not devote sufficient resources to or prioritize our clinical trial.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, disruptions caused by the COVID-19 pandemic have caused and may continue to cause difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable ex-U.S. regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable ex-U.S. regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs or ethics committees for reexamination, which may impact the costs, timing or successful completion of a clinical trial.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, conducting clinical trials in ex-U.S. countries, as we may do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in ex-U.S. countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with ex-U.S. regulatory schemes, as well as political and economic risks relevant to such ex-U.S. countries.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable ex-U.S. regulatory authorities. The FDA or comparable ex-U.S. regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable ex-U.S. regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable ex-U.S. regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Any delays to our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize our product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to successfully develop diagnostic tools for biomarkers that enable patient selection, or experience significant delays in doing so, we may not realize the full commercial potential of our product candidates.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A component of our strategy may include the use of diagnostic tools to guide patient selection of our product candidates. In some cases, a diagnostic tool may be commercially available, for example, on a tumor-profiling panel. If not already commercially available, we may be required to seek collaborations with diagnostic companies for the development of diagnostics for biomarkers associated with our product candidates. We may have difficulty in establishing or maintaining such development relationships, and we will face competition from other companies in establishing these collaborations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also several risks associated with biomarker identification and validation. We, in collaboration with any diagnostic partners, may not be able to identify predictive biomarkers for one or more of our programs. We may not be able to validate potential biomarkers (e.g., certain genomic mutations) or their functional relevance preclinically in relevant </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> models. Data analytics and information from databases that we rely on for identifying or validating some of our biomarker-target relationships may not accurately reflect potential patient populations or may be based on incorrect methodology. Potential biomarkers, even if validated preclinically, may not be functionally effective or validated in human clinical trials. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, in collaboration with these parties, are unable to successfully develop diagnostic tools for our product candidates, or experience delays in doing so, the development of our product candidates may be adversely affected. The development of certain diagnostic tools, such as companion diagnostics, require a significant investment of working capital and may not result in any future income. This could require us to raise additional funds, which could dilute our current investors or impact our ability to continue our operations in the future.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also risks associated with diagnostics that are commercially available, including that we may not have access to reliable supply for such diagnostics, and that we may not be able to obtain reimbursement for its use without obtaining regulatory approval.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, initial, &#8220;topline&#8221;, and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose initial, preliminary or topline data from our preclinical studies and clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the initial, topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Certain of these data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, initial, topline and preliminary data should be viewed with caution until the final data are available.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initial, interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if approved, our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our product candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients, healthcare payors and others in the medical community. The degree of market acceptance of any of our approved product candidates will depend on a number of factors, including:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the efficacy and safety profile as demonstrated in clinical trials compared to alternative treatments;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing of market introduction of the product candidate as well as competitive products;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the clinical indications for which the product candidate is approved;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if applicable, the availability of diagnostic tools for biomarkers associated with our product candidates or any other future product candidates;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on the use of our product candidates, such as boxed warnings or contraindications in labeling, or a REMS, or similar risk management measures, if any, which may not be required of alternative treatments and competitor products;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential and perceived advantages of product candidates over alternative treatments;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of treatment in relation to alternative treatments;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the availability of coverage and adequate reimbursement, as well as pricing, by third-party payors, including government authorities;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the availability of the approved product candidate for use as a combination therapy;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">relative convenience and ease of administration;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the effectiveness of sales and marketing efforts;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">unfavorable publicity relating to our products or product candidates or similar approved products or product candidates in development by third parties; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the approval of other new therapies for the same indications.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate or derive sufficient revenue from that product candidate and our financial results could be negatively impacted.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment is a significant factor in the timing of clinical trials, and the timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to such trial&#8217;s conclusion as required by the FDA or comparable ex-U.S. regulatory authorities. Additionally, certain clinical trials for future product candidates may be focused on indications with relatively small patient populations, which may further limit enrollment of eligible patients or may result in slower enrollment than we anticipate. The eligibility criteria of our clinical trials, once established, may further limit the pool of available trial participants.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment may also be affected if our competitors have ongoing clinical trials for product candidates that are under development for the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment for any of our clinical trials may be affected by other factors, including:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">size and nature of the patient population;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">severity of the disease under investigation;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">availability and efficacy of approved drugs for the disease under investigation;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">patient eligibility criteria for the trial in question as defined in the protocol;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">perceived risks and benefits of the product candidate under study;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">patient referral practices of physicians;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ability to monitor patients adequately during and after treatment;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">proximity and availability of clinical trial sites for prospective patients;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continued enrollment of prospective patients by clinical trial sites; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may be late-stage cancer patients, will not survive the full terms of the clinical trials.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain marketing approval for the sale of our product candidates. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining enrollment of such patients in our clinical trials.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are developing our product candidates in combination with other therapies, which exposes us to additional risks.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing azenosertib and ZN-d5 in combination with one or more other approved or unapproved therapies to treat cancer or other diseases and may in the future develop additional product candidates in combination with other approved or unapproved therapies. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the risks that the FDA or comparable ex-U.S. regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing therapies. If the therapies we use in combination with our product candidates are replaced as the standard of care for the indications we choose for any of our product candidates, the FDA or comparable ex-U.S. regulatory authorities may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may choose to evaluate our product candidates in combination with one or more cancer therapies that have not yet been approved for marketing by the FDA or comparable ex-U.S. regulatory authorities. We will not be able to market and sell any product candidate we develop in combination with an unapproved cancer therapy for a combination indication if that unapproved therapy does not ultimately obtain marketing approval either alone or in combination with our product. In addition, unapproved cancer therapies face the same risks described with respect to our product candidates currently in development and clinical trials, including the potential for serious adverse effects, delay in their clinical trials and lack of regulatory approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or comparable ex-U.S. regulatory authorities do not approve these other drugs or revoke their approval of, or if safety, efficacy, quality, manufacturing or supply issues arise with, the drugs we choose to evaluate in combination with our product candidate we develop, we may be unable to obtain approval of or market such combination therapy. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market opportunity for any product candidate that we or our strategic partners develop is smaller than we believe, our revenue may be adversely affected and our business may suffer.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our projections of addressable patient populations that may benefit from treatment with our product candidates are based on our estimates. These estimates, which have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations and market research, may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. Additionally, the potentially addressable patient population for our product candidates may not ultimately be amenable to treatment with our product candidates. Our market opportunity may also be limited by future competitor treatments that enter the market. If any of our estimates proves to be inaccurate, the market opportunity for any product candidate that we or our strategic partners develop could be significantly diminished and have an adverse material impact on our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In addition, our products may need to compete with off-label drugs used by physicians to treat the indications for which we seek approval. This may make it difficult for us to replace existing therapies with our products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, there is intense competition in the fields of oncology we are pursuing. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, emerging and start-up companies, universities and other research institutions. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling subjects for clinical trials and in identifying and in-licensing new product candidates.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have chosen to initially address well-validated biochemical targets, and therefore expect to face competition from existing products and products in development for each of our product candidates. There are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. Many of these current and potential competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources and commercial expertise than we do. Large pharmaceutical and biotechnology companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing biotechnology products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result of all of these factors, our competitors may succeed in obtaining approval from the FDA or other comparable ex-U.S. regulatory authorities or in discovering, developing and commercializing products in our field before we do.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any products that we may develop. Our competitors also may obtain marketing approval from the FDA or other comparable ex-U.S. regulatory authorities for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Even if the product candidates we develop achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs, therapeutic platforms and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other therapeutic platforms or product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs, therapeutic platforms and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As product candidates progress through preclinical and clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenue.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage such inability could have an adverse effect on our business and financial condition.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA or other regulatory authority investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs. FDA or other regulatory authority investigations could potentially lead to a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources and substantial monetary awards to trial participants or patients. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to marketing any of our product candidates, if approved. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have an adverse effect on our business and financial condition. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, may apply to diagnostic tools, such as companion diagnostics, that we or our collaborators may develop.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability and extent of coverage and adequate reimbursement by third-party payors, including government health administration authorities, private health coverage insurers, managed care organizations and other third-party payors is essential for most patients to be able to afford expensive treatments. Sales of any of our product candidates that receive marketing approval will depend substantially, both in the United States and internationally, on the extent to which the costs of our product candidates will be covered and reimbursed by third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, for example, principal decisions about reimbursement for new products are typically made by the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. As a result, the coverage determination process is often time-consuming and costly. This process will require us to provide scientific and clinical support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical product candidates. There may be especially significant delays in obtaining coverage and reimbursement for newly approved </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our products. Nonetheless, our product candidates may not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). For more information about the IRA and pricing regulations at the state level, see &#8220;Risks Related to Regulatory Approval and Other Legal Compliance Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211; We may face difficulties from changes to current regulations and future legislation.&#8221; below</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the member states of the EU, medical product prices are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after a product receives marketing authorization. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, product prices under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products, but monitor and control company profits. Additional ex-U.S. price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we or our collaborators may develop diagnostic tests, including companion diagnostic tests, for use with our product candidates. Companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical products, will apply to companion diagnostics. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize any product candidates that we develop.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval and Other Legal Compliance Matters</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to obtain U.S. or ex-U.S. regulatory approvals and, as a result, may be unable to commercialize our product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process must be successfully completed in the United States and in many ex-U.S. jurisdictions before a new drug can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. We cannot provide any </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assurance that any product candidate we may develop will progress through required clinical testing and obtain the regulatory approvals necessary for us to begin selling them.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not conducted, managed or completed large-scale or pivotal clinical trials nor managed the regulatory approval process with the FDA or any other regulatory authority. The time required to obtain approvals from the FDA and other regulatory authorities is unpredictable, and requires successful completion of extensive clinical trials which typically takes many years, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its ex-U.S. counterparts use when evaluating clinical trial data can and often changes during drug development, which makes it difficult to predict with any certainty how they will be applied. In addition, the FDA and its ex-U.S. counterparts may require approval or clearance of a companion diagnostic for a particular product candidate and may not approve the product candidate for marketing if such regulatory authority does not approve or clear the companion diagnostic. We may also encounter unexpected delays or increased costs due to new government regulations, including future legislation or administrative action, or changes in FDA or ex-U.S. regulatory authorities policy during the period of drug development, clinical trials and FDA or ex-U.S. regulatory authorities  regulatory review.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay or failure in seeking or obtaining required approvals would have a material and adverse effect on our ability to generate revenue from the particular product candidate for which we developing and seeking approval. Furthermore, any regulatory approval to market a drug may be subject to significant limitations on the approved uses or indications for which we may market the drug or the labeling or other restrictions. In addition, the FDA has the authority to require a REMS as part of approving a NDA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. Similar requirements may exist in ex-U.S. jurisdictions. These requirements or restrictions might include limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may significantly limit the size of the market for the drug and affect reimbursement by third-party payors.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to numerous ex-U.S. regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The ex-U.S. regulatory approval process varies among countries, and generally includes all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in ex-U.S. jurisdictions. Moreover, the time required to obtain approval in ex-U.S. jurisdictions may differ from that required to obtain FDA approval.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current or future product candidates may cause significant AEs, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with pharmaceuticals generally, it is likely that there may be side effects and AEs associated with our product candidates&#8217; use. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable ex-U.S. regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidates are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical trials when used alone or in combination with other approved products or investigational new drugs, we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial, or result in potential product liability </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">claims. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected product candidate and may harm our business, financial condition and prospects significantly.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in our ongoing and planned clinical trials may in the future suffer significant AEs or other side effects not observed in our preclinical studies or previous clinical trials. Some of our product candidates may be used as chronic therapies or be used in pediatric populations, for which safety concerns may be particularly scrutinized by regulatory agencies. In addition, if our product candidates are used in combination with other therapies, our product candidates may exacerbate AEs associated with the therapy. Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments, which can cause side effects or AEs that are unrelated to our product candidate, but may still impact the success of our clinical trials. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients&#8217; illnesses.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If significant AEs or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to the clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of that product candidate altogether. We, the FDA other comparable regulatory authorities or an IRB may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if any of our product candidates obtains marketing approval, toxicities associated with such product candidates and not seen during clinical testing may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional contraindications, warnings and precautions being added to the drug label, significant restrictions on the use of the product or the withdrawal of the product from the market. We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on preclinical studies or early-stage clinical trials.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA and other comparable ex-U.S. regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may choose to conduct international clinical trials in the future. The acceptance of study data by the FDA or other comparable ex-U.S. regulatory authority from clinical trials conducted outside of their respective jurisdictions may be subject to certain conditions. The acceptance of study data from clinical trials conducted outside the U.S. or another jurisdiction by the FDA or comparable ex-U.S. regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from ex-U.S. clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of ex-U.S. data alone unless i) the data are applicable to the U.S. population and U.S. medical practice; ii) the trials were performed by clinical investigators of recognized competence and pursuant to current GCP requirements; and iii) the FDA is able to validate the data through an on-site inspection or other appropriate means. Additionally, the FDA's clinical trial requirements, including the adequacy of the patient population studied and statistical powering, must be met. Furthermore, even where the ex-U.S. study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many ex-U.S. regulatory authorities have similar approval requirements. In addition, such ex-U.S. trials would be subject to the applicable local laws of the ex-U.S. jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable ex-U.S. regulatory authority will accept data from trials conducted outside of its applicable jurisdiction. If the FDA or any comparable ex-U.S. regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval for commercialization in the applicable jurisdiction.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in ex-U.S. jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the product candidate in those countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining ex-U.S. regulatory approvals and establishing and maintaining compliance with ex-U.S. regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or ex-U.S. regulatory authorities approve our product candidates, the manufacturing processes, labeling, packaging, distribution, AE reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with cGMPs or similar ex-U.S. requirements and GCP for any clinical trials that we conduct post-approval. In addition, CMOs and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations or similar ex-U.S. requirements and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA and other comparable ex-U.S. regulatory requirements may subject our company to administrative or judicially imposed sanctions, including:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in or the rejection of product approvals;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on the products, manufacturers or manufacturing process;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">warning or untitled letters;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">civil and criminal penalties;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">injunctions;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">suspension or withdrawal of regulatory approvals;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">product seizures, detentions or import bans;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">voluntary or mandatory product recalls and publicity requirements;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">total or partial suspension of production; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">imposition of restrictions on operations, including costly new manufacturing requirements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA, the SEC and other government agencies caused by funding shortages or global health concerns could prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA and other regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes, and other events that may otherwise affect the FDA&#8217;s and ex-U.S. regulatory authorities&#8217; ability to perform routine functions. Average review times at the FDA and ex-U.S. regulatory authorities have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies, such as the EMA, following its relocation to Amsterdam and resulting staff changes, may also slow the time necessary for new drugs to be reviewed and/or approved by necessary </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government agencies, which would adversely affect our business. For example, in recent years, including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. Further, in our operations as a public company, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the COVID-19 pandemic, the FDA postponed most inspections of domestic and ex-U.S. manufacturing facilities at various points. Even though the FDA has since resumed standard inspection operations of domestic facilities where feasible, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the entities it regulates as it adapts to the evolving COVID-19 pandemic, and any resurgence of the virus or emergence of new variants may lead to further inspectional delays.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities outside the United States may have adopted similar restrictions and other policy measures in response to the COVID-19 pandemic. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain accelerated approval or any other form of expedited development or review from the FDA or comparable ex-U.S. regulatory authorities, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future seek accelerated approval or another form of expedited development or review for our one or more of our product candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional confirmatory studies to verity and describe the drug&#8217;s clinical benefit. If such confirmatory studies fail to confirm the drug&#8217;s clinical benefit, the FDA may withdraw its approval of the drug on an expedited basis. In addition, in December 2022, the President signed an omnibus appropriations bill to fund the U.S. government through fiscal year 2023. Included in the omnibus bill is the Food and Drug Omnibus Reform Act of 2022, which among other things, introduced reforms intended to expand the FDA&#8217;s ability to regulate products receiving accelerated approval, including by increasing the FDA&#8217;s oversight over the conduct of confirmatory trials; however, the ultimate impact of these reforms remains unclear.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, under the centralized procedure, the EMA&#8217;s Committee for Medicinal Products for Human Use may perform an accelerated assessment of a marketing authorization application. Applicants requesting an accelerated assessment procedure must justify that the product candidate is expected to be of major public health interest, particularly from the point of view of therapeutic innovation.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Prior to seeking accelerated approval or another form of expedited development or review for any of our product candidates, we intend to seek feedback from the FDA or ex-U.S. regulatory authorities and will otherwise evaluate our ability to seek and receive accelerated approval or another form of expedited development or review. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA for accelerated approval or another form of expedited development, review or approval. Furthermore, if we decide to submit an application for accelerated approval or another form of expedited development, review or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">approval for our product candidates, there can be no assurance that such submission or application will be accepted or that any such expedited development, review or approval will be granted on a timely basis, or at all. The FDA or other comparable ex-U.S. regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidate would result in a longer time period to commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face difficulties from changes to current regulations and future legislation.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in March 2010, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, was passed, which substantially changes the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures will impact our business. We are continuing to monitor any changes to the ACA that, in turn, may potentially impact our business in the future.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes include the American Rescue Plan Act of 2021, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, beginning January 1, 2024.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Most recently, on August 16, 2022, the IRA was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. For that and other reasons, it is currently unclear how the IRA will be effectuated. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA or ex-U.S. regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with healthcare professionals, clinical investigators, CROs and third party payors in connection with our current and future business activities may be subject to  fraud and abuse laws and other healthcare laws and regulations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, clinical investigators, CROs, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal, state and ex-U.S. healthcare laws and regulations include the following:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal false claims laws, including the civil False Claims Act, which can be enforced by private citizens through civil whistleblower or qui tam actions, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Physician Payments Sunshine Act (renamed the Open Payments Act) requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to CMS information regarding payments and other transfers of value to physicians, as defined by such law, certain non-physician practitioners including physician assistants and nurse practitioners, and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. The information reported is publicly available on a searchable website, with disclosure required annually; and</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">analogous state and ex-U.S. laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some state laws require biotechnology companies to comply with the biotechnology industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. Some state laws require biotechnology companies to report information on the pricing of certain drug products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and ex-U.S. laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal information, such as information that we may collect in connection with clinical trials. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or ex-U.S. laws or regulations, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our business, results of operation, and financial condition.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. We do not believe that we are currently acting as a covered entity or business associate under HIPAA and thus are not directly subject to its requirements or penalties, but we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPAA. Certain states have also adopted comparable privacy and security laws and regulations governing the privacy, processing and protection of personal information. For example, the State of California enacted the California Consumer Privacy Act, or CCPA, which went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that has increased the likelihood of, and risks associated with, data breach litigation. Further, the California Privacy Rights Act, or CPRA, generally went into effect on January 1, 2023, and significantly amends the CCPA. The CPRA imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also creates a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. Additional compliance investment and potential business process changes may be required. Similar laws have passed in Virginia, Connecticut, Iowa, Utah and Colorado, and have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations abroad may also be subject to increased scrutiny or attention from data protection authorities. For instance, the EU General Data Protection Regulation, or GDPR, went into effect in May 2018 and imposes strict </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements for processing the personal data of individuals within the EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements, administrative penalties and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States. In July 2020, the Court of Justice of the EU, or CJEU, limited how organizations could lawfully transfer personal data from the EEA to the United States by invalidating the Privacy Shield for purposes of international transfers and imposing further restrictions on the use of standard contractual clauses, or SCCs. In March 2022, the US and EU announced a new regulatory regime intended to replace the invalidated regulations; however, this new EU-US Data Privacy Framework has not been implemented beyond an executive order signed on October 7, 2022 on Enhancing Safeguards for Untied States Signals Intelligence Activities. The European Commission issued revised SCCs on June 4, 2021 to account for the decision of the CJEU and recommendations made by the European Data Protection Board. The revised SCCs have been required for relevant new data transfers since September 27, 2021; existing standard contractual clauses arrangements had to be migrated to the revised clauses by December 27, 2022. The new SCCs apply only to the transfer of personal data outside of the EEA and not the UK. The UK&#8217;s Information Commissioner&#8217;s Office has published new data transfer standard contracts for transfers from the United Kingdom under the UK GDPR. This new documentation has been mandatory for relevant data transfers since September 21, 2022; existing SCCs arrangements must be migrated to the new documentation by March 21, 2024. European court and regulatory decisions subsequent to the CJEU decision of July 16, 2020 have taken a restrictive approach to international data transfers.  As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, from January 1, 2021, we have had to comply with both the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in United Kingdom national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#163;17.5 million or 4% of global turnover. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities. Misconduct by these parties could include failures to comply with FDA and other ex-U.S. authorities regulations, provide accurate information to the FDA or ex-U.S. regulatory authorities, comply with federal, state and ex-U.S. health care fraud and abuse laws and regulations, accurately report financial information or data or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by these parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of hazardous and flammable materials, including chemicals and biological materials.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain laws and regulations require us to test our product candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted, delayed or become more expensive.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business activities may be subject to the U.S. Foreign Corrupt Practices Act, or the FCPA, and similar anti-bribery and anti-corruption laws of other countries in which we operate, as well as U.S. and certain ex-U.S. export controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in ex-U.S. markets and subject us to liability if we violate them.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we further expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate. The FCPA generally prohibits companies and their employees and third party intermediaries from offering, promising, giving or authorizing the provision of anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, hospitals owned and operated by the government, and doctors and other hospital employees would be considered ex-U.S. officials under the FCPA. Recently the SEC and the U.S. Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pharmaceutical companies. There is no certainty that all of our employees, agents or contractors, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, disgorgement, and other sanctions and remedial measures, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international activities, our ability to attract and retain employees and our business, prospects, operating results and financial condition.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our products and activities may be subject to U.S. and ex-U.S. export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our products, or our failure to obtain any required import or export authorization for our products, when applicable, could harm our international sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export of our products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons, or products targeted by such regulations, could result in decreased use of our products by, or in our decreased ability to export our products to existing or potential customers with international operations. Any decreased use of our products or limitation on our ability to export or sell access to our products would likely adversely affect our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 pandemic has adversely impacted, and may continue to adversely impact, our business, including our preclinical studies and clinical trials.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, a strain of the novel coronavirus disease, COVID-19, was declared a pandemic and spread across the world, including throughout the United States, Europe and Asia. The pandemic and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. Our employees are working based on a hybrid work model, in which they work both from our offices and remotely. As a result of the COVID-19 pandemic, we have experienced and we may continue to experience disruptions that could severely impact our business, preclinical studies and clinical trials, including:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays or difficulties in enrolling patients in our clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in receiving authorizations from regulatory authorities to initiate our planned clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state or ex-U.S. governments, employers and others or interruption of clinical trial subject visits and study procedures (such as endoscopies that are deemed non-essential), which may impact the integrity of subject data and clinical study endpoints;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">risk that participants enrolled in our clinical trials will contract COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed AEs;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risk that we are unable to enroll participants in our clinical trials in adequate numbers;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">interruptions in preclinical studies due to restricted or limited operations at our laboratory facility;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in local regulations as part of a response to the COVID-19 pandemic, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue such clinical trials altogether;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">interruption or delays to our sourced discovery and clinical activities; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the COVID-19 pandemic continue to evolve. The extent to which the pandemic impacts our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and we face significant competition for experienced personnel. We are highly dependent on the principal members of our management and scientific and medical staff. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our business plan and harm our operating results. In particular, the loss of one or more of our executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner. The competition for qualified personnel in the biotechnology field is intense and as a result, we may be unable to continue to attract and retain qualified personnel necessary for the future success of our business. We could in the future have difficulty attracting experienced personnel to our company and may be required to expend significant financial resources in our employee recruitment and retention efforts.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better prospects for career advancement. Some of these characteristics may be more </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover, develop and commercialize our product candidates will be limited and the potential for successfully growing our business will be harmed.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish effective sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be able to successfully sell or market our product candidates that obtain regulatory approval.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never commercialized a product candidate. In order to commercialize any product candidates, if approved, for which we retain commercialization rights, we must build marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services for each of the territories in which we may have approval to sell or market our product candidates. We may not be successful in accomplishing these required tasks. In addition, for product candidates for which we do not retain commercialization rights, we will rely on the assistance of collaborators to successfully commercialize any product candidates that are approved. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Establishing an internal sales or marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates will be expensive and time-consuming, and will require significant attention of our executives to manage. Factors that may affect our ability to commercialize our product candidates on our own include recruiting and retaining adequate numbers of effective sales and marketing personnel, obtaining access to or persuading adequate numbers of physicians to prescribe our product candidates and other unforeseen costs associated with creating an independent sales and marketing organization. Any failure or delay in the development of our internal sales, marketing and distribution capabilities could adversely impact the commercialization of any of our product candidates that we obtain approval to market, especially if we also do not have arrangements in place with third parties to provide such services on our behalf. Alternatively, if we choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, we will be required to negotiate and enter into arrangements with such third parties relating to the proposed collaboration. If we are unable to enter into such arrangements when needed, on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval or any such commercialization may experience delays or limitations. If we are unable to successfully commercialize our approved product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to successfully implement our development and commercialization plans and strategies, and as we continue to operate as a public company, we expect to need additional managerial, operational, sales, marketing, financial, legal, compliance and other personnel. Future growth would impose significant added responsibilities on members of management, including:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">managing our internal development efforts effectively, including the clinical, FDA and other comparable ex-U.S. regulatory agencies&#8217; review process for our product candidates, while complying with any contractual obligations to contractors and other third parties we may have; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">improving our operational, financial and management controls, reporting systems and procedures.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to successfully develop and, if approved, commercialize, our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a substantial amount of time to managing these growth activities. Furthermore, certain of our employees, including members of our management team perform services on behalf of Kalyra Pharmaceuticals, Inc., and Zentera Therapeutics, pursuant to intercompany and collaborative agreements, respectively. As a result, such individuals do not allocate all of their time and resources to us and our other subsidiaries which, coupled with the need to manage growth activities, could further limit their ability to devote a sufficient amount of attention to day-to-day activities of our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including key aspects of clinical development and manufacturing. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by third party service providers is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of our product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing third party service providers or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to effectively expand our organization by hiring new employees and/or engaging additional third party service providers, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations may suffer in the event of information technology system failures, cyberattacks or deficiencies in our cybersecurity.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our information systems and those of our current and any future CROs, CMOs and other contractors, consultants, collaborators and third-party service providers, are vulnerable to attack, damage and interruption from computer viruses and malware (e.g., ransomware), malicious code, natural disasters, terrorism, war, telecommunication and electrical failure, hacking, cyberattacks, phishing attacks and other social engineering schemes, employee theft or misuse, human error, fraud, denial or degradation of service attacks, sophisticated nation-state and nation-state-supported actors or unauthorized access or use by persons inside our organization, or persons with access to systems inside our organization. Attacks upon information technology systems are also increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of the COVID-19 pandemic and continued hybrid working environment, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain of our service providers are from time to time subject to cyberattacks and security incidents. If such an event were to occur and cause interruptions in our operations or result in the unauthorized acquisition of or access to our trade secrets, personal information or other proprietary or sensitive information, it could result in a material disruption of our drug discovery and development programs. Some federal, state and ex-U.S. government requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Notifications and follow-up actions related to a security breach could impact our reputation, cause us to incur significant costs, including legal expenses and remediation costs. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the lost data. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could be exposed to litigation and governmental investigations, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant fines or penalties for any noncompliance with certain state, federal and/or international privacy and security laws.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption, failure or security breach. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EU pricing, drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the European member states.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek approval to market our product candidates in both the United States and in selected ex-U.S. jurisdictions. If we obtain approval in one or more ex-U.S. jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some ex-U.S. countries, particularly those in the EU, the pricing of drugs is subject to governmental control and other market regulations which could put pressure on the pricing and usage of our product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future healthcare reform measures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Much like the federal Anti-Kickback Statute prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to physicians is governed by the national laws of EU member states, such as the UK Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments made to physicians in certain EU member states must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and/or approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU member states. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for biopharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the EU do not follow price structures of the United States and generally prices tend to be significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in scope or amount, our revenues from sales and the potential profitability of any of our product candidates in those countries would be negatively affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable U.S., global, political or economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the U.S. and global economy and in the U.S. and global financial markets. For example, the recent global economic downturn has caused rising inflation and interest rates and has led to extreme volatility and disruptions in the capital and credit markets. A worsening or prolonged economic downturn or recession could result in a variety of risks to our business, including our ability to raise additional capital when needed on acceptable terms, if at all. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, and cause the prices of our supplies to increase or cause our customers to delay making payments for our services. In addition, the current military conflict between Russia and Ukraine could disrupt or otherwise adversely impact our operations and those of third parties upon which we rely. Related sanctions, export controls or other actions have and may in the future be initiated by nations including the U.S., the EU or Russia (e.g., potential cyberattacks, disruption of energy flows, etc.), which could adversely affect our business and/or our supply chain, our CROs, CMOs and other third parties with which we conduct business. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations are vulnerable to interruption by fire, severe weather conditions, power loss, telecommunications failure, terrorist activity and other events beyond our control, which could harm our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities are located in regions that experience severe weather from time to time. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major tornado, flood, fire, earthquake, power loss, terrorist activity or other disasters and do not have a recovery plan for such disasters. In addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us could harm our business. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had available federal and state net operating loss carryforwards, or NOLs, of approximately $390.3 million and $192.4 million, respectively. $369.4 million of our federal NOLs were generated in taxable years beginning after December 31, 2017 and can be carried forward indefinitely, but may only be used to offset up to 80% of our taxable income in future periods. This limitation may require us to pay U.S. federal income taxes in future years despite generating federal NOLs in prior years. Our federal NOLs generated in tax years beginning prior to January 1, 2018 are not subject to this limitation, but are only permitted to be carried forward for 20 taxable years under applicable U.S. federal tax law, and will start to expire in 2033 if not utilized. Our state NOLs begin to expire in 2033.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a cumulative change in its ownership by one or more &#8220;5-percent shareholders&#8221; that exceeds 50 percentage points over a rolling three-year period), the corporation&#8217;s ability to use its pre-ownership change federal NOLs and certain other pre-change tax attributes to offset its post-change taxable income and income tax liabilities may be limited. Similar rules may apply under state tax laws. We may have experienced such ownership changes in the past and we may experience ownership changes in the future as a result of shifts in our stock ownership, some of which are outside our control. We have not conducted any studies to determine whether any such ownership changes have occurred or the annual limitations, if any, that could result from such ownership changes. Our ability to utilize our NOLs and certain other tax attributes could be limited by an ownership change as described above and consequently, we may not be able to utilize a material portion of our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs and certain other tax attributes, which could have a material adverse effect on our cash flows and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek regulatory approval of our product candidates outside of the United States and, accordingly, we expect that we will be subject to additional risks related to operating in ex-U.S. countries if we obtain the necessary approvals, including:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">differing regulatory requirements and reimbursement regimes in ex-U.S. countries;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">economic weakness, including inflation, or political instability in particular ex-U.S. economies and markets;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">ex-U.S. taxes, including withholding of payroll taxes;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">ex-U.S. currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">difficulties staffing and managing ex-U.S. operations;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">potential liability under the FCPA or comparable ex-U.S. regulations;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">challenges enforcing our contractual and intellectual property rights, especially in those ex-U.S. countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">business interruptions resulting from geo-political actions, including war and terrorism.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other risks associated with our international operations may materially adversely affect our ability to attain or maintain profitable operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may evaluate various acquisition opportunities and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including: </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">increased operating expenses and cash requirements; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the assumption of additional indebtedness or contingent liabilities; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the issuance of our equity securities; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the diversion of our management&#8217;s attention from our existing programs and initiatives in pursuing such a strategic merger or acquisition; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships; </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and marketing approvals; and </span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we undertake acquisitions or pursue partnerships in the future, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities, and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The requirements of being a public company may strain our resources, result in more litigation and divert management&#8217;s attention. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are and will continue to be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, the listing requirements of Nasdaq and other applicable securities rules and regulations. Complying with these rules and regulations has increased and will increase our legal and financial compliance costs, make some activities more difficult, time consuming or costly and increase demand on our systems and resources. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are required to disclose changes made in our internal control over financial reporting on a quarterly basis. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management&#8217;s attention may be diverted from other business concerns, which could adversely affect our business and operating results. We may also need to hire additional employees or engage outside consultants to comply with these requirements, which will increase our costs and expenses. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We have invested and intend to continue to invest in resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These new rules and regulations may make it more expensive for us to obtain director and officer liability insurance and, in the future, we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our Board of Directors, particularly to serve on our Audit Committee and Compensation Committee, and qualified executive officers. By disclosing information in filings required of us as a public company, our business and financial condition will continue to become more visible, which we believe may result in threatened or actual litigation, including by competitors and other third parties. If those claims are successful, our business could be seriously harmed. Even if the claims do not result in litigation or are resolved in our favor, the time and resources needed to resolve them could divert our management&#8217;s resources and seriously harm our business. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A portion of our manufacturing of our lead product candidates takes place in ex-U.S. countries, including China, through third-party manufacturers. A significant disruption in the operation of those manufacturers, a trade war or political unrest in such ex-U.S. countries, including China, could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently contract manufacturing operations to third parties, and clinical quantities of our lead product candidates are manufactured by certain of these third parties outside the United States, including in China, and we expect to continue to use such third-party manufacturers for such product candidates. Any disruption in production or inability of our manufacturers in such ex-U.S. countries, including in China, to produce adequate quantities to meet our needs, whether as a result of a natural disaster or other causes, could impair our ability to operate our business on a day-to-day basis and to continue our development of our product candidates. Furthermore, since these manufacturers are located outside the United States, we are exposed to the possibility of product supply disruption and increased costs in the event of changes in the policies of the United States or ex-U.S. governments, political unrest or unstable economic conditions in such ex-U.S. countries, including in China. For example, a trade war could lead to tariffs on the chemical intermediates we use that are manufactured in China. Any of these matters could materially and adversely affect our business and results of operations. In addition, manufacturing interruptions or failure to comply with regulatory requirements by any of these manufacturers could significantly delay clinical development of potential products and reduce third-party or clinical researcher interest and support of proposed trials. These interruptions or failures could also impede commercialization of our product candidates and impair our competitive position. Further, we may be exposed to fluctuations in the value of the local currency in the ex-U.S. countries. Future appreciation of the local currency could increase our costs. In addition, our labor costs could continue to rise as wage rates increase due to increased demand for skilled laborers and the availability of skilled labor declines in the ex-U.S. countries, including in China.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on our ability to protect our intellectual property and our proprietary platform. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies and their uses, our and our licensors&#8217; ability to operate without infringing the proprietary rights of others, and our and our licensors' ability to successfully defend our patents, including those that we have in-licensed, against third-party challenges. If we or our licensors are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology or our product candidates, our competitive position could be harmed. We and our licensors generally seek to protect our proprietary position by filing patent applications in the United States and outside of the United States related to our product candidates, proprietary technologies and their uses that are important to our business. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our patent applications will result in patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents, if issued, will be infringed or will not be designed around by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our and our licensors&#8217; proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our or our licensors&#8217; rights or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">permit us or our licensors to gain or keep any competitive advantage. These uncertainties and/or limitations in our and our licensors&#8217; ability to properly protect the intellectual property rights relating to our product candidates could have a material adverse effect on our financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we license issued patents in the United States and ex-U.S. countries, we cannot be certain that the claims in our other U.S. pending patent applications, corresponding international patent applications and patent applications in certain ex-U.S. countries will be considered patentable by the United States Patent and Trademark Office, or USPTO, courts in the United States or by the patent offices and courts in ex-U.S. countries, nor can we be certain that the claims in our issued patents will not be found invalid or unenforceable if challenged.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or our licensors or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdictions;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">patent applications may not result in any patents being issued;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our competitors, many of whom have substantially greater resources than we or our licensors do and many of whom have made significant investments in competing technologies, may seek, may have filed patent applications, or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">there may be significant pressure on the U.S. and ex-U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing ex-U.S. competitors a better opportunity to create, develop and market competing products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is also expensive and time-consuming, and we or our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we or our licensors may not identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, directed to technology that we license, including those from our licensors and from third parties. We also may require the cooperation of our licensors in order to enforce the licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by our licensors have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we in-license, and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, CMOs, consultants, advisors, licensors, and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from our licensors and third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to license agreements under which we are granted rights to intellectual property that are important to our business and we may enter into additional license agreements in the future. For example, our wholly owned subsidiary, ZMI, is party to a license agreement with Recurium IP under which we have an exclusive license to certain intellectual property rights, including certain intellectual property covering azenosertib, ZN-d5, and our BCL-xL product candidate.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This and our other existing license agreements impose on us, and we expect that any future license agreements where we in-license intellectual property will impose on us, various development, regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our obligations under these agreements, or we are subject to bankruptcy-related proceedings, the licensors may have the right to terminate the licenses, in which event we would not be able to market products covered by the licenses.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we cannot provide any assurances that third-party patents do not exist that might be enforced against our product candidates in the absence of such a license. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether and the extent to which our technology and processes infringe intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our right to sublicense patents and other rights to third parties;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our right to transfer or assign the license; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and its affiliates and sublicensees and by us and our partners and sublicensees.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain of our agreements may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. For example, if we choose to sublicense or assign to any third parties certain patent rights exclusively in-licensed under the Recurium Agreement, we may be required to pay to Recurium a specified percentage of certain sublicensing income to be received in connection with such transaction.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the scope of any patent protection our licensors obtain is not sufficiently broad, or if our licensors lose any of the patent protection we license, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the existence, issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our product candidates or that effectively prevent others from commercializing competitive product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the scope of claims in a patent application can be significantly reduced before any claims in a patent issue, and claim scope can be reinterpreted after issuance. Even if patent applications we license currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we license may be challenged or circumvented by third parties or may be narrowed or invalidated as a result of challenges by third parties. Consequently, we do not know whether our product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner, which could materially adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our in-licensed patents may not cover our product candidates or may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third party pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant review, or PGR, and inter partes review, or IPR, or other similar proceedings in the USPTO or ex-U.S. patent offices challenging our patent rights. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity of our patents, for example, we cannot be certain that there is no invalidating prior art, of which we or our licensors and the patent examiner were unaware during prosecution. There is no assurance that all potentially relevant prior art relating to our patents and patent applications or those of our licensors has been found. There is also no assurance that there is not prior art of which we or licensors were or are aware of, but which we do not believe affects the validity or enforceability of a claim in our patents and patent applications or those of our licensors, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our product candidates and compete directly with us, without payment to us. Such loss of in-licensed patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our product candidates. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The patent protection and patent prosecution for some of our product candidates may be dependent on our licensors and third parties.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. It is possible that defects as to form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our licensors, whether current or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our in-licensed patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a licensee, we rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property under some of our license agreements. We have not had and do not have primary control over these activities for certain of our patents or patent applications and other intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. If any of our licensors or any of our future licensors or future collaborators fails to appropriately prosecute and maintain patent protection for patents covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even where we have the right to control patent prosecution of patents and patent applications we have acquired or licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensors and their counsel that took place prior to us assuming control over patent prosecution.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our technology acquired or licensed from various third parties, including our licensors, may be subject to retained rights. Our licensors often retain certain rights under their agreements with us, including the right to use the underlying technology for use in fields other than the fields licensed to us or for use in noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are limited in our ability to utilize acquired or licensed technologies, or if we lose our rights to critical licensed technology, we may be unable to successfully develop, out-license, market and sell our products, which could prevent or delay new product introductions. Our business strategy depends on the successful development of licensed and acquired technologies into commercial products. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop, out-license or market and sell our product candidate.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our intellectual property may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies if it is determined that our intellectual property has been discovered through government-funded programs. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the intellectual property rights we have acquired or licensed or may acquire or license in the future may have been generated through the use of U.S. government funding and may therefore be subject to certain federal </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulations. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or (iii)&#160;government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products relating to such intellectual property. To the extent any of our future intellectual property is also generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">others may be able to develop products that are similar to our product candidates but that are not covered by the claims of the patents that we own or license;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we or our licensors might not have been the first to make the inventions covered by the issued patents or patent application that we own or license;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we or our licensors might not have been the first to file patent applications covering certain of our inventions;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">it is possible that our licensors&#8217; pending patent applications will not lead to issued patents;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">issued patents that we own or license may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may not develop additional proprietary technologies that are patentable; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Should any of these events occur, it could significantly harm our business, results of operations and prospects.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary rights that could limit, interfere or block our ability to make, use, sell, offer for sale or import our product candidates and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation and administrative proceedings, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industry, including patent invalidity and infringement lawsuits, oppositions, reexaminations, IPR proceedings and PGR proceedings before the USPTO, ex-U.S. patent offices and/or in a court of law. Numerous third-party U.S. and ex-U.S. issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the biopharmaceutical industry expands and more patents issue, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published we may be unaware of third-party patents that may be infringed by commercialization of any of our product candidates, and we cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes these patents. Any claims of patent infringement asserted by third parties would be time consuming and could:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">result in costly litigation that may cause negative publicity;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">divert the time and attention of our technical personnel and management;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">cause development delays;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">prevent us from commercializing any of our product candidates until the asserted patent expires or is held finally invalid or unenforceable or not infringed in a court of law;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">require us to develop non-infringing technology, which may not be possible on a cost-effective basis;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subject us to significant liability to third parties; or</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors gaining access to the same technology.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although no third party has asserted a claim of patent infringement against us as of the date of this periodic report, others may hold proprietary rights that could prevent our product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin activities relating to our product candidates or processes could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or develop our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. We cannot predict whether we would prevail </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we or our future strategic partners were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign our product candidates or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates, which could harm our business, financial condition and operating results.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our intellectual property rights or those of our licensors. To prevent infringement or unauthorized use, we and/or our licensors may be required to file infringement claims, which can be expensive and time-consuming. Further, our licensors may need to file infringement claims, but they may elect not file such claims. In addition, in a patent infringement proceeding, a court may decide that a patent we own or license is not valid, is unenforceable and/or is not infringed. If we or any of our licensors or potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our product candidates, the defendant could assert that our patent is invalid, not infringed and/or unenforceable in whole or in part. In patent litigation, defendant allegations of invalidity and/or unenforceability of asserted patents are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including patent-ineligible subject matter, lack of utility, lack of novelty, obviousness or lack of written description, obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent intentionally withheld material information from the USPTO or an ex-U.S. patent office made a misleading statement during prosecution.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. In addition, if the breadth or strength of protection provided by our patents and patent applications or those of our licensors is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection would have a material adverse impact on our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivation or interference proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivation or interference proceedings provoked by third parties or brought by us or our licensors, or declared by the USPTO or similar proceedings in ex-U.S. patent offices may be necessary to determine the priority of inventions with respect to our or our licensors&#8217; patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our or our licensors&#8217; defense of such proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2011, the Leahy-Smith America Invents Act, or Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#8220;first inventor to file&#8221; system in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled to the patent regardless of whether a third party was first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013 but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (1)&#160;file any patent application related to our product candidates or (2)&#160;invent any of the inventions claimed in our patents or patent applications.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications are prosecuted and also affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including PGR, IPR, and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time-consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. In addition, Congress or other ex-U.S. legislative bodies may pass patent reform legislation that is unfavorable to us.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our or our licensors&#8217; ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in ex-U.S. jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our or our licensors&#8217; ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or our licensors may be subject to claims challenging the inventorship or ownership of our or our patents and other intellectual property.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors may be subject to claims that former employees or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we or our licensors are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the term of a patent, and the protection it affords, is limited. Even if patents directed to our product candidates are obtained, once the patent term has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of product candidates, patents directed to our product candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our licensors do not obtain patent term extension for our product candidates, our business may be materially harmed.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA-approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it for an FDA-approved indication or a method for manufacturing it may be extended. Patent term extension may also be available in certain ex-U.S. countries upon regulatory approval of our product candidates. However, we or our licensors may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we or our licensors are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have issued patents and pending patent applications in the United States and certain other countries, filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some ex-U.S. countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we or our licensors have patent protection but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our or our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in ex-U.S. jurisdictions. The legal systems of many ex-U.S. countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our or our licensors&#8217; patents or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our or our licensors&#8217; patent rights in ex-U.S. jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our or our licensors&#8217; patents at risk of being invalidated or interpreted narrowly and our or our licensors&#8217; patent applications at risk of not issuing and could provoke third parties to assert claims against us. We or our licensors may not prevail in any lawsuits that we or our licensors initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our or our licensors&#8217; efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various ex-U.S. patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on third parties to pay these fees when due. Additionally, the USPTO and various ex-U.S. patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information to maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants, licensors and advisors, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we or our licensors do not apply for patent protection prior to public disclosure or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biopharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biopharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct certain aspects of our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third-party CROs, to conduct certain aspects of our preclinical studies and clinical trials and to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors, including CROs, are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable ex-U.S. regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable ex-U.S. regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations and similar ex-U.S. requirements. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be adversely affected if any of these third parties violates federal, state or ex-U.S. fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed or precluded entirely.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and government measures taken in response have also had a significant impact on our CROs, and we expect that they will face further disruption which may affect our ability to initiate and complete our preclinical studies and clinical trials.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, CROs may lack the capacity to absorb higher workloads or take on additional capacity to support our needs. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We contract with third parties for the manufacture of our product candidates for preclinical studies and our ongoing clinical trials, and expect to continue to do so for additional clinical trials and ultimately for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">our product candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have the infrastructure or internal capability to manufacture supplies of our product candidates for use in development and commercialization. We rely, and expect to continue to rely, on third-party manufacturers for the production of our product candidates for preclinical studies and clinical trials under the guidance of members of our organization. We do not have long-term supply agreements, and we purchase our required supply on a purchase order basis. Furthermore, the raw materials for our product candidates are sourced, in some cases, from a single-source supplier. We currently mitigate potential supply risks for azenosertib and ZN-d5, if any, through inventory management. If we were to experience an unexpected loss of supply of any of our product candidates or any of our future product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to rely on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. We may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the failure of the third-party manufacturers to manufacture our product candidates according to our schedule, or at all, including if our third-party manufacturers  give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the reduction or termination of production or deliveries by suppliers, or the raising of prices or renegotiation of terms;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the termination or nonrenewal of arrangements or agreements by our third-party manufacturers  at a time that is costly or inconvenient for us;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the breach by the third-party manufacturers of our agreements with them;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the failure of third-party manufacturers to comply with applicable regulatory requirements;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the failure of the third-party manufacturers to manufacture our product candidates according to our specifications;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the misappropriation of our proprietary information, including our trade secrets and know-how.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our third-party contract manufacturing partners for compliance with cGMP regulations or similar ex-U.S. requirements for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our third-party contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable ex-U.S. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations. Our current and anticipated future dependence upon others for the manufacture of our product candidates or drugs may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing drugs, especially in large quantities, is complex and may require the use of innovative technologies. Each lot of an approved drug product must undergo thorough testing for identity, strength, quality, purity and potency. Manufacturing drugs requires facilities specifically designed for and validated for this purpose, and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, stock recovery, product recalls or spoilage. Any stock recovery of the manufacturing lots or similar action regarding our product candidates used in clinical trials could delay the trials or detract from the integrity of the trial data and its potential use in future regulatory filings. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. If microbial, viral or other contaminations are discovered at the facilities of our manufacturer, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. The use of biologically derived ingredients can also lead to allegations of harm, including infections or allergic reactions, or closure of product facilities due to possible contamination. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization as a result of these challenges, or otherwise, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we decide to establish collaborations in the future, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. We may continue to seek to selectively form collaborations to expand our capabilities, potentially accelerate research and development activities and provide for commercialization activities by third parties. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We would face significant competition in seeking appropriate collaborators and the negotiation process is time-consuming and complex. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable ex-U.S. regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of intellectual property and industry and market conditions generally. The potential collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such collaboration could be more attractive than the one with us for our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidate. Further, we may not be successful in our efforts to establish a collaboration or other alternative arrangements for future product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Even if we are successful in entering into a collaboration, the terms and conditions of that collaboration may restrict us from entering into future agreements on certain terms with potential collaborators.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If and when we seek to enter into collaborations, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our stock may be volatile, and you could lose all or part of your investment.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock is likely to be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. The stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section these factors include:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing and results of preclinical studies and clinical trials of our product candidates or those of our competitors;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the success of competitive products or announcements by potential competitors of their product development efforts;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory actions with respect to our products or our competitors&#8217; products;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">actual or anticipated changes in our growth rate relative to our competitors;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the recruitment or departure of key personnel;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">market conditions in the pharmaceutical and biotechnology sector;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">speculative trading in and short sales of our common stock, as well as trading phenomena such as the "short squeeze";</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">announcement or expectation of additional financing efforts;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">sales of our common stock by us, our insiders or our other stockholders;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expiration of market stand-off or lock-up agreements; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">general economic, industry and market conditions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the trading prices for common stock of other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic and U.S. and global economic conditions. The extent to which these events may impact our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk Factors&#8221; section, could have a dramatic and adverse impact on the market price of our common stock.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">variations in the level of expense related to the ongoing development of our product candidates or future development programs;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">results of clinical trials, or the addition or termination of clinical trials or funding support by us or potential future partners;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our execution of any collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under potential future arrangements or the termination or modification of any such potential future arrangements;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any intellectual property infringement, misappropriation or violation lawsuit or opposition, interference or cancellation proceeding in which we may become involved;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">additions and departures of key personnel;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if any of our product candidates receives regulatory approval, the terms of such approval and market acceptance and demand for such product candidates;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory developments affecting our product candidates or those of our competitors; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in general market and economic conditions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our stock and are able to exert significant influence over matters subject to stockholder approval.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, our executive officers and directors, combined with our stockholders who owned more than 5% of our common stock, together with their respective affiliates, owned a significant percentage of our outstanding common stock. As a result, if these stockholders were to choose to act together, they would be able to significantly influence all matters submitted to our stockholders for approval, as well as matters related to our management and affairs. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. Outstanding shares of our common stock may be freely sold in the public market at any time to the extent permitted by Rules 144 and 701 under the Securities Act, or to the extent that such shares have already been registered under the Securities Act and are held by non-affiliates of ours. Moreover, holders of a substantial number of shares of our common stock have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also register all shares of common stock that we may issue under our equity compensation plans or that are issuable upon exercise of outstanding options. These shares can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek additional capital through a variety of means, including through public or private equity, debt financings or other sources, including up-front payments and milestone payments from strategic collaborations. For example, in August 2020, July 2021 and May 2022, we completed underwritten public offerings of our common stock and in April 2022, we completed a direct offering of our common stock. To the extent that we raise additional capital through the sale of equity or convertible debt or equity securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Such financing may result in dilution to stockholders, imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect our business. If we raise additional funds through up-front payments or milestone payments pursuant to strategic collaborations with third parties, we may have to relinquish valuable rights to our product candidates, or grant licenses on terms that are not favorable to us. In addition, we may seek additional </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will be influenced by the research and reports that securities or industry analysts publish about us, our business or our market. If any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our certificate of incorporation and bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation and bylaws contain provisions that could depress the market price of our common stock by acting to discourage, delay or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establish a classified Board of Directors so that not all members of our Board of Directors are elected at one time;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">permit only the Board of Directors to establish the number of directors and fill vacancies on the Board of Directors;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provide that directors may only be removed &#8220;for cause&#8221; and only with the approval of two-thirds of our stockholders;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">authorize the issuance of &#8220;blank check&#8221; preferred stock that our Board of Directors could use to implement a stockholder rights plan (also known as a &#8220;poison pill&#8221;);</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">eliminate the ability of our stockholders to call special meetings of stockholders;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">prohibit cumulative voting;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">authorize our Board of Directors to amend the bylaws;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establish advance notice requirements for nominations for election to our Board of Directors or for proposing matters that can be acted upon by stockholders at annual stockholder meetings; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">require a super-majority vote of stockholders to amend some provisions described above.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Section&#160;203 of the General Corporation Law of the State of Delaware, or the DGCL, prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any provision of our certificate of incorporation, bylaws or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any derivative action or proceeding brought on our behalf;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any action asserting a claim of breach of fiduciary duty;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any action asserting a claim against us arising under the DGCL, our certificate of incorporation or our bylaws; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any action asserting a claim against us that is governed by the internal-affairs doctrine.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This exclusive-forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to this provision. If a court were to find this exclusive-forum provision in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business. Nothing in our certificate of incorporation precludes stockholders that assert claims under the Securities Act or the Exchange Act from bringing such claims in state or federal court, subject to applicable law.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not currently intend to pay dividends on our common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation of the value of our common stock.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our equity securities. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to any appreciation in the value of our common stock, which is not certain. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to disclose changes made in our internal controls and procedures on a quarterly basis and our management is required to assess the effectiveness of these controls annually. Now that we are no longer an </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">emerging growth company, our independent registered public accounting firm is required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404. An independent assessment of the effectiveness of our internal controls over financial reporting could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls over financial reporting could lead to restatements of our financial statements and require us to incur the expense of remediation. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to securities litigation, which is expensive and could divert management attention.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business. </span></div><div id="iede2e4c8548c40d4910b7a838a08d814_94"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-49pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="iede2e4c8548c40d4910b7a838a08d814_97"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-49pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="iede2e4c8548c40d4910b7a838a08d814_100"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="iede2e4c8548c40d4910b7a838a08d814_103"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On and effective May 8, 2023, the Company&#8217;s Board of Directors, or the Board, increased its size from six to seven directors and appointed Diana Hausman, M.D., as a Class I director. Dr. Hausman's initial term is scheduled to expire at the Company's 2024 Annual Meeting of Stockholders, subject to the election and qualification of her successor and her earlier death, resignation or removal. Dr. Hausman has also been appointed to serve on the Compensation Committee of the Board, or the Compensation Committee, and the Nominating and Corporate Governance Committee of the Board, or the Nominating Committee. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Hausman is entitled to receive compensation for her service as a director in accordance with the Company's Non-Employee Director Compensation Program applicable to all non-employee directors, or the Director Compensation Program, which provides for an annual retainer of $45,000 for her Board service, and additional annual retainers of $7,500 for her service as a member of the Compensation Committee and $5,000 for her service as a member of the Nominating Committee.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Director Compensation Program, as a new non-employee director, Dr. Hausman was granted restricted stock units, or RSUs, covering 39,732 shares of the Company's common stock on May 8, 2023, which number of shares was determined by dividing (i) $800,000, by (ii) the average closing price per share of the Company's common stock for the thirty (30) calendar days preceding the date of grant. The initial RSU grant vests over three years with one-third of the underlying shares vesting on each of the first, second and third anniversaries of the date of grant. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in accordance with the Director Compensation Program, after Dr. Hausman has served on the Board for at least six months, Dr. Hausman is entitled to receive an annual equity grant on the date of the Company&#8217;s annual meeting of stockholders of RSUs covering that number of shares of the Company's common stock as is determined by dividing (i) $425,000, by (ii) the average closing price per share of the Company's common stock for the thirty (30) calendar days preceding the grant date. Annual RSU awards granted to non-employee directors vest in full on the first to occur of (i) the first anniversary of the applicable grant date, and (ii) the next occurring annual meeting of the Company's stockholders.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Director Compensation Program, the initial and annual equity awards granted to Dr. Hausman under the Director Compensation Program vest in full upon a change in control and, in each case, are subject to Dr. Hausman's continued service through the applicable vesting date.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Hausman has also entered into the Company's standard indemnification agreement for directors and officers.</span></div><div style="margin-bottom:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing information is included for the purpose of providing the disclosures required under &#8220;Item 5.02 &#8211; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers&#8221; of Form 8-K.</span></div><div id="iede2e4c8548c40d4910b7a838a08d814_106"></div><div style="-sec-extract:summary;margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:10.172%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.161%"></td><td style="width:0.0%"></td><td style="width:1.0%"></td><td style="width:36.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:29pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing<br/>Date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/Furnished Herewith</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1725160/000172516020000007/zentalis-eleaxplanofconv.htm">Plan of Conversion Converting Zentalis Pharmaceuticals, LLC (a Delaware limited liability company) into Zentalis Pharmaceuticals, Inc. (a Delaware corporation)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39263</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/15/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1725160/000172516020000007/zntl-certificateofconver.htm">Certificate of Conversion Converting Zentalis Pharmaceuticals, LLC (a Delaware limited liability company) into Zentalis Pharmaceuticals, Inc. (a Delaware corporation)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39263</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/15/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1725160/000119312520100536/d914800dex41.htm">Certificate of Incorporation of Zentalis Pharmaceuticals, Inc.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-237593</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04/07/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001725160/000172516021000063/exhibit-31xzntlxamendedres.htm">Bylaws of Zentalis Pharmaceuticals, Inc.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39263</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/19/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101-zntlxformofindemnifi.htm">10.1#</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101-zntlxformofindemnifi.htm">Form of Indemnification Agreement for Directors</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101-zntlxformofindemnifi.htm"> and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101-zntlxformofindemnifi.htm">Officers</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex102-zntlxsublease_zental.htm">10.2&#8224;</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex102-zntlxsublease_zental.htm">Sublease, effective March 6, 2023,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex102-zntlxsublease_zental.htm"> between Zentalis Pharmaceuticals, Inc. and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex102-zntlxsublease_zental.htm">L.M. Cohen &amp; Co. LLP Certified Public Accountants, as amended on April 10, 2023</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1725160/000172516023000028/rothiris-zntlemploymenta.htm">10.3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1725160/000172516023000028/rothiris-zntlemploymenta.htm">Employment Agreement, dated February 8, 2023, between Zeno Management, Inc. and Iris Roth.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39263</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/13/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="zentalis10-qq12023ex311.htm">31.1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="zentalis10-qq12023ex311.htm">Certification of Chief Executive Officer pursuant to Exchange Act Rule&#160;13a-14(a).</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="zentalis10-qq12023ex312.htm">31.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="zentalis10-qq12023ex312.htm">Certification of Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a).</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="zentalis10-qq12023ex321.htm">32.1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="zentalis10-qq12023ex321.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="zentalis10-qq12023ex322.htm">32.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="zentalis10-qq12023ex322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:10.172%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.161%"></td><td style="width:0.0%"></td><td style="width:1.0%"></td><td style="width:36.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:29pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing<br/>Date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/Furnished Herewith</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data file (formatted as inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:15.865%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"># &#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Portions of this exhibit (indicated by asterisks) have been redacted in compliance with Regulation S-K Item 601(b)(10)(iv).</span></div><div style="padding-left:36pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="iede2e4c8548c40d4910b7a838a08d814_109"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.222%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zentalis Pharmaceuticals, Inc.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May 10, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Kimberly Blackwell, M.D.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kimberly Blackwell, M.D.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal executive officer)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May 10, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Melissa B. Epperly</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Melissa B. Epperly</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial and accounting officer)</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex101-zntlxformofindemnifi.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i3ef95b75532149d5b3a2f39fab43ae2d_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Zentalis Pharmaceuticals, Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indemnification Agreement</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THIS INDEMNIFICATION AGREEMENT (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is made and entered into as of ______________, between Zentalis Pharmaceuticals, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and &#91;Name&#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering indemnification and advancement of expenses.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WITNESSETH THAT&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, highly competent persons have become more reluctant to serve corporations as directors, officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities.  Although the furnishing of such insurance has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in the future only at higher premiums and with more exclusions.  At the same time, directors, officers, and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise itself.  The Bylaws of the Company (as amended and&#47;or restated from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Bylaws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) require indemnification of the directors, officers and any person who,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">while a director or officer of the Company,&#160;at the request of the Company is or was serving as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (including, without limitation, any employee benefit plan).  Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">DGCL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Bylaws and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the Board, officers and other persons with respect to indemnification&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the uncertainties relating to such liability insurance and to indemnification have increased the difficulty of attracting and retaining such persons&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company&#8217;s stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, this Agreement is a supplement to and in furtherance of the Bylaws and any resolutions adopted pursuant thereto, as well as any rights of Indemnitee under any directors&#8217; and officers&#8217; liability insurance policy, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder&#59; &#91;and&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Indemnitee does not regard the protection available under the Bylaws and insurance as adequate in the present circumstances, and may not be willing to serve as a director, officer or otherwise without adequate protection, and the Company desires Indemnitee to serve in such capacity.  Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that Indemnitee be so indemnified&#59; &#91;and&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;WHEREAS, Indemnitee has certain rights to indemnification and&#47;or insurance provided by &#91;NAME&#93; which Indemnitee and &#91;NAME&#93; intend to be secondary to the primary obligation of the Company to indemnify Indemnitee as provided herein, with the Company&#8217;s acknowledgement and agreement to the foregoing being a material condition to Indemnitee&#8217;s willingness to serve on the Board&#59;&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of Indemnitee&#8217;s agreement to serve as &#91;an officer&#93;&#91;a director&#93;&#91;an officer and director&#93; from and after the date hereof, the parties hereto agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Indemnity of Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company hereby agrees to hold harmless and indemnify Indemnitee to the fullest extent permitted by law, as such may be amended from time to time.  In furtherance of the foregoing indemnification, and without limiting the generality thereof&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Proceedings Other Than Proceedings by or in the Right of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Indemnitee shall be entitled to the rights of indemnification provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section l(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> if, by reason of Indemnitee&#8217;s Corporate Status (as hereinafter defined), Indemnitee is, or is threatened to be made, a party to or participant in any Proceeding (as hereinafter defined) other than a Proceeding by or in the right of the Company.  Pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Indemnitee shall be indemnified against all Expenses (as hereinafter defined), judgments, penalties, fines and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with, or in respect of, such Expenses, judgments, penalties, fines and amounts paid in settlement) actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and with respect to any criminal Proceeding, had no reasonable cause to believe Indemnitee&#8217;s conduct was unlawful. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Proceedings by or in the Right of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Indemnitee shall be entitled to the rights of indemnification provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> if, by reason of Indemnitee&#8217;s Corporate Status, Indemnitee is, or is threatened to be made, a party to or participant in any Proceeding brought by or in the right of the Company.  Pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by Indemnitee, or on Indemnitee&#8217;s behalf, in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company&#59; provided, however, if applicable law so provides, no indemnification for such Expenses shall be made</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under this Section 1(b) in respect of any claim, issue or matter in such Proceeding as to which Indemnitee shall have been finally adjudged to be liable to the Company unless and only to the extent that the Court of Chancery of the State of Delaware (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Delaware Court</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or any court in which the Proceeding was brought shall determine upon application that, despite the adjudication of liability but in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to such indemnification for such Expenses as the Delaware Court or other court shall deem proper.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Indemnification for Expenses of a Party Who is Wholly or Partly Successful</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of Indemnitee&#8217;s Corporate Status, a party to and is successful, on the merits or otherwise, in any Proceeding, Indemnitee shall be indemnified to the maximum extent permitted by law, as such may be amended from time to time, against all Expenses actually and reasonably incurred by or on behalf of Indemnitee in connection therewith.  If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by or on behalf of Indemnitee in connection with each successfully resolved claim, issue or matter.  For purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Additional Indemnity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition to, and without regard to any limitations on, the indemnification provided for in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Agreement, the Company shall and hereby does indemnify and hold harmless Indemnitee against all Expenses, judgments, penalties, fines and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, penalties, fines and amounts paid in settlement) actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf if, by reason of Indemnitee&#8217;s Corporate Status, Indemnitee is, or is threatened to be made, a party to or participant in any Proceeding (including a Proceeding by or in the right of the Company), including, without limitation, all liability arising out of the negligence or active or passive wrongdoing of Indemnitee.  The only limitation that shall exist upon the Company&#8217;s obligations pursuant to this Agreement shall be that the Company shall not be obligated to make any payment to Indemnitee that is finally determined (under the procedures, and subject to the presumptions, set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof) to be unlawful.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Contribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Whether or not the indemnification provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof is available, in respect of any threatened, pending or completed action, suit or proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), the Company shall pay, in the first instance, the entire amount of any judgment or settlement of such action, suit or proceeding without requiring Indemnitee to contribute to such payment and the Company hereby waives and relinquishes any right of contribution it may have against Indemnitee.  The Company shall not enter into any settlement of any Proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such Proceeding) unless such settlement provides for a full and final release of all claims asserted against Indemnitee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Without diminishing or impairing the obligations of the Company set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if, for any reason, Indemnitee shall elect or be required to pay all or any portion of any judgment,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">penalty, fine or settlement in any threatened, pending or completed action, suit or proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), the Company shall contribute to the amount of Expenses, judgments, penalties, fines and amounts paid in settlement actually and reasonably incurred and paid or payable by Indemnitee in proportion to the relative benefits received by the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, from the transaction or events from which such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">action, suit or proceeding arose&#59; provided, however, that the proportion determined on the basis of relative benefit may, to the extent necessary to conform to law, be further adjusted by reference to the relative fault of the Company and all officers, directors or employees of the Company other than Indemnitee who are jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, in connection with the transaction or events that resulted in such Expenses, judgments, penalties, fines or settlement amounts, as well as any other equitable considerations which applicable law may require to be considered.  The relative fault of the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, shall be determined by reference to, among other things, the degree to which their actions were motivated by intent to gain personal profit or advantage, the degree to which their liability is primary or secondary and the degree to which their conduct is active or passive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Company hereby agrees to fully indemnify and hold Indemnitee harmless from any claims for contribution which may be brought by officers, directors or employees of the Company, other than Indemnitee, who may be jointly liable with Indemnitee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and&#47;or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Company and Indemnitee as a result of the event(s) and&#47;or transaction(s) giving cause to such Proceeding and&#47;or (ii) the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and&#47;or transaction(s).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Indemnification for Expenses of a Witness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of Indemnitee&#8217;s Corporate Status, a witness, or is made (or asked) to respond to discovery requests, in any Proceeding to which Indemnitee is not a party, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection therewith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Advancement of Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision of this Agreement, Indemnitee shall, in all events, control the defense of Indemnitee in any Proceeding (or any part of any Proceeding) by reason of Indemnitee&#8217;s Corporate Status, and the Company shall advance all Expenses incurred by or on behalf of Indemnitee in connection with any Proceeding (x) not initiated by Indemnitee or (y) initiated by Indemnitee with the prior approval of the Board as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and such advancement will be made within thirty (30) days after the receipt by the Company of a statement or statements from Indemnitee requesting such advances from time to time, whether prior to or after final disposition of such Proceeding.  Such statement or statements shall reasonably evidence the Expenses incurred by Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and shall include or be preceded or accompanied by a written undertaking by or on behalf of Indemnitee to repay any Expenses advanced if it shall ultimately be determined that Indemnitee is not entitled to be indemnified against such Expenses.  Any advances and undertakings to repay pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be unsecured and interest free, and shall be made without regard to Indemnitee&#8217;s ability to repay the Expenses and without regard to Indemnitee&#8217;s ultimate entitlement to indemnification under the other provisions of this Agreement. Advances shall include any and all reasonable Expenses incurred pursuing an action to enforce this right of advancement, including Expenses incurred preparing and forwarding statements to the Company </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to support the advances claimed. Indemnitee shall qualify for advances upon the execution and delivery to the Company of this Agreement, which shall constitute an undertaking providing that Indemnitee undertakes to repay the amounts advanced (without interest) to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company. No other form of undertaking shall be required other than the execution of this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Procedures and Presumptions for Determination of Entitlement to Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  It is the intent of this Agreement to secure for Indemnitee rights of indemnity that are as favorable as may be permitted under the DGCL and public policy of the State of Delaware.  Accordingly, the parties agree that the following procedures and presumptions shall apply in the event of any question as to whether Indemnitee is entitled to indemnification under this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification.  The Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification.  Notwithstanding the foregoing, any failure of Indemnitee to provide such a request to the Company, or to provide such a request in a timely fashion, shall not relieve the Company of any liability that it may have to Indemnitee unless, and to the extent that, such failure actually and materially prejudices the interests of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Upon written request by Indemnitee for indemnification pursuant to the first sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof, a determination with respect to Indemnitee&#8217;s entitlement thereto shall be made in the specific case&#58; (i) if a Change in Control shall have occurred, by Independent Counsel (as hereinafter defined) in a written opinion to the Board, a copy of which shall be delivered to Indemnitee, (ii) if a Change in Control shall not have occurred, by one of the following four methods, which shall be at the election of the Board&#58; (1) by a majority vote of the Disinterested Directors (as hereinafter defined), even if less than a quorum, (2) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even if less than a quorum, (3) if there are no Disinterested Directors or if the Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee, or (4) if so directed by the Board, by the stockholders of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">If the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof, the Independent Counsel shall be selected as provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If a Change in Control shall not have occurred, the Independent Counsel shall be selected by the Board, and the Company shall give written notice to Indemnitee advising Indemnitee of the identity of the Independent Counsel so selected. If a Change in Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either event, Indemnitee or the Company, as the case may be, may, within ten (10) days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection&#59; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#8220;Independent Counsel&#8221; as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If a written objection is made and substantiated, the Independent Counsel selected may not serve as Independent Counsel unless and until such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">objection is withdrawn or the Delaware Court has determined that such objection is without merit. If, within twenty (20) days after the later of submission by Indemnitee of a written request for indemnification pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof and the final disposition of the Proceeding, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition the Delaware Court for resolution of any objection which shall have been made by the Company or Indemnitee to the Company&#8217;s selection of Independent Counsel and&#47;or for the appointment as Independent Counsel of a person selected by the court or by such other person as the court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.  The Company shall pay any and all reasonable fees and expenses of Independent Counsel incurred by such Independent Counsel in connection with acting pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof, and the Company shall pay all reasonable fees and expenses incident to the procedures of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, regardless of the manner in which such Independent Counsel was selected or appointed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In making a determination with respect to entitlement to indemnification or advancement of Expenses hereunder, the person or persons or entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement.  Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence.  Neither the failure of the Company (including by its directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or Independent Counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Indemnitee shall be deemed to have acted in good faith if Indemnitee&#8217;s action is based on the records or books of account of the Enterprise (as hereinafter defined), including financial statements, or on information supplied to Indemnitee by the officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise or on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Enterprise.  In addition, the knowledge and&#47;or actions, or failure to act, of any director, officer, agent or employee of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.  Whether or not the foregoing provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are satisfied, it shall in any event be presumed that Indemnitee has at all times acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company.  Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">If the person, persons or entity empowered or selected under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall be deemed to have been made and Indemnitee shall be entitled to such indemnification absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law&#59; provided, however, that such 60-day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making such determination with respect to entitlement to indemnification in good faith requires such additional time to obtain or evaluate documentation and&#47;or information relating thereto&#59; and provided, further, that the foregoing provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not apply if the determination of entitlement to indemnification is to be made by the stockholders pursuant to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Agreement and if (A) within fifteen (15) days after receipt by the Company of the request for such determination, the Board or the Disinterested Directors, if appropriate, resolve to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy-five (75) days after such receipt and such determination is made thereat, or (B) a special meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60) days after having been so called and such determination is made thereat.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee&#8217;s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination.  Any Independent Counsel, member of the Board or stockholder of the Company shall act reasonably and in good faith in making a determination regarding Indemnitee&#8217;s entitlement to indemnification under this Agreement.  Any costs or expenses (including attorneys&#8217; fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee&#8217;s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company acknowledges that a settlement or other disposition short of final judgment may be successful if it permits a party to avoid expense, delay, distraction, disruption and uncertainty.  In the event that any action, claim or proceeding to which Indemnitee is a party is resolved in any manner other than by adverse judgment against Indemnitee (including, without limitation, settlement of such action, claim or proceeding with or without payment of money or other consideration) it shall be presumed that Indemnitee has been successful on the merits or otherwise in such action, suit or proceeding.  Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that Indemnitee&#8217;s conduct was unlawful.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Remedies of Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">In the event that (i) a determination is made pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Agreement, (iii) no determination of entitlement to indemnification is made pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Agreement within ninety (90) days after the conclusion of the Proceeding giving rise to the request for indemnification, (iv) payment of indemnification required by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is not made pursuant to this Agreement within thirty (30) days after receipt by the Company of a written request therefor or (v) payment of indemnification is not made within thirty (30) days after a determination has been made that Indemnitee is entitled to indemnification or such determination is deemed to have been made pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Agreement, Indemnitee shall be entitled to an adjudication in Court of Chancery of the State of Delaware of Indemnitee&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">entitlement to such indemnification.  Indemnitee shall commence such proceeding seeking an adjudication within one hundred eighty (180) days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall not oppose Indemnitee&#8217;s right to seek any such adjudication.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In the event that a determination shall have been made pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding commenced pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be conducted in all respects as a de novo trial on the merits, and Indemnitee shall not be prejudiced by reason of the adverse determination under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In any judicial proceeding  commenced pursuant to this Section 7(b), the Company shall have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">If a determination shall have been made pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding commenced pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s misstatement not materially misleading in connection with the application for indemnification, or (ii) a prohibition of such indemnification under applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In the event that Indemnitee, pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, seeks a judicial adjudication of Indemnitee&#8217;s rights under, or to recover damages for breach of, this Agreement, or to recover under any directors&#8217; and officers&#8217; liability insurance policies maintained by the Company, the Company shall pay on Indemnitee&#8217;s behalf, in advance, any and all expenses (of the types described in the definition of Expenses in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Agreement) actually and reasonably incurred by Indemnitee in such judicial adjudication, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of expenses or insurance recovery.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Company shall be precluded from asserting in any judicial proceeding commenced pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court that the Company is bound by all the provisions of this Agreement.  The Company shall indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefore) advance, to the extent not prohibited by law, such Expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advance of Expenses from the Company under this Agreement or under any directors&#8217; and officers&#8217; liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of Expenses or insurance recovery, as the case may be.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement of Indemnitee to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Non-Exclusivity&#59; Survival of Rights&#59; Insurance&#59; Primacy of Indemnification&#59; Subrogation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The rights of indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation of the Company (as amended and&#47;or restated from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Certificate of Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Bylaws, any agreement, a vote of stockholders, a resolution of the Board, or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">otherwise.  No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in Indemnitee&#8217;s Corporate Status prior to such amendment, alteration or repeal.  To the extent that a change in the DGCL, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Certificate of Incorporation, the Bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change.  No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise.  The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">To the extent that the Company maintains an insurance policy or policies providing liability insurance for certain directors, officers, employees, or agents or fiduciaries of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that such person serves at the request of the Company, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, officer, employee, agent or fiduciary under such policy or policies.  If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has directors&#8217; and officers&#8217; liability insurance in effect, the Company shall give prompt notice of such a claim or the commencement of a Proceeding, as the case may be, to the insurers in accordance with the procedures set forth in the respective policies.  The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#91;The Company hereby acknowledges that Indemnitee has certain rights to indemnification, advancement of expenses and&#47;or insurance provided by &#91;&#160;</font><font style="font-family:'Wingdings 2',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#93; and certain of its affiliates (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Fund Indemnitors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Company hereby agrees (i) that it is the indemnitor of first resort (i.e., its obligations to Indemnitee are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary), (ii) that it shall be required to advance the full amount of Expenses incurred by Indemnitee and shall be liable for the full amount of all Expenses, judgments, penalties, fines and amounts paid in settlement to the extent legally permitted and as required by the terms of this Agreement, the Certificate of Incorporation or the Bylaws (or any other agreement between the Company and Indemnitee), without regard to any rights Indemnitee may have against the Fund Indemnitors, and, (iii)  that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof.  The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of Indemnitee with respect to any claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and&#47;or be subrogated to the extent of such advancement or payment to all of the rights of recovery of Indemnitee against the Company.  The Company and Indemnitee agree that the Fund Indemnitors are express third party beneficiaries of the terms of this Section 8(c).&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#91;Except as provided in paragraph (c) above,&#93; in the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee (other than against the Fund Indemnitors), who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#91;Except as provided in paragraph (c) above,&#93; the Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">&#91;Except as provided in paragraph (c) above,&#93; the Company&#8217;s obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director, officer, employee or agent of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement of Expenses from such other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Exception to Right of Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnity in connection with any claim made against Indemnitee&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision&#91;, provided, that the foregoing shall not affect the rights of Indemnitee or the Fund Indemnitors set forth in Section 8(c) above&#93;&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">for (i) an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Securities Exchange Act of 1934, as amended, or similar provisions of state statutory law or common law, (ii) any reimbursement of the Company by the Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by the Indemnitee from the sale of securities of the Company, as required in each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Sarbanes-Oxley Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act), or (iii) any reimbursement of the Company by Indemnitee of any compensation pursuant to any compensation recoupment or clawback policy adopted by the Board or the Compensation Committee of the Board, including but not limited to any such policy adopted to comply with stock exchange listing requirements implementing Section 10D of the Exchange Act&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Duration of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All agreements and obligations of the Company contained herein shall continue during the period Indemnitee is an officer or director of the Company (or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise) and shall continue thereafter so long as Indemnitee shall be subject to any Proceeding (or any proceeding commenced under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof) by reason of Indemnitee&#8217;s Corporate Status, whether or not Indemnitee is acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification can be provided under this Agreement.  This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">respective successors (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), assigns, spouses, heirs, executors and personal and legal representatives.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Security</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent requested by Indemnitee and approved by the Board, the Company may at any time and from time to time provide security to Indemnitee for the Company&#8217;s obligations hereunder through an irrevocable bank line of credit, funded trust or other collateral.  Any such security, once provided to Indemnitee, may not be revoked or released without the prior written consent of Indemnitee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any ambiguity in the terms of this Agreement will be resolved in favor of Indemnitee and in a manner to provide the maximum indemnification and advancement of Expenses permitted by law. The Company and Indemnitee intend that this Agreement provide to the fullest extent permitted by law for indemnification and advancement of Expenses in excess of that expressly provided, without limitation, by the Certificate of Incorporation, the Bylaws, vote of the Company&#8217;s stockholders or Disinterested Directors (as hereinafter defined), or applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Company expressly confirms and agrees that it has entered into this Agreement and assumes the obligations imposed on it hereby in order to induce Indemnitee to serve as a director, an officer or other person in service of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director, an officer or other person in service of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof&#59; provided, however, that this Agreement is a supplement to and in furtherance of the Certificate of Incorporation, the Bylaws, any directors&#8217; and officers&#8217; insurance maintained by the Company, and applicable law, is not a substitute therefor, and does not diminish or abrogate any rights of Indemnitee thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Company shall not seek from a court, or agree to, a &#8220;bar order&#8221; which would have the effect of prohibiting or limiting Indemnitee&#8217;s rights to receive advancement of expenses under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For purposes of this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">References to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any person who is authorized by the Company or an Enterprise to act for or represent the interests of the Company or an Enterprise, respectively.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">A &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:148.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.17pt"> Acquisition of Stock by Third Party.  Any Person (as defined below) is or becomes the Beneficial Owner (as defined below), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the combined voting power of the Company&#8217;s then outstanding securities unless the change in relative Beneficial Ownership of the Company&#8217;s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:148.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.84pt">Change in Board of Directors.  During any period of two (2) consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in Sections 13(b)(i), 13(b)(iii) or 13(b)(iv)) whose election by the Board or nomination for election by the Company&#8217;s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:148.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.51pt">Corporate Transactions.  The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its ultimate parent, as applicable) more than fifty percent (50%) of the combined voting power of the voting securities of the surviving entity or its ultimate parent, as applicable, outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the Board or other governing body of such surviving entity or its ultimate parent, as applicable&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:148.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.17pt">Liquidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or Sale of Assets.  The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company&#8217;s assets&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:148.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">v.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.5pt">Other Events.  There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below), whether or not the Company is then subject to such reporting requirement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:148.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">vi.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.17pt">For purposes of this Section 14(b), the following terms have the following meanings&#58;</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Securities Exchange Act of 1934, as amended from time to time.</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act&#59; provided, however, that Person shall exclude (i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii) any entity owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Beneficial Owner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall have the meaning given to such term in Rule 13d-3 under the Exchange Act&#59; provided, however, that Beneficial Owner shall exclude any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Company approving a merger of the Company with another entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Corporate Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; describes the status of a person who is or was a director, officer, employee, member, trustee or agent of the Company or of any other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">corporation, partnership, joint venture, trust, nonprofit entity or other enterprise (including service with respect to employee benefit plans) that such person is or was serving at the express written request of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Disinterested Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Enterprise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Company and any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that Indemnitee is or was serving at the express written request of the Company as a director, officer, employee, agent or fiduciary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall include all reasonable attorneys&#8217; fees, retainers, court costs, transcript costs, fees of experts and other professionals, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, ERISA excise taxes and penalties and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, participating, or being or preparing to be a witness in a Proceeding, or responding to, or objecting to, a request to provide discovery in any Proceeding. Expenses also shall include (i) Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersede as bond, or other appeal bond or its equivalent and (ii) Expenses incurred in connection with recovery under any directors&#8217; and officers&#8217; liability insurance policies maintained by the Company, regardless of whether Indemnitee is ultimately determined to be entitled to such indemnification, advancement, or Expenses or insurance recovery, as the case may be.  Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Independent Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent&#58;  (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder.  Notwithstanding the foregoing, the term &#8220;Independent Counsel&#8221; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee&#8217;s rights under this Agreement.  The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; includes any threatened, pending or completed action, suit, claim, counterclaim, cross claim, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought by or in the right of the Company or otherwise and whether civil, criminal, administrative, legislative, regulatory or investigative, in which Indemnitee was, is or will be involved as a party, potential party, non-party witness or otherwise by reason of Indemnitee&#8217;s Corporate Status, by reason of any action taken by Indemnitee or of any inaction on Indemnitee&#8217;s part while acting in Indemnitee&#8217;s Corporate Status&#59; in each case whether or not Indemnitee is acting or serving in any such capacity at the time any liability or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expense is incurred for which indemnification, reimbursement, or advancement of Expenses can be provided under this Agreement&#59; including one pending on or before the date of this Agreement, but excluding one initiated by an Indemnitee pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Agreement to enforce Indemnitee&#8217;s rights under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Reference to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">other enterprise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall include employee benefit plans&#59; references to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">fines</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall include any excise tax assessed with respect to any employee benefit plan&#59; references to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">serving at the request of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries&#59; and a person who acted in good faith and in a manner Indemnitee reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &#8220;not opposed to the best interests of the Company&#8221; as referred to in this Agreement</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Partial Indemnification.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of Expenses, but not, however, for the total amount thereof, the Company will indemnify Indemnitee for the portion thereof to which Indemnitee is entitled.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision.  Further, the invalidity or unenforceability of any provision hereof as to Indemnitee shall in no way affect the validity or enforceability of any provision hereof as to the other.  Without limiting the generality of the foregoing, this Agreement is intended to confer upon Indemnitee indemnification rights to the fullest extent permitted by applicable laws.  In the event any provision hereof conflicts with any applicable law, such provision shall be deemed modified, consistent with the aforementioned intent, to the extent necessary to resolve such conflict.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Modification and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No supplement, modification, termination or amendment of this Agreement shall be binding unless executed in writing by both of the parties hereto.  No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Notice By Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Indemnitee agrees promptly to notify the Company in writing upon being served with or otherwise receiving any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification covered hereunder.  The failure to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise unless and only to the extent that such failure or delay materially prejudices the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given&#58;  (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, and if not so confirmed, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.  All communications shall be sent&#58;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">To Indemnitee at the address set forth below Indemnitee signature hereto.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">To the Company at&#58;</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Zentalis Pharmaceuticals, Inc.<br>1359 Broadway<br>Suite 801</font></div><div style="margin-bottom:12pt;padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">New York, NY 10018<br>Attention&#58; General Counsel<br>Email&#58; legal&#64;zentalis.com</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or to such other address as may have been furnished to Indemnitee by the Company or to the Company by Indemnitee, as the case may be.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, www.docusign.com) or any other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Governing Law and Consent to Jurisdiction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This Agreement and the legal relations between the parties hereto shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules.  The Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court, and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (iv) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">SIGNATURE PAGE TO FOLLOW</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have executed this Indemnification Agreement on and as of the day and year first above written.</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ZENTALIS PHARMACEUTICALS, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br><br><br><br>By&#58;____________________________________<br>Name&#58; </font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; <br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INDEMNITEE<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">______________________________________<br>Name&#58;  ________________________________<br><br>Address&#58;<br>______________________________________<br>______________________________________<br>______________________________________<br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex102-zntlxsublease_zental.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5e9ab117be0b4286b0e3e798e7aa1455_1"></div><div style="min-height:127.44pt;width:100%"><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Certain information in this document has been excluded pursuant to Regulation&#160;S-K,&#160;Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AGREEMENT OF SUBLEASE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;AGREEMENT OF SUBLEASE </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sublease Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sublease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), dated as of the 6th day of March, 2023, by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ZENTALIS PHARMACEUTICALS, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware corporation, whose address is 1359 Broadway, Suite 1710, New York, NY 10018</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sublessor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LM COHEN &#38; CO. LLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a New York limited liability partnership whose address is 535 Fifth Avenue, 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Floor, New York, New York (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sublessee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Basic Sublease Definitions.</font></div><div style="padding-left:252pt;text-align:justify;text-indent:-252pt"><font><br></font></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NAME OF SUBLESSOR&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Zentalis Pharmaceuticals, Inc.</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">STATE OF FORMATION&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Delaware</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SUBLESSOR'S ADDRESS(ES)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FOR NOTICES&#58; </font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Zentalis Pharmaceuticals, Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10275 Science Center Drive, Suite 200</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">San Diego, CA 92121</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PAYMENT OF RENT ADDRESS&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Zentalis Pharmaceuticals, Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10275 Science Center Drive, Suite 200</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">San Diego, CA 92121</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NAME OF SUBLESSEE&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LM Cohen &#38; Co. LLP</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">STATE OF FORMATION&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">New York</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SUBLESSEE'S ADDRESS</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">535 Fifth Avenue, 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> Floor, New York, New York</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNDERLYING LANDLORD&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ESRT 1359 Broadway, L.L.C.</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNDERLYING LEASE AND </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDMENTS&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">See Exhibit B</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SUBLET PREMISES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Suites 1710 and 1800, totaling an agreed-upon 31,362 rentable square feet</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BUILDING&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1359 Broadway</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">New York, NY 10018</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COMMENCEMENT DATE&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">The later of&#58; (i) ten (10) business days following written notice of the date and time of receipt of written consent to this Sublease Agreement by Underlying Landlord&#59; or (ii) May 1, 2023.</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">  </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Certain information in this document has been excluded pursuant to Regulation&#160;S-K,&#160;Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div><div><font><br></font></div></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.054%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TERM&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">From the Commencement Date through November 29, 2032 (the &#8220;Expiration Date&#8221;)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PERMITTED USES&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Solely as general, administrative and executive offices for the conduct of Tenant&#8217;s business, and such incidental uses as permitted by the Underlying Lease</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FF&#38;E</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">See Schedule 7(B)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECURITY DEPOSIT&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; LOC (See Section 1(G) below)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.52pt 2px 1pt;text-align:justify;text-indent:-2.52pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BROKER(S)&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CBRE, Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LSLNY, LLC d&#47;b&#47;a LSL Advisors</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">All capitalized terms used in the text of this Sublease without definition are defined above or if not defined above, then defined in the Underlying Lease.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SUBLESSOR&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SUBLESSEE&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Zentalis Pharmaceuticals, Inc.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;LM Cohen &#38; Co. LLP </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">By&#58; &#47;s&#47; Kimberly Blackwell, M.D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58; &#47;s&#47; &#91;***&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Name&#58; Kimberly Blackwell, M.D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58; &#91;***&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Title&#58; Chief Executive Officer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Managing Partner</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Zentalis Pharmaceuticals, Inc.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">By&#58; &#47;s&#47; Melissa Epperly&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Name&#58; Melissa Epperly&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Title&#58; Chief Financial Officer</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Certain information in this document has been excluded pursuant to Regulation&#160;S-K,&#160;Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">W</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Sublessor is the tenant of the Premises in the Building, as defined in the Underlying Lease and Sublessee is desirous of subletting all of such Premises (hereafter, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sublet Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from Sublessor upon the terms and conditions hereinafter set forth&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in consideration of the rental payments to be made hereunder by Sublessee to Sublessor and the mutual terms, covenants, conditions, provisions and agreements hereinafter set forth, Sublessor does hereby sublet to Sublessee and Sublessee does hereby take and hire from Sublessor, the Sublet Premises.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Fixed Basic Rent&#59; Additional Rent&#59; Security Deposit.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;A.  &#160;&#160;&#160;&#160;During the Term, Sublessee shall pay basic rent to Sublessor on the first day of each and every calendar month in the monthly amounts set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Basic Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  If the Commencement Date is not the first day of the month, the first month&#8217;s Basic Rent will be prorated and payable (with the Security Deposit) on the Commencement Date (or following business day if such payments cannot be reasonably made on the Commencement Date).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All Basic Rent shall be paid by Sublessee at the Payment of Rent Address set forth above, or at such other place as Sublessor may designate, without any notice, setoff or deduction whatsoever.  Sublessee&#8217;s obligation to make such payments shall survive the expiration or sooner termination of this Sublease.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;B.  &#160;&#160;&#160;&#160;The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; as used herein shall mean any and all amounts, sums, fees or other charges payable by Sublessee to Sublessor hereunder specifically including, without limitation, Operating Expense Escalations (as defined below), Tax Escalations (as defined below) and IT Equipment Fee (as defined below), but specifically excluding Basic Rent and use and occupancy charges following any holdover. Unless otherwise expressly set forth herein, Additional Rent shall be due within thirty (30) days after Sublessor gives Sublessee notice thereof. Sublessor shall have the same rights and remedies provided herein or by law with respect to Sublessee&#8217;s non-payment of Additional Rent as it has with respect to Sublessee&#8217;s non-payment of Basic Rent.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;C.&#160;&#160;&#160;&#160;In the event of non-payment of Rent (which shall mean collectively, Basic Rent and Additional Rent), Sublessor shall have all the rights and remedies herein provided for in case of non-payment of Rent (or its equivalent term) in the Underlying Lease.  If Sublessee shall fail to duly and timely pay any installment of Rent within five (5) business days of when due, Sublessee shall also pay to Sublessor a late charge equal to &#91;***&#93; per month of the overdue amount, such late charge to be payable hereunder.  The payment of such late charge shall be in addition to all other rights and remedies available to Sublessor in the case of non-payment of Rent.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;D.  &#160;&#160;&#160;&#160;In the event Sublessor incurs any reasonable costs or expenses (after written notice and Sublessee&#8217;s failure to cure as herein specifically set forth) which are directly attributable to damage to the Sublet Premises caused by Sublessee, its agents, contractors, servants, licensees, employees or invitees outside of normal wear and tear, Sublessee shall pay </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Certain information in this document has been excluded pursuant to Regulation&#160;S-K,&#160;Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sublessor or the applicable provider, as the case may be, the full amount of such costs and expenses within ten days after receipt of the applicable invoices as Additional Rent hereunder.   &#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;E. &#160;&#160;&#160;&#160;During the Term, Sublessee shall also pay to Sublessor, at the same time and in the same manner as Basic Rent, and otherwise in compliance with the terms of Section 2(C) of the Underlying Lease, one hundred percent (100%) of the Expense Payment (including the Building Electricity Payment) as set forth in Section 2(C) of the Underlying Lease (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Operating Expense Escalations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; provided, however, that the Base Expense Year as it applies to this Sublease shall mean the calendar year 2023.  Sublessor shall promptly provide Sublessee with a copy of any Monthly Expense Payment Amount or Expense Statement (as applicable) promptly upon receipt from Underlying Landlord.  Sublessee shall not have the right to audit Operating Expense Escalations absent manifest error.  Pending the resolution of any audit permitted hereunder, Sublessee shall pay the Operating Expense Escalations to Sublessor in accordance with the Expense Statement furnished by Sublessor, and otherwise in accordance with the terms of Section 2(C) of the Underlying Lease.  Notwithstanding anything to the contrary contained herein, and provided Sublessee is not in default beyond any applicable notice and grace periods, Sublessee shall not be obligated to make any Operating Expense Escalations with respect to periods prior to the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) anniversary of the Commencement Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;F.&#160;&#160;&#160;&#160;During the Term, Sublessee shall also pay to Sublessor, at the same time and in the same manner as Basic Rent, and otherwise in compliance with the terms of Section 2(D) of the Underlying Lease, one hundred percent (100%) of the Tax Payment as set forth in Section 2(D) of the Underlying Lease (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Escalations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; provided, however, that the Base Tax Year as it applies to this Sublease shall mean the Tax Year commencing on July 1, 2023 and ending on June 30, 2024.  Sublessor shall promptly provide Sublessee with a copy of any Tax Payment statement promptly upon receipt from Underlying Landlord.  Sublessor shall deliver any refunds or adjustments received by Sublessor applicable to the Sublet Premises during the Term of this Sublease for which Sublessee shall have previously made any Additional Tax Rent.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;G.&#160;&#160;&#160;&#160;The Security Deposit shall be in the form of an irrevocable, unconditional Letter of Credit in favor of Sublessor, in a form acceptable to Sublessor and otherwise in compliance with Article 32 of the Underlying Lease.  Provided there has been no default by Sublessee under this Sublease, and the original Sublessee remains the subtenant hereunder, Sublessee shall be entitled to reduce the Security Deposit to an amount equal to &#91;***&#93; on the third (3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) anniversary of the Commencement Date, in which event the Letter of Credit shall be reduced thereby.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Underlying Lease.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;This Sublease shall be expressly subject and subordinate to the terms of the Underlying Lease, which provision shall be self-operative, but Sublessee shall within ten (10) days of Sublessor&#8217;s request execute any instrument reasonably requested by Sublessor or Underlying Landlord to evidence or confirm the same.  If the Underlying Lease is terminated for any reason whatsoever, Underlying Landlord, at Underlying Landlord's option, may take over all of the right, title and interest of Sublessor under the Sublease and the Sublessee, at Underlying Landlord's option, shall attorn to Underlying Landlord and perform for Underlying Landlord&#8217;s benefit all the terms, covenants and conditions of such Sublease as if such Sublease were a direct lease between Underlying Landlord and Sublessee&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Underlying Landlord shall not be (1) liable for any act or omission of the transferor under such Sublease (except for any such acts or omissions that (x) continue after the date that Landlord succeeds to the interest of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Certain information in this document has been excluded pursuant to Regulation&#160;S-K,&#160;Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sublessor under the Sublease, and (y) may be remedied by providing a service or performing a repair), (2)&#160;subject to any defense or offsets which the Sublessee may have against the Sublessor that accrue prior to the date that Underlying Landlord succeeds to the interest of the Sublessor, (3) bound by any previous payment that the Sublessee made to the Sublessor more than thirty (30) days in advance of the date that such payment was due, (4) bound by any obligation to make any payment to or on behalf of the Sublessee that accrues prior to the date that Underlying Landlord succeeds to the interest of the Sublessor under this Sublease, (5) bound by any obligation to perform any work or to make improvements to the Sublet Premises (other than the obligation to perform maintenance, repairs or restoration that in each case first becomes necessary from and after the date that Underlying Landlord succeeds to the interest of the Sublessor under the Sublease), (6)&#160;bound by any amendment or modification of this Sublease made without Underlying Landlord's consent (it being agreed that no such consent shall be required pursuant to this subclause (6) for any amendment or modification of the Sublease expressly contemplated herein or otherwise previously approved by Underlying Landlord (e.g., a renewal right), and (7) bound to return the Sublessee's security deposit, if any, until such deposit has come into Underlying Landlord's actual possession and the Sublessee is entitled to such security deposit pursuant to the terms of this Sublease. If the Underlying Lease shall be rejected pursuant to Section 365 of the Bankruptcy Code (as hereinafter defined) or any similar or successor statute, such rejection shall be treated by Sublessee as a termination of the Term hereunder, notwithstanding any alternative interpretation given by law to such rejection and the provisions of Section 4.(D)(xiii) of the Underlying Lease shall be applicable thereto. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;The provisions of the Underlying Lease are specifically incorporated herein by reference, except such terms, covenants, conditions, provisions and agreements as are specifically inconsistent with the terms hereof or are set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 2(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Excluded Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and except that all references therein to &#8220;Landlord&#8221; shall mean Sublessor, all references therein to &#8220;Tenant&#8221; shall mean Sublessee, all references to &#8220;Premises&#8221; shall mean the Sublet Premises, and all references to &#8220;this Lease&#8221; shall mean this Sublease, and all Fixed Rent and recurring items of Additional Rent payable by Sublessee shall be as set forth in this Sublease only.  If any provisions of this Sublease shall conflict with any provision of the Underlying Lease, then, as between Sublessor and Sublessee, the provisions of this Sublease shall control, provided, however, that if such construction of terms would cause Sublessor to be in default under the terms of the Underlying Lease, then such inconsistency shall be resolved in favor of the Underlying Lease. Sublessee covenants and agrees to observe and perform all of the terms, covenants, conditions, provisions and agreements to be performed by Sublessor, as tenant pursuant to the Underlying Lease, except for any Excluded Provisions, and further covenants and agrees not to do or suffer or permit anything to be done which would result in a default under or cause the Underlying Lease to be terminated.  Notwithstanding the foregoing, all grace periods specified in the Underlying Lease shall, for purposes of determining compliance by Sublessee with the provisions hereof, be each reduced by three (3) days, unless a shorter time period is specifically set forth in this Sublease.  If (a) Sublessee shall fail to perform any of its obligations hereunder and such failure shall continue beyond receipt of written notice and the expiration of any cure period provided for herein, or (b) Underlying Landlord or Sublessor shall give any notice of failure or default under the Underlying Lease arising out of any failure by Sublessee to perform any of its obligations hereunder and Sublessee shall fail to cure such failure or default within any grace or cure period provided in this Sublease, then, in either case, Sublessor shall have the right (but not the obligation) to perform or endeavor to perform such obligation, at Sublessee&#8217;s expense, and Sublessee shall, within ten (10) days of Sublessor&#8217;s demand from time to time, reimburse Sublessor for all costs and expenses incurred by Sublessor in doing so as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Certain information in this document has been excluded pursuant to Regulation&#160;S-K,&#160;Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Additional Rent.  If the Underlying Lease shall terminate for any reason, then this Sublease shall also terminate.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;C.&#160;&#160;&#160;&#160;Sublessor shall not be deemed to have made any representation, warranty or indemnity (including without limitation any environmental representations, warranties or indemnities) made by Underlying Landlord in the Underlying Lease.  Moreover, except as otherwise expressly set forth in this Sublease, Sublessor shall not be obligated&#58; (i) to provide to Sublessee any of the insurance coverages or services that Underlying Landlord has agreed in the Underlying Lease to provide to Sublessor&#59; (ii) to make any of the repairs or restorations that Underlying Landlord has agreed in the Underlying Lease to make, or to provide any improvement allowance&#59; (iii) to comply with any laws (including without limitation environmental laws) or requirements of public authorities with which Underlying Landlord has agreed in the Underlying Lease to comply with&#59; or (iv) to take any action with respect to the operation, administration or control of the Sublet Premises that the Underlying Landlord has agreed in the Underlying Lease to take (all of the foregoing being herein referred to as the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Underlying Landlord Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  Sublessor shall have no liability to Sublessee on account of any failure of Underlying Landlord to undertake or provide the Underlying Landlord Services, or on account of any failure by Underlying Landlord to observe or perform any of the terms, covenants or conditions of the Underlying Lease required to be observed or performed by Underlying Landlord&#59; provided, however, Sublessor shall use commercially reasonable efforts (excepting the institution of any litigation) to enforce its rights to such services and Underlying Landlord&#8217;s performance under the Underlying Lease to the extent Sublessor is entitled to same and Sublessee so requests.  If Underlying Landlord Services are suspended solely as a result of a default by Sublessor under the Underlying Lease, same shall be deemed a default by Sublessor under this Sublease. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;D.&#160;&#160;&#160;&#160;Whenever Sublessee desires to do any act or thing which, pursuant to the terms of the Underlying Lease, requires the consent or approval of Underlying Landlord&#58; (i) Sublessee shall not do such act or thing without first having obtained the consent or approval of Sublessor (and Sublessor&#8217;s right to withhold consent or approval shall be independent of Underlying Landlord&#8217;s right)&#59; (ii) unless permitted to do so by Sublessor, Sublessee shall not request Underlying Landlord&#8217;s consent or approval directly (and no efforts by Sublessor to obtain Underlying Landlord&#8217;s consent or approval shall constitute Sublessor&#8217;s consent or approval or prejudice Sublessor&#8217;s right to withhold consent or approval)&#59; and (iii) in no event shall Sublessor be required to give its consent or approval prior to Underlying Landlord doing so.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;E.&#160;&#160;&#160;&#160;The provisions of the Underlying Lease relating to Underlying Landlord Services and Underlying Landlord&#8217;s obligations to undertake maintenance and repairs shall apply to Sublessee&#8217;s benefit.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Non-Liability&#59; Indemnity.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Except and to the extent caused by or due to the willful acts or gross negligence of Sublessor, or its agents, contractors, servants, licensees and employees, Sublessee shall and hereby does indemnify, defend and hold Sublessor harmless from and against any and all actions, claims, demands, damages, liabilities and expenses (including, without limitation, reasonable attorneys&#8217; fees and disbursements) asserted against, imposed upon or incurred by Sublessor by reason of (a) any violation caused, suffered or permitted by Sublessee, its agents, contractors, servants, licensees, employees or invitees, of any of the terms, covenants, conditions, provisions </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Certain information in this document has been excluded pursuant to Regulation&#160;S-K,&#160;Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or agreements of this Sublease, (b) any damage or injury to persons or property occurring upon or in connection with the use or occupancy of the Sublet Premises, (c) the use of the Sublet Premises or any business therein or any work or thing whatsoever done, or any condition created in or about the Sublet Premises during the Term (or any time prior to the Commencement Date to the extent Sublessee may have been given access to the Sublet Premises), or (d) any negligent or otherwise wrongful act or omission of Sublessee or any of its agents, contractors, servants, licensees, employees or invitees.  In case any action or proceeding be brought against Sublessor or any agent, contractor, servant, licensee, employee or invitee of Sublessor by reason of any of the foregoing, Sublessee, upon notice from Sublessor, shall defend such action or proceeding by counsel chosen by Sublessee.  Sublessee or its counsel shall keep Sublessor fully apprised at all times of the status of such defense and shall not settle same without the written consent of Sublessor, not to be unreasonably withheld, delayed or conditioned.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Performance by Underlying Landlord.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sublessor does not assume any obligation to perform the terms, covenants, conditions, provisions and agreements contained in the Underlying Lease on the part of Underlying Landlord to be performed.  The representations of Underlying Landlord are not the representations of Sublessor.  In the event Underlying Landlord shall fail to perform any of the terms, covenants, conditions, provisions and agreements contained in the Underlying Lease on its part to be performed, Sublessor shall be under no obligation or liability whatsoever to Sublessee.  Sublessor shall cooperate with Sublessee, at no cost to Sublessor, in seeking to obtain the performance of Underlying Landlord under the Underlying Lease.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;Maintenance Obligations</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Sublessee shall assume the responsibility for and pay for all maintenance of and repair and replacements of the Sublet Premises and FF&#38;E (hereafter defined) during the Term, pursuant to the terms of Article 10 of the Underlying Lease.  Notwithstanding the above or provisions of the Underlying Lease to the contrary, Sublessee shall not be required to make any repairs necessitated by any condition predating the Commencement Date.</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;Alterations.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Sublessee shall not make any changes, alterations, additions or improvements to the Sublet Premises during the Term of this Sublease, except in strict conformance with Article 8 of the Underlying Lease.  Sublessor shall not withhold approval to alterations otherwise approved by Underlying Landlord.  As used in Article 8, the term &#8220;Designated Landlord Parties&#8221; shall collectively mean Underlying Landlord&#59; the specific Landlord Parties designated by Underlying Landlord or Underlying Landlord&#8217;s representative&#59; Sublessor&#59; Sublessor&#8217;s partners, members, managers, officers, directors, employees, principals, trustees, agents, and such other parties designated by Sublessor.  Subject to the terms of the Underlying Lease, and Underlying Landlord&#8217;s consent, Sublessee shall have the right to maintain identifying signage on the entrance door to the Sublet Premises. The location, size, materials, quality, design, color and lettering of any signs desired by Sublessee shall be in compliance with Building standards and the Underlying Lease.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;Initial Condition of Sublet Premises&#59; FF&#38;E.  </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Certain information in this document has been excluded pursuant to Regulation&#160;S-K,&#160;Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;A.&#160;&#160;&#160;&#160;Sublessee represents that it has inspected the Sublet Premises and agrees to take the same vacant, broom clean, and otherwise in its present &#34;AS-IS&#34; condition, and Sublessee acknowledges that no representations with respect to the condition thereof have been made by Sublessor or anyone on Sublessor's behalf except that Sublessor represents and warrants that the Sublet Premises and all fixtures and systems that are Sublessor&#8217;s obligation to repair and maintain pursuant to Section 10(A) of the Underlying Lease shall be in good working order and condition, and in compliance with the Underlying Lease, as of the Commencement Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;During the term of this Sublease, Sublessee shall have the right to use such existing furniture, furnishings and equipment located in or serving the Sublet Premises as identified on the inventory list annexed hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 7(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FF&#38;E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The FF&#38;E shall be delivered to Sublessee on the Commencement Date in their current &#8220;AS-IS&#8221; condition, normal wear and tear excepted.  Upon the Expiration Date of the Term, Sublessee shall purchase the FF&#38;E for a price of $10.00.  On or prior to the Expiration Date, at Sublessee&#8217;s sole cost and expense, the Sublessee shall have the responsibility to remove the FF&#38;E and repair and restore in good and workmanlike manner to good condition, any damage to the Sublet Premises or the Building caused by such removal, subject to and in accordance with Article 8 of the Underlying Lease.  Notwithstanding the foregoing, if this Sublease is terminated prior to the natural Expiration Date of the Term, the FF&#38;E shall remain the property of Sublessor and Sublessee shall surrender same to Sublessor in good order and condition, except for reasonable wear and tear and damage by fire or other casualty.  Sublessee has inspected the FF&#38;E and hereby acknowledges that the FF&#38;E is in good condition as of the date hereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;Assignment and Subletting.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This Sublease Agreement may not be assigned or the Sublet Premises further sublet, or encumbered in any manner, in whole or in part, during the Term of this Sublease, unless&#58; (i) Sublessee obtains in each instance, the consent of Sublessor, which consent shall not be unreasonably withheld, and which assignment or subletting shall otherwise be subject to compliance with the provisions of Section 4 of the Underlying Lease&#59; and (ii) Sublessee obtains, at its sole cost and expense, a waiver from Underlying Landlord of the provisions of the Underlying Lease prohibiting a permitted subtenant from assigning or further subletting the Sublet Premises, and Underlying Landlord&#8217;s consent to each such proposed assignment or subletting by Sublessee.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;Insurance.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;During the Term, Sublessee shall be responsible for maintaining commercial liability insurance in amount required to be carried by Sublessor and upon the terms contained in Article 42 of the Underlying Lease. Sublessee shall cause Sublessor and Underlying Landlord to be included as additional insureds in said policy which shall contain provisions, if and to the extent available, that it or they will not be cancelable except upon at least thirty (30) days' prior notice to all insureds, and that the act or omission of one insured will not invalidate the policy as to the other insureds.  Sublessee shall also be responsible to maintain insurance covering its personal property and the FF&#38;E.  Sublessee shall furnish to Sublessor a certificate of insurance confirming that all such insurance is in effect at or before the Commencement Date and, on request, at reasonable intervals thereafter.  </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Certain information in this document has been excluded pursuant to Regulation&#160;S-K,&#160;Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Each party shall look first to any insurance in its favor before making any claim against the other party for recovery for loss or damage resulting from fire or other casualty. To the extent that such insurance is in force and collectible and to the extent permitted by law, Sublessor and Sublessee each hereby releases and waives all right of recovery against the other or anyone claiming through or under the other by way of subrogation or otherwise. The foregoing release and waiver shall be in force only if the insurance policies of Sublessor and Sublessee provide that such release or waiver does not invalidate the insurance. Each party agrees to use its best efforts to include in its applicable insurance policies such a provision. If the inclusion of said provision would involve an additional expense, either party, at its expense, may require such provision to be inserted in the other&#8217;s policy. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Sublessee hereby releases Underlying Landlord or anyone claiming through or under Underlying Landlord by way of subrogation or otherwise to the extent that Sublessor released Underlying Landlord or Underlying Landlord was relieved of liability or responsibility pursuant to the provisions of the Underlying Lease, and Sublessee will cause its insurance carriers to include any clauses or endorsements in favor of Underlying Landlord which Sublessor is required to provide pursuant to the provisions of the Underlying Lease.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;Default.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;In the event Sublessee defaults in the performance of any of the terms, covenants, conditions, provisions and agreements of this Sublease Agreement, Sublessor shall be entitled to exercise any and all of the rights and remedies to which it is entitled by law and also any and all of the rights and remedies specifically provided to or for the benefit of Underlying Landlord in the Underlying Lease, which rights and remedies are hereby incorporated herein and made a part hereof with the same force and effect as if herein specifically set forth in full, and that wherever in the Underlying Lease rights and remedies are given to Underlying Landlord, the same shall be deemed to apply to Sublessor.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;Sublease Consent.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">All references herein to the Underlying Lease terms are noted only as a convenience, not representation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This Sublease shall become effective only if the written consent hereto of Underlying Landlord is obtained.  Upon execution and delivery of this Sublease by Sublessor and Sublessee, Sublessor shall promptly request the consent of Underlying Landlord to this Sublease. Sublessee agrees to provide such information in connection with such request as Underlying Landlord shall reasonably request. If the foregoing consent is not obtained within sixty (60) days following the execution and delivery of this Sublease by both parties, then Sublessee may, at any time following the expiration of said sixty (60) day period, cancel this Sublease by giving written notice to Sublessor of its election to cancel. Upon Sublessor&#8217;s receipt of a valid notice of cancellation, this Sublease shall be null and void and thereupon neither party shall have any further obligation to the other. In the event that Underlying Landlord shall notify Sublessor that it will not consent to this Sublease (or any similar agreement between the Sublessee and Sublessor), then Sublessor will promptly notify Sublessee of such fact, and thereupon this Sublease shall be null and void and neither party shall have any further obligation to the other</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sublessor shall pay the cost of obtaining the Underlying Landlord&#8217;s consent to this Sublease.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;Notice.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Certain information in this document has been excluded pursuant to Regulation&#160;S-K,&#160;Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Any notice to be given under this Sublease shall be in writing and shall be sent by nationally-recognized overnight courier, with recipient&#8217;s signature required, to the address(es) herein stated above in Basic Sublease Definitions.  Each party shall have the right upon ten (10) days' prior written notice, to change, by notice in writing, the address to which such party&#8217;s notice is to be sent.  Any notice to be given by Sublessor may be given by the attorneys for Sublessor.  Notices shall be deemed given upon receipt or refusal thereof.  Any notice that Sublessor receives from or transmits to Underlying Landlord regarding all or any portion of the Sublet Premises shall be delivered by Sublessor to Sublessee within five (5) business days following such receipt or transmission. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;Quiet Enjoyment.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Sublessor covenants that Sublessee, on paying the Rent and performing all the terms, covenants, conditions, provisions and agreements hereunder, shall and may peacefully and quietly have, hold and enjoy the Sublet Premises for the term aforesaid, free from any interference or hindrance by Sublessor, but subject to the exceptions, reservations and conditions hereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.&#160;&#160;&#160;&#160;Surrender of Sublet Premises.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;On the date upon which the Term hereof shall expire and come to an end, whether on the Expiration Date, by lapse of time or otherwise, Sublessee, at Sublessee&#8217;s sole cost and expense, shall quit and surrender the Sublet Premises and all improvements thereon to Sublessor in the same good order and condition as Sublessor is delivering them to Sublessee, ordinary wear and tear excepted, together with all keys and security cards. Within thirty (30) days of such date, Sublessor shall return to Sublessee the Security Deposit, less any amounts used by Sublessor to offset expenses incurred by Sublessor due to Sublessee&#8217;s breach of this Sublease.  If at the end of the Term of the Sublease, Sublessee fails to vacate the Sublet Premises in accordance with the terms of this Section 14 and Sublessor incurs any damages as a direct result thereof, then Sublessee shall be responsible for all costs, expenses and damages incurred by Sublessor as a result of Sublessee&#8217;s failure to comply in all respects with this Section 14, and any limitations on punitive, special and consequential damages set forth in the Underlying Lease shall not be applicable thereto.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;Successors and Assigns.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This Sublease shall be binding upon and, except as prohibited by this Sublease or the Underlying Lease, inure to the benefit of the parties hereto and their respective successors and assigns.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.&#160;&#160;&#160;&#160;No Modifications.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This Sublease may not be modified except by written agreement signed by Sublessor and Sublessee.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.&#160;&#160;&#160;&#160;Representations and Covenants.  </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Certain information in this document has been excluded pursuant to Regulation&#160;S-K,&#160;Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Sublessor hereby represents to Sublessee that (i) the Underlying Lease annexed hereto is a full and complete copy of same and all amendments thereto, (ii) the Underlying Lease is in full force and effect&#59; (iii) Sublessor has received no written notice of default from the Underlying Landlord which default remains uncured on the date hereof and there are no set of circumstances on the date hereof which, to Sublessor&#8217;s knowledge, would lead to a default under the Underlying Lease&#59; (iv) to the best of Sublessor&#8217;s knowledge, neither Sublessor nor Underlying Landlord is in default beyond applicable notice and grace periods under the Underlying Lease, and no event has occurred or is continuing which would constitute a default under the Underlying Lease but for the requirement of the giving of notice and&#47;or the expiration of the period of time to cure&#59; (v) Sublessor has not assigned, granted a security interest in or encumbered in any way whatsoever its interest in the Underlying Lease, except as may be terminated prior to the Commencement Date&#59; (vi) as of the Commencement Date, there will be no other leases or rights of third parties to occupy the Sublet Premises&#59; and (vii) Sublessor has not received any notices of any violations of Requirements relating to the Sublet Premises.  The foregoing representations shall be true as of the Commencement Date of this Sublease.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17A.&#160;&#160;&#160;&#160;Other Sublessor Representations&#59; Obligations. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;Notwithstanding anything contained in this Section to the contrary, in exercising its rights under this Sublease or in the event of a material default by Sublessee beyond any applicable grace and cure periods, Sublessor shall take all reasonable action to mitigate damages.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;Intentionally omitted.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(c)&#160;&#160;&#160;&#160;Whenever the consent of Underlying Landlord is required under the Underlying Lease for the exercise of a right hereunder, Sublessor agrees to use its reasonable, good faith efforts to obtain Underlying Landlord&#8217;s consent thereto, at Sublessee&#8217;s sole cost and expense</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(d)&#160;&#160;&#160;&#160;Sublessor shall timely perform all of its payment and other obligations to Underlying Landlord under the Underlying Lease.  In the event Sublessor receives a default notice from Underlying Landlord regarding a non-monetary default relating to the Sublet Premises, Sublessor shall promptly provide a copy of such notice to Sublessee, and if Sublessor shall fail to remedy such default within the cure period set forth in the Underlying Lease, then upon ten (10) days&#8217; prior written notice to Sublessor of its intent, and provided such cure has not been commenced by Sublessor within such ten-day period, then Sublessee shall have the right to cure such Sublessor default and may offset the reasonable, out-of-pocket costs of Sublessee in so doing (subject to Sublessor&#8217;s right to contest such amount or the need for such cure) against the rental obligations becoming due.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(e)&#160;&#160;&#160;&#160;Sublessor shall not do, omit to do, or permit to be done any act or thing which may constitute a breach or violation of any term, covenant or condition of the Underlying Lease by the Sublessor thereunder.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.&#160;&#160;&#160;&#160;Inability to Perform&#59; Delays.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;If Sublessee shall be delayed in obtaining possession of the Sublet Premises or Sublessee&#8217;s use of the Sublet Premises becomes materially impaired, because of delays in obtaining consent or for any other reason beyond the reasonable control of Sublessor (including casualty or condemnation), Sublessor shall not be subject to any liability, the effectiveness of this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Certain information in this document has been excluded pursuant to Regulation&#160;S-K,&#160;Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sublease shall not be affected and the Term shall not be extended, but the Rent shall be equitably abated (provided Sublessee is not responsible for the delay in obtaining consent or the impairment of the Sublet Premises) until possession shall have been made available to Sublessee or Sublessee&#8217;s use of the Sublet Premises shall become unimpaired.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.&#160;&#160;&#160;&#160;Notice of Accidents.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Sublessee shall give Sublessor and Underlying Landlord notice of any fire, casualty or accident in or about the Sublet Premises promptly after Sublessee becomes aware of such event.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.&#160;&#160;&#160;&#160;Casualty&#47;Condemnation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The terms of Article 11 of the Underlying Lease shall apply in the event of a casualty in or to the Sublet Premises.  If the Underlying Lease is terminated pursuant to the provisions thereof as the result of a taking of all or any portion of the Building by condemnation (or deed in lieu thereof), this Sublease shall likewise terminate. In such event, Sublessee shall have no claim to any portion of the award with respect to any such taking, except to file a claim for the value of its fixtures or for moving expenses&#59; provided, however, that Sublessor&#8217;s award is not thereby reduced or otherwise adversely affected.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.&#160;&#160;&#160;&#160;Bankruptcy.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;In the event Sublessee becomes the subject of proceedings involving bankruptcy, insolvency or reorganization of Sublessee, or if Sublessee makes an assignment for the benefit of creditors, or petitions for, or enters into an arrangement with creditors, Sublessor shall have the same rights as to Sublessee as are afforded Underlying Landlord under the Underlying Lease under similar circumstances involving Sublessor.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22.&#160;&#160;&#160;&#160;No Waiver, etc.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The failure of Sublessor or Sublessee to enforce any terms, covenants, conditions, provisions or agreements of this Sublease shall not prevent the later enforcement thereof or a subsequent act which would have constituted a violation from having all the force and effect of an original violation. The receipt by Sublessor or payment by Sublessee of Rent or other amounts with knowledge of the breach of any covenant of this Sublease shall not be deemed a waiver of such breach.  The parties hereto, to the fullest extent permitted by law, waive trial by jury in any action or proceeding relating hereto and consent to the jurisdiction of the applicable court system of the jurisdiction in which the Sublet Premises is situated.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23.&#160;&#160;&#160;&#160;Limitations on Sublessee&#8217;s Remedies.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;With respect to any provision of this Sublease which specifically requires that Sublessor shall not unreasonably withhold or unreasonably delay its consent or approval, Sublessee in no event shall be entitled to make, nor shall Sublessee make, any claim, and Sublessee hereby waives any claim, for any sum of money whatsoever as damages, costs, expenses, attorneys&#8217; fees or disbursements, whether affirmatively or by way of setoff, counterclaim or defense, based upon any claim or assertion by Sublessee that Sublessor has unreasonably withheld or unreasonably delayed such consent or approval. Sublessee&#8217;s sole remedy for claimed unreasonable withholding or unreasonable delaying by Sublessor of its consent or approval shall be an action </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Certain information in this document has been excluded pursuant to Regulation&#160;S-K,&#160;Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or proceeding brought and prosecuted solely at Sublessee&#8217;s own cost and expense to enforce such provision, for specific performance, injunction or declaratory judgment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24.&#160;&#160;&#160;&#160;Rules and Regulations.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Sublessee agrees to comply in all material respects with all rules and regulations that Underlying Landlord has made or may hereafter from time to time promulgate for the Building which are provided to Sublessee in writing.  Sublessor shall not be liable in any way for damage caused by the non-observance by any of the other tenants of such similar covenants in their leases or of such rules and regulations. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Access&#59; Occupancy&#59; Consents.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Access.  Sublessee shall have access to the Sublet Premises during the Term of this Sublease Agreement, 24&#47;7.  Sublessee shall be provided with one or more badges, which will provide Sublessee&#8217;s employees with access to the Building and Sublet Premises.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;B.&#160;&#160;&#160;&#160;Consents.  Sublessor agrees that, whenever a provision in the Underlying Lease requires the consent of the Underlying Landlord, Sublessor shall request Underlying Landlord&#8217;s consent in each case.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;C. &#160;&#160;&#160;&#160;Conference Rooms.  Sublessee hereby agrees to grant Sublessor a limited right to use some of the conference rooms within the Sublet Premises. Sublessor shall provide sufficient notice to reserve the use of the conference rooms.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.&#160;&#160;&#160;&#160;Entire Agreement&#59; Miscellaneous.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;A.&#160;&#160;&#160;&#160;This Sublease shall be governed by and construed in accordance with the laws of the state of New Jersey, without regard to the conflicts of law principles thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;B.&#160;&#160;&#160;&#160;The paragraph headings in this Sublease are inserted only as a matter of convenience for reference and are not to be given any effect in construing this Sublease.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;C.&#160;&#160;&#160;&#160;If any of the provisions of this Sublease or the application thereof to any person or circumstance shall be, to any extent, held to be invalid or unenforceable, the remainder of this Sublease shall not be affected thereby and shall be valid and enforceable to the fullest extent permitted by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;D.&#160;&#160;&#160;&#160;All of the terms and provisions of this Sublease shall be binding upon and inure to the benefit of the parties hereto and their respective permitted successors and assigns.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;E.&#160;&#160;&#160;&#160;All prior negotiations and agreements relating to this Sublease and the Sublet Premises are merged into this Sublease, and this Sublease contains the entire agreement of the parties with respect to the subject matter hereof. This Sublease may not be amended, modified or terminated, in whole or in part, nor may any of the provisions be waived, except by a written instrument executed by the party against whom enforcement of such amendment, modification, termination or waiver is sought and unless the same is permitted under the provisions of the Underlying Lease.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Certain information in this document has been excluded pursuant to Regulation&#160;S-K,&#160;Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;F.&#160;&#160;&#160;&#160;Each of Sublessor and Sublessee represents and warrants to the other that each person executing this Sublease is a duly authorized representative of Sublessor or Sublessee, as the case may be, and has full authority to execute and deliver this Sublease.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;G.&#160;&#160;&#160;&#160;This Sublease shall have no binding force and effect and shall not confer any rights or impose any obligations upon either party unless and until both parties have executed it and Sublessor shall have obtained Underlying Landlord&#8217;s written consent to this Sublease pursuant to the provisions hereof and delivered to Sublessee an executed copy of such consent. Under no circumstances shall the submission of this Sublease in draft form by or to either party be deemed to constitute an offer for the subleasing of the Sublet Premises.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;H.&#160;&#160;&#160;&#160;This Sublease may be executed in several counterparts each of which shall be deemed an original but all of which together shall constitute one and the same instrument. Execution of this Sublease Agreement by facsimile or e-mailed signatures, shall be the equivalent of an original ink signature and shall be binding on the party that transmits its signature in such manner. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;I.&#160;&#160;&#160;&#160;Each and every right and remedy of Sublessor under this Sublease shall be cumulative and in addition to every other right and remedy herein contained or now or hereafter existing at law or in equity, by statute or otherwise.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;J.&#160;&#160;&#160;&#160;At any time and from time to time Sublessee shall, within ten (10) days after written request by Sublessor, execute, acknowledge and deliver to Sublessor a written statement certifying (i) that this Sublease has not been modified and is in full force and effect or, if modified, that this Sublease is in full force and effect as modified, and specifying such modification(s), (ii) the dates to which Rent and other amounts have been paid, (iii) that, to the best of Sublessee&#8217;s knowledge, no defaults exist under this Sublease or, if any do exist, the nature of such default(s) and (iv) as to such other matters as Sublessor may reasonably request.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Certain information in this document has been excluded pursuant to Regulation&#160;S-K,&#160;Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the parties hereto have executed this Sublease Agreement as of the day and year first above written.</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SUBLESSOR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#58;</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Zentalis Pharmaceuticals, Inc.</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Kimberly Blackwell, M.D.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Kimberly Blackwell</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, M.D.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Title&#58; Chief Executive Officer</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Zentalis Pharmaceuticals, Inc.</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Melissa Epperly</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58; Melissa Epperly</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Title&#58; Chief Financial Officer</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SUBLESSEE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#58;</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LM COHEN &#38; CO. LLP </font></div><div style="padding-left:180pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; &#91;***&#93;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58; &#91;***&#93;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Title&#58; Managing Partner</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FEID#&#58; __________________</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Federal Identification Number</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Certain information in this document has been excluded pursuant to Regulation&#160;S-K,&#160;Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Floorplan Identifying Sublet Premises</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Exhibit A omitted in accordance with Item 601(a)(5) of Regulation S-K&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Certain information in this document has been excluded pursuant to Regulation&#160;S-K,&#160;Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT B</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Underlying Lease </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Exhibit B omitted in accordance with Item 601(a)(5) of Regulation S-K&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Certain information in this document has been excluded pursuant to Regulation&#160;S-K,&#160;Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SCHEDULE 1(A)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BASIC RENT SCHEDULE</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Schedule 1(A) omitted in accordance with Item 601(a)(5) of Regulation S-K&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Certain information in this document has been excluded pursuant to Regulation&#160;S-K,&#160;Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SCHEDULE 2(B)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXCLUSIONS FROM SUBLEASE</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Schedule 2(B) omitted in accordance with Item 601(a)(5) of Regulation S-K&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Certain information in this document has been excluded pursuant to Regulation&#160;S-K,&#160;Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SCHEDULE 7(B)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FF&#38;E Inventory</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Schedule 7(B) omitted in accordance with Item 601(a)(5) of Regulation S-K&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div></div></div><div id="i5e9ab117be0b4286b0e3e798e7aa1455_4"></div><hr style="page-break-after:always"><div style="min-height:101.52pt;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Certain information in this document has been excluded pursuant to Regulation&#160;S-K,&#160;Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">AMENDMENT TO THE AGREEMENT OF SUBLEASE</font></div><div style="margin-bottom:8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">This Amendment (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221;) is made as of April 10, 2023, by and between Zentalis Pharmaceuticals, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Sublessor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221;), and L.M. Cohen &#38; Co. LLP Certified Public Accountants, a New York limited liability partnership (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Sublessee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221;).</font></div><div style="margin-bottom:8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">WHEREAS, the parties entered into that certain Agreement of Sublease (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221;), dated as of March 6, 2023, in which the Sublessee&#8217;s name was incorrectly stated to be &#8220;LM Cohen &#38; Co. LLP&#8221;&#59; and</font></div><div style="margin-bottom:8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">WHEREAS, the parties desire to amend the Agreement to correct the legal name of the Sublessee.</font></div><div style="margin-bottom:8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">NOW, THEREFORE, the parties hereby agree as follows&#58; </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:9pt">The Agreement is hereby amended by replacing each and every instance of &#8220;LM Cohen &#38; Co. LLP&#8221; with &#8220;L.M. Cohen &#38; Co. LLP Certified Public Accountants.&#8221;</font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">  </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9424743 v5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:101.52pt;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Certain information in this document has been excluded pursuant to Regulation&#160;S-K,&#160;Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div><div><font><br></font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">IN WITNESS WHEREOF, the parties have duly executed this Amendment as of the date set forth above.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SUBLESSOR&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SUBLESSEE&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:-252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Zentalis Pharmaceuticals, Inc.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;L.M. Cohen &#38; Co. LLP Certified Public Accountants</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">By&#58; &#47;s&#47; Melissa Epperly&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58; &#47;s&#47; &#91;***&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Name&#58; Melissa Epperly&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58; &#91;***&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Title&#58; Chief Financial Officer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Managing Partner</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>zentalis10-qq12023ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ibc3a25787cd34712977de7958bf1189a_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">CERTIFICATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">I, Kimberly Blackwell, M.D. certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Zentalis Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.287%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 10, 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Kimberly Blackwell, M.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kimberly Blackwell, M.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Chief Executive Officer</font></div><div style="margin-bottom:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:161%">(principal executive officer)</font></div></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>zentalis10-qq12023ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i64006859436e4d428d417bcf6201b785_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Exhibit 31.2</font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">CERTIFICATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">I, Melissa B. Epperly, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Zentalis Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.287%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 10, 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Melissa B. Epperly</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Melissa B. Epperly</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Chief Financial Officer</font></div><div style="margin-bottom:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:161%">principal financial officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">)</font></div></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>zentalis10-qq12023ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0097d2b16e8e497787f27e7009f22a86_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:187%">Exhibit 32.1</font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:187%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:187%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:187%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">In connection with the Quarterly Report on Form 10-Q of Zentalis Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%;padding-left:6.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt;padding-left:9pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.314%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 10, 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kimberly Blackwell M.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kimberly Blackwell, M.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">Chief Executive Officer</font></div><div style="margin-bottom:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:187%">principal executive officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">)</font></div></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>zentalis10-qq12023ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2addd3ecee874995b92f799fe81b3f56_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:187%">Exhibit 32.2</font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:187%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:187%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:187%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">In connection with the Quarterly Report on Form 10-Q of Zentalis Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%;padding-left:6.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt;padding-left:9pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.287%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 10, 2023</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Melissa B. Epperly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Melissa B. Epperly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%">Chief Financial Officer</font></div><div style="margin-bottom:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:187%">(principal financial and accounting officer)</font></div></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>zntl-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:b3a2bb04-db5e-4a01-a061-9002e22e0a2d,g:6cdaa420-7596-4787-9871-3e57ed815727-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:zntl="http://www.zentalis.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.zentalis.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zntl-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zntl-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zntl-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zntl-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.zentalis.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsUnaudited" roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLossUnaudited" roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBusiness" roleURI="http://www.zentalis.com/role/OrganizationandBusiness">
        <link:definition>0000008 - Disclosure - Organization and Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterimUnauditedFinancialStatements" roleURI="http://www.zentalis.com/role/InterimUnauditedFinancialStatements">
        <link:definition>0000009 - Disclosure - Interim Unaudited Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantTransactions" roleURI="http://www.zentalis.com/role/SignificantTransactions">
        <link:definition>0000010 - Disclosure - Significant Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinations" roleURI="http://www.zentalis.com/role/BusinessCombinations">
        <link:definition>0000011 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.zentalis.com/role/FairValueMeasurement">
        <link:definition>0000012 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherAssets" roleURI="http://www.zentalis.com/role/PrepaidExpensesandOtherAssets">
        <link:definition>0000013 - Disclosure - Prepaid Expenses and Other Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnet" roleURI="http://www.zentalis.com/role/PropertyandEquipmentnet">
        <link:definition>0000014 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.zentalis.com/role/AccruedExpenses">
        <link:definition>0000015 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.zentalis.com/role/StockholdersEquity">
        <link:definition>0000016 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.zentalis.com/role/CommitmentandContingencies">
        <link:definition>0000017 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShare" roleURI="http://www.zentalis.com/role/NetLossPerCommonShare">
        <link:definition>0000018 - Disclosure - Net Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDisclosures" roleURI="http://www.zentalis.com/role/RelatedPartyDisclosures">
        <link:definition>0000019 - Disclosure - Related Party Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterimUnauditedFinancialStatementsPolicies" roleURI="http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies">
        <link:definition>0000020 - Disclosure - Interim Unaudited Financial Statements (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTables" roleURI="http://www.zentalis.com/role/BusinessCombinationsTables">
        <link:definition>0000021 - Disclosure - Business Combinations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.zentalis.com/role/FairValueMeasurementTables">
        <link:definition>0000022 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherAssetsTables" roleURI="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsTables">
        <link:definition>0000023 - Disclosure - Prepaid Expenses and Other Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetTables" roleURI="http://www.zentalis.com/role/PropertyandEquipmentnetTables">
        <link:definition>0000024 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.zentalis.com/role/AccruedExpensesTables">
        <link:definition>0000025 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.zentalis.com/role/StockholdersEquityTables">
        <link:definition>0000026 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesTables" roleURI="http://www.zentalis.com/role/CommitmentandContingenciesTables">
        <link:definition>0000027 - Disclosure - Commitment and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareTables" roleURI="http://www.zentalis.com/role/NetLossPerCommonShareTables">
        <link:definition>0000028 - Disclosure - Net Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantTransactionsDetails" roleURI="http://www.zentalis.com/role/SignificantTransactionsDetails">
        <link:definition>0000029 - Disclosure - Significant Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsNarrativeDetails" roleURI="http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails">
        <link:definition>0000030 - Disclosure - Business Combinations - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails" roleURI="http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails">
        <link:definition>0000031 - Disclosure - Business Combinations - Reconciliation of Equity (Net Assets) Attributable to Noncontrolling Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" roleURI="http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails">
        <link:definition>0000032 - Disclosure - Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementNarrativeDetails" roleURI="http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails">
        <link:definition>0000033 - Disclosure - Fair Value Measurement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails" roleURI="http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails">
        <link:definition>0000034 - Disclosure - Fair Value Measurement - Contractual Maturities of Available-for-sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" roleURI="http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails">
        <link:definition>0000035 - Disclosure - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherAssetsDetails" roleURI="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails">
        <link:definition>0000036 - Disclosure - Prepaid Expenses and Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherAssetsDetails_1" roleURI="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1">
        <link:definition>0000036 - Disclosure - Prepaid Expenses and Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetSummaryDetails" roleURI="http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails">
        <link:definition>0000037 - Disclosure - Property and Equipment, net - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetNarrativeDetails" roleURI="http://www.zentalis.com/role/PropertyandEquipmentnetNarrativeDetails">
        <link:definition>0000038 - Disclosure - Property and Equipment, net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.zentalis.com/role/AccruedExpensesDetails">
        <link:definition>0000039 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails_1" roleURI="http://www.zentalis.com/role/AccruedExpensesDetails_1">
        <link:definition>0000039 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.zentalis.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>0000040 - Disclosure - Stockholders&#8217; Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySharebasedCompensationDetails" roleURI="http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails">
        <link:definition>0000041 - Disclosure - Stockholders&#8217; Equity - Share-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySharebasedCompensationExpenseDetails" roleURI="http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails">
        <link:definition>0000042 - Disclosure - Stockholders&#8217; Equity - Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityFairValueAssumptionsforStockOptionsDetails" roleURI="http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails">
        <link:definition>0000043 - Disclosure - Stockholders&#8217; Equity - Fair Value Assumptions for Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityFairValueAssumptionsforESPPDetails" roleURI="http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails">
        <link:definition>0000044 - Disclosure - Stockholders&#8217; Equity - Fair Value Assumptions for ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityUnrecognizedCompensationCostDetails" roleURI="http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails">
        <link:definition>0000045 - Disclosure - Stockholders&#8217; Equity - Unrecognized Compensation Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesFutureMinimumLeasePaymentsDetails" roleURI="http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails">
        <link:definition>0000046 - Disclosure - Commitment and Contingencies - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1">
        <link:definition>0000046 - Disclosure - Commitment and Contingencies - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesNarrativeDetails" roleURI="http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails">
        <link:definition>0000047 - Disclosure - Commitment and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareCalculationDetails" roleURI="http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails">
        <link:definition>0000048 - Disclosure - Net Loss Per Common Share - Calculation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareAntidilutiveSecuritiesDetails" roleURI="http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails">
        <link:definition>0000049 - Disclosure - Net Loss Per Common Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDisclosuresDetails" roleURI="http://www.zentalis.com/role/RelatedPartyDisclosuresDetails">
        <link:definition>0000050 - Disclosure - Related Party Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="zntl_PrepaidSoftwareLicenseAndMaintenance" abstract="false" name="PrepaidSoftwareLicenseAndMaintenance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_PrepaidResearchAndDevelopmentCosts" abstract="false" name="PrepaidResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_AccruedResearchAndDevelopmentCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="zntl_A2020IncentiveAwardPlanMember" abstract="true" name="A2020IncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember" abstract="true" name="RestrictedStockAwardsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="zntl_ReconciliationOfNoncontrollingInterestTableTextBlock" abstract="false" name="ReconciliationOfNoncontrollingInterestTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="zntl_ZenteraTherapeuticsMember" abstract="true" name="ZenteraTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="zntl_OfficeEquipmentAndFurnitureMember" abstract="true" name="OfficeEquipmentAndFurnitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="zntl_A2022EmploymentInducementIncentiveAwardPlanMember" abstract="true" name="A2022EmploymentInducementIncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="zntl_KalyraPharmaceuticalsIncMember" abstract="true" name="KalyraPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="zntl_ResearchAndDevelopmentExpenseReimbursements" abstract="false" name="ResearchAndDevelopmentExpenseReimbursements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_ForeignResearchAndDevelopmentCreditRefund" abstract="false" name="ForeignResearchAndDevelopmentCreditRefund" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_MasterServicesAgreementMember" abstract="true" name="MasterServicesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_OtherPrepaidExpense" abstract="false" name="OtherPrepaidExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_EarningsPerShareDenominatorAbstract" abstract="true" name="EarningsPerShareDenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="zntl_EarningsPerShareNumeratorAbstract" abstract="true" name="EarningsPerShareNumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="zntl_InvestmentAndOtherIncomeExpense" abstract="false" name="InvestmentAndOtherIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_AccruedGeneralAndAdministrativeCostsCurrent" abstract="false" name="AccruedGeneralAndAdministrativeCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="zntl_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>zntl-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:b3a2bb04-db5e-4a01-a061-9002e22e0a2d,g:6cdaa420-7596-4787-9871-3e57ed815727-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="zntl-20230331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_135d2d10-2350-4b8a-abdc-7db9a7a82df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_1cb7a58c-efd7-48b4-a671-31fcb231c7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_135d2d10-2350-4b8a-abdc-7db9a7a82df9" xlink:to="loc_us-gaap_MinorityInterest_1cb7a58c-efd7-48b4-a671-31fcb231c7a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_48f06cd0-1a03-471f-8e98-76445b8c8690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_135d2d10-2350-4b8a-abdc-7db9a7a82df9" xlink:to="loc_us-gaap_StockholdersEquity_48f06cd0-1a03-471f-8e98-76445b8c8690" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_55ac263a-039c-40fe-9de5-516b8d3e8b93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1c9db289-4fbd-47f1-9e80-30fe3b73b249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_55ac263a-039c-40fe-9de5-516b8d3e8b93" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1c9db289-4fbd-47f1-9e80-30fe3b73b249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b231ebd0-1550-4cbb-b148-35af9b10f932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_55ac263a-039c-40fe-9de5-516b8d3e8b93" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b231ebd0-1550-4cbb-b148-35af9b10f932" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fdc7dd2d-8e75-473a-9fb2-7ba741aa6bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_55ac263a-039c-40fe-9de5-516b8d3e8b93" xlink:to="loc_us-gaap_LiabilitiesCurrent_fdc7dd2d-8e75-473a-9fb2-7ba741aa6bdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e529335b-5703-466f-a6ba-19c3fe576249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_55ac263a-039c-40fe-9de5-516b8d3e8b93" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e529335b-5703-466f-a6ba-19c3fe576249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_02fba2ef-4190-4119-80d2-004852afb69f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8d22baa3-2503-47f2-aeb9-b048c4e112d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_02fba2ef-4190-4119-80d2-004852afb69f" xlink:to="loc_us-gaap_CommonStockValue_8d22baa3-2503-47f2-aeb9-b048c4e112d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d2ac4d5c-fd35-409b-a589-c7b4a91d1c11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_02fba2ef-4190-4119-80d2-004852afb69f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d2ac4d5c-fd35-409b-a589-c7b4a91d1c11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_7117a431-f097-4049-8ec9-2155315094ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_02fba2ef-4190-4119-80d2-004852afb69f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_7117a431-f097-4049-8ec9-2155315094ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_46e06dab-819b-4873-9fae-b975114c8563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_02fba2ef-4190-4119-80d2-004852afb69f" xlink:to="loc_us-gaap_PreferredStockValue_46e06dab-819b-4873-9fae-b975114c8563" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_903c416d-0136-4ad8-b604-39781638ad28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_02fba2ef-4190-4119-80d2-004852afb69f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_903c416d-0136-4ad8-b604-39781638ad28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f702a234-c0f4-40c9-bb6e-ad5b533b7d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_758d314e-17d1-40c3-ae85-cc763d7e01fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f702a234-c0f4-40c9-bb6e-ad5b533b7d44" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_758d314e-17d1-40c3-ae85-cc763d7e01fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7af3e543-6c04-46bf-a88b-7bc5236c50c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f702a234-c0f4-40c9-bb6e-ad5b533b7d44" xlink:to="loc_us-gaap_Goodwill_7af3e543-6c04-46bf-a88b-7bc5236c50c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_162a6391-4ebc-48b4-9098-fbb2b707c2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f702a234-c0f4-40c9-bb6e-ad5b533b7d44" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_162a6391-4ebc-48b4-9098-fbb2b707c2cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_3e0a70b9-f9dd-45a1-a20a-94689cf47bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f702a234-c0f4-40c9-bb6e-ad5b533b7d44" xlink:to="loc_us-gaap_EquityMethodInvestments_3e0a70b9-f9dd-45a1-a20a-94689cf47bcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_e97287b8-9b75-4499-b07e-adab944c1213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f702a234-c0f4-40c9-bb6e-ad5b533b7d44" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_e97287b8-9b75-4499-b07e-adab944c1213" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_40a134df-6e57-4867-acaf-337566534c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f702a234-c0f4-40c9-bb6e-ad5b533b7d44" xlink:to="loc_us-gaap_AssetsCurrent_40a134df-6e57-4867-acaf-337566534c19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d5f78498-4025-4101-b6a7-5ac8d13af223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f702a234-c0f4-40c9-bb6e-ad5b533b7d44" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d5f78498-4025-4101-b6a7-5ac8d13af223" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1db62170-93d2-4eb0-9242-bbb3a1aa1d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4fc838f5-560d-448a-8dd3-325eb6807c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1db62170-93d2-4eb0-9242-bbb3a1aa1d4f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4fc838f5-560d-448a-8dd3-325eb6807c85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f96e535a-395f-4139-badb-a7cf6dd47d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1db62170-93d2-4eb0-9242-bbb3a1aa1d4f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f96e535a-395f-4139-badb-a7cf6dd47d6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_573c3bb0-f174-49b5-86d6-646f1a8c42d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1db62170-93d2-4eb0-9242-bbb3a1aa1d4f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_573c3bb0-f174-49b5-86d6-646f1a8c42d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bddded7a-b9b8-49cb-baa7-7479ddd849fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1b9fe36b-48f6-4673-8146-265c13967506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bddded7a-b9b8-49cb-baa7-7479ddd849fe" xlink:to="loc_us-gaap_AccountsPayableCurrent_1b9fe36b-48f6-4673-8146-265c13967506" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_67665f89-9b46-4a84-9a36-72ade50e8d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bddded7a-b9b8-49cb-baa7-7479ddd849fe" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_67665f89-9b46-4a84-9a36-72ade50e8d84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ea68a9cd-93cb-4ada-8a8c-4c61bba4981c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_204734ae-ad4f-48bb-9980-dfef4f8065d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ea68a9cd-93cb-4ada-8a8c-4c61bba4981c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_204734ae-ad4f-48bb-9980-dfef4f8065d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f0a36d32-1455-4d22-8b0d-7a3c35d0ae50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ea68a9cd-93cb-4ada-8a8c-4c61bba4981c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f0a36d32-1455-4d22-8b0d-7a3c35d0ae50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_43155d5b-fccd-4b1b-aae8-2daba5bb9d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ea68a9cd-93cb-4ada-8a8c-4c61bba4981c" xlink:to="loc_us-gaap_Liabilities_43155d5b-fccd-4b1b-aae8-2daba5bb9d04" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="zntl-20230331.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a2b1286e-5b8f-4c47-8aa9-01733b19a65d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6497d548-84f8-477e-81b9-57c08e345381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2b1286e-5b8f-4c47-8aa9-01733b19a65d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6497d548-84f8-477e-81b9-57c08e345381" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_fc989454-7d8e-47a1-a0db-fa4b42794dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2b1286e-5b8f-4c47-8aa9-01733b19a65d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_fc989454-7d8e-47a1-a0db-fa4b42794dd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6eb7eca2-f432-41be-9620-de22f83a57d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7d848a2f-3865-48a2-898a-8603099c0f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6eb7eca2-f432-41be-9620-de22f83a57d8" xlink:to="loc_us-gaap_ProfitLoss_7d848a2f-3865-48a2-898a-8603099c0f73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_24c8ed4b-9c01-4527-a36a-50eae9b5c21f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6eb7eca2-f432-41be-9620-de22f83a57d8" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_24c8ed4b-9c01-4527-a36a-50eae9b5c21f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_103da647-f576-42d8-8dd4-46926a5df036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9993cc86-c7af-4968-96bc-5d45860ab12b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_103da647-f576-42d8-8dd4-46926a5df036" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9993cc86-c7af-4968-96bc-5d45860ab12b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_66d0f438-b988-42e7-b967-55a41ae10132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_103da647-f576-42d8-8dd4-46926a5df036" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_66d0f438-b988-42e7-b967-55a41ae10132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_49d039fa-ff07-4237-8aec-decf5c49e518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_103da647-f576-42d8-8dd4-46926a5df036" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_49d039fa-ff07-4237-8aec-decf5c49e518" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_887371de-43f4-4fcf-95fb-c7e9baa0cb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_649ccbfe-2096-455a-afee-d4944e0d8dad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_887371de-43f4-4fcf-95fb-c7e9baa0cb0a" xlink:to="loc_us-gaap_OperatingExpenses_649ccbfe-2096-455a-afee-d4944e0d8dad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_330cf96f-89ee-4ceb-8cc0-855cc8c31790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d561db24-ae7f-419a-bd78-178d143138a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_330cf96f-89ee-4ceb-8cc0-855cc8c31790" xlink:to="loc_us-gaap_OperatingIncomeLoss_d561db24-ae7f-419a-bd78-178d143138a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_InvestmentAndOtherIncomeExpense_ecb8ed8b-5652-45a6-b235-8cbd3733b843" xlink:href="zntl-20230331.xsd#zntl_InvestmentAndOtherIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_330cf96f-89ee-4ceb-8cc0-855cc8c31790" xlink:to="loc_zntl_InvestmentAndOtherIncomeExpense_ecb8ed8b-5652-45a6-b235-8cbd3733b843" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="zntl-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9c30392b-91dc-4b7d-b49a-b98bda8bb1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_fd375473-0213-4efa-b604-b683fd5129d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9c30392b-91dc-4b7d-b49a-b98bda8bb1e9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_fd375473-0213-4efa-b604-b683fd5129d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ac0c3a77-42ca-40ca-b473-6064266b0fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9c30392b-91dc-4b7d-b49a-b98bda8bb1e9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ac0c3a77-42ca-40ca-b473-6064266b0fb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b8733914-2a9d-4b97-ba07-b57f5a162718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ce6b0702-9933-4d04-be1d-251de90debba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b8733914-2a9d-4b97-ba07-b57f5a162718" xlink:to="loc_us-gaap_ProfitLoss_ce6b0702-9933-4d04-be1d-251de90debba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_16fce24a-140d-4ba6-9d1f-6649de734997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b8733914-2a9d-4b97-ba07-b57f5a162718" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_16fce24a-140d-4ba6-9d1f-6649de734997" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="zntl-20230331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dff06959-55f6-43a7-bbd0-e2363e27579c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_42dcbe10-b58c-4379-a92b-bf15fca8b916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dff06959-55f6-43a7-bbd0-e2363e27579c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_42dcbe10-b58c-4379-a92b-bf15fca8b916" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9f1040fd-0120-4548-a7f6-686efd3d638b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dff06959-55f6-43a7-bbd0-e2363e27579c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9f1040fd-0120-4548-a7f6-686efd3d638b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d82551f0-588e-44dc-9d9a-cfeb7c3baf5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dff06959-55f6-43a7-bbd0-e2363e27579c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d82551f0-588e-44dc-9d9a-cfeb7c3baf5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54566ac3-b038-4f3b-bba5-2ffedd22f2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cc6c40c2-4236-4338-9227-14e96b2fb76a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54566ac3-b038-4f3b-bba5-2ffedd22f2f7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cc6c40c2-4236-4338-9227-14e96b2fb76a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_e73f546b-7a37-49f2-84d4-27280f941ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54566ac3-b038-4f3b-bba5-2ffedd22f2f7" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_e73f546b-7a37-49f2-84d4-27280f941ec3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_67969385-a445-4112-9624-8c9dbbd4458e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54566ac3-b038-4f3b-bba5-2ffedd22f2f7" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_67969385-a445-4112-9624-8c9dbbd4458e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a441905d-bcc2-49d1-bf6a-d29665e69e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6773d662-b410-455b-8780-05e31a3d9144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a441905d-bcc2-49d1-bf6a-d29665e69e42" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6773d662-b410-455b-8780-05e31a3d9144" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_28274363-cd05-4926-936d-24768913f54d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a441905d-bcc2-49d1-bf6a-d29665e69e42" xlink:to="loc_us-gaap_RestrictedCash_28274363-cd05-4926-936d-24768913f54d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_667b2b59-3f4d-4452-9d82-c938fde0d3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4a5ab5de-3c34-4cca-8071-e7969f0f9cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_667b2b59-3f4d-4452-9d82-c938fde0d3ba" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4a5ab5de-3c34-4cca-8071-e7969f0f9cca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_ecd5803a-b2f1-4021-acbe-b2e3fb6afe1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_667b2b59-3f4d-4452-9d82-c938fde0d3ba" xlink:to="loc_us-gaap_AssetImpairmentCharges_ecd5803a-b2f1-4021-acbe-b2e3fb6afe1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a19e3b58-2bbe-4c8a-ab27-7e8dfa7c4027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_667b2b59-3f4d-4452-9d82-c938fde0d3ba" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a19e3b58-2bbe-4c8a-ab27-7e8dfa7c4027" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2dc98820-460f-4746-9a83-60e5ead05f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_667b2b59-3f4d-4452-9d82-c938fde0d3ba" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2dc98820-460f-4746-9a83-60e5ead05f16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5ad6854f-a310-481a-963a-4e1998c0320a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_667b2b59-3f4d-4452-9d82-c938fde0d3ba" xlink:to="loc_us-gaap_ShareBasedCompensation_5ad6854f-a310-481a-963a-4e1998c0320a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_6102cf07-7598-4874-9878-080f83cce237" xlink:href="zntl-20230331.xsd#zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_667b2b59-3f4d-4452-9d82-c938fde0d3ba" xlink:to="loc_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_6102cf07-7598-4874-9878-080f83cce237" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_84274a70-f443-43c5-94cf-b2277cb79b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_667b2b59-3f4d-4452-9d82-c938fde0d3ba" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_84274a70-f443-43c5-94cf-b2277cb79b28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bfe3748c-9196-4ec3-9de8-4ac6ee25801c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_667b2b59-3f4d-4452-9d82-c938fde0d3ba" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bfe3748c-9196-4ec3-9de8-4ac6ee25801c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_45830c9a-8b98-4493-89b4-c757df0ba9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_667b2b59-3f4d-4452-9d82-c938fde0d3ba" xlink:to="loc_us-gaap_ProfitLoss_45830c9a-8b98-4493-89b4-c757df0ba9ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a1292260-8dc3-46a0-807f-fc214b72796f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_667b2b59-3f4d-4452-9d82-c938fde0d3ba" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a1292260-8dc3-46a0-807f-fc214b72796f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b7ab4190-f50e-4465-9232-18ad24121581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2c5aecad-081f-4dd6-8a86-814896d15ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b7ab4190-f50e-4465-9232-18ad24121581" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2c5aecad-081f-4dd6-8a86-814896d15ea4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e0d42038-ddf9-4db8-bb10-fd093ccfcf3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_71b78485-b2b9-41a7-a722-5f40b465ebcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e0d42038-ddf9-4db8-bb10-fd093ccfcf3d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_71b78485-b2b9-41a7-a722-5f40b465ebcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_078a39bb-1197-4430-ac3c-95efc837bad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e0d42038-ddf9-4db8-bb10-fd093ccfcf3d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_078a39bb-1197-4430-ac3c-95efc837bad0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c55c7ced-2f93-4a2c-8576-3f748d55d3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e0d42038-ddf9-4db8-bb10-fd093ccfcf3d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c55c7ced-2f93-4a2c-8576-3f748d55d3f1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#FairValueMeasurementNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_80296f52-787a-4985-861e-1064917337b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_a592f5e9-9b42-436f-9106-b7b0f5c22f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_80296f52-787a-4985-861e-1064917337b1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_a592f5e9-9b42-436f-9106-b7b0f5c22f24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_ba981138-80e4-423f-800f-0728b68669dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_80296f52-787a-4985-861e-1064917337b1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_ba981138-80e4-423f-800f-0728b68669dd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_2856dad7-7f37-4b62-95f8-5a7c281bd128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_9ec23b58-55d5-4e23-b884-3ce1fc7c0ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_2856dad7-7f37-4b62-95f8-5a7c281bd128" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_9ec23b58-55d5-4e23-b884-3ce1fc7c0ddd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e20265c6-4929-42a6-b6e5-56dc3901f918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e615c5ce-711a-46ca-b5ae-9e30bf85f054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_e20265c6-4929-42a6-b6e5-56dc3901f918" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e615c5ce-711a-46ca-b5ae-9e30bf85f054" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_86fb52c3-7e0a-4932-9fa1-8557f4ac5bff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_e20265c6-4929-42a6-b6e5-56dc3901f918" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_86fb52c3-7e0a-4932-9fa1-8557f4ac5bff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#PrepaidExpensesandOtherAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_e518cf15-147d-48a9-b31f-7387428f6c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_3cafa462-b30a-4ad7-bf4c-8cb8609606c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_e518cf15-147d-48a9-b31f-7387428f6c19" xlink:to="loc_us-gaap_InterestReceivable_3cafa462-b30a-4ad7-bf4c-8cb8609606c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_OtherPrepaidExpense_a354b73b-c822-4833-81d9-d777062087dd" xlink:href="zntl-20230331.xsd#zntl_OtherPrepaidExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_e518cf15-147d-48a9-b31f-7387428f6c19" xlink:to="loc_zntl_OtherPrepaidExpense_a354b73b-c822-4833-81d9-d777062087dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_PrepaidResearchAndDevelopmentCosts_3e4a52f0-ca36-4008-8b66-99eda74bf205" xlink:href="zntl-20230331.xsd#zntl_PrepaidResearchAndDevelopmentCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_e518cf15-147d-48a9-b31f-7387428f6c19" xlink:to="loc_zntl_PrepaidResearchAndDevelopmentCosts_3e4a52f0-ca36-4008-8b66-99eda74bf205" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_fd5a74d6-f027-4570-be54-9f93fce044ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_e518cf15-147d-48a9-b31f-7387428f6c19" xlink:to="loc_us-gaap_PrepaidInsurance_fd5a74d6-f027-4570-be54-9f93fce044ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_6cf50352-8bc6-4231-b191-1aa35ce5cd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_e518cf15-147d-48a9-b31f-7387428f6c19" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_6cf50352-8bc6-4231-b191-1aa35ce5cd6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_PrepaidSoftwareLicenseAndMaintenance_0a633f32-cc57-44b0-aedf-d7c13e64b3a2" xlink:href="zntl-20230331.xsd#zntl_PrepaidSoftwareLicenseAndMaintenance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_e518cf15-147d-48a9-b31f-7387428f6c19" xlink:to="loc_zntl_PrepaidSoftwareLicenseAndMaintenance_0a633f32-cc57-44b0-aedf-d7c13e64b3a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ForeignResearchAndDevelopmentCreditRefund_f38e3783-1d0d-4970-9445-5bbf6702aa0e" xlink:href="zntl-20230331.xsd#zntl_ForeignResearchAndDevelopmentCreditRefund"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_e518cf15-147d-48a9-b31f-7387428f6c19" xlink:to="loc_zntl_ForeignResearchAndDevelopmentCreditRefund_f38e3783-1d0d-4970-9445-5bbf6702aa0e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1" xlink:type="simple" xlink:href="zntl-20230331.xsd#PrepaidExpensesandOtherAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_36458650-aa66-4ae5-8a50-f05f22f589fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fb6234d8-14d7-419a-95e7-4cf9e8532cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_36458650-aa66-4ae5-8a50-f05f22f589fd" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fb6234d8-14d7-419a-95e7-4cf9e8532cdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_5bba3a8f-8abc-4379-9572-d6cc5a724e88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_36458650-aa66-4ae5-8a50-f05f22f589fd" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_5bba3a8f-8abc-4379-9572-d6cc5a724e88" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#PropertyandEquipmentnetSummaryDetails"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ae2bc95c-e6b9-436f-8299-25106672c9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e1309513-d796-4406-9af4-14151c399723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_ae2bc95c-e6b9-436f-8299-25106672c9fa" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e1309513-d796-4406-9af4-14151c399723" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_066c5162-0866-4807-b529-b75531352c07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_ae2bc95c-e6b9-436f-8299-25106672c9fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_066c5162-0866-4807-b529-b75531352c07" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_77082c06-c14c-4000-87bf-88d5342d869a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_185f60cf-8209-4353-9cfc-6b0e745d3b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_77082c06-c14c-4000-87bf-88d5342d869a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_185f60cf-8209-4353-9cfc-6b0e745d3b38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_763c1d1d-edaf-4044-95b4-c0bd6d065233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_77082c06-c14c-4000-87bf-88d5342d869a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_763c1d1d-edaf-4044-95b4-c0bd6d065233" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/AccruedExpensesDetails_1" xlink:type="simple" xlink:href="zntl-20230331.xsd#AccruedExpensesDetails_1"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/AccruedExpensesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_77821e02-8316-46c2-ac9f-54f0f15d2a82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_AccruedResearchAndDevelopmentCostsCurrent_46dd7708-37aa-43c0-aa16-6ebcf0c6bac4" xlink:href="zntl-20230331.xsd#zntl_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_77821e02-8316-46c2-ac9f-54f0f15d2a82" xlink:to="loc_zntl_AccruedResearchAndDevelopmentCostsCurrent_46dd7708-37aa-43c0-aa16-6ebcf0c6bac4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_0d6757d2-d96b-49f7-bf35-eaf19d6b9240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_77821e02-8316-46c2-ac9f-54f0f15d2a82" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_0d6757d2-d96b-49f7-bf35-eaf19d6b9240" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_f18a07fa-ffdf-4c60-a405-03e86ffbd838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_77821e02-8316-46c2-ac9f-54f0f15d2a82" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_f18a07fa-ffdf-4c60-a405-03e86ffbd838" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c56e0869-715d-44e7-b791-3946545a3fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_77821e02-8316-46c2-ac9f-54f0f15d2a82" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c56e0869-715d-44e7-b791-3946545a3fcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e5f6c14d-d0b1-49be-a80f-767abd306eec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_77821e02-8316-46c2-ac9f-54f0f15d2a82" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e5f6c14d-d0b1-49be-a80f-767abd306eec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_AccruedGeneralAndAdministrativeCostsCurrent_2e72310e-e92d-4d34-9581-e71a62ca5a71" xlink:href="zntl-20230331.xsd#zntl_AccruedGeneralAndAdministrativeCostsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_77821e02-8316-46c2-ac9f-54f0f15d2a82" xlink:to="loc_zntl_AccruedGeneralAndAdministrativeCostsCurrent_2e72310e-e92d-4d34-9581-e71a62ca5a71" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c7e95c6-890b-4b47-9815-cb108084e03f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_8d5f47d5-416d-4845-87b3-ea4d27e21512" xlink:href="zntl-20230331.xsd#zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c7e95c6-890b-4b47-9815-cb108084e03f" xlink:to="loc_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_8d5f47d5-416d-4845-87b3-ea4d27e21512" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a3665332-f81c-4c7b-931a-2ba63be65f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c7e95c6-890b-4b47-9815-cb108084e03f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a3665332-f81c-4c7b-931a-2ba63be65f04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8e360d00-10c4-41cf-bb2d-57aa1049b120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c7e95c6-890b-4b47-9815-cb108084e03f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8e360d00-10c4-41cf-bb2d-57aa1049b120" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_706ddb63-566b-4b61-be1e-7982b2c31279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c7e95c6-890b-4b47-9815-cb108084e03f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_706ddb63-566b-4b61-be1e-7982b2c31279" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_010889ff-cf0c-4cd8-99fb-23751d63b365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c7e95c6-890b-4b47-9815-cb108084e03f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_010889ff-cf0c-4cd8-99fb-23751d63b365" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b79fa7bb-7727-4dd2-939e-23e787b5bec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c7e95c6-890b-4b47-9815-cb108084e03f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b79fa7bb-7727-4dd2-939e-23e787b5bec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ca1ca9f2-0a90-487d-a45d-505b2398928a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1328c2c9-0199-4641-aaf5-175fa204fcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_ca1ca9f2-0a90-487d-a45d-505b2398928a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1328c2c9-0199-4641-aaf5-175fa204fcf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_887edf2a-31fb-4c4d-9887-a6583a7695b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_ca1ca9f2-0a90-487d-a45d-505b2398928a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_887edf2a-31fb-4c4d-9887-a6583a7695b4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="zntl-20230331.xsd#CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_74780260-eb65-4652-b80e-b7475718e5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e62d2731-834a-4d00-9a1d-89f6e524b6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_74780260-eb65-4652-b80e-b7475718e5c0" xlink:to="loc_us-gaap_OperatingLeaseLiability_e62d2731-834a-4d00-9a1d-89f6e524b6ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a5426b84-8836-49e9-ab9e-c717a0786606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_74780260-eb65-4652-b80e-b7475718e5c0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a5426b84-8836-49e9-ab9e-c717a0786606" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>zntl-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:b3a2bb04-db5e-4a01-a061-9002e22e0a2d,g:6cdaa420-7596-4787-9871-3e57ed815727-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="zntl-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="if7a80e59651a418bb868df5b57f4e5e1_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6d3feb4a-33b6-4025-8d11-495c7d490596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6d3feb4a-33b6-4025-8d11-495c7d490596" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_2c5d5f8f-6823-4c90-a346-077cc0f4a537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_SharesOutstanding_2c5d5f8f-6823-4c90-a346-077cc0f4a537" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2d7cc313-be17-42b0-be42-69976bfbf50e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2d7cc313-be17-42b0-be42-69976bfbf50e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_999afa73-f957-4460-a1d8-45f695348599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_999afa73-f957-4460-a1d8-45f695348599" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6e58a92a-8f84-4e1f-8967-647c0b95bb86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6e58a92a-8f84-4e1f-8967-647c0b95bb86" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_9a4fa768-ca7b-4c8d-b7d1-f123f37bc2df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_9a4fa768-ca7b-4c8d-b7d1-f123f37bc2df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_55d9b100-f054-4c7e-b4a0-ff3f68166791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_55d9b100-f054-4c7e-b4a0-ff3f68166791" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e346be1d-002b-4457-aa85-6f11ded095cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e346be1d-002b-4457-aa85-6f11ded095cf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e79539ee-c518-4b87-aec8-2a2fd62d18a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e79539ee-c518-4b87-aec8-2a2fd62d18a6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_930732d4-d93d-4982-99d7-3287edeaaa41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_930732d4-d93d-4982-99d7-3287edeaaa41" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a07cd9d5-cce2-4ac4-b9e2-00807ac9aa3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a07cd9d5-cce2-4ac4-b9e2-00807ac9aa3b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_ca1a0b9f-807d-4a35-8ebc-3d83d6e6d295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_ca1a0b9f-807d-4a35-8ebc-3d83d6e6d295" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b9dfc7b4-d8f9-405c-8370-77e0d5b3c8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b9dfc7b4-d8f9-405c-8370-77e0d5b3c8cf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e32fc483-e0d4-4e08-9eec-df380c8929af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_NetIncomeLoss_e32fc483-e0d4-4e08-9eec-df380c8929af" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_98925dac-3157-4d29-ac56-889e9d210949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_63a23270-d052-491b-9dc6-436461754977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8e143ec9-91ca-4a62-8729-90f8c83f3a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6d3feb4a-33b6-4025-8d11-495c7d490596" xlink:to="loc_us-gaap_StatementTable_8e143ec9-91ca-4a62-8729-90f8c83f3a2f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_793c57ea-3034-4cc2-a3dc-46dab28535b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8e143ec9-91ca-4a62-8729-90f8c83f3a2f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_793c57ea-3034-4cc2-a3dc-46dab28535b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_793c57ea-3034-4cc2-a3dc-46dab28535b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_793c57ea-3034-4cc2-a3dc-46dab28535b4" xlink:to="loc_us-gaap_EquityComponentDomain_793c57ea-3034-4cc2-a3dc-46dab28535b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ffcb1d07-15ca-44bc-a0f9-273e24a45732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_793c57ea-3034-4cc2-a3dc-46dab28535b4" xlink:to="loc_us-gaap_EquityComponentDomain_ffcb1d07-15ca-44bc-a0f9-273e24a45732" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d099f45b-0f96-4595-8344-c423b7bf0156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ffcb1d07-15ca-44bc-a0f9-273e24a45732" xlink:to="loc_us-gaap_CommonStockMember_d099f45b-0f96-4595-8344-c423b7bf0156" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_10483be7-737f-4c27-a5fa-32d019155b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ffcb1d07-15ca-44bc-a0f9-273e24a45732" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_10483be7-737f-4c27-a5fa-32d019155b79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f5794414-4bc7-4da1-be31-e0047a167692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ffcb1d07-15ca-44bc-a0f9-273e24a45732" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f5794414-4bc7-4da1-be31-e0047a167692" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0e3a676c-e5d2-4dac-b2a9-21f458910190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ffcb1d07-15ca-44bc-a0f9-273e24a45732" xlink:to="loc_us-gaap_RetainedEarningsMember_0e3a676c-e5d2-4dac-b2a9-21f458910190" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_b649edc1-172d-461e-ae25-f5ce72209b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ffcb1d07-15ca-44bc-a0f9-273e24a45732" xlink:to="loc_us-gaap_NoncontrollingInterestMember_b649edc1-172d-461e-ae25-f5ce72209b00" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/SignificantTransactionsDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#SignificantTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/SignificantTransactionsDetails" xlink:type="extended" id="i4d3890db4da747fb99a5ff3f6078033f_SignificantTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_72530334-7078-4329-a95f-00620e8fefcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_c8154d17-e81a-49ce-8598-ecef96df643b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_72530334-7078-4329-a95f-00620e8fefcd" xlink:to="loc_us-gaap_EquityMethodInvestments_c8154d17-e81a-49ce-8598-ecef96df643b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_a465dda6-bb47-4946-8aa4-39626a0c9c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_72530334-7078-4329-a95f-00620e8fefcd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_a465dda6-bb47-4946-8aa4-39626a0c9c33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_a11d00f1-2878-40fc-a2ea-f00c7947aa11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_72530334-7078-4329-a95f-00620e8fefcd" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_a11d00f1-2878-40fc-a2ea-f00c7947aa11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_403c56dd-8c80-4494-9175-c1835d75b63d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_72530334-7078-4329-a95f-00620e8fefcd" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_403c56dd-8c80-4494-9175-c1835d75b63d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ResearchAndDevelopmentExpenseReimbursements_d182d547-595f-4f3d-892d-c9a61d832465" xlink:href="zntl-20230331.xsd#zntl_ResearchAndDevelopmentExpenseReimbursements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_72530334-7078-4329-a95f-00620e8fefcd" xlink:to="loc_zntl_ResearchAndDevelopmentExpenseReimbursements_d182d547-595f-4f3d-892d-c9a61d832465" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b246d044-e083-49a1-9fd3-4d9daa3b8972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_72530334-7078-4329-a95f-00620e8fefcd" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b246d044-e083-49a1-9fd3-4d9daa3b8972" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_570258ea-f88d-4944-8a0b-3ec349522670" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b246d044-e083-49a1-9fd3-4d9daa3b8972" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_570258ea-f88d-4944-8a0b-3ec349522670" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_570258ea-f88d-4944-8a0b-3ec349522670_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_570258ea-f88d-4944-8a0b-3ec349522670" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_570258ea-f88d-4944-8a0b-3ec349522670_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_277d106f-5176-43cb-a1e7-4be1679bc1aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_570258ea-f88d-4944-8a0b-3ec349522670" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_277d106f-5176-43cb-a1e7-4be1679bc1aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ZenteraTherapeuticsMember_9aede722-72ae-4c4e-bfdc-f6ed683c7b02" xlink:href="zntl-20230331.xsd#zntl_ZenteraTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_277d106f-5176-43cb-a1e7-4be1679bc1aa" xlink:to="loc_zntl_ZenteraTherapeuticsMember_9aede722-72ae-4c4e-bfdc-f6ed683c7b02" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#BusinessCombinationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails" xlink:type="extended" id="ibbe6a62f61e04d4ba91998682e284d32_BusinessCombinationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_231d368e-07b7-4f9c-9ef7-fc90fd912b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_807a1b52-ed24-4c0c-948f-377a3cf2c90d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_231d368e-07b7-4f9c-9ef7-fc90fd912b2b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_807a1b52-ed24-4c0c-948f-377a3cf2c90d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_af24f92c-9524-4b2a-a3a2-9f6f6b2a3216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_231d368e-07b7-4f9c-9ef7-fc90fd912b2b" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_af24f92c-9524-4b2a-a3a2-9f6f6b2a3216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_9fa76157-0331-4770-b170-f846d4850939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_231d368e-07b7-4f9c-9ef7-fc90fd912b2b" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_9fa76157-0331-4770-b170-f846d4850939" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2cfc4e89-094e-497a-968d-2d1ddbf408a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_9fa76157-0331-4770-b170-f846d4850939" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2cfc4e89-094e-497a-968d-2d1ddbf408a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2cfc4e89-094e-497a-968d-2d1ddbf408a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2cfc4e89-094e-497a-968d-2d1ddbf408a8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2cfc4e89-094e-497a-968d-2d1ddbf408a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fdf02b0c-fdb5-46d0-9094-7d1b82dc97c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2cfc4e89-094e-497a-968d-2d1ddbf408a8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fdf02b0c-fdb5-46d0-9094-7d1b82dc97c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_KalyraPharmaceuticalsIncMember_30ff0636-7121-4e3e-adcd-62ebd9113b99" xlink:href="zntl-20230331.xsd#zntl_KalyraPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fdf02b0c-fdb5-46d0-9094-7d1b82dc97c4" xlink:to="loc_zntl_KalyraPharmaceuticalsIncMember_30ff0636-7121-4e3e-adcd-62ebd9113b99" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails" xlink:type="extended" id="i671393234d004fad9cdb6cc9b2c2dda3_BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_d881a93f-47d8-4c38-ae5e-2aca4bb144fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_452618d5-dad2-4671-b22f-c871aa339bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d881a93f-47d8-4c38-ae5e-2aca4bb144fc" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_452618d5-dad2-4671-b22f-c871aa339bfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9acd3a4e-e0a9-4b5b-8fb2-48c5171685cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_452618d5-dad2-4671-b22f-c871aa339bfa" xlink:to="loc_us-gaap_MinorityInterest_9acd3a4e-e0a9-4b5b-8fb2-48c5171685cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6a0447d4-f01e-4878-b87e-026c6e86209e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_452618d5-dad2-4671-b22f-c871aa339bfa" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6a0447d4-f01e-4878-b87e-026c6e86209e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_d3b1f09f-ec55-46ef-ab32-85b1b8dcf4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_bbf4b23a-fd1d-431f-ab8e-c9aeeb42396a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d881a93f-47d8-4c38-ae5e-2aca4bb144fc" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_bbf4b23a-fd1d-431f-ab8e-c9aeeb42396a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_72d6dbd0-0aaf-4b22-9050-3db27c3f56b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_bbf4b23a-fd1d-431f-ab8e-c9aeeb42396a" xlink:to="loc_srt_ConsolidatedEntitiesAxis_72d6dbd0-0aaf-4b22-9050-3db27c3f56b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_72d6dbd0-0aaf-4b22-9050-3db27c3f56b7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_72d6dbd0-0aaf-4b22-9050-3db27c3f56b7" xlink:to="loc_srt_ConsolidatedEntitiesDomain_72d6dbd0-0aaf-4b22-9050-3db27c3f56b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_b13cf5d7-0fb3-450a-8e93-8514790c81f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_72d6dbd0-0aaf-4b22-9050-3db27c3f56b7" xlink:to="loc_srt_ConsolidatedEntitiesDomain_b13cf5d7-0fb3-450a-8e93-8514790c81f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_fcb8d509-2b9c-49ce-9b52-16c9314c422a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_b13cf5d7-0fb3-450a-8e93-8514790c81f8" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_fcb8d509-2b9c-49ce-9b52-16c9314c422a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="extended" id="i98a02898e22c4e109c6868743716f244_FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0976611c-443d-4444-9430-380b94307a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3782f9cb-6f84-44a3-9359-6590d157f907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0976611c-443d-4444-9430-380b94307a7d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3782f9cb-6f84-44a3-9359-6590d157f907" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_178304dd-a9c6-41a1-b8b6-5122d4a89455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0976611c-443d-4444-9430-380b94307a7d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_178304dd-a9c6-41a1-b8b6-5122d4a89455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c9690ff0-e4b1-4f89-8aba-34edb44f3fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0976611c-443d-4444-9430-380b94307a7d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c9690ff0-e4b1-4f89-8aba-34edb44f3fda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ded9b21-18df-4a78-8d0f-f7eb5cf6f438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0976611c-443d-4444-9430-380b94307a7d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ded9b21-18df-4a78-8d0f-f7eb5cf6f438" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bccff716-437c-4ffa-a2a3-5aa232b7d2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0976611c-443d-4444-9430-380b94307a7d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bccff716-437c-4ffa-a2a3-5aa232b7d2ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d504f282-78fc-4346-99e6-d8127174029f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bccff716-437c-4ffa-a2a3-5aa232b7d2ef" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d504f282-78fc-4346-99e6-d8127174029f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d504f282-78fc-4346-99e6-d8127174029f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d504f282-78fc-4346-99e6-d8127174029f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d504f282-78fc-4346-99e6-d8127174029f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_298c4d1c-2a3e-43d2-b1f0-a201aca8c973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d504f282-78fc-4346-99e6-d8127174029f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_298c4d1c-2a3e-43d2-b1f0-a201aca8c973" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b9e5b93b-bc26-4a4f-b352-0a71734b688c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_298c4d1c-2a3e-43d2-b1f0-a201aca8c973" xlink:to="loc_us-gaap_CommercialPaperMember_b9e5b93b-bc26-4a4f-b352-0a71734b688c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d7d5552c-96ea-4ff4-bfb2-b12795194a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_298c4d1c-2a3e-43d2-b1f0-a201aca8c973" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d7d5552c-96ea-4ff4-bfb2-b12795194a80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0d76ecf7-c723-4da6-8708-7beb206ef87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_298c4d1c-2a3e-43d2-b1f0-a201aca8c973" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0d76ecf7-c723-4da6-8708-7beb206ef87d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_6d078fea-fa56-4eb4-8e00-cf8611ab3408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_298c4d1c-2a3e-43d2-b1f0-a201aca8c973" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_6d078fea-fa56-4eb4-8e00-cf8611ab3408" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="extended" id="i79191a00aab3402da91c9fef45610ad1_FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2d192a77-e598-49ca-8875-5c4845b22009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1f8e0483-9e41-405a-ad80-d41e85c22144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2d192a77-e598-49ca-8875-5c4845b22009" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1f8e0483-9e41-405a-ad80-d41e85c22144" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_36147cd8-53e3-4835-9e13-67d0c118c2df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2d192a77-e598-49ca-8875-5c4845b22009" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_36147cd8-53e3-4835-9e13-67d0c118c2df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b54f197c-771b-4d27-a472-cf2abd0d2d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2d192a77-e598-49ca-8875-5c4845b22009" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b54f197c-771b-4d27-a472-cf2abd0d2d3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_bd34a3d7-2f07-4fbe-84c5-bc54796e31cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2d192a77-e598-49ca-8875-5c4845b22009" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_bd34a3d7-2f07-4fbe-84c5-bc54796e31cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_fda673f3-3e20-4a05-90db-17db58567d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_bd34a3d7-2f07-4fbe-84c5-bc54796e31cc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_fda673f3-3e20-4a05-90db-17db58567d07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fda673f3-3e20-4a05-90db-17db58567d07_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_fda673f3-3e20-4a05-90db-17db58567d07" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fda673f3-3e20-4a05-90db-17db58567d07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5ec7d635-cc92-45d1-862f-2792b85fbd5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_fda673f3-3e20-4a05-90db-17db58567d07" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5ec7d635-cc92-45d1-862f-2792b85fbd5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_91da05ee-093a-4dee-9a16-c7c129117fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5ec7d635-cc92-45d1-862f-2792b85fbd5c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_91da05ee-093a-4dee-9a16-c7c129117fa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_09cb3724-61b5-4dee-8705-e1a59d927afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5ec7d635-cc92-45d1-862f-2792b85fbd5c" xlink:to="loc_us-gaap_CommercialPaperMember_09cb3724-61b5-4dee-8705-e1a59d927afc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0c3bacca-5ba9-4f03-869b-46328b47d8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_bd34a3d7-2f07-4fbe-84c5-bc54796e31cc" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0c3bacca-5ba9-4f03-869b-46328b47d8f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0c3bacca-5ba9-4f03-869b-46328b47d8f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0c3bacca-5ba9-4f03-869b-46328b47d8f8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0c3bacca-5ba9-4f03-869b-46328b47d8f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10b5c7de-56a1-496e-a44c-b852bb2ff30a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0c3bacca-5ba9-4f03-869b-46328b47d8f8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10b5c7de-56a1-496e-a44c-b852bb2ff30a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_58120815-160c-45f9-a10d-628c98acf81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10b5c7de-56a1-496e-a44c-b852bb2ff30a" xlink:to="loc_us-gaap_CommercialPaperMember_58120815-160c-45f9-a10d-628c98acf81e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_28185037-3e72-4333-930d-5320c1cae165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10b5c7de-56a1-496e-a44c-b852bb2ff30a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_28185037-3e72-4333-930d-5320c1cae165" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6169902b-f00a-4d19-b5aa-eb56e08488bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10b5c7de-56a1-496e-a44c-b852bb2ff30a" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6169902b-f00a-4d19-b5aa-eb56e08488bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_d08dce3a-3941-40ca-b67b-3cb138cacea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10b5c7de-56a1-496e-a44c-b852bb2ff30a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_d08dce3a-3941-40ca-b67b-3cb138cacea8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5489a5a4-29ed-47a9-a481-0789cd32c448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_bd34a3d7-2f07-4fbe-84c5-bc54796e31cc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5489a5a4-29ed-47a9-a481-0789cd32c448" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5489a5a4-29ed-47a9-a481-0789cd32c448_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5489a5a4-29ed-47a9-a481-0789cd32c448" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5489a5a4-29ed-47a9-a481-0789cd32c448_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2c6d571-784f-4077-a84a-6f960b9196fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5489a5a4-29ed-47a9-a481-0789cd32c448" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2c6d571-784f-4077-a84a-6f960b9196fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a2d15571-aa84-42ac-a4b7-cf402445e7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2c6d571-784f-4077-a84a-6f960b9196fd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a2d15571-aa84-42ac-a4b7-cf402445e7bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_edf78d03-5768-4960-a57a-c6ae7db75e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2c6d571-784f-4077-a84a-6f960b9196fd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_edf78d03-5768-4960-a57a-c6ae7db75e70" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#PropertyandEquipmentnetSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" xlink:type="extended" id="i8ffdfa1f48634c29a8150da2ac5eaba5_PropertyandEquipmentnetSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d1825f5-f4a6-4818-98fa-6b47e28ca25d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b1a43a18-3389-4d3f-b09f-739cde7de0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d1825f5-f4a6-4818-98fa-6b47e28ca25d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b1a43a18-3389-4d3f-b09f-739cde7de0f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5756d4f0-9f46-42ce-b873-072a68e6f414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d1825f5-f4a6-4818-98fa-6b47e28ca25d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5756d4f0-9f46-42ce-b873-072a68e6f414" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_da87ae0d-52e1-464f-856f-6de4157afe81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d1825f5-f4a6-4818-98fa-6b47e28ca25d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_da87ae0d-52e1-464f-856f-6de4157afe81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_80797731-4f8f-496d-8728-fbb8adee7bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d1825f5-f4a6-4818-98fa-6b47e28ca25d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_80797731-4f8f-496d-8728-fbb8adee7bf1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_18c1827e-dcfb-4117-8d9c-c462b9a13f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_80797731-4f8f-496d-8728-fbb8adee7bf1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_18c1827e-dcfb-4117-8d9c-c462b9a13f74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_18c1827e-dcfb-4117-8d9c-c462b9a13f74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_18c1827e-dcfb-4117-8d9c-c462b9a13f74" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_18c1827e-dcfb-4117-8d9c-c462b9a13f74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b341db67-93c0-4ccd-8e19-713ae9537c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_18c1827e-dcfb-4117-8d9c-c462b9a13f74" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b341db67-93c0-4ccd-8e19-713ae9537c74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_LaboratoryEquipmentMember_4452432f-e600-451f-aa4c-19a8d9922ce1" xlink:href="zntl-20230331.xsd#zntl_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b341db67-93c0-4ccd-8e19-713ae9537c74" xlink:to="loc_zntl_LaboratoryEquipmentMember_4452432f-e600-451f-aa4c-19a8d9922ce1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_87ef32f8-479a-489d-b8d2-ff512b3c60e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b341db67-93c0-4ccd-8e19-713ae9537c74" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_87ef32f8-479a-489d-b8d2-ff512b3c60e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_OfficeEquipmentAndFurnitureMember_60a6fd40-b7ee-4114-bcda-b9d15bbc1a44" xlink:href="zntl-20230331.xsd#zntl_OfficeEquipmentAndFurnitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b341db67-93c0-4ccd-8e19-713ae9537c74" xlink:to="loc_zntl_OfficeEquipmentAndFurnitureMember_60a6fd40-b7ee-4114-bcda-b9d15bbc1a44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_169451b1-2e0d-4272-ae5a-ab417bb6b0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b341db67-93c0-4ccd-8e19-713ae9537c74" xlink:to="loc_us-gaap_ComputerEquipmentMember_169451b1-2e0d-4272-ae5a-ab417bb6b0d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_7c53c08a-4ede-45f8-8fc6-ddbc642039a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b341db67-93c0-4ccd-8e19-713ae9537c74" xlink:to="loc_us-gaap_ConstructionInProgressMember_7c53c08a-4ede-45f8-8fc6-ddbc642039a4" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="ic1d101de53ac4de0a272d2a04fc21009_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d904b0b2-2813-46c8-9707-9ba740a73691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d904b0b2-2813-46c8-9707-9ba740a73691" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease_0b9f5989-db90-441c-9483-22720db51331" xlink:href="zntl-20230331.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease_0b9f5989-db90-441c-9483-22720db51331" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_9e8f38f5-54f3-41e2-a902-782d19aa1314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_9e8f38f5-54f3-41e2-a902-782d19aa1314" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4f463e38-0ab3-4d55-9107-1abdfde84595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4f463e38-0ab3-4d55-9107-1abdfde84595" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_45148371-9b6c-4725-93d6-d7226ef690d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_45148371-9b6c-4725-93d6-d7226ef690d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm_4bff976d-e0dc-4558-ad72-0911043151c9" xlink:href="zntl-20230331.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm_4bff976d-e0dc-4558-ad72-0911043151c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e6b7a74e-ba74-4900-aac0-7c45edcab086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e6b7a74e-ba74-4900-aac0-7c45edcab086" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_48d0e73f-740e-4c36-b111-4671224cf56d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_48d0e73f-740e-4c36-b111-4671224cf56d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_e32c9c78-cd2c-4d17-a2ac-3cf39b4c73cd" xlink:href="zntl-20230331.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_e32c9c78-cd2c-4d17-a2ac-3cf39b4c73cd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_677eee23-9432-461c-a317-55e617dc980f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_677eee23-9432-461c-a317-55e617dc980f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_0034f5cd-cbe5-4bf5-9c62-18db6fa8ba67" xlink:href="zntl-20230331.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_0034f5cd-cbe5-4bf5-9c62-18db6fa8ba67" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6b64385e-3efa-4942-9195-ea0caf0ac4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6b64385e-3efa-4942-9195-ea0caf0ac4c9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_dc7ae4c8-3219-4c86-a73e-18af4cd91f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_dc7ae4c8-3219-4c86-a73e-18af4cd91f1c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_06636df0-a2a3-4e5a-bc15-e9da093a5cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_06636df0-a2a3-4e5a-bc15-e9da093a5cb6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_de9a373f-2fdf-4019-8a77-7c5875873de5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_de9a373f-2fdf-4019-8a77-7c5875873de5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ea12a7df-36cb-4940-a8e9-a0dbcb6e9f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_de9a373f-2fdf-4019-8a77-7c5875873de5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ea12a7df-36cb-4940-a8e9-a0dbcb6e9f9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ea12a7df-36cb-4940-a8e9-a0dbcb6e9f9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ea12a7df-36cb-4940-a8e9-a0dbcb6e9f9d" xlink:to="loc_us-gaap_ClassOfStockDomain_ea12a7df-36cb-4940-a8e9-a0dbcb6e9f9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_03bf3a23-39ca-4358-93ae-7f2fe7b1ebe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ea12a7df-36cb-4940-a8e9-a0dbcb6e9f9d" xlink:to="loc_us-gaap_ClassOfStockDomain_03bf3a23-39ca-4358-93ae-7f2fe7b1ebe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4d509273-656b-4ba9-8d9a-d8e3bf0f17aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_03bf3a23-39ca-4358-93ae-7f2fe7b1ebe5" xlink:to="loc_us-gaap_CommonStockMember_4d509273-656b-4ba9-8d9a-d8e3bf0f17aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_7d8502b0-9634-4104-8452-59d5d59a583a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_03bf3a23-39ca-4358-93ae-7f2fe7b1ebe5" xlink:to="loc_us-gaap_CommonClassBMember_7d8502b0-9634-4104-8452-59d5d59a583a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_a8439968-9722-4383-abed-11e5e68d5505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_03bf3a23-39ca-4358-93ae-7f2fe7b1ebe5" xlink:to="loc_us-gaap_RestrictedStockMember_a8439968-9722-4383-abed-11e5e68d5505" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_12057611-28e2-418d-ada7-e6333976cced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_de9a373f-2fdf-4019-8a77-7c5875873de5" xlink:to="loc_us-gaap_PlanNameAxis_12057611-28e2-418d-ada7-e6333976cced" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_12057611-28e2-418d-ada7-e6333976cced_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_12057611-28e2-418d-ada7-e6333976cced" xlink:to="loc_us-gaap_PlanNameDomain_12057611-28e2-418d-ada7-e6333976cced_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9614d4d8-75f0-442f-8e92-38f6fde7d792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_12057611-28e2-418d-ada7-e6333976cced" xlink:to="loc_us-gaap_PlanNameDomain_9614d4d8-75f0-442f-8e92-38f6fde7d792" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_A2020IncentiveAwardPlanMember_d7621751-6c2c-46b6-a19f-98f3dd336f0c" xlink:href="zntl-20230331.xsd#zntl_A2020IncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9614d4d8-75f0-442f-8e92-38f6fde7d792" xlink:to="loc_zntl_A2020IncentiveAwardPlanMember_d7621751-6c2c-46b6-a19f-98f3dd336f0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_A2022EmploymentInducementIncentiveAwardPlanMember_30d5c916-e920-41d4-8c6b-0e53120f48fc" xlink:href="zntl-20230331.xsd#zntl_A2022EmploymentInducementIncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9614d4d8-75f0-442f-8e92-38f6fde7d792" xlink:to="loc_zntl_A2022EmploymentInducementIncentiveAwardPlanMember_30d5c916-e920-41d4-8c6b-0e53120f48fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8cc28e9d-1eb0-47bc-81e6-1da1dc7937b0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_de9a373f-2fdf-4019-8a77-7c5875873de5" xlink:to="loc_srt_RangeAxis_8cc28e9d-1eb0-47bc-81e6-1da1dc7937b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8cc28e9d-1eb0-47bc-81e6-1da1dc7937b0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8cc28e9d-1eb0-47bc-81e6-1da1dc7937b0" xlink:to="loc_srt_RangeMember_8cc28e9d-1eb0-47bc-81e6-1da1dc7937b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f8aa92ed-2cd5-4da9-a92f-839bd3d9783b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8cc28e9d-1eb0-47bc-81e6-1da1dc7937b0" xlink:to="loc_srt_RangeMember_f8aa92ed-2cd5-4da9-a92f-839bd3d9783b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2bcc52a7-6c02-4f70-9bde-dc0c55ebd366" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f8aa92ed-2cd5-4da9-a92f-839bd3d9783b" xlink:to="loc_srt_MaximumMember_2bcc52a7-6c02-4f70-9bde-dc0c55ebd366" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b1c9fb8f-d5dd-48ea-96a0-4a055c5f6440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_de9a373f-2fdf-4019-8a77-7c5875873de5" xlink:to="loc_us-gaap_AwardTypeAxis_b1c9fb8f-d5dd-48ea-96a0-4a055c5f6440" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1c9fb8f-d5dd-48ea-96a0-4a055c5f6440_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b1c9fb8f-d5dd-48ea-96a0-4a055c5f6440" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1c9fb8f-d5dd-48ea-96a0-4a055c5f6440_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41c0d4ca-85dd-44e7-a484-0c29e1bf80ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b1c9fb8f-d5dd-48ea-96a0-4a055c5f6440" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41c0d4ca-85dd-44e7-a484-0c29e1bf80ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ca5bf476-e0ec-438f-91ab-5907b6926d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41c0d4ca-85dd-44e7-a484-0c29e1bf80ba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ca5bf476-e0ec-438f-91ab-5907b6926d9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_1881c325-20ec-455c-8e6e-16bcc78cdd42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41c0d4ca-85dd-44e7-a484-0c29e1bf80ba" xlink:to="loc_us-gaap_EmployeeStockMember_1881c325-20ec-455c-8e6e-16bcc78cdd42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_537ba1b7-ba2e-4373-98cd-0b4f06e157ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41c0d4ca-85dd-44e7-a484-0c29e1bf80ba" xlink:to="loc_us-gaap_RestrictedStockMember_537ba1b7-ba2e-4373-98cd-0b4f06e157ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7db04e33-f0a8-4836-b16b-b85f65c87edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41c0d4ca-85dd-44e7-a484-0c29e1bf80ba" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7db04e33-f0a8-4836-b16b-b85f65c87edc" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#StockholdersEquitySharebasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails" xlink:type="extended" id="i837c0aacc3084f058a1478fdec680e99_StockholdersEquitySharebasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1a81afba-9396-470c-adf7-db94eb4de4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_490d3021-8411-4b4d-a71b-b6b69a24886a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1a81afba-9396-470c-adf7-db94eb4de4d7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_490d3021-8411-4b4d-a71b-b6b69a24886a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0eadc271-d9c7-4274-86a8-9316b561ceeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1a81afba-9396-470c-adf7-db94eb4de4d7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0eadc271-d9c7-4274-86a8-9316b561ceeb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_db876d51-35bf-4203-9118-9a090c2dbbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0eadc271-d9c7-4274-86a8-9316b561ceeb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_db876d51-35bf-4203-9118-9a090c2dbbc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_db876d51-35bf-4203-9118-9a090c2dbbc9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_db876d51-35bf-4203-9118-9a090c2dbbc9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_db876d51-35bf-4203-9118-9a090c2dbbc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_be37bb0c-364e-44f8-a0c2-436e061ef571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_db876d51-35bf-4203-9118-9a090c2dbbc9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_be37bb0c-364e-44f8-a0c2-436e061ef571" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c7fddd38-10a6-40ad-9424-a8027bd96982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_be37bb0c-364e-44f8-a0c2-436e061ef571" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c7fddd38-10a6-40ad-9424-a8027bd96982" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_87f246af-128f-4575-a1ca-2316a7ffdf1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_be37bb0c-364e-44f8-a0c2-436e061ef571" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_87f246af-128f-4575-a1ca-2316a7ffdf1f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#StockholdersEquitySharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails" xlink:type="extended" id="ie7e12841221b4021b4f45a8358826bed_StockholdersEquitySharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a16bd81d-492a-472f-8abf-3d521534eabf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_af78e1f2-23b2-4b69-81aa-184a8f5cf2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a16bd81d-492a-472f-8abf-3d521534eabf" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_af78e1f2-23b2-4b69-81aa-184a8f5cf2ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8237fb89-f481-491b-90fe-ea8092446083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a16bd81d-492a-472f-8abf-3d521534eabf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8237fb89-f481-491b-90fe-ea8092446083" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4e2706b9-93c0-48cc-a2e3-946fcfbfadb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8237fb89-f481-491b-90fe-ea8092446083" xlink:to="loc_us-gaap_AwardTypeAxis_4e2706b9-93c0-48cc-a2e3-946fcfbfadb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2706b9-93c0-48cc-a2e3-946fcfbfadb8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4e2706b9-93c0-48cc-a2e3-946fcfbfadb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2706b9-93c0-48cc-a2e3-946fcfbfadb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9748f5b3-c2ca-47b2-b655-6c670a34f446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4e2706b9-93c0-48cc-a2e3-946fcfbfadb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9748f5b3-c2ca-47b2-b655-6c670a34f446" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ab4d35fe-9380-498b-a6eb-f94a91899439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9748f5b3-c2ca-47b2-b655-6c670a34f446" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ab4d35fe-9380-498b-a6eb-f94a91899439" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_68e3591c-f8f9-49e4-89c6-572662b7bf4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9748f5b3-c2ca-47b2-b655-6c670a34f446" xlink:to="loc_us-gaap_EmployeeStockMember_68e3591c-f8f9-49e4-89c6-572662b7bf4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember_c138b3da-498a-4d73-9089-cdaf07b4ce2d" xlink:href="zntl-20230331.xsd#zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9748f5b3-c2ca-47b2-b655-6c670a34f446" xlink:to="loc_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember_c138b3da-498a-4d73-9089-cdaf07b4ce2d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#StockholdersEquityFairValueAssumptionsforStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails" xlink:type="extended" id="i3e57d745439d4cf09ab3f0ebcc6b2c3d_StockholdersEquityFairValueAssumptionsforStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28c511ad-5be3-4524-b710-1db28709a55c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ec04b654-022a-4cc8-9818-24a644f8d068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28c511ad-5be3-4524-b710-1db28709a55c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ec04b654-022a-4cc8-9818-24a644f8d068" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_7eb9d0a5-34d4-41fc-ab9c-68f619623bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28c511ad-5be3-4524-b710-1db28709a55c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_7eb9d0a5-34d4-41fc-ab9c-68f619623bbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f903f9ef-9863-4463-aa8e-aa9bb3eb1778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28c511ad-5be3-4524-b710-1db28709a55c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f903f9ef-9863-4463-aa8e-aa9bb3eb1778" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_c0fcc406-e1de-4b15-b7ac-d73c40ee9b03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28c511ad-5be3-4524-b710-1db28709a55c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_c0fcc406-e1de-4b15-b7ac-d73c40ee9b03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_86ab3a21-cb3c-4cb5-9dcc-6a4a13ba1969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28c511ad-5be3-4524-b710-1db28709a55c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_86ab3a21-cb3c-4cb5-9dcc-6a4a13ba1969" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3862859b-7c8f-4a06-a1b7-6c0ad8ed909c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28c511ad-5be3-4524-b710-1db28709a55c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3862859b-7c8f-4a06-a1b7-6c0ad8ed909c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2a608868-cf87-4fe7-b4d7-7b8805c3622c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28c511ad-5be3-4524-b710-1db28709a55c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2a608868-cf87-4fe7-b4d7-7b8805c3622c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5fd9cf52-9b61-44f2-b3c3-ba47f24cddd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2a608868-cf87-4fe7-b4d7-7b8805c3622c" xlink:to="loc_us-gaap_AwardTypeAxis_5fd9cf52-9b61-44f2-b3c3-ba47f24cddd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5fd9cf52-9b61-44f2-b3c3-ba47f24cddd0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5fd9cf52-9b61-44f2-b3c3-ba47f24cddd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5fd9cf52-9b61-44f2-b3c3-ba47f24cddd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7f8d5ae-6d67-4eeb-a406-821831a33598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5fd9cf52-9b61-44f2-b3c3-ba47f24cddd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7f8d5ae-6d67-4eeb-a406-821831a33598" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d288e4a3-c7cf-4891-a17d-2aca7dfd35ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7f8d5ae-6d67-4eeb-a406-821831a33598" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d288e4a3-c7cf-4891-a17d-2aca7dfd35ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_00aa1cfd-c732-49a7-a755-ee1f2e3faeb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2a608868-cf87-4fe7-b4d7-7b8805c3622c" xlink:to="loc_srt_RangeAxis_00aa1cfd-c732-49a7-a755-ee1f2e3faeb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_00aa1cfd-c732-49a7-a755-ee1f2e3faeb0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_00aa1cfd-c732-49a7-a755-ee1f2e3faeb0" xlink:to="loc_srt_RangeMember_00aa1cfd-c732-49a7-a755-ee1f2e3faeb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6a3e88de-9ae9-4cc4-9c02-c9ee6fb0c280" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_00aa1cfd-c732-49a7-a755-ee1f2e3faeb0" xlink:to="loc_srt_RangeMember_6a3e88de-9ae9-4cc4-9c02-c9ee6fb0c280" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_560ba85f-aff2-4924-ac6e-9df1358b7c14" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6a3e88de-9ae9-4cc4-9c02-c9ee6fb0c280" xlink:to="loc_srt_MinimumMember_560ba85f-aff2-4924-ac6e-9df1358b7c14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c1eb1a36-2f4c-4d89-aa5c-f611c7f894ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6a3e88de-9ae9-4cc4-9c02-c9ee6fb0c280" xlink:to="loc_srt_MaximumMember_c1eb1a36-2f4c-4d89-aa5c-f611c7f894ac" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#StockholdersEquityFairValueAssumptionsforESPPDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails" xlink:type="extended" id="i514bc9c57b5b4618b0b7b07671986c80_StockholdersEquityFairValueAssumptionsforESPPDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8589bdc3-946a-47a1-9498-3134445ab1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7b2d3267-c39d-4e96-bfea-b26582142156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8589bdc3-946a-47a1-9498-3134445ab1ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7b2d3267-c39d-4e96-bfea-b26582142156" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ff346f51-3372-4cb9-bb83-14cbaab1c762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8589bdc3-946a-47a1-9498-3134445ab1ab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ff346f51-3372-4cb9-bb83-14cbaab1c762" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_92e53c08-7cb9-4865-807e-d86893d1a42f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8589bdc3-946a-47a1-9498-3134445ab1ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_92e53c08-7cb9-4865-807e-d86893d1a42f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a46aeec6-5075-4c4e-9016-a57fad7167d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8589bdc3-946a-47a1-9498-3134445ab1ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a46aeec6-5075-4c4e-9016-a57fad7167d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e56cde62-1b69-4802-8b49-2c8dba6a405c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8589bdc3-946a-47a1-9498-3134445ab1ab" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e56cde62-1b69-4802-8b49-2c8dba6a405c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_963940b8-9aee-49aa-aa5e-b94f693372e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e56cde62-1b69-4802-8b49-2c8dba6a405c" xlink:to="loc_us-gaap_AwardTypeAxis_963940b8-9aee-49aa-aa5e-b94f693372e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_963940b8-9aee-49aa-aa5e-b94f693372e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_963940b8-9aee-49aa-aa5e-b94f693372e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_963940b8-9aee-49aa-aa5e-b94f693372e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2642c3d-b87d-4715-b875-5465f37f5340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_963940b8-9aee-49aa-aa5e-b94f693372e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2642c3d-b87d-4715-b875-5465f37f5340" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_1b359ee4-940a-4820-b67d-8273524739b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2642c3d-b87d-4715-b875-5465f37f5340" xlink:to="loc_us-gaap_EmployeeStockMember_1b359ee4-940a-4820-b67d-8273524739b1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#StockholdersEquityUnrecognizedCompensationCostDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails" xlink:type="extended" id="i2412e16bec294a0aa4c57759bfffd5b0_StockholdersEquityUnrecognizedCompensationCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_094be4f3-6936-49a2-9968-8d785d0c573e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0890f32b-d695-4d6c-8b41-454d8274108d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_094be4f3-6936-49a2-9968-8d785d0c573e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0890f32b-d695-4d6c-8b41-454d8274108d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_dcdb4dc9-7628-45ee-beae-9cf219b54b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_094be4f3-6936-49a2-9968-8d785d0c573e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_dcdb4dc9-7628-45ee-beae-9cf219b54b8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a85e84e8-7e37-4c0c-9a4d-1925fd19624c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_094be4f3-6936-49a2-9968-8d785d0c573e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a85e84e8-7e37-4c0c-9a4d-1925fd19624c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1f43cdf-c6be-4185-954b-ef55a3a5cb33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_094be4f3-6936-49a2-9968-8d785d0c573e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1f43cdf-c6be-4185-954b-ef55a3a5cb33" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_617a7e77-5b9f-4651-a5cf-3265354a4b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1f43cdf-c6be-4185-954b-ef55a3a5cb33" xlink:to="loc_us-gaap_AwardTypeAxis_617a7e77-5b9f-4651-a5cf-3265354a4b0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_617a7e77-5b9f-4651-a5cf-3265354a4b0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_617a7e77-5b9f-4651-a5cf-3265354a4b0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_617a7e77-5b9f-4651-a5cf-3265354a4b0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cef4fd2-2dd9-4b64-810f-5f85c0c1e40a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_617a7e77-5b9f-4651-a5cf-3265354a4b0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cef4fd2-2dd9-4b64-810f-5f85c0c1e40a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1fd6c758-450e-4465-8d08-d20bbb0f6145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cef4fd2-2dd9-4b64-810f-5f85c0c1e40a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1fd6c758-450e-4465-8d08-d20bbb0f6145" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_3fe4d219-2bcd-47a5-9184-741249b8abab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cef4fd2-2dd9-4b64-810f-5f85c0c1e40a" xlink:to="loc_us-gaap_RestrictedStockMember_3fe4d219-2bcd-47a5-9184-741249b8abab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_38ab585a-64e7-4adc-98d1-bdda092b5e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cef4fd2-2dd9-4b64-810f-5f85c0c1e40a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_38ab585a-64e7-4adc-98d1-bdda092b5e00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a531e910-2c66-44d5-95b8-8459ced89c99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cef4fd2-2dd9-4b64-810f-5f85c0c1e40a" xlink:to="loc_us-gaap_EmployeeStockMember_a531e910-2c66-44d5-95b8-8459ced89c99" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#NetLossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended" id="i9ee569dfc84d48f48f8066d22a6cbc03_NetLossPerCommonShareAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dbd5cbf0-c10e-4c36-9ae7-6ee84fba5839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d5fe70dc-970c-43c8-a7f9-00fc471f1b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dbd5cbf0-c10e-4c36-9ae7-6ee84fba5839" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d5fe70dc-970c-43c8-a7f9-00fc471f1b7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_71b057d4-2b3c-48c1-9666-158a1ee93d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dbd5cbf0-c10e-4c36-9ae7-6ee84fba5839" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_71b057d4-2b3c-48c1-9666-158a1ee93d92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_22a5aa80-a976-4b8d-90fb-b0b9d22732a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_71b057d4-2b3c-48c1-9666-158a1ee93d92" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_22a5aa80-a976-4b8d-90fb-b0b9d22732a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_22a5aa80-a976-4b8d-90fb-b0b9d22732a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_22a5aa80-a976-4b8d-90fb-b0b9d22732a1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_22a5aa80-a976-4b8d-90fb-b0b9d22732a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec9ee6c1-d2ff-4113-ae0d-19ee835c75f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_22a5aa80-a976-4b8d-90fb-b0b9d22732a1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec9ee6c1-d2ff-4113-ae0d-19ee835c75f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_14212836-34b4-4a85-9b24-5fe26c9dcdce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec9ee6c1-d2ff-4113-ae0d-19ee835c75f5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_14212836-34b4-4a85-9b24-5fe26c9dcdce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_58432008-9d4d-4404-81b5-c9e81f9e9728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec9ee6c1-d2ff-4113-ae0d-19ee835c75f5" xlink:to="loc_us-gaap_RestrictedStockMember_58432008-9d4d-4404-81b5-c9e81f9e9728" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c3e799fa-5dd2-4a51-927e-4f6d9714479e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec9ee6c1-d2ff-4113-ae0d-19ee835c75f5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c3e799fa-5dd2-4a51-927e-4f6d9714479e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#RelatedPartyDisclosuresDetails"/>
  <link:definitionLink xlink:role="http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" xlink:type="extended" id="i2d7fc49ffdbb438ab4f34ae053ce632f_RelatedPartyDisclosuresDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_e16bc265-a4c2-4ac0-9168-41a9db9750ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_46727d18-c93f-4101-b3cc-75c44ea215aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e16bc265-a4c2-4ac0-9168-41a9db9750ea" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_46727d18-c93f-4101-b3cc-75c44ea215aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ResearchAndDevelopmentExpenseReimbursements_4a21bbe7-1984-4c9a-8a37-5a9f3c21d53e" xlink:href="zntl-20230331.xsd#zntl_ResearchAndDevelopmentExpenseReimbursements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e16bc265-a4c2-4ac0-9168-41a9db9750ea" xlink:to="loc_zntl_ResearchAndDevelopmentExpenseReimbursements_4a21bbe7-1984-4c9a-8a37-5a9f3c21d53e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e910c4c5-2fa0-42aa-a3bc-fff3a2173aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e16bc265-a4c2-4ac0-9168-41a9db9750ea" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e910c4c5-2fa0-42aa-a3bc-fff3a2173aba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7bfb7365-6739-4cf9-ae6f-87eea8cbbe0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e910c4c5-2fa0-42aa-a3bc-fff3a2173aba" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7bfb7365-6739-4cf9-ae6f-87eea8cbbe0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7bfb7365-6739-4cf9-ae6f-87eea8cbbe0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7bfb7365-6739-4cf9-ae6f-87eea8cbbe0e" xlink:to="loc_us-gaap_RelatedPartyDomain_7bfb7365-6739-4cf9-ae6f-87eea8cbbe0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a11d4fe4-892f-463c-9f7b-72f6f10d1fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7bfb7365-6739-4cf9-ae6f-87eea8cbbe0e" xlink:to="loc_us-gaap_RelatedPartyDomain_a11d4fe4-892f-463c-9f7b-72f6f10d1fda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_29d73b2a-0eb4-4ec7-b180-7e044ef8b0d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a11d4fe4-892f-463c-9f7b-72f6f10d1fda" xlink:to="loc_srt_AffiliatedEntityMember_29d73b2a-0eb4-4ec7-b180-7e044ef8b0d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_3195d89a-6cd6-4000-a3a1-1f46eae0840a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e910c4c5-2fa0-42aa-a3bc-fff3a2173aba" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_3195d89a-6cd6-4000-a3a1-1f46eae0840a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3195d89a-6cd6-4000-a3a1-1f46eae0840a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3195d89a-6cd6-4000-a3a1-1f46eae0840a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3195d89a-6cd6-4000-a3a1-1f46eae0840a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_45768352-edb3-4708-9389-bdc056b6f97e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3195d89a-6cd6-4000-a3a1-1f46eae0840a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_45768352-edb3-4708-9389-bdc056b6f97e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_MasterServicesAgreementMember_68269fca-7747-489b-a9df-8a38510f32a8" xlink:href="zntl-20230331.xsd#zntl_MasterServicesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_45768352-edb3-4708-9389-bdc056b6f97e" xlink:to="loc_zntl_MasterServicesAgreementMember_68269fca-7747-489b-a9df-8a38510f32a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2e27d5e6-8b1a-48aa-a3f4-45c565b71004" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e910c4c5-2fa0-42aa-a3bc-fff3a2173aba" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2e27d5e6-8b1a-48aa-a3f4-45c565b71004" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2e27d5e6-8b1a-48aa-a3f4-45c565b71004_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2e27d5e6-8b1a-48aa-a3f4-45c565b71004" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2e27d5e6-8b1a-48aa-a3f4-45c565b71004_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_cabfa017-ac27-4716-988b-9e1320d27208" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2e27d5e6-8b1a-48aa-a3f4-45c565b71004" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_cabfa017-ac27-4716-988b-9e1320d27208" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ZenteraTherapeuticsMember_8abad044-9c6c-4b95-95d9-c897e269de27" xlink:href="zntl-20230331.xsd#zntl_ZenteraTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_cabfa017-ac27-4716-988b-9e1320d27208" xlink:to="loc_zntl_ZenteraTherapeuticsMember_8abad044-9c6c-4b95-95d9-c897e269de27" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>zntl-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:b3a2bb04-db5e-4a01-a061-9002e22e0a2d,g:6cdaa420-7596-4787-9871-3e57ed815727-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ffe46817-d0fc-44ab-a04c-8ef0755da0ab_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_d304280f-609a-4d76-b5b4-61ba083dc026_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3874470b-c4ae-4782-b16d-81786afcaf6a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f467b68c-1d78-4e54-84d3-64c7145a7e76_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3433a062-f13e-478e-b697-92773f30521e_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments:</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_da0cd4e2-9a3c-44d4-8fbb-54fc0609125a_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_9c8be307-9824-457a-a17a-69f1c6f955bc_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_222bef91-9fa6-4df4-a451-507a6f947151_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_dec113f3-56a1-4cb2-9ef5-4a5ed85d9b97_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_5914b139-5837-41c4-9bfd-ac0a09374f85_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIE, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_7475da38-a19e-45ff-a081-b884f42053b8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0f454fce-9e0b-46f2-89da-2564543ec202_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3fcdba95-0ba9-49b0-87b6-86c91081280a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_52f4a4ad-bab8-4d5f-bb7e-39a4f6b518fc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_469240a5-5f0e-404b-8bf5-01af22238ea9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_ForeignResearchAndDevelopmentCreditRefund_954833fa-434a-4263-b8d2-209106c83b38_terseLabel_en-US" xlink:label="lab_zntl_ForeignResearchAndDevelopmentCreditRefund" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign R&amp;D credit refund</link:label>
    <link:label id="lab_zntl_ForeignResearchAndDevelopmentCreditRefund_label_en-US" xlink:label="lab_zntl_ForeignResearchAndDevelopmentCreditRefund" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Research and Development Credit Refund</link:label>
    <link:label id="lab_zntl_ForeignResearchAndDevelopmentCreditRefund_documentation_en-US" xlink:label="lab_zntl_ForeignResearchAndDevelopmentCreditRefund" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Research and Development Credit Refund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ForeignResearchAndDevelopmentCreditRefund" xlink:href="zntl-20230331.xsd#zntl_ForeignResearchAndDevelopmentCreditRefund"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_ForeignResearchAndDevelopmentCreditRefund" xlink:to="lab_zntl_ForeignResearchAndDevelopmentCreditRefund" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7c1da119-cef1-4f94-9971-d6b893b786d4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ad0adca1-60fa-43c2-ab98-50f579f525d1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_34e3935e-ffaf-4349-8c8f-5ef3db5dffa3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b1652ad9-8b0e-4c0e-9929-5a0245990b64_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares used in computing net loss per share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_53b3a692-7808-4ea3-9832-ef1c2dcd15dc_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_a4b3b509-e803-4a9f-b57b-58368da4fdff_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_51e98d92-0e35-4c36-b7d2-290d89a2f900_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8b2b9d5b-cb2a-4163-8b06-8df8265bd058_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_01e06699-c292-46d7-893e-f0926f4b483a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_96f7bfe7-4ab1-4831-933b-6bd799e5fe11_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_b1a7f89f-0196-4dca-87de-db3a07d50910_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_OfficeEquipmentAndFurnitureMember_4b3cd79a-243b-4150-9459-16159e3b4ce2_terseLabel_en-US" xlink:label="lab_zntl_OfficeEquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment and furniture</link:label>
    <link:label id="lab_zntl_OfficeEquipmentAndFurnitureMember_label_en-US" xlink:label="lab_zntl_OfficeEquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment And Furniture [Member]</link:label>
    <link:label id="lab_zntl_OfficeEquipmentAndFurnitureMember_documentation_en-US" xlink:label="lab_zntl_OfficeEquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment And Furniture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_OfficeEquipmentAndFurnitureMember" xlink:href="zntl-20230331.xsd#zntl_OfficeEquipmentAndFurnitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_OfficeEquipmentAndFurnitureMember" xlink:to="lab_zntl_OfficeEquipmentAndFurnitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0f7f31f1-5196-45c7-b772-df19e08b957e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_e7f31907-15fc-4a81-b762-7b5d4f6a34d3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 250,000,000 shares authorized; 59,442,342 and 59,280,247 shares issued and outstanding at March&#160;31, 2023 and December 31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_e1efd71e-1612-4a45-9264-834c1b9234bc_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_b6f3d9aa-82af-4d00-bd1a-9aabdc267c62_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_A2022EmploymentInducementIncentiveAwardPlanMember_ea21b63d-2c2c-404b-a6c4-669f70ddacac_terseLabel_en-US" xlink:label="lab_zntl_A2022EmploymentInducementIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Inducement Plan</link:label>
    <link:label id="lab_zntl_A2022EmploymentInducementIncentiveAwardPlanMember_label_en-US" xlink:label="lab_zntl_A2022EmploymentInducementIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Employment Inducement Incentive Award Plan [Member]</link:label>
    <link:label id="lab_zntl_A2022EmploymentInducementIncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_zntl_A2022EmploymentInducementIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Employment Inducement Incentive Award Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_A2022EmploymentInducementIncentiveAwardPlanMember" xlink:href="zntl-20230331.xsd#zntl_A2022EmploymentInducementIncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_A2022EmploymentInducementIncentiveAwardPlanMember" xlink:to="lab_zntl_A2022EmploymentInducementIncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_61e589d9-ed35-4d1e-a6a0-6bc926281e9d_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale marketable securities:</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_3c3dee1f-714e-412e-99d6-d36d945752fb_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_f2c64416-74a1-455f-94ec-840eace4145c_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with restricted stock unit vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_79dfe34e-4751-49bd-9b4f-b19216c26857_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon vesting of certain RSAs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_73e53903-5c60-4005-8553-6b9ccd7f0eba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Unit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c7774ec8-0c5b-437e-8cb1-23ae8d095284_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of options, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_EarningsPerShareNumeratorAbstract_ee28c8e4-992f-4442-a881-b3e8a93bd5df_terseLabel_en-US" xlink:label="lab_zntl_EarningsPerShareNumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_zntl_EarningsPerShareNumeratorAbstract_label_en-US" xlink:label="lab_zntl_EarningsPerShareNumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Numerator [Abstract]</link:label>
    <link:label id="lab_zntl_EarningsPerShareNumeratorAbstract_documentation_en-US" xlink:label="lab_zntl_EarningsPerShareNumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Numerator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_EarningsPerShareNumeratorAbstract" xlink:href="zntl-20230331.xsd#zntl_EarningsPerShareNumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_EarningsPerShareNumeratorAbstract" xlink:to="lab_zntl_EarningsPerShareNumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2c4f5103-0508-47b7-a1c3-780c3d3b163a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_b02dd991-7860-4973-9e8a-26bc7ffe2c34_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_35fd6683-d95e-41b8-8e7c-46ac6e1cfdbe_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_568cc130-684f-4c3f-bfd5-d9072f6b8b05_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ca74dc98-834f-4d3d-b4dc-9fb1b4217ba1_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dd49f316-f441-4970-9f22-bfaa6ed3cd8b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash reported in the Condensed Consolidated Statement of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_13c9ffcf-dc4a-4722-98e1-6b29247ed898_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_85234f2a-e7c9-4f67-9393-28767a203cf7_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_LaboratoryEquipmentMember_58e73913-de1f-4741-ac79-4530955c0190_terseLabel_en-US" xlink:label="lab_zntl_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_zntl_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_zntl_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_zntl_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_zntl_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_LaboratoryEquipmentMember" xlink:href="zntl-20230331.xsd#zntl_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_LaboratoryEquipmentMember" xlink:to="lab_zntl_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bf43c86f-cb39-40a7-829b-e38fcea6fbc3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_3bb5c860-f3a9-4290-9971-2c97ec3b0d62_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_aec14aad-f506-46d0-8a0f-d2bb197b1553_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_13b2e438-48f5-4e14-95e2-a72fa28a891d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Zentalis</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ea9bcd5d-dc84-461b-b495-eced71c2f0bc_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Zentalis</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_8f811229-77b3-479d-9820-89a5fd815e7d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Zentera Therapeutics</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0dc2c748-9e7d-49a1-98a3-b27491fd4f02_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_cfc0e06e-fcf8-4fa1-a70f-a114d6afc9bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions, ESPP</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_66a79c8a-3ee1-4dcb-bd12-dcb7c7fbca55_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per unit (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_dd742a87-44d0-4ad5-9d6b-2730836c0ebf_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_6eb45a03-9be8-4fd1-add6-59c6548809bb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_2305e184-c972-4af9-8c75-99b2ff6f7f7a_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of available-for-sale securities in unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_a64a33b8-326e-4692-8a6c-d6cafa9c1987_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_75e73638-6b74-42b7-851b-f982bacc6d68_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair market value of available-for-sale securities in unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_d00c2c94-37a9-4517-9bdb-479d27182755_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_890b8fac-5852-4a73-b86e-b53d15b7f2c3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5002cb9d-4f24-4e58-91f3-fdc8dd2bb7db_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_bb3d3873-7899-4d44-98af-e009d275ec19_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c109ce01-9f59-438c-821a-be1564476671_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_0f67cd83-ee40-48dc-ba18-947be7ba3066_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Zentalis</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_6811f147-b6ca-4c06-980a-727960989293_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8f21ab92-089c-4523-9b34-22bfe8d1b51b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_79b0bb34-82df-4670-bd1f-3a6027b8c02a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_67c3999d-0775-4d58-b7fc-626271e39475_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_0ff51fde-7323-4b5c-95cc-21b578b9cab2_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4566c000-e50b-4097-a3bd-5468aa6e6a09_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5acfec74-5442-4eef-a103-f8ca26fe3f55_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1e3712e5-231b-4449-97e5-12c22e2fc3b7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2e534588-b358-4d28-b60b-9c14b00e6b5a_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_691be0b2-4fe1-4398-a665-aeeaf053ad26_terseLabel_en-US" xlink:label="lab_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_label_en-US" xlink:label="lab_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, Due After Year Four</link:label>
    <link:label id="lab_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_documentation_en-US" xlink:label="lab_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, Due After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:href="zntl-20230331.xsd#zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:to="lab_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_2102081a-d3ec-4cdc-9eba-3d78c3631d00_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_127fd29a-724b-402d-b13d-4b661e683e71_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP purchase price of common stock, percent of market price</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4a2c17c9-12dc-49e2-b61f-cd60ed7e2cd1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized expense, other than options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_041bc4d9-d53f-4db2-ac19-37bb772188c0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_84353ce6-64ad-40cc-a214-ec60f8d2d25f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 (remaining)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_b0c57719-52ec-4263-9029-3864eafe761e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d445c0e4-e949-4e71-a6c6-869af347349c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_6a9fcc28-0526-4e32-a9fc-48d279a5a739_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_909115b4-236f-4869-a786-e2113ce49e65_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_24df5f43-035c-4b93-8754-e0bc72d09b9b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_22110cff-bba7-43f9-ac9d-cb618a652ff4_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_78b91676-18a3-483a-8a15-a29db52365fc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_44591905-a367-406c-aef3-34f2f7b7402c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_cca49214-5039-41c8-9cf0-4509fdd52a6a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_43c6161c-7153-47ee-9c60-8be832ea7236_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_9d218c5f-3f64-41d0-afe4-95bcb956fa38_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_6120de91-992a-405d-b2a0-a66b248987da_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of available-for-sale securities in unrealized loss position for less than one year</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8878416b-6f9d-44af-80fe-f5383a48a241_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_e7ef102f-f0b0-4ffe-bc10-936c862c0c41_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_95466fdb-5535-4e0e-bd4e-8c533013a073_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ce296410-c4e4-4421-8484-0abe0d85c275_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1d2b26fe-99cf-46df-8d0f-b0ffe240a5d9_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c7e3a1d1-df04-47ea-a108-cfe6f990b7a5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_80672370-3c15-4efd-b4ce-21a824546d3c_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_10cd34f7-35fe-47e4-9a42-df26f7ef81fe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Available-for-sale Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_b2865e01-01b9-4163-8a75-55f5f2eaf0fa_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3832a5d3-82ef-451f-bdd3-df43ae2fb2c3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_331cd9cf-cb55-4fb9-abe7-905250d9e366_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e433e4bc-6154-4c29-927b-2162f9c4e964_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_80111fd6-a816-4cf7-86cf-04c2c2602357_netLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e10673aa-cefb-48ca-b977-661cb12fb077_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e1e64930-5ba8-4367-a088-e8ec355777bf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_eaed802f-4f3e-4a04-a790-74f0ecff6528_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_31e5d7d2-7319-4e01-a213-e2e856cffb56_terseLabel_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contribution amount</link:label>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_label_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_documentation_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:href="zntl-20230331.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:to="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5c49de50-e663-4105-94c6-7f1820ced62e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of options, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_9a70dea1-4776-4fc7-be45-e040dd1af4af_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_bed76255-c7ef-432b-aa57-ef4fd5571d3e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_69e9800a-4e5f-4ada-8578-dd1b38955e62_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_381fe63b-2ee2-4054-a314-96fb6d59d794_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_350dce60-aa56-4877-9bdc-9f8000a3e2f0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_31759988-cfaa-4a1d-bd5b-46750eb8c10a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_fa0c08c3-552c-42e4-aaa2-ff2c78cfde7a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40994f6b-abd1-451b-992b-e607a3280c38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_7c2537a9-9bfe-41c7-8122-8e00b5212965_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_51dc3bb1-835f-4668-b68e-c030e26a6eea_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_74d1162c-d122-4e96-b2e1-e11b799e4767_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20f5c036-774f-4ce6-b359-1d190e115319_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_95585745-a99f-44aa-b9af-88cbc766ecbf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_e61f58e3-d77a-4e6e-91ee-41b5bd9869b6_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_d997d865-44ea-44bd-828f-12dda1d6f8bd_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less long-term portion</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e099b6f7-69b1-438a-b954-c8cbad405508_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4d136dcd-7b58-44cd-831c-84a971635e2d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d23c57f4-ccce-4d78-9203-e64c069953ba_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a4cc13c2-5f32-4149-92f5-9ea97c56aa7a_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1e79cda6-442f-47d1-be2e-bd0fa35e9c35_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ba19e212-9b90-465f-ab1a-3b064b4df4c0_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_ec0b7c70-5fc7-4158-8d7e-3644b5c27c4e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_9f780663-c646-4497-ae14-c2cd23704dcc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b09e8322-b7aa-43d3-9760-99b764fb3ebd_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_4d3975b2-af08-402b-ad4e-8f9f3a478bff_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_33461280-f5ec-447a-9c20-514b99e0cc75_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_1b880a84-3c4d-466f-8829-15f117703efa_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ab5c4b99-df5c-48ad-aec0-8894669e9785_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_488be9da-60c1-4e66-b23d-d7ed2768ed60_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_4d2bbd8b-1db0-42d7-a584-71e0ab4ce0e9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability, deconsolidation of Zentera</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Investment in Noncontrolled Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c926734b-dede-4c8a-b563-8a8aeb73c806_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_41b2d9af-f079-455b-805e-dccd0721e49e_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interim Unaudited Financial Statements</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassBMember_d7285032-2aa8-4da5-a169-a87ad704ba2f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class B</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_03f9041e-ac90-4e34-b318-ca3326cbac77_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_88a7962b-7c8e-486f-8cee-edf2863a25b4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_adcf7732-391e-43c6-8df1-42914c7e9947_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_42335dff-8bdf-409c-9411-20219e6828e9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_e3fe381a-e394-44ae-9095-3538ad242fd5_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_InvestmentAndOtherIncomeExpense_7a1c8f4d-4358-4721-8dc7-a6578115d16b_terseLabel_en-US" xlink:label="lab_zntl_InvestmentAndOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment and other income, net</link:label>
    <link:label id="lab_zntl_InvestmentAndOtherIncomeExpense_label_en-US" xlink:label="lab_zntl_InvestmentAndOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment and Other Income (Expense)</link:label>
    <link:label id="lab_zntl_InvestmentAndOtherIncomeExpense_documentation_en-US" xlink:label="lab_zntl_InvestmentAndOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment and Other Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_InvestmentAndOtherIncomeExpense" xlink:href="zntl-20230331.xsd#zntl_InvestmentAndOtherIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_InvestmentAndOtherIncomeExpense" xlink:to="lab_zntl_InvestmentAndOtherIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3394e529-4041-45a2-bc5c-70e70958905c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock_6af909fd-a708-40b8-a608-0213579ff51f_terseLabel_en-US" xlink:label="lab_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Equity Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock_label_en-US" xlink:label="lab_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Noncontrolling Interest [Table Text Block]</link:label>
    <link:label id="lab_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock_documentation_en-US" xlink:label="lab_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock" xlink:href="zntl-20230331.xsd#zntl_ReconciliationOfNoncontrollingInterestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock" xlink:to="lab_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_53e65a9b-5858-49e9-b76e-401ffef3d350_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_6a29cf7d-862f-401f-9de5-c24974b8c5c7_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_63aca83f-faf7-4244-b243-34d295fb2840_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_29c101e4-405b-4456-b2f4-2a691b89e403_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_PrepaidResearchAndDevelopmentCosts_42bf80dd-c31a-4548-b7a4-2cb89f0e19fc_terseLabel_en-US" xlink:label="lab_zntl_PrepaidResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid research and development expenses</link:label>
    <link:label id="lab_zntl_PrepaidResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_zntl_PrepaidResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development Costs</link:label>
    <link:label id="lab_zntl_PrepaidResearchAndDevelopmentCosts_documentation_en-US" xlink:label="lab_zntl_PrepaidResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_PrepaidResearchAndDevelopmentCosts" xlink:href="zntl-20230331.xsd#zntl_PrepaidResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_PrepaidResearchAndDevelopmentCosts" xlink:to="lab_zntl_PrepaidResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_13ad4394-9659-4acb-8fb7-c06084edafd5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_8aeeb7ba-07e5-4f4a-bdc1-ff296bdb5e0e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized loss position for less than one year</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_5054554a-2eff-438b-b14e-987d5b18bcbc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_ae7ce5fc-7d41-498e-86aa-9fc35649364b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_dcc77980-dc71-408f-90f9-eba57b1b4b8d_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_26da6caf-f832-4ac4-b915-235aa972a024_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_fb373bb4-988c-4df5-88a4-3c93a9549030_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1688a043-c458-43c6-9c7a-0e475bf373e5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Accretion of discounts)/amortization of premiums on marketable securities, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_095f0b13-b59f-4926-81ff-79be05f04625_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_0f3b76c7-1b9e-40a3-b862-923cca32858a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized loss position for more than one year</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_61294348-3f88-45dd-ae5a-b092881ef99d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0abc5c70-31fb-482f-ad83-424cc70f95e5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES&#160;AND&#160;STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_5ab89744-626c-40fe-8cdc-ffa3f3933097_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_077d5b70-4f63-46c1-ade7-9a14ca7421aa_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_dca57353-6859-437c-ad5a-d99b1bdd78b1_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_50c544b1-15c5-425e-8fa5-fc2dfcd1c4ae_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8d741380-144f-44af-a458-f164b11cab25_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_ZenteraTherapeuticsMember_0ea45b49-ef77-4756-a7b5-3a4965426808_terseLabel_en-US" xlink:label="lab_zntl_ZenteraTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zentera</link:label>
    <link:label id="lab_zntl_ZenteraTherapeuticsMember_label_en-US" xlink:label="lab_zntl_ZenteraTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zentera Therapeutics [Member]</link:label>
    <link:label id="lab_zntl_ZenteraTherapeuticsMember_documentation_en-US" xlink:label="lab_zntl_ZenteraTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zentera Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ZenteraTherapeuticsMember" xlink:href="zntl-20230331.xsd#zntl_ZenteraTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_ZenteraTherapeuticsMember" xlink:to="lab_zntl_ZenteraTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9269aa9a-6080-4ae5-8062-3c53f46fd3b6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_68c62de9-5be3-45b7-a196-380981105b40_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued employee expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a66ffa8d-30b9-4bf1-8bed-f674520a84d2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_AccruedGeneralAndAdministrativeCostsCurrent_09f5f0e8-fcf0-4ffc-bdcc-e693d79bdc9c_terseLabel_en-US" xlink:label="lab_zntl_AccruedGeneralAndAdministrativeCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued general and administrative expenses</link:label>
    <link:label id="lab_zntl_AccruedGeneralAndAdministrativeCostsCurrent_label_en-US" xlink:label="lab_zntl_AccruedGeneralAndAdministrativeCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued General And Administrative Costs, Current</link:label>
    <link:label id="lab_zntl_AccruedGeneralAndAdministrativeCostsCurrent_documentation_en-US" xlink:label="lab_zntl_AccruedGeneralAndAdministrativeCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued General And Administrative Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_AccruedGeneralAndAdministrativeCostsCurrent" xlink:href="zntl-20230331.xsd#zntl_AccruedGeneralAndAdministrativeCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_AccruedGeneralAndAdministrativeCostsCurrent" xlink:to="lab_zntl_AccruedGeneralAndAdministrativeCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7a3db2b3-26b2-47f6-b6b6-703c7e56f5c0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4acc5b85-67fa-4dac-92ea-874db123c511_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other assets, current</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_ab0ba878-1fc9-453c-b540-51f501c79835_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_6fb7b4c0-40e9-40ba-8cad-e807982140f3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_OtherPrepaidExpense_36ff2b94-8d06-45d9-aef8-71fd98da01b1_terseLabel_en-US" xlink:label="lab_zntl_OtherPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid expenses</link:label>
    <link:label id="lab_zntl_OtherPrepaidExpense_label_en-US" xlink:label="lab_zntl_OtherPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense</link:label>
    <link:label id="lab_zntl_OtherPrepaidExpense_documentation_en-US" xlink:label="lab_zntl_OtherPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_OtherPrepaidExpense" xlink:href="zntl-20230331.xsd#zntl_OtherPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_OtherPrepaidExpense" xlink:to="lab_zntl_OtherPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_ef2f39a8-7aaa-4ace-90d7-6fe5725a012b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Expense by Type of Share-based Award</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_54b632ed-ca2c-4910-a332-6fadac0db988_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_42934d25-79e3-468d-b172-b9fc308b45b2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Maturities of Available-for-sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0dcb08ed-b88c-430c-8d57-76aeac6c9d3a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_1cc48998-0404-40b9-8c0e-92b880577cf6_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_af8a6e78-09ab-4c4a-9fdd-896467a4bcb8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4d3df490-2ea6-4013-b2e7-22c422b2adc1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares used in computing net loss per share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_570785f9-1f40-44d6-9901-b1e32cd8cad9_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cc8765f-1c61-455b-95bc-85aedd1a011b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3ecbcc73-04c8-432d-b666-a9895d5db752_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Weighted-Average Recognition Period (years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_d3721a27-281c-43da-9278-e355b1f03559_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with restricted stock unit vesting</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_3093980a-4170-4c25-9abf-ecca708f9c55_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecuritiesDebt_ff398776-9afc-4ed8-8bf2-37ecb2858c2f_terseLabel_en-US" xlink:label="lab_us-gaap_TradingSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities fair market value</link:label>
    <link:label id="lab_us-gaap_TradingSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_TradingSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecuritiesDebt" xlink:to="lab_us-gaap_TradingSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_fbd185e5-4a0f-44e9-977e-f1199dbbd794_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a85a668e-7a90-4032-a349-26985987c26e_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of&#160;non-cash&#160;investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_c4d1e977-c03f-4183-b50f-bd3cfff902a9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ffa904fd-dde8-4830-9df2-92636f189f23_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_dfde5f66-e55a-4da8-88a6-0c879282c308_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_8d361f26-46c3-49d7-b2ba-6b741182b891_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March&#160;31, 2023 and December 31, 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e5566cb6-90b8-4cf3-9e67-ede9965b6f0c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cdfb1ccb-da08-456d-974b-5745544b67a2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_22277d5b-925b-4c1c-ab9d-fd981308852c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSAs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_8d3dfa9d-17e4-45d9-a300-5586ace85223_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested RSAs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_bf061b88-3e4f-4d3d-90a4-8bfc21a6ac1d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_6a9ffbda-b864-4cfa-a474-b760cf27836f_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e4d637a6-5136-48a3-b0ff-cdf743c0b6ee_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_884a2ff7-6d2f-423f-bacb-38284529e956_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_277c86fd-4ea1-4dfc-8513-47c9e59503ca_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2bc86c34-4a4b-4115-892d-a04848656e2f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1526ea6f-7286-4597-be34-aa7b52ae16ec_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_86e35844-b60c-49f3-8a42-00c51d6e6aad_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_f2175e06-fb47-4e2e-a83a-61bdb7022ddc_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e469678a-ed6d-4396-ae80-01a5801ca0da_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_ResearchAndDevelopmentExpenseReimbursements_3183c906-b0cc-446b-8f49-0462d46b8ecf_terseLabel_en-US" xlink:label="lab_zntl_ResearchAndDevelopmentExpenseReimbursements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contra-research and development expense</link:label>
    <link:label id="lab_zntl_ResearchAndDevelopmentExpenseReimbursements_label_en-US" xlink:label="lab_zntl_ResearchAndDevelopmentExpenseReimbursements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Reimbursements</link:label>
    <link:label id="lab_zntl_ResearchAndDevelopmentExpenseReimbursements_documentation_en-US" xlink:label="lab_zntl_ResearchAndDevelopmentExpenseReimbursements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Reimbursements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ResearchAndDevelopmentExpenseReimbursements" xlink:href="zntl-20230331.xsd#zntl_ResearchAndDevelopmentExpenseReimbursements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_ResearchAndDevelopmentExpenseReimbursements" xlink:to="lab_zntl_ResearchAndDevelopmentExpenseReimbursements" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_aea92d34-ab75-480e-bbd9-128b041f7b4b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_KalyraPharmaceuticalsIncMember_8cfdb3bc-5859-450a-ac04-4936ef69170d_terseLabel_en-US" xlink:label="lab_zntl_KalyraPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kalyra Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_zntl_KalyraPharmaceuticalsIncMember_label_en-US" xlink:label="lab_zntl_KalyraPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kalyra Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_zntl_KalyraPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_zntl_KalyraPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kalyra Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_KalyraPharmaceuticalsIncMember" xlink:href="zntl-20230331.xsd#zntl_KalyraPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_KalyraPharmaceuticalsIncMember" xlink:to="lab_zntl_KalyraPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_eb904ebd-b6ca-487f-95dd-8c5e2ae2056f_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_ab410741-6c2b-41dd-b099-ed28247c1d38_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest at beginning of period</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_1fb9b1e3-860a-4c0b-b185-a8b99e6738f8_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest at end of period</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_de678dca-de27-4adb-870e-50297dee7657_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_573d0a8a-64e4-4cb0-bdef-e9b286b980d6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_e9aead40-858f-41ff-a82a-3a202bc05fa9_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_8d5bfaa7-1942-4604-a86a-f973089138a5_terseLabel_en-US" xlink:label="lab_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets and liabilities, net</link:label>
    <link:label id="lab_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_label_en-US" xlink:label="lab_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-Of-Use Assets And Liabilities, Net</link:label>
    <link:label id="lab_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_documentation_en-US" xlink:label="lab_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-Of-Use Assets And Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:href="zntl-20230331.xsd#zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:to="lab_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_59bcf2f4-e381-48fb-a69d-e932983a4a2f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e6fdb1b5-aaa9-48bf-81f7-8e57398bfd07_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_d224378d-f42c-4fbf-9fc7-e98eb28a77be_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsDisclosureTextBlock_ae200e8a-75b5-4eab-842b-72da94211a17_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9aabe5ba-2574-440b-ab3a-11ba3e60f2c2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9aa85e75-e945-46c8-b216-742dc5f54360_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_53d5c789-e01b-42ba-a054-7b2149442a34_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember_1c844f18-2618-452c-9556-d88e389dde83_terseLabel_en-US" xlink:label="lab_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSAs and RSUs</link:label>
    <link:label id="lab_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Awards And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Awards And Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember" xlink:href="zntl-20230331.xsd#zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember" xlink:to="lab_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_746db4e7-07b4-4ec3-9847-a424a7627923_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_AccruedResearchAndDevelopmentCostsCurrent_b54ff0a6-8652-4f19-a543-8492e15afa70_terseLabel_en-US" xlink:label="lab_zntl_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expenses</link:label>
    <link:label id="lab_zntl_AccruedResearchAndDevelopmentCostsCurrent_label_en-US" xlink:label="lab_zntl_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Costs, Current</link:label>
    <link:label id="lab_zntl_AccruedResearchAndDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_zntl_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_AccruedResearchAndDevelopmentCostsCurrent" xlink:href="zntl-20230331.xsd#zntl_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_zntl_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_aec2ac80-cbd1-4885-8092-4278418372c2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_5866fcd1-5310-46fc-b15a-d69a6514c0c7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of restricted stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_c18cccb0-7028-444a-965b-81768b20ed26_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_5f78dfc5-d956-46a3-818f-78804992c546_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_c058e3e9-b36e-4570-98a0-3ec3c2543dd9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_PrepaidSoftwareLicenseAndMaintenance_9a0a528e-040d-41e4-b6ca-0f3b7cfcbfe8_terseLabel_en-US" xlink:label="lab_zntl_PrepaidSoftwareLicenseAndMaintenance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid software licenses and maintenance</link:label>
    <link:label id="lab_zntl_PrepaidSoftwareLicenseAndMaintenance_label_en-US" xlink:label="lab_zntl_PrepaidSoftwareLicenseAndMaintenance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Software License And Maintenance</link:label>
    <link:label id="lab_zntl_PrepaidSoftwareLicenseAndMaintenance_documentation_en-US" xlink:label="lab_zntl_PrepaidSoftwareLicenseAndMaintenance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Software License And Maintenance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_PrepaidSoftwareLicenseAndMaintenance" xlink:href="zntl-20230331.xsd#zntl_PrepaidSoftwareLicenseAndMaintenance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_PrepaidSoftwareLicenseAndMaintenance" xlink:to="lab_zntl_PrepaidSoftwareLicenseAndMaintenance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_2d7aa45e-74a3-4422-8a56-91fe8884e518_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_dc41893c-1bfb-4452-91fc-36ca55097aa7_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_fa0fc0b0-af3f-4e7c-82b8-b2e08d663c74_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_23f3c6cf-bea5-4fc9-96d3-d7709131d790_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_eb706014-4e18-44f8-ac19-e3d5fbc164d4_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_f9f72247-3206-45dc-8306-d1103ff9b696_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zentera receivable</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_66ae4ed6-0996-433b-b345-9c3496627fd8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share outstanding, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_9f701ac1-2bfb-4d5a-a03b-0d360ee96e58_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_acc9799a-7752-4536-843c-8315e1ff6633_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9cc89aa0-c1ca-44a7-b509-e52ff4f0919f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_7a5cc3da-ad95-4c65-b5e7-0ad297e0644d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_93690505-b291-4532-b3fe-17e1d0414333_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_7cca2ad4-4488-4d1f-a0c3-5497931f726c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_57f626f2-d885-4dac-a176-e777aa3543cf_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_899a9965-efa9-42d5-b8d0-bc60add3ea66_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_92ed1393-861e-4da6-951f-68a9b5f7ab82_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_5a731c18-8914-421a-8a21-751346a9ddab_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of available-for-sale securities in unrealized loss position for more than one year</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3fca1acd-2018-44cf-84ab-287ca253dd57_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76d73ef7-2596-4b89-83a4-7bb9a0484deb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_16673928-5b47-4a51-be8c-93b52f87c5b4_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_cb56bc5c-cada-4093-8348-079256edfca2_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_27db2f91-b54c-4ab4-823b-7a0b673a0171_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_01119748-d2cd-463f-82d3-f95a0885178d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share outstanding, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_adcb63a8-08d2-4b6e-98ee-26c183918e0e_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e7001100-b626-4061-a393-6c0b02c96ab6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_086c363c-297c-4f7f-83e8-a1b73d675351_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9cfbc983-4b16-42ee-b7a8-64d2f038c0e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_e7e0060d-bf6c-4162-ad8c-7309c6a74026_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_08afeabd-e918-4be9-a8e4-bf28c4043715_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ed5619ec-e518-4b82-ab84-a68c447aa56d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Operating Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_40da0d0a-9193-4ecf-b051-ef03e7ad9134_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3a884edd-4f2a-4668-b3cd-2b313aadf7a2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a7defe68-0577-434b-aea5-fa0f820cf1d5_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_6a5529ea-bcdc-4f8b-8894-e96e2a3e4dae_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_a0969e3f-345c-40a2-abd6-4a8abf7738f4_terseLabel_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering period (in months)</link:label>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_label_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</link:label>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_documentation_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:href="zntl-20230331.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_0d157002-1609-4736-84fd-5e0fc479e310_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a5232507-d983-4345-b578-18812831cd2e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b90a34ae-0d52-4bfc-b388-720267e54e1c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_50a5b018-f20a-49da-acc7-dd756abd9b23_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_23d6b611-da10-45a2-b04f-53115ea96250_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_dabe4443-55fa-41ed-9729-c252e9ae93bd_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_130b056c-c9cd-4250-87fe-3664d23856ba_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_192e2ddf-86dc-4d49-bab4-1da906ec7fc0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EQUITY</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_fe68f580-39f1-45fb-b1d4-f54a4f4afe04_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_052bcb9c-0b73-44aa-bcde-dcbfe6216083_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized expense, stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9711b7ec-30ee-473b-b1e9-8cbbb581d3e7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_93d4a825-d3da-4d91-81a3-dad1bf435f7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized to be issued under plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_a280dfb9-b297-4923-94f5-a5187a209a13_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4b75aa6e-2f00-4626-9eaf-847837764fa2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP maximum percent of compensation to contribute</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_18a076d3-fc51-4cd8-86ec-9b7ffb619d18_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_be78ec35-6ce6-4ea0-8045-8f233753b49f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_66ec9808-0b16-44ea-a2df-592d03199201_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-option equity instruments, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_91398af6-0262-4b0f-87fb-b197b313a832_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for future grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_586b537c-3412-43c2-be33-e77f2e7aba14_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_fdb58209-4d08-42f0-9d8b-63c441911807_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_8a91848a-ba68-4ba6-9d97-90867a8c2f83_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_EarningsPerShareDenominatorAbstract_54bab591-3acf-449a-925b-f5246cce135b_terseLabel_en-US" xlink:label="lab_zntl_EarningsPerShareDenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_zntl_EarningsPerShareDenominatorAbstract_label_en-US" xlink:label="lab_zntl_EarningsPerShareDenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Denominator [Abstract]</link:label>
    <link:label id="lab_zntl_EarningsPerShareDenominatorAbstract_documentation_en-US" xlink:label="lab_zntl_EarningsPerShareDenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Denominator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_EarningsPerShareDenominatorAbstract" xlink:href="zntl-20230331.xsd#zntl_EarningsPerShareDenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_EarningsPerShareDenominatorAbstract" xlink:to="lab_zntl_EarningsPerShareDenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_47a6c438-d6d8-4856-9acc-46d794a048ef_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_435e7899-7f56-4040-8828-c82932072f60_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_b54f7e2d-2300-453d-91c5-9425c91eb4ef_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on deconsolidation of Zentera, net of tax</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_d906d3af-bd5f-4de5-9534-053ef1d6113f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_39458e73-a791-48ea-b1b8-7c762728aaf1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_e3ead0b4-95ea-4aa1-98c0-4dc6aaa281f3_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_MasterServicesAgreementMember_20e472ad-8cda-46e8-ab38-ae78507deeac_terseLabel_en-US" xlink:label="lab_zntl_MasterServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Master Services Agreement</link:label>
    <link:label id="lab_zntl_MasterServicesAgreementMember_label_en-US" xlink:label="lab_zntl_MasterServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Master Services Agreement [Member]</link:label>
    <link:label id="lab_zntl_MasterServicesAgreementMember_documentation_en-US" xlink:label="lab_zntl_MasterServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Master Services Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_MasterServicesAgreementMember" xlink:href="zntl-20230331.xsd#zntl_MasterServicesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_MasterServicesAgreementMember" xlink:to="lab_zntl_MasterServicesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_440ee575-2d6c-40ff-8e15-3c1224d3ab12_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_A2020IncentiveAwardPlanMember_82f285df-dd05-4ea5-afaa-6719e2cef322_terseLabel_en-US" xlink:label="lab_zntl_A2020IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2020 Plan</link:label>
    <link:label id="lab_zntl_A2020IncentiveAwardPlanMember_label_en-US" xlink:label="lab_zntl_A2020IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Incentive Award Plan [Member]</link:label>
    <link:label id="lab_zntl_A2020IncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_zntl_A2020IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Incentive Award Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_A2020IncentiveAwardPlanMember" xlink:href="zntl-20230331.xsd#zntl_A2020IncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_A2020IncentiveAwardPlanMember" xlink:to="lab_zntl_A2020IncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_8062f5c0-7230-4253-a6cd-fda817c381e8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_50d36457-90d6-4b5c-a7bf-eb2a7978f202_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4f50ce59-7e0d-4777-8822-61cbeb41cf73_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm_b041ca05-3e3d-444a-bc65-e7031446e68f_terseLabel_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generally expected vesting term of the option contract (in years)</link:label>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm_label_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Generally Expected Term</link:label>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm_documentation_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Generally Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm" xlink:href="zntl-20230331.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm" xlink:to="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_9e2e0430-23ff-4396-94e4-bdb067f5f297_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_963893b3-a4da-47d0-9a53-d1d5c378c3ee_netLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_09f4bb95-1b38-4c81-ab66-c67fafcadac5_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_16f42fcf-7196-4c17-b861-3ec001cdbe35_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_4dd358ec-54db-406a-a2de-a5be8a414c9e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_53fa0bd8-9d67-43f0-8b2e-d08975ac5ce6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b1426def-42fe-40fa-a392-ed263afdab4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_7d55294a-0fbe-4c6b-bcb8-5e0dd31fb58f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Disclosures</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_32143f49-7ccf-448f-90b4-f91802f0ef12_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments to acquire interest</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_710411be-0036-41a9-8ea2-c96ba48e2ed5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c86dc885-6a12-47d7-b58b-55c7a900b73d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7c30fb78-7e49-4a21-bfee-1b6eb879265f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_c6f8bfad-2fbc-4a3c-b4fd-686ed36273a2_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued legal expenses</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f9c3e274-19a9-468d-9cee-1bed0268d236_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_1625b88a-f3d8-4487-92c2-fcadb3377022_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_434863a1-8ec6-45ee-8e38-164053b42c8d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_98a1e24e-798e-4de2-bc3c-7b253d19942f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_de9d8ce1-a1e2-4084-92a6-f24085636cd2_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:to="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f376c2ce-f22e-4d59-b589-e788678d20d2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_9251cbbe-775d-402f-bfc7-09696e585547_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fc979437-8cad-43ea-8d10-e7c9149fff76_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_38a32e31-ea8d-48c1-a0e7-f449df11448d_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_5839c079-fb77-457b-b4d6-1d86bc723658_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease&#160;right-of-use&#160;assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4950810f-76c1-4e73-bb1c-003a382700bf_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease_25829f3f-3ea6-4104-b88b-ad2ab703a0bd_terseLabel_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of common stock outstanding used as threshold to calculate shares available for issuance</link:label>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease_label_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Shares Authorized, Percent Threshold Used To Calculate Increase</link:label>
    <link:label id="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease_documentation_en-US" xlink:label="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Shares Authorized, Percent Threshold Used To Calculate Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease" xlink:href="zntl-20230331.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease" xlink:to="lab_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_39f91c1f-e76d-4ee1-af55-8acc094f5aa9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Prepaid Expenses and Other Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_1c0d32a5-17db-4005-9806-a6a0d222a873_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_51ee8647-5d2d-4867-8347-4f2dd0a16d96_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_beb175d2-dbd3-4867-a99f-d563364a93fb_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less long-term portion</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_818a389e-4edc-45c5-92bf-521f7a2b7846_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Transactions</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_99cd02ea-333d-4dd8-bcb8-a589bbd0dff1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_9c93d479-7a4f-46e0-bcab-629e285cd94d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_d4cef3b2-0aeb-4467-a7d0-6b89db69ea27_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d44c7a7b-933e-45f3-a5ae-edbfcac2ae41_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1d0a765b-39e9-4f18-8d32-692450382d4a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_6482bccc-f860-43b8-b98c-a5fd6909fc46_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset and fixed asset impairment</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a2f6bd02-ef3d-405e-8c0d-d7edbdb55785_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_37379933-3fb6-454f-a0c1-2eaabda2e0ae_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_9ed3173e-9971-49dc-9bf2-f8076d3c2931_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2865ed0a-490d-412a-851b-bfce16cd3ef1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Basic and Diluted Net Loss Per Unit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7d680e45-69d5-4b34-9500-d34c52b4c589_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1e38f201-b781-447f-95c1-5d443912b52a_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_eacbfec1-4c8e-4647-8d1f-ce3e0a668f1b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_82ba116b-781f-4b9f-8631-28028d0f3ff1_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>zntl-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:b3a2bb04-db5e-4a01-a061-9002e22e0a2d,g:6cdaa420-7596-4787-9871-3e57ed815727-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.zentalis.com/role/Cover" xlink:type="simple" xlink:href="zntl-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_bd719ab8-1183-4772-804b-72f5a445d4ed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_DocumentType_bd719ab8-1183-4772-804b-72f5a445d4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_0fd95650-4ed0-4390-820d-38424c614955" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_DocumentQuarterlyReport_0fd95650-4ed0-4390-820d-38424c614955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_10637c91-92db-4970-9f3e-a173b12f1e65" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_DocumentPeriodEndDate_10637c91-92db-4970-9f3e-a173b12f1e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c1adfd69-7af2-4e59-8045-7c462d5bc8f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_DocumentTransitionReport_c1adfd69-7af2-4e59-8045-7c462d5bc8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4c5dce30-20fe-4f24-a2fb-75c4449a55de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_EntityFileNumber_4c5dce30-20fe-4f24-a2fb-75c4449a55de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_df13d0c1-d202-45b6-aec8-cff91c1db12c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_EntityRegistrantName_df13d0c1-d202-45b6-aec8-cff91c1db12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_98704cc1-228d-4a04-9a22-69690b3df8a5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_EntityIncorporationStateCountryCode_98704cc1-228d-4a04-9a22-69690b3df8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d8926417-6998-4dde-9106-aa699abbc59d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_EntityTaxIdentificationNumber_d8926417-6998-4dde-9106-aa699abbc59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_fd37ca7b-1608-4e96-9c07-58187db611ad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_EntityAddressAddressLine1_fd37ca7b-1608-4e96-9c07-58187db611ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_684c36c5-9941-418d-a5e4-d789aba8dfbf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_EntityAddressAddressLine2_684c36c5-9941-418d-a5e4-d789aba8dfbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_47cb9253-dfa5-4342-b729-0aaf73255d17" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_EntityAddressCityOrTown_47cb9253-dfa5-4342-b729-0aaf73255d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_aea86ee1-62ca-4c11-9f78-0731508c5599" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_EntityAddressStateOrProvince_aea86ee1-62ca-4c11-9f78-0731508c5599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_21681167-58e2-4465-a3be-59a03464d5eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_EntityAddressPostalZipCode_21681167-58e2-4465-a3be-59a03464d5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_bc42cd13-3066-46d3-897a-1d9f19659c87" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_CityAreaCode_bc42cd13-3066-46d3-897a-1d9f19659c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_eee8138b-18b5-4b80-9f61-6a428b234cf0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_LocalPhoneNumber_eee8138b-18b5-4b80-9f61-6a428b234cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_541f7c09-85a0-4625-b9ad-cafd0a34f3d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_Security12bTitle_541f7c09-85a0-4625-b9ad-cafd0a34f3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_406c666a-cdcf-4fde-85ae-51c44ed53201" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_TradingSymbol_406c666a-cdcf-4fde-85ae-51c44ed53201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e83e714c-edbc-4e30-932e-d44f591bfc29" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_SecurityExchangeName_e83e714c-edbc-4e30-932e-d44f591bfc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ec91e7b9-29d5-4fa2-95b1-1772cd456e6a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_EntityCurrentReportingStatus_ec91e7b9-29d5-4fa2-95b1-1772cd456e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_eb7729d5-fe4f-4f35-8ea6-4cea6c302357" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_EntityInteractiveDataCurrent_eb7729d5-fe4f-4f35-8ea6-4cea6c302357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_286554c4-1cf7-4d10-8628-4ef5afccb265" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_EntityFilerCategory_286554c4-1cf7-4d10-8628-4ef5afccb265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9e60cd29-3086-4be2-a61d-7602750788e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_EntitySmallBusiness_9e60cd29-3086-4be2-a61d-7602750788e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_584e8bea-b083-4ba4-9843-ca2fe32008fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_EntityEmergingGrowthCompany_584e8bea-b083-4ba4-9843-ca2fe32008fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_511444de-d246-4432-ad30-0cf17a14e69c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_EntityShellCompany_511444de-d246-4432-ad30-0cf17a14e69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_bd56ce4e-df41-4dc2-b32e-9e7917ba4c20" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_bd56ce4e-df41-4dc2-b32e-9e7917ba4c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_26dca8b6-8a24-443c-9b17-002a293aca85" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_EntityCentralIndexKey_26dca8b6-8a24-443c-9b17-002a293aca85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2852fdb3-b1ad-4671-af5d-ef6ef69934df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_AmendmentFlag_2852fdb3-b1ad-4671-af5d-ef6ef69934df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_2b03d137-9c40-4ca8-82e2-cc2ee9217de6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_DocumentFiscalPeriodFocus_2b03d137-9c40-4ca8-82e2-cc2ee9217de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5ee31afb-fd63-4b96-83cc-e71411574c38" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_CurrentFiscalYearEndDate_5ee31afb-fd63-4b96-83cc-e71411574c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b4c90597-5b74-4e8a-9846-419e401cbe25" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6658daf2-a4a7-4510-9dff-376ea11e3478" xlink:to="loc_dei_DocumentFiscalYearFocus_b4c90597-5b74-4e8a-9846-419e401cbe25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="zntl-20230331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d9ef69e5-5bc9-4ca9-9469-0a36dd4aec51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_507ce815-623a-4593-a388-d59875bb61be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d9ef69e5-5bc9-4ca9-9469-0a36dd4aec51" xlink:to="loc_us-gaap_AssetsAbstract_507ce815-623a-4593-a388-d59875bb61be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3d14e4d2-0e91-41a6-acfd-bb7dbae8cbd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_507ce815-623a-4593-a388-d59875bb61be" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3d14e4d2-0e91-41a6-acfd-bb7dbae8cbd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e94406e3-4198-4d4c-bfba-bc58d7d8e67b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3d14e4d2-0e91-41a6-acfd-bb7dbae8cbd9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e94406e3-4198-4d4c-bfba-bc58d7d8e67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_22dd60bc-b15d-4b57-80b2-e1998e75ddbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3d14e4d2-0e91-41a6-acfd-bb7dbae8cbd9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_22dd60bc-b15d-4b57-80b2-e1998e75ddbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a62121f8-f89d-4f34-89bc-50422729ad1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3d14e4d2-0e91-41a6-acfd-bb7dbae8cbd9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a62121f8-f89d-4f34-89bc-50422729ad1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_668f750b-1e28-4b8a-b952-cbf28fdc5398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3d14e4d2-0e91-41a6-acfd-bb7dbae8cbd9" xlink:to="loc_us-gaap_AssetsCurrent_668f750b-1e28-4b8a-b952-cbf28fdc5398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_553db584-a45c-4fa2-a81b-c3ca1734b89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_507ce815-623a-4593-a388-d59875bb61be" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_553db584-a45c-4fa2-a81b-c3ca1734b89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_76c4e922-07e1-45b3-a9c5-0cfb4aaf6a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_507ce815-623a-4593-a388-d59875bb61be" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_76c4e922-07e1-45b3-a9c5-0cfb4aaf6a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_5333f067-ae20-4851-ad56-c85c0ddd953c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_507ce815-623a-4593-a388-d59875bb61be" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_5333f067-ae20-4851-ad56-c85c0ddd953c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8aa6093a-f4f9-45b6-9155-ef68f9eab70a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_507ce815-623a-4593-a388-d59875bb61be" xlink:to="loc_us-gaap_Goodwill_8aa6093a-f4f9-45b6-9155-ef68f9eab70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_05093f96-9623-4d37-862a-8e65def41024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_507ce815-623a-4593-a388-d59875bb61be" xlink:to="loc_us-gaap_EquityMethodInvestments_05093f96-9623-4d37-862a-8e65def41024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_a50d94b0-ac9e-4aba-8371-b1f38403368e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_507ce815-623a-4593-a388-d59875bb61be" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_a50d94b0-ac9e-4aba-8371-b1f38403368e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3aa641e2-fd8e-4757-8d43-e153205e1830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_507ce815-623a-4593-a388-d59875bb61be" xlink:to="loc_us-gaap_Assets_3aa641e2-fd8e-4757-8d43-e153205e1830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1ca2c59-1fd5-421e-9416-9f58c963d067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d9ef69e5-5bc9-4ca9-9469-0a36dd4aec51" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1ca2c59-1fd5-421e-9416-9f58c963d067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d6be329f-a78d-4d3b-997b-3ea3ad3a04e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1ca2c59-1fd5-421e-9416-9f58c963d067" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d6be329f-a78d-4d3b-997b-3ea3ad3a04e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_68b24f14-ae02-4924-90cc-dfc19f774e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d6be329f-a78d-4d3b-997b-3ea3ad3a04e1" xlink:to="loc_us-gaap_AccountsPayableCurrent_68b24f14-ae02-4924-90cc-dfc19f774e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1c46f269-281b-4bf3-8332-39ddaab4b592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d6be329f-a78d-4d3b-997b-3ea3ad3a04e1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1c46f269-281b-4bf3-8332-39ddaab4b592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_32ab37ba-9180-4792-afe3-ab9beaa1764c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d6be329f-a78d-4d3b-997b-3ea3ad3a04e1" xlink:to="loc_us-gaap_LiabilitiesCurrent_32ab37ba-9180-4792-afe3-ab9beaa1764c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e1d8899a-4714-42d8-9aad-6573610d9b94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1ca2c59-1fd5-421e-9416-9f58c963d067" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e1d8899a-4714-42d8-9aad-6573610d9b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cba83844-c4f3-4c5b-9b81-b5f76146e687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1ca2c59-1fd5-421e-9416-9f58c963d067" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cba83844-c4f3-4c5b-9b81-b5f76146e687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3d78185d-1508-4a43-a609-4ba74a91939b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1ca2c59-1fd5-421e-9416-9f58c963d067" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3d78185d-1508-4a43-a609-4ba74a91939b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_399491d6-99b3-4e26-ba31-fc5fb4f82203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1ca2c59-1fd5-421e-9416-9f58c963d067" xlink:to="loc_us-gaap_Liabilities_399491d6-99b3-4e26-ba31-fc5fb4f82203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ed99cb57-a487-4925-8f7c-bea82e0d988e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1ca2c59-1fd5-421e-9416-9f58c963d067" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ed99cb57-a487-4925-8f7c-bea82e0d988e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a6af2797-6326-4f91-8fef-818a0134cadd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1ca2c59-1fd5-421e-9416-9f58c963d067" xlink:to="loc_us-gaap_EquityAbstract_a6af2797-6326-4f91-8fef-818a0134cadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5d6d5c72-51b5-4730-ae15-411bf8cba75b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a6af2797-6326-4f91-8fef-818a0134cadd" xlink:to="loc_us-gaap_PreferredStockValue_5d6d5c72-51b5-4730-ae15-411bf8cba75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_727751cd-545c-4664-9b11-97e1164a5cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a6af2797-6326-4f91-8fef-818a0134cadd" xlink:to="loc_us-gaap_CommonStockValue_727751cd-545c-4664-9b11-97e1164a5cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6536d333-2150-4341-a23f-817a7b5e6582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a6af2797-6326-4f91-8fef-818a0134cadd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6536d333-2150-4341-a23f-817a7b5e6582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2f8b2764-dfc5-4031-a524-6e144b406826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a6af2797-6326-4f91-8fef-818a0134cadd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2f8b2764-dfc5-4031-a524-6e144b406826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9aa6eb80-e647-476d-90fa-e85da9ed9ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a6af2797-6326-4f91-8fef-818a0134cadd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9aa6eb80-e647-476d-90fa-e85da9ed9ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4ad45fc3-780b-46da-b7ad-33118278e26c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a6af2797-6326-4f91-8fef-818a0134cadd" xlink:to="loc_us-gaap_StockholdersEquity_4ad45fc3-780b-46da-b7ad-33118278e26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_af69c920-741a-4155-8890-f3bb27302985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a6af2797-6326-4f91-8fef-818a0134cadd" xlink:to="loc_us-gaap_MinorityInterest_af69c920-741a-4155-8890-f3bb27302985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5f7cdcbe-76e6-4491-868b-87de0bd1860f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a6af2797-6326-4f91-8fef-818a0134cadd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5f7cdcbe-76e6-4491-868b-87de0bd1860f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_88eae696-e953-4a7f-af52-b267dc8020d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1ca2c59-1fd5-421e-9416-9f58c963d067" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_88eae696-e953-4a7f-af52-b267dc8020d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="zntl-20230331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_29b8b0b3-0617-44be-97d7-c8762b018977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6aa56b62-f706-479f-94a5-355c68a2045d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29b8b0b3-0617-44be-97d7-c8762b018977" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6aa56b62-f706-479f-94a5-355c68a2045d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a9811011-8103-409b-9563-7fc8ccb218c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29b8b0b3-0617-44be-97d7-c8762b018977" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a9811011-8103-409b-9563-7fc8ccb218c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_56b3078d-5c9e-4db3-9efe-3320ced6bff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29b8b0b3-0617-44be-97d7-c8762b018977" xlink:to="loc_us-gaap_PreferredStockSharesIssued_56b3078d-5c9e-4db3-9efe-3320ced6bff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_a84c13d8-1701-42bc-9f61-292d1070ce6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29b8b0b3-0617-44be-97d7-c8762b018977" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_a84c13d8-1701-42bc-9f61-292d1070ce6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_82f46012-569f-482d-a944-fa5ba9370a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29b8b0b3-0617-44be-97d7-c8762b018977" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_82f46012-569f-482d-a944-fa5ba9370a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2064c131-2e3a-4ff3-b458-034744cc0a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29b8b0b3-0617-44be-97d7-c8762b018977" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2064c131-2e3a-4ff3-b458-034744cc0a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_16db0880-f56c-4c8d-a8de-f1c8062b3569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29b8b0b3-0617-44be-97d7-c8762b018977" xlink:to="loc_us-gaap_CommonStockSharesIssued_16db0880-f56c-4c8d-a8de-f1c8062b3569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b66836a5-bc13-4e7d-a8cd-ff09798c9673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29b8b0b3-0617-44be-97d7-c8762b018977" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b66836a5-bc13-4e7d-a8cd-ff09798c9673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="zntl-20230331.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_1168ff1f-4c68-4b10-aaf7-2a2d461c9827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_549b3eeb-fc39-4f27-892d-a490f18f048d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1168ff1f-4c68-4b10-aaf7-2a2d461c9827" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_549b3eeb-fc39-4f27-892d-a490f18f048d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_dd3829e6-0139-492a-934d-4f98deb30778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_549b3eeb-fc39-4f27-892d-a490f18f048d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_dd3829e6-0139-492a-934d-4f98deb30778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8d1a5bf2-02fa-4c92-828b-9f747ab8eb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_549b3eeb-fc39-4f27-892d-a490f18f048d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8d1a5bf2-02fa-4c92-828b-9f747ab8eb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d36d589e-d3b7-4cda-ad56-8a0e96118db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_549b3eeb-fc39-4f27-892d-a490f18f048d" xlink:to="loc_us-gaap_OperatingExpenses_d36d589e-d3b7-4cda-ad56-8a0e96118db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_55f1152e-880b-49af-b618-82b3cae9d44a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1168ff1f-4c68-4b10-aaf7-2a2d461c9827" xlink:to="loc_us-gaap_OperatingIncomeLoss_55f1152e-880b-49af-b618-82b3cae9d44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_62f863e5-0df5-4ab9-abbb-b9f7aeb88097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1168ff1f-4c68-4b10-aaf7-2a2d461c9827" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_62f863e5-0df5-4ab9-abbb-b9f7aeb88097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_InvestmentAndOtherIncomeExpense_1c62edc8-41b1-46fb-a3b0-76119dbedd23" xlink:href="zntl-20230331.xsd#zntl_InvestmentAndOtherIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_62f863e5-0df5-4ab9-abbb-b9f7aeb88097" xlink:to="loc_zntl_InvestmentAndOtherIncomeExpense_1c62edc8-41b1-46fb-a3b0-76119dbedd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_69aa7183-3b04-4007-ba7f-aed77e993a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1168ff1f-4c68-4b10-aaf7-2a2d461c9827" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_69aa7183-3b04-4007-ba7f-aed77e993a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c3a51119-79a4-4171-8543-f939bcfac238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1168ff1f-4c68-4b10-aaf7-2a2d461c9827" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c3a51119-79a4-4171-8543-f939bcfac238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4ea2b94f-36fe-4d17-be27-eb1525c6a236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1168ff1f-4c68-4b10-aaf7-2a2d461c9827" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4ea2b94f-36fe-4d17-be27-eb1525c6a236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_676f34af-d6e8-4adc-9f04-9e756888b45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1168ff1f-4c68-4b10-aaf7-2a2d461c9827" xlink:to="loc_us-gaap_ProfitLoss_676f34af-d6e8-4adc-9f04-9e756888b45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6902a7b5-4db6-4291-802d-a3a99ab0a741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1168ff1f-4c68-4b10-aaf7-2a2d461c9827" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6902a7b5-4db6-4291-802d-a3a99ab0a741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9ba44ca7-02ac-4345-b2d7-a4a73b09ad7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1168ff1f-4c68-4b10-aaf7-2a2d461c9827" xlink:to="loc_us-gaap_NetIncomeLoss_9ba44ca7-02ac-4345-b2d7-a4a73b09ad7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e48bdf2a-6a08-4757-a6a9-84459670a4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1168ff1f-4c68-4b10-aaf7-2a2d461c9827" xlink:to="loc_us-gaap_EarningsPerShareBasic_e48bdf2a-6a08-4757-a6a9-84459670a4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_24cb7869-c211-4006-a95b-e568b583b1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1168ff1f-4c68-4b10-aaf7-2a2d461c9827" xlink:to="loc_us-gaap_EarningsPerShareDiluted_24cb7869-c211-4006-a95b-e568b583b1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d7c9b33f-aa4c-4a95-ae1d-faaf9fa20a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1168ff1f-4c68-4b10-aaf7-2a2d461c9827" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d7c9b33f-aa4c-4a95-ae1d-faaf9fa20a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6fdf7dcc-53a9-4ee0-91d4-0c0f3006d6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1168ff1f-4c68-4b10-aaf7-2a2d461c9827" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6fdf7dcc-53a9-4ee0-91d4-0c0f3006d6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="zntl-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d43e79dd-30df-4ade-b1c5-883e7a63e18b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_343f7598-f42d-4f8d-b410-a8686a1310e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d43e79dd-30df-4ade-b1c5-883e7a63e18b" xlink:to="loc_us-gaap_ProfitLoss_343f7598-f42d-4f8d-b410-a8686a1310e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4dc198a9-bc18-46be-a9a5-32574fd58673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d43e79dd-30df-4ade-b1c5-883e7a63e18b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4dc198a9-bc18-46be-a9a5-32574fd58673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ddc8c74e-433c-4cb2-b0e4-5654d3df84ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4dc198a9-bc18-46be-a9a5-32574fd58673" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ddc8c74e-433c-4cb2-b0e4-5654d3df84ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5f7f062d-b93e-495a-ab8e-9940c6843814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d43e79dd-30df-4ade-b1c5-883e7a63e18b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5f7f062d-b93e-495a-ab8e-9940c6843814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2625d4b3-848a-473f-a8b0-5c07f1f9ddef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d43e79dd-30df-4ade-b1c5-883e7a63e18b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2625d4b3-848a-473f-a8b0-5c07f1f9ddef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3c0401c5-aee6-4a49-97a2-aca3edcd0749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d43e79dd-30df-4ade-b1c5-883e7a63e18b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_3c0401c5-aee6-4a49-97a2-aca3edcd0749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="zntl-20230331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_5b722d51-5660-447b-894a-390b6d54353a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8781175b-86bb-4da3-a092-721a527aac18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5b722d51-5660-447b-894a-390b6d54353a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8781175b-86bb-4da3-a092-721a527aac18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b8dbc182-99de-450f-9a9b-4f30f100212c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8781175b-86bb-4da3-a092-721a527aac18" xlink:to="loc_us-gaap_ProfitLoss_b8dbc182-99de-450f-9a9b-4f30f100212c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1ff026bd-6e02-4fdc-b0d8-81173d341d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8781175b-86bb-4da3-a092-721a527aac18" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1ff026bd-6e02-4fdc-b0d8-81173d341d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6bb17a34-eb80-4746-9255-9dba97811b88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1ff026bd-6e02-4fdc-b0d8-81173d341d5e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6bb17a34-eb80-4746-9255-9dba97811b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_6b389d65-a245-4d3f-9c11-63ff178976cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1ff026bd-6e02-4fdc-b0d8-81173d341d5e" xlink:to="loc_us-gaap_AssetImpairmentCharges_6b389d65-a245-4d3f-9c11-63ff178976cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_96220e32-4957-4c21-bfbd-b969458905b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1ff026bd-6e02-4fdc-b0d8-81173d341d5e" xlink:to="loc_us-gaap_ShareBasedCompensation_96220e32-4957-4c21-bfbd-b969458905b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1766c9f3-0800-4efe-979a-4fc1b2b20d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1ff026bd-6e02-4fdc-b0d8-81173d341d5e" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1766c9f3-0800-4efe-979a-4fc1b2b20d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_54f1305f-f98b-4da2-bf41-28046bab3079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1ff026bd-6e02-4fdc-b0d8-81173d341d5e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_54f1305f-f98b-4da2-bf41-28046bab3079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_b57eb228-042b-4864-81f5-c17bff36b420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1ff026bd-6e02-4fdc-b0d8-81173d341d5e" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_b57eb228-042b-4864-81f5-c17bff36b420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_485cb225-93f1-4b4a-b740-cbbe43b948f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1ff026bd-6e02-4fdc-b0d8-81173d341d5e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_485cb225-93f1-4b4a-b740-cbbe43b948f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c6f7a84d-48a1-4493-8c8f-2dfa9a9525c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_485cb225-93f1-4b4a-b740-cbbe43b948f3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c6f7a84d-48a1-4493-8c8f-2dfa9a9525c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0bdbc380-6e64-4cf7-9103-4205fabddf59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_485cb225-93f1-4b4a-b740-cbbe43b948f3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0bdbc380-6e64-4cf7-9103-4205fabddf59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_ff08ac95-f720-4de2-ae1a-9cebcd6f47be" xlink:href="zntl-20230331.xsd#zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_485cb225-93f1-4b4a-b740-cbbe43b948f3" xlink:to="loc_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_ff08ac95-f720-4de2-ae1a-9cebcd6f47be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d40c8256-2d19-43b9-87f9-e995e5d5c102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8781175b-86bb-4da3-a092-721a527aac18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d40c8256-2d19-43b9-87f9-e995e5d5c102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00596b2f-a20f-4986-906d-1da9f199731c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5b722d51-5660-447b-894a-390b6d54353a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00596b2f-a20f-4986-906d-1da9f199731c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_161b3463-7fb3-48bd-945f-9a2bb7a89780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00596b2f-a20f-4986-906d-1da9f199731c" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_161b3463-7fb3-48bd-945f-9a2bb7a89780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_00596fb2-dd87-46c0-afee-24c10de8ec27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00596b2f-a20f-4986-906d-1da9f199731c" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_00596fb2-dd87-46c0-afee-24c10de8ec27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_84c74dd4-8998-4695-a39a-5105a80dfb72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00596b2f-a20f-4986-906d-1da9f199731c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_84c74dd4-8998-4695-a39a-5105a80dfb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dfc9e6f4-e6b6-45ae-a780-f6eb0cb48cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00596b2f-a20f-4986-906d-1da9f199731c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dfc9e6f4-e6b6-45ae-a780-f6eb0cb48cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ae7abcd-a9aa-47c2-8dad-2467695e8b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5b722d51-5660-447b-894a-390b6d54353a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ae7abcd-a9aa-47c2-8dad-2467695e8b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_89ab6c17-225a-488c-9bbc-9add6fe461cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ae7abcd-a9aa-47c2-8dad-2467695e8b5f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_89ab6c17-225a-488c-9bbc-9add6fe461cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_02f5ed63-47a3-48b0-a72d-a18c8989be2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ae7abcd-a9aa-47c2-8dad-2467695e8b5f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_02f5ed63-47a3-48b0-a72d-a18c8989be2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f850e3b6-9d07-4efb-959b-4507429ccf17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5b722d51-5660-447b-894a-390b6d54353a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f850e3b6-9d07-4efb-959b-4507429ccf17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9a86a658-c3c6-426d-a5ab-ed7c4f5629c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5b722d51-5660-447b-894a-390b6d54353a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9a86a658-c3c6-426d-a5ab-ed7c4f5629c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b8d6aa4-2f57-410d-83e7-9e898ebe77d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5b722d51-5660-447b-894a-390b6d54353a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b8d6aa4-2f57-410d-83e7-9e898ebe77d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_130b320d-8eb0-464a-8720-3d37389bcd98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5b722d51-5660-447b-894a-390b6d54353a" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_130b320d-8eb0-464a-8720-3d37389bcd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_770c5d4f-aed4-4064-90d4-c0292734f23a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_130b320d-8eb0-464a-8720-3d37389bcd98" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_770c5d4f-aed4-4064-90d4-c0292734f23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_8ebc21c9-109d-449f-870e-7e81427ac22f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5b722d51-5660-447b-894a-390b6d54353a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_8ebc21c9-109d-449f-870e-7e81427ac22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2e63c960-1b8b-43ef-9240-a92869205d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_8ebc21c9-109d-449f-870e-7e81427ac22f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2e63c960-1b8b-43ef-9240-a92869205d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_ceef78ed-3b15-4eb5-867f-6e9f7b35397d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_8ebc21c9-109d-449f-870e-7e81427ac22f" xlink:to="loc_us-gaap_RestrictedCash_ceef78ed-3b15-4eb5-867f-6e9f7b35397d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_03a179b5-186e-4a72-beaa-f707f0f6bd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_8ebc21c9-109d-449f-870e-7e81427ac22f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_03a179b5-186e-4a72-beaa-f707f0f6bd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="zntl-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_59354b3b-d880-4758-8c8f-f208c048ff41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8e143ec9-91ca-4a62-8729-90f8c83f3a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_59354b3b-d880-4758-8c8f-f208c048ff41" xlink:to="loc_us-gaap_StatementTable_8e143ec9-91ca-4a62-8729-90f8c83f3a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_793c57ea-3034-4cc2-a3dc-46dab28535b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8e143ec9-91ca-4a62-8729-90f8c83f3a2f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_793c57ea-3034-4cc2-a3dc-46dab28535b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ffcb1d07-15ca-44bc-a0f9-273e24a45732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_793c57ea-3034-4cc2-a3dc-46dab28535b4" xlink:to="loc_us-gaap_EquityComponentDomain_ffcb1d07-15ca-44bc-a0f9-273e24a45732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d099f45b-0f96-4595-8344-c423b7bf0156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ffcb1d07-15ca-44bc-a0f9-273e24a45732" xlink:to="loc_us-gaap_CommonStockMember_d099f45b-0f96-4595-8344-c423b7bf0156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_10483be7-737f-4c27-a5fa-32d019155b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ffcb1d07-15ca-44bc-a0f9-273e24a45732" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_10483be7-737f-4c27-a5fa-32d019155b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f5794414-4bc7-4da1-be31-e0047a167692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ffcb1d07-15ca-44bc-a0f9-273e24a45732" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f5794414-4bc7-4da1-be31-e0047a167692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0e3a676c-e5d2-4dac-b2a9-21f458910190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ffcb1d07-15ca-44bc-a0f9-273e24a45732" xlink:to="loc_us-gaap_RetainedEarningsMember_0e3a676c-e5d2-4dac-b2a9-21f458910190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_b649edc1-172d-461e-ae25-f5ce72209b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ffcb1d07-15ca-44bc-a0f9-273e24a45732" xlink:to="loc_us-gaap_NoncontrollingInterestMember_b649edc1-172d-461e-ae25-f5ce72209b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6d3feb4a-33b6-4025-8d11-495c7d490596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8e143ec9-91ca-4a62-8729-90f8c83f3a2f" xlink:to="loc_us-gaap_StatementLineItems_6d3feb4a-33b6-4025-8d11-495c7d490596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6d3feb4a-33b6-4025-8d11-495c7d490596" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_2c5d5f8f-6823-4c90-a346-077cc0f4a537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_SharesOutstanding_2c5d5f8f-6823-4c90-a346-077cc0f4a537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2d7cc313-be17-42b0-be42-69976bfbf50e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2d7cc313-be17-42b0-be42-69976bfbf50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_999afa73-f957-4460-a1d8-45f695348599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_999afa73-f957-4460-a1d8-45f695348599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6e58a92a-8f84-4e1f-8967-647c0b95bb86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6e58a92a-8f84-4e1f-8967-647c0b95bb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_9a4fa768-ca7b-4c8d-b7d1-f123f37bc2df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_9a4fa768-ca7b-4c8d-b7d1-f123f37bc2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_55d9b100-f054-4c7e-b4a0-ff3f68166791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_55d9b100-f054-4c7e-b4a0-ff3f68166791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e346be1d-002b-4457-aa85-6f11ded095cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e346be1d-002b-4457-aa85-6f11ded095cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e79539ee-c518-4b87-aec8-2a2fd62d18a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e79539ee-c518-4b87-aec8-2a2fd62d18a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_930732d4-d93d-4982-99d7-3287edeaaa41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_930732d4-d93d-4982-99d7-3287edeaaa41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a07cd9d5-cce2-4ac4-b9e2-00807ac9aa3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a07cd9d5-cce2-4ac4-b9e2-00807ac9aa3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_ca1a0b9f-807d-4a35-8ebc-3d83d6e6d295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_ca1a0b9f-807d-4a35-8ebc-3d83d6e6d295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b9dfc7b4-d8f9-405c-8370-77e0d5b3c8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b9dfc7b4-d8f9-405c-8370-77e0d5b3c8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e32fc483-e0d4-4e08-9eec-df380c8929af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_NetIncomeLoss_e32fc483-e0d4-4e08-9eec-df380c8929af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_98925dac-3157-4d29-ac56-889e9d210949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_SharesOutstanding_98925dac-3157-4d29-ac56-889e9d210949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_63a23270-d052-491b-9dc6-436461754977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64e565c-ad1d-4d9a-bcea-633d04975412" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_63a23270-d052-491b-9dc6-436461754977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/OrganizationandBusiness" xlink:type="simple" xlink:href="zntl-20230331.xsd#OrganizationandBusiness"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/OrganizationandBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_11826442-9434-4595-9e9f-016ce87616b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_971135d5-d683-405b-b13b-3520fc6b4cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_11826442-9434-4595-9e9f-016ce87616b4" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_971135d5-d683-405b-b13b-3520fc6b4cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/InterimUnauditedFinancialStatements" xlink:type="simple" xlink:href="zntl-20230331.xsd#InterimUnauditedFinancialStatements"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/InterimUnauditedFinancialStatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_446114ef-50cb-4597-8d64-362e3ce59c78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3f85b40a-30ae-4ea8-8480-2a90ee42a868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_446114ef-50cb-4597-8d64-362e3ce59c78" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3f85b40a-30ae-4ea8-8480-2a90ee42a868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/SignificantTransactions" xlink:type="simple" xlink:href="zntl-20230331.xsd#SignificantTransactions"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/SignificantTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_12621348-7fb1-4286-a667-80187b3a4a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_667b8d05-4356-4c0b-997c-aa4759c8c625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_12621348-7fb1-4286-a667-80187b3a4a58" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_667b8d05-4356-4c0b-997c-aa4759c8c625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/BusinessCombinations" xlink:type="simple" xlink:href="zntl-20230331.xsd#BusinessCombinations"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/BusinessCombinations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ed3aa1af-b5eb-4779-96bc-91fc75957de5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_f94a6c0e-4f7c-4940-ba2e-bdebebbb997a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ed3aa1af-b5eb-4779-96bc-91fc75957de5" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_f94a6c0e-4f7c-4940-ba2e-bdebebbb997a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="zntl-20230331.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b06f908e-f848-485e-8500-ee79d95764d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ae952eed-d552-4d8f-aa22-822a4e2bfbee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b06f908e-f848-485e-8500-ee79d95764d3" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_ae952eed-d552-4d8f-aa22-822a4e2bfbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/PrepaidExpensesandOtherAssets" xlink:type="simple" xlink:href="zntl-20230331.xsd#PrepaidExpensesandOtherAssets"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/PrepaidExpensesandOtherAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_a9033464-6521-42c7-8198-f04a9fb1ee66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock_e969d6e2-106e-48c1-8a66-64d6d4e724a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_a9033464-6521-42c7-8198-f04a9fb1ee66" xlink:to="loc_us-gaap_OtherAssetsDisclosureTextBlock_e969d6e2-106e-48c1-8a66-64d6d4e724a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/PropertyandEquipmentnet" xlink:type="simple" xlink:href="zntl-20230331.xsd#PropertyandEquipmentnet"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/PropertyandEquipmentnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_679fbc75-a9ed-4a69-9658-ed0fd826a038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_40a01e7d-1b1b-49a6-bfce-a73f8f77a572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_679fbc75-a9ed-4a69-9658-ed0fd826a038" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_40a01e7d-1b1b-49a6-bfce-a73f8f77a572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/AccruedExpenses" xlink:type="simple" xlink:href="zntl-20230331.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0952bf62-801d-4855-a79c-cd057df8ab1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_453e1fa5-7ca5-492c-aeb2-42d11c37660e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0952bf62-801d-4855-a79c-cd057df8ab1a" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_453e1fa5-7ca5-492c-aeb2-42d11c37660e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquity" xlink:type="simple" xlink:href="zntl-20230331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5b51ad4b-495a-4b5a-95b4-08558d5d60b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8086299c-2b63-432a-bcae-91a79348b320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5b51ad4b-495a-4b5a-95b4-08558d5d60b0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8086299c-2b63-432a-bcae-91a79348b320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="zntl-20230331.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_62b9e5a3-1ee9-4a24-8e30-4602d31f797a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a35932d5-4628-41a8-80fe-b56dfc435c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_62b9e5a3-1ee9-4a24-8e30-4602d31f797a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a35932d5-4628-41a8-80fe-b56dfc435c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/NetLossPerCommonShare" xlink:type="simple" xlink:href="zntl-20230331.xsd#NetLossPerCommonShare"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/NetLossPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7e924eae-6f95-4b50-8cc1-c5f74b197498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_f618dac9-9faa-4e6e-a6b6-264297a44be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7e924eae-6f95-4b50-8cc1-c5f74b197498" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_f618dac9-9faa-4e6e-a6b6-264297a44be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/RelatedPartyDisclosures" xlink:type="simple" xlink:href="zntl-20230331.xsd#RelatedPartyDisclosures"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/RelatedPartyDisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_dcb6d535-b8bf-4652-a72d-423a6c384b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_56810b60-f898-47ab-a691-28b800c5bc73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_dcb6d535-b8bf-4652-a72d-423a6c384b96" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_56810b60-f898-47ab-a691-28b800c5bc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies" xlink:type="simple" xlink:href="zntl-20230331.xsd#InterimUnauditedFinancialStatementsPolicies"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_69b322e5-6069-409e-a64c-6a3c4b7a13df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d671d436-0461-48eb-ad5e-9c40380ef2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69b322e5-6069-409e-a64c-6a3c4b7a13df" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d671d436-0461-48eb-ad5e-9c40380ef2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_acfaea67-69dc-4e41-896a-fffccfc5ce0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69b322e5-6069-409e-a64c-6a3c4b7a13df" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_acfaea67-69dc-4e41-896a-fffccfc5ce0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_0409e4e2-35ac-4da6-b552-322b853cf81d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69b322e5-6069-409e-a64c-6a3c4b7a13df" xlink:to="loc_us-gaap_UseOfEstimates_0409e4e2-35ac-4da6-b552-322b853cf81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="zntl-20230331.xsd#BusinessCombinationsTables"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/BusinessCombinationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_18a872a2-8c88-484f-bbb9-3e173015faf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock_13aed276-41c8-487e-a79b-cbe0f75b3f54" xlink:href="zntl-20230331.xsd#zntl_ReconciliationOfNoncontrollingInterestTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_18a872a2-8c88-484f-bbb9-3e173015faf3" xlink:to="loc_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock_13aed276-41c8-487e-a79b-cbe0f75b3f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="zntl-20230331.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0df4739d-c543-48a6-aa85-d7129f6fce1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_875d457a-fcf0-4fc0-b5de-bbe45492620f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0df4739d-c543-48a6-aa85-d7129f6fce1b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_875d457a-fcf0-4fc0-b5de-bbe45492620f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_086fb88a-892b-4e03-9ce6-53b83f766b02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0df4739d-c543-48a6-aa85-d7129f6fce1b" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_086fb88a-892b-4e03-9ce6-53b83f766b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_eea5b957-9788-499f-8a0b-c8f6b8d7d9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0df4739d-c543-48a6-aa85-d7129f6fce1b" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_eea5b957-9788-499f-8a0b-c8f6b8d7d9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsTables" xlink:type="simple" xlink:href="zntl-20230331.xsd#PrepaidExpensesandOtherAssetsTables"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_a1e34c4c-fc5c-4eff-a400-79625ad2b290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_ddabbba7-8402-49bc-98c1-a1a9be43282a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_a1e34c4c-fc5c-4eff-a400-79625ad2b290" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_ddabbba7-8402-49bc-98c1-a1a9be43282a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/PropertyandEquipmentnetTables" xlink:type="simple" xlink:href="zntl-20230331.xsd#PropertyandEquipmentnetTables"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/PropertyandEquipmentnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_23e20fcf-5e0e-40bf-9573-359a13e1dfca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b495eabe-5698-4143-a41b-763bd055df82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_23e20fcf-5e0e-40bf-9573-359a13e1dfca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b495eabe-5698-4143-a41b-763bd055df82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="zntl-20230331.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_7f3ecc86-f5cb-40e1-922d-74937202a6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_420e48f3-adb4-4d75-b0e4-2f6ff7398e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7f3ecc86-f5cb-40e1-922d-74937202a6a5" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_420e48f3-adb4-4d75-b0e4-2f6ff7398e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="zntl-20230331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7ee2ab75-1997-45bd-94eb-bdc76e597dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_277d6e13-4d39-40c1-8ebc-115703e624ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7ee2ab75-1997-45bd-94eb-bdc76e597dcd" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_277d6e13-4d39-40c1-8ebc-115703e624ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_34e6ac10-948a-4b71-a1d0-cd24c376a20e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7ee2ab75-1997-45bd-94eb-bdc76e597dcd" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_34e6ac10-948a-4b71-a1d0-cd24c376a20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_ed6f2771-8bc2-4521-95a5-73e1febc6d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7ee2ab75-1997-45bd-94eb-bdc76e597dcd" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_ed6f2771-8bc2-4521-95a5-73e1febc6d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_6c94783b-b609-423f-ad72-9c7c0ece154c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7ee2ab75-1997-45bd-94eb-bdc76e597dcd" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_6c94783b-b609-423f-ad72-9c7c0ece154c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CommitmentandContingenciesTables" xlink:type="simple" xlink:href="zntl-20230331.xsd#CommitmentandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/CommitmentandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d7bf1855-dcf8-4bd8-b0eb-bd27e4b4de8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_89913b66-4c68-4c0a-8df6-f2edd5557a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d7bf1855-dcf8-4bd8-b0eb-bd27e4b4de8f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_89913b66-4c68-4c0a-8df6-f2edd5557a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/NetLossPerCommonShareTables" xlink:type="simple" xlink:href="zntl-20230331.xsd#NetLossPerCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/NetLossPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a5b277ce-1af0-4fe6-b986-adfc8f2b2202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b7d2ac8e-4371-452e-b539-5f59b4ee034f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a5b277ce-1af0-4fe6-b986-adfc8f2b2202" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b7d2ac8e-4371-452e-b539-5f59b4ee034f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_31b10f4b-381a-413d-bebd-4a29ba6a8214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a5b277ce-1af0-4fe6-b986-adfc8f2b2202" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_31b10f4b-381a-413d-bebd-4a29ba6a8214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/SignificantTransactionsDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#SignificantTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/SignificantTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_52b2f76d-5969-487c-b615-950c90255503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b246d044-e083-49a1-9fd3-4d9daa3b8972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_52b2f76d-5969-487c-b615-950c90255503" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b246d044-e083-49a1-9fd3-4d9daa3b8972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_570258ea-f88d-4944-8a0b-3ec349522670" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b246d044-e083-49a1-9fd3-4d9daa3b8972" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_570258ea-f88d-4944-8a0b-3ec349522670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_277d106f-5176-43cb-a1e7-4be1679bc1aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_570258ea-f88d-4944-8a0b-3ec349522670" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_277d106f-5176-43cb-a1e7-4be1679bc1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ZenteraTherapeuticsMember_9aede722-72ae-4c4e-bfdc-f6ed683c7b02" xlink:href="zntl-20230331.xsd#zntl_ZenteraTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_277d106f-5176-43cb-a1e7-4be1679bc1aa" xlink:to="loc_zntl_ZenteraTherapeuticsMember_9aede722-72ae-4c4e-bfdc-f6ed683c7b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_72530334-7078-4329-a95f-00620e8fefcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b246d044-e083-49a1-9fd3-4d9daa3b8972" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_72530334-7078-4329-a95f-00620e8fefcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_c8154d17-e81a-49ce-8598-ecef96df643b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_72530334-7078-4329-a95f-00620e8fefcd" xlink:to="loc_us-gaap_EquityMethodInvestments_c8154d17-e81a-49ce-8598-ecef96df643b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_a465dda6-bb47-4946-8aa4-39626a0c9c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_72530334-7078-4329-a95f-00620e8fefcd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_a465dda6-bb47-4946-8aa4-39626a0c9c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_a11d00f1-2878-40fc-a2ea-f00c7947aa11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_72530334-7078-4329-a95f-00620e8fefcd" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_a11d00f1-2878-40fc-a2ea-f00c7947aa11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_403c56dd-8c80-4494-9175-c1835d75b63d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_72530334-7078-4329-a95f-00620e8fefcd" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_403c56dd-8c80-4494-9175-c1835d75b63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ResearchAndDevelopmentExpenseReimbursements_d182d547-595f-4f3d-892d-c9a61d832465" xlink:href="zntl-20230331.xsd#zntl_ResearchAndDevelopmentExpenseReimbursements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_72530334-7078-4329-a95f-00620e8fefcd" xlink:to="loc_zntl_ResearchAndDevelopmentExpenseReimbursements_d182d547-595f-4f3d-892d-c9a61d832465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#BusinessCombinationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_fec07cf8-6dea-46a9-b13a-40fc1d134f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_9fa76157-0331-4770-b170-f846d4850939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_fec07cf8-6dea-46a9-b13a-40fc1d134f36" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_9fa76157-0331-4770-b170-f846d4850939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2cfc4e89-094e-497a-968d-2d1ddbf408a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_9fa76157-0331-4770-b170-f846d4850939" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2cfc4e89-094e-497a-968d-2d1ddbf408a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fdf02b0c-fdb5-46d0-9094-7d1b82dc97c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2cfc4e89-094e-497a-968d-2d1ddbf408a8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fdf02b0c-fdb5-46d0-9094-7d1b82dc97c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_KalyraPharmaceuticalsIncMember_30ff0636-7121-4e3e-adcd-62ebd9113b99" xlink:href="zntl-20230331.xsd#zntl_KalyraPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fdf02b0c-fdb5-46d0-9094-7d1b82dc97c4" xlink:to="loc_zntl_KalyraPharmaceuticalsIncMember_30ff0636-7121-4e3e-adcd-62ebd9113b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_231d368e-07b7-4f9c-9ef7-fc90fd912b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_9fa76157-0331-4770-b170-f846d4850939" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_231d368e-07b7-4f9c-9ef7-fc90fd912b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_807a1b52-ed24-4c0c-948f-377a3cf2c90d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_231d368e-07b7-4f9c-9ef7-fc90fd912b2b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_807a1b52-ed24-4c0c-948f-377a3cf2c90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_af24f92c-9524-4b2a-a3a2-9f6f6b2a3216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_231d368e-07b7-4f9c-9ef7-fc90fd912b2b" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_af24f92c-9524-4b2a-a3a2-9f6f6b2a3216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5978e368-29be-4c24-b2cc-01fef7844af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_bbf4b23a-fd1d-431f-ab8e-c9aeeb42396a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5978e368-29be-4c24-b2cc-01fef7844af2" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_bbf4b23a-fd1d-431f-ab8e-c9aeeb42396a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_72d6dbd0-0aaf-4b22-9050-3db27c3f56b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_bbf4b23a-fd1d-431f-ab8e-c9aeeb42396a" xlink:to="loc_srt_ConsolidatedEntitiesAxis_72d6dbd0-0aaf-4b22-9050-3db27c3f56b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_b13cf5d7-0fb3-450a-8e93-8514790c81f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_72d6dbd0-0aaf-4b22-9050-3db27c3f56b7" xlink:to="loc_srt_ConsolidatedEntitiesDomain_b13cf5d7-0fb3-450a-8e93-8514790c81f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_fcb8d509-2b9c-49ce-9b52-16c9314c422a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_b13cf5d7-0fb3-450a-8e93-8514790c81f8" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_fcb8d509-2b9c-49ce-9b52-16c9314c422a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_d881a93f-47d8-4c38-ae5e-2aca4bb144fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_bbf4b23a-fd1d-431f-ab8e-c9aeeb42396a" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_d881a93f-47d8-4c38-ae5e-2aca4bb144fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_452618d5-dad2-4671-b22f-c871aa339bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_d881a93f-47d8-4c38-ae5e-2aca4bb144fc" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_452618d5-dad2-4671-b22f-c871aa339bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9acd3a4e-e0a9-4b5b-8fb2-48c5171685cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_452618d5-dad2-4671-b22f-c871aa339bfa" xlink:to="loc_us-gaap_MinorityInterest_9acd3a4e-e0a9-4b5b-8fb2-48c5171685cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6a0447d4-f01e-4878-b87e-026c6e86209e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_452618d5-dad2-4671-b22f-c871aa339bfa" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6a0447d4-f01e-4878-b87e-026c6e86209e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_d3b1f09f-ec55-46ef-ab32-85b1b8dcf4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_452618d5-dad2-4671-b22f-c871aa339bfa" xlink:to="loc_us-gaap_MinorityInterest_d3b1f09f-ec55-46ef-ab32-85b1b8dcf4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a668c8c5-2fa4-4257-8715-ab7be73e20c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bccff716-437c-4ffa-a2a3-5aa232b7d2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a668c8c5-2fa4-4257-8715-ab7be73e20c5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bccff716-437c-4ffa-a2a3-5aa232b7d2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d504f282-78fc-4346-99e6-d8127174029f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bccff716-437c-4ffa-a2a3-5aa232b7d2ef" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d504f282-78fc-4346-99e6-d8127174029f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_298c4d1c-2a3e-43d2-b1f0-a201aca8c973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d504f282-78fc-4346-99e6-d8127174029f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_298c4d1c-2a3e-43d2-b1f0-a201aca8c973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b9e5b93b-bc26-4a4f-b352-0a71734b688c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_298c4d1c-2a3e-43d2-b1f0-a201aca8c973" xlink:to="loc_us-gaap_CommercialPaperMember_b9e5b93b-bc26-4a4f-b352-0a71734b688c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d7d5552c-96ea-4ff4-bfb2-b12795194a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_298c4d1c-2a3e-43d2-b1f0-a201aca8c973" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d7d5552c-96ea-4ff4-bfb2-b12795194a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0d76ecf7-c723-4da6-8708-7beb206ef87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_298c4d1c-2a3e-43d2-b1f0-a201aca8c973" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0d76ecf7-c723-4da6-8708-7beb206ef87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_6d078fea-fa56-4eb4-8e00-cf8611ab3408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_298c4d1c-2a3e-43d2-b1f0-a201aca8c973" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_6d078fea-fa56-4eb4-8e00-cf8611ab3408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0976611c-443d-4444-9430-380b94307a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bccff716-437c-4ffa-a2a3-5aa232b7d2ef" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0976611c-443d-4444-9430-380b94307a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3782f9cb-6f84-44a3-9359-6590d157f907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0976611c-443d-4444-9430-380b94307a7d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3782f9cb-6f84-44a3-9359-6590d157f907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_178304dd-a9c6-41a1-b8b6-5122d4a89455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0976611c-443d-4444-9430-380b94307a7d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_178304dd-a9c6-41a1-b8b6-5122d4a89455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c9690ff0-e4b1-4f89-8aba-34edb44f3fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0976611c-443d-4444-9430-380b94307a7d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c9690ff0-e4b1-4f89-8aba-34edb44f3fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ded9b21-18df-4a78-8d0f-f7eb5cf6f438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0976611c-443d-4444-9430-380b94307a7d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ded9b21-18df-4a78-8d0f-f7eb5cf6f438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#FairValueMeasurementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_64aab1ca-44fa-4cd3-8716-5e175bd931ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_dfb5cf43-443b-4488-b67e-749541abf70d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_64aab1ca-44fa-4cd3-8716-5e175bd931ff" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_dfb5cf43-443b-4488-b67e-749541abf70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesDebt_7d698faa-a5ac-4fb2-8b05-f7d0fd308708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_64aab1ca-44fa-4cd3-8716-5e175bd931ff" xlink:to="loc_us-gaap_TradingSecuritiesDebt_7d698faa-a5ac-4fb2-8b05-f7d0fd308708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_a7b0f97f-4cae-4c2f-8222-7f778d2cf833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_64aab1ca-44fa-4cd3-8716-5e175bd931ff" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_a7b0f97f-4cae-4c2f-8222-7f778d2cf833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_1efcacc2-0ddc-4e09-ae7a-b77bffce905d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_64aab1ca-44fa-4cd3-8716-5e175bd931ff" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_1efcacc2-0ddc-4e09-ae7a-b77bffce905d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_9d669f6f-3b9a-4fc6-b6b2-aae98efd4496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_64aab1ca-44fa-4cd3-8716-5e175bd931ff" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_9d669f6f-3b9a-4fc6-b6b2-aae98efd4496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_c5d7df98-cd48-4fd1-8a50-322ac2dd2289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_64aab1ca-44fa-4cd3-8716-5e175bd931ff" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_c5d7df98-cd48-4fd1-8a50-322ac2dd2289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_0449dd2a-4a7e-4d99-a19e-b26375c4a562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_64aab1ca-44fa-4cd3-8716-5e175bd931ff" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_0449dd2a-4a7e-4d99-a19e-b26375c4a562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_977c3631-3d6b-471c-9969-175134f1325b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_e227b916-d3ba-46f8-9939-016a5c5c7cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_977c3631-3d6b-471c-9969-175134f1325b" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_e227b916-d3ba-46f8-9939-016a5c5c7cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_2cd7baf7-f82e-4f8c-a3d6-8394e826e451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_977c3631-3d6b-471c-9969-175134f1325b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_2cd7baf7-f82e-4f8c-a3d6-8394e826e451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_02f0b0ce-eb0c-40b8-aa93-1d3862d7d28f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_bd34a3d7-2f07-4fbe-84c5-bc54796e31cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_02f0b0ce-eb0c-40b8-aa93-1d3862d7d28f" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_bd34a3d7-2f07-4fbe-84c5-bc54796e31cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_fda673f3-3e20-4a05-90db-17db58567d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_bd34a3d7-2f07-4fbe-84c5-bc54796e31cc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_fda673f3-3e20-4a05-90db-17db58567d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5ec7d635-cc92-45d1-862f-2792b85fbd5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_fda673f3-3e20-4a05-90db-17db58567d07" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5ec7d635-cc92-45d1-862f-2792b85fbd5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_91da05ee-093a-4dee-9a16-c7c129117fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5ec7d635-cc92-45d1-862f-2792b85fbd5c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_91da05ee-093a-4dee-9a16-c7c129117fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_09cb3724-61b5-4dee-8705-e1a59d927afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5ec7d635-cc92-45d1-862f-2792b85fbd5c" xlink:to="loc_us-gaap_CommercialPaperMember_09cb3724-61b5-4dee-8705-e1a59d927afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0c3bacca-5ba9-4f03-869b-46328b47d8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_bd34a3d7-2f07-4fbe-84c5-bc54796e31cc" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0c3bacca-5ba9-4f03-869b-46328b47d8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10b5c7de-56a1-496e-a44c-b852bb2ff30a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0c3bacca-5ba9-4f03-869b-46328b47d8f8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10b5c7de-56a1-496e-a44c-b852bb2ff30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_58120815-160c-45f9-a10d-628c98acf81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10b5c7de-56a1-496e-a44c-b852bb2ff30a" xlink:to="loc_us-gaap_CommercialPaperMember_58120815-160c-45f9-a10d-628c98acf81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_28185037-3e72-4333-930d-5320c1cae165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10b5c7de-56a1-496e-a44c-b852bb2ff30a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_28185037-3e72-4333-930d-5320c1cae165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6169902b-f00a-4d19-b5aa-eb56e08488bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10b5c7de-56a1-496e-a44c-b852bb2ff30a" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6169902b-f00a-4d19-b5aa-eb56e08488bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_d08dce3a-3941-40ca-b67b-3cb138cacea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10b5c7de-56a1-496e-a44c-b852bb2ff30a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_d08dce3a-3941-40ca-b67b-3cb138cacea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5489a5a4-29ed-47a9-a481-0789cd32c448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_bd34a3d7-2f07-4fbe-84c5-bc54796e31cc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5489a5a4-29ed-47a9-a481-0789cd32c448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2c6d571-784f-4077-a84a-6f960b9196fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5489a5a4-29ed-47a9-a481-0789cd32c448" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2c6d571-784f-4077-a84a-6f960b9196fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a2d15571-aa84-42ac-a4b7-cf402445e7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2c6d571-784f-4077-a84a-6f960b9196fd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a2d15571-aa84-42ac-a4b7-cf402445e7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_edf78d03-5768-4960-a57a-c6ae7db75e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2c6d571-784f-4077-a84a-6f960b9196fd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_edf78d03-5768-4960-a57a-c6ae7db75e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2d192a77-e598-49ca-8875-5c4845b22009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_bd34a3d7-2f07-4fbe-84c5-bc54796e31cc" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2d192a77-e598-49ca-8875-5c4845b22009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1f8e0483-9e41-405a-ad80-d41e85c22144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2d192a77-e598-49ca-8875-5c4845b22009" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1f8e0483-9e41-405a-ad80-d41e85c22144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_36147cd8-53e3-4835-9e13-67d0c118c2df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2d192a77-e598-49ca-8875-5c4845b22009" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_36147cd8-53e3-4835-9e13-67d0c118c2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b54f197c-771b-4d27-a472-cf2abd0d2d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2d192a77-e598-49ca-8875-5c4845b22009" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b54f197c-771b-4d27-a472-cf2abd0d2d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#PrepaidExpensesandOtherAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_a4150b29-dd95-416d-bd31-8cfe37dc2fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_250500cc-bc90-4233-b512-3503b3ce4d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_a4150b29-dd95-416d-bd31-8cfe37dc2fe4" xlink:to="loc_us-gaap_PrepaidInsurance_250500cc-bc90-4233-b512-3503b3ce4d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_PrepaidSoftwareLicenseAndMaintenance_114a468f-5481-4deb-b8d8-ddedf0d865ef" xlink:href="zntl-20230331.xsd#zntl_PrepaidSoftwareLicenseAndMaintenance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_a4150b29-dd95-416d-bd31-8cfe37dc2fe4" xlink:to="loc_zntl_PrepaidSoftwareLicenseAndMaintenance_114a468f-5481-4deb-b8d8-ddedf0d865ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ForeignResearchAndDevelopmentCreditRefund_386c1e5a-ec1d-4a70-9c14-8cebc62e4ba2" xlink:href="zntl-20230331.xsd#zntl_ForeignResearchAndDevelopmentCreditRefund"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_a4150b29-dd95-416d-bd31-8cfe37dc2fe4" xlink:to="loc_zntl_ForeignResearchAndDevelopmentCreditRefund_386c1e5a-ec1d-4a70-9c14-8cebc62e4ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_PrepaidResearchAndDevelopmentCosts_3dd079ba-d294-45e9-9254-3bf321b5f9e3" xlink:href="zntl-20230331.xsd#zntl_PrepaidResearchAndDevelopmentCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_a4150b29-dd95-416d-bd31-8cfe37dc2fe4" xlink:to="loc_zntl_PrepaidResearchAndDevelopmentCosts_3dd079ba-d294-45e9-9254-3bf321b5f9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_2e823716-f30b-4d98-b51a-d1b75aaab69f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_a4150b29-dd95-416d-bd31-8cfe37dc2fe4" xlink:to="loc_us-gaap_InterestReceivable_2e823716-f30b-4d98-b51a-d1b75aaab69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_c033b698-3377-4a4e-8c4b-69000542cc96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_a4150b29-dd95-416d-bd31-8cfe37dc2fe4" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_c033b698-3377-4a4e-8c4b-69000542cc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_OtherPrepaidExpense_71f00014-799f-4563-9b98-ade29231351a" xlink:href="zntl-20230331.xsd#zntl_OtherPrepaidExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_a4150b29-dd95-416d-bd31-8cfe37dc2fe4" xlink:to="loc_zntl_OtherPrepaidExpense_71f00014-799f-4563-9b98-ade29231351a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_2db7f81f-6e29-443a-ba5e-75a9cfbae277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_a4150b29-dd95-416d-bd31-8cfe37dc2fe4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_2db7f81f-6e29-443a-ba5e-75a9cfbae277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_b0a13f32-ab30-4ce4-9fec-63f177dd92a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_a4150b29-dd95-416d-bd31-8cfe37dc2fe4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_b0a13f32-ab30-4ce4-9fec-63f177dd92a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_460b33b0-d495-4717-9025-5aff38b7a54c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_a4150b29-dd95-416d-bd31-8cfe37dc2fe4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_460b33b0-d495-4717-9025-5aff38b7a54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1" xlink:type="simple" xlink:href="zntl-20230331.xsd#PrepaidExpensesandOtherAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#PropertyandEquipmentnetSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a3613553-f23b-4f5f-a463-8cf98ab416d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_80797731-4f8f-496d-8728-fbb8adee7bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a3613553-f23b-4f5f-a463-8cf98ab416d4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_80797731-4f8f-496d-8728-fbb8adee7bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_18c1827e-dcfb-4117-8d9c-c462b9a13f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_80797731-4f8f-496d-8728-fbb8adee7bf1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_18c1827e-dcfb-4117-8d9c-c462b9a13f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b341db67-93c0-4ccd-8e19-713ae9537c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_18c1827e-dcfb-4117-8d9c-c462b9a13f74" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b341db67-93c0-4ccd-8e19-713ae9537c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_LaboratoryEquipmentMember_4452432f-e600-451f-aa4c-19a8d9922ce1" xlink:href="zntl-20230331.xsd#zntl_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b341db67-93c0-4ccd-8e19-713ae9537c74" xlink:to="loc_zntl_LaboratoryEquipmentMember_4452432f-e600-451f-aa4c-19a8d9922ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_87ef32f8-479a-489d-b8d2-ff512b3c60e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b341db67-93c0-4ccd-8e19-713ae9537c74" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_87ef32f8-479a-489d-b8d2-ff512b3c60e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_OfficeEquipmentAndFurnitureMember_60a6fd40-b7ee-4114-bcda-b9d15bbc1a44" xlink:href="zntl-20230331.xsd#zntl_OfficeEquipmentAndFurnitureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b341db67-93c0-4ccd-8e19-713ae9537c74" xlink:to="loc_zntl_OfficeEquipmentAndFurnitureMember_60a6fd40-b7ee-4114-bcda-b9d15bbc1a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_169451b1-2e0d-4272-ae5a-ab417bb6b0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b341db67-93c0-4ccd-8e19-713ae9537c74" xlink:to="loc_us-gaap_ComputerEquipmentMember_169451b1-2e0d-4272-ae5a-ab417bb6b0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_7c53c08a-4ede-45f8-8fc6-ddbc642039a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b341db67-93c0-4ccd-8e19-713ae9537c74" xlink:to="loc_us-gaap_ConstructionInProgressMember_7c53c08a-4ede-45f8-8fc6-ddbc642039a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d1825f5-f4a6-4818-98fa-6b47e28ca25d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_80797731-4f8f-496d-8728-fbb8adee7bf1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d1825f5-f4a6-4818-98fa-6b47e28ca25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b1a43a18-3389-4d3f-b09f-739cde7de0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d1825f5-f4a6-4818-98fa-6b47e28ca25d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b1a43a18-3389-4d3f-b09f-739cde7de0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5756d4f0-9f46-42ce-b873-072a68e6f414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d1825f5-f4a6-4818-98fa-6b47e28ca25d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5756d4f0-9f46-42ce-b873-072a68e6f414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_da87ae0d-52e1-464f-856f-6de4157afe81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d1825f5-f4a6-4818-98fa-6b47e28ca25d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_da87ae0d-52e1-464f-856f-6de4157afe81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/PropertyandEquipmentnetNarrativeDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#PropertyandEquipmentnetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/PropertyandEquipmentnetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dcc5ff37-70e8-48af-b46c-03858a45f8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_06d0af43-31af-453a-927f-1beecbc265b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dcc5ff37-70e8-48af-b46c-03858a45f8fb" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_06d0af43-31af-453a-927f-1beecbc265b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_497bea56-aba1-43d8-b71f-5087252071c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_AccruedResearchAndDevelopmentCostsCurrent_3db214f0-c691-4caf-8f9e-2cf6e33d4d75" xlink:href="zntl-20230331.xsd#zntl_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_497bea56-aba1-43d8-b71f-5087252071c4" xlink:to="loc_zntl_AccruedResearchAndDevelopmentCostsCurrent_3db214f0-c691-4caf-8f9e-2cf6e33d4d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d67f3083-7dfe-4446-88ad-9b4d75031917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_497bea56-aba1-43d8-b71f-5087252071c4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d67f3083-7dfe-4446-88ad-9b4d75031917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_70be2086-9d69-4e1a-b704-ba706217b686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_497bea56-aba1-43d8-b71f-5087252071c4" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_70be2086-9d69-4e1a-b704-ba706217b686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_AccruedGeneralAndAdministrativeCostsCurrent_727847b3-675f-40c7-8455-f7c936a16a18" xlink:href="zntl-20230331.xsd#zntl_AccruedGeneralAndAdministrativeCostsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_497bea56-aba1-43d8-b71f-5087252071c4" xlink:to="loc_zntl_AccruedGeneralAndAdministrativeCostsCurrent_727847b3-675f-40c7-8455-f7c936a16a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cf7f2dc2-5d2f-440e-ae71-e182c57423a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_497bea56-aba1-43d8-b71f-5087252071c4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cf7f2dc2-5d2f-440e-ae71-e182c57423a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_7b79776f-3b49-484c-9f51-43be18926440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_497bea56-aba1-43d8-b71f-5087252071c4" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_7b79776f-3b49-484c-9f51-43be18926440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_fd2fad1c-a338-435d-942c-fbf49de0831e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_497bea56-aba1-43d8-b71f-5087252071c4" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_fd2fad1c-a338-435d-942c-fbf49de0831e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3b704b51-cd4c-40ab-910b-f2b38b56b304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_497bea56-aba1-43d8-b71f-5087252071c4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3b704b51-cd4c-40ab-910b-f2b38b56b304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bc7b5d19-255a-4e9a-a8fa-2e9f7e6f9581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_497bea56-aba1-43d8-b71f-5087252071c4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bc7b5d19-255a-4e9a-a8fa-2e9f7e6f9581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/AccruedExpensesDetails_1" xlink:type="simple" xlink:href="zntl-20230331.xsd#AccruedExpensesDetails_1"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/AccruedExpensesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_13763883-657b-4523-b73c-a3b66c1c4d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_de9a373f-2fdf-4019-8a77-7c5875873de5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_13763883-657b-4523-b73c-a3b66c1c4d39" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_de9a373f-2fdf-4019-8a77-7c5875873de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ea12a7df-36cb-4940-a8e9-a0dbcb6e9f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_de9a373f-2fdf-4019-8a77-7c5875873de5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ea12a7df-36cb-4940-a8e9-a0dbcb6e9f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_03bf3a23-39ca-4358-93ae-7f2fe7b1ebe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ea12a7df-36cb-4940-a8e9-a0dbcb6e9f9d" xlink:to="loc_us-gaap_ClassOfStockDomain_03bf3a23-39ca-4358-93ae-7f2fe7b1ebe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4d509273-656b-4ba9-8d9a-d8e3bf0f17aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_03bf3a23-39ca-4358-93ae-7f2fe7b1ebe5" xlink:to="loc_us-gaap_CommonStockMember_4d509273-656b-4ba9-8d9a-d8e3bf0f17aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_7d8502b0-9634-4104-8452-59d5d59a583a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_03bf3a23-39ca-4358-93ae-7f2fe7b1ebe5" xlink:to="loc_us-gaap_CommonClassBMember_7d8502b0-9634-4104-8452-59d5d59a583a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_a8439968-9722-4383-abed-11e5e68d5505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_03bf3a23-39ca-4358-93ae-7f2fe7b1ebe5" xlink:to="loc_us-gaap_RestrictedStockMember_a8439968-9722-4383-abed-11e5e68d5505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_12057611-28e2-418d-ada7-e6333976cced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_de9a373f-2fdf-4019-8a77-7c5875873de5" xlink:to="loc_us-gaap_PlanNameAxis_12057611-28e2-418d-ada7-e6333976cced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9614d4d8-75f0-442f-8e92-38f6fde7d792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_12057611-28e2-418d-ada7-e6333976cced" xlink:to="loc_us-gaap_PlanNameDomain_9614d4d8-75f0-442f-8e92-38f6fde7d792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_A2020IncentiveAwardPlanMember_d7621751-6c2c-46b6-a19f-98f3dd336f0c" xlink:href="zntl-20230331.xsd#zntl_A2020IncentiveAwardPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9614d4d8-75f0-442f-8e92-38f6fde7d792" xlink:to="loc_zntl_A2020IncentiveAwardPlanMember_d7621751-6c2c-46b6-a19f-98f3dd336f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_A2022EmploymentInducementIncentiveAwardPlanMember_30d5c916-e920-41d4-8c6b-0e53120f48fc" xlink:href="zntl-20230331.xsd#zntl_A2022EmploymentInducementIncentiveAwardPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9614d4d8-75f0-442f-8e92-38f6fde7d792" xlink:to="loc_zntl_A2022EmploymentInducementIncentiveAwardPlanMember_30d5c916-e920-41d4-8c6b-0e53120f48fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8cc28e9d-1eb0-47bc-81e6-1da1dc7937b0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_de9a373f-2fdf-4019-8a77-7c5875873de5" xlink:to="loc_srt_RangeAxis_8cc28e9d-1eb0-47bc-81e6-1da1dc7937b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f8aa92ed-2cd5-4da9-a92f-839bd3d9783b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8cc28e9d-1eb0-47bc-81e6-1da1dc7937b0" xlink:to="loc_srt_RangeMember_f8aa92ed-2cd5-4da9-a92f-839bd3d9783b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2bcc52a7-6c02-4f70-9bde-dc0c55ebd366" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f8aa92ed-2cd5-4da9-a92f-839bd3d9783b" xlink:to="loc_srt_MaximumMember_2bcc52a7-6c02-4f70-9bde-dc0c55ebd366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b1c9fb8f-d5dd-48ea-96a0-4a055c5f6440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_de9a373f-2fdf-4019-8a77-7c5875873de5" xlink:to="loc_us-gaap_AwardTypeAxis_b1c9fb8f-d5dd-48ea-96a0-4a055c5f6440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41c0d4ca-85dd-44e7-a484-0c29e1bf80ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b1c9fb8f-d5dd-48ea-96a0-4a055c5f6440" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41c0d4ca-85dd-44e7-a484-0c29e1bf80ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ca5bf476-e0ec-438f-91ab-5907b6926d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41c0d4ca-85dd-44e7-a484-0c29e1bf80ba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ca5bf476-e0ec-438f-91ab-5907b6926d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_1881c325-20ec-455c-8e6e-16bcc78cdd42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41c0d4ca-85dd-44e7-a484-0c29e1bf80ba" xlink:to="loc_us-gaap_EmployeeStockMember_1881c325-20ec-455c-8e6e-16bcc78cdd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_537ba1b7-ba2e-4373-98cd-0b4f06e157ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41c0d4ca-85dd-44e7-a484-0c29e1bf80ba" xlink:to="loc_us-gaap_RestrictedStockMember_537ba1b7-ba2e-4373-98cd-0b4f06e157ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7db04e33-f0a8-4836-b16b-b85f65c87edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41c0d4ca-85dd-44e7-a484-0c29e1bf80ba" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7db04e33-f0a8-4836-b16b-b85f65c87edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_de9a373f-2fdf-4019-8a77-7c5875873de5" xlink:to="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d904b0b2-2813-46c8-9707-9ba740a73691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d904b0b2-2813-46c8-9707-9ba740a73691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease_0b9f5989-db90-441c-9483-22720db51331" xlink:href="zntl-20230331.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease_0b9f5989-db90-441c-9483-22720db51331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_9e8f38f5-54f3-41e2-a902-782d19aa1314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_9e8f38f5-54f3-41e2-a902-782d19aa1314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4f463e38-0ab3-4d55-9107-1abdfde84595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4f463e38-0ab3-4d55-9107-1abdfde84595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_45148371-9b6c-4725-93d6-d7226ef690d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_45148371-9b6c-4725-93d6-d7226ef690d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm_4bff976d-e0dc-4558-ad72-0911043151c9" xlink:href="zntl-20230331.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm_4bff976d-e0dc-4558-ad72-0911043151c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e6b7a74e-ba74-4900-aac0-7c45edcab086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e6b7a74e-ba74-4900-aac0-7c45edcab086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_48d0e73f-740e-4c36-b111-4671224cf56d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_48d0e73f-740e-4c36-b111-4671224cf56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_e32c9c78-cd2c-4d17-a2ac-3cf39b4c73cd" xlink:href="zntl-20230331.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_e32c9c78-cd2c-4d17-a2ac-3cf39b4c73cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_677eee23-9432-461c-a317-55e617dc980f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_677eee23-9432-461c-a317-55e617dc980f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_0034f5cd-cbe5-4bf5-9c62-18db6fa8ba67" xlink:href="zntl-20230331.xsd#zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_0034f5cd-cbe5-4bf5-9c62-18db6fa8ba67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6b64385e-3efa-4942-9195-ea0caf0ac4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6b64385e-3efa-4942-9195-ea0caf0ac4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_dc7ae4c8-3219-4c86-a73e-18af4cd91f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_dc7ae4c8-3219-4c86-a73e-18af4cd91f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_06636df0-a2a3-4e5a-bc15-e9da093a5cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5358d8da-1d49-4e6a-ad53-d4b0a3dab0d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_06636df0-a2a3-4e5a-bc15-e9da093a5cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#StockholdersEquitySharebasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_92e9cc76-8a9e-42e9-af64-72702e2dedf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0eadc271-d9c7-4274-86a8-9316b561ceeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_92e9cc76-8a9e-42e9-af64-72702e2dedf3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0eadc271-d9c7-4274-86a8-9316b561ceeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_db876d51-35bf-4203-9118-9a090c2dbbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0eadc271-d9c7-4274-86a8-9316b561ceeb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_db876d51-35bf-4203-9118-9a090c2dbbc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_be37bb0c-364e-44f8-a0c2-436e061ef571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_db876d51-35bf-4203-9118-9a090c2dbbc9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_be37bb0c-364e-44f8-a0c2-436e061ef571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c7fddd38-10a6-40ad-9424-a8027bd96982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_be37bb0c-364e-44f8-a0c2-436e061ef571" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c7fddd38-10a6-40ad-9424-a8027bd96982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_87f246af-128f-4575-a1ca-2316a7ffdf1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_be37bb0c-364e-44f8-a0c2-436e061ef571" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_87f246af-128f-4575-a1ca-2316a7ffdf1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1a81afba-9396-470c-adf7-db94eb4de4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0eadc271-d9c7-4274-86a8-9316b561ceeb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1a81afba-9396-470c-adf7-db94eb4de4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_490d3021-8411-4b4d-a71b-b6b69a24886a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1a81afba-9396-470c-adf7-db94eb4de4d7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_490d3021-8411-4b4d-a71b-b6b69a24886a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#StockholdersEquitySharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_dc5a419b-0dce-4a86-80b5-c82d74f7aba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8237fb89-f481-491b-90fe-ea8092446083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dc5a419b-0dce-4a86-80b5-c82d74f7aba4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8237fb89-f481-491b-90fe-ea8092446083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4e2706b9-93c0-48cc-a2e3-946fcfbfadb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8237fb89-f481-491b-90fe-ea8092446083" xlink:to="loc_us-gaap_AwardTypeAxis_4e2706b9-93c0-48cc-a2e3-946fcfbfadb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9748f5b3-c2ca-47b2-b655-6c670a34f446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4e2706b9-93c0-48cc-a2e3-946fcfbfadb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9748f5b3-c2ca-47b2-b655-6c670a34f446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ab4d35fe-9380-498b-a6eb-f94a91899439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9748f5b3-c2ca-47b2-b655-6c670a34f446" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ab4d35fe-9380-498b-a6eb-f94a91899439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_68e3591c-f8f9-49e4-89c6-572662b7bf4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9748f5b3-c2ca-47b2-b655-6c670a34f446" xlink:to="loc_us-gaap_EmployeeStockMember_68e3591c-f8f9-49e4-89c6-572662b7bf4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember_c138b3da-498a-4d73-9089-cdaf07b4ce2d" xlink:href="zntl-20230331.xsd#zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9748f5b3-c2ca-47b2-b655-6c670a34f446" xlink:to="loc_zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember_c138b3da-498a-4d73-9089-cdaf07b4ce2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a16bd81d-492a-472f-8abf-3d521534eabf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8237fb89-f481-491b-90fe-ea8092446083" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a16bd81d-492a-472f-8abf-3d521534eabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_af78e1f2-23b2-4b69-81aa-184a8f5cf2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a16bd81d-492a-472f-8abf-3d521534eabf" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_af78e1f2-23b2-4b69-81aa-184a8f5cf2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#StockholdersEquityFairValueAssumptionsforStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e506618b-244a-499f-b7af-388efe2d7be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2a608868-cf87-4fe7-b4d7-7b8805c3622c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e506618b-244a-499f-b7af-388efe2d7be6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2a608868-cf87-4fe7-b4d7-7b8805c3622c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5fd9cf52-9b61-44f2-b3c3-ba47f24cddd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2a608868-cf87-4fe7-b4d7-7b8805c3622c" xlink:to="loc_us-gaap_AwardTypeAxis_5fd9cf52-9b61-44f2-b3c3-ba47f24cddd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7f8d5ae-6d67-4eeb-a406-821831a33598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5fd9cf52-9b61-44f2-b3c3-ba47f24cddd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7f8d5ae-6d67-4eeb-a406-821831a33598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d288e4a3-c7cf-4891-a17d-2aca7dfd35ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7f8d5ae-6d67-4eeb-a406-821831a33598" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d288e4a3-c7cf-4891-a17d-2aca7dfd35ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_00aa1cfd-c732-49a7-a755-ee1f2e3faeb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2a608868-cf87-4fe7-b4d7-7b8805c3622c" xlink:to="loc_srt_RangeAxis_00aa1cfd-c732-49a7-a755-ee1f2e3faeb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6a3e88de-9ae9-4cc4-9c02-c9ee6fb0c280" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_00aa1cfd-c732-49a7-a755-ee1f2e3faeb0" xlink:to="loc_srt_RangeMember_6a3e88de-9ae9-4cc4-9c02-c9ee6fb0c280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_560ba85f-aff2-4924-ac6e-9df1358b7c14" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6a3e88de-9ae9-4cc4-9c02-c9ee6fb0c280" xlink:to="loc_srt_MinimumMember_560ba85f-aff2-4924-ac6e-9df1358b7c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c1eb1a36-2f4c-4d89-aa5c-f611c7f894ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6a3e88de-9ae9-4cc4-9c02-c9ee6fb0c280" xlink:to="loc_srt_MaximumMember_c1eb1a36-2f4c-4d89-aa5c-f611c7f894ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28c511ad-5be3-4524-b710-1db28709a55c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2a608868-cf87-4fe7-b4d7-7b8805c3622c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28c511ad-5be3-4524-b710-1db28709a55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ec04b654-022a-4cc8-9818-24a644f8d068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28c511ad-5be3-4524-b710-1db28709a55c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ec04b654-022a-4cc8-9818-24a644f8d068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_7eb9d0a5-34d4-41fc-ab9c-68f619623bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28c511ad-5be3-4524-b710-1db28709a55c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_7eb9d0a5-34d4-41fc-ab9c-68f619623bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f903f9ef-9863-4463-aa8e-aa9bb3eb1778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28c511ad-5be3-4524-b710-1db28709a55c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f903f9ef-9863-4463-aa8e-aa9bb3eb1778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_c0fcc406-e1de-4b15-b7ac-d73c40ee9b03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28c511ad-5be3-4524-b710-1db28709a55c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_c0fcc406-e1de-4b15-b7ac-d73c40ee9b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_86ab3a21-cb3c-4cb5-9dcc-6a4a13ba1969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28c511ad-5be3-4524-b710-1db28709a55c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_86ab3a21-cb3c-4cb5-9dcc-6a4a13ba1969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3862859b-7c8f-4a06-a1b7-6c0ad8ed909c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_28c511ad-5be3-4524-b710-1db28709a55c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3862859b-7c8f-4a06-a1b7-6c0ad8ed909c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#StockholdersEquityFairValueAssumptionsforESPPDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2a3473de-a5b2-424b-a47b-09b9d1834500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e56cde62-1b69-4802-8b49-2c8dba6a405c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2a3473de-a5b2-424b-a47b-09b9d1834500" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e56cde62-1b69-4802-8b49-2c8dba6a405c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_963940b8-9aee-49aa-aa5e-b94f693372e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e56cde62-1b69-4802-8b49-2c8dba6a405c" xlink:to="loc_us-gaap_AwardTypeAxis_963940b8-9aee-49aa-aa5e-b94f693372e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2642c3d-b87d-4715-b875-5465f37f5340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_963940b8-9aee-49aa-aa5e-b94f693372e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2642c3d-b87d-4715-b875-5465f37f5340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_1b359ee4-940a-4820-b67d-8273524739b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2642c3d-b87d-4715-b875-5465f37f5340" xlink:to="loc_us-gaap_EmployeeStockMember_1b359ee4-940a-4820-b67d-8273524739b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8589bdc3-946a-47a1-9498-3134445ab1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e56cde62-1b69-4802-8b49-2c8dba6a405c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8589bdc3-946a-47a1-9498-3134445ab1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7b2d3267-c39d-4e96-bfea-b26582142156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8589bdc3-946a-47a1-9498-3134445ab1ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7b2d3267-c39d-4e96-bfea-b26582142156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ff346f51-3372-4cb9-bb83-14cbaab1c762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8589bdc3-946a-47a1-9498-3134445ab1ab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ff346f51-3372-4cb9-bb83-14cbaab1c762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_92e53c08-7cb9-4865-807e-d86893d1a42f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8589bdc3-946a-47a1-9498-3134445ab1ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_92e53c08-7cb9-4865-807e-d86893d1a42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a46aeec6-5075-4c4e-9016-a57fad7167d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8589bdc3-946a-47a1-9498-3134445ab1ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a46aeec6-5075-4c4e-9016-a57fad7167d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#StockholdersEquityUnrecognizedCompensationCostDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5ce10857-5aa5-44a4-9446-9d296410f89a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1f43cdf-c6be-4185-954b-ef55a3a5cb33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5ce10857-5aa5-44a4-9446-9d296410f89a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1f43cdf-c6be-4185-954b-ef55a3a5cb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_617a7e77-5b9f-4651-a5cf-3265354a4b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1f43cdf-c6be-4185-954b-ef55a3a5cb33" xlink:to="loc_us-gaap_AwardTypeAxis_617a7e77-5b9f-4651-a5cf-3265354a4b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cef4fd2-2dd9-4b64-810f-5f85c0c1e40a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_617a7e77-5b9f-4651-a5cf-3265354a4b0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cef4fd2-2dd9-4b64-810f-5f85c0c1e40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1fd6c758-450e-4465-8d08-d20bbb0f6145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cef4fd2-2dd9-4b64-810f-5f85c0c1e40a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1fd6c758-450e-4465-8d08-d20bbb0f6145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_3fe4d219-2bcd-47a5-9184-741249b8abab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cef4fd2-2dd9-4b64-810f-5f85c0c1e40a" xlink:to="loc_us-gaap_RestrictedStockMember_3fe4d219-2bcd-47a5-9184-741249b8abab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_38ab585a-64e7-4adc-98d1-bdda092b5e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cef4fd2-2dd9-4b64-810f-5f85c0c1e40a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_38ab585a-64e7-4adc-98d1-bdda092b5e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a531e910-2c66-44d5-95b8-8459ced89c99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cef4fd2-2dd9-4b64-810f-5f85c0c1e40a" xlink:to="loc_us-gaap_EmployeeStockMember_a531e910-2c66-44d5-95b8-8459ced89c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_094be4f3-6936-49a2-9968-8d785d0c573e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1f43cdf-c6be-4185-954b-ef55a3a5cb33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_094be4f3-6936-49a2-9968-8d785d0c573e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0890f32b-d695-4d6c-8b41-454d8274108d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_094be4f3-6936-49a2-9968-8d785d0c573e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0890f32b-d695-4d6c-8b41-454d8274108d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_dcdb4dc9-7628-45ee-beae-9cf219b54b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_094be4f3-6936-49a2-9968-8d785d0c573e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_dcdb4dc9-7628-45ee-beae-9cf219b54b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a85e84e8-7e37-4c0c-9a4d-1925fd19624c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_094be4f3-6936-49a2-9968-8d785d0c573e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a85e84e8-7e37-4c0c-9a4d-1925fd19624c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48786418-50bd-4ace-b0d2-e86d7948f855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b6447d5d-3e4f-4564-b034-239c0588f276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48786418-50bd-4ace-b0d2-e86d7948f855" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b6447d5d-3e4f-4564-b034-239c0588f276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6598edc8-a13c-478b-9735-5746662f2ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48786418-50bd-4ace-b0d2-e86d7948f855" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6598edc8-a13c-478b-9735-5746662f2ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_709a0cd1-7e9e-4840-b4c4-3042c1a36f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48786418-50bd-4ace-b0d2-e86d7948f855" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_709a0cd1-7e9e-4840-b4c4-3042c1a36f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_50aadb90-bd89-4cdd-b5db-34bac4e941ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48786418-50bd-4ace-b0d2-e86d7948f855" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_50aadb90-bd89-4cdd-b5db-34bac4e941ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3627afa1-fd66-4a7a-8f91-d2a99770418a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48786418-50bd-4ace-b0d2-e86d7948f855" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3627afa1-fd66-4a7a-8f91-d2a99770418a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_f26499f4-0b81-463b-828a-e36ffed46bc6" xlink:href="zntl-20230331.xsd#zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48786418-50bd-4ace-b0d2-e86d7948f855" xlink:to="loc_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_f26499f4-0b81-463b-828a-e36ffed46bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_79255768-b04f-4c0e-bc32-47455c68bbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48786418-50bd-4ace-b0d2-e86d7948f855" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_79255768-b04f-4c0e-bc32-47455c68bbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1c982b06-d661-4bdf-92f0-c0b25bcf24b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48786418-50bd-4ace-b0d2-e86d7948f855" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1c982b06-d661-4bdf-92f0-c0b25bcf24b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0670c5d6-7d82-4b95-a41d-01e324329780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48786418-50bd-4ace-b0d2-e86d7948f855" xlink:to="loc_us-gaap_OperatingLeaseLiability_0670c5d6-7d82-4b95-a41d-01e324329780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1d34a920-9128-45b4-9fae-244d11a328ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48786418-50bd-4ace-b0d2-e86d7948f855" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1d34a920-9128-45b4-9fae-244d11a328ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f49ca650-5d97-4add-b003-049dd32df146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48786418-50bd-4ace-b0d2-e86d7948f855" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f49ca650-5d97-4add-b003-049dd32df146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="zntl-20230331.xsd#CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_338cec93-23e7-4788-8f80-5076cb48956b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_360a7189-eb44-4777-821f-91441dae4730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_338cec93-23e7-4788-8f80-5076cb48956b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_360a7189-eb44-4777-821f-91441dae4730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_ef45c78e-7e7e-4011-a1ce-c48bc416c778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_338cec93-23e7-4788-8f80-5076cb48956b" xlink:to="loc_us-gaap_AssetImpairmentCharges_ef45c78e-7e7e-4011-a1ce-c48bc416c778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#NetLossPerCommonShareCalculationDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6f07d05a-4f9a-4809-ab0d-309a7e19f2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_EarningsPerShareNumeratorAbstract_fb9de398-2b63-4f55-8b73-4e21cff8d962" xlink:href="zntl-20230331.xsd#zntl_EarningsPerShareNumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6f07d05a-4f9a-4809-ab0d-309a7e19f2e8" xlink:to="loc_zntl_EarningsPerShareNumeratorAbstract_fb9de398-2b63-4f55-8b73-4e21cff8d962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1c97fb95-d38a-41dd-87e1-3ee40e3bf7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_zntl_EarningsPerShareNumeratorAbstract_fb9de398-2b63-4f55-8b73-4e21cff8d962" xlink:to="loc_us-gaap_NetIncomeLoss_1c97fb95-d38a-41dd-87e1-3ee40e3bf7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_EarningsPerShareDenominatorAbstract_035ec020-c838-48d8-bbe0-a862eca869a6" xlink:href="zntl-20230331.xsd#zntl_EarningsPerShareDenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6f07d05a-4f9a-4809-ab0d-309a7e19f2e8" xlink:to="loc_zntl_EarningsPerShareDenominatorAbstract_035ec020-c838-48d8-bbe0-a862eca869a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e9e92a13-7b92-4517-8383-a60f4a150821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_zntl_EarningsPerShareDenominatorAbstract_035ec020-c838-48d8-bbe0-a862eca869a6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e9e92a13-7b92-4517-8383-a60f4a150821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_16c172bf-92fb-41c2-b335-51f6691014bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_zntl_EarningsPerShareDenominatorAbstract_035ec020-c838-48d8-bbe0-a862eca869a6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_16c172bf-92fb-41c2-b335-51f6691014bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9e774426-64f8-432e-894f-6ff7854227e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6f07d05a-4f9a-4809-ab0d-309a7e19f2e8" xlink:to="loc_us-gaap_EarningsPerShareBasic_9e774426-64f8-432e-894f-6ff7854227e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_14485c2e-813a-49c0-8d69-04d6a0e110d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6f07d05a-4f9a-4809-ab0d-309a7e19f2e8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_14485c2e-813a-49c0-8d69-04d6a0e110d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#NetLossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8aa92aa8-4be0-40a7-aed4-a2ecd8619209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_71b057d4-2b3c-48c1-9666-158a1ee93d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8aa92aa8-4be0-40a7-aed4-a2ecd8619209" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_71b057d4-2b3c-48c1-9666-158a1ee93d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_22a5aa80-a976-4b8d-90fb-b0b9d22732a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_71b057d4-2b3c-48c1-9666-158a1ee93d92" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_22a5aa80-a976-4b8d-90fb-b0b9d22732a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec9ee6c1-d2ff-4113-ae0d-19ee835c75f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_22a5aa80-a976-4b8d-90fb-b0b9d22732a1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec9ee6c1-d2ff-4113-ae0d-19ee835c75f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_14212836-34b4-4a85-9b24-5fe26c9dcdce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec9ee6c1-d2ff-4113-ae0d-19ee835c75f5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_14212836-34b4-4a85-9b24-5fe26c9dcdce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_58432008-9d4d-4404-81b5-c9e81f9e9728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec9ee6c1-d2ff-4113-ae0d-19ee835c75f5" xlink:to="loc_us-gaap_RestrictedStockMember_58432008-9d4d-4404-81b5-c9e81f9e9728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c3e799fa-5dd2-4a51-927e-4f6d9714479e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec9ee6c1-d2ff-4113-ae0d-19ee835c75f5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c3e799fa-5dd2-4a51-927e-4f6d9714479e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dbd5cbf0-c10e-4c36-9ae7-6ee84fba5839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_71b057d4-2b3c-48c1-9666-158a1ee93d92" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dbd5cbf0-c10e-4c36-9ae7-6ee84fba5839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d5fe70dc-970c-43c8-a7f9-00fc471f1b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dbd5cbf0-c10e-4c36-9ae7-6ee84fba5839" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d5fe70dc-970c-43c8-a7f9-00fc471f1b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" xlink:type="simple" xlink:href="zntl-20230331.xsd#RelatedPartyDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_eed5c4ba-6633-4094-b022-3be80764a9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e910c4c5-2fa0-42aa-a3bc-fff3a2173aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_eed5c4ba-6633-4094-b022-3be80764a9bb" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e910c4c5-2fa0-42aa-a3bc-fff3a2173aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7bfb7365-6739-4cf9-ae6f-87eea8cbbe0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e910c4c5-2fa0-42aa-a3bc-fff3a2173aba" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7bfb7365-6739-4cf9-ae6f-87eea8cbbe0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a11d4fe4-892f-463c-9f7b-72f6f10d1fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7bfb7365-6739-4cf9-ae6f-87eea8cbbe0e" xlink:to="loc_us-gaap_RelatedPartyDomain_a11d4fe4-892f-463c-9f7b-72f6f10d1fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_29d73b2a-0eb4-4ec7-b180-7e044ef8b0d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a11d4fe4-892f-463c-9f7b-72f6f10d1fda" xlink:to="loc_srt_AffiliatedEntityMember_29d73b2a-0eb4-4ec7-b180-7e044ef8b0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_3195d89a-6cd6-4000-a3a1-1f46eae0840a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e910c4c5-2fa0-42aa-a3bc-fff3a2173aba" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_3195d89a-6cd6-4000-a3a1-1f46eae0840a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_45768352-edb3-4708-9389-bdc056b6f97e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3195d89a-6cd6-4000-a3a1-1f46eae0840a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_45768352-edb3-4708-9389-bdc056b6f97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_MasterServicesAgreementMember_68269fca-7747-489b-a9df-8a38510f32a8" xlink:href="zntl-20230331.xsd#zntl_MasterServicesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_45768352-edb3-4708-9389-bdc056b6f97e" xlink:to="loc_zntl_MasterServicesAgreementMember_68269fca-7747-489b-a9df-8a38510f32a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2e27d5e6-8b1a-48aa-a3f4-45c565b71004" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e910c4c5-2fa0-42aa-a3bc-fff3a2173aba" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2e27d5e6-8b1a-48aa-a3f4-45c565b71004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_cabfa017-ac27-4716-988b-9e1320d27208" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2e27d5e6-8b1a-48aa-a3f4-45c565b71004" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_cabfa017-ac27-4716-988b-9e1320d27208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ZenteraTherapeuticsMember_8abad044-9c6c-4b95-95d9-c897e269de27" xlink:href="zntl-20230331.xsd#zntl_ZenteraTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_cabfa017-ac27-4716-988b-9e1320d27208" xlink:to="loc_zntl_ZenteraTherapeuticsMember_8abad044-9c6c-4b95-95d9-c897e269de27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_e16bc265-a4c2-4ac0-9168-41a9db9750ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e910c4c5-2fa0-42aa-a3bc-fff3a2173aba" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_e16bc265-a4c2-4ac0-9168-41a9db9750ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_46727d18-c93f-4101-b3cc-75c44ea215aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e16bc265-a4c2-4ac0-9168-41a9db9750ea" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_46727d18-c93f-4101-b3cc-75c44ea215aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_zntl_ResearchAndDevelopmentExpenseReimbursements_4a21bbe7-1984-4c9a-8a37-5a9f3c21d53e" xlink:href="zntl-20230331.xsd#zntl_ResearchAndDevelopmentExpenseReimbursements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e16bc265-a4c2-4ac0-9168-41a9db9750ea" xlink:to="loc_zntl_ResearchAndDevelopmentExpenseReimbursements_4a21bbe7-1984-4c9a-8a37-5a9f3c21d53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>zntl-20230331_g1.jpg
<TEXT>
begin 644 zntl-20230331_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" )\!5L# 2(  A$! Q$!_\0
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MN-O_ .CUKG:SAO+U_1&]7X8>GZL****T, HHHH **** "BBB@ HHHH ****
M"BBB@ K6\ _\CWHO_7_!_P"C%K)K6\ _\CWHO_7_  ?^C%J)_"S6C_$CZHJ>
M(/\ D/7O_7Q)_P"A&JE6_$'_ "'KW_KXD_\ 0C52G'9$3^)A1115$A1110 4
M444 %%%% !1110 4444 %%%% !71>.O^07X;_P"P6O\ Z.EKG:Z+QU_R"_#?
M_8+7_P!'2UG+XD;T_@GZ?JCG:***T, HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^I?!G_(GZ3_ -></_H
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MU*".ZL[RUF6:"ZAD4,DD;J2KHRD$,"00010/S+=%%% @HHHH **** "BBB@
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MH&CZGKVH6FI7SV=C';?VI>MX<N/WUPR!3)(QQEV)8^M?IK11]06FNWEYW_X
MGF4G?3?7?KRV?XZGY,_#H^$=6_9L^$4F@FSN?VRT\?6+:Y(%'_";17@OY1J@
MU @"Y6P%G]H1_.Q;>3L7H4!\X_:^LO$?P"\!?M6>/+ 7NJ>!_BGXQU[P/XEL
MTY&C7T4D<VF7ZC^XYDGMY,D &2$_,2!7[6T5E++;QMS6?IY6OOUZ]S>&<<L^
M;DNK[-^=[+31+IV/F[QG\2/V@++]NS0=#TKPAX;G^&$VA7TT]P^M7"V\KK=6
MBQS33C2W\F[6-YO+M%E9)078RKY8KR?]O?\ X53_ ,/*?A%_PN3_ (0+_A#?
M^$'U_/\ PE_V7^S_ +1]HL]F/M/R>;C?MQ\W7%?=-%==3#N47%RO=IZZ[=.A
MP4\4H24E&UDUIH];Z]3\?/$=A%J<O[)$7Q'U7P7HOA@R_$ Z'=_%_2?[4L$T
M826G]F"Z@NKFV9G-OY(B,DH8 QG!X%>I_M?7TW[-/Q8UOPY\-4T\Z7^UWX*T
MSPYX9FT.U TN'6(G@T[SX/++1PV_]EW@F!!VXM1ACUK],**YUE]DTI:Z:_*W
M?L=?]JWDFXZ*^E]-9<RZ=';UMTN?FG!\+/AE\,O^"KNI^&M8U'X)Z#HWA3PI
MX0T_0;+QWHUO?WMTL)GC2+2Y9;F#R+G"Q@R+',=QC.S@!LK2/C3<:5^QM^V-
MX2\ >)[9/BV?BCXNO[/1-*U)!XA^Q?VE$+FXM[=6\_(@$Y5U7AEX.17Z@T57
MU&U^5VO?IW^?0G^TKVYHWMR]?Y?EUZGYS:3;?"=OVE_ 1_9A'A1_"=OX"\0#
MXA2^#UC%D;1K)!I7]I&(!?MAN%E*"7]_@3EAC->+_![]D_6?#?\ P2Z\4?%5
M=/\ "'@[P_?_  %N=(>P\/7,DEQXNN7W3+J6IK]GAC2:) R( 9W/GOF8 ;6_
M8&BD\O3=V^^RTUM_E\QK-915HKMN[MV;>NGG\DC\6/VA-'UZ?]EKQU^SM/8Z
M@O@WX*:-J?Q$BO6ES#<Z?=6B2Z/9[_O/Y5U?7AVM@ :?%RV"![IX&L? ^I?\
M%4M>F\:ZU\%=/N(O#G@E]-@\=:/;WVIZA.;>3Y=)FENH3;W&[R\NL<Q+-#\H
M(&[],Z*F.76DGS=NG:]EOYE2S9N+CRVNGUZNS;VZV_JQ^*/Q$T_Q'\ ?AS\5
M-:M_MNJ> ?CG\5+_ $;4H@"R^'];T_Q49K>Y]H;BUB>$C&?,BC);! 'V:G[,
M7PUB_P""V@5?A[X'55^%7_"3 #0;4 :K_;W_ "$/N?\ 'U_TV_UG^U7W#154
M\O4=W?;IVO\ G<FKFLIK16>JW[VM]R5CX$_X*JV&N_M8?&.U^$7A3PUXG\52
M>!O"]YXON?["NK&%]-UNXCDM=$FE-U<VZ[8F6[F*H7?F(A.]>4_&"XG_ ."F
M/Q9^#5[I?A+P%XLU?QO\%-<62V\63O:V6B:C]I@MKB="EM<.)[:Y\Q5"K&WR
MMB2,BOU1HJJF!YY.3EOOIVV)I9E[.,8QC\-[:]]_Q]-K'Y8>.?V%/$GQI_:]
M\=?#6RNO#NN^)?#?@3P-9-\1]?N)HM>\/26TLADU2P$<,LCW<@@9L&Y@^;9N
ME<%JPOB9X"AT7]LGXF_$75[;08_"_A?XX^'[77-?M]+6+Q/H<4EI9K#/%J)<
MK'9&YD@2> 0Y=))-K@D ?K914/+8O9];_G;\_F:1S>:>JTM;\K_?;Y'Y5_&:
M?P'J?PV_:;3XCC3I_P!IA?%VI1> H;E-_BR-!)'_ ,(^-#4#[5Y);RG7[+QN
M:4OCYJN_MM^)_B)\7_B%J&NZ5X2\3>)_$/[+OAK2;];[2KNQ%E8>)=UKJFI&
M=9+F.29?L5ND&VWCG/[^9=N2%/ZCT4Y8"Z<>;?R]?QN]_(F.:<K4N3;N].BT
M\K)JWF?GU?\ Q'^$OQE_;2\6^(_C;/H5QX+\0>#-"U'X13>("JP36L\+27SZ
M9DY&I&X:W!^S_P"D@"#;T6O#OVN-+\77'[,7[=MSI6N^';3PE%XXB&H:=>Z%
M<7&I7;>3I>#%=_:XTA'*9#V\I^5N?F^7]=J*<\#SQ:<M[].Z?GTOIY:!2S/V
M<E*,=K:7TT:VTTO;7SU"BBBO0/)"BBB@ HHHH **** .^^%O_).?%?\ UWL?
MYS5#4WPM_P"2<^*_^N]C_.:H:^=Q7\>?JOR1[]+^!3]'_P"E2/R]_P""<_[(
MFM?%#]I#7/B+IFF^#?"MEX)^-7C.YU+Q)97,G_"2>)8FN)H1I4\:VZ(+,,XD
MW/<2<Q@")2=U>*?\$M?A_;?";0?@7X@UBR\.Z-!\0OA;XNM-!U/PYI0TRZUN
M^CF\RXL=;EWR?;BL$*S6SCRMIB==C;-U?M;17!]66FO]:?Y'I?VA)W36C_X/
M^9^-W[-EOIVB_P#!&36+CX;:U\*-2\;W'AS0CXGM_AOH<-CXVTO1_MJ?VH-1
MGBNYIKF8VQD^?RH"NV4A2S#9[#^UWXE_9R\"> _@EK7P>U+X<Z1X+T[XX>$;
MS7K[PY<PP>'[,I'>GS)I(R+2.Y6)<S$D3",0&;Y?)K],**%A[*UR7C;RYFNM
M]_\ @?<?DS_P4@\2>'OC3\4?VC[_ $35],\0^'-?^$'A-8-0TN\CN;:[B;Q'
M(A:.6,E6'49!/(KD=7G\5_#?Q]\<?@SXU^V7NK_!;]F+QQH>FZW,/E\1:))+
M8R:9=Y_YZ"#]S(!D"2W;YB<X_92BAX>[O<J./M'EY=/7R2[>1^7/P,E^&MW\
M9+:']I,:"NA)\)_""_"K_A(RJVYC.GK_ &FVE$G=_:?VOR 3;8NL+;[.BUD?
MM6?&?7=>_:P\2?M%Z+X3\9:KX2_9V\7:5X<M/$-G-9&PM=*M5FB\2QRPR72W
M;O(=19-T=O( ;"(EQAU7]7:*?L-+7)6,2ES<O2V^GG;U/B7]AGXX^"M%_P""
MA/[4/AR\\8>%[3Q#XH\8:7<:-I<VJP1WNKQC0[9B]O"6WS* "<H", U]M445
MK"+BK'+5J*<KI=%^"L%%%%69!1110 4444 =%X4_Y$OQ1_U[0?\ I0E<[71>
M%/\ D2_%'_7M!_Z4)7.UG#>7K^B-ZOP0]/U9^7G[.7[(6M?M ?MW_$[Q7HVG
M^#_#G_"O?V@YM;OO&:7,B^*)K6'3(EDT6&-+< V=SYX60O=;=LDO[ACM8Y?_
M  3G^-WC/X >%/@Q;6OB36]6\'_$'4_B0M[X8BTNSF^R/IUQ>7D,MFPB6X>=
MW212DD[1MY@ 52,G]5Z*S5"SNF;O&\RY91T_X#7ZW/RF_9Z_X*1_%CXO>!OB
MI_9GQ8\*&-/ 6@>)M%UK6]6TW4E\)W5[>^7/;WMW9:/:6]O,D,B"5)K6XCM9
M KR2&/S -#QO_P %$/BKXR^'7PCC\/?$*'X8:5XM\-:W>3^,_B)K6AZ7'?:U
M:WJVZVHOXM)NM.N;= SR1?9[>W-U B.)D8,'_4FBCV,[6YA_6J5[JFOZ5NWS
M/F']MRXT[Q9_P3(U9_B?X[T?PP^I>%HI=4U+P_X@_LW3-8O3:B0VEO<R%7>T
MN904" J\L3[?XB*T_P#@DGXZT3QS_P $W?@P=$UC2]8&D^$=+TR^-C=QW'V*
M[BLX1+;R["=DJ$@,C89<\@5]%T5IR>]S'.ZMZ?L[=;A1116A@%=%X5_Y$GQ1
M_P!<+?\ ]*$KG:Z+PK_R)/BC_KA;_P#I0E9U-OFOS-Z'Q/T?Y,YVOR\_9R_9
M"UK]H#]N_P")WBO1M/\ !_AS_A7O[0<VMWWC-+F1?%$UK#ID2R:+#&EN ;.Y
M\\+(7NMNV27]PQVL?U#HHG34FK] HUW34K=3\H?^";/QV\9_L[?!_P" MO#X
MEU[6?!GCRP^)5S=^&8-*LIFL)-+U"XN89;%A$EQ).[><"DTSQMYJ@*FT&KG[
M._\ P4:^+/Q:^'/Q?2R^*_A O8^"O#GB/1-<U;5].U2'PQ/?W;QSPW=Y9Z/:
M6\,B1X5Q-:31VTB[I)#&L@7]4J*R5&222E_5CHEBX2;DX*[_ ,[]OD?EMXW_
M ."B'Q5\9?#KX1Q^'OB%#\,-*\6^&M;O)_&?Q$UK0]+COM:M;U;=;47\6DW6
MG7-N@9Y(OL]O;FZ@1'$R,&#_ $]^WY<Z=XK_ ."6>NR?$WQWH_ANXU/PCYE_
M?:!X@_L[2]=U!K%G^QV\\A5YK2YERJQ@AYHR%/#,I^JZ*M4G9W=[F<L1&\7&
M-K._]:'Y%W?QC\,S^'?^"=VK6GQ=TSP!I6A_#;6=,U7Q;826-XOAZYBT718Y
M+>5KA)K:&7SBD#+.A(:78 LC(1^AG_!.SXM^,OCO^P_\,O%_Q LVLO&&OZ'#
M=:DK6_V<SL<A9S&  GG($EVJ H\S@ 8%>T440IN+O?\ K3_(5;$*I%1Y?ZNW
MV\_P"BBBMCE.B\+?\B-XH_ZXV_\ Z/6N=KHO"W_(C>*/^N-O_P"CUKG:SAO+
MU_1&]7X8>GZL_+S]G+]D+6OV@/V[_B=XKT;3_!_AS_A7O[0<VMWWC-+F1?%$
MUK#ID2R:+#&EN ;.Y\\+(7NMNV27]PQVL<3_ ()L_';QG^SM\'_@+;P^)=>U
MGP9X\L/B5<W?AF#2K*9K"32]0N+F&6Q81)<23NWG I-,\;>:H"IM!K]7J*S5
M"SNG_6AT/&\RY91NM/P37ZW/RM_9W_X*-?%GXM?#GXOI9?%?P@7L?!7ASQ'H
MFN:MJ^G:I#X8GO[MXYX;N\L]'M+>&1(\*XFM)H[:1=TDAC60+9\;_P#!1#XJ
M^,OAU\(X_#WQ"A^&&E>+?#6MWD_C/XB:UH>EQWVM6MZMNMJ+^+2;K3KFW0,\
MD7V>WMS=0(CB9&#!_P!2:*/8SM;F#ZU3O?V:_I6[?,^9?VOOCGX&^%?[!^A^
M*?CU;>$O%\-U;:<L^E65TKZ!XGUB:'Y(8_M!6&6T:4O*C70\M$C69@#$&6Q_
MP23\&6/PX_8.\&Z#9>.?"WC]M,-U]IOO#FJ1ZEI=A++<23FPMY4=P8[995A7
M)Z(#A00H^DJ*TY/>YCG=7]WR)=;A1116A@%%%% !1110 4444 %:W@'_ )'O
M1?\ K_@_]&+636MX!_Y'O1?^O^#_ -&+43^%FM'^)'U14\0?\AZ]_P"OB3_T
M(U^>7_!53X1S?'/]OS]GWPS;^#/ ?CNXU+PMXQ2+3?%]PUOIB/Y-B!.76UN6
MWQD[EVQ@Y'#H?FK]#?$'_(>O?^OB3_T(U4J7#FAR^A=.JZ=1S7G^.A^2/Q5\
M'_$/]B[XT^.&T7XHZTOB_P"#G[-.F7LNL+8VMV?$$]I?WI$4XNXIR+=B""$V
MRX5,2KA@WHOQT_X*7>.="_;?\#^']"\3KH]E>>,?"'AW5?#&IWVGC^T[?5HX
M6GN;*Q_LYKU[=!-C[6=11%F4)Y3#A_TIHJ/8M?"[&_UR+UG"[_X;R/S%\6?\
M%%OBQX)\%?M)QV7BEO&/C#P01>V-UI?]G77ASPGI<^K?9F:6&.Q&H66HV5N9
MC);Z@+D9LY)MLD89#]4?\$[/B;XP^)/PQ\77GB[XE_#OXIV-KJS1:7J?@_Q#
M;Z_/:0?9XV>VN[BRL;&%IU8EE$5LC;)4!W$!C])454:<D[MF52O"4>6,$C\]
M/^"?.G^%O#G_  5 \;0>!;OP7XJT34/AU;2:EJW@6S?3M.T>YCU2<1VNLPM+
M<O/K$RR2.;F>Y2X86\P:W'+U^A=%%7"'*K&=:K[27,%%%%68A1110 4444 %
M%%% !71>.O\ D%^&_P#L%K_Z.EKG:Z+QU_R"_#?_ &"U_P#1TM9R^)&]/X)^
MGZH^=O\ @H9X)TOXE_L7_$#PYK?C>Z^&^DZ_IZZ;=>)88WD72$FFCC,DH5EQ
M;G=MF+.B+"TA=T0,P_.+X_Z=X3^-'_!&#X[:GJ'PN^"]IJWPVU1K/1/$G@2R
M\_PQ>/+-I_GW>AM,FZUC(VPS+ Q1YH97+,SMC]A**FI2YG?RL:4,4Z22ML[G
MYR_\%*O@YIWQ5\6^%OV:/AC\-KN7P[X?\/ZIXWU31? Z:7HZ:9>3Q7%EI,Q6
M>XM(55;N:XNF56+E[>)MC#)'*_M%3>"?VV?V8OV/OB;XG\$^$]3\:>)?BAX8
M\+^*[F_T6WDO)'B:[@U#3IF="Y@^TQRYA<E2,$CFOU$HJ70NWKN5'&-)*VWG
M]_W_ *'YP_%7Q-X*_8__ &J/VIM.U^?0/AYH7BWX4Z/9>";.58]/MM8%I97\
M#VFG1 !9I(VDA000@O\ O$ 3D5Y+\3?#$?[+/@?]G;Q-KP\$>+?'O@_X<>%=
M"?X2>+([FV\1I</*NVZ\,NN735?M0BBD\J)BOV<;I$VK7Z\44.A?K_6Y4<;:
MVGKKV5CYD_X*CZI)XV^$?A?X-Z?-/'JWQW\26OA.3[.W[Z'203=:M,!_=6P@
MG4^\J_6O,?\ @N+H6AZ;^S]\#=-OI?!VC>'+?XN>'K::3Q+9)=:#96RPW:DW
M<#2Q+);*@^=#(@* C<O6OK_7?@KX9\3?%SP_XZO],^U>*?"ME=Z?I-X]Q+ML
M8;LQ&X"1;O*W/Y,0+E=^%P& )!ZJKE3YKWZF-.NH<MNFOS_X:Q^3W[?&F!O"
M/PL@_99N_!.J_$O3?!/B6?4;[X7VD&F:'+X3(F6^%O##)<+'))J.!;!))&%T
MLISG<1B^./V:/"W[8/[4'AKPC\%?#W@+4O"FH?LT:1'X6U?Q%<R1W'A"%M7N
MTCU&V\NWF=M1A)^92\#>9OW2@[@?U[HK-X=-ZLW6/<59+5>9^8OPI\(>!]"_
MX+,_%2S\<^*O@K-KNC3>![;2&\>Z+;WOB76[Q-*14DTBXENXFM[DS+$S%(IV
M9VBP%(&>M_X)]>&O@[\3GUG3/C-IGA/6/VGM4\7Z]!XKT_6H$GU^YC:6=883
M$<ROI']F&U"(P-GLV8'"U^AM%4J-G]Y$L6Y*WDEOV7IL^Q^//BGX">!? _\
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MB^G5;(@_G6]' XFLN:C3E)>2;_(T<DMS[KHKX0_XB9/V(_\ HM?_ )9^O?\
MR#1_Q$R?L1_]%K_\L_7O_D&MO[(QW_/F?_@+_P A<\>Y]WT5\(?\1,G[$?\
MT6O_ ,L_7O\ Y!H_XB9/V(_^BU_^6?KW_P @T?V1CO\ GS/_ ,!?^0<\>Y]W
MT5\(?\1,G[$?_1:__+/U[_Y!H_XB9/V(_P#HM?\ Y9^O?_(-']D8[_GS/_P%
M_P"0<\>Y]WT5\(?\1,G[$?\ T6O_ ,L_7O\ Y!H_XB9/V(_^BU_^6?KW_P @
MT?V1CO\ GS/_ ,!?^0<\>Y]WT5\(?\1,G[$?_1:__+/U[_Y!H_XB9/V(_P#H
MM?\ Y9^O?_(-']D8[_GS/_P%_P"0<\>Y]WT5\(?\1,G[$?\ T6O_ ,L_7O\
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MSYG_ . O_(TYX]S[OHKX0_XB9/V(_P#HM?\ Y9^O?_(-'_$3)^Q'_P!%K_\
M+/U[_P"0:/[(QW_/F?\ X"_\@YX]S[OHKX0_XB9/V(_^BU_^6?KW_P @T?\
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MWN[:H.72Q^.6J?MG_M5?L7?LY_ ;PCX@U'Q!)XX^.OPOM?"_A*VU?2(KK4-
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M+NC ^SMG<,C*^O(XKP+X5:SH/A+X5?#'PE^S_P#%7]GG35\??%1M#\3:_P#
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M#_@0]%^1S/<****Z1!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI7.FP::H9V2%;HV$<,\;*J(99HIJ_3RL'7_AIHGBCQOX?\1WUEY^L^%OM/\
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M_" U7_XQ7]HE%'^O-?\ Y]+[V'L%W/XN_P#AUI^TY_T;G\=__" U7_XQ7<?
MW_@AO^UA\?/%UKI&G? WQ_H/VB0*][XFTJ70K2V7(R[R72Q\ <X4,QQPI/%?
MV&45,N.<2U[M.-_F/V"/B'_@B7_P1IT+_@DS\&=06[U"V\2_$OQ<(G\0:S#$
M5@B1,E+.VW?-Y*$L2QP9&^8A0%5?MZBBOCL5B:N(JNM6=Y,U225D%%%%8#"B
MBB@ HHHH *SO%W_(J:G_ ->DO_H!K1K.\7?\BIJ?_7I+_P"@&KI_&B*OP/T+
M>G?\@^#_ *YK_*IJAT[_ )!\'_7-?Y5-4O<J.R"BBBD,**** "BBB@ HHHH
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 ?U>?\&U_B+^R_P#@B?\
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MO_ 7_P"O1_PF?_4*UK_P%_\ KUM44<]/^7\0Y*G\WX&+_P )G_U"M:_\!?\
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MU_X"_P#UZVJ*.>G_ "_B')4_F_ Q?^$S_P"H5K7_ ("__7H_X3/_ *A6M?\
M@+_]>MJBCGI_R_B')4_F_ Q?^$S_ .H5K7_@+_\ 7H_X3/\ ZA6M?^ O_P!>
MMJBCGI_R_B')4_F_ Q?^$S_ZA6M?^ O_ ->C_A,_^H5K7_@+_P#7K:HHYZ?\
MOXAR5/YOP,7_ (3/_J%:U_X"_P#UZ/\ A,_^H5K7_@+_ /7K:HHYZ?\ +^(<
ME3^;\#%_X3/_ *A6M?\ @+_]>C_A,_\ J%:U_P" O_UZVJ*.>G_+^(<E3^;\
M#C]=\8YU_1/^)7K/%Q)_RZ]?W,GO6M_PF?\ U"M:_P# 7_Z]/U[_ )&#0_\
MKXD_]$25KU<IT[1]WIW\V94X5.:7O=>WDC%_X3/_ *A6M?\ @+_]>C_A,_\
MJ%:U_P" O_UZVJ*CGI_R_B:\E3^;\#%_X3/_ *A6M?\ @+_]>C_A,_\ J%:U
M_P" O_UZVJ*.>G_+^(<E3^;\#%_X3/\ ZA6M?^ O_P!>C_A,_P#J%:U_X"__
M %ZVJ*.>G_+^(<E3^;\#%_X3/_J%:U_X"_\ UZ/^$S_ZA6M?^ O_ ->MJBCG
MI_R_B')4_F_ Q?\ A,_^H5K7_@+_ /7K)USQCGQ!HI_LO6>)Y/\ EUZ_N7]Z
M["LC7?\ D8M$_P"N\O\ Z)>KISIW^'H^OD9585.7XNJZ>:&?\)G_ -0K6O\
MP%_^O1_PF?\ U"M:_P# 7_Z];5%1ST_Y?Q->2I_-^!B_\)G_ -0K6O\ P%_^
MO1_PF?\ U"M:_P# 7_Z];5%'/3_E_$.2I_-^!B_\)G_U"M:_\!?_ *]'_"9_
M]0K6O_ 7_P"O6U11ST_Y?Q#DJ?S?@8O_  F?_4*UK_P%_P#KT?\ "9_]0K6O
M_ 7_ .O6U11ST_Y?Q#DJ?S?@8O\ PF?_ %"M:_\  7_Z]'_"9_\ 4*UK_P !
M?_KUM44<]/\ E_$.2I_-^!R&M>,<^(=&/]EZSQ++_P NO7]TWO6K_P )G_U"
MM:_\!?\ Z]2:W_R,>B_]=9?_ $4U:U7*=.T?=Z=_-F5.%3FE[W7MY(Q?^$S_
M .H5K7_@+_\ 7H_X3/\ ZA6M?^ O_P!>MJBHYZ?\OXFO)4_F_ Q?^$S_ .H5
MK7_@+_\ 7H_X3/\ ZA6M?^ O_P!>MJBCGI_R_B')4_F_ Q?^$S_ZA6M?^ O_
M ->C_A,_^H5K7_@+_P#7K:HHYZ?\OXAR5/YOP,7_ (3/_J%:U_X"_P#UZ/\
MA,_^H5K7_@+_ /7K:HHYZ?\ +^(<E3^;\#%_X3/_ *A6M?\ @+_]>C_A,_\
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M'_4/U3_P'_\ KUJ44<\/Y?Q#DG_-^!E_\)1_U#]4_P# ?_Z]'_"4?]0_5/\
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MGB#2_#NK^)-'L=6N7MGO8(IS=HD.FRV7V6!+B%I#<7]O+M\QEA954O7\!?\
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M!OB67P)+\9[[6[C4O$]K:6MWJ%A::39)=/;VD=W%+;^?.TB+NEBD"1),P7<
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MBF[T_P >&_%N-=BMI;*XLT.GQ&Y:,3GSXY# $Q'Y<D^Y_*[/P9_P5L@\5?\
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MSX[_ /A?ZK_\?KP>BCZI0_D7W(+L]X_X>F?M.?\ 1QGQW_\ "_U7_P"/T?\
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MK\#]"WIW_(/@_P"N:_RJ:H=._P"0?!_US7^535+W*CL@HHHI#"BBB@ HHHH
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MUM?$M\+?4[NUN1J:SQ7"7D-Q%*LUO,DT$4B- Z%&C!7!KR[Q#_P2N^'%_?\
M@F+3)/$NAZ/X2U;5M>E6U\2ZNFL7^H:A"L4UT-76\6^BF;#>8XE)E$LBN<2/
MNFG4P3C[\6G\[6MZ[W_I#]XY*+_@K2D'PY_MJ^^'\]I?ZGX,?6_#^F#65>37
M=;@U7^Q[S14?R0H\J_FT^-;@;O,6^5_*3;M;[!M&E>TB,Z1QSE 9$C<NBMCD
M!B 2,]\#/H*\*\:_\$_/!OB/Q'\"O[.M;#1?#/P(U*74]+TB.T:1KI_LCP0(
M9S)N"I*R7+%ED:6:WA9F!5MWO-<V)E0:7L5;>_WZ+[M?F-7ZA1117(,****
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MU\=__!UI7_RMIOB_+EU?W"5-MM+H?S545_2K_P 0;_[,?_0]?'?_ ,'6E?\
MRMH_X@W_ -F/_H>OCO\ ^#K2O_E;2_UQR[N_N'[&1_-517]*O_$&_P#LQ_\
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MANS\$_L\>#_ASX9\4Z+HND&PTCQGJ5[JVJV27<[6[W-X!]J>)&<K;B5MTCI
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M7BN/EE>W)KMUW^\?(_YG^'^1T_V[7/\ H&:;_P"#!_\ XS1]NUS_ *!FF_\
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MJM<&WA9@\HB5T+E =@=2<9%&JT<//KM]X<C_ )G^'^0_[=KG_0,TW_P8/_\
M&:/MVN?] S3?_!@__P 9K7K(\=^/M"^%OA"_\0>)M:TGP[H.E1&>^U+5+R.T
ML[.,<%Y)9"$1>1RQ YJ5)-V4?S_S#V<OYG^'^0?;M<_Z!FF_^#!__C-'V[7/
M^@9IO_@P?_XS5J^\2Z=I?AR;6+F_LK?2;>V:\EOI9U2VB@5=[2M(3M"!06+$
MXQSG%<E\%/VH?AI^TK%J+_#GXB>!?'Z:.8UOV\-Z]:ZJ+$R;O+$I@D?9NV/M
MW8SL;'0U2NTY*&B]?\PY)?S/\/\ (Z/[=KG_ $#--_\ !@__ ,9H^W:Y_P!
MS3?_  8/_P#&:UZ*GG7\J_'_ ##V<OYG^'^1D?;M<_Z!FF_^#!__ (S1]NUS
M_H&:;_X,'_\ C-8OP5^/WA+]HC0]7U+P=JW]L66@ZW>^';Z3[+-;^1?V<QAN
M8<2HI;9(I7<H*-C*L1S78TY>Z^64;/Y_YAR2_F?X?Y&1]NUS_H&:;_X,'_\
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M?_!@_P#\9K7HHYU_*OQ_S#V<OYG^'^1D?;M<_P"@9IO_ (,'_P#C-'V[7/\
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MJJ*/]3LN[/[P]M(_I5_XC(/V8_\ H1?CO_X)=*_^65'_ !&0?LQ_]"+\=_\
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M,OAW0?%:W6H+)I\']FZW-<0:5,9+A44-<RVLT:Q$^8&559%+H&]/K\T_@O\
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MGTJ'XWZ++K?PN\53VVB_V?XPD/AS7X[ZW73[>SU#5;RYCO+L023%)=+BMH)
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MDSX.HK[O_P"(9O\ ;<_Z(I_Y>&@__)U'_$,W^VY_T13_ ,O#0?\ Y.KI_M?
M_P#/Z'_@2_S%RR['PA17W?\ \0S?[;G_ $13_P O#0?_ ).H_P"(9O\ ;<_Z
M(I_Y>&@__)U']KX'_G]#_P "7^8<LNQ\(45]W_\ $,W^VY_T13_R\-!_^3J/
M^(9O]MS_ *(I_P"7AH/_ ,G4?VO@?^?T/_ E_F'++L?"%%?=_P#Q#-_MN?\
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M; _\_H?^!+_,.5K<^%:*^[_^(9O]MS_HBG_EX:#_ /)U'_$,W^VY_P!$4_\
M+PT'_P"3J7]KX'_G]#_P)?YARR['PA17W?\ \0S?[;G_ $13_P O#0?_ ).H
M_P"(9O\ ;<_Z(I_Y>&@__)U']KX'_G]#_P "7^8<LNQ\(45]W_\ $,W^VY_T
M13_R\-!_^3J/^(9O]MS_ *(I_P"7AH/_ ,G4?VO@?^?T/_ E_F'++L?"%%?=
M_P#Q#-_MN?\ 1%/_ "\-!_\ DZC_ (AF_P!MS_HBG_EX:#_\G4?VO@?^?T/_
M  )?YARR['PA17W?_P 0S?[;G_1%/_+PT'_Y.H_XAF_VW/\ HBG_ )>&@_\
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M:Q> _B7\&;^\D^SZ9#K$TEW<,#MA59;-B3C_ &0Q_ UTOQZ^,GP._:0\!?\
M"/:SX]L8K<7"7,4MI*5EBD4, 1E"#PS#!'?UKV+XN?!;PM\>/"AT3Q;HUMK6
MF^8)5BE+(T;@$!D="'1L$C*D'!([UY;I?_!,3X':/>13P^"/GB8,HDUC4)4)
M'JK3E6'L017XQF?"^;/'8VK@O8SI8ODYXU>?[,%"WN[II7[GZ5E6?Y&L#A(8
MUUZ=?#\W+*ER6?-)R3]YIIJ]MFC@_P!EK]G.Q\#_ +*WC.Q^)$/]G^&-:O1>
M(\\H$B6ZA/+F)7.T[@"..W(P>?.)?V;_ -FPN2/BSJ:#/ \^+C_R!7W+XW\
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MLZZ_J>J_#[X8_#WP+JFMJ$U&\\/>'+/3+B_4,7 F>"-6D&XD_,3R2:]#HHH
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M=%5/[?L?^?VT_P"_R_XT?V_8_P#/[:?]_E_QHY9=@YX]RW153^W['_G]M/\
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M53^W['_G]M/^_P O^-']OV/_ #^VG_?Y?\:.678.>/<MT54_M^Q_Y_;3_O\
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M]OV/_/[:?]_E_P :.678.>/<MT54_M^Q_P"?VT_[_+_C1_;]C_S^VG_?Y?\
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M+7^M^)+&PU*T_L_2KV^LX;:_?R[&2YNX87M[07+X2'[1)'YK%0FXD \O:?\
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M_P#"/V'_ #Y6G_?E?\*/^$?L/^?*T_[\K_A5RBCGEW#DCV*?_"/V'_/E:?\
M?E?\*/\ A'[#_GRM/^_*_P"%7**.>7<.2/8I_P#"/V'_ #Y6G_?E?\*/^$?L
M/^?*T_[\K_A5RBCGEW#DCV*?_"/V'_/E:?\ ?E?\*/\ A'[#_GRM/^_*_P"%
M7**.>7<.2/8I_P#"/V'_ #Y6G_?E?\*/^$?L/^?*T_[\K_A5RBCGEW#DCV.>
MU+0K(>+]+'V.UP8;C(\E>?\ 5^U:O_"/V'_/E:?]^5_PJIJ?_(XZ5_UQN/\
MVG6=\;?C%H7[/?P?\3^.O%%T;+P]X1TRXU;49@-S)!#&9'VCC+$+@#N2!WK6
M\Y<L8[O_ #9E"$>:6G7]$:&OMH'A32)K_5/[(TVPMEWS7-UY<,,0]6=L #ZF
MO&+O_@H_^RUI\YBG^//P!AE4X9)/&VD*P[=#-7\LO_!3[_@K%\3O^"GWQFU'
M6/%&K7MAX-@NW?0/"L$Y%AI$ XCW*.)9]O+RMDEF;;M7"CY<K[S"\%2=-2Q%
M5J79=/F0YQZ(_LY_X>6?LJ?]%_\ V?/_  N-'_\ C]'_  \L_94_Z+_^SY_X
M7&C_ /Q^OXQJ*Z?]2*7_ #^E^ N==D?V<_\ #RS]E3_HO_[/G_A<:/\ _'Z/
M^'EG[*G_ $7_ /9\_P#"XT?_ ./U_&-11_J12_Y_2_ .==D?V<_\/+/V5/\
MHO\ ^SY_X7&C_P#Q^C_AY9^RI_T7_P#9\_\ "XT?_P"/U_&-11_J12_Y_2_
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M/+/V5/\ HO\ ^SY_X7&C_P#Q^OXQJ*;X*I-+][+\"4TFW;<_LY_X>6?LJ?\
M1?\ ]GS_ ,+C1_\ X_1_P\L_94_Z+_\ L^?^%QH__P ?K^,:BE_J12_Y_2_
MKG79']G/_#RS]E3_ *+_ /L^?^%QH_\ \?H_X>6?LJ?]%_\ V?/_  N-'_\
MC]?QC44?ZD4O^?TOP#G79']G/_#RS]E3_HO_ .SY_P"%QH__ ,?H_P"'EG[*
MG_1?_P!GS_PN-'_^/U_&-11_J12_Y_2_ .==D?V<_P##RS]E3_HO_P"SY_X7
M&C__ !^C_AY9^RI_T7_]GS_PN-'_ /C]?QC44?ZD4O\ G]+\ YUV1_9S_P /
M+/V5/^B__L^?^%QH_P#\?K,UC_@I/^RR^N:04^/OP ,:32&0KXXTC"CRG S^
M_P#7%?QLT54>"J2=_:R_ F34E:Q_9S_P\L_94_Z+_P#L^?\ A<:/_P#'Z/\
MAY9^RI_T7_\ 9\_\+C1__C]?QC45/^I%+_G]+\"N==D?V<_\/+/V5/\ HO\
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M_"C_ (1^P_Y\K3_ORO\ A7 ?MD?M#?\ #)?[*GQ!^)O]E1ZY_P ()H-UK?\
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MO<J.R"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH *R/#/_(1UO_K_ /\
MVA#6O61X9_Y".M_]?_\ [0AJX_"_ZZF4_BC_ %T9QW[87[/[_M6?LL^/_AM'
MK"^'W\;Z'=:,NI-9_;!8F:,H)3#OC\S;G.W>N?[PZUR2?LW_ !%^(6K_  ]U
M/XC^/O!6M:E\._&)\46C>&O!EUHL%U$=)U#3_LSI/J=XP?=?F7S0^,1!/+^;
M>/4/C!\7_#?P"^&.M>,_&&JPZ'X8\.6K7NI:A,CM'9PK]Z1@H+;1GD@<#FO+
MO$'_  4B^$WA/P]I&J:KJ/C'3+35K&35I/M?@37H9="L$FDA-]JL368DTFT+
M0S%+F_6WA=()I$=HXG98-2M\%?V&/^%/_%3PUXF_X2C^T?\ A';SQ]=?9O[-
M\G[1_P )1XBBUK;O\UMOV7R_)S@^;G?^ZQLKFOA__P $]_$GAKQ7X5L-7^)&
MGZQ\-?ASJ^JZ_P"$M$A\,&TU:VO+V*]@C%]J'VMX[J"W@U&[2-(K6W=L0-)+
M(8W\WT3Q;^W?\-/ ^K_$*VU+4O$4-O\ "O2KO6?%.J1^$]7FT?2X+6V2ZN%_
MM!+5K26>.%U8V\4KS=1Y>Y2!G?M/?MAV7PG\,:U;>&;FPO\ QAH+>%;Z[L;R
MTG,4.G:WK9TV&?<-BLS"WOMJJY9&@4NNUE#@'GGAG_@ES_PCOP]MM!_X3GSO
ML_@7X=^"O/\ [%V[O^$3U.\O_M.WSS_Q]_:_+\O/[GR]VZ7=M'<1?L3RZ=/I
M-S!XC2:;1?B=J'Q)CC>Q,:W#74%[$+$L)&*!3>9\[:V?+_U?S<8O@?\ X*C^
M ]>B^)4NM:3X]T"'X=^*QX5&?!.O7,NMS.T21?8XEL ]S,SR-FWMA,Z1H)FQ
M$P>O4/B1^T/9>#/@YX?\96T*Q6/B+5]"TRWC\00:AHTR?VKJ-I80K) ;22YB
MGWW<86&:"/\ >$+*]NN^6, ^ _\ @G%^S?\ M.?LD>#/$L-O\*]+'B6'X?C1
M])O_ !7J!=(]8A>-;*"%H_$FI1_V2))KN>Y2UM-(&V*/R;8LRP0_<?[6W[(&
MB?ME^"_!_A[QC'H>JZ)X>\2V7B'4M-U+1H]0L-<6W253;/!*Q4(YDW9;S-NT
M<-UJ/P)^WU\*_B5\9CX!T;7]2N?$?]IZCHJ^9X>U*WL)=0T]YEO+)+Z2W6T>
MZB$$KF!93(8D\T*8R')\?_VHM7^"'QR^%/A6/P/<ZIHGQ(U_^P)_$+ZK#;P:
M9.UC?W:(D #S3OML6W!EBC E0K([!D !>LOV4=#\+_&GX;^)/#46E>%] ^&O
MAG6?#-AX<TS2X[:S6*_FTR13$(RJ0I%_9V!&L9#>=U79AOE'Q+_P0S;7]#^%
M>F2>//"&IP_#CP=X/\*)?:]X 75M4L7\/R^8;K1IY+T)I)OL*ER!%.[(B 2!
MD1E[?]I?_@M7\,OV6HOVC-.\3:QX$TOQI\#L?V/X7U3QI::?JGCG=H-CJL7V
M>&1?-3S)+QK5=B39:$L,D^6OT[\:O$WC7PSX5@;P#X3T?Q?X@NKI8%MM7UXZ
M)IUK'M=WFGN4M[F55^0(HBMY6,DL8(1-\J 'S+\6/^"4=U\=O$WQ;?Q%XP\*
MZ;X;^)6G75HF@^&?",VGV%S=M?VMY:ZGK-O-J%Q:ZK?0_8H86G6WMFGADFCD
MRAA2'U[]B/\ 9*C_ &1_!.L:6-'^"NDS:M?"Z;_A6WPZ'@FRE41JJ^?;_;;L
MS2@AOWF]?E(7;QD^5:-_P4O\9?%WX<^$KKX9?"C1O$OBS5_!][XPUG2]7\9G
M2K'3HK2Z^QM!:W<5E<M>//<I/]G<P0Q210F1WA+I&V[XC_X*(:S%X.^%'Q%T
M/X>VNH_!GXI'PM';ZW>>(Q::_')X@G@AM?(TI+:59TB-U;M-NNHG5?.*1R"+
M+@'3?L]?LS?$SX5_M.?$7QUXF^(?@7Q'HWQ":WDETC3/!%UI5U9/:Q+!;%;J
M35;E6 B!\P& ;W(93&!L/*>-_P#@GEXG\0_%;7+K3/B98:7X \0_$+1/B9>:
M!+X6^TZC_:>GSZ;(\"7_ -J51:3#3E.S[.94EDW"9HU\AMCP)^W=J/B_]N2_
M^$+>'O!4UO9I?---HOC=-7\0:$+?RS%-J^EQVP33X+I7W0,;N21@\(:)&:18
MOI"@#Y>\!_L">+?!_CGPY#<?$S2M0^'/@'Q'JGBWPKH7_"*&+4[>_O%O1''?
M:@+PI=6MN=0N2D<5M;RML@\R=]DGF^::O_P1B;QE\$W\,^(/$?PQU%]*\7V/
MBWPSX>'P[F?X=Z$UO9SV<EL/#ESJDZ^5-%>7;.L%U;QB=H9E02(YF^[** /G
MU/V"-&U__@G_ *]\"-6M_ GA_3O$NE7^F7C_  _\(1^&='MC<O(PFMM->:Z2
M-EW(7#RR+*ZNQ #[!YIX:_X)97OA'X"Z]X2TO3OV3="U'7-3LKZ2\T'X%3Z-
M9D6R2^7*T%MKB3?;HI9!)!=QW,;6YW[%W,'3[-HH ^;O@W^QG\0_V?O'NBZE
MX>^+5EK6GW.B:#H_C$>+O#<^L:IX@?3(6MVO(+U+^!K>XN(F_>-<)=_.BO@D
MN'\0^&/_  0W/@"S\>12>.?!QN?&?@K4?!DNK:9X 6PUG5#=W<-S_:FL7AO9
M)-4O\Q,'E;RE<R%E2/+!OT HH ^.S_P2D:;_ (*$V7QPF\3^#KE=-\4S>*;?
MSO!"R^+&,NCOIG]FOKK79/\ 9L?FR2QVT=J@4^6"S;2S=%\/?^"=NIZ-H/A?
M0?$WCG3M?\.>#-1U\Z7!9>'GT^[?3-4MKF 6MQ,;N59)XOM+G[1''$KA5'DH
M<L?J*B@#XVU;_@E_XP^)GPKU;PSX^^+>E^(/L?PUU'X9>$KS3O!W]F/IEI?Q
MVT=S>Z@IO95OKMA8V6/)^QPC;/B(>:OE?1G@[X(_\(G^T1XY\??VG]H_X3/2
MM(TS[#]FV_8_L#7IW^9N._S/MG3:NWR^K;N.]HH **** "BBB@ K$\)_\@R;
M_K^N_P#TIEK;K$\)_P#(,F_Z_KO_ -*9:UC\#^7ZF,_C7H_T/XUO^"I?_*3C
M]HS_ +*AXF_].MS7@]>\?\%2_P#E)Q^T9_V5#Q-_Z=;FO3/^"'G[!WPX_P""
MD/[:TOPM^).O>)O#]KJ7AR^O=%ET*ZMX+BXU&!HG$;&>&56C^SBY<JJAOW8.
MX '/[A#$0H8-5JFT8IO[CGM=V/CNBOU$_P"")O\ P0*T3_@H+XH^..F?%C5/
M%WA<_"W4X_#5E+H-W;1)<:L&N1<QN9H)2ZQ"&,D*$.)1SZ>0?L9_\$KM ^(W
M['O[6GQ.^+5YXH\,/\ +)M,T:/3[JVB@O?$/[^/[+<>9%(719Q:(50QLWV@;
M7STSEF^&4YPOK'EO_P!O;6[CY&?#5%?6VF_\$)?VMM7^!G_"QH/@GXD;PM_9
MYU0,UU9I?O;A/,WK8F87;$KR%$)8]@:Y/]CW_@DS^T/^WQX2OM?^$_PRU3Q1
MH>G3&VEU%[VTTZU:4#)2.2ZEB61AQD(6*Y&<9%='U_#<KG[2-EN[K3U%ROL?
M.M%?0/PH_9)\+_#G]JKQ'X!_:<\3:_\ !*W\$V[3:K;PZ&^IZI?7"R0;;&W1
M"8U>:*5I4G<F'8@;+!ESZG_P7@_X)P^"?^"7?[9VE?#KP%JOBG6-%OO"EIKD
MD^OW$$]T)Y;BZB90T,,*[,0*0-N<D\GC"^O4O;1H+>2NM-&EY[/?H%G:Y\5T
M5]J?\$NO^"</@K]MW]EG]JWQQXIU;Q3IVJ_ KP,_B;08M*N(([>\N5M-1GV7
M2R0R,\>ZTC&(VC.&;YNF,+X._P#!"C]J[X_>#?"WB'PC\(K_ %C0O&FE?VUI
M%^NM:9#;W%J=N'=Y+E1"QW#:DNQV&2%.TXF68X:,Y0J34>6R=W;=7Z^0<KZ'
MR117ZB?\$1O^"1?A[XX_M/?M!?"_]H/X<:M+XL^''A1IK71Y;ZZL[C3M09P(
MY%^S2J)MRLC)DO&ZNK ,&!KY<^.?_!(C]H']C%_!FM?%OX3:WH_AGQ/K%MIT
M+0ZC97'VF21@1;,\$S_9Y77<%\[9R#_=.(CFF&E6E0YO>5NJUNK^[KJ'*[7/
MEZBOW ^!?_!(_P" OQ;_ ."U?C_X3ZS^S_XO\ >"-)^#K>)=/\)ZYXF>XO8]
M2%[9PK>+<6&HW.Y66:11&;AUR#E < ?FC^U5_P $A/VC_P!B7X46OCCXG?"W
M5O#/A6[FCMQJ'VVSO4MY),[%F6WFD:#<1@>:%^8A>I K/#9QAJT_9IV;2:NU
MK?M9N_G8;@UJ?-M%?L-\0O\ @WXM?VQ_^"B.C_#[X:?#KQ7^S1X%TGX=Z=KG
MB6X\0WUEXDN%N[B?4$ANHXHM5F+QW!M3$ LRF,P.S1H&7=\0_$'_ ((P_M%>
M"OVQI/@=:_#K4]9\=26#:U9VMI=V<JS:7YTD4=[++'.\-NCM&1B652"54\LN
M:H9QA*NBFD[7:;6B_+\0<&CY7HKZ5_:5_P""/W[2'[(.M>$['XB?"_4O#\GC
MC58M#T28:C97EK>7TIQ%;F>WFDBCD;D@2.N0K'HK$3_M*_\ !&S]I7]C[X1Z
MOX[^(_PPO/#/A/0KZ+3KS4)-7T^X1)I2JH$6&=WD4LP7>BL@.06!! Z(X[#2
MY>6I'WMM5KZ=Q<K/F.BBBNLD**** "BBB@ HHHH **** /ZS?^#9K_E"+\%/
M^X[_ .G[4:^T?B;\+/#'QJ\$7OAGQEX<T'Q;X;U+R_MFDZUI\5_8W?ER+*GF
M0RJR/MD1'&0<,BD<@5\/_P#!M7XDMM,_X(G?!2*5+TL!KAS%932K_P A[4?X
ME4C]:^Z/^$TLO^>>I_\ @MN?_B*_$,TA46/K2BG\<O\ TIG4JM-*S:/,OV(?
MV)_!G["WP5LO"?A31/#%C=;%_M74])T*#2I-:E4MMEG6/)=E5MH+LQ []J\H
M\!_\$G-,\'?$;X2Z_+XRN[N/X=_:O[9TY--6.U\8%;ZZU#2C.#(QB.G7=Y/-
M$5+;G?)P.*^I/^$TLO\ GGJ?_@MN?_B*/^$TLO\ GGJ?_@MN?_B*Y_;XKFE+
M6\M]/5?K_5D'M:7\R^\^6['_ ()H^)O OAOP!#X,^*.GZ)J_A/PMK/@O4KZ^
M\*?V@FIZ=J=W!=2/!%]KC^SW43VZ^7([3Q_,V^%Q@"[+_P $SKB#X4ZSH%EX
M[C@U"]\&>"_#%E?2:'YD=I<^&[FXN8;N2'[0#+'-),FZ$.A58R!*2P9?I?\
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M_P#PD_V?_A+_ (B^&?'_ )?]G;_LG]C+I*_9,^:-_G?V7_K,+L\_[C[/FPO
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MG_A-++_GGJ?_ (+;G_XBC_A-++_GGJ?_ (+;G_XBCV4^S#VU/^9?>:U%9/\
MPFEE_P \]3_\%MS_ /$4?\)I9?\ //4__!;<_P#Q%'LI]F'MJ?\ ,OO-:BLG
M_A-++_GGJ?\ X+;G_P"(H_X32R_YYZG_ ."VY_\ B*/93[,/;4_YE]XFO?\
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MF_X32R_YYZG_ ."VY_\ B*3I3OLRHUJ=OB7WFM163_PFEE_SSU/_ ,%MS_\
M$4?\)I9?\\]3_P#!;<__ !%+V4^S*]M3_F7WFM163_PFEE_SSU/_ ,%MS_\
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M4&DK\;OV@6^)'BAL&19M+$,$6I#_ &5)GC<8_BR0#\PKA?\ @O'/X _X)N_
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M5L_X*T7OA7P/\-?"4GQ&\)> [)]9T7P_X\M-6AMXHIOF>:^NDLT,Z&]MXWC
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MRJTX[N<E]\F=T?A1[A17Q&G_  4L\2_LH_%*YT+]H.\\&7OAZ[^&]Q\2=/\
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M"G1]"\56FN^!-$FLAJ>FZI=+8&.33[F\G:.:"[W$LMTXEB<$(CIMDQ?VKO\
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MUND@Q@^88J[_ /:.^.VL?"'4OA-%IUC9X\>>-;3PYJ$=\A>2UMY;.\G8H8Y
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MS2LF]S*&?F5E 45?#G_!&'X>:3X(OO#NI>,_B9XFTB/P!JGPS\.0:I>:>?\
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MK7A77_$'BFYU:XO+0W?B/4];M9+2\N;W;;+&2(I (U@2%$\J,;2J[3RFK_\
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M"3'QM\4Z)<RV>J1Z(FF6]Q%GS(#?74%B74CD,HN20W8@'M7TWJ?_ "..E?\
M7&X_]IUY[^W7^RU9?ML?L??$/X5WTZ6:>-=%FL8+EUW+:7/#V\Q'<1S)&Y Y
M(7C%=F%G"%>E.I\*:OZ<VIC'>=N_Z(_B<HKJ_CE\$?%/[-OQ>\0^!/&NCW>@
M^*?"]X]CJ-C<IM>*1>A!Z,C*5='7*NC*RDJP)Y2OW:,E)*4=F<H44450!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '[/_ /!F7\>-;TW]
MJ;XK?#'[3(_AS6?"H\4&W9B5AN[2[MK8.@Z*7CO2&(QN\J/.=HQ_0[7XQ?\
M!HG_ ,$[M>^"OPO\7_'?Q9I\^F3_ !#M8=(\,P3HT<KZ:C^;-<E3_!-*L(0X
MY$!8?*X)_9VOQSBBK3J9E-TO)/U2U_R.RE=1U"BBBOGC0*R-=_Y&+1/^N\O_
M *)>M>LC7?\ D8M$_P"N\O\ Z)>KI[_)_D95OA^:_-&O1114&H4444 %%%%
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M$VPC.I>(=:TS2;>ZTZ.RT*_USSS?W4#"S^T/(9;AY8_M$TPB; 0"/*&_:_\
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M .E,M;=8GA/_ )!DW_7]=_\ I3+6L?@?R_4QG\:]'^A_&M_P5+_Y2<?M&?\
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MM'_$&_\ LQ_]#U\=_P#P=:5_\K:_5#^V]2_Z LW_ ($Q?XT?VWJ7_0%F_P#
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MX\LJSMZH.:GV?W/_ "-2WMTM($BB1(XHU"(B+A4 X  ["GUD?VWJ7_0%F_\
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M?^!,7^-']MZE_P! 6;_P)B_QH]F_+[T'M8^?W/\ R->LCPS_ ,A'6_\ K_\
M_:$-']MZE_T!9O\ P)B_QK+\.ZSJ"W^L8T>9LWV2/M$?RGR8N.O^<UI&F[/;
M[UW,IU8\T=_N?;T(OC]\$='_ &CO@]KW@K7GOH--UZW$37-C,(;NRE1UDAN(
M7((66*5(Y$)5E#1KE6&0?(Q_P3@TBZL=;N]0^(_Q0U3QKK6L:;KX\87%SIJ:
MKI]_81O#;S6\,=DEC&/L\C0/%]E,4B,Y>-I))'?W7^V]2_Z LW_@3%_C1_;>
MI?\ 0%F_\"8O\:NG4JP7+%Z>J_KHC3VD?/[G_D>!^//^":6C?$/X%:WX O\
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M]+TK1X=$;3UEDBD@G=_M6G3SL989&C8>=@#!0(WS5ZE_;>I?] 6;_P "8O\
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M3[<1@:=;F?39+NVM9#&K2)!<HSN=Y;<%9?9?[;U+_H"S?^!,7^-']MZE_P!
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MA22T>UQ);VV)$D@="9Y=JH"@3V3^V]2_Z LW_@3%_C1_;>I?] 6;_P "8O\
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MO'_!4O\ Y2<?M&?]E0\3?^G6YKP>OW3!_P "'HOR,'N%%%%=(@HHHH ****
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M-4.G?\@^#_KFO\JFJ7N5'9!1112&%%%% !1110 4444 %%%% !1110 4444
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M 4444 %%%% !1110!_6;_P &S7_*$7X*?]QW_P!/VHU]WU\ _P#!M7%J;_\
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MW?#OXJ^%]3T3Q1X"\%^)-%UN_75=1T_5-$MKRUO[Q55%N9HY$99)@J(H=@6
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M ,<H\C7?^?K2?_ 63_XY6GUBM_S\?WL7/_=?X?YGCO\ PZT_9C_Z-S^!'_A
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MI7_QBO8O(UW_ )^M)_\  63_ ..4>1KO_/UI/_@+)_\ '*/K%;_GX_O8<_\
M=?X?YGCO_#K3]F/_ *-S^!'_ (0&E?\ QBC_ (=:?LQ_]&Y_ C_P@-*_^,5[
M%Y&N_P#/UI/_ ("R?_'*/(UW_GZTG_P%D_\ CE'UBM_S\?WL.?\ NO\ #_,\
M=_X=:?LQ_P#1N?P(_P#" TK_ .,4?\.M/V8_^C<_@1_X0&E?_&*]B\C7?^?K
M2?\ P%D_^.4>1KO_ #]:3_X"R?\ QRCZQ6_Y^/[V'/\ W7^'^9X5K7_!+O\
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M_P".4>1KO_/UI/\ X"R?_'*.1=T'M'_*_P /\S6HK)\C7?\ GZTG_P !9/\
MXY1Y&N_\_6D_^ LG_P <HY%W0>T?\K_#_,-;_P"1CT7_ *ZR_P#HIJUJY768
M=:_M_1\W.E[O-EVXMI,#]TW7]Y6IY&N_\_6D_P#@+)_\<K24%:.JV_5F<*CY
MI>Z]_+LO,UJ*R?(UW_GZTG_P%D_^.4>1KO\ S]:3_P" LG_QRL^1=T:>T?\
M*_P_S-:BLGR-=_Y^M)_\!9/_ (Y1Y&N_\_6D_P#@+)_\<HY%W0>T?\K_  _S
M-:BLGR-=_P"?K2?_  %D_P#CE'D:[_S]:3_X"R?_ !RCD7=![1_RO\/\S6HK
M)\C7?^?K2?\ P%D_^.4>1KO_ #]:3_X"R?\ QRCD7=![1_RO\/\ ,UJ*R?(U
MW_GZTG_P%D_^.4>1KO\ S]:3_P" LG_QRCD7=![1_P K_#_,UJ*R?(UW_GZT
MG_P%D_\ CE'D:[_S]:3_ . LG_QRCD7=![1_RO\ #_,UJ*R?(UW_ )^M)_\
M 63_ ..4>1KO_/UI/_@+)_\ '*.1=T'M'_*_P_S-:L[Q=_R*FI_]>DO_ * :
MB\C7?^?K2?\ P%D_^.50\50:V/#&H[KG2ROV67<!:R D;#T_>5=."YEJB*E1
M\C]U[>7^9OZ=_P @^#_KFO\ *IJP["#7/L,.+K2L>6N,VLGI_P!=*F\C7?\
MGZTG_P !9/\ XY4N"ONBHU';X7^'^9K45D^1KO\ S]:3_P" LG_QRCR-=_Y^
MM)_\!9/_ (Y2Y%W0_:/^5_A_F:U%9/D:[_S]:3_X"R?_ !RCR-=_Y^M)_P#
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M)_\ '*/(UW_GZTG_ ,!9/_CE'(NZ#VC_ )7^'^9K45D^1KO_ #]:3_X"R?\
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M#7[-7QM^-NN>)[OXZ:M;Z_J3HLJ6.DMJMC!Y<:QJB-'&H*@*.DAZFO%?#'[
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MR3R9-I.QL;U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %8GA/_D&3?]?UW_Z4RUMUB>$_^09-_P!?UW_Z4RUK'X'\OU,9
M_&O1_H?QK?\ !4O_ )2<?M&?]E0\3?\ IUN:\'KWC_@J7_RDX_:,_P"RH>)O
M_3K<UX/7[M@_X$/1?D<SW"BBBND04444 %%%% !1110 4444 %%%% !1110
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M9]>J;[=D',C[]L?%.F:GKU_I5MJ-A<:GI2Q/>V<5PCSV:RAC$9$!W('"L5+
M;MIQG!J_7Y3^,OVC]7^"?Q&\2:MX>^*$'@WQS-X'\"77A7P);:1IJ1?$N^\E
ME;2XXY8&=T(DCB\K33!+ +H.S;3$%^F?^"MW[36O_L^^%O!-GX9\=/\ #K5O
M$EU?;-8O=;TO1=((M[;S!;S7%]I.J&2YD<H(+6"!7FVS?O%\L*Q++)^TA"+^
M+U[)OI^5PYM#Z_K/\1>*]+\(6<%QJVI6&EP7-U!8PRW=PD"2W$\JPPPJ6(!D
MDD=$11RS.J@$D"OSP\5?M=_&7QE\&-9^(FG_ !'NO#*^!_V>_!GQ5FT6PT/3
M9;37-6OO[<ENXIWN()94M94T^.,I"Z.N%9)$(?S(OVJ?V@=5\>?M-W7A;7_B
MHVBZEX8^-O@K3])^&*:?8_\ $QT8:CHTZ:PS&$WQW7,SC[0LPM5\L6YC\X[C
M4<KGS\LFO/?R\O->7=AS:'Z245\L?MV?M"?\*S^.?@+PUK_QF_X9]\"ZSHVJ
MZC<^+3_9$']H:C!-91V^FBZU6WN+.+,4]U,8_+\Z7R0495BE#^0^ _VM/BS\
M0?\ @H3JW@^Z^*OPQ\)Z=9>*;K0H?!6J>+K"WUW4M)2V+0:A9Z4^C&ZFN)4:
M.Y28:DULP#@P85E&-/+ZDZ?M$U:S?7IIV_KK8.;6Q^@M%?F?^Q_^U):_LI?#
MGX3V>O\ QTBN/"4?Q"\4^&_'S^)IM%M(/"=U''JLMM8W<L-M ;)Y)X!*!<,'
M=Y JG8Z1TSXA?\%$OB9;?"/X6:[I/CR>&T\8VNJOXWOGT"U,W@'0TU]+6+Q,
MT;PCRFBB+V_DW",C9:<Q$65T'V>4U>?EBU:]KZ^?EY?BNXN='Z9T5\)Q^/\
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MU'$<:*%51]  *M5PU)*3NE8[(1<59NX4445!84444 9.M_\ (QZ+_P!=9?\
MT4U:U9.M_P#(QZ+_ -=9?_135K5<MH^GZLRI_%+U_1!1114&H4444 %%%% !
M1110 4444 %%%% !1110 5G>+O\ D5-3_P"O27_T UHUG>+O^14U/_KTE_\
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M/:V$5]=31V4+?9[<,ELL:D6\(((C0#V.@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *Q/"?_(,F_P"OZ[_]*9:VZQ/"?_(,F_Z_
MKO\ ]*9:UC\#^7ZF,_C7H_T/XUO^"I?_ "DX_:,_[*AXF_\ 3K<UX/7O'_!4
MO_E)Q^T9_P!E0\3?^G6YKP>OW;!_P(>B_(YGN%%%%=(@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^LW_ (-FO^4(
MOP4_[CO_ *?M1K[OKX!_X-J]%DO_ /@B=\%'74;^V&-<&R$Q[?\ D/:EZH3^
MM?='_",3?]!G5O\ OJ+_ .-U^'9M&/UZMK]N7YLZHSE;2/Y%_5+ :KIMQ:M)
M/"MS$T1D@D,<B!@1E6'*L,\$<@UY9_PSUXLOO^/_ .*WBJX^W?Z/JGV>"&T^
MTVJ?ZH6_E@?9+CC][/%S)YLV%CQ;_9O1/^$8F_Z#.K?]]1?_ !NC_A&)O^@S
MJW_?47_QNO*J8:E4^)_FOR_K?N>E@<XQ>#35!+7O&$ONYD[=]+:I/>*:\[_X
M9Z\67W_'_P#%;Q5<?;O]'U3[/!#:?:;5/]4+?RP/LEQQ^]GBYD\V;"QXM_LQ
M_P ,]>++[_C_ /BMXJN/MW^CZI]G@AM/M-JG^J%OY8'V2XX_>SQ<R>;-A8\6
M_P!F]$_X1B;_ *#.K?\ ?47_ ,;H_P"$8F_Z#.K?]]1?_&ZR^H4.[^^7^?\
M6O=G?_K5F711_P#!=+_Y'2VENW+&WPQMYW_PSUXLOO\ C_\ BMXJN/MW^CZI
M]G@AM/M-JG^J%OY8'V2XX_>SQ<R>;-A8\6_V8_X9Z\67W_'_ /%;Q5<?;O\
M1]4^SP0VGVFU3_5"W\L#[)<<?O9XN9/-FPL>+?[-Z)_PC$W_ $&=6_[ZB_\
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M)O\ H,ZM_P!]1?\ QNC_ (1B;_H,ZM_WU%_\;HY8]PYY?R_D:U%9/_",3?\
M09U;_OJ+_P"-T?\ ",3?]!G5O^^HO_C='+'N'/+^7\C6HK)_X1B;_H,ZM_WU
M%_\ &Z/^$8F_Z#.K?]]1?_&Z.6/<.>7\OY&M163_ ,(Q-_T&=6_[ZB_^-T?\
M(Q-_T&=6_P"^HO\ XW1RQ[ASR_E_(UJ*R?\ A&)O^@SJW_?47_QNC_A&)O\
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M'2O^N-Q_[3K7KE-1\.3+XLTQ?[6U0[H9_F)BR/\ 5]/DK5_X1B;_ *#.K?\
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M^8T2NRJ7"E0S 9R0*_+WXDZ3\8O!/[+WA;0=*\7_ !P^(FE^(/&>M7<GB?\
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MI=R6G]G#3M!F:33-.F?[!*YNQ=$321NJR)*-RKYH/%>.[?XJGX+?$9/A+?\
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M]HVF=UD10I8&,4_?V\K=&^NVP<Q]P^)?&>C^"X[)M8U73=)74KR+3K-KRZ2
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M*_\ C%'^O-#_ )]/[T'L'W/XNZ*_M$_X=:?LQ_\ 1N?P(_\ " TK_P",4?\
M#K3]F/\ Z-S^!'_A :5_\8H_UYH?\^G]Z#V#[G\7=%?VB?\ #K3]F/\ Z-S^
M!'_A :5_\8H_X=:?LQ_]&Y_ C_P@-*_^,4?Z\T/^?3^]![!]S^+NBO[,=:_X
M)=_LSQ:YHZ+^SM\"U66>0.H\!:4 X$+G!_<<\@'\*T_^'6G[,?\ T;G\"/\
MP@-*_P#C%4^.*"2?LG]Z)5)MM=C^+NBO[1/^'6G[,?\ T;G\"/\ P@-*_P#C
M%'_#K3]F/_HW/X$?^$!I7_QBI_UYH?\ /I_>BO8/N?Q=UM?#OX<>(/BYXTT_
MPYX6T75/$6OZK*(+/3M.M7N;FY<]DC0%CZ]. ":_LJ_X=:?LQ_\ 1N?P(_\
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MBB@ HHHH **** "BBB@ K$\)_P#(,F_Z_KO_ -*9:VZQ/"?_ "#)O^OZ[_\
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MLU?YT'_$1,/_ ,^9?>CXTHK[+_X5?X9_Z%W0O_ "+_XFC_A5_AG_ *%W0O\
MP B_^)H_U9J_SH/^(B8?_GS+[T?&E%?9?_"K_#/_ $+NA?\ @!%_\31_PJ_P
MS_T+NA?^ $7_ ,31_JS5_G0?\1$P_P#SYE]Z/C2BOLO_ (5?X9_Z%W0O_ "+
M_P")H_X5?X9_Z%W0O_ "+_XFC_5FK_.@_P"(B8?_ )\R^]'QI17V7_PJ_P ,
M_P#0NZ%_X 1?_$T?\*O\,_\ 0NZ%_P" $7_Q-'^K-7^=!_Q$3#_\^9?>CXTH
MK[+_ .%7^&?^A=T+_P  (O\ XFC_ (5?X9_Z%W0O_ "+_P")H_U9J_SH/^(B
M8?\ Y\R^]'] 7_!LU_RA%^"G_<=_]/VHU]WU\2_\$&O FC)_P3%\"1)IEG%%
M%<ZDL<<<81$!OIF.%& ,EB?J37V'_P ()I'_ #X0?E7\W9]1C2S+$4Y/53ET
M\WYGZ)E^+EB<-3Q$8V4DGOW^1KUP'PB_90^%O[/VO:EJG@+X:^ /!&IZRNS4
M+S0/#UIIL]\N[=B5X8U9QN)/S$\G-=1_P@FD?\^$'Y4?\()I'_/A!^5>8I))
MI2=G_7<Z[U.R^_\ X!KT5D?\()I'_/A!^5'_  @FD?\ /A!^53:'=_=_P1WJ
M=E]__ ->BLC_ (032/\ GP@_*C_A!-(_Y\(/RHM#N_N_X(7J=E]__ ->BLC_
M (032/\ GP@_*C_A!-(_Y\(/RHM#N_N_X(7J=E]__ ->BLC_ (032/\ GP@_
M*C_A!-(_Y\(/RHM#N_N_X(7J=E]__ ->BLC_ (032/\ GP@_*C_A!-(_Y\(/
MRHM#N_N_X(7J=E]__ ->BLC_ (032/\ GP@_*C_A!-(_Y\(/RHM#N_N_X(7J
M=E]__ ->BLC_ (032/\ GP@_*C_A!-(_Y\(/RHM#N_N_X(7J=E]__ ->BLC_
M (032/\ GP@_*C_A!-(_Y\(/RHM#N_N_X(7J=E]__ ->BLC_ (032/\ GP@_
M*C_A!-(_Y\(/RHM#N_N_X(7J=E]__ ->BLC_ (032/\ GP@_*C_A!-(_Y\(/
MRHM#N_N_X(7J=E]__ ->BLC_ (032/\ GP@_*C_A!-(_Y\(/RHM#N_N_X(7J
M=E]__ ->BLC_ (032/\ GP@_*C_A!-(_Y\(/RHM#N_N_X(7J=E]__ ->BLC_
M (032/\ GP@_*C_A!-(_Y\(/RHM#N_N_X(7J=E]__ ->BLC_ (032/\ GP@_
M*C_A!-(_Y\(/RHM#N_N_X(7J=E]__ ->BLC_ (032/\ GP@_*C_A!-(_Y\(/
MRHM#N_N_X(7J=E]__ ->BLC_ (032/\ GP@_*C_A!-(_Y\(/RHM#N_N_X(7J
M=E]__ ->BLC_ (032/\ GP@_*C_A!-(_Y\(/RHM#N_N_X(7J=E]__ #4_P#D
M<=*_ZXW'_M.M>N4U'P5I2^+-,06,&UX9R1CKCR\5J?\ "":1_P ^$'Y5<E"R
MU>W;S?F94W4YI:+?OY+R->BORH_X*.?\%R=&^#WC?4?!/P:T+0M;U+2Y&MK_
M ,0WRM-9Q2CAH[>-67S"IX,C';D'"L.:^)K[_@L[^T9=W)>/QU96RGI'%X;T
MLJO_ 'U;D_K7WV6>&6;8V@J_NTT]4IW3MZ).WSL?(X_CS 86JZ-G-K?EU7WN
MWX']&%%?SE?\/E/VC_\ HH4'_A-:3_\ (M'_  ^4_:/_ .BA0?\ A-:3_P#(
MM>C_ ,0BS7_G[3^^7_R)P_\ $2<!_P ^I_A_F?T:T5_.5_P^4_:/_P"BA0?^
M$UI/_P BT?\ #Y3]H_\ Z*%!_P"$UI/_ ,BT?\0BS7_G[3^^7_R(?\1)P'_/
MJ?X?YG]&M%?SE?\ #Y3]H_\ Z*%!_P"$UI/_ ,BT?\/E/VC_ /HH4'_A-:3_
M /(M'_$(LU_Y^T_OE_\ (A_Q$G ?\^I_A_F?T:T5_.5_P^4_:/\ ^BA0?^$U
MI/\ \BT?\/E/VC_^BA0?^$UI/_R+1_Q"+-?^?M/[Y?\ R(?\1)P'_/J?X?YG
M]&M%?SE?\/E/VC_^BA0?^$UI/_R+1_P^4_:/_P"BA0?^$UI/_P BT?\ $(LU
M_P"?M/[Y?_(A_P 1)P'_ #ZG^'^9_1K17\Y7_#Y3]H__ **%!_X36D__ "+1
M_P /E/VC_P#HH4'_ (36D_\ R+1_Q"+-?^?M/[Y?_(A_Q$G ?\^I_A_F?T:T
M5_.5_P /E/VC_P#HH4'_ (36D_\ R+1_P^4_:/\ ^BA0?^$UI/\ \BT?\0BS
M7_G[3^^7_P B'_$2<!_SZG^'^9_0]KW_ ",&A_\ 7Q)_Z(DK7K^<:7_@L9^T
M9-+&[?$&#=$2R_\ %-Z3P2"/^?7G@FI/^'RG[1__ $4*#_PFM)_^1:I^$F:-
M)>UI_?+_ .1(CXCX%-OV<]?3LO,_HUHK^<K_ (?*?M'_ /10H/\ PFM)_P#D
M6C_A\I^T?_T4*#_PFM)_^1:G_B$6:_\ /VG]\O\ Y$O_ (B3@/\ GU/\/\S^
MC6BOYRO^'RG[1_\ T4*#_P )K2?_ )%KU/\ 9U_X+Z_$SX?>)K<?$#1O#OC_
M $)W N@+*/3K^->YB>$+%D9Z-&<XQE<YK&OX3YO3@YQG"371-W_%)?B:T?$7
M+YS491E%=W:WX7?X'[Q45Y7^S3\6?AU^UK\'=*\<>"C!?Z+JBD;779<6<J_?
M@F3)V2H>HR00002K*Q[W_A!-(_Y\(/RK\WK4/8U'2JW4D[--:I_>?<4JSJ05
M2G9IZII_\ UZ*R/^$$TC_GP@_*C_ (032/\ GP@_*L[0[O[O^":7J=E]_P#P
M#7K(UW_D8M$_Z[R_^B7H_P"$$TC_ )\(/RK+UKP5I4>O:,HL8 'FD##'7]TY
MJZ:A?=[/IY>IE5=3EV6ZZ^:\CJZ*R/\ A!-(_P"?"#\J/^$$TC_GP@_*HM#N
M_N_X)K>IV7W_ / ->BLC_A!-(_Y\(/RH_P"$$TC_ )\(/RHM#N_N_P""%ZG9
M??\ \ UZ*R/^$$TC_GP@_*C_ (032/\ GP@_*BT.[^[_ ((7J=E]_P#P#7HK
M(_X032/^?"#\J/\ A!-(_P"?"#\J+0[O[O\ @A>IV7W_ / ->BLC_A!-(_Y\
M(/RH_P"$$TC_ )\(/RHM#N_N_P""%ZG9??\ \ 76_P#D8]%_ZZR_^BFK6KE-
M9\$Z4FOZ.HL80KRR!ACK^Z8UJ?\ "":1_P ^$'Y5<E"RU>W;S?F94W4YI:+?
MOY+R->BLC_A!-(_Y\(/RH_X032/^?"#\JBT.[^[_ ()K>IV7W_\  ->BLC_A
M!-(_Y\(/RH_X032/^?"#\J+0[O[O^"%ZG9??_P  UZ*R/^$$TC_GP@_*C_A!
M-(_Y\(/RHM#N_N_X(7J=E]__  #7HK(_X032/^?"#\J/^$$TC_GP@_*BT.[^
M[_@A>IV7W_\  ->BLC_A!-(_Y\(/RH_X032/^?"#\J+0[O[O^"%ZG9??_P
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M]CQDI+FCL?S*TT[/<****H04444 %%%% !1110 4444 %%%% !1110 4444
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M21S,L&GPR0:G#)Y@=%N5B*,KY)$QV:NAA'*RE:U^J=]=-79;??T"[/J_Q/\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9&I_\
M(XZ5_P!<;C_VG6O61J?_ "..E?\ 7&X_]IUKU<MH^GZLRI_%+U_1'R]^W7_P
M22^%7[>%X-8UFVN_#?C!%5/[>T?9'/<JHPJ7","DP P 2 X"J X48KXYN/\
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M?\0M_P#U7/\ \LS_ .[J_6JBC_B(W$7_ $$?^20_^1#_ %(R3_GS_P"33_\
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MM7LO&7[8OPC^'/@WPSXB\0_%/X<:%X?\:JC^'=3U'Q+96MGKP=5=#:3/($N
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MJG=?=_P3(_X3[1/^@OIW_@0O^-'_  GVB?\ 07T[_P "%_QK7HHO#L_O_P"
M%JG=?=_P3(_X3[1/^@OIW_@0O^-'_"?:)_T%]._\"%_QK7HHO#L_O_X 6J=U
M]W_!,C_A/M$_Z"^G?^!"_P"-'_"?:)_T%]._\"%_QK7HHO#L_O\ ^ %JG=?=
M_P $R/\ A/M$_P"@OIW_ ($+_C1_PGVB?]!?3O\ P(7_ !K7HHO#L_O_ . %
MJG=?=_P3(_X3[1/^@OIW_@0O^-'_  GVB?\ 07T[_P "%_QK7HHO#L_O_P"
M%JG=?=_P3(_X3[1/^@OIW_@0O^-'_"?:)_T%]._\"%_QK7HHO#L_O_X 6J=U
M]W_!,C_A/M$_Z"^G?^!"_P"-'_"?:)_T%]._\"%_QK7HHO#L_O\ ^ %JG=?=
M_P $R/\ A/M$_P"@OIW_ ($+_C1_PGVB?]!?3O\ P(7_ !K7HHO#L_O_ . %
MJG=?=_P3(_X3[1/^@OIW_@0O^-'_  GVB?\ 07T[_P "%_QK7HHO#L_O_P"
M%JG=?=_P3(_X3[1/^@OIW_@0O^-'_"?:)_T%]._\"%_QK7HHO#L_O_X 6J=U
M]W_!,C_A/M$_Z"^G?^!"_P"-'_"?:)_T%]._\"%_QK7HHO#L_O\ ^ %JG=?=
M_P $R/\ A/M$_P"@OIW_ ($+_C1_PGVB?]!?3O\ P(7_ !K7HHO#L_O_ . %
MJG=?=_P3(_X3[1/^@OIW_@0O^-'_  GVB?\ 07T[_P "%_QK7HHO#L_O_P"
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M!:IW7W?\$R/^$^T3_H+Z=_X$+_C1_P )]HG_ $%]._\  A?\:UZ*+P[/[_\
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M\"%_QH_X3[1/^@OIW_@0O^-:]%%X=G]__ "U3NON_P""9'_"?:)_T%]._P#
MA?\ &C_A/M$_Z"^G?^!"_P"-:]%%X=G]_P#P M4[K[O^"9'_  GVB?\ 07T[
M_P "%_QH_P"$^T3_ *"^G?\ @0O^-:]%%X=G]_\ P M4[K[O^"9'_"?:)_T%
M]._\"%_QH_X3[1/^@OIW_@0O^-:]%%X=G]__   M4[K[O^"9'_"?:)_T%]._
M\"%_QH_X3[1/^@OIW_@0O^-:]%%X=G]__ "U3NON_P""9'_"?:)_T%]._P#
MA?\ &C_A/M$_Z"^G?^!"_P"-:]%%X=G]_P#P M4[K[O^"9'_  GVB?\ 07T[
M_P "%_QH_P"$^T3_ *"^G?\ @0O^-:]%%X=G]_\ P M4[K[O^"9'_"?:)_T%
M]._\"%_QH_X3[1/^@OIW_@0O^-:]%%X=G]__   M4[K[O^"9'_"?:)_T%]._
M\"%_QH_X3[1/^@OIW_@0O^-:]%%X=G]__ "U3NON_P""9'_"?:)_T%]._P#
MA?\ &C_A/M$_Z"^G?^!"_P"-:]%%X=G]_P#P M4[K[O^"9'_  GVB?\ 07T[
M_P "%_QH_P"$^T3_ *"^G?\ @0O^-:]%%X=G]_\ P M4[K[O^"9'_"?:)_T%
M]._\"%_QH_X3[1/^@OIW_@0O^-:]%%X=G]__   M4[K[O^"9'_"?:)_T%]._
M\"%_QH_X3[1/^@OIW_@0O^-:]%%X=G]__ "U3NON_P""9'_"?:)_T%]._P#
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ME'='MF=BZ[#RN#P>E>3_ *I59T:-*<HQ]E&:3C>_,W"49Z_:4HN3[W]3T?\
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MFKP7$_@[6;'2[^R240_:K;4+BUCM+F%G("20S.L@Y0L 37M% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B>$_^09-_P!?UW_Z
M4RUMUB>$_P#D&3?]?UW_ .E,M:Q^!_+]3&?QKT?Z'\F^B?\ ']X@_P"QDUG_
M -.5S7J?[*7[-&O?M@_'W0?ASX9NM)LM;\1?:/LT^IRR16J>3;RW#[VC1V'R
M1,!A3R1T'(\LT3_C^\0?]C)K/_IRN:^Q/^"%_P#RE.^%W_<6_P#31>U_5.%Q
M53#<+PQ-+XH8=27JJ=T?S[B,/"OG\J%3X95FGZ.=F-^,'_!';XB?"WX/^*O&
MVF^+_A5\0=)\#R/'K\?A+Q U_<:24_U@E1H8PK(.63.X $[>*YK]FC_@E_\
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M7CM%+^S,':WLHVU?PK=KE?3K'W7W6FP_K^*O?VDNG5]'S+[GJO/7<]T\)?\
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MUKT4<T>P<D_YOP,C_A+/^H9JW_@./\:/^$L_ZAFK?^ X_P :UZ*.:/8.2?\
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MQ_C1J?\ R..E?]<;C_VG6O5RE&T=.GZLSIQGS2][K^B,C_A+/^H9JW_@./\
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M_GE_X"?LUK?B??KNC'^SM4&VXD.#!RW[F0<<UJ?\)9_U#-6_\!Q_C7XDW?\
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M>BCFCV#DG_-^!D?\)9_U#-6_\!Q_C1_PEG_4,U;_ ,!Q_C6O11S1[!R3_F_
MR/\ A+/^H9JW_@./\:/^$L_ZAFK?^ X_QK7HHYH]@Y)_S?@9'_"6?]0S5O\
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M _43XX_L,?"S]H_Q9JNN>,O"_P#:NJZYX3N? VH7$>I7EH;S1;B432V;B"5
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M'G<^2Z)%"GV)XV^$'A[XC1>'4UNQDU#_ (1/5(-:TMGNI@UO>0*Z1RE@X,A
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MGP9X-TS^Q_#6AH\=E9_:);CR%>1I&&^5G=LN['YF/7TKJJ "BBB@ K$\)_\
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M_P#EF?\ W=1_Q"W_ /5<_P#RS/\ [NK]:J*G_B(W$7_01_Y)#_Y$O_4C)/\
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M !BC[=KO_0-TK_P8O_\ &*UZ*.9?RK\?\P]G+^9_A_D9'V[7?^@;I7_@Q?\
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M#=*_\&+_ /QBC[=KO_0-TK_P8O\ _&*UZ*.9?RK\?\P]G+^9_A_D9'V[7?\
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MQ1J?_(XZ5_UQN/\ VG6O6DI*RT6WGW?F9PA+FE[SW\NR\C(^W:[_ - W2O\
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MS+^5?C_F'LY?S/\ #_(R/MVN_P#0-TK_ ,&+_P#QBC[=KO\ T#=*_P#!B_\
M\8K7HHYE_*OQ_P P]G+^9_A_D9'V[7?^@;I7_@Q?_P",4?;M=_Z!NE?^#%__
M (Q6O11S+^5?C_F'LY?S/\/\C(^W:[_T#=*_\&+_ /QBC[=KO_0-TK_P8O\
M_&*UZ*.9?RK\?\P]G+^9_A_D9'V[7?\ H&Z5_P"#%_\ XQ1]NUW_ *!NE?\
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MQ?\ ^,5KT4<R_E7X_P"8>SE_,_P_R,C[=KO_ $#=*_\ !B__ ,8H^W:[_P!
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M@WS1>E^CZ:/[@NCU2BBBN884444 %%%% !1110 4444 9&I_\CCI7_7&X_\
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MPA\+W?P$^'GC?PWXMMO%NAZEX%^$)\/Z(\T=I<63QZCIRZH\EYNM;R\0.EU
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M2,;=H%=UXZ_;K\$>,-3NO$"S_&6TU:XM=O\ 8EIXB-IHPF";0P,<@D49 SM
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M33;79W2:['E4.-LTHT:=&$E:'+;W5M%-)/NK-I]SZ6UK]J[X?>#OV=-3\#^
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M $*/AC_P5P?_ !-=7_$0,/\ \^I?>CA_XA-B_P#G_'[F?G=17Z(_\*3\&?\
M0H^&/_!7!_\ $T?\*3\&?]"CX8_\%<'_ ,31_P 1 P__ #ZE]Z#_ (A-B_\
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M@&KI_&B*OP/T+>G?\@^#_KFO\JFJ'3O^0?!_US7^535+W*CL@HHHI#"BBB@
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M8TOQT/"6ARVN@:D^G2>9IUG=00W>H"-[."[E>>41Q22Q-(/*"1L6!>'X2?\
M!0FVN?!PU?QZ_AS1;&TT3QGXEU*XM?MS3VNGZ!K7V%Y4ME@E61! Z/(WV@2^
M9M$<$BNQAI>(?^">/B;Q/\:M6O;KXEZ>_P ,O$'Q#TSXEZAX:_X18C5!J.G+
M9/:0PZD+L(EM]ITZSFD5[61W"2(LD8?Y:>N?\$NO[:^'FKZ#_P )SY?]J^!?
M'G@KS_[&SY7_  D^IQ7_ -IV^?S]F\OR_+R/-W;MT>-M 'H>D?\ !1WX0:WX
M)\2:_#XBU>.Q\*S6$%Y%<^&-5MKZY;4)?)T\V=I);+<7R7<O[NW>UCE6X<%8
MBY!%=-\$_P!K;P7^T-\+]=\8>%3XLN=&\-WMYIM^E]X0U?3-02YM #<11V5U
M;174SH24Q%$V9%>,9D1E'SE_P4A_86\8_$3P1XW\1>!!=>)?$/B'3_ .CQZ/
M9A;2\M4\/:_?:DUY;S'4+ M*PU#*HE]8R1_92Z7)=EC/3?L=?LY>/=;_ .">
M/C+X:>-]-G^$^M>)UUS3;/4-)N'&MV\=^CYU6=VU35&&H&XGGEWG4KEFVQR,
MZ.S11@'HND?\%#_A5J_@'Q!XA.I^*=.@\,7]KI=_INJ>"];TW7!<W6S[+%%I
M=Q:)?3M/O B\F!_,(<+N*,!SA_X*5>&;W]H'1O =GX8^(2-K_A*Y\3VNH:IX
M(\0Z9% 8I_*$-TLNG VJ$!V:68KL_=KM)EC#>5_!;_@CU?\ P,\-:Y+X=\6_
M#+PIXHN=>T/Q'HW_  B?PR71/#FF76F13P?OM-6_>2Y6XAN)!*WVJ.7<VY9%
M 55]EUG]EGXA>)_BEX2\8ZC\0O!YUBU\+ZGX4\5QVW@VXBM-:M[F:*:&6R1M
M2=[&2)HL-YLEVL@8X6,X( -;P;^WC\/=9^$[>)=4U^QLFT[2=!U+5XK."^N8
MK8ZRD?V!;=GMHIKE9I)!'&5A5V;Y6CC<,B\;=?\ !2_1-%^+_@GPE>>']8U%
M_&OB;Q%X<BOO#FD:WK-M8-I5[)9YF>/355)&DC(F!(B@PS"::$"9J%C_ ,$P
M;6S^(/P,UG_A,9?L7PJ\-Z7X>\0Z<NE*(O'']DCS='ED8R$V_P!CO7GND4>9
MEI<;AMRVMIO[".O^"==\(:OX8\>:59ZIX9\>^)O%EP=2\-O>V]_8Z[>W5U<6
M(1+N%HYHQ<(L=SO9<Q%F@8-L4 VS_P %"/ WA?X9:)K_ (EN;LW.N/J#167A
M/0]:\421P6=T]O-<O';6 N8X$94$DTL"1([A1(P*,_7^&/VN? GCGXQ'P-H6
MH:OKVLI;Q74MWIGA_4;W1;99;9+J)9=5B@:PBD>WDBE6-YP[)-$0I$B;OFOX
MH_\ !&G3/',/@F\%U\)?%.L^$++6-,:/XC_#*/Q=H]Q;W^IG4!)%:&]MY+>Y
MA<M&)5G*NDD@:,DH8_3?#O["^L:!^USX9^(EGXA\"^%] \-645D^C>$/"%SH
M5YX@ACTQK**TU.Y74I+:\LK>21Y[:%[,/:E(DCE \XS@'7?$W]M;PA\#?%GC
M*#QIJ>G:-HWA)-!5KF!;Z]O'GU>YFM;:.2WCM-J[YXT2,Q2S%BS;UA"J7I:;
M^WCX.\86G@O4/#TT]WIGB?7M2\/W,&I:3J^F:W97-CIUY>RP)ICV)N3<A;0G
MR;@6^Z-M\;2,8HIJ7Q>_8=_X6K\5M>\3_P#"3_8/[;U;P5JGV;^S?-\G_A'=
M6DU'9O\ -7=]HW^7G \K&[$F=M&G_L._8/CG8>-/^$GW?8OB1>_$'['_ &;C
M?]I\-OH?V3?YO&W?Y_F[><;-@^_0!C_LP_\ !2'1_P!I_P %?#[6[+0-6T!/
M&:ZCY]CK.EZS8WT;VD"SM]BCFTY!?(589D5HTSE4,KJR"C\6?^"LGP[\ _"/
M7_$NE:5\0=8U#PSJFB:?J.@7G@3Q#I.KVT6J7GV:"Z-I/IXN?)(CN2D@A,<L
MEN85?S& I/AI_P $\_$/A+PIX3T/5/B7'<67@-->T_0+K1=!DTK4K6PU&V,,
M0DG-W,K7=N69Q<1I&KD)B%"I+>7_  (_X(K7'P3^&?Q*TJS\8?#C1]8\<Z7X
M4LK.X\)_#0:#IUG<^'[VYO8+Z[M1?RO?3W$MPOGNT\;NL8 =?EV 'TGJG[>'
MPTT/Q5H>CWNH^)+2\UR&QE#S>$=8CMM(:]V?98=3N#:^3I=Q)YD8$%\\$N9$
M!0%E!XCQA_P4@\,7_P"U9\,?AAX+NVUB^\1^.M2\*>(;BXT#4DL8DL="UB]N
M$LM0:-+.>X@O;"V@F6*28Q;Y8W1).4Y#Q-_P2F3Q3^U<GQ:U./X ^*/$&N-H
MM[XFG\5?"(:S??;[""*WDFT:[?4EETR.2."(I%)]K\F1-^^0LP;>^''_  3P
M\3> ?C!X+NS\2["Z^'/PZ\>Z[X]T#PVOA?R]02?5K768I[>XU W;"6.*36IV
MA*V\;!%"2&9B)5 /JFBBB@ HHHH **** "L3PG_R#)O^OZ[_ /2F6MNL3PG_
M ,@R;_K^N_\ TIEK6/P/Y?J8S^->C_0_)S]I?_DX[X@?]C)J/_I5)7$U^PFI
M_L]^ =:U*XO+SP/X0N[N[E::>>;1K:22:1B2SLQ3+,2223R2:@_X9H^''_1/
M_!/_ ((K7_XBOW'">+>$HT(4GAY>ZDMUT5C\+Q?A!C*U>=98B*YFWL^KN?D%
M17Z^_P##-'PX_P"B?^"?_!%:_P#Q%'_#-'PX_P"B?^"?_!%:_P#Q%='_ !&'
M!_\ 0/+[T<__ !!K&_\ 01'[F?D%17Z^_P##-'PX_P"B?^"?_!%:_P#Q%'_#
M-'PX_P"B?^"?_!%:_P#Q%'_$8<'_ - \OO0?\0:QO_01'[F?D%17Z^_\,T?#
MC_HG_@G_ ,$5K_\ $4?\,T?#C_HG_@G_ ,$5K_\ $4?\1AP?_0/+[T'_ !!K
M&_\ 01'[F?D%17Z^_P##-'PX_P"B?^"?_!%:_P#Q%'_#-'PX_P"B?^"?_!%:
M_P#Q%'_$8<'_ - \OO0?\0:QO_01'[F?D%17Z^_\,T?#C_HG_@G_ ,$5K_\
M$4?\,T?#C_HG_@G_ ,$5K_\ $4?\1AP?_0/+[T'_ !!K&_\ 01'[F?D%17Z^
M_P##-'PX_P"B?^"?_!%:_P#Q%'_#-'PX_P"B?^"?_!%:_P#Q%'_$8<'_ - \
MOO0?\0:QO_01'[F?D%17Z^_\,T?#C_HG_@G_ ,$5K_\ $4?\,T?#C_HG_@G_
M ,$5K_\ $4?\1AP?_0/+[T'_ !!K&_\ 01'[F?D%17Z^_P##-'PX_P"B?^"?
M_!%:_P#Q%'_#-'PX_P"B?^"?_!%:_P#Q%'_$8<'_ - \OO0?\0:QO_01'[F?
MD%17Z^_\,T?#C_HG_@G_ ,$5K_\ $4?\,T?#C_HG_@G_ ,$5K_\ $4?\1AP?
M_0/+[T'_ !!K&_\ 01'[F?D%17Z^_P##-'PX_P"B?^"?_!%:_P#Q%'_#-'PX
M_P"B?^"?_!%:_P#Q%'_$8<'_ - \OO0?\0:QO_01'[F?D%17Z^_\,T?#C_HG
M_@G_ ,$5K_\ $4?\,T?#C_HG_@G_ ,$5K_\ $4?\1AP?_0/+[T'_ !!K&_\
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M^4'_ 'S1_P (GIO_ #Y0?]\T6AW?W?\ !"]3LOO_ . :-%9W_")Z;_SY0?\
M?-'_  B>F_\ /E!_WS1:'=_=_P $+U.R^_\ X!HT5G?\(GIO_/E!_P!\T?\
M")Z;_P ^4'_?-%H=W]W_  0O4[+[_P#@&C16=_PB>F_\^4'_ 'S1_P (GIO_
M #Y0?]\T6AW?W?\ !"]3LOO_ . :-%9W_")Z;_SY0?\ ?-'_  B>F_\ /E!_
MWS1:'=_=_P $+U.R^_\ X!HT5G?\(GIO_/E!_P!\T?\ ")Z;_P ^4'_?-%H=
MW]W_  0O4[+[_P#@&C16=_PB>F_\^4'_ 'S1_P (GIO_ #Y0?]\T6AW?W?\
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M^"%ZG9??_P  T:*SO^$3TW_GR@_[YH_X1/3?^?*#_OFBT.[^[_@A>IV7W_\
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MLOO_ . :-%9W_")Z;_SY0?\ ?-'_  B>F_\ /E!_WS1:'=_=_P $+U.R^_\
MX!HUB>$_^09-_P!?UW_Z4RU:_P"$3TW_ )\H/^^:MV6GP:=;"*")(HU)(55P
5 223^9)/XT[Q4;(GEFY)O^MO(__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460886337600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 08, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Zentalis Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3607803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1359 Broadway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">433-3791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock,$0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ZNTL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,477,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001725160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460886845360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 36,280<span></span>
</td>
<td class="nump">$ 43,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">356,239<span></span>
</td>
<td class="nump">394,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">17,707<span></span>
</td>
<td class="nump">14,562<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">410,226<span></span>
</td>
<td class="nump">451,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">6,880<span></span>
</td>
<td class="nump">7,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease&#160;right-of-use&#160;assets</a></td>
<td class="nump">37,475<span></span>
</td>
<td class="nump">42,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">9,495<span></span>
</td>
<td class="nump">9,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,736<span></span>
</td>
<td class="nump">3,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Zentera Therapeutics</a></td>
<td class="nump">18,903<span></span>
</td>
<td class="nump">21,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,627<span></span>
</td>
<td class="nump">2,627<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">489,342<span></span>
</td>
<td class="nump">539,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">12,818<span></span>
</td>
<td class="nump">11,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">43,540<span></span>
</td>
<td class="nump">45,400<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">56,358<span></span>
</td>
<td class="nump">56,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">756<span></span>
</td>
<td class="nump">853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liability</a></td>
<td class="nump">44,771<span></span>
</td>
<td class="nump">45,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,792<span></span>
</td>
<td class="nump">2,620<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">103,677<span></span>
</td>
<td class="nump">105,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March&#160;31, 2023 and December 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 250,000,000 shares authorized; 59,442,342 and 59,280,247 shares issued and outstanding at March&#160;31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,045,568<span></span>
</td>
<td class="nump">1,031,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(556)<span></span>
</td>
<td class="num">(1,353)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(659,584)<span></span>
</td>
<td class="num">(596,365)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">385,487<span></span>
</td>
<td class="nump">433,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">385,665<span></span>
</td>
<td class="nump">434,024<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 489,342<span></span>
</td>
<td class="nump">$ 539,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460886262192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="nump">59,442,342<span></span>
</td>
<td class="nump">59,280,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">59,442,342<span></span>
</td>
<td class="nump">59,280,247<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460882173968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 48,584<span></span>
</td>
<td class="nump">$ 46,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">16,369<span></span>
</td>
<td class="nump">11,767<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">64,953<span></span>
</td>
<td class="nump">57,879<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(64,953)<span></span>
</td>
<td class="num">(57,879)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zntl_InvestmentAndOtherIncomeExpense', window );">Investment and other income, net</a></td>
<td class="nump">4,109<span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Net loss before income taxes</a></td>
<td class="num">(60,844)<span></span>
</td>
<td class="num">(57,453)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="nump">2,310<span></span>
</td>
<td class="nump">1,751<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(63,262)<span></span>
</td>
<td class="num">(59,237)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Zentalis</a></td>
<td class="num">$ (63,219)<span></span>
</td>
<td class="num">$ (59,077)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share outstanding, basic (in dollars per share)</a></td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (1.31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share outstanding, diluted (in dollars per share)</a></td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (1.31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Common shares used in computing net loss per share, basic (in shares)</a></td>
<td class="nump">59,277<span></span>
</td>
<td class="nump">45,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Common shares used in computing net loss per share, diluted (in shares)</a></td>
<td class="nump">59,277<span></span>
</td>
<td class="nump">45,244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_InvestmentAndOtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment and Other Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_InvestmentAndOtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460882377840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (63,262)<span></span>
</td>
<td class="num">$ (59,237)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">797<span></span>
</td>
<td class="num">(984)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive loss</a></td>
<td class="num">(62,465)<span></span>
</td>
<td class="num">(60,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to noncontrolling interests</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Zentalis</a></td>
<td class="num">$ (62,422)<span></span>
</td>
<td class="num">$ (60,061)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460886026880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Consolidated net loss</a></td>
<td class="num">$ (63,262)<span></span>
</td>
<td class="num">$ (59,237)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Operating lease right-of-use asset and fixed asset impairment</a></td>
<td class="nump">4,953<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">13,733<span></span>
</td>
<td class="nump">10,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">(Accretion of discounts)/amortization of premiums on marketable securities, net</a></td>
<td class="num">(3,261)<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="nump">2,310<span></span>
</td>
<td class="nump">1,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(97)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(2,917)<span></span>
</td>
<td class="num">(4,154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(1,411)<span></span>
</td>
<td class="num">(500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet', window );">Operating lease right-of-use assets and liabilities, net</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">1,381<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(49,283)<span></span>
</td>
<td class="num">(50,196)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(63,879)<span></span>
</td>
<td class="num">(79,254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">106,000<span></span>
</td>
<td class="nump">99,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(450)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">42,121<span></span>
</td>
<td class="nump">19,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under equity incentive plans</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">1,258<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">1,258<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(6,789)<span></span>
</td>
<td class="num">(29,142)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">45,696<span></span>
</td>
<td class="nump">62,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">38,907<span></span>
</td>
<td class="nump">33,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of&#160;non-cash&#160;investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued capital expenditures</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">36,280<span></span>
</td>
<td class="nump">30,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">2,627<span></span>
</td>
<td class="nump">2,870<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash reported in the Condensed Consolidated Statement of Cash Flows</a></td>
<td class="nump">$ 38,907<span></span>
</td>
<td class="nump">$ 33,442<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Right-Of-Use Assets And Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460886401904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,491,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 364,482<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 723,593<span></span>
</td>
<td class="num">$ (125)<span></span>
</td>
<td class="num">$ (359,559)<span></span>
</td>
<td class="nump">$ 528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">10,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(984)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(984)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock in connection with restricted stock unit vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock in connection with restricted stock unit vesting</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options, net</a></td>
<td class="nump">645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued under employee stock purchase plan</a></td>
<td class="nump">612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancellation of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">(160)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Zentalis</a></td>
<td class="num">(59,077)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59,077)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,584,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">315,666<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">734,997<span></span>
</td>
<td class="num">(1,109)<span></span>
</td>
<td class="num">(418,636)<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,491,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">364,482<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">723,593<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="num">(359,559)<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">434,024<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">1,031,462<span></span>
</td>
<td class="num">(1,353)<span></span>
</td>
<td class="num">(596,365)<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">13,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="nump">$ 797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock in connection with restricted stock unit vesting (in shares)</a></td>
<td class="nump">41,100<span></span>
</td>
<td class="nump">139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options, net (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued under employee stock purchase plan</a></td>
<td class="nump">$ 373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancellation of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Zentalis</a></td>
<td class="num">(63,219)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63,219)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,442,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 385,665<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 1,045,568<span></span>
</td>
<td class="num">$ (556)<span></span>
</td>
<td class="num">$ (659,584)<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460888493344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Business</a></td>
<td class="text">Organization and Business<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zentalis Pharmaceuticals, Inc. (&#8220;Zentalis&#8221;, &#8220;We&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancer. The Company is developing a focused pipeline of potentially best-in-class oncology candidates. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. All of the Company&#8217;s tangible assets are held in the United States.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div>Substantial doubt about an entity&#8217;s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year from the financial statement issuance date. The Company determined that there are no conditions or events that raise substantial doubt about its ability to continue as a going concern within one year after the date that the interim unaudited condensed consolidated financial statements for the quarter ended March&#160;31, 2023 are issued.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460888667744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Unaudited Financial Statements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Interim Unaudited Financial Statements</a></td>
<td class="text">Interim Unaudited Financial Statements <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form 10-Q. The year-end condensed consolidated balance sheet data was derived from the Company&#8217;s audited financial statements but do not include all disclosures required by U.S. GAAP. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on March 1, 2023. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operation for the periods presented, with such adjustments consisting only of normal recurring adjustments. Certain reclassifications have been made to the prior period condensed consolidated balance sheet to conform to the current period presentation.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements include our wholly-owned subsidiaries and variable interest entity (&#8220;VIE&#8221;), for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether we are the primary beneficiary of the VIE. In determining whether we are the primary beneficiary of a VIE and therefore required to consolidate the VIE, we apply a qualitative approach that determines whether we have both (1)&#160;the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2)&#160;the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continuously assess whether we are the primary beneficiary of a VIE, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of such VIE. During the </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periods presented, we have not provided any other material financial or other support to our VIEs that we were not contractually required to provide.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The equity method is used to account for investments in which we have the ability to exercise significant influence, but not control, over the investee. Such investments are recorded on the balance sheet, and the share of net income or losses of equity investments is recognized on a one quarter lag in investment and other income (expense), net.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#8217;s estimates.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.</span></div><div style="margin-bottom:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, there have been no changes to the Company&#8217;s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460889103200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Significant Transactions</a></td>
<td class="text">Significant Transactions<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zentera Therapeutics</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we became a majority common shareholder of Zentera Therapeutics, a Shanghai-based clinical-stage biopharmaceutical company focused on developing cancer therapeutics (&#8220;Zentera&#8221;), concurrent with its Series A convertible preferred stock offering. The financial position and results of operations of Zentera were included in our consolidated financial statements from the date of the initial investment as a result of our control of the entity and our determination that we were the primary beneficiary of Zentera. In July 2021, Zentera completed a Series B convertible preferred stock offering which diluted our investment to a position of less than majority owned. Upon review of the facts and circumstances, together with the authoritative accounting literature, we determined that while Zentera is a VIE, consolidation of Zentera is no longer appropriate. After the July 2021 Series B convertible preferred offering in which we did not participate, our review concluded that we ceased to be the primary beneficiary of Zentera as our equity ownership was reduced and changes were made to the corporate governance of Zentera. As a result, we no longer individually have the ability to direct the activities that most significantly impact Zentera's economic performance. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in July 2021, the financial position and results of operations of Zentera were no longer included in our consolidated financial statements. During the period of deconsolidation we measured the fair value of our retained investment in Zentera using the backsolve method with consideration for a lack of marketability. An equity method investment of $18.9 million is recorded on our balance sheet at March&#160;31, 2023. This amount represents our maximum exposure to loss as a result of our involvement with Zentera. A deferred tax liability of $4.0 million representing the tax impact of the unrealized gain on deconsolidation is recorded on our balance sheet at March&#160;31, 2023. A gain of $51.6&#160;million, measured as the difference between the fair value of our retained noncontrolling interest together with the carrying amount of the Zentera noncontrolling interest, and the carrying amount of Zentera&#8217;s assets and liabilities was recognized during the year ended December 31, 2021. The difference between the carrying amount of our investment in Zentera and our portion of the Zentera net assets was $5.5 million as of </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023. This difference is accounted for in our equity method investment analogous to in-process research and development. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2020, each of our subsidiaries Zeno Alpha, Inc., K-Group Alpha, Inc., and K-Group Beta, Inc. entered into a collaboration and royalty-bearing license agreement with Zentera, which we refer to as the &#8220;Zentera Sublicenses,&#8221; pursuant to which we collaborate with Zentera on the development and commercialization of ZN-c5, ZN-d5 and azenosertib, respectively, collectively referred to as the &#8220;Collaboration Products,&#8221; respectively, in the People&#8217;s Republic of China, Macau, Hong Kong and Taiwan, which is referred to as the &#8220;Zentera Collaboration Territory.&#8221; Under each Zentera Sublicense, Zentera will lead development, and upon regulatory approval, the commercialization, of the Collaboration Products in the Zentera Collaboration Territory.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Zentera Sublicenses, Zentera is generally responsible for the costs of developing the Collaboration Products in the Zentera Collaboration Territory, and we are generally responsible for the costs of developing the Collaboration Products outside the Zentera Collaboration Territory, provided that Zentera will reimburse us for a portion of the costs for global data management, pharmacovigilance, safety database management, and chemistry, manufacturing and controls activities with respect to each Collaboration Product. Prior to the deconsolidation of Zentera in July 2021, these costs were eliminated in consolidation. For the three months ended March&#160;31, 2023 and 2022 the amounts incurred under this arrangement totaled $2.2 million and $2.1 million, respectively, and are presented as contra-research and development expense in the unaudited condensed consolidated statement of operations. A corresponding receivable is recorded within prepaid expenses and other current assets on the unaudited condensed consolidated balance sheet. We have not provided material financial or other support to Zentera during the periods ended March&#160;31, 2023 and 2022 that was not  contractually required.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460974272192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations</a></td>
<td class="text">Business Combinations<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Kalyra Pharmaceuticals, Inc.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;21, 2017, we acquired $4.5&#160;million of Kalyra Pharmaceuticals, Inc.&#8217;s (&#8220;Kalyra&#8221;) Series B Preferred Stock representing a 25% equity interest in Kalyra for purposes of entering the analgesics therapeutic research space. The acquisition price was paid entirely in cash.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the authoritative guidance, we concluded that Kalyra is a business consisting of inputs, employees, intellectual property and processes capable of producing outputs. Additionally, we have concluded that Kalyra is a VIE, we are the primary beneficiary and have the power to direct the activities that most significantly affect Kalyra&#8217;s economic performance through common management and our board representation. Prior to December 21, 2017, the Company and Kalyra transacted for the delivery of research and development services and support. The financial position and results of operations of Kalyra have been included in our consolidated financial statements from the date of the initial investment.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant with authoritative guidance, we have recorded the identifiable assets, liabilities and noncontrolling interests in the VIE at their fair value upon initial consolidation. The identified goodwill is comprised of the workforce and expected synergies from combining the entities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">otal assets and liabilities of Kalyra as of March&#160;31, 2023 and December&#160;31, 2022 are immaterial. The liabilities recognized as a result of consolidating Kalyra do not represent additional claims on our general assets. Pursuant to the authoritative guidance, the equity interest in Kalyra not owned by Zentalis is reported as a noncontrolling interest on our condensed consolidated balance sheets.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of equity (net assets) attributable to the noncontrolling interest (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460888667744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Government Agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(587)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Government Agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(629)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,655&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,424)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">fifty</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of our available-for-sale debt securities with a fair market value of $268.0 million were in a gross unrealized loss position of $0.6 million. Of those, forty-seven have been in a gross unrealized loss position of $0.5 million for less than one year and three have been in a gross unrealized loss position of $0.1 million for more than one year. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">When evaluating an investment for impairment, we review factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, our intent to sell or the likelihood that we would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. Based on our review of these marketable securities, we believe none of the unrealized loss is as a result of a credit loss as of March&#160;31, 2023, because we do not intend to sell these securities, and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis. </span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of available-for-sale debt securities are as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.044%"><tr><td style="width:1.0%"/><td style="width:51.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.362%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.256%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,239&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,302&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:19.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.357%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total estimated fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents:</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,329&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,329&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Government Agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale marketable securities:</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value<br/></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,062&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,506&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,568&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,084&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423,111&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level&#160;1 and Level&#160;2 of the fair value hierarchy during the three months ended March&#160;31, 2023. We had no instruments that were classified within Level&#160;3 as of March&#160;31, 2023 or December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460886224976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Assets</a></td>
<td class="text">Prepaid Expenses and Other Assets<div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid software licenses and maintenance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign R&amp;D credit refund</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zentera receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,202&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,285&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other assets, current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,707&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,562&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460886856896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text">Property and Equipment, net<div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,973&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,765&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,093)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,060)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,880&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,705&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the three months ended March&#160;31, 2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span> was approximately $360 thousand and $344 thousand, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460974272192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,020&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,540&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460889143216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text">Stockholders&#8217; Equity <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2020, the Company&#8217;s Board of Directors adopted, and the Company&#8217;s stockholders approved, the 2020 Incentive Award Plan (the &#8220;2020 Plan&#8221;), which allows for grants to selected employees, consultants and non-employee members of the Board of Directors. We currently grant stock options and restricted stock units (&#8220;RSUs&#8221;), under the 2020 Plan. Awards may be made under the 2020 Plan covering up to the sum of (1) 5,600,000 shares of common stock; plus (2) any shares forfeited from the unvested restricted shares of our common stock issued upon conversion of unvested Class B common units (up to 1,250,000 shares); plus (3) an annual increase on the first day of each fiscal year beginning with the fiscal year ending December 31, 2021 and continuing to, and including, the fiscal year ending December 31, 2030, equal to the lesser of (a) 5% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by our Board of Directors. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, 9,975,086 shares were subject to outstanding awards under the 2020 Plan and 1,350,490 shares were available for future grants of share-based awards under the 2020 Plan.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, the Company&#8217;s Board of Directors approved the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (the &#8220;2022 Inducement Plan&#8221;), which is used exclusively for the grant of equity awards to new employees as an inducement material to the employees&#8217; entering into employment with the </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company. The Board of Directors has initially reserved 1,500,000 shares of the Company&#8217;s common stock for issuance pursuant to awards granted under the 2022 Inducement Plan. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, 1,485,975 shares were subject to outstanding awards under the 2022 Inducement Plan and 14,025 shares were available for future grants of share-based awards under the 2022 Inducement Plan. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense related to share based awards was comprised of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.570%"><tr><td style="width:1.0%"/><td style="width:53.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.100%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.585%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.102%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,873&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,733&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,147&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by type of share-based award (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.211%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.929%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,733&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options granted is equal to the closing price of the Company&#8217;s common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes model. Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of a group of similar companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards. The Company uses the &#8220;simplified method&#8221; for estimating the expected term of employee options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option (generally 10 years). The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero. The fair value of the stock options granted during the three months ended March&#160;31, 2023 and March&#160;31, 2022 was determined with the following assumptions:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.839%"><tr><td style="width:1.0%"/><td style="width:44.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.454%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.0% - 80.8%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.6% - 74.3%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 - 6.1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 - 6.1</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4% - 4.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5% - 2.3%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2020, the Company&#8217;s Board of Directors adopted, and the Company&#8217;s stockholders approved the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which was subsequently amended and restated effective March 15, 2021. The maximum aggregate number of shares of the Company&#8217;s common stock available for issuance under the ESPP at March 31, 2023 was 1,929,891. Under the terms of the ESPP, the Company&#8217;s employees may elect to have up to 20% of their compensation, up to a maximum value of $25,000 per calendar year, withheld to purchase shares of the Company&#8217;s common stock for a purchase price equal to 85% of the lower of the fair market value per share (at closing) of the Company&#8217;s common stock on (i) the first trading day of a six-month offering period, or (ii) the applicable purchase date, defined as the last trading day of the six-month offering period. The weighted average assumptions used to estimate the fair value of stock purchase rights under the ESPP during the period ended March 31, 2023 are as follows:</span></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.846%"><tr><td style="width:1.0%"/><td style="width:48.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.173%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.173%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.652%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense Summary</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized estimated compensation cost by type of award and the weighted average requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.256%"><tr><td style="width:1.0%"/><td style="width:31.878%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.878%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.881%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized <br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining <br/>Weighted-Average Recognition Period <br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.16</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we issued zero shares of common stock in connection with the exercises of stock options. For the three months ended March&#160;31, 2023, 41.1 thousand shares of common stock </span></div>issued in conjunction with certain restricted stock awards (&#8220;RSAs&#8221;), vested. Outstanding stock options, unvested RSAs, and unvested RSUs totaling approximately 9.9&#160;million shares, 0.1&#160;million shares and 1.6&#160;million shares of our common stock, respectively, were outstanding as of March&#160;31, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460888505280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Contingencies </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, we may be involved in various disputes, including lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters. Any of these claims could subject us to costly legal expenses. The Company records a liability in its consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amounts of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary to make the consolidated financial statements not misleading. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in our consolidated financial statements. While we do generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage, or our policy limits may be inadequate to fully satisfy any damage awards or settlement. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We are currently not a party to any legal proceedings that require a loss liability to be recorded.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitments include payments related to operating leases. Approximate annual future minimum operating lease payments as of March&#160;31, 2023 are as follows (in thousands): </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: imputed interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,740)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: current portion</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, net of current portion</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,771&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease term of our operating leases is approximately 9.5 years. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 6, 2023, we entered into a sublease agreement pursuant to which we will sublease the office space located at 1359 Broadway, Suites 1710 and 1800 in New York, New York to a subtenant. As a result of certain triggering events, we performed an interim impairment test by comparing the carrying value of the long-lived asset group to its estimated fair value, which was determined based on the income approach using a discounted cash flow model. Estimates and assumptions used in the model included projected cash flows and a discount rate. As a result, </span></div>we recorded an impairment expense of $5.0 million within our operating expenses against our operating lease right-of-use asset and fixed assets associated with our New York lease during the three months ended March 31, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460888463648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text">Net Loss Per Common Share <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share were calculated as follows (in thousands except per share amounts):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.967%"><tr><td style="width:1.0%"/><td style="width:50.002%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:22.948%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.949%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Zentalis</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,077)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.07)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.31)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential and dilutive securities, which include outstanding stock options, unvested RSAs and unvested RSUs have been excluded from the computation of diluted net loss per common share as the effect would be anti-dilutive. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents have been excluded from the calculations of diluted net loss per common share because their inclusion would be antidilutive (in thousands).</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.166%"><tr><td style="width:1.0%"/><td style="width:52.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.776%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSAs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,543&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,092&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460888615632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Disclosures</a></td>
<td class="text">Related Party Disclosures<div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tempus</span></div><div style="text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kimberly Blackwell, M.D., our Chief Executive Officer and a member of our Board of Directors, was previously employed by Tempus Labs, Inc. ("Tempus") and now serves as an advisor of Tempus. The Company entered into a Master Services Agreement with Tempus in December 2020 to provide data licensing and research services. There were $0.4 million and immaterial fees incurred for services performed by Tempus for the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zentera</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kevin D. Bunker, Ph.D., our Chief Scientific Officer, serves as a member of the Board of Directors of Zentera. Accordingly, the Company identifies Zentera as a related party.</span></div>In May 2020, each of our wholly owned subsidiaries, Zeno Alpha, Inc., K-Group Alpha, Inc. and K-Group Beta, Inc., entered into the Zentera Sublicenses, pursuant to which we collaborate with Zentera on the development and commercialization of the Collaboration Products in the Zentera Collaboration Territory. Under the terms of the Zentera Sublicenses, Zentera is responsible for the costs of developing the Collaboration Products in the Zentera Collaboration Territory, and we are responsible for the costs of developing the Collaboration Products outside the Zentera Collaboration Territory, provided that Zentera will reimburse us for a portion of its costs for global data management, pharmacovigilance, safety database management, and chemistry, manufacturing and controls activities with respect to each Collaboration Product. For the three months ended March 31, 2023 and 2022, the amounts incurred under this arrangement totaled $2.2 million and $2.1&#160;million, respectively, and are presented as contra-research and development expense in the consolidated statement of operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460886268464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Unaudited Financial Statements (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form 10-Q. The year-end condensed consolidated balance sheet data was derived from the Company&#8217;s audited financial statements but do not include all disclosures required by U.S. GAAP. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on March 1, 2023. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operation for the periods presented, with such adjustments consisting only of normal recurring adjustments. Certain reclassifications have been made to the prior period condensed consolidated balance sheet to conform to the current period presentation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements include our wholly-owned subsidiaries and variable interest entity (&#8220;VIE&#8221;), for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether we are the primary beneficiary of the VIE. In determining whether we are the primary beneficiary of a VIE and therefore required to consolidate the VIE, we apply a qualitative approach that determines whether we have both (1)&#160;the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2)&#160;the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continuously assess whether we are the primary beneficiary of a VIE, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of such VIE. During the </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periods presented, we have not provided any other material financial or other support to our VIEs that we were not contractually required to provide.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The equity method is used to account for investments in which we have the ability to exercise significant influence, but not control, over the investee. Such investments are recorded on the balance sheet, and the share of net income or losses of equity investments is recognized on a one quarter lag in investment and other income (expense), net.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#8217;s estimates.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460888706928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock', window );">Reconciliation of Equity Attributable to Noncontrolling Interest</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of equity (net assets) attributable to the noncontrolling interest (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_ReconciliationOfNoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_ReconciliationOfNoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460889140848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Components of Available-for-sale Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Government Agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(587)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Government Agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(629)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,655&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,424)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Contractual Maturities of Available-for-sale Debt Securities</a></td>
<td class="text">Contractual maturities of available-for-sale debt securities are as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.044%"><tr><td style="width:1.0%"/><td style="width:51.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.362%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.256%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,239&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,302&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:19.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.357%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total estimated fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents:</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,329&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,329&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Government Agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale marketable securities:</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value<br/></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,062&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,506&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,568&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,084&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423,111&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460888645312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of Prepaid Expenses and Other Assets</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid software licenses and maintenance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign R&amp;D credit refund</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zentera receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,202&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,285&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other assets, current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,707&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,562&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460888596416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, net</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,973&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,765&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,093)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,060)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,880&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,705&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460888706928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,020&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,540&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460886064416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense related to share based awards was comprised of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.570%"><tr><td style="width:1.0%"/><td style="width:53.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.100%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.585%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.102%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,873&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,733&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,147&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by type of share-based award (in thousands):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.211%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.929%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,733&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text">The fair value of the stock options granted during the three months ended March&#160;31, 2023 and March&#160;31, 2022 was determined with the following assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.839%"><tr><td style="width:1.0%"/><td style="width:44.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.454%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.0% - 80.8%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.6% - 74.3%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 - 6.1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 - 6.1</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4% - 4.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5% - 2.3%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions, ESPP</a></td>
<td class="text">The weighted average assumptions used to estimate the fair value of stock purchase rights under the ESPP during the period ended March 31, 2023 are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.846%"><tr><td style="width:1.0%"/><td style="width:48.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.173%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.173%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.652%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Share-based Compensation Expense by Type of Share-based Award</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized estimated compensation cost by type of award and the weighted average requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.256%"><tr><td style="width:1.0%"/><td style="width:31.878%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.878%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.881%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized <br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining <br/>Weighted-Average Recognition Period <br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.16</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460888550512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Operating Lease Payments</a></td>
<td class="text">Approximate annual future minimum operating lease payments as of March&#160;31, 2023 are as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: imputed interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,740)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: current portion</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, net of current portion</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,771&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460890793088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Unit</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share were calculated as follows (in thousands except per share amounts):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.967%"><tr><td style="width:1.0%"/><td style="width:50.002%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:22.948%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.949%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Zentalis</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,077)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.07)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.31)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Unit</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents have been excluded from the calculations of diluted net loss per common share because their inclusion would be antidilutive (in thousands).</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.166%"><tr><td style="width:1.0%"/><td style="width:52.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.776%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSAs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,543&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,092&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460886418160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Zentera Therapeutics</a></td>
<td class="nump">$ 18,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=zntl_ZenteraTherapeuticsMember', window );">Zentera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates', window );">Deferred tax liability, deconsolidation of Zentera</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Zentera, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">In-process research and development</a></td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zntl_ResearchAndDevelopmentExpenseReimbursements', window );">Contra-research and development expense</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_ResearchAndDevelopmentExpenseReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Expense, Reimbursements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_ResearchAndDevelopmentExpenseReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=zntl_ZenteraTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=zntl_ZenteraTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460886024912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations - Narrative (Details) - Kalyra Pharmaceuticals, Inc.<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 21, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Cash payments to acquire interest</a></td>
<td class="nump">$ 4.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Ownership percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=zntl_KalyraPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=zntl_KalyraPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460883576288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Reconciliation of Equity (Net Assets) Attributable to Noncontrolling Interest (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest at beginning of period</a></td>
<td class="nump">$ 221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">$ (160)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest at end of period</a></td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">VIE, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest at beginning of period</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">$ 528<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(307)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest at end of period</a></td>
<td class="nump">$ 178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInMinorityInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInMinorityInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460886714448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 356,829<span></span>
</td>
<td class="nump">$ 395,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(613)<span></span>
</td>
<td class="num">(1,424)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">356,239<span></span>
</td>
<td class="nump">394,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">281,405<span></span>
</td>
<td class="nump">296,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(286)<span></span>
</td>
<td class="num">(587)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">281,142<span></span>
</td>
<td class="nump">295,793<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,486<span></span>
</td>
<td class="nump">7,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">2,480<span></span>
</td>
<td class="nump">7,446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">21,982<span></span>
</td>
<td class="nump">23,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(98)<span></span>
</td>
<td class="num">(182)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">21,884<span></span>
</td>
<td class="nump">23,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">50,956<span></span>
</td>
<td class="nump">67,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(223)<span></span>
</td>
<td class="num">(629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 50,733<span></span>
</td>
<td class="nump">$ 67,275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460882262480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>security</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of available-for-sale securities in unrealized loss position | security</a></td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Debt securities fair market value</a></td>
<td class="nump">$ 268.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair market value of available-for-sale securities in unrealized loss position</a></td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of available-for-sale securities in unrealized loss position for less than one year | security</a></td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Gross unrealized loss position for less than one year</a></td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of available-for-sale securities in unrealized loss position for more than one year | security</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Gross unrealized loss position for more than one year</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460886327632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Contractual Maturities of Available-for-sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">$ 356,239<span></span>
</td>
<td class="nump">$ 394,302<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total</a></td>
<td class="nump">$ 356,239<span></span>
</td>
<td class="nump">$ 394,302<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269825-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460886993872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 33,329<span></span>
</td>
<td class="nump">$ 28,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">356,239<span></span>
</td>
<td class="nump">394,302<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="nump">389,568<span></span>
</td>
<td class="nump">423,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">33,329<span></span>
</td>
<td class="nump">28,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">50,733<span></span>
</td>
<td class="nump">67,275<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="nump">84,062<span></span>
</td>
<td class="nump">96,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">305,506<span></span>
</td>
<td class="nump">327,027<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="nump">305,506<span></span>
</td>
<td class="nump">327,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">281,142<span></span>
</td>
<td class="nump">295,793<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">281,142<span></span>
</td>
<td class="nump">295,793<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">2,480<span></span>
</td>
<td class="nump">7,446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">2,480<span></span>
</td>
<td class="nump">7,446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">21,884<span></span>
</td>
<td class="nump">23,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">21,884<span></span>
</td>
<td class="nump">23,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">50,733<span></span>
</td>
<td class="nump">67,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">50,733<span></span>
</td>
<td class="nump">67,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">33,329<span></span>
</td>
<td class="nump">26,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">33,329<span></span>
</td>
<td class="nump">26,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460882234240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 523<span></span>
</td>
<td class="nump">$ 1,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zntl_PrepaidSoftwareLicenseAndMaintenance', window );">Prepaid software licenses and maintenance</a></td>
<td class="nump">870<span></span>
</td>
<td class="nump">958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zntl_ForeignResearchAndDevelopmentCreditRefund', window );">Foreign R&amp;D credit refund</a></td>
<td class="nump">940<span></span>
</td>
<td class="nump">659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zntl_PrepaidResearchAndDevelopmentCosts', window );">Prepaid research and development expenses</a></td>
<td class="nump">16,154<span></span>
</td>
<td class="nump">15,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">385<span></span>
</td>
<td class="nump">508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Zentera receivable</a></td>
<td class="nump">7,908<span></span>
</td>
<td class="nump">5,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zntl_OtherPrepaidExpense', window );">Other prepaid expenses</a></td>
<td class="nump">422<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Total prepaid expenses and other assets</a></td>
<td class="nump">27,202<span></span>
</td>
<td class="nump">24,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Less long-term portion</a></td>
<td class="nump">9,495<span></span>
</td>
<td class="nump">9,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other assets, current</a></td>
<td class="nump">$ 17,707<span></span>
</td>
<td class="nump">$ 14,562<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_ForeignResearchAndDevelopmentCreditRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign Research and Development Credit Refund</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_ForeignResearchAndDevelopmentCreditRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_OtherPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Prepaid Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_OtherPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_PrepaidResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research And Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_PrepaidResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_PrepaidSoftwareLicenseAndMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Software License And Maintenance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_PrepaidSoftwareLicenseAndMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460882183456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, net - Summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 9,973<span></span>
</td>
<td class="nump">$ 9,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(3,093)<span></span>
</td>
<td class="num">(2,060)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">6,880<span></span>
</td>
<td class="nump">7,705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=zntl_LaboratoryEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">2,659<span></span>
</td>
<td class="nump">2,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">4,890<span></span>
</td>
<td class="nump">4,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=zntl_OfficeEquipmentAndFurnitureMember', window );">Office equipment and furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">2,065<span></span>
</td>
<td class="nump">2,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 209<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=zntl_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=zntl_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=zntl_OfficeEquipmentAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=zntl_OfficeEquipmentAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460888469360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 360<span></span>
</td>
<td class="nump">$ 344<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460890873888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zntl_AccruedResearchAndDevelopmentCostsCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 34,227<span></span>
</td>
<td class="nump">$ 32,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee expenses</a></td>
<td class="nump">6,879<span></span>
</td>
<td class="nump">11,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal expenses</a></td>
<td class="nump">828<span></span>
</td>
<td class="nump">1,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zntl_AccruedGeneralAndAdministrativeCostsCurrent', window );">Accrued general and administrative expenses</a></td>
<td class="nump">726<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability</a></td>
<td class="nump">2,247<span></span>
</td>
<td class="nump">2,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Taxes payable</a></td>
<td class="nump">425<span></span>
</td>
<td class="nump">384<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses</a></td>
<td class="nump">45,332<span></span>
</td>
<td class="nump">48,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Less long-term portion</a></td>
<td class="nump">1,792<span></span>
</td>
<td class="nump">2,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 43,540<span></span>
</td>
<td class="nump">$ 45,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_AccruedGeneralAndAdministrativeCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued General And Administrative Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_AccruedGeneralAndAdministrativeCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460883389520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued upon vesting of certain RSAs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm', window );">Generally expected vesting term of the option contract (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,929,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">ESPP maximum percent of compensation to contribute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount', window );">Maximum contribution amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">ESPP purchase price of common stock, percent of market price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">RSAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Non-option equity instruments, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Non-option equity instruments, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=zntl_A2020IncentiveAwardPlanMember', window );">The 2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Non-option equity instruments, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,975,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=zntl_A2022EmploymentInducementIncentiveAwardPlanMember', window );">2022 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Non-option equity instruments, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,485,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | The 2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized to be issued under plan (in shares)</a></td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease', window );">Percent of common stock outstanding used as threshold to calculate shares available for issuance</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B | The 2020 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized to be issued under plan (in shares)</a></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Generally Expected Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Shares Authorized, Percent Threshold Used To Calculate Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=zntl_A2020IncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=zntl_A2020IncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=zntl_A2022EmploymentInducementIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=zntl_A2022EmploymentInducementIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460886692624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Share-based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 13,733<span></span>
</td>
<td class="nump">$ 10,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">5,873<span></span>
</td>
<td class="nump">5,042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 7,860<span></span>
</td>
<td class="nump">$ 5,105<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460886421536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 13,733<span></span>
</td>
<td class="nump">$ 10,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">10,609<span></span>
</td>
<td class="nump">7,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember', window );">RSAs and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 3,019<span></span>
</td>
<td class="nump">$ 2,267<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460882546272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Fair Value Assumptions for Stock Options (Details) - Stock Options<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">73.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">80.80%<span></span>
</td>
<td class="nump">74.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460886713296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Fair Value Assumptions for ESPP (Details) - Employee Stock Purchase Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">101.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460887291808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Unrecognized Compensation Cost (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized expense, stock options</a></td>
<td class="nump">$ 119,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (years)</a></td>
<td class="text">3 years 1 month 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">RSAs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized expense, other than options</a></td>
<td class="nump">$ 218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (years)</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized expense, other than options</a></td>
<td class="nump">$ 34,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (years)</a></td>
<td class="text">3 years 1 month 28 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized expense, other than options</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (years)</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460882548912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023 (remaining)</a></td>
<td class="nump">$ 4,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">6,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">6,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">7,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">7,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">38,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments:</a></td>
<td class="nump">71,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(24,740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">47,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(2,247)<span></span>
</td>
<td class="num">$ (2,162)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">$ 44,771<span></span>
</td>
<td class="nump">$ 45,166<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, Due After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460886334976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted-average remaining lease term (in years)</a></td>
<td class="text">9 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Operating lease right-of-use asset and fixed asset impairment</a></td>
<td class="nump">$ 4,953<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460886725552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Calculation (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zntl_EarningsPerShareNumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Zentalis</a></td>
<td class="num">$ (63,219)<span></span>
</td>
<td class="num">$ (59,077)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zntl_EarningsPerShareDenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding, basic (in shares)</a></td>
<td class="nump">59,277<span></span>
</td>
<td class="nump">45,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding, diluted (in shares)</a></td>
<td class="nump">59,277<span></span>
</td>
<td class="nump">45,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in dollars per share)</a></td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (1.31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted (in dollars per share)</a></td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (1.31)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_EarningsPerShareDenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Denominator</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_EarningsPerShareDenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_EarningsPerShareNumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Numerator</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_EarningsPerShareNumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460886133744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Antidilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per unit (in shares)</a></td>
<td class="nump">11,543<span></span>
</td>
<td class="nump">6,092<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per unit (in shares)</a></td>
<td class="nump">9,895<span></span>
</td>
<td class="nump">5,372<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested RSAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per unit (in shares)</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per unit (in shares)</a></td>
<td class="nump">1,566<span></span>
</td>
<td class="nump">433<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140460886036912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=zntl_ZenteraTherapeuticsMember', window );">Zentera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zntl_ResearchAndDevelopmentExpenseReimbursements', window );">Contra-research and development expense</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Master Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zntl_ResearchAndDevelopmentExpenseReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Expense, Reimbursements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zntl_ResearchAndDevelopmentExpenseReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zntl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=zntl_ZenteraTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=zntl_ZenteraTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=zntl_MasterServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=zntl_MasterServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>zntl-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:zntl="http://www.zentalis.com/20230331">
    <link:schemaRef xlink:href="zntl-20230331.xsd" xlink:type="simple"/>
    <context id="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia48f187fdc694ec0a436fbbe630672db_I20230508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="i3e95cef051ea47c385703716fa2a0497_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibc4b56c1868744f5b822318ab0a0bd57_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i952b505edf2c4ed8969edcd9dd637d0b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i94cbb15018ea46098ad9249cb81ecbd5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie7e45d5095eb4183b28589ea3d638b55_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i45b55ea2c54349ec90158494f177ec3d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7921e87cee7146e4aaa27c62453d6118_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id87bc3ab81a548e8accd9e1b819b5bf8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5aa6d947913f4a7d8075467238402e4b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7baae8bf509c4eea871e58fce347a357_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaaab72f9bd1f4b3497c269553c88fda8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia44df45deeac4a16be141cf7af1287d1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i395ba3df136f49c6a25790e6923789ec_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9ea4061b88a64ee98000673bd1783d8b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id2e8bcaca2ae474db63161b8e88a7c52_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i610df3d7d3254dbeab79d57a582a4636_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iace7d762ee1c45ad98a341537427e32e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i94f3732fa0324bb6bf7f1984084ff4ef_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifa0fa90a552e423ba8d1643810caf083_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8fd115a5bb984e3b9b063c8e4aa9ff7a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i695f99adc41f4c8999aa3b6012882f02_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie9fbed8715344dabb36930b6006326a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id75a0e799fe54633ad1d1d401d14de96_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iafaecb2d14b0479c99a524aaae490852_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64968b563eff48948e2e24b37867c00a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic40194aeff86496eb4c5f12057c31115_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i47afaacc781e4b58940615c4b23bc5c2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i545b3742a8c44d08a0306fb64b39b848_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1bb99470d90047cd99a51fc8bee670ee_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic9d78fa526224fafa319798fa29dbe0c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4c97f79d62ab413ba0fa4b3ab5ea6198_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6cbaa2e908e04b1f879853beb7b39556_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib8e9a378813b4bcc9f882c0a7318ebe1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic86274b750794080aa0a3b9b4a40044d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4df1e7317eb24fb4960e2db40e43b0ae_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">zntl:ZenteraTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if503536b265745f78bee8b2c10f7dd63_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">zntl:ZenteraTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7c81d5274f084d8ca588db925f2f294d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">zntl:ZenteraTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4a32b2ade07d41f4b1cad2d93ca61367_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">zntl:ZenteraTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4817ffa176c043dcaa4bcc0e640d9ac8_D20171221-20171221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">zntl:KalyraPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-21</startDate>
            <endDate>2017-12-21</endDate>
        </period>
    </context>
    <context id="i9ff9bd8c8cc546c2bfa853ff3951cad7_I20171221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">zntl:KalyraPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-21</instant>
        </period>
    </context>
    <context id="i56332e226885432ebe62ee97b3aa1f96_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2e5d1442f22141d2ad21e2f741cecbe5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6809bcb1666148168afab58d0ffe577e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9d2a23e4bb2343d588f6a5d196d2a18b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i52d0e027780241b79c9c17cfcdd13982_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0c2420fac1a84e158a6092ec05ed0417_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0fdc062e1b6242f3bfa7722f537c5cc0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i410ff4f16a8040efb58e3e8e477cb639_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i84739e60c7164232abd1054fd4938e36_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3fcb530524114c769687f7c9f1fb749a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie5fcea6723664d4697c80360ebeed61d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib1b64d6100e743e984f7d8b3995bd09b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i32d2e7ccd63b4e078ab5c066f13b44d2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i49f1fa2e5d5d4f479e5668a21e82148b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia30f21df13f94f9ebd972a8a09ca6fac_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icf38ee1491e140b8adacc29d8bb9760f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i74f300d2e9d948a683e65b0cdc3aa411_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i380c135ffd6844f7997d78a2b67138ec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i48ff0df351ef40fe8a05cd86f1008d36_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i101ae399b06242f49e876e6d8e25a264_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7c6f54b010c64504bbd0705c0ac17af0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idd6ec7e59ffb4b9eb4453d5218e35173_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia9c408849fc84006b3a025992352774f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3150edba5268450db0756b69a3a1addf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6d89135319bc455fa6a091097227fc6e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i512ef6b869c04c8a878f93105c57c41a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i598f17c497e545c58b325723fdc76f66_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i71a8b179af364abb8287fabef06e5efe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i617ebbcc5095463d8013bb0f56fc9a65_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0843a9ee0f4743b7b17b8de5c7778791_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iadc356695ac24c8cb111a3afaaa7ff8c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3b730087c46740158ea57877aa0ae9a6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4459dcf3fc2c4ce79822c49134d753a4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifcf1f1860f224f7783c2b7814b873ab3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i128d0fd7cbbf49d2b23f8f6ed5e8b638_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ica67869b706548afa466add7912fddd6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1c53bb5c6ef84b26a856ac6cf9e2e408_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3b44713e1e994101839f64aec91e45b1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id5c6ab2386b6421d83ee4eb9753b73cd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i94ff901c1e7144e985fe76366d30065a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3727eb6a2b984c7ca52fc3f51b6afa97_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4e83e26bd72349338171ae705edbe7f0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1a2cf14e1f2448cdbc8fb71792150777_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iadaa692c5c72427cbb64934ad0fa3730_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5a695ef0eca441ed8cac49e237e173fa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i073dd536aa7f4e92a0c00f9b8001ea13_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">zntl:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i846b0f7b2bec4d4e9f5a806b4294790a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">zntl:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaecf109643ad41c2acacd554e5a7f04a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9990e1c841ed44748d68c3e408a17ce7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i65c0b3ee517a4e78a0b1cf3438d6c138_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">zntl:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifd91a2b14d264c7f801b908e210ab0e1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">zntl:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i19492fb07b694a8f831a804dd56146ac_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i716b7da8349e417aab51c34f8ddc80f4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iea20b17bd4be4aaeac426373ae7aa5ca_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i313676da216b4874b3024ccf5d0337d9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i107f398d916b45ab840efc6b49511a32_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:A2020IncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i2b8527f1b94449b499e8720cddbb6d40_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:A2020IncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i0a9d42e696914ee6ac56aebc0b0ccdf1_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:A2020IncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i892983c302494b99a210a868ff39cecd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:A2020IncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i91b8baeaf3fd40eea9dc65835916019a_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:A2022EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="i9548270e5788494cb09db3f66fae3c93_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">zntl:A2022EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icc1a500ef2574f02955ba6e37b2c81ac_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie297eca60e624e8d93b5c2d311094db0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6f732ecb401746458a388bfa07d3afc2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0f721a2929d54ac5ba6903405fe9cba7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i037f9049a8294a5c99bf21de04775e11_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i32bfab5a7c4d46cbb67792b462367d55_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i45742a89bf3246eb9070cc158debe73f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic196aacc6ecf4e049fc4defb2ff097a4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ied35ca1f9fa14bff85ddf36999e934ec_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">zntl:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i95aef8aaac164782aafe41f536dfd292_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">zntl:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i011753e6eaf2413a911eecf0b87cca62_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibfa47905419248b98bc84b2436b91faf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iae4fb48df2fa4ca3ab3a8ec68fdbb56b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2547f09e3d334b9e9a5869e04478bfe6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib06002bdaeab4e58a39c96013dac6a87_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia9df9a5968b2476b88207ca1aa4feb7a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1ae26c0f79da45b29f5451ae2499e17f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib2487cf2d4d34a84be4fe6513ad27639_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie2b9ea7d02e840689c4b7f3112d26cf8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if4fa1db40e4948c89927ea38cf78d599_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia9be73cf481a40aaba4c6cc6e675a708_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie7a5cbabc41941ada32f7ae938592fa6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i37ef16e02d7e43ba862a5c169d0332ea_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6fb0cb9f5b6a4708aab9cfcff606daf7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5e96002c4838463f94c1dab336a29f92_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8d916b6b431a4bb1b63b1b45fcaf58c3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4be5fa9930e7403c9c0f8ba0f46352fe_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">zntl:MasterServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8d0fc8e3ccd3496085dc4e71a7cfa31e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001725160</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">zntl:MasterServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="security">
        <measure>zntl:security</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80L2ZyYWc6NWU1MWM3Zjg2ODlkNGUxYThlMDQyYjc5NDI0MjM1ODIvdGFibGU6MDQ4YTgyMzMzMzMzNGY4ZDhkNWFhMjg1YzMxYjk5ZTMvdGFibGVyYW5nZTowNDhhODIzMzMzMzM0ZjhkOGQ1YWEyODVjMzFiOTllM18wLTEtMS0xLTc5Mjgz_6d001a30-fc95-41c3-ad47-c5d1c113d98b">0001725160</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80L2ZyYWc6NWU1MWM3Zjg2ODlkNGUxYThlMDQyYjc5NDI0MjM1ODIvdGFibGU6MDQ4YTgyMzMzMzMzNGY4ZDhkNWFhMjg1YzMxYjk5ZTMvdGFibGVyYW5nZTowNDhhODIzMzMzMzM0ZjhkOGQ1YWEyODVjMzFiOTllM18xLTEtMS0xLTc5Mjgz_dc006dea-f4cb-4c64-9641-5fd3cda74982">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80L2ZyYWc6NWU1MWM3Zjg2ODlkNGUxYThlMDQyYjc5NDI0MjM1ODIvdGFibGU6MDQ4YTgyMzMzMzMzNGY4ZDhkNWFhMjg1YzMxYjk5ZTMvdGFibGVyYW5nZTowNDhhODIzMzMzMzM0ZjhkOGQ1YWEyODVjMzFiOTllM18yLTEtMS0xLTc5Mjgz_fb6a5c5a-dc58-4d29-827e-7afdac717cab">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80L2ZyYWc6NWU1MWM3Zjg2ODlkNGUxYThlMDQyYjc5NDI0MjM1ODIvdGFibGU6MDQ4YTgyMzMzMzMzNGY4ZDhkNWFhMjg1YzMxYjk5ZTMvdGFibGVyYW5nZTowNDhhODIzMzMzMzM0ZjhkOGQ1YWEyODVjMzFiOTllM18zLTEtMS0xLTc5Mjgz_b8cc2a97-3c76-4e09-b18f-f343d922a6a8">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80L2ZyYWc6NWU1MWM3Zjg2ODlkNGUxYThlMDQyYjc5NDI0MjM1ODIvdGFibGU6MDQ4YTgyMzMzMzMzNGY4ZDhkNWFhMjg1YzMxYjk5ZTMvdGFibGVyYW5nZTowNDhhODIzMzMzMzM0ZjhkOGQ1YWEyODVjMzFiOTllM180LTEtMS0xLTc5Mjgz_118fbb5d-9905-4bcb-b11e-934edee06b2b">2023</dei:DocumentFiscalYearFocus>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i8d0fc8e3ccd3496085dc4e71a7cfa31e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNjIvZnJhZzpjYzk2NDhkNTc3MDI0Nzc0YTBlOGEzZjNjZTUyNTNjZi90ZXh0cmVnaW9uOmNjOTY0OGQ1NzcwMjQ3NzRhMGU4YTNmM2NlNTI1M2NmXzE2NDkyNjc0NDE2ODI_12403860-2023-49c6-b915-c77ce1a11a7c"
      unitRef="usd">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <dei:DocumentType
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjg4_4aaf24c0-0d00-4a88-b6f3-eda2cf4eb3e5">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjg0_66e8165e-38a6-47d2-9fc3-02ad23f6f90d">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjQ_8d491b0f-d30a-4ce9-9dea-b6a9e5631491">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjg1_1573c380-7ae7-4c5a-9461-41eae0f0fce7">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjg2_d53eea4a-6296-4bea-8085-7d94b7f2fabd">001-39263</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjky_d0ddd708-9035-41fd-8150-1d57ea6867d6">Zentalis Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6OTlhZmViODU2YjRlNDE4ZDllN2E2YjYyZTg0NzRlMDYvdGFibGVyYW5nZTo5OWFmZWI4NTZiNGU0MThkOWU3YTZiNjJlODQ3NGUwNl8wLTAtMS0xLTc5Mjgz_ca517937-b12c-40ad-8398-9ec89c8ee204">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6OTlhZmViODU2YjRlNDE4ZDllN2E2YjYyZTg0NzRlMDYvdGFibGVyYW5nZTo5OWFmZWI4NTZiNGU0MThkOWU3YTZiNjJlODQ3NGUwNl8wLTEtMS0xLTc5Mjgz_7d771d7a-5935-4d3d-b627-1a5716ad7ade">82-3607803</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6OTlhZmViODU2YjRlNDE4ZDllN2E2YjYyZTg0NzRlMDYvdGFibGVyYW5nZTo5OWFmZWI4NTZiNGU0MThkOWU3YTZiNjJlODQ3NGUwNl8zLTAtMS0xLTc5MjgzL3RleHRyZWdpb246Njk2MTgyZGI1Mzg1NGFmOTliYTJlNTFlNmZkNzEwYWRfNA_80a7ada8-9a9b-4594-96a4-592af9260854">1359 Broadway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6OTlhZmViODU2YjRlNDE4ZDllN2E2YjYyZTg0NzRlMDYvdGFibGVyYW5nZTo5OWFmZWI4NTZiNGU0MThkOWU3YTZiNjJlODQ3NGUwNl8zLTAtMS0xLTc5MjgzL3RleHRyZWdpb246Njk2MTgyZGI1Mzg1NGFmOTliYTJlNTFlNmZkNzEwYWRfOA_62cb3613-1d30-424c-a083-cb4f91b7f64b">Suite 801</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6OTlhZmViODU2YjRlNDE4ZDllN2E2YjYyZTg0NzRlMDYvdGFibGVyYW5nZTo5OWFmZWI4NTZiNGU0MThkOWU3YTZiNjJlODQ3NGUwNl81LTAtMS0xLTc5Mjgz_57391e08-8021-4354-897a-054555d3987e">New York,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6OTlhZmViODU2YjRlNDE4ZDllN2E2YjYyZTg0NzRlMDYvdGFibGVyYW5nZTo5OWFmZWI4NTZiNGU0MThkOWU3YTZiNjJlODQ3NGUwNl82LTAtMS0xLTc5Mjgz_9e5a542e-a03e-46ce-8cbb-048b5d005bb3">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6OTlhZmViODU2YjRlNDE4ZDllN2E2YjYyZTg0NzRlMDYvdGFibGVyYW5nZTo5OWFmZWI4NTZiNGU0MThkOWU3YTZiNjJlODQ3NGUwNl82LTEtMS0xLTc5Mjgz_4728392a-5f56-4653-85c4-36c61626706b">10018</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjgy_cb1398ec-2a3f-4cc9-afa1-0ee7515b01d1">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjk0_2104507f-1fbc-457e-abd9-19a2fe3d98e2">433-3791</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6ZmEzNTBiZTJlNjVhNDI1NDkwZmNkZDJjNjc4ZmUyMDQvdGFibGVyYW5nZTpmYTM1MGJlMmU2NWE0MjU0OTBmY2RkMmM2NzhmZTIwNF8xLTAtMS0xLTc5Mjgz_2800914a-2040-47b2-87f7-94b7470c4f2f">Common Stock,$0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6ZmEzNTBiZTJlNjVhNDI1NDkwZmNkZDJjNjc4ZmUyMDQvdGFibGVyYW5nZTpmYTM1MGJlMmU2NWE0MjU0OTBmY2RkMmM2NzhmZTIwNF8xLTEtMS0xLTc5Mjgz_48e041dc-9fc6-4336-9ff9-b20620da229d">ZNTL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6ZmEzNTBiZTJlNjVhNDI1NDkwZmNkZDJjNjc4ZmUyMDQvdGFibGVyYW5nZTpmYTM1MGJlMmU2NWE0MjU0OTBmY2RkMmM2NzhmZTIwNF8xLTItMS0xLTc5MjgzL3RleHRyZWdpb246NGQ4ZGE2OWJhNjc0NDNhMmJhMzFjMzMxOTkzNTYyNTRfNA_2c273c0b-b707-4458-be92-ab82393894e8">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjkw_c8f50a07-db02-4045-a100-456a30e67858">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjkz_4f776ba0-8df0-4ded-ac8b-773ad4e69e28">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6NGVlNTM2NzE0MzJlNDlhOWE2NWZlYTAzZjYyZjcxODUvdGFibGVyYW5nZTo0ZWU1MzY3MTQzMmU0OWE5YTY1ZmVhMDNmNjJmNzE4NV8wLTAtMS0xLTc5Mjgz_ebf8a40e-1a58-48e2-8e52-c33cfb5576b3">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6NGVlNTM2NzE0MzJlNDlhOWE2NWZlYTAzZjYyZjcxODUvdGFibGVyYW5nZTo0ZWU1MzY3MTQzMmU0OWE5YTY1ZmVhMDNmNjJmNzE4NV8xLTQtMS0xLTc5Mjgz_98ebb5af-469b-49c0-8632-9b03498a5283">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGFibGU6NGVlNTM2NzE0MzJlNDlhOWE2NWZlYTAzZjYyZjcxODUvdGFibGVyYW5nZTo0ZWU1MzY3MTQzMmU0OWE5YTY1ZmVhMDNmNjJmNzE4NV8yLTQtMS0xLTc5Mjgz_9b52efdb-4fb8-4ab2-9212-d8ffc1a0052d">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjgz_93e53e11-93ef-4b82-b4b1-7968a217176b">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ia48f187fdc694ec0a436fbbe630672db_I20230508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8xL2ZyYWc6ZDQwYjEyOTQ3YjVjNDU2ZWJkZjVkNjEyOTJkNTBiNmYvdGV4dHJlZ2lvbjpkNDBiMTI5NDdiNWM0NTZlYmRmNWQ2MTI5MmQ1MGI2Zl8yMjE0_71e843e5-7f1e-4b6a-beac-1e7c551b3afb"
      unitRef="shares">59477824</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfNC0xLTEtMS03OTI4Mw_446576aa-a79e-44ce-b443-ce7724f7f7bc"
      unitRef="usd">36280000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfNC0zLTEtMS03OTI4Mw_11b9249b-2cbf-46d7-9a8d-5c6da2f641bb"
      unitRef="usd">43069000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfNS0xLTEtMS03OTI4Mw_de04d5ef-04b4-4cc7-b419-1c76fbb5dbb6"
      unitRef="usd">356239000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfNS0zLTEtMS03OTI4Mw_add160a7-1254-4513-b0e7-f67b46f26d3b"
      unitRef="usd">394302000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfNy0xLTEtMS03OTI4Mw_2aa59922-c4e0-4125-8b31-42e9f4b61741"
      unitRef="usd">17707000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfNy0zLTEtMS03OTI4Mw_9468ca43-11a6-4583-9646-d23e7b18d155"
      unitRef="usd">14562000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfOS0xLTEtMS03OTI4Mw_51138908-e10a-4b15-9b6f-91e64d0f192d"
      unitRef="usd">410226000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfOS0zLTEtMS03OTI4Mw_31699c1f-c6d0-4adc-aadb-7dc90f61ea06"
      unitRef="usd">451933000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTAtMS0xLTEtNzkyODM_3bf927b0-1250-4410-8b36-57e1c92187c4"
      unitRef="usd">6880000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTAtMy0xLTEtNzkyODM_7ea8e684-b762-47f1-a664-d578be89d412"
      unitRef="usd">7705000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTEtMS0xLTEtNzkyODM_f840d1f3-133d-4142-9a3a-9e704b110152"
      unitRef="usd">37475000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTEtMy0xLTEtNzkyODM_f4d67c72-78f5-4c87-b7da-6d20c72624d6"
      unitRef="usd">42373000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTItMS0xLTEtNzkyODM_6886f5a2-76f8-4232-af4a-f2f02138cfbf"
      unitRef="usd">9495000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTItMy0xLTEtNzkyODM_aba921ad-2ee3-4225-8f87-165060564e48"
      unitRef="usd">9723000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:Goodwill
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTMtMS0xLTEtNzkyODM_b4db6484-069d-4cbf-aefe-8a7d828f6394"
      unitRef="usd">3736000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTMtMy0xLTEtNzkyODM_43c48609-e5a1-4dac-b009-25a6c743d638"
      unitRef="usd">3736000</us-gaap:Goodwill>
    <us-gaap:EquityMethodInvestments
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTUtMS0xLTEtNzkyODM_dd08cb9d-b839-4593-98c4-94839f869a51"
      unitRef="usd">18903000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTUtMy0xLTEtNzkyODM_635ec20e-c6b0-4a4b-a458-5f45aafe5a66"
      unitRef="usd">21213000</us-gaap:EquityMethodInvestments>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTYtMS0xLTEtNzkyODM_605bffca-8186-4be4-94a3-617da759fa3a"
      unitRef="usd">2627000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTYtMy0xLTEtNzkyODM_2c04d82c-2d09-42a8-b93f-960335386c5f"
      unitRef="usd">2627000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:Assets
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTctMS0xLTEtNzkyODM_be321f87-8a1b-48d6-a8d4-9915ca4ab691"
      unitRef="usd">489342000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMTctMy0xLTEtNzkyODM_720b4afd-6464-4ff3-b944-808f62449f99"
      unitRef="usd">539310000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjAtMS0xLTEtNzkyODM_49be8359-8b34-4597-a68f-672758694b16"
      unitRef="usd">12818000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjAtMy0xLTEtNzkyODM_46a1f4b4-e170-4af0-945c-42cfcd2d7776"
      unitRef="usd">11247000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjEtMS0xLTEtNzkyODM_cb56cf76-7548-40c1-8dde-2dd56c3556b3"
      unitRef="usd">43540000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjEtMy0xLTEtNzkyODM_daf49620-4bb4-47af-be1c-5771a08e7da6"
      unitRef="usd">45400000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjItMS0xLTEtNzkyODM_2027cd53-6ebb-4272-9a66-226411828874"
      unitRef="usd">56358000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjItMy0xLTEtNzkyODM_73b84e18-88b3-45fd-b7c8-4e2e975fa33a"
      unitRef="usd">56647000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjMtMS0xLTEtNzkyODM_5836646a-23ab-4837-93d2-713a5784240e"
      unitRef="usd">756000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjMtMy0xLTEtNzkyODM_32d26dab-7221-4c7c-a81c-1498cc8ea31c"
      unitRef="usd">853000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjQtMS0xLTEtNzkzNTM_7159c60d-4880-49a6-9242-1515cbb4b838"
      unitRef="usd">44771000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjQtMy0xLTEtNzkzNTM_5faff354-3edd-44d4-9aa6-c50641a623e2"
      unitRef="usd">45166000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjQtMS0xLTEtNzkyODM_53942095-2459-4a9c-b704-fff94594cad2"
      unitRef="usd">1792000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjQtMy0xLTEtNzkyODM_22d8a3d9-6ee0-45e9-9187-51a3f20c7b39"
      unitRef="usd">2620000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjUtMS0xLTEtNzkyODM_ffcc9756-bc7e-4720-819c-0aab9f55cea1"
      unitRef="usd">103677000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjUtMy0xLTEtNzkyODM_895c1077-92e9-45a5-99e3-305fda3b8037"
      unitRef="usd">105286000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjYtMS0xLTEtNzkyODM_03a34e9e-406f-4988-b815-ec395e50bfc4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMjYtMy0xLTEtNzkyODM_e312d495-96eb-478e-a796-b4f9975fdf02"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzEtMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjowYjJkN2JjNzI3MWY0YjIxOWY1Y2EyODczNTM3NmQ2Nl8yMQ_41e4ddb2-6d1c-47da-b496-924ceb08495a"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzEtMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjowYjJkN2JjNzI3MWY0YjIxOWY1Y2EyODczNTM3NmQ2Nl8yMQ_df5fa202-d45d-480d-a2af-13f90c9f3c60"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzEtMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjowYjJkN2JjNzI3MWY0YjIxOWY1Y2EyODczNTM3NmQ2Nl8zNQ_54d67a79-ea8f-4002-a5f1-d7513119f389"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzEtMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjowYjJkN2JjNzI3MWY0YjIxOWY1Y2EyODczNTM3NmQ2Nl8zNQ_70dee25d-104e-42fe-923e-bcf06480f25f"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzEtMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjowYjJkN2JjNzI3MWY0YjIxOWY1Y2EyODczNTM3NmQ2Nl81Nw_6a9b1e52-9331-43f4-96de-0dd76142c7b4"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzEtMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjowYjJkN2JjNzI3MWY0YjIxOWY1Y2EyODczNTM3NmQ2Nl81Nw_6f24f0e6-a895-455c-aeca-841679f9e984"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzEtMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjowYjJkN2JjNzI3MWY0YjIxOWY1Y2EyODczNTM3NmQ2Nl81Nw_b1f6d536-a425-471b-826d-6361252e71f7"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzEtMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjowYjJkN2JjNzI3MWY0YjIxOWY1Y2EyODczNTM3NmQ2Nl81Nw_d26b767d-3226-4724-ae0b-7b4a13f3423a"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzEtMS0xLTEtNzkyODM_b97558cd-3488-44fc-81ca-333bc47d891f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzEtMy0xLTEtNzkyODM_f026cd4b-82c5-4b71-95ee-ee7cf059bb8f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzItMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjpjZTM2ZTIwMGY3OTA0ODI0ODk2Y2E0MTU1MTEwOGNhZF8xOA_bbcfe703-8340-479f-b644-df56e3053e8d"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzItMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjpjZTM2ZTIwMGY3OTA0ODI0ODk2Y2E0MTU1MTEwOGNhZF8xOA_d1d568cf-67e9-46fe-83c6-b821d14efc8d"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzItMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjpjZTM2ZTIwMGY3OTA0ODI0ODk2Y2E0MTU1MTEwOGNhZF8zMg_0d5800cd-d0d7-4127-b8ef-751c18d4d33a"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzItMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjpjZTM2ZTIwMGY3OTA0ODI0ODk2Y2E0MTU1MTEwOGNhZF8zMg_a7d3e378-f685-48d4-b921-3cad717c77f8"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzItMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjpjZTM2ZTIwMGY3OTA0ODI0ODk2Y2E0MTU1MTEwOGNhZF81NA_3b36ec2f-fde2-4051-babe-9a1cdecf0b0f"
      unitRef="shares">59442342</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzItMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjpjZTM2ZTIwMGY3OTA0ODI0ODk2Y2E0MTU1MTEwOGNhZF81NA_a844b3e4-a70a-4d71-959e-ccd31e188df1"
      unitRef="shares">59442342</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzItMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjpjZTM2ZTIwMGY3OTA0ODI0ODk2Y2E0MTU1MTEwOGNhZF82MQ_40aeafa6-c631-474c-aad9-b110b084d1c0"
      unitRef="shares">59280247</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzItMC0xLTEtNzkyODMvdGV4dHJlZ2lvbjpjZTM2ZTIwMGY3OTA0ODI0ODk2Y2E0MTU1MTEwOGNhZF82MQ_bbf6b591-1a68-4927-bfde-98e247184b1c"
      unitRef="shares">59280247</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzItMS0xLTEtNzkyODM_6eebf656-f7fe-4758-96ae-d3ae2c5d65b3"
      unitRef="usd">59000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzItMy0xLTEtNzkyODM_5d8c1386-82a5-4823-9d56-885a2fe08670"
      unitRef="usd">59000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzMtMS0xLTEtNzkyODM_33a201ef-a720-4a8f-b7bc-97f0cad8f01f"
      unitRef="usd">1045568000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzMtMy0xLTEtNzkyODM_628cbc57-eaba-4069-8d0e-d9cfed24100a"
      unitRef="usd">1031462000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzQtMS0xLTEtNzkyODM_41aeeefa-b57c-45c6-b6cf-271c74fe8d0f"
      unitRef="usd">-556000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzQtMy0xLTEtNzkyODM_57a9eb80-97d0-4a66-a6c4-0af28c7651ee"
      unitRef="usd">-1353000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzUtMS0xLTEtNzkyODM_41b9728f-feac-4a9f-b5e6-5713981fdcaa"
      unitRef="usd">-659584000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzUtMy0xLTEtNzkyODM_80d8c88c-cc7d-40d9-b9c5-c0dfa70241f8"
      unitRef="usd">-596365000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzYtMS0xLTEtNzkyODM_dbfd49e2-09fd-49a4-a3be-1600edff4515"
      unitRef="usd">385487000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzYtMy0xLTEtNzkyODM_e07e2fb0-cfce-4c33-bcdb-ee479bb9db22"
      unitRef="usd">433803000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzctMS0xLTEtNzkyODM_66d3cf56-c67d-4a09-a109-7f22d4a73c4c"
      unitRef="usd">178000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzctMy0xLTEtNzkyODM_ac83834c-205e-4142-ba34-c90b39b1bfe4"
      unitRef="usd">221000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzgtMS0xLTEtNzkyODM_0daefcb4-336e-4a39-9bb0-a64be3891d5a"
      unitRef="usd">385665000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzgtMy0xLTEtNzkyODM_823de688-a4c7-449c-986f-97dace42c770"
      unitRef="usd">434024000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzktMS0xLTEtNzkyODM_054ca176-99f3-4bbc-b5b1-99ee902499da"
      unitRef="usd">489342000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yMi9mcmFnOmEwZDE5ZGI1Y2ZiODQxM2E5YjY1NzI0Y2FjM2UxNjk5L3RhYmxlOjFjNjc3NzNhYzExYzRiYjJhOWQ1ZjIzNzViZTU5MTJmL3RhYmxlcmFuZ2U6MWM2Nzc3M2FjMTFjNGJiMmE5ZDVmMjM3NWJlNTkxMmZfMzktMy0xLTEtNzkyODM_e69b21af-7771-488f-a527-ae9a647bbaf9"
      unitRef="usd">539310000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMy01LTEtMS03OTI4Mw_682e9064-e372-40e1-81f8-87635cd41273"
      unitRef="usd">48584000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMy03LTEtMS03OTI4Mw_1a3a932c-6905-46f5-ba80-400cfb235fb4"
      unitRef="usd">46112000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfNC01LTEtMS03OTI4Mw_0f6da4d3-40ee-4706-a88d-d9946198b1da"
      unitRef="usd">16369000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfNC03LTEtMS03OTI4Mw_371b682e-b77c-474b-b6de-1669e338ebca"
      unitRef="usd">11767000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfNS01LTEtMS03OTI4Mw_a852cf1f-9f31-4010-8ec4-06884baa59c6"
      unitRef="usd">64953000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfNS03LTEtMS03OTI4Mw_8ba223ac-6314-45cc-bf65-33b945ed01e7"
      unitRef="usd">57879000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfNi01LTEtMS03OTI4Mw_5e7d9b92-8c7b-48cc-982b-382f1c63bb0a"
      unitRef="usd">-64953000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfNi03LTEtMS03OTI4Mw_06ad06f3-d7fb-4599-9cbf-1c0968311d15"
      unitRef="usd">-57879000</us-gaap:OperatingIncomeLoss>
    <zntl:InvestmentAndOtherIncomeExpense
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfOC01LTEtMS03OTI4Mw_1e9c94a2-51aa-4179-9701-4a81d5b091d8"
      unitRef="usd">4109000</zntl:InvestmentAndOtherIncomeExpense>
    <zntl:InvestmentAndOtherIncomeExpense
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfOC03LTEtMS03OTI4Mw_2b683fff-2b36-4ed1-88ac-1f9bef9b8335"
      unitRef="usd">426000</zntl:InvestmentAndOtherIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTEtNS0xLTEtNzkyODM_5866f0e8-8190-4665-b943-e1fc66e5d524"
      unitRef="usd">-60844000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTEtNy0xLTEtNzkyODM_0d41cf32-bc83-4791-a1f7-b0187e144394"
      unitRef="usd">-57453000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTItNS0xLTEtNzkyODM_41a97563-9d4f-40b0-b398-37549091f421"
      unitRef="usd">108000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTItNy0xLTEtNzkyODM_af36cbdb-32ba-4bc3-a467-83c13df504ef"
      unitRef="usd">33000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTMtNS0xLTEtNzkyODM_10220cb6-06e8-417d-a3a4-8da944197601"
      unitRef="usd">-2310000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTMtNy0xLTEtNzkyODM_9b73d9b8-9ac7-4b82-81de-6a35ca884969"
      unitRef="usd">-1751000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTQtNS0xLTEtNzkyODM_1dcd9a13-2d83-441a-8465-0c718a93bce1"
      unitRef="usd">-63262000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTQtNy0xLTEtNzkyODM_ab85f3b0-e9f8-413e-9aaa-554f8437563e"
      unitRef="usd">-59237000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTUtNS0xLTEtNzkyODM_cba9625a-ac71-4e80-bbea-84493583aab2"
      unitRef="usd">-43000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTUtNy0xLTEtNzkyODM_7b363f1e-4b37-4538-ac27-67a458196feb"
      unitRef="usd">-160000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTYtNS0xLTEtNzkyODM_729a7073-efbe-474c-a4dd-8615bb16eae0"
      unitRef="usd">-63219000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTYtNy0xLTEtNzkyODM_bbcf9612-27af-4bf7-be82-68105c62a851"
      unitRef="usd">-59077000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTctNS0xLTEtNzkyODM_0abed70d-55f7-4c65-b5b1-c5f419c55407"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTctNS0xLTEtNzkyODM_b31ed39d-5b14-401b-94fb-92936d3132d6"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTctNy0xLTEtNzkyODM_7e24d30b-38f8-4ca8-ad4f-51a440397d3c"
      unitRef="usdPerShare">-1.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTctNy0xLTEtNzkyODM_98fc2b24-f27a-4351-b1cc-7a5e3cfe4fa8"
      unitRef="usdPerShare">-1.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTktNS0xLTEtNzkyODM_940e4707-2d41-4943-877a-b749dfb9146c"
      unitRef="shares">59277000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTktNS0xLTEtNzkyODM_dd940558-eaa1-4a94-88fd-a94b5197df6a"
      unitRef="shares">59277000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTktNy0xLTEtNzkyODM_bf540d4c-f842-4192-b41b-206916468515"
      unitRef="shares">45244000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yNS9mcmFnOmQ1NmY4ZDQ2NDUzMzQ0NjY4MjhjOWRmZDc3ZmRhYjM3L3RhYmxlOjRkZGVhNDE3NDQ0NTRkZWM5MTdlNDgzNjM2NzhlZDlhL3RhYmxlcmFuZ2U6NGRkZWE0MTc0NDQ1NGRlYzkxN2U0ODM2MzY3OGVkOWFfMTktNy0xLTEtNzkyODM_dff258d7-5492-4ccc-b037-6c638f9e43aa"
      unitRef="shares">45244000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yOC9mcmFnOjBiNjE5Y2NmZDA5NTQ1N2Y5NTRkMzE5ZWEyOTUxZjc4L3RhYmxlOjUzMDkxMzc5ZmE1MTQ0N2Q4YWVjOTgwZmYxZGNhODExL3RhYmxlcmFuZ2U6NTMwOTEzNzlmYTUxNDQ3ZDhhZWM5ODBmZjFkY2E4MTFfMi0zLTEtMS03OTI4Mw_1dcd9a13-2d83-441a-8465-0c718a93bce1"
      unitRef="usd">-63262000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yOC9mcmFnOjBiNjE5Y2NmZDA5NTQ1N2Y5NTRkMzE5ZWEyOTUxZjc4L3RhYmxlOjUzMDkxMzc5ZmE1MTQ0N2Q4YWVjOTgwZmYxZGNhODExL3RhYmxlcmFuZ2U6NTMwOTEzNzlmYTUxNDQ3ZDhhZWM5ODBmZjFkY2E4MTFfMi00LTEtMS03OTI4Mw_ab85f3b0-e9f8-413e-9aaa-554f8437563e"
      unitRef="usd">-59237000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yOC9mcmFnOjBiNjE5Y2NmZDA5NTQ1N2Y5NTRkMzE5ZWEyOTUxZjc4L3RhYmxlOjUzMDkxMzc5ZmE1MTQ0N2Q4YWVjOTgwZmYxZGNhODExL3RhYmxlcmFuZ2U6NTMwOTEzNzlmYTUxNDQ3ZDhhZWM5ODBmZjFkY2E4MTFfNS0zLTEtMS03OTI4Mw_e0ef115a-c92b-43ea-ba4f-84b09b934f82"
      unitRef="usd">797000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yOC9mcmFnOjBiNjE5Y2NmZDA5NTQ1N2Y5NTRkMzE5ZWEyOTUxZjc4L3RhYmxlOjUzMDkxMzc5ZmE1MTQ0N2Q4YWVjOTgwZmYxZGNhODExL3RhYmxlcmFuZ2U6NTMwOTEzNzlmYTUxNDQ3ZDhhZWM5ODBmZjFkY2E4MTFfNS00LTEtMS03OTI4Mw_1a4143bd-b2bf-4ae6-a513-ef880205ba12"
      unitRef="usd">-984000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yOC9mcmFnOjBiNjE5Y2NmZDA5NTQ1N2Y5NTRkMzE5ZWEyOTUxZjc4L3RhYmxlOjUzMDkxMzc5ZmE1MTQ0N2Q4YWVjOTgwZmYxZGNhODExL3RhYmxlcmFuZ2U6NTMwOTEzNzlmYTUxNDQ3ZDhhZWM5ODBmZjFkY2E4MTFfNi0zLTEtMS03OTI4Mw_b8d008f1-fdfe-4e3c-8fa0-d3a90ac6e71b"
      unitRef="usd">-62465000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yOC9mcmFnOjBiNjE5Y2NmZDA5NTQ1N2Y5NTRkMzE5ZWEyOTUxZjc4L3RhYmxlOjUzMDkxMzc5ZmE1MTQ0N2Q4YWVjOTgwZmYxZGNhODExL3RhYmxlcmFuZ2U6NTMwOTEzNzlmYTUxNDQ3ZDhhZWM5ODBmZjFkY2E4MTFfNi00LTEtMS03OTI4Mw_608699f4-727f-4d85-a429-eb747d7336a6"
      unitRef="usd">-60221000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yOC9mcmFnOjBiNjE5Y2NmZDA5NTQ1N2Y5NTRkMzE5ZWEyOTUxZjc4L3RhYmxlOjUzMDkxMzc5ZmE1MTQ0N2Q4YWVjOTgwZmYxZGNhODExL3RhYmxlcmFuZ2U6NTMwOTEzNzlmYTUxNDQ3ZDhhZWM5ODBmZjFkY2E4MTFfNy0zLTEtMS03OTI4Mw_3563dcde-10a0-48c1-bb15-ca7a45b5c30e"
      unitRef="usd">-43000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yOC9mcmFnOjBiNjE5Y2NmZDA5NTQ1N2Y5NTRkMzE5ZWEyOTUxZjc4L3RhYmxlOjUzMDkxMzc5ZmE1MTQ0N2Q4YWVjOTgwZmYxZGNhODExL3RhYmxlcmFuZ2U6NTMwOTEzNzlmYTUxNDQ3ZDhhZWM5ODBmZjFkY2E4MTFfNy00LTEtMS03OTI4Mw_07427fc6-212b-4075-8da8-d6ef66760bed"
      unitRef="usd">-160000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yOC9mcmFnOjBiNjE5Y2NmZDA5NTQ1N2Y5NTRkMzE5ZWEyOTUxZjc4L3RhYmxlOjUzMDkxMzc5ZmE1MTQ0N2Q4YWVjOTgwZmYxZGNhODExL3RhYmxlcmFuZ2U6NTMwOTEzNzlmYTUxNDQ3ZDhhZWM5ODBmZjFkY2E4MTFfOC0zLTEtMS03OTI4Mw_38dd7ca7-2fd0-4373-9e75-1fd3ca89dfba"
      unitRef="usd">-62422000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8yOC9mcmFnOjBiNjE5Y2NmZDA5NTQ1N2Y5NTRkMzE5ZWEyOTUxZjc4L3RhYmxlOjUzMDkxMzc5ZmE1MTQ0N2Q4YWVjOTgwZmYxZGNhODExL3RhYmxlcmFuZ2U6NTMwOTEzNzlmYTUxNDQ3ZDhhZWM5ODBmZjFkY2E4MTFfOC00LTEtMS03OTI4Mw_9289c225-95b6-48a2-8387-4a2056898894"
      unitRef="usd">-60061000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMy0xLTEtMS03OTI4Mw_8a322ce0-88fb-4110-8ce2-851e81225b55"
      unitRef="usd">-63262000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMy0zLTEtMS03OTI4Mw_b4d8e686-77b4-4026-b69f-3a773c0effc5"
      unitRef="usd">-59237000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfNS0xLTEtMS03OTI4Mw_1831b7e9-5fa3-4ef7-9e21-ee3775e97586"
      unitRef="usd">360000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfNS0zLTEtMS03OTI4Mw_1af148a9-7711-4b55-9574-fc29cf5ec9b8"
      unitRef="usd">344000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AssetImpairmentCharges
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfNi0xLTEtMS05NzE0NA_882ef0d9-a68f-4f8f-9807-1964de56f590"
      unitRef="usd">4953000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfNi0zLTEtMS05NzE1Mg_bda14b87-6298-4a62-aa26-2b5cb3039464"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:ShareBasedCompensation
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfOS0xLTEtMS03OTI4Mw_0b96707c-6e2f-4e28-8468-10098c022827"
      unitRef="usd">13733000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfOS0zLTEtMS03OTI4Mw_140414f7-ccef-45bc-984a-9618b924cf4b"
      unitRef="usd">10147000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTEtMS0xLTEtNzkyODM_f0437820-3c06-41f2-a271-a1a44c5a93fc"
      unitRef="usd">3261000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTEtMy0xLTEtNzkyODM_7888cf90-6e00-4290-b34e-46ab454f2aa6"
      unitRef="usd">-146000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTItMS0xLTEtNzkyODM_87282eea-236b-48c9-be44-dd18ec65ae09"
      unitRef="usd">-2310000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTItMy0xLTEtNzkyODM_3b68b422-2f34-4495-b97d-2e48841e86d0"
      unitRef="usd">-1751000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTMtMS0xLTEtOTUxNzA_8f0435ea-b19e-4392-a9e2-d13dc10c4e75"
      unitRef="usd">-97000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTMtMy0xLTEtOTUxNzA_d59ddb3c-089f-4de4-affe-138684f177f3"
      unitRef="usd">-74000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTUtMS0xLTEtNzkyODM_58f90e1f-9d82-4891-8081-66aa9e3e0ed0"
      unitRef="usd">2917000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTUtMy0xLTEtNzkyODM_d5b7ded5-c8d9-49c8-a916-029ae26dd67c"
      unitRef="usd">4154000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTYtMS0xLTEtNzkyODM_9ec5a93e-f34b-4fa9-8f04-a00d08ed2010"
      unitRef="usd">-1411000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTYtMy0xLTEtNzkyODM_df247ad2-3d22-4b15-b62d-124d81acd09f"
      unitRef="usd">-500000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <zntl:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTctMS0xLTEtNzkyODM_e068c9f8-fe0a-420b-a8b9-51ad1e4a0cc1"
      unitRef="usd">309000</zntl:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet>
    <zntl:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTctMy0xLTEtNzkyODM_c2b69d51-a628-4bd8-adde-221bbe81a97e"
      unitRef="usd">1381000</zntl:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTgtMS0xLTEtNzkyODM_70a6422d-c64e-47e1-88e7-4d35fa908f19"
      unitRef="usd">-49283000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMTgtMy0xLTEtNzkyODM_48d987eb-bf0d-4d40-8bbf-40733238dc7e"
      unitRef="usd">-50196000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMjAtMS0xLTEtNzkyODM_122c7882-03ec-4307-8b5b-1c977579ab0a"
      unitRef="usd">63879000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMjAtMy0xLTEtNzkyODM_a875ccbd-2f95-47d4-be11-642e7c0c655e"
      unitRef="usd">79254000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMjEtMS0xLTEtNzkyODM_ac9237b5-3a79-48dd-99d3-00ae7b46885a"
      unitRef="usd">106000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMjEtMy0xLTEtNzkyODM_e6d745b9-aa09-42ab-854e-848388502ff9"
      unitRef="usd">99500000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMjMtMS0xLTEtNzkyODM_b55ec276-e4a6-4743-99fb-601684384ac9"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMjMtMy0xLTEtNzkyODM_6ad487cf-4e9c-4e9e-a82a-1ca15898d839"
      unitRef="usd">450000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMjQtMS0xLTEtNzkyODM_5b33b345-884c-44c0-a833-141481b5e000"
      unitRef="usd">42121000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMjQtMy0xLTEtNzkyODM_429c735d-ad3b-41a7-924f-46cd1369f1ba"
      unitRef="usd">19796000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMjgtMS0xLTEtNzkyODM_233fa620-c28c-4224-8e0d-a4cef7787a2b"
      unitRef="usd">373000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMjgtMy0xLTEtNzkyODM_22c98957-93b8-4085-8b8b-1981a0360409"
      unitRef="usd">1258000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMzMtMS0xLTEtNzkyODM_1f785ed6-ef92-4d52-b793-d8070163a43b"
      unitRef="usd">373000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMzMtMy0xLTEtNzkyODM_55de1dd6-4385-4646-90d9-702b50287a98"
      unitRef="usd">1258000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMzQtMS0xLTEtNzkyODM_2bcb7a9d-5bf6-4357-a866-b6d15f50e5e1"
      unitRef="usd">-6789000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMzQtMy0xLTEtNzkyODM_6cde5394-8442-497b-ae41-f008cc2baf86"
      unitRef="usd">-29142000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMzUtMS0xLTEtNzkyODM_e0615932-7e2d-472c-9793-3734538f9db7"
      unitRef="usd">45696000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i952b505edf2c4ed8969edcd9dd637d0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMzUtMy0xLTEtNzkyODM_57f69c6b-26d9-45fd-a3f2-0f11b7f8cb39"
      unitRef="usd">62584000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMzYtMS0xLTEtNzkyODM_0a85e626-4b3d-4ab9-b15f-b14da2291849"
      unitRef="usd">38907000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i94cbb15018ea46098ad9249cb81ecbd5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMzYtMy0xLTEtNzkyODM_7bfd0abe-ffec-4233-8071-2242b05a683a"
      unitRef="usd">33442000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMzgtMS0xLTEtNzkyODM_bbcb0f27-8197-4bd8-a8f6-06ff33fb4d9e"
      unitRef="usd">209000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOjM5MGMyM2JmODNhYjQxNzg5NjA2ZTg4ZTAzZTllZTA3L3RhYmxlcmFuZ2U6MzkwYzIzYmY4M2FiNDE3ODk2MDZlODhlMDNlOWVlMDdfMzgtMy0xLTEtNzkyODM_f588b2b4-d4ee-45bc-96fb-7bbb6f21b83e"
      unitRef="usd">226000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOmRjMTUyOGU4MTQ3MTQzODg5MWIyMGQyZGE5MzFlOGRiL3RhYmxlcmFuZ2U6ZGMxNTI4ZTgxNDcxNDM4ODkxYjIwZDJkYTkzMWU4ZGJfMi0xLTEtMS03OTI4Mw_7c0f413b-65c6-463a-ba0e-23f5fa52d35a"
      unitRef="usd">36280000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i94cbb15018ea46098ad9249cb81ecbd5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOmRjMTUyOGU4MTQ3MTQzODg5MWIyMGQyZGE5MzFlOGRiL3RhYmxlcmFuZ2U6ZGMxNTI4ZTgxNDcxNDM4ODkxYjIwZDJkYTkzMWU4ZGJfMi0zLTEtMS03OTI4Mw_ced14540-de30-430d-88e8-861ae6ab1c06"
      unitRef="usd">30572000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOmRjMTUyOGU4MTQ3MTQzODg5MWIyMGQyZGE5MzFlOGRiL3RhYmxlcmFuZ2U6ZGMxNTI4ZTgxNDcxNDM4ODkxYjIwZDJkYTkzMWU4ZGJfMy0xLTEtMS03OTI4Mw_7bfd63a3-18b8-46f6-8f50-cbde3cbfd396"
      unitRef="usd">2627000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i94cbb15018ea46098ad9249cb81ecbd5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOmRjMTUyOGU4MTQ3MTQzODg5MWIyMGQyZGE5MzFlOGRiL3RhYmxlcmFuZ2U6ZGMxNTI4ZTgxNDcxNDM4ODkxYjIwZDJkYTkzMWU4ZGJfMy0zLTEtMS03OTI4Mw_24ff1d8b-ada2-4c99-9d75-200205435572"
      unitRef="usd">2870000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOmRjMTUyOGU4MTQ3MTQzODg5MWIyMGQyZGE5MzFlOGRiL3RhYmxlcmFuZ2U6ZGMxNTI4ZTgxNDcxNDM4ODkxYjIwZDJkYTkzMWU4ZGJfNC0xLTEtMS03OTI4Mw_d6722527-ade0-4c08-9dc8-6dbb89b05fbb"
      unitRef="usd">38907000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i94cbb15018ea46098ad9249cb81ecbd5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zMS9mcmFnOmYyMGY5MWRkMDM2ZTQ4YjdiNDFjNDc4ZTExYTY1NjEzL3RhYmxlOmRjMTUyOGU4MTQ3MTQzODg5MWIyMGQyZGE5MzFlOGRiL3RhYmxlcmFuZ2U6ZGMxNTI4ZTgxNDcxNDM4ODkxYjIwZDJkYTkzMWU4ZGJfNC0zLTEtMS03OTI4Mw_d77b4f3b-b182-435f-ad2e-1372c8874e47"
      unitRef="usd">33442000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SharesOutstanding
      contextRef="ie7e45d5095eb4183b28589ea3d638b55_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfNC0xLTEtMS03OTI4Mw_9eec6cc8-0e6a-4687-9f14-7fd884531a34"
      unitRef="shares">59280000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie7e45d5095eb4183b28589ea3d638b55_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfNC0zLTEtMS03OTI4Mw_3fd555c9-39e8-43d2-a21c-4c8985951081"
      unitRef="usd">59000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i45b55ea2c54349ec90158494f177ec3d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfNC01LTEtMS03OTI4Mw_8558e57c-ab56-465b-8623-432cf9235132"
      unitRef="usd">1031462000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7921e87cee7146e4aaa27c62453d6118_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfNC03LTEtMS03OTI4Mw_b059d580-a8da-458b-a14b-a79351721612"
      unitRef="usd">-1353000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id87bc3ab81a548e8accd9e1b819b5bf8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfNC05LTEtMS03OTI4Mw_03ed9791-2e11-44cd-922b-fa077c574394"
      unitRef="usd">-596365000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5aa6d947913f4a7d8075467238402e4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfNC0xMS0xLTEtNzkyODM_4ba26c5b-3f81-4f0c-8e55-38b382bd3aca"
      unitRef="usd">221000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfNC0xMy0xLTEtNzkyODM_10baf0dd-b564-4748-bc38-75ad28a60abb"
      unitRef="usd">434024000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7baae8bf509c4eea871e58fce347a357_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfNS01LTEtMS03OTI4Mw_07d1fc78-03a1-43bf-a54f-92c41c472903"
      unitRef="usd">13733000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfNS0xMy0xLTEtNzkyODM_60b83f53-61f4-47b6-89cb-68314d2a4652"
      unitRef="usd">13733000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iaaab72f9bd1f4b3497c269553c88fda8_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfNi03LTEtMS03OTI4Mw_99a4f9fe-1748-417e-a5ad-4bac3ae19a4b"
      unitRef="usd">797000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfNi0xMy0xLTEtNzkyODM_3eb9ed1d-3bca-40cc-89cc-e6b3f461cf12"
      unitRef="usd">797000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ia44df45deeac4a16be141cf7af1287d1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfOC0xLTEtMS03OTI4Mw_e425aace-a9de-403e-9802-4aaefa0ac2b3"
      unitRef="shares">139000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ia44df45deeac4a16be141cf7af1287d1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTEtMS0xLTEtNzkyODM_924abd44-14b0-4486-938b-fb858b7942d6"
      unitRef="shares">25000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i7baae8bf509c4eea871e58fce347a357_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTEtNS0xLTEtNzkyODM_fabca4c1-77aa-4961-84dd-23944b6e8c9d"
      unitRef="usd">373000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTEtMTMtMS0xLTc5Mjgz_f7d6adad-51b7-4acb-b92a-09718c898f8e"
      unitRef="usd">373000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="ia44df45deeac4a16be141cf7af1287d1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTItMS0xLTEtNzkyODM_c1aa915c-1a2c-4aec-bb68-a058df52d6ba"
      unitRef="shares">2000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i395ba3df136f49c6a25790e6923789ec_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTMtMTEtMS0xLTc5Mjgz_8b66afc3-4bbe-4d8c-96c7-6ff7b3506f30"
      unitRef="usd">-43000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTMtMTMtMS0xLTc5Mjgz_a978ddb8-983a-46b8-a752-09202386acef"
      unitRef="usd">-43000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i9ea4061b88a64ee98000673bd1783d8b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTQtOS0xLTEtNzkyODM_4e388cdb-860a-4842-83c4-e9fd97639ca7"
      unitRef="usd">-63219000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTQtMTMtMS0xLTc5Mjgz_44d94728-6711-4195-b0d5-f50bc9148f17"
      unitRef="usd">-63219000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="id2e8bcaca2ae474db63161b8e88a7c52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTUtMS0xLTEtNzkyODM_55f0f574-e3d2-4737-896a-08d83fe21231"
      unitRef="shares">59442000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id2e8bcaca2ae474db63161b8e88a7c52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTUtMy0xLTEtNzkyODM_f8336319-5d21-4a80-bf3c-dc78052098b5"
      unitRef="usd">59000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i610df3d7d3254dbeab79d57a582a4636_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTUtNS0xLTEtNzkyODM_bdeb32f8-bbbd-420d-8bbd-6601416b81f1"
      unitRef="usd">1045568000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iace7d762ee1c45ad98a341537427e32e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTUtNy0xLTEtNzkyODM_cc634b58-c8d0-4e3d-903b-4ae300ddd9fb"
      unitRef="usd">-556000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i94f3732fa0324bb6bf7f1984084ff4ef_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTUtOS0xLTEtNzkyODM_458075c6-549c-4655-8897-c473f8e5d821"
      unitRef="usd">-659584000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa0fa90a552e423ba8d1643810caf083_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTUtMTEtMS0xLTc5Mjgz_0ab70a97-94fa-4017-b623-777921694844"
      unitRef="usd">178000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjI4YWJhYzI1MDMwZDQwMmI4ZWY1NTdjMmFjN2FkODIyL3RhYmxlcmFuZ2U6MjhhYmFjMjUwMzBkNDAyYjhlZjU1N2MyYWM3YWQ4MjJfMTUtMTMtMS0xLTc5Mjgz_52cf2e37-36e4-4f4b-be0a-b392bfadcd43"
      unitRef="usd">385665000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i8fd115a5bb984e3b9b063c8e4aa9ff7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfNC0xLTEtMS03OTI4Mw_56cbae90-dcca-4fe1-8833-299c633d2a6f"
      unitRef="shares">45491000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8fd115a5bb984e3b9b063c8e4aa9ff7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfNC0zLTEtMS03OTI4Mw_00a067c7-9f74-41a9-856d-1b3849a9176e"
      unitRef="usd">45000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i695f99adc41f4c8999aa3b6012882f02_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfNC01LTEtMS03OTI4Mw_39971fc7-e6f5-4141-91f2-0351ded7a237"
      unitRef="usd">723593000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie9fbed8715344dabb36930b6006326a2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfNC03LTEtMS03OTI4Mw_473ae60d-97c9-4fd9-8a1e-71f1da8385a9"
      unitRef="usd">-125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id75a0e799fe54633ad1d1d401d14de96_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfNC05LTEtMS03OTI4Mw_ca20dc01-75b9-4a8c-8d6a-d60b1114d8d2"
      unitRef="usd">-359559000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iafaecb2d14b0479c99a524aaae490852_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfNC0xMS0xLTEtNzkyODM_2322e555-bf12-4e99-a208-d7111050f154"
      unitRef="usd">528000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i952b505edf2c4ed8969edcd9dd637d0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfNC0xMy0xLTEtNzkyODM_d4df9dd2-e01e-4075-ab69-6645ddc76d2f"
      unitRef="usd">364482000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i64968b563eff48948e2e24b37867c00a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfNS01LTEtMS03OTI4Mw_6c5064d2-db51-40ba-a157-692b53998e3b"
      unitRef="usd">10147000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfNS0xMy0xLTEtNzkyODM_83b1aa8b-1522-473d-9545-477f91794098"
      unitRef="usd">10147000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic40194aeff86496eb4c5f12057c31115_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfNi03LTEtMS03OTI4Mw_0921d9fc-1ca3-49c4-a7d0-57ebaff1d4bf"
      unitRef="usd">-984000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfNi0xMy0xLTEtNzkyODM_2e700c47-cbe1-4be3-a506-c6a3457b750a"
      unitRef="usd">-984000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i47afaacc781e4b58940615c4b23bc5c2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfOC0xLTEtMS03OTI4Mw_77574df5-7280-416f-a1ff-bfc8aabdea61"
      unitRef="shares">45000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i47afaacc781e4b58940615c4b23bc5c2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfOC0zLTEtMS03OTI4Mw_4d865278-b9bd-4678-9e26-ee2ae34cd635"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfOC0xMy0xLTEtNzkyODM_6e6945bd-2690-46a1-b39c-27cdd2508b0c"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i47afaacc781e4b58940615c4b23bc5c2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTAtMS0xLTEtNzkyODM_16a79b6b-212c-426e-9be7-aaaf13017ecb"
      unitRef="shares">33000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i64968b563eff48948e2e24b37867c00a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTAtNS0xLTEtNzkyODM_0e378538-185f-430c-a992-565ea75cd4a2"
      unitRef="usd">645000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTAtMTMtMS0xLTc5Mjgz_7ff9286b-26d9-4460-a861-a0eacf12a18b"
      unitRef="usd">645000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i47afaacc781e4b58940615c4b23bc5c2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTEtMS0xLTEtNzkyODM_7dbd1d9c-0874-4a34-a03c-838f4a7a1e2a"
      unitRef="shares">16000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i64968b563eff48948e2e24b37867c00a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTEtNS0xLTEtNzkyODM_3f5770b9-121f-42e6-b06b-2b8fc72e35e5"
      unitRef="usd">612000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTEtMTMtMS0xLTc5Mjgz_2583c7bf-7d88-4ee9-8391-32fbb3e80a63"
      unitRef="usd">612000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="i47afaacc781e4b58940615c4b23bc5c2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTItMS0xLTEtNzkyODM_9bbe8b8f-58a3-428b-b888-38e291713f08"
      unitRef="shares">1000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i545b3742a8c44d08a0306fb64b39b848_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTMtMTEtMS0xLTc5Mjgz_09357836-f464-4723-b7d1-96d2cf6f9710"
      unitRef="usd">-160000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTMtMTMtMS0xLTc5Mjgz_bbaf6594-dd81-4ec1-9ec6-5759238eefb9"
      unitRef="usd">-160000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i1bb99470d90047cd99a51fc8bee670ee_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTQtOS0xLTEtNzkyODM_6d15ec12-bc4b-4105-bf09-64999b6cf96b"
      unitRef="usd">-59077000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTQtMTMtMS0xLTc5Mjgz_0500ee43-464f-4fca-9c64-1acee3b83a64"
      unitRef="usd">-59077000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ic9d78fa526224fafa319798fa29dbe0c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTUtMS0xLTEtNzkyODM_ffe744ff-248e-467c-9a04-c18ecd44e970"
      unitRef="shares">45584000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9d78fa526224fafa319798fa29dbe0c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTUtMy0xLTEtNzkyODM_17105041-ec67-4209-8008-7d98b77325ea"
      unitRef="usd">46000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4c97f79d62ab413ba0fa4b3ab5ea6198_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTUtNS0xLTEtNzkyODM_83bc8d4f-f5ee-484d-9def-849d4ee1f47c"
      unitRef="usd">734997000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6cbaa2e908e04b1f879853beb7b39556_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTUtNy0xLTEtNzkyODM_364d15dd-066a-4657-8699-f9465567e9eb"
      unitRef="usd">-1109000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib8e9a378813b4bcc9f882c0a7318ebe1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTUtOS0xLTEtNzkyODM_1c962946-db9b-45bc-85f1-9937cbcfda4e"
      unitRef="usd">-418636000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic86274b750794080aa0a3b9b4a40044d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTUtMTEtMS0xLTc5Mjgz_1a849401-985b-448e-88a3-1dccde6ce2df"
      unitRef="usd">368000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i94cbb15018ea46098ad9249cb81ecbd5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF8zNC9mcmFnOjNjZDJiYzkwY2QwODQ5N2E4Y2M0ZWU4NTA1NGM1MzI3L3RhYmxlOjE1OTZjNjAxNzNkOTQ1NTZiYmEzNDgwMTI2MWFlYTg4L3RhYmxlcmFuZ2U6MTU5NmM2MDE3M2Q5NDU1NmJiYTM0ODAxMjYxYWVhODhfMTUtMTMtMS0xLTc5Mjgz_dcaf2200-842a-47ea-8a9b-15557415f216"
      unitRef="usd">315666000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80MC9mcmFnOjQ5ZTZjMjIwMDQzMTQ3ZGE4M2ViMjdkMDIwMzMyODRjL3RleHRyZWdpb246NDllNmMyMjAwNDMxNDdkYTgzZWIyN2QwMjAzMzI4NGNfMTEwNQ_97ecf856-31e0-4b0f-8357-41fdc1e43888">Organization and Business&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Zentalis Pharmaceuticals, Inc. (&#x201c;Zentalis&#x201d;, &#x201c;We&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancer. The Company is developing a focused pipeline of potentially best-in-class oncology candidates. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. All of the Company&#x2019;s tangible assets are held in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;Substantial doubt about an entity&#x2019;s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year from the financial statement issuance date. The Company determined that there are no conditions or events that raise substantial doubt about its ability to continue as a going concern within one year after the date that the interim unaudited condensed consolidated financial statements for the quarter ended March&#160;31, 2023 are issued.</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80My9mcmFnOjAzNjU0ZmMwYjVhYjRkZGJiMWExYjg5NmEzNTIwMTUwL3RleHRyZWdpb246MDM2NTRmYzBiNWFiNGRkYmIxYTFiODk2YTM1MjAxNTBfNDAzNw_d8505ae3-8678-4a56-b948-768369f722a3">Interim Unaudited Financial Statements &lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) related to a quarterly report on Form 10-Q. The year-end condensed consolidated balance sheet data was derived from the Company&#x2019;s audited financial statements but do not include all disclosures required by U.S. GAAP. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the Company&#x2019;s audited financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on March 1, 2023. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operation for the periods presented, with such adjustments consisting only of normal recurring adjustments. Certain reclassifications have been made to the prior period condensed consolidated balance sheet to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim unaudited condensed consolidated financial statements include our wholly-owned subsidiaries and variable interest entity (&#x201c;VIE&#x201d;), for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate our ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether we are the primary beneficiary of the VIE. In determining whether we are the primary beneficiary of a VIE and therefore required to consolidate the VIE, we apply a qualitative approach that determines whether we have both (1)&#160;the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (2)&#160;the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will continuously assess whether we are the primary beneficiary of a VIE, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of such VIE. During the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;periods presented, we have not provided any other material financial or other support to our VIEs that we were not contractually required to provide.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The equity method is used to account for investments in which we have the ability to exercise significant influence, but not control, over the investee. Such investments are recorded on the balance sheet, and the share of net income or losses of equity investments is recognized on a one quarter lag in investment and other income (expense), net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2023, there have been no changes to the Company&#x2019;s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80My9mcmFnOjAzNjU0ZmMwYjVhYjRkZGJiMWExYjg5NmEzNTIwMTUwL3RleHRyZWdpb246MDM2NTRmYzBiNWFiNGRkYmIxYTFiODk2YTM1MjAxNTBfNDAzOA_d7564d15-f0d8-489a-bc10-fd2af0f94095">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) related to a quarterly report on Form 10-Q. The year-end condensed consolidated balance sheet data was derived from the Company&#x2019;s audited financial statements but do not include all disclosures required by U.S. GAAP. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the Company&#x2019;s audited financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on March 1, 2023. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operation for the periods presented, with such adjustments consisting only of normal recurring adjustments. Certain reclassifications have been made to the prior period condensed consolidated balance sheet to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80My9mcmFnOjAzNjU0ZmMwYjVhYjRkZGJiMWExYjg5NmEzNTIwMTUwL3RleHRyZWdpb246MDM2NTRmYzBiNWFiNGRkYmIxYTFiODk2YTM1MjAxNTBfNDA0MA_2b0d29dc-f87a-4ed4-80f0-dab9bf415764">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim unaudited condensed consolidated financial statements include our wholly-owned subsidiaries and variable interest entity (&#x201c;VIE&#x201d;), for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate our ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether we are the primary beneficiary of the VIE. In determining whether we are the primary beneficiary of a VIE and therefore required to consolidate the VIE, we apply a qualitative approach that determines whether we have both (1)&#160;the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (2)&#160;the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will continuously assess whether we are the primary beneficiary of a VIE, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of such VIE. During the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;periods presented, we have not provided any other material financial or other support to our VIEs that we were not contractually required to provide.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The equity method is used to account for investments in which we have the ability to exercise significant influence, but not control, over the investee. Such investments are recorded on the balance sheet, and the share of net income or losses of equity investments is recognized on a one quarter lag in investment and other income (expense), net.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80My9mcmFnOjAzNjU0ZmMwYjVhYjRkZGJiMWExYjg5NmEzNTIwMTUwL3RleHRyZWdpb246MDM2NTRmYzBiNWFiNGRkYmIxYTFiODk2YTM1MjAxNTBfNDAzNA_e248ab14-dff7-4cde-ae38-32c76668aa05">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80Ni9mcmFnOjk4ODg0OWNkYWYyNjQxMzFhNzFmNTAxNzk3OTdjZTZmL3RleHRyZWdpb246OTg4ODQ5Y2RhZjI2NDEzMWE3MWY1MDE3OTc5N2NlNmZfNDQ2OA_0b5ff854-002d-47af-bf02-33101018ff6a">Significant Transactions&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Zentera Therapeutics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, we became a majority common shareholder of Zentera Therapeutics, a Shanghai-based clinical-stage biopharmaceutical company focused on developing cancer therapeutics (&#x201c;Zentera&#x201d;), concurrent with its Series A convertible preferred stock offering. The financial position and results of operations of Zentera were included in our consolidated financial statements from the date of the initial investment as a result of our control of the entity and our determination that we were the primary beneficiary of Zentera. In July 2021, Zentera completed a Series B convertible preferred stock offering which diluted our investment to a position of less than majority owned. Upon review of the facts and circumstances, together with the authoritative accounting literature, we determined that while Zentera is a VIE, consolidation of Zentera is no longer appropriate. After the July 2021 Series B convertible preferred offering in which we did not participate, our review concluded that we ceased to be the primary beneficiary of Zentera as our equity ownership was reduced and changes were made to the corporate governance of Zentera. As a result, we no longer individually have the ability to direct the activities that most significantly impact Zentera's economic performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in July 2021, the financial position and results of operations of Zentera were no longer included in our consolidated financial statements. During the period of deconsolidation we measured the fair value of our retained investment in Zentera using the backsolve method with consideration for a lack of marketability. An equity method investment of $18.9 million is recorded on our balance sheet at March&#160;31, 2023. This amount represents our maximum exposure to loss as a result of our involvement with Zentera. A deferred tax liability of $4.0 million representing the tax impact of the unrealized gain on deconsolidation is recorded on our balance sheet at March&#160;31, 2023. A gain of $51.6&#160;million, measured as the difference between the fair value of our retained noncontrolling interest together with the carrying amount of the Zentera noncontrolling interest, and the carrying amount of Zentera&#x2019;s assets and liabilities was recognized during the year ended December 31, 2021. The difference between the carrying amount of our investment in Zentera and our portion of the Zentera net assets was $5.5 million as of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023. This difference is accounted for in our equity method investment analogous to in-process research and development. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2020, each of our subsidiaries Zeno Alpha, Inc., K-Group Alpha, Inc., and K-Group Beta, Inc. entered into a collaboration and royalty-bearing license agreement with Zentera, which we refer to as the &#x201c;Zentera Sublicenses,&#x201d; pursuant to which we collaborate with Zentera on the development and commercialization of ZN-c5, ZN-d5 and azenosertib, respectively, collectively referred to as the &#x201c;Collaboration Products,&#x201d; respectively, in the People&#x2019;s Republic of China, Macau, Hong Kong and Taiwan, which is referred to as the &#x201c;Zentera Collaboration Territory.&#x201d; Under each Zentera Sublicense, Zentera will lead development, and upon regulatory approval, the commercialization, of the Collaboration Products in the Zentera Collaboration Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Zentera Sublicenses, Zentera is generally responsible for the costs of developing the Collaboration Products in the Zentera Collaboration Territory, and we are generally responsible for the costs of developing the Collaboration Products outside the Zentera Collaboration Territory, provided that Zentera will reimburse us for a portion of the costs for global data management, pharmacovigilance, safety database management, and chemistry, manufacturing and controls activities with respect to each Collaboration Product. Prior to the deconsolidation of Zentera in July 2021, these costs were eliminated in consolidation. For the three months ended March&#160;31, 2023 and 2022 the amounts incurred under this arrangement totaled $2.2 million and $2.1 million, respectively, and are presented as contra-research and development expense in the unaudited condensed consolidated statement of operations. A corresponding receivable is recorded within prepaid expenses and other current assets on the unaudited condensed consolidated balance sheet. We have not provided material financial or other support to Zentera during the periods ended March&#160;31, 2023 and 2022 that was not  contractually required.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80Ni9mcmFnOjk4ODg0OWNkYWYyNjQxMzFhNzFmNTAxNzk3OTdjZTZmL3RleHRyZWdpb246OTg4ODQ5Y2RhZjI2NDEzMWE3MWY1MDE3OTc5N2NlNmZfMTcwMQ_ab43214d-f510-4777-b86c-6b68877c9ba7"
      unitRef="usd">18900000</us-gaap:EquityMethodInvestments>
    <us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
      contextRef="i4df1e7317eb24fb4960e2db40e43b0ae_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80Ni9mcmFnOjk4ODg0OWNkYWYyNjQxMzFhNzFmNTAxNzk3OTdjZTZmL3RleHRyZWdpb246OTg4ODQ5Y2RhZjI2NDEzMWE3MWY1MDE3OTc5N2NlNmZfMTg3Nw_444f0a57-f405-41c4-abb9-cf7ae3736360"
      unitRef="usd">4000000.0</us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="if503536b265745f78bee8b2c10f7dd63_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80Ni9mcmFnOjk4ODg0OWNkYWYyNjQxMzFhNzFmNTAxNzk3OTdjZTZmL3RleHRyZWdpb246OTg4ODQ5Y2RhZjI2NDEzMWE3MWY1MDE3OTc5N2NlNmZfMjAwOA_11754f72-0bd5-40b3-9acc-eda6482ea516"
      unitRef="usd">51600000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="i4df1e7317eb24fb4960e2db40e43b0ae_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80Ni9mcmFnOjk4ODg0OWNkYWYyNjQxMzFhNzFmNTAxNzk3OTdjZTZmL3RleHRyZWdpb246OTg4ODQ5Y2RhZjI2NDEzMWE3MWY1MDE3OTc5N2NlNmZfMjQxMA_61af6e02-9c31-40ec-bb3a-c68addb89db3"
      unitRef="usd">5500000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <zntl:ResearchAndDevelopmentExpenseReimbursements
      contextRef="i7c81d5274f084d8ca588db925f2f294d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80Ni9mcmFnOjk4ODg0OWNkYWYyNjQxMzFhNzFmNTAxNzk3OTdjZTZmL3RleHRyZWdpb246OTg4ODQ5Y2RhZjI2NDEzMWE3MWY1MDE3OTc5N2NlNmZfNDAwNw_d5423e18-5f8d-4317-913a-42dc00fdc021"
      unitRef="usd">2200000</zntl:ResearchAndDevelopmentExpenseReimbursements>
    <zntl:ResearchAndDevelopmentExpenseReimbursements
      contextRef="i4a32b2ade07d41f4b1cad2d93ca61367_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80Ni9mcmFnOjk4ODg0OWNkYWYyNjQxMzFhNzFmNTAxNzk3OTdjZTZmL3RleHRyZWdpb246OTg4ODQ5Y2RhZjI2NDEzMWE3MWY1MDE3OTc5N2NlNmZfNDAyMg_e1d15803-d254-48de-8099-646e34cf6cb1"
      unitRef="usd">2100000</zntl:ResearchAndDevelopmentExpenseReimbursements>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80OS9mcmFnOjQ4OWNkNTA5ZWUyNjRjZGFhY2JjOWM3NTY3MWU0NzFjL3RleHRyZWdpb246NDg5Y2Q1MDllZTI2NGNkYWFjYmM5Yzc1NjcxZTQ3MWNfMTgyMg_2da7e2bf-fc3e-431c-b818-a09ed0bea8a9">Business Combinations&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Kalyra Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;21, 2017, we acquired $4.5&#160;million of Kalyra Pharmaceuticals, Inc.&#x2019;s (&#x201c;Kalyra&#x201d;) Series B Preferred Stock representing a 25% equity interest in Kalyra for purposes of entering the analgesics therapeutic research space. The acquisition price was paid entirely in cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the authoritative guidance, we concluded that Kalyra is a business consisting of inputs, employees, intellectual property and processes capable of producing outputs. Additionally, we have concluded that Kalyra is a VIE, we are the primary beneficiary and have the power to direct the activities that most significantly affect Kalyra&#x2019;s economic performance through common management and our board representation. Prior to December 21, 2017, the Company and Kalyra transacted for the delivery of research and development services and support. The financial position and results of operations of Kalyra have been included in our consolidated financial statements from the date of the initial investment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant with authoritative guidance, we have recorded the identifiable assets, liabilities and noncontrolling interests in the VIE at their fair value upon initial consolidation. The identified goodwill is comprised of the workforce and expected synergies from combining the entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. T&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;otal assets and liabilities of Kalyra as of March&#160;31, 2023 and December&#160;31, 2022 are immaterial. The liabilities recognized as a result of consolidating Kalyra do not represent additional claims on our general assets. Pursuant to the authoritative guidance, the equity interest in Kalyra not owned by Zentalis is reported as a noncontrolling interest on our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of equity (net assets) attributable to the noncontrolling interest (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interest at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interest at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i4817ffa176c043dcaa4bcc0e640d9ac8_D20171221-20171221"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80OS9mcmFnOjQ4OWNkNTA5ZWUyNjRjZGFhY2JjOWM3NTY3MWU0NzFjL3RleHRyZWdpb246NDg5Y2Q1MDllZTI2NGNkYWFjYmM5Yzc1NjcxZTQ3MWNfOTQ_d9c8ef4b-e68a-4136-94d0-a141c127759a"
      unitRef="usd">4500000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i9ff9bd8c8cc546c2bfa853ff3951cad7_I20171221"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80OS9mcmFnOjQ4OWNkNTA5ZWUyNjRjZGFhY2JjOWM3NTY3MWU0NzFjL3RleHRyZWdpb246NDg5Y2Q1MDllZTI2NGNkYWFjYmM5Yzc1NjcxZTQ3MWNfMTgy_a33c530d-6721-4d80-9389-1e59a4e37ee3"
      unitRef="number">0.25</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <zntl:ReconciliationOfNoncontrollingInterestTableTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80OS9mcmFnOjQ4OWNkNTA5ZWUyNjRjZGFhY2JjOWM3NTY3MWU0NzFjL3RleHRyZWdpb246NDg5Y2Q1MDllZTI2NGNkYWFjYmM5Yzc1NjcxZTQ3MWNfMTgyMw_3969a824-3217-49a0-aea8-9c6ee188126b">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of equity (net assets) attributable to the noncontrolling interest (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interest at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interest at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</zntl:ReconciliationOfNoncontrollingInterestTableTextBlock>
    <us-gaap:MinorityInterest
      contextRef="i56332e226885432ebe62ee97b3aa1f96_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80OS9mcmFnOjQ4OWNkNTA5ZWUyNjRjZGFhY2JjOWM3NTY3MWU0NzFjL3RhYmxlOjBhZmU1YmVkOTRhYzQ0YzFhOTY3NDY2NzI2ZGM4M2VkL3RhYmxlcmFuZ2U6MGFmZTViZWQ5NGFjNDRjMWE5Njc0NjY3MjZkYzgzZWRfMi0xLTEtMS03OTI4Mw_9fcc66aa-7dfd-47d6-9b63-876de3055876"
      unitRef="usd">221000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i2e5d1442f22141d2ad21e2f741cecbe5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80OS9mcmFnOjQ4OWNkNTA5ZWUyNjRjZGFhY2JjOWM3NTY3MWU0NzFjL3RhYmxlOjBhZmU1YmVkOTRhYzQ0YzFhOTY3NDY2NzI2ZGM4M2VkL3RhYmxlcmFuZ2U6MGFmZTViZWQ5NGFjNDRjMWE5Njc0NjY3MjZkYzgzZWRfMi0zLTEtMS03OTI4Mw_6c7b9aea-4508-4f19-b1b4-611589b909bd"
      unitRef="usd">528000</us-gaap:MinorityInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6809bcb1666148168afab58d0ffe577e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80OS9mcmFnOjQ4OWNkNTA5ZWUyNjRjZGFhY2JjOWM3NTY3MWU0NzFjL3RhYmxlOjBhZmU1YmVkOTRhYzQ0YzFhOTY3NDY2NzI2ZGM4M2VkL3RhYmxlcmFuZ2U6MGFmZTViZWQ5NGFjNDRjMWE5Njc0NjY3MjZkYzgzZWRfMy0xLTEtMS03OTI4Mw_bc6d2def-8766-46bc-a3bb-083a89a89c4d"
      unitRef="usd">-43000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i9d2a23e4bb2343d588f6a5d196d2a18b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80OS9mcmFnOjQ4OWNkNTA5ZWUyNjRjZGFhY2JjOWM3NTY3MWU0NzFjL3RhYmxlOjBhZmU1YmVkOTRhYzQ0YzFhOTY3NDY2NzI2ZGM4M2VkL3RhYmxlcmFuZ2U6MGFmZTViZWQ5NGFjNDRjMWE5Njc0NjY3MjZkYzgzZWRfMy0zLTEtMS03OTI4Mw_9f43f497-2d8f-4d8a-a7cf-2ee79bd8ed88"
      unitRef="usd">-307000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterest
      contextRef="i52d0e027780241b79c9c17cfcdd13982_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80OS9mcmFnOjQ4OWNkNTA5ZWUyNjRjZGFhY2JjOWM3NTY3MWU0NzFjL3RhYmxlOjBhZmU1YmVkOTRhYzQ0YzFhOTY3NDY2NzI2ZGM4M2VkL3RhYmxlcmFuZ2U6MGFmZTViZWQ5NGFjNDRjMWE5Njc0NjY3MjZkYzgzZWRfNy0xLTEtMS03OTI4Mw_330ad2d4-476e-417a-b896-202db4f8c4f3"
      unitRef="usd">178000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i56332e226885432ebe62ee97b3aa1f96_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF80OS9mcmFnOjQ4OWNkNTA5ZWUyNjRjZGFhY2JjOWM3NTY3MWU0NzFjL3RhYmxlOjBhZmU1YmVkOTRhYzQ0YzFhOTY3NDY2NzI2ZGM4M2VkL3RhYmxlcmFuZ2U6MGFmZTViZWQ5NGFjNDRjMWE5Njc0NjY3MjZkYzgzZWRfNy0zLTEtMS03OTI4Mw_6337e674-a8d0-4b70-ae08-07b642b782e9"
      unitRef="usd">221000</us-gaap:MinorityInterest>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RleHRyZWdpb246Y2EzYzFlNWI5YmVjNDQ2Nzg3M2I2YWUzNzZiNWRkNTZfMTQ4OQ_28613736-5f3f-4f0d-95a6-500e71dea77f">Fair Value Measurement&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Government Agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Government Agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(629)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2023, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;fifty&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; of our available-for-sale debt securities with a fair market value of $268.0 million were in a gross unrealized loss position of $0.6 million. Of those, forty-seven have been in a gross unrealized loss position of $0.5 million for less than one year and three have been in a gross unrealized loss position of $0.1 million for more than one year. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;When evaluating an investment for impairment, we review factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, our intent to sell or the likelihood that we would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. Based on our review of these marketable securities, we believe none of the unrealized loss is as a result of a credit loss as of March&#160;31, 2023, because we do not intend to sell these securities, and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual maturities of available-for-sale debt securities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.044%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.357%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.247%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Government Agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between Level&#160;1 and Level&#160;2 of the fair value hierarchy during the three months ended March&#160;31, 2023. We had no instruments that were classified within Level&#160;3 as of March&#160;31, 2023 or December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RleHRyZWdpb246Y2EzYzFlNWI5YmVjNDQ2Nzg3M2I2YWUzNzZiNWRkNTZfMTQ5MA_2e154df2-a076-41c9-a0be-5b7a94c559b7">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Government Agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Government Agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(629)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0c2420fac1a84e158a6092ec05ed0417_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfMi0xLTEtMS03OTI4Mw_5b1a2008-7733-4f18-bce8-c8c38311bce6"
      unitRef="usd">281405000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0c2420fac1a84e158a6092ec05ed0417_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfMi0zLTEtMS03OTI4Mw_cfe95026-93c4-466a-936c-9e7afc319748"
      unitRef="usd">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0c2420fac1a84e158a6092ec05ed0417_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfMi01LTEtMS03OTI4Mw_26665c8a-f168-45fb-aaec-8a67acf2c9e0"
      unitRef="usd">286000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0c2420fac1a84e158a6092ec05ed0417_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfMi03LTEtMS03OTI4Mw_1992e56b-4269-4bc5-bff5-53cce83ed1ca"
      unitRef="usd">281142000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0fdc062e1b6242f3bfa7722f537c5cc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfMy0xLTEtMS03OTI4Mw_15717981-fb97-41cd-a63c-3ea8bf78bdc3"
      unitRef="usd">2486000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0fdc062e1b6242f3bfa7722f537c5cc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfMy0zLTEtMS03OTI4Mw_32de54f8-a398-4757-a6e2-4a5cd6f0051a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0fdc062e1b6242f3bfa7722f537c5cc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfMy01LTEtMS03OTI4Mw_94d776f3-3540-4b43-913b-c4208feeccc8"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0fdc062e1b6242f3bfa7722f537c5cc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfMy03LTEtMS03OTI4Mw_ab2004c3-da8d-4e11-b83a-1d5ee4f587fb"
      unitRef="usd">2480000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i410ff4f16a8040efb58e3e8e477cb639_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNC0xLTEtMS03OTI4Mw_885d9942-5d9f-40cf-b0fb-cc6a506aa511"
      unitRef="usd">21982000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i410ff4f16a8040efb58e3e8e477cb639_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNC0zLTEtMS03OTI4Mw_f3a06828-037a-4b9f-a903-6dd6c57e26c1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i410ff4f16a8040efb58e3e8e477cb639_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNC01LTEtMS03OTI4Mw_4d7c7204-5e36-406a-b85d-d18c6b0d5120"
      unitRef="usd">98000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i410ff4f16a8040efb58e3e8e477cb639_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNC03LTEtMS03OTI4Mw_d1f3733b-e627-4cbf-be1c-4ff1141dd3b1"
      unitRef="usd">21884000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i84739e60c7164232abd1054fd4938e36_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNS0xLTEtMS03OTI4Mw_2ede1de8-ea5b-46f3-8949-51710200b5eb"
      unitRef="usd">50956000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i84739e60c7164232abd1054fd4938e36_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNS0zLTEtMS03OTI4Mw_0830cfce-720b-49eb-94bb-74eeb5ca1172"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i84739e60c7164232abd1054fd4938e36_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNS01LTEtMS03OTI4Mw_ba07f945-51b6-41a5-91a1-092da474262f"
      unitRef="usd">223000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i84739e60c7164232abd1054fd4938e36_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNS03LTEtMS03OTI4Mw_94b23a39-37ea-4d0f-9c45-d11816513f31"
      unitRef="usd">50733000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNi0xLTEtMS03OTI4Mw_9758828c-4776-4423-9020-8ede31ebd1b0"
      unitRef="usd">356829000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNi0zLTEtMS03OTI4Mw_fd5a1c11-60ce-41ee-91b5-5e7655683860"
      unitRef="usd">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNi01LTEtMS03OTI4Mw_723db981-8222-4d5a-9494-63978fa9f919"
      unitRef="usd">613000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmMxYTliNTIyYTIwODQ1NTM4NDUyZjM0OTkyMjA4NGE2L3RhYmxlcmFuZ2U6YzFhOWI1MjJhMjA4NDU1Mzg0NTJmMzQ5OTIyMDg0YTZfNi03LTEtMS03OTI4Mw_eb37ae47-2f7f-4013-8f77-4ac12400ab4a"
      unitRef="usd">356239000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3fcb530524114c769687f7c9f1fb749a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfMi0xLTEtMS03OTI4Mw_e410de22-bc21-4823-b0cb-0fc35d7c37bd"
      unitRef="usd">296309000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3fcb530524114c769687f7c9f1fb749a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfMi0zLTEtMS03OTI4Mw_8d3dee48-a3de-4d84-a469-7d77576cb4b2"
      unitRef="usd">71000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3fcb530524114c769687f7c9f1fb749a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfMi01LTEtMS03OTI4Mw_034e5cd9-9eab-4c29-87af-958f8f65ba55"
      unitRef="usd">587000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3fcb530524114c769687f7c9f1fb749a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfMi03LTEtMS03OTI4Mw_054a1686-e9a9-4a83-9fca-49e1a2d92fa9"
      unitRef="usd">295793000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie5fcea6723664d4697c80360ebeed61d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfMy0xLTEtMS03OTI4Mw_6b2ac4ca-4733-4b98-bcb7-2948c9547555"
      unitRef="usd">7472000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie5fcea6723664d4697c80360ebeed61d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfMy0zLTEtMS03OTI4Mw_ccc1e2de-a2d8-4844-8772-acfc49973a1e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie5fcea6723664d4697c80360ebeed61d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfMy01LTEtMS03OTI4Mw_1f672ffc-c5ba-4a59-98e0-29872de4d9ff"
      unitRef="usd">26000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie5fcea6723664d4697c80360ebeed61d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfMy03LTEtMS03OTI4Mw_eb031c48-8a18-471c-8347-35a30e45bad1"
      unitRef="usd">7446000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib1b64d6100e743e984f7d8b3995bd09b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNC0xLTEtMS03OTI4Mw_03699d88-daf4-4eb2-b50f-66f94e1c13a6"
      unitRef="usd">23970000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib1b64d6100e743e984f7d8b3995bd09b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNC0zLTEtMS03OTI4Mw_457aad71-3a20-404b-9798-beb3d55b4ec1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib1b64d6100e743e984f7d8b3995bd09b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNC01LTEtMS03OTI4Mw_4d02dc14-4614-4984-8a2f-49f6177c70c2"
      unitRef="usd">182000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib1b64d6100e743e984f7d8b3995bd09b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNC03LTEtMS03OTI4Mw_97f30cc8-b83d-417c-b678-fb935f46ed32"
      unitRef="usd">23788000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i32d2e7ccd63b4e078ab5c066f13b44d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNS0xLTEtMS03OTI4Mw_3590c5ab-d0df-4b85-bce4-b5a4d7f56c65"
      unitRef="usd">67904000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i32d2e7ccd63b4e078ab5c066f13b44d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNS0zLTEtMS03OTI4Mw_37d46b1e-a5f7-452e-8328-96553a189b8a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i32d2e7ccd63b4e078ab5c066f13b44d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNS01LTEtMS03OTI4Mw_243e3977-6bcb-488d-b131-1cb497bf1319"
      unitRef="usd">629000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i32d2e7ccd63b4e078ab5c066f13b44d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNS03LTEtMS03OTI4Mw_cfe24660-0062-401a-8d06-60c486a83f63"
      unitRef="usd">67275000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNi0xLTEtMS03OTI4Mw_67a98d4c-65ec-4a29-8d34-67dec37f0c49"
      unitRef="usd">395655000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNi0zLTEtMS03OTI4Mw_bbf22ed9-b73e-4610-b58d-2ea222b54f48"
      unitRef="usd">71000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNi01LTEtMS03OTI4Mw_d8876da2-2a6c-41e2-9b7b-de860ad74f42"
      unitRef="usd">1424000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmU3MTU0NDljZTFjZDQ3Y2ZiMjQ0NDVlNzRhM2Y5Zjc2L3RhYmxlcmFuZ2U6ZTcxNTQ0OWNlMWNkNDdjZmIyNDQ0NWU3NGEzZjlmNzZfNi03LTEtMS03OTI4Mw_4efc4a37-958a-4a2a-b1e0-f598502a7081"
      unitRef="usd">394302000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RleHRyZWdpb246Y2EzYzFlNWI5YmVjNDQ2Nzg3M2I2YWUzNzZiNWRkNTZfMTI5_5cdda0d7-ed94-49c1-ad43-eb52ba6b9076"
      unitRef="security">50</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RleHRyZWdpb246Y2EzYzFlNWI5YmVjNDQ2Nzg3M2I2YWUzNzZiNWRkNTZfMjAy_92547de4-1c2e-4577-bdfa-ec1faff295c2"
      unitRef="usd">268000000.0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RleHRyZWdpb246Y2EzYzFlNWI5YmVjNDQ2Nzg3M2I2YWUzNzZiNWRkNTZfMjU3_19c72843-fcea-4ed0-9ef2-5f0d783f228d"
      unitRef="usd">600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RleHRyZWdpb246Y2EzYzFlNWI5YmVjNDQ2Nzg3M2I2YWUzNzZiNWRkNTZfNTQ5NzU1ODE1NDA3_9493596e-5017-4dc4-a4d1-75d95b26c2cc"
      unitRef="security">47</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RleHRyZWdpb246Y2EzYzFlNWI5YmVjNDQ2Nzg3M2I2YWUzNzZiNWRkNTZfNTQ5NzU1ODE1NTky_4ee18ea9-6347-41de-999a-6dcc92afd4f6"
      unitRef="usd">500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RleHRyZWdpb246Y2EzYzFlNWI5YmVjNDQ2Nzg3M2I2YWUzNzZiNWRkNTZfNTQ5NzU1ODE1NjQ0_cb4a71ab-ae36-419b-b223-af141b9b0c33"
      unitRef="security">3</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RleHRyZWdpb246Y2EzYzFlNWI5YmVjNDQ2Nzg3M2I2YWUzNzZiNWRkNTZfNTQ5NzU1ODE1NzAx_c004b869-8637-4cc3-af55-3b2a9695c006"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RleHRyZWdpb246Y2EzYzFlNWI5YmVjNDQ2Nzg3M2I2YWUzNzZiNWRkNTZfMTQ5MQ_d0247bb4-b4f2-408e-942b-eaed22f8ab3e">Contractual maturities of available-for-sale debt securities are as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.044%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOjg5YzQzYmMyOWM0NTQzYWZhNWNlNDQ5MDQxN2FmYmM1L3RhYmxlcmFuZ2U6ODljNDNiYzI5YzQ1NDNhZmE1Y2U0NDkwNDE3YWZiYzVfMy0xLTEtMS03OTI4Mw_468aa8d0-7fe9-47ac-9773-05c9bd641d25"
      unitRef="usd">356239000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOjg5YzQzYmMyOWM0NTQzYWZhNWNlNDQ5MDQxN2FmYmM1L3RhYmxlcmFuZ2U6ODljNDNiYzI5YzQ1NDNhZmE1Y2U0NDkwNDE3YWZiYzVfMy0zLTEtMS03OTI4Mw_5ee7a157-20bd-43e6-a9b0-17a49dc7d332"
      unitRef="usd">394302000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOjg5YzQzYmMyOWM0NTQzYWZhNWNlNDQ5MDQxN2FmYmM1L3RhYmxlcmFuZ2U6ODljNDNiYzI5YzQ1NDNhZmE1Y2U0NDkwNDE3YWZiYzVfNS0xLTEtMS03OTI4Mw_17005b6e-ce42-4cfe-9c85-88ed8f4cac74"
      unitRef="usd">356239000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOjg5YzQzYmMyOWM0NTQzYWZhNWNlNDQ5MDQxN2FmYmM1L3RhYmxlcmFuZ2U6ODljNDNiYzI5YzQ1NDNhZmE1Y2U0NDkwNDE3YWZiYzVfNS0zLTEtMS03OTI4Mw_0f599769-f9e0-4443-9dc5-858a6ecb151d"
      unitRef="usd">394302000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RleHRyZWdpb246Y2EzYzFlNWI5YmVjNDQ2Nzg3M2I2YWUzNzZiNWRkNTZfMTQ5Mg_4f74949f-d940-413b-bff2-f8e43cae35d9">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.357%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.247%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Government Agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i49f1fa2e5d5d4f479e5668a21e82148b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMy0xLTEtMS03OTI4Mw_b3296add-cede-4826-9272-062dacaa965d"
      unitRef="usd">33329000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia30f21df13f94f9ebd972a8a09ca6fac_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMy0zLTEtMS03OTI4Mw_d3d9d2af-d028-4ff1-984b-e373d478f75e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icf38ee1491e140b8adacc29d8bb9760f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMy01LTEtMS03OTI4Mw_dff07e7a-d379-4e3f-b26b-deba13987a10"
      unitRef="usd">33329000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i74f300d2e9d948a683e65b0cdc3aa411_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMy03LTEtMS03OTI4Mw_580f5af1-f9bd-4c2a-8990-60af9300dff5"
      unitRef="usd">26811000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i380c135ffd6844f7997d78a2b67138ec_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMy05LTEtMS03OTI4Mw_af560f7e-c700-4d70-84f2-2e1c0e72bdfd"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i48ff0df351ef40fe8a05cd86f1008d36_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMy0xMS0xLTEtNzkyODM_be628eef-1fa3-4248-9d39-0556acbd32d3"
      unitRef="usd">26811000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i101ae399b06242f49e876e6d8e25a264_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNC0xLTEtMS03OTI4Mw_327b2c23-7140-4835-8cdf-bc54bedb3f88"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7c6f54b010c64504bbd0705c0ac17af0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNC0zLTEtMS03OTI4Mw_83f22675-4dea-4671-8d75-13b6fc0e9185"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="idd6ec7e59ffb4b9eb4453d5218e35173_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNC01LTEtMS03OTI4Mw_2c6355bf-7ec2-4985-9bda-8093448ed318"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia9c408849fc84006b3a025992352774f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNC03LTEtMS03OTI4Mw_0ef27e77-1767-4ebd-a757-1632a6eee85c"
      unitRef="usd">1998000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3150edba5268450db0756b69a3a1addf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNC05LTEtMS03OTI4Mw_c74cef7a-eae5-43a9-9cec-9ae6191e935c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6d89135319bc455fa6a091097227fc6e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNC0xMS0xLTEtNzkyODM_92619e13-791d-4e20-9853-a22ad6dc64db"
      unitRef="usd">1998000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i512ef6b869c04c8a878f93105c57c41a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNS0xLTEtMS03OTI4Mw_b7be0205-00d2-45ca-acec-21c1d014168f"
      unitRef="usd">33329000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i598f17c497e545c58b325723fdc76f66_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNS0zLTEtMS03OTI4Mw_e6af028b-02e8-4d30-8c77-5b8abef1316d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNS01LTEtMS03OTI4Mw_56320b14-616b-406a-8e17-5599e8fb811a"
      unitRef="usd">33329000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i71a8b179af364abb8287fabef06e5efe_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNS03LTEtMS03OTI4Mw_6a7ada94-0761-4959-9eed-02f656c374e2"
      unitRef="usd">28809000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i617ebbcc5095463d8013bb0f56fc9a65_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNS05LTEtMS03OTI4Mw_6b333428-1d3c-41f7-98cf-a1fd2518de52"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfNS0xMS0xLTEtNzkyODM_91edd335-2d40-470e-8af2-04020dd6667d"
      unitRef="usd">28809000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0843a9ee0f4743b7b17b8de5c7778791_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOC0xLTEtMS03OTI4Mw_9aa1bbea-f666-4cd3-a46d-b90123a9ce10"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iadc356695ac24c8cb111a3afaaa7ff8c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOC0zLTEtMS03OTI4Mw_4d94574f-4306-41f1-9b04-941d76461886"
      unitRef="usd">281142000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0c2420fac1a84e158a6092ec05ed0417_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOC01LTEtMS03OTI4Mw_54d0b36b-f34f-44de-a1ec-827d052b57ed"
      unitRef="usd">281142000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3b730087c46740158ea57877aa0ae9a6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOC03LTEtMS03OTI4Mw_bb33b158-5e44-42ae-b531-15a5395d403a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4459dcf3fc2c4ce79822c49134d753a4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOC05LTEtMS03OTI4Mw_4f68762d-aa53-4f30-a904-8d6d695650eb"
      unitRef="usd">295793000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3fcb530524114c769687f7c9f1fb749a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOC0xMS0xLTEtNzkyODM_f67e1eba-8dbc-4861-8d92-2c6b8dd7d5cf"
      unitRef="usd">295793000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifcf1f1860f224f7783c2b7814b873ab3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOS0xLTEtMS03OTI4Mw_313f65f4-7067-4109-a753-cf7cfc375b38"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i128d0fd7cbbf49d2b23f8f6ed5e8b638_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOS0zLTEtMS03OTI4Mw_615c0ad5-a999-4ca8-8279-cb51221be98d"
      unitRef="usd">2480000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0fdc062e1b6242f3bfa7722f537c5cc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOS01LTEtMS03OTI4Mw_4af91fc7-f07e-47d0-9149-ea0e86995316"
      unitRef="usd">2480000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ica67869b706548afa466add7912fddd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOS03LTEtMS03OTI4Mw_83d7b7b8-32d4-40f9-b5d0-7b631be7da7e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1c53bb5c6ef84b26a856ac6cf9e2e408_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOS05LTEtMS03OTI4Mw_aa8e0ecf-42dd-491c-bf17-e710aa6665e8"
      unitRef="usd">7446000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie5fcea6723664d4697c80360ebeed61d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfOS0xMS0xLTEtNzkyODM_f2d64856-ae0d-44ea-a410-c3bf81e0398c"
      unitRef="usd">7446000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3b44713e1e994101839f64aec91e45b1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTAtMS0xLTEtNzkyODM_2e40a1b2-393f-49c2-bcd1-c8cf5cbacb2d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id5c6ab2386b6421d83ee4eb9753b73cd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTAtMy0xLTEtNzkyODM_ad11ddcb-117e-4278-b909-a16fb3199f26"
      unitRef="usd">21884000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i410ff4f16a8040efb58e3e8e477cb639_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTAtNS0xLTEtNzkyODM_62dd8ba5-1090-473f-a3e3-afea6151c52a"
      unitRef="usd">21884000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i94ff901c1e7144e985fe76366d30065a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTAtNy0xLTEtNzkyODM_df133759-7031-4ca1-9986-4b5494a55ffb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3727eb6a2b984c7ca52fc3f51b6afa97_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTAtOS0xLTEtNzkyODM_1549cde1-5229-4b8c-b267-0d4b7b65d9d3"
      unitRef="usd">23788000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib1b64d6100e743e984f7d8b3995bd09b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTAtMTEtMS0xLTc5Mjgz_32226697-5988-44c3-9494-2e220924d669"
      unitRef="usd">23788000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4e83e26bd72349338171ae705edbe7f0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTEtMS0xLTEtNzkyODM_43b754f0-9c4d-45ed-b296-64627716a36d"
      unitRef="usd">50733000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1a2cf14e1f2448cdbc8fb71792150777_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTEtMy0xLTEtNzkyODM_efae90c5-7099-4f65-81e3-7399388d732b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i84739e60c7164232abd1054fd4938e36_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTEtNS0xLTEtNzkyODM_99501b05-888e-40d5-b19d-ab498e7773bd"
      unitRef="usd">50733000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iadaa692c5c72427cbb64934ad0fa3730_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTEtNy0xLTEtNzkyODM_3765ed08-72ef-4550-824b-82f1b9b08571"
      unitRef="usd">67275000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5a695ef0eca441ed8cac49e237e173fa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTEtOS0xLTEtNzkyODM_f5489a32-5272-4c45-9844-3e1bd7b65ceb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i32d2e7ccd63b4e078ab5c066f13b44d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTEtMTEtMS0xLTc5Mjgz_96c76449-eacb-429b-95e7-001040023731"
      unitRef="usd">67275000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i512ef6b869c04c8a878f93105c57c41a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTItMS0xLTEtNzkyODM_f54d0061-2404-4385-92b0-34f2fb3bffdf"
      unitRef="usd">50733000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i598f17c497e545c58b325723fdc76f66_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTItMy0xLTEtNzkyODM_102f47e4-eba1-43b9-b37c-3104bdc764ba"
      unitRef="usd">305506000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTItNS0xLTEtNzkyODM_428660e7-a3e4-4323-afac-c5eea3676a31"
      unitRef="usd">356239000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i71a8b179af364abb8287fabef06e5efe_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTItNy0xLTEtNzkyODM_3775a31c-b8e5-44c6-84a6-c14a1129fcae"
      unitRef="usd">67275000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i617ebbcc5095463d8013bb0f56fc9a65_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTItOS0xLTEtNzkyODM_3742de71-4044-4b4c-9532-31678ce2e0db"
      unitRef="usd">327027000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTItMTEtMS0xLTc5Mjgz_90bb2153-ff1e-44b4-b356-4b585a7b9907"
      unitRef="usd">394302000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i512ef6b869c04c8a878f93105c57c41a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTQtMS0xLTEtNzkyODM_93ee0831-d48b-49c9-a833-7252f411d6e7"
      unitRef="usd">84062000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i598f17c497e545c58b325723fdc76f66_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTQtMy0xLTEtNzkyODM_ffd6c77a-f85e-4d48-a910-cf93a3cb9807"
      unitRef="usd">305506000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTQtNS0xLTEtNzkyODM_9048acd0-195d-49ef-b1d6-0f67b7cde8b7"
      unitRef="usd">389568000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i71a8b179af364abb8287fabef06e5efe_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTQtNy0xLTEtNzkyODM_830e0736-6e38-452b-99d7-62326e97704d"
      unitRef="usd">96084000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i617ebbcc5095463d8013bb0f56fc9a65_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTQtOS0xLTEtNzkyODM_11e2e6f7-cb45-4afb-9c42-3187765b0aec"
      unitRef="usd">327027000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81Mi9mcmFnOmNhM2MxZTViOWJlYzQ0Njc4NzNiNmFlMzc2YjVkZDU2L3RhYmxlOmIzYzA1NmIyZmVkMjRkYjBhMDdmZGNiZTNkM2E5MTM4L3RhYmxlcmFuZ2U6YjNjMDU2YjJmZWQyNGRiMGEwN2ZkY2JlM2QzYTkxMzhfMTQtMTEtMS0xLTc5Mjgz_f365abc5-1e6b-41a0-a2bc-0638b0ebb85e"
      unitRef="usd">423111000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:OtherAssetsDisclosureTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RleHRyZWdpb246MDdlMzMxYTdhNGI2NGRhNGIxYTUxYWMyZDhlNjVlOWJfMTIw_3a7b3a46-b010-4ba1-9dcd-c096988b72bb">Prepaid Expenses and Other Assets&lt;div style="margin-bottom:12pt;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid software licenses and maintenance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign R&amp;amp;D credit refund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest receivable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zentera receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other assets, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RleHRyZWdpb246MDdlMzMxYTdhNGI2NGRhNGIxYTUxYWMyZDhlNjVlOWJfMTIx_cb3b8a3b-784e-4b09-ae0a-4b720c59d1f2">&lt;div style="margin-bottom:12pt;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid software licenses and maintenance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign R&amp;amp;D credit refund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest receivable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zentera receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other assets, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfMi0xLTEtMS03OTI4Mw_08b4a189-625d-49f8-ae87-2020aba8c7a1"
      unitRef="usd">523000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfMi0zLTEtMS03OTI4Mw_2dcffd43-2e0c-4a01-9018-d3235c7a4888"
      unitRef="usd">1018000</us-gaap:PrepaidInsurance>
    <zntl:PrepaidSoftwareLicenseAndMaintenance
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfMy0xLTEtMS03OTI4Mw_758e2aa8-5826-48e8-939c-81c2da52003d"
      unitRef="usd">870000</zntl:PrepaidSoftwareLicenseAndMaintenance>
    <zntl:PrepaidSoftwareLicenseAndMaintenance
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfMy0zLTEtMS03OTI4Mw_8f2cc97c-f5b2-4a4a-b888-7277173c8a6e"
      unitRef="usd">958000</zntl:PrepaidSoftwareLicenseAndMaintenance>
    <zntl:ForeignResearchAndDevelopmentCreditRefund
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfNC0xLTEtMS03OTI4Mw_d1a53754-a04d-48f0-aad0-8317362336a6"
      unitRef="usd">940000</zntl:ForeignResearchAndDevelopmentCreditRefund>
    <zntl:ForeignResearchAndDevelopmentCreditRefund
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfNC0zLTEtMS03OTI4Mw_91d4d81a-ea91-4db8-ba6e-11b740af01ed"
      unitRef="usd">659000</zntl:ForeignResearchAndDevelopmentCreditRefund>
    <zntl:PrepaidResearchAndDevelopmentCosts
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfNS0xLTEtMS03OTI4Mw_05e87ca1-5ba8-4415-9c06-30ac9d0e8f7b"
      unitRef="usd">16154000</zntl:PrepaidResearchAndDevelopmentCosts>
    <zntl:PrepaidResearchAndDevelopmentCosts
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfNS0zLTEtMS03OTI4Mw_a6f4c580-b0d2-46d8-835b-6284402aa29f"
      unitRef="usd">15002000</zntl:PrepaidResearchAndDevelopmentCosts>
    <us-gaap:InterestReceivable
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfNi0xLTEtMS03OTI4Mw_4cbf2348-4ece-4f56-ae90-e49340446be7"
      unitRef="usd">385000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfNi0zLTEtMS03OTI4Mw_3e217170-e288-4914-a6e2-366b310679c2"
      unitRef="usd">508000</us-gaap:InterestReceivable>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfNy0xLTEtMS03OTI4Mw_6b8e64c5-d458-4f7f-8d1c-60bf38c3d0ac"
      unitRef="usd">7908000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfNy0zLTEtMS03OTI4Mw_928fef0e-b788-4dd1-b21f-3c9896a0f861"
      unitRef="usd">5874000</us-gaap:DueFromRelatedPartiesCurrent>
    <zntl:OtherPrepaidExpense
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfOC0xLTEtMS03OTI4Mw_2162a29d-1047-4034-afa5-11619a340f93"
      unitRef="usd">422000</zntl:OtherPrepaidExpense>
    <zntl:OtherPrepaidExpense
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfOC0zLTEtMS03OTI4Mw_0b8d2553-852d-4a49-ae10-ada5c913c972"
      unitRef="usd">266000</zntl:OtherPrepaidExpense>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfOS0xLTEtMS03OTI4Mw_157922de-20d2-47e9-8c80-563fd1357ae9"
      unitRef="usd">27202000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfOS0zLTEtMS03OTI4Mw_68ca4646-6420-4013-a75b-823e2f86124a"
      unitRef="usd">24285000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfMTAtMS0xLTEtNzkyODM_061437ba-8956-41bd-aec2-f1fd03261d19"
      unitRef="usd">9495000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfMTAtMy0xLTEtNzkyODM_e4e64edf-a061-4e7c-9eea-bacd15c3e594"
      unitRef="usd">9723000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfMTEtMS0xLTEtNzkyODM_e3810f88-1645-4a56-a387-88f63f91c181"
      unitRef="usd">17707000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81NS9mcmFnOjA3ZTMzMWE3YTRiNjRkYTRiMWE1MWFjMmQ4ZTY1ZTliL3RhYmxlOjIyMWJlYzE0ZjNlNTRlNmI4YWEyYjc1MmYyZGI4ZjJmL3RhYmxlcmFuZ2U6MjIxYmVjMTRmM2U1NGU2YjhhYTJiNzUyZjJkYjhmMmZfMTEtMy0xLTEtNzkyODM_aa9ce420-4c68-4557-83ce-00b3f87bee2e"
      unitRef="usd">14562000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RleHRyZWdpb246M2QwODgyMzc4YmZiNDI4Y2FjM2IxZDc5MjZiZDJjMWZfMzcz_381ad0c4-82d9-4889-83ea-6cc5814b14a5">Property and Equipment, net&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,093)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense for the three months ended March&#160;31, 2023 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt; was approximately $360 thousand and $344 thousand, respectively.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RleHRyZWdpb246M2QwODgyMzc4YmZiNDI4Y2FjM2IxZDc5MjZiZDJjMWZfMzc0_4b149287-4373-4fa7-b18f-6c6038e50049">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,093)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i073dd536aa7f4e92a0c00f9b8001ea13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfMy0xLTEtMS03OTI4Mw_45a0fe29-8f64-45ad-9743-6afb4a4f9d53"
      unitRef="usd">2659000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i846b0f7b2bec4d4e9f5a806b4294790a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfMy0zLTEtMS03OTI4Mw_011fbf3b-db76-4a7c-9cd6-25d5dba7b95e"
      unitRef="usd">2622000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iaecf109643ad41c2acacd554e5a7f04a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfNC0xLTEtMS03OTI4Mw_baf13d2d-c1f8-40f7-855e-9dda94f9aea5"
      unitRef="usd">4890000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9990e1c841ed44748d68c3e408a17ce7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfNC0zLTEtMS03OTI4Mw_a6d87ce5-dbd1-4879-a742-34e2cf97a405"
      unitRef="usd">4891000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i65c0b3ee517a4e78a0b1cf3438d6c138_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfNS0xLTEtMS03OTI4Mw_71650114-4d2d-4e86-a1f6-377b6cbff2e9"
      unitRef="usd">2065000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifd91a2b14d264c7f801b908e210ab0e1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfNS0zLTEtMS03OTI4Mw_af693944-41dd-46ef-8948-1fe9f136218c"
      unitRef="usd">2065000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i19492fb07b694a8f831a804dd56146ac_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfNi0xLTEtMS03OTI4Mw_fb70b36a-1122-4195-b8fe-9c6e77582d86"
      unitRef="usd">150000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i716b7da8349e417aab51c34f8ddc80f4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfNi0zLTEtMS03OTI4Mw_1c6ffd5c-3ad2-4c88-a07a-ca7a26eaa4af"
      unitRef="usd">150000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iea20b17bd4be4aaeac426373ae7aa5ca_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfNy0xLTEtMS03OTI4Mw_f9aa962b-a48e-4084-9fde-e72bfb28af38"
      unitRef="usd">209000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i313676da216b4874b3024ccf5d0337d9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfNy0zLTEtMS03OTI4Mw_7d0292f8-5b35-42ab-b57c-1f6295f4d5ba"
      unitRef="usd">37000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfOC0xLTEtMS03OTI4Mw_4c14f1e3-8d29-4861-b3c6-b7b926fb4f68"
      unitRef="usd">9973000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfOC0zLTEtMS03OTI4Mw_a4798c03-c4cc-437c-8993-000b95e77b5a"
      unitRef="usd">9765000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfOS0xLTEtMS03OTI4Mw_655e20af-9573-410c-89cc-c026b67ae005"
      unitRef="usd">3093000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfOS0zLTEtMS03OTI4Mw_1068b43b-287f-4099-9bec-2699839169cf"
      unitRef="usd">2060000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfMTAtMS0xLTEtNzkyODM_c975f10e-ec6e-4310-ae1a-c9383c33e7ec"
      unitRef="usd">6880000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RhYmxlOjFjYjc4NmNlOGY5MjQwYmY4OTZjYmYzZjQ1NTQ0ZDRiL3RhYmxlcmFuZ2U6MWNiNzg2Y2U4ZjkyNDBiZjg5NmNiZjNmNDU1NDRkNGJfMTAtMy0xLTEtNzkyODM_ffe625af-f5f7-4d01-8ba6-c90de1db64b9"
      unitRef="usd">7705000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RleHRyZWdpb246M2QwODgyMzc4YmZiNDI4Y2FjM2IxZDc5MjZiZDJjMWZfMjAy_eff615c7-ca1d-4b7d-8388-8ead63547781"
      unitRef="usd">360000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF81OC9mcmFnOjNkMDg4MjM3OGJmYjQyOGNhYzNiMWQ3OTI2YmQyYzFmL3RleHRyZWdpb246M2QwODgyMzc4YmZiNDI4Y2FjM2IxZDc5MjZiZDJjMWZfMjE5_d13e365f-ed99-4e0b-b642-cd2923ecf58b"
      unitRef="usd">344000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RleHRyZWdpb246ZmEyMmI0NWMwYjM0NGIxZjg3YmY5YTMzYzBiM2Q0MDlfODM_2bdd54b1-7998-431e-805c-cf3398d1b59b">Accrued Expenses&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued employee expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RleHRyZWdpb246ZmEyMmI0NWMwYjM0NGIxZjg3YmY5YTMzYzBiM2Q0MDlfODQ_a6a15476-6720-4ab6-87c8-396bdd90c8bb">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued employee expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <zntl:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfMi0xLTEtMS03OTI4Mw_1ea0f09d-e563-4876-8ceb-f927df5b8077"
      unitRef="usd">34227000</zntl:AccruedResearchAndDevelopmentCostsCurrent>
    <zntl:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfMi0zLTEtMS03OTI4Mw_74c09848-012f-47f7-836b-b5d7da0b8a55"
      unitRef="usd">32310000</zntl:AccruedResearchAndDevelopmentCostsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfMy0xLTEtMS03OTI4Mw_0fa1f7c7-0ff7-4219-8a93-3915017fb2f1"
      unitRef="usd">6879000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfMy0zLTEtMS03OTI4Mw_80e5f274-affb-4dba-a87f-b2832f1f276c"
      unitRef="usd">11246000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfNC0xLTEtMS03OTI4Mw_4e2ea4c1-e40a-4d4e-835e-d51e55fa8fc7"
      unitRef="usd">828000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfNC0zLTEtMS03OTI4Mw_d05dd22f-71cb-42ba-8736-fc81c23eee74"
      unitRef="usd">1256000</us-gaap:AccruedProfessionalFeesCurrent>
    <zntl:AccruedGeneralAndAdministrativeCostsCurrent
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfNS0xLTEtMS03OTI4Mw_e530641f-dfdd-45c7-8057-21ed88ead7a1"
      unitRef="usd">726000</zntl:AccruedGeneralAndAdministrativeCostsCurrent>
    <zntl:AccruedGeneralAndAdministrativeCostsCurrent
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfNS0zLTEtMS03OTI4Mw_c495554a-185c-41c4-b9a1-6487da3c4b87"
      unitRef="usd">662000</zntl:AccruedGeneralAndAdministrativeCostsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfNi0xLTEtMS03OTI4Mw_9f3dec3c-7f5f-4dac-a092-72c4e6a0499f"
      unitRef="usd">2247000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfNi0zLTEtMS03OTI4Mw_7c757ae2-5c66-4cfe-b19c-ee89ff6b8ae7"
      unitRef="usd">2162000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfNy0xLTEtMS03OTI4Mw_07d584be-da08-41cd-98c0-1598c69eff21"
      unitRef="usd">425000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfNy0zLTEtMS03OTI4Mw_4df48ee5-f19e-42dc-91ff-498277eefc4c"
      unitRef="usd">384000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfOC0xLTEtMS04ODExOA_b2bb31d5-8489-4745-a689-57de1c5879c1"
      unitRef="usd">45332000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfOC0zLTEtMS04ODExOA_9cdddf89-9159-43c2-8a69-25d4972f87cc"
      unitRef="usd">48020000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfMTAtMS0xLTEtODgxMjk_73b67154-e759-47aa-977c-0f1841653aee"
      unitRef="usd">1792000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfMTAtMy0xLTEtODgxMjk_a7ee9602-4516-4541-b52e-555e3aa4f9a9"
      unitRef="usd">2620000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfOS0xLTEtMS03OTI4Mw_ecd25b68-39fa-4d6f-a6b6-4f9aec28f312"
      unitRef="usd">43540000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ibc4b56c1868744f5b822318ab0a0bd57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82MS9mcmFnOmZhMjJiNDVjMGIzNDRiMWY4N2JmOWEzM2MwYjNkNDA5L3RhYmxlOjU1NzgzODY4NzBhNTQxYWJiY2E4MTMwZmVhYzYxOWY2L3RhYmxlcmFuZ2U6NTU3ODM4Njg3MGE1NDFhYmJjYTgxMzBmZWFjNjE5ZjZfOS0zLTEtMS03OTI4Mw_e604461d-ac50-459b-9ccc-b61201fa157a"
      unitRef="usd">45400000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjk3Mw_38e43e7c-668e-4b9b-a43a-de27423a6833">Stockholders&#x2019; Equity &lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April 2020, the Company&#x2019;s Board of Directors adopted, and the Company&#x2019;s stockholders approved, the 2020 Incentive Award Plan (the &#x201c;2020 Plan&#x201d;), which allows for grants to selected employees, consultants and non-employee members of the Board of Directors. We currently grant stock options and restricted stock units (&#x201c;RSUs&#x201d;), under the 2020 Plan. Awards may be made under the 2020 Plan covering up to the sum of (1) 5,600,000 shares of common stock; plus (2) any shares forfeited from the unvested restricted shares of our common stock issued upon conversion of unvested Class B common units (up to 1,250,000 shares); plus (3) an annual increase on the first day of each fiscal year beginning with the fiscal year ending December 31, 2021 and continuing to, and including, the fiscal year ending December 31, 2030, equal to the lesser of (a) 5% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by our Board of Directors. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023, 9,975,086 shares were subject to outstanding awards under the 2020 Plan and 1,350,490 shares were available for future grants of share-based awards under the 2020 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2022, the Company&#x2019;s Board of Directors approved the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (the &#x201c;2022 Inducement Plan&#x201d;), which is used exclusively for the grant of equity awards to new employees as an inducement material to the employees&#x2019; entering into employment with the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company. The Board of Directors has initially reserved 1,500,000 shares of the Company&#x2019;s common stock for issuance pursuant to awards granted under the 2022 Inducement Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023, 1,485,975 shares were subject to outstanding awards under the 2022 Inducement Plan and 14,025 shares were available for future grants of share-based awards under the 2022 Inducement Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense related to share based awards was comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.570%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.100%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.585%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense by type of share-based award (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.211%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSAs and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options and Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exercise price of stock options granted is equal to the closing price of the Company&#x2019;s common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes model. Due to the Company&#x2019;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of a group of similar companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of the stock-based awards. The Company uses the &#x201c;simplified method&#x201d; for estimating the expected term of employee options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option (generally 10 years). The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero. The fair value of the stock options granted during the three months ended March&#160;31, 2023 and March&#160;31, 2022 was determined with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.0% - 80.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.6% - 74.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5 - 6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0 - 6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4% - 4.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5% - 2.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April 2020, the Company&#x2019;s Board of Directors adopted, and the Company&#x2019;s stockholders approved the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), which was subsequently amended and restated effective March 15, 2021. The maximum aggregate number of shares of the Company&#x2019;s common stock available for issuance under the ESPP at March 31, 2023 was 1,929,891. Under the terms of the ESPP, the Company&#x2019;s employees may elect to have up to 20% of their compensation, up to a maximum value of $25,000 per calendar year, withheld to purchase shares of the Company&#x2019;s common stock for a purchase price equal to 85% of the lower of the fair market value per share (at closing) of the Company&#x2019;s common stock on (i) the first trading day of a six-month offering period, or (ii) the applicable purchase date, defined as the last trading day of the six-month offering period. The weighted average assumptions used to estimate the fair value of stock purchase rights under the ESPP during the period ended March 31, 2023 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.846%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Compensation Expense Summary&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unrecognized estimated compensation cost by type of award and the weighted average requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.256%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.878%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.878%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.863%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrecognized &lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining &lt;br/&gt;Weighted-Average Recognition Period &lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSAs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, we issued zero shares of common stock in connection with the exercises of stock options. For the three months ended March&#160;31, 2023, 41.1 thousand shares of common stock &lt;/span&gt;&lt;/div&gt;issued in conjunction with certain restricted stock awards (&#x201c;RSAs&#x201d;), vested. Outstanding stock options, unvested RSAs, and unvested RSUs totaling approximately 9.9&#160;million shares, 0.1&#160;million shares and 1.6&#160;million shares of our common stock, respectively, were outstanding as of March&#160;31, 2023.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i107f398d916b45ab840efc6b49511a32_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfMTk3Ng_5e615fdd-ab83-471d-a9f9-90c34785caff"
      unitRef="shares">5600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i2b8527f1b94449b499e8720cddbb6d40_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfMjE1Mg_a6ae1cd1-05c6-4977-9f9b-1dc2249d9d1d"
      unitRef="shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease
      contextRef="i0a9d42e696914ee6ac56aebc0b0ccdf1_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfMjM4OA_12c9f520-140d-43f1-a057-f26b3a0445be"
      unitRef="number">0.05</zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i892983c302494b99a210a868ff39cecd_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfMjU4MQ_b483a64b-a3e3-4d80-a19c-c4f5ff15284c"
      unitRef="shares">9975086</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i892983c302494b99a210a868ff39cecd_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfMjY1MA_126e4375-d904-49f7-8a18-3a8fa82e9038"
      unitRef="shares">1350490</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i91b8baeaf3fd40eea9dc65835916019a_I20220731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfMzExMg_97ad46a3-086e-4035-acab-bd5ffee681a9"
      unitRef="shares">1500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i9548270e5788494cb09db3f66fae3c93_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfMzIzMg_191a916c-1355-4fc6-9040-a455264936ae"
      unitRef="shares">1485975</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i9548270e5788494cb09db3f66fae3c93_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfMzMxMg_3bfc5277-d574-4164-ae4a-256d2b131807"
      unitRef="shares">14025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjk3NA_d3fb8851-7a81-4b03-a062-b33a3c3a95d4">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense related to share based awards was comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.570%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.100%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.585%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense by type of share-based award (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.211%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSAs and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icc1a500ef2574f02955ba6e37b2c81ac_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmQxMjA5ZmNhY2U2MjRhY2U4ZjBlNmFkZWUwOTlhY2I1L3RhYmxlcmFuZ2U6ZDEyMDlmY2FjZTYyNGFjZThmMGU2YWRlZTA5OWFjYjVfMi0xLTEtMS03OTI4Mw_1ea56a97-8130-4288-aebe-ef6b97261967"
      unitRef="usd">5873000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie297eca60e624e8d93b5c2d311094db0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmQxMjA5ZmNhY2U2MjRhY2U4ZjBlNmFkZWUwOTlhY2I1L3RhYmxlcmFuZ2U6ZDEyMDlmY2FjZTYyNGFjZThmMGU2YWRlZTA5OWFjYjVfMi0zLTEtMS03OTI4Mw_c1c4669c-52b8-4268-8637-ec6924cf0361"
      unitRef="usd">5042000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6f732ecb401746458a388bfa07d3afc2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmQxMjA5ZmNhY2U2MjRhY2U4ZjBlNmFkZWUwOTlhY2I1L3RhYmxlcmFuZ2U6ZDEyMDlmY2FjZTYyNGFjZThmMGU2YWRlZTA5OWFjYjVfMy0xLTEtMS03OTI4Mw_a6192fb3-76f2-4f5c-8ab5-f9f30e39e42e"
      unitRef="usd">7860000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0f721a2929d54ac5ba6903405fe9cba7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmQxMjA5ZmNhY2U2MjRhY2U4ZjBlNmFkZWUwOTlhY2I1L3RhYmxlcmFuZ2U6ZDEyMDlmY2FjZTYyNGFjZThmMGU2YWRlZTA5OWFjYjVfMy0zLTEtMS03OTI4Mw_9bb5bedd-6c8f-42c4-9e68-570b1a4ac5ec"
      unitRef="usd">5105000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmQxMjA5ZmNhY2U2MjRhY2U4ZjBlNmFkZWUwOTlhY2I1L3RhYmxlcmFuZ2U6ZDEyMDlmY2FjZTYyNGFjZThmMGU2YWRlZTA5OWFjYjVfNC0xLTEtMS03OTI4Mw_07cfcca2-bca0-4309-ac41-7bde0a37802d"
      unitRef="usd">13733000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmQxMjA5ZmNhY2U2MjRhY2U4ZjBlNmFkZWUwOTlhY2I1L3RhYmxlcmFuZ2U6ZDEyMDlmY2FjZTYyNGFjZThmMGU2YWRlZTA5OWFjYjVfNC0zLTEtMS03OTI4Mw_6ad22535-940e-4526-8027-7d7a9c29dd4d"
      unitRef="usd">10147000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i037f9049a8294a5c99bf21de04775e11_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmY5NTM2YjFlYTAxNjQyNTk5ZGQ5MjkxYWFlMGQyNWZmL3RhYmxlcmFuZ2U6Zjk1MzZiMWVhMDE2NDI1OTlkZDkyOTFhYWUwZDI1ZmZfMy0xLTEtMS03OTI4Mw_36e428d3-c18b-4b73-87fe-9e9fdd311431"
      unitRef="usd">10609000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i32bfab5a7c4d46cbb67792b462367d55_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmY5NTM2YjFlYTAxNjQyNTk5ZGQ5MjkxYWFlMGQyNWZmL3RhYmxlcmFuZ2U6Zjk1MzZiMWVhMDE2NDI1OTlkZDkyOTFhYWUwZDI1ZmZfMy0zLTEtMS03OTI4Mw_bedc85e3-bb18-4a62-bdf9-2b9750ea257c"
      unitRef="usd">7778000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i45742a89bf3246eb9070cc158debe73f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmY5NTM2YjFlYTAxNjQyNTk5ZGQ5MjkxYWFlMGQyNWZmL3RhYmxlcmFuZ2U6Zjk1MzZiMWVhMDE2NDI1OTlkZDkyOTFhYWUwZDI1ZmZfNC0xLTEtMS03OTI4Mw_3c077298-b222-4e6b-8a0d-2d81135854fa"
      unitRef="usd">105000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic196aacc6ecf4e049fc4defb2ff097a4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmY5NTM2YjFlYTAxNjQyNTk5ZGQ5MjkxYWFlMGQyNWZmL3RhYmxlcmFuZ2U6Zjk1MzZiMWVhMDE2NDI1OTlkZDkyOTFhYWUwZDI1ZmZfNC0zLTEtMS03OTI4Mw_c59e3d6c-1cc7-4504-9509-cb32226ad4e4"
      unitRef="usd">102000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ied35ca1f9fa14bff85ddf36999e934ec_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmY5NTM2YjFlYTAxNjQyNTk5ZGQ5MjkxYWFlMGQyNWZmL3RhYmxlcmFuZ2U6Zjk1MzZiMWVhMDE2NDI1OTlkZDkyOTFhYWUwZDI1ZmZfNS0xLTEtMS03OTI4Mw_84a29685-431c-46f9-a6f0-01c9511b9fe5"
      unitRef="usd">3019000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i95aef8aaac164782aafe41f536dfd292_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmY5NTM2YjFlYTAxNjQyNTk5ZGQ5MjkxYWFlMGQyNWZmL3RhYmxlcmFuZ2U6Zjk1MzZiMWVhMDE2NDI1OTlkZDkyOTFhYWUwZDI1ZmZfNS0zLTEtMS03OTI4Mw_515aa008-7ffd-45e3-8856-0a4dfea8a08b"
      unitRef="usd">2267000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmY5NTM2YjFlYTAxNjQyNTk5ZGQ5MjkxYWFlMGQyNWZmL3RhYmxlcmFuZ2U6Zjk1MzZiMWVhMDE2NDI1OTlkZDkyOTFhYWUwZDI1ZmZfNi0xLTEtMS03OTI4Mw_9661150d-e4e4-49d3-ad77-5bf93c8f9ffd"
      unitRef="usd">13733000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOmY5NTM2YjFlYTAxNjQyNTk5ZGQ5MjkxYWFlMGQyNWZmL3RhYmxlcmFuZ2U6Zjk1MzZiMWVhMDE2NDI1OTlkZDkyOTFhYWUwZDI1ZmZfNi0zLTEtMS03OTI4Mw_b320f47e-bc91-4fb3-a113-941373a73d95"
      unitRef="usd">10147000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjk4MA_2db4c632-3baa-41d6-b3d9-c6903d2abb4b">The fair value of the stock options granted during the three months ended March&#160;31, 2023 and March&#160;31, 2022 was determined with the following assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.0% - 80.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.6% - 74.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5 - 6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0 - 6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4% - 4.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5% - 2.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm
      contextRef="i037f9049a8294a5c99bf21de04775e11_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNDc0Mw_e2d01c74-16b9-4baf-ba20-837881df2f0c">P10Y</zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i037f9049a8294a5c99bf21de04775e11_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNTA4Mw_0cc20a65-1b84-498f-b788-54539b59b752"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i037f9049a8294a5c99bf21de04775e11_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMS0xLTEtMS03OTI4My90ZXh0cmVnaW9uOjZiYTM0M2ZkZDI5ZjRiZTQ5MWY1ZWY0ZWJkZjNlNmQ0XzQ_e0ad6d8e-4e18-4926-bfd1-294be15008c7"
      unitRef="number">0.790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i037f9049a8294a5c99bf21de04775e11_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMS0xLTEtMS03OTI4My90ZXh0cmVnaW9uOjZiYTM0M2ZkZDI5ZjRiZTQ5MWY1ZWY0ZWJkZjNlNmQ0Xzk_b3fba750-c209-4edb-a69f-7f2ede845f12"
      unitRef="number">0.808</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i32bfab5a7c4d46cbb67792b462367d55_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMS0zLTEtMS03OTI4My90ZXh0cmVnaW9uOjhjMTUxZjQ2MmNlNDQ1NWNhZTcwMGFkYmM3YjMzODVmXzQ_1b3f8b92-5350-4bb1-a9c9-4b00bcc9aa26"
      unitRef="number">0.736</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i32bfab5a7c4d46cbb67792b462367d55_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMS0zLTEtMS03OTI4My90ZXh0cmVnaW9uOjhjMTUxZjQ2MmNlNDQ1NWNhZTcwMGFkYmM3YjMzODVmXzk_2435d0a2-ea4b-4071-8140-c569deea906f"
      unitRef="number">0.743</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i011753e6eaf2413a911eecf0b87cca62_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMi0xLTEtMS03OTI4My90ZXh0cmVnaW9uOmQ3ZjcxNjlmZDg1ZTQzMWViNmZlNGU1ZWEzZDEzMjg4XzQ_9b814873-d9a2-4d33-b966-b05cb7c5f96f">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ibfa47905419248b98bc84b2436b91faf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMi0xLTEtMS03OTI4My90ZXh0cmVnaW9uOmQ3ZjcxNjlmZDg1ZTQzMWViNmZlNGU1ZWEzZDEzMjg4Xzk_080e6c66-b39e-4121-ab1e-7f9306353bd0">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iae4fb48df2fa4ca3ab3a8ec68fdbb56b_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMi0zLTEtMS03OTI4My90ZXh0cmVnaW9uOjZhNjFiNzc0NmQxNzQ2YWU5M2E3NjUxNDliNTYwMzAwXzQ_1e2e9c37-7220-415c-b409-8275f64fe6f6">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2547f09e3d334b9e9a5869e04478bfe6_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMi0zLTEtMS03OTI4My90ZXh0cmVnaW9uOjZhNjFiNzc0NmQxNzQ2YWU5M2E3NjUxNDliNTYwMzAwXzk_b0404b0e-746f-4845-be6c-96535b42e697">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i037f9049a8294a5c99bf21de04775e11_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMy0xLTEtMS03OTI4My90ZXh0cmVnaW9uOjM3NjAxMzlhM2ZhMzQ0ZjM4MjJjOWRmOWM5ZmM0YTBjXzQ_59584149-6d7c-46e9-8aa3-5095b76f5f8d"
      unitRef="number">0.034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i037f9049a8294a5c99bf21de04775e11_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMy0xLTEtMS03OTI4My90ZXh0cmVnaW9uOjM3NjAxMzlhM2ZhMzQ0ZjM4MjJjOWRmOWM5ZmM0YTBjXzk_2481a983-8b0e-4fba-a16b-a1e1129e3b9d"
      unitRef="number">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i32bfab5a7c4d46cbb67792b462367d55_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMy0zLTEtMS03OTI4My90ZXh0cmVnaW9uOjE1YjMxN2NkNDhjODQ4MGQ4OGU0Zjk3ZjMyMDY1NWExXzQ_2a1f04e4-006b-4f07-92ad-fc28109c73d6"
      unitRef="number">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i32bfab5a7c4d46cbb67792b462367d55_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfMy0zLTEtMS03OTI4My90ZXh0cmVnaW9uOjE1YjMxN2NkNDhjODQ4MGQ4OGU0Zjk3ZjMyMDY1NWExXzk_3de7de37-bf2d-4727-b1de-b74fd91ef027"
      unitRef="number">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i037f9049a8294a5c99bf21de04775e11_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfNC0xLTEtMS03OTI4Mw_f31ae8c6-eb54-400e-8cf8-9043c7a1f679"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i32bfab5a7c4d46cbb67792b462367d55_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjdlNGY0MjJlNDY0MTQzZDQ5N2UwOGRlOTdlYWFjY2U4L3RhYmxlcmFuZ2U6N2U0ZjQyMmU0NjQxNDNkNDk3ZTA4ZGU5N2VhYWNjZThfNC0zLTEtMS03OTI4Mw_710b956b-5a65-4586-856b-acdbe686f7be"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib06002bdaeab4e58a39c96013dac6a87_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNTYzMQ_7fb4a99e-6374-41bd-ae3c-39afd0cdfd6c"
      unitRef="shares">1929891</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="ib06002bdaeab4e58a39c96013dac6a87_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNTcxMg_e9020ee9-8525-4cd0-b503-2e8629d1ccad"
      unitRef="number">0.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount
      contextRef="i45742a89bf3246eb9070cc158debe73f_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNTc2Mw_061230c6-6257-40da-9506-e421fd3e39ee"
      unitRef="usd">25000</zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i45742a89bf3246eb9070cc158debe73f_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNTg3Mw_fe244901-d0a4-48d0-b551-f51ad91dbc1d"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="i45742a89bf3246eb9070cc158debe73f_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjk3NQ_7b26bb6f-74a0-4b77-9a99-5e3a17f07b70">P6M</zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="i45742a89bf3246eb9070cc158debe73f_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjk4MQ_16a2b472-2f95-4728-8ef6-87704698f070">P6M</zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjk3OA_9da337b0-8d17-4bce-8389-38d2dd8b3f99">The weighted average assumptions used to estimate the fair value of stock purchase rights under the ESPP during the period ended March 31, 2023 are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.846%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i45742a89bf3246eb9070cc158debe73f_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjAyNmMzODg1ZWUzNzRiNjBhNjI5YWYxMzc5MjEwNTliL3RhYmxlcmFuZ2U6MDI2YzM4ODVlZTM3NGI2MGE2MjlhZjEzNzkyMTA1OWJfMy0zLTEtMS03OTI4Mw_d23a724d-db57-46a3-90a2-c2905f1e702f"
      unitRef="number">1.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i45742a89bf3246eb9070cc158debe73f_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjAyNmMzODg1ZWUzNzRiNjBhNjI5YWYxMzc5MjEwNTliL3RhYmxlcmFuZ2U6MDI2YzM4ODVlZTM3NGI2MGE2MjlhZjEzNzkyMTA1OWJfNC0zLTEtMS03OTI4Mw_f5ee70aa-3906-4b21-869e-c3822597ae61">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i45742a89bf3246eb9070cc158debe73f_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjAyNmMzODg1ZWUzNzRiNjBhNjI5YWYxMzc5MjEwNTliL3RhYmxlcmFuZ2U6MDI2YzM4ODVlZTM3NGI2MGE2MjlhZjEzNzkyMTA1OWJfNS0zLTEtMS03OTI4Mw_1b346ca8-7e80-499e-ac6e-9151bc3434ae"
      unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i45742a89bf3246eb9070cc158debe73f_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjAyNmMzODg1ZWUzNzRiNjBhNjI5YWYxMzc5MjEwNTliL3RhYmxlcmFuZ2U6MDI2YzM4ODVlZTM3NGI2MGE2MjlhZjEzNzkyMTA1OWJfNi0zLTEtMS03OTI4Mw_24024855-c9fd-4323-a952-0b03771eb101"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjk3Nw_56cdffd6-9531-4730-a77a-881fba167c2f">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unrecognized estimated compensation cost by type of award and the weighted average requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.256%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.878%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.878%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.863%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrecognized &lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining &lt;br/&gt;Weighted-Average Recognition Period &lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSAs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ia9df9a5968b2476b88207ca1aa4feb7a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjU0ZjQ2Y2JkNTg1YTRiYTNhMGZlYjYwMGE0OGU2ZDBhL3RhYmxlcmFuZ2U6NTRmNDZjYmQ1ODVhNGJhM2EwZmViNjAwYTQ4ZTZkMGFfMi0xLTEtMS03OTI4Mw_612aa336-4ceb-4bb1-b053-4f86d20ff09e"
      unitRef="usd">119878000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i037f9049a8294a5c99bf21de04775e11_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjU0ZjQ2Y2JkNTg1YTRiYTNhMGZlYjYwMGE0OGU2ZDBhL3RhYmxlcmFuZ2U6NTRmNDZjYmQ1ODVhNGJhM2EwZmViNjAwYTQ4ZTZkMGFfMi0zLTEtMS03OTI4Mw_7c348bb2-2f18-4414-836f-2d2ac70d3915">P3Y1M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i1ae26c0f79da45b29f5451ae2499e17f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjU0ZjQ2Y2JkNTg1YTRiYTNhMGZlYjYwMGE0OGU2ZDBhL3RhYmxlcmFuZ2U6NTRmNDZjYmQ1ODVhNGJhM2EwZmViNjAwYTQ4ZTZkMGFfMy0xLTEtMS03OTI4Mw_c0e02084-1fe9-4c4e-8a08-05fa18330fb5"
      unitRef="usd">218000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib2487cf2d4d34a84be4fe6513ad27639_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjU0ZjQ2Y2JkNTg1YTRiYTNhMGZlYjYwMGE0OGU2ZDBhL3RhYmxlcmFuZ2U6NTRmNDZjYmQ1ODVhNGJhM2EwZmViNjAwYTQ4ZTZkMGFfMy0zLTEtMS03OTI4Mw_72e65623-46da-4000-a56e-9bce56b67479">P0Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ie2b9ea7d02e840689c4b7f3112d26cf8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjU0ZjQ2Y2JkNTg1YTRiYTNhMGZlYjYwMGE0OGU2ZDBhL3RhYmxlcmFuZ2U6NTRmNDZjYmQ1ODVhNGJhM2EwZmViNjAwYTQ4ZTZkMGFfNC0xLTEtMS03OTI4Mw_90c6755d-b4a5-47d3-837b-634c563cd2d3"
      unitRef="usd">34006000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="if4fa1db40e4948c89927ea38cf78d599_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjU0ZjQ2Y2JkNTg1YTRiYTNhMGZlYjYwMGE0OGU2ZDBhL3RhYmxlcmFuZ2U6NTRmNDZjYmQ1ODVhNGJhM2EwZmViNjAwYTQ4ZTZkMGFfNC0zLTEtMS03OTI4Mw_7bfc1a79-9407-45ae-91b3-1e862ca49a34">P3Y1M28D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ib06002bdaeab4e58a39c96013dac6a87_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjU0ZjQ2Y2JkNTg1YTRiYTNhMGZlYjYwMGE0OGU2ZDBhL3RhYmxlcmFuZ2U6NTRmNDZjYmQ1ODVhNGJhM2EwZmViNjAwYTQ4ZTZkMGFfNS0xLTEtMS03OTI4Mw_20e6b1a8-7d6e-4181-9181-1c1d7c0da3ea"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i45742a89bf3246eb9070cc158debe73f_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RhYmxlOjU0ZjQ2Y2JkNTg1YTRiYTNhMGZlYjYwMGE0OGU2ZDBhL3RhYmxlcmFuZ2U6NTRmNDZjYmQ1ODVhNGJhM2EwZmViNjAwYTQ4ZTZkMGFfNS0zLTEtMS03OTI4Mw_ea313e20-9f2e-4c9b-b9e1-1430c340136e">P0Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjU3Nw_a3afc7a5-a25b-43f8-9c77-e7051e70ffd5"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjY4Mg_9ba0ea2f-811a-4516-ba1b-1489dd25b9c2"
      unitRef="shares">41100</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia9df9a5968b2476b88207ca1aa4feb7a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjg3Ng_1bcef152-1fcd-48e4-b6d1-09724082ea8c"
      unitRef="shares">9900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i1ae26c0f79da45b29f5451ae2499e17f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjg4Nw_dadbaf0b-975b-4503-88b6-87efd2dc7f82"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="ie2b9ea7d02e840689c4b7f3112d26cf8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82NC9mcmFnOjlkN2JkOTBlZDY3NzQ0YzliNDBkMDA5MjdkMGM5YTI4L3RleHRyZWdpb246OWQ3YmQ5MGVkNjc3NDRjOWI0MGQwMDkyN2QwYzlhMjhfNjkwMQ_ad00ce5f-043f-4a25-bf99-32c3eed5eb35"
      unitRef="shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RleHRyZWdpb246OTlhY2ZmMjliMGJlNGU5Nzg4ZDE2ODI0MmU1Yzg0NTBfMTkyNg_ad616d2c-b3ba-4f47-b152-562c6cc2e5f1">Commitments and Contingencies&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;From time to time, we may be involved in various disputes, including lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters. Any of these claims could subject us to costly legal expenses. The Company records a liability in its consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amounts of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary to make the consolidated financial statements not misleading. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in our consolidated financial statements. While we do generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage, or our policy limits may be inadequate to fully satisfy any damage awards or settlement. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We are currently not a party to any legal proceedings that require a loss liability to be recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our commitments include payments related to operating leases. Approximate annual future minimum operating lease payments as of March&#160;31, 2023 are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability, net of current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average remaining lease term of our operating leases is approximately 9.5 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 6, 2023, we entered into a sublease agreement pursuant to which we will sublease the office space located at 1359 Broadway, Suites 1710 and 1800 in New York, New York to a subtenant. As a result of certain triggering events, we performed an interim impairment test by comparing the carrying value of the long-lived asset group to its estimated fair value, which was determined based on the income approach using a discounted cash flow model. Estimates and assumptions used in the model included projected cash flows and a discount rate. As a result, &lt;/span&gt;&lt;/div&gt;we recorded an impairment expense of $5.0 million within our operating expenses against our operating lease right-of-use asset and fixed assets associated with our New York lease during the three months ended March 31, 2023.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RleHRyZWdpb246OTlhY2ZmMjliMGJlNGU5Nzg4ZDE2ODI0MmU1Yzg0NTBfMTkyNw_9689e997-6d97-4cd2-b922-a1ad4cb577ca">Approximate annual future minimum operating lease payments as of March&#160;31, 2023 are as follows (in thousands): &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability, net of current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RhYmxlOmQ1NTM5NDNlNWRiYjQ1M2ZhNmNkNjRmYzA0MzU0MzRmL3RhYmxlcmFuZ2U6ZDU1Mzk0M2U1ZGJiNDUzZmE2Y2Q2NGZjMDQzNTQzNGZfMi0yLTEtMS03OTI4Mw_71b3acea-82a3-4c35-8203-9a1b75712b8d"
      unitRef="usd">4966000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RhYmxlOmQ1NTM5NDNlNWRiYjQ1M2ZhNmNkNjRmYzA0MzU0MzRmL3RhYmxlcmFuZ2U6ZDU1Mzk0M2U1ZGJiNDUzZmE2Y2Q2NGZjMDQzNTQzNGZfMy0yLTEtMS03OTI4Mw_9002d604-de40-490a-a200-84d21fb385fc"
      unitRef="usd">6486000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RhYmxlOmQ1NTM5NDNlNWRiYjQ1M2ZhNmNkNjRmYzA0MzU0MzRmL3RhYmxlcmFuZ2U6ZDU1Mzk0M2U1ZGJiNDUzZmE2Y2Q2NGZjMDQzNTQzNGZfNC0yLTEtMS03OTI4Mw_bcffedc3-a5cd-4eb2-a985-7934728229e8"
      unitRef="usd">6799000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RhYmxlOmQ1NTM5NDNlNWRiYjQ1M2ZhNmNkNjRmYzA0MzU0MzRmL3RhYmxlcmFuZ2U6ZDU1Mzk0M2U1ZGJiNDUzZmE2Y2Q2NGZjMDQzNTQzNGZfNS0yLTEtMS03OTI4Mw_6df65400-8cc8-4fc1-ab5e-14943f495685"
      unitRef="usd">7278000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RhYmxlOmQ1NTM5NDNlNWRiYjQ1M2ZhNmNkNjRmYzA0MzU0MzRmL3RhYmxlcmFuZ2U6ZDU1Mzk0M2U1ZGJiNDUzZmE2Y2Q2NGZjMDQzNTQzNGZfNi0yLTEtMS05MTk0OA_4141fb45-b600-4a6d-9b73-5bcbc417adda"
      unitRef="usd">7451000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <zntl:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RhYmxlOmQ1NTM5NDNlNWRiYjQ1M2ZhNmNkNjRmYzA0MzU0MzRmL3RhYmxlcmFuZ2U6ZDU1Mzk0M2U1ZGJiNDUzZmE2Y2Q2NGZjMDQzNTQzNGZfNi0yLTEtMS03OTI4Mw_e3aed668-897e-40ec-b21e-3ade55aad458"
      unitRef="usd">38778000</zntl:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RhYmxlOmQ1NTM5NDNlNWRiYjQ1M2ZhNmNkNjRmYzA0MzU0MzRmL3RhYmxlcmFuZ2U6ZDU1Mzk0M2U1ZGJiNDUzZmE2Y2Q2NGZjMDQzNTQzNGZfNy0yLTEtMS03OTI4Mw_f030ce02-a009-4e60-9036-175f6a6585cd"
      unitRef="usd">71758000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RhYmxlOmQ1NTM5NDNlNWRiYjQ1M2ZhNmNkNjRmYzA0MzU0MzRmL3RhYmxlcmFuZ2U6ZDU1Mzk0M2U1ZGJiNDUzZmE2Y2Q2NGZjMDQzNTQzNGZfOC0yLTEtMS03OTI4Mw_2e93f725-e11c-478e-8a81-601053008e6d"
      unitRef="usd">24740000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RhYmxlOmQ1NTM5NDNlNWRiYjQ1M2ZhNmNkNjRmYzA0MzU0MzRmL3RhYmxlcmFuZ2U6ZDU1Mzk0M2U1ZGJiNDUzZmE2Y2Q2NGZjMDQzNTQzNGZfOS0yLTEtMS03OTI4Mw_7a191104-80eb-435b-bcb4-724cd90a5fd1"
      unitRef="usd">47018000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RhYmxlOmQ1NTM5NDNlNWRiYjQ1M2ZhNmNkNjRmYzA0MzU0MzRmL3RhYmxlcmFuZ2U6ZDU1Mzk0M2U1ZGJiNDUzZmE2Y2Q2NGZjMDQzNTQzNGZfMTAtMi0xLTEtNzkyODM_1cc15087-6f8f-4f09-b66e-b4ca273207e6"
      unitRef="usd">2247000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RhYmxlOmQ1NTM5NDNlNWRiYjQ1M2ZhNmNkNjRmYzA0MzU0MzRmL3RhYmxlcmFuZ2U6ZDU1Mzk0M2U1ZGJiNDUzZmE2Y2Q2NGZjMDQzNTQzNGZfMTEtMi0xLTEtNzkyODM_22e2d77e-3bbd-4516-8651-5bfcb59aa888"
      unitRef="usd">44771000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i3e95cef051ea47c385703716fa2a0497_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RleHRyZWdpb246OTlhY2ZmMjliMGJlNGU5Nzg4ZDE2ODI0MmU1Yzg0NTBfMTkyMQ_0e4adb80-141f-4f87-a688-b2bcac1d7f19">P9Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:AssetImpairmentCharges
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF82Ny9mcmFnOjk5YWNmZjI5YjBiZTRlOTc4OGQxNjgyNDJlNWM4NDUwL3RleHRyZWdpb246OTlhY2ZmMjliMGJlNGU5Nzg4ZDE2ODI0MmU1Yzg0NTBfNTQ5NzU1ODE2MDA1_da39ad32-385e-4f6e-b61c-2af1f6f27ab1"
      unitRef="usd">5000000.0</us-gaap:AssetImpairmentCharges>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RleHRyZWdpb246N2Q5MTA5OTUzMjUwNDI1MzkxMWQ3ZWMwNjZlOTlhOTJfNTYx_c7adbb74-a6aa-4d9c-86b6-69c96172e08b">Net Loss Per Common Share &lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per common share were calculated as follows (in thousands except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.967%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Zentalis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our potential and dilutive securities, which include outstanding stock options, unvested RSAs and unvested RSUs have been excluded from the computation of diluted net loss per common share as the effect would be anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents have been excluded from the calculations of diluted net loss per common share because their inclusion would be antidilutive (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.166%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested RSAs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested RSUs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RleHRyZWdpb246N2Q5MTA5OTUzMjUwNDI1MzkxMWQ3ZWMwNjZlOTlhOTJfNTU4_cec49798-b3db-4cb3-95fc-3cfa33da0274">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per common share were calculated as follows (in thousands except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.967%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Zentalis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjE1ZmY2ZTU3MjFmZjQyYzBhN2IzZDI3ODQ0NzFjZWZjL3RhYmxlcmFuZ2U6MTVmZjZlNTcyMWZmNDJjMGE3YjNkMjc4NDQ3MWNlZmNfMy0xMC0xLTEtNzkyODM_729a7073-efbe-474c-a4dd-8615bb16eae0"
      unitRef="usd">-63219000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjE1ZmY2ZTU3MjFmZjQyYzBhN2IzZDI3ODQ0NzFjZWZjL3RhYmxlcmFuZ2U6MTVmZjZlNTcyMWZmNDJjMGE3YjNkMjc4NDQ3MWNlZmNfMy0xMi0xLTEtNzkyODM_bbcf9612-27af-4bf7-be82-68105c62a851"
      unitRef="usd">-59077000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjE1ZmY2ZTU3MjFmZjQyYzBhN2IzZDI3ODQ0NzFjZWZjL3RhYmxlcmFuZ2U6MTVmZjZlNTcyMWZmNDJjMGE3YjNkMjc4NDQ3MWNlZmNfNS0xMC0xLTEtNzkyODM_940e4707-2d41-4943-877a-b749dfb9146c"
      unitRef="shares">59277000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjE1ZmY2ZTU3MjFmZjQyYzBhN2IzZDI3ODQ0NzFjZWZjL3RhYmxlcmFuZ2U6MTVmZjZlNTcyMWZmNDJjMGE3YjNkMjc4NDQ3MWNlZmNfNS0xMC0xLTEtNzkyODM_dd940558-eaa1-4a94-88fd-a94b5197df6a"
      unitRef="shares">59277000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjE1ZmY2ZTU3MjFmZjQyYzBhN2IzZDI3ODQ0NzFjZWZjL3RhYmxlcmFuZ2U6MTVmZjZlNTcyMWZmNDJjMGE3YjNkMjc4NDQ3MWNlZmNfNS0xMi0xLTEtNzkyODM_bf540d4c-f842-4192-b41b-206916468515"
      unitRef="shares">45244000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjE1ZmY2ZTU3MjFmZjQyYzBhN2IzZDI3ODQ0NzFjZWZjL3RhYmxlcmFuZ2U6MTVmZjZlNTcyMWZmNDJjMGE3YjNkMjc4NDQ3MWNlZmNfNS0xMi0xLTEtNzkyODM_dff258d7-5492-4ccc-b037-6c638f9e43aa"
      unitRef="shares">45244000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjE1ZmY2ZTU3MjFmZjQyYzBhN2IzZDI3ODQ0NzFjZWZjL3RhYmxlcmFuZ2U6MTVmZjZlNTcyMWZmNDJjMGE3YjNkMjc4NDQ3MWNlZmNfNi0xMC0xLTEtNzkyODM_572eab0c-3e1a-4388-b5e1-84493c607411"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjE1ZmY2ZTU3MjFmZjQyYzBhN2IzZDI3ODQ0NzFjZWZjL3RhYmxlcmFuZ2U6MTVmZjZlNTcyMWZmNDJjMGE3YjNkMjc4NDQ3MWNlZmNfNi0xMC0xLTEtNzkyODM_e3677941-74be-48fc-956d-ba9a8d8c611c"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjE1ZmY2ZTU3MjFmZjQyYzBhN2IzZDI3ODQ0NzFjZWZjL3RhYmxlcmFuZ2U6MTVmZjZlNTcyMWZmNDJjMGE3YjNkMjc4NDQ3MWNlZmNfNi0xMi0xLTEtNzkyODM_5a572ea5-8bf8-4309-829b-264d285fae87"
      unitRef="usdPerShare">-1.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjE1ZmY2ZTU3MjFmZjQyYzBhN2IzZDI3ODQ0NzFjZWZjL3RhYmxlcmFuZ2U6MTVmZjZlNTcyMWZmNDJjMGE3YjNkMjc4NDQ3MWNlZmNfNi0xMi0xLTEtNzkyODM_70341e37-30d1-41f8-988b-48fbc01d3f21"
      unitRef="usdPerShare">-1.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RleHRyZWdpb246N2Q5MTA5OTUzMjUwNDI1MzkxMWQ3ZWMwNjZlOTlhOTJfNTYw_a86fbc07-85ac-470c-8cab-02bda7009d77">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents have been excluded from the calculations of diluted net loss per common share because their inclusion would be antidilutive (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.166%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested RSAs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested RSUs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia9be73cf481a40aaba4c6cc6e675a708_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjY3MTc4MGQ0MzUzODQxYThhYmZlODQ1ZmI3NmZkZDlmL3RhYmxlcmFuZ2U6NjcxNzgwZDQzNTM4NDFhOGFiZmU4NDVmYjc2ZmRkOWZfMi0xLTEtMS03OTI4Mw_9905209c-4e18-4a3a-9286-d18cfead88b4"
      unitRef="shares">9895000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie7a5cbabc41941ada32f7ae938592fa6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjY3MTc4MGQ0MzUzODQxYThhYmZlODQ1ZmI3NmZkZDlmL3RhYmxlcmFuZ2U6NjcxNzgwZDQzNTM4NDFhOGFiZmU4NDVmYjc2ZmRkOWZfMi0zLTEtMS03OTI4Mw_5913e5f4-87a7-487e-b3a1-cab4be1c087f"
      unitRef="shares">5372000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i37ef16e02d7e43ba862a5c169d0332ea_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjY3MTc4MGQ0MzUzODQxYThhYmZlODQ1ZmI3NmZkZDlmL3RhYmxlcmFuZ2U6NjcxNzgwZDQzNTM4NDFhOGFiZmU4NDVmYjc2ZmRkOWZfMy0xLTEtMS03OTI4Mw_b3f20311-67ae-47da-b78c-0f42df154a20"
      unitRef="shares">82000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6fb0cb9f5b6a4708aab9cfcff606daf7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjY3MTc4MGQ0MzUzODQxYThhYmZlODQ1ZmI3NmZkZDlmL3RhYmxlcmFuZ2U6NjcxNzgwZDQzNTM4NDFhOGFiZmU4NDVmYjc2ZmRkOWZfMy0zLTEtMS03OTI4Mw_51650912-a925-4ee4-ad1c-ecfff6fe42d4"
      unitRef="shares">287000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5e96002c4838463f94c1dab336a29f92_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjY3MTc4MGQ0MzUzODQxYThhYmZlODQ1ZmI3NmZkZDlmL3RhYmxlcmFuZ2U6NjcxNzgwZDQzNTM4NDFhOGFiZmU4NDVmYjc2ZmRkOWZfNC0xLTEtMS03OTI4Mw_b380f22e-7210-407b-9379-8d940ad7cdb9"
      unitRef="shares">1566000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8d916b6b431a4bb1b63b1b45fcaf58c3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjY3MTc4MGQ0MzUzODQxYThhYmZlODQ1ZmI3NmZkZDlmL3RhYmxlcmFuZ2U6NjcxNzgwZDQzNTM4NDFhOGFiZmU4NDVmYjc2ZmRkOWZfNC0zLTEtMS03OTI4Mw_1206172c-59d9-4191-bca9-77458d2f07be"
      unitRef="shares">433000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjY3MTc4MGQ0MzUzODQxYThhYmZlODQ1ZmI3NmZkZDlmL3RhYmxlcmFuZ2U6NjcxNzgwZDQzNTM4NDFhOGFiZmU4NDVmYjc2ZmRkOWZfNS0xLTEtMS03OTI4Mw_8242b8fa-3aca-4823-9a1e-b01f92b4c518"
      unitRef="shares">11543000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83MC9mcmFnOjdkOTEwOTk1MzI1MDQyNTM5MTFkN2VjMDY2ZTk5YTkyL3RhYmxlOjY3MTc4MGQ0MzUzODQxYThhYmZlODQ1ZmI3NmZkZDlmL3RhYmxlcmFuZ2U6NjcxNzgwZDQzNTM4NDFhOGFiZmU4NDVmYjc2ZmRkOWZfNS0zLTEtMS03OTI4Mw_1d7776ec-754b-4c07-9671-418112aa6ca7"
      unitRef="shares">6092000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83My9mcmFnOmFjY2ZkMjU2OTE3NTRiYTJhYWE2YWU5YmM0MTE1ODM1L3RleHRyZWdpb246YWNjZmQyNTY5MTc1NGJhMmFhYTZhZTliYzQxMTU4MzVfMTg0Mw_1a75d528-12e0-45ba-a348-c3835c395649">Related Party Disclosures&lt;div style="margin-bottom:12pt;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Tempus&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Kimberly Blackwell, M.D., our Chief Executive Officer and a member of our Board of Directors, was previously employed by Tempus Labs, Inc. ("Tempus") and now serves as an advisor of Tempus. The Company entered into a Master Services Agreement with Tempus in December 2020 to provide data licensing and research services. There were $0.4 million and immaterial fees incurred for services performed by Tempus for the three months ended March&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Zentera&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Kevin D. Bunker, Ph.D., our Chief Scientific Officer, serves as a member of the Board of Directors of Zentera. Accordingly, the Company identifies Zentera as a related party.&lt;/span&gt;&lt;/div&gt;In May 2020, each of our wholly owned subsidiaries, Zeno Alpha, Inc., K-Group Alpha, Inc. and K-Group Beta, Inc., entered into the Zentera Sublicenses, pursuant to which we collaborate with Zentera on the development and commercialization of the Collaboration Products in the Zentera Collaboration Territory. Under the terms of the Zentera Sublicenses, Zentera is responsible for the costs of developing the Collaboration Products in the Zentera Collaboration Territory, and we are responsible for the costs of developing the Collaboration Products outside the Zentera Collaboration Territory, provided that Zentera will reimburse us for a portion of its costs for global data management, pharmacovigilance, safety database management, and chemistry, manufacturing and controls activities with respect to each Collaboration Product. For the three months ended March 31, 2023 and 2022, the amounts incurred under this arrangement totaled $2.2 million and $2.1&#160;million, respectively, and are presented as contra-research and development expense in the consolidated statement of operations.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i4be5fa9930e7403c9c0f8ba0f46352fe_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83My9mcmFnOmFjY2ZkMjU2OTE3NTRiYTJhYWE2YWU5YmM0MTE1ODM1L3RleHRyZWdpb246YWNjZmQyNTY5MTc1NGJhMmFhYTZhZTliYzQxMTU4MzVfMzc0_a67a924f-dbae-4f40-9a0f-f74a42d44298"
      unitRef="usd">400000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <zntl:ResearchAndDevelopmentExpenseReimbursements
      contextRef="i7c81d5274f084d8ca588db925f2f294d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83My9mcmFnOmFjY2ZkMjU2OTE3NTRiYTJhYWE2YWU5YmM0MTE1ODM1L3RleHRyZWdpb246YWNjZmQyNTY5MTc1NGJhMmFhYTZhZTliYzQxMTU4MzVfNjU5NzA2OTc2ODg2MA_d5423e18-5f8d-4317-913a-42dc00fdc021"
      unitRef="usd">2200000</zntl:ResearchAndDevelopmentExpenseReimbursements>
    <zntl:ResearchAndDevelopmentExpenseReimbursements
      contextRef="i4a32b2ade07d41f4b1cad2d93ca61367_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVkZTJlNGM4NTQ4YzQwZDQ5MTBiN2E4MzhhMDhkODE0L3NlYzplZGUyZTRjODU0OGM0MGQ0OTEwYjdhODM4YTA4ZDgxNF83My9mcmFnOmFjY2ZkMjU2OTE3NTRiYTJhYWE2YWU5YmM0MTE1ODM1L3RleHRyZWdpb246YWNjZmQyNTY5MTc1NGJhMmFhYTZhZTliYzQxMTU4MzVfMTY0OTI2NzQ0Mzg0Nw_9e1a7d51-45ce-468a-9a7e-6df46e864aa7"
      unitRef="usd">2100000</zntl:ResearchAndDevelopmentExpenseReimbursements>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>65
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M205ME9MF>T*F&CHHD8J,999HM8'?P%H9!]2OKFW$>%!3Y%=N@M9!?N0OY#:
M=(4SR%#>7:M;]0')/FM[9VZO[UK;-1[<E)>5O*P.[R@(0!T:XNZ"W,%WY'-B
MSRLN2;WN.;E4D@=KOK$BH_%-D4M'1%$/@B,_KJ45&9><9B%TB;Y+K;C'L$2T
M]$04=S7O<<?F#GKOHUPG5E1<[AX6-D^PL#FQHA[#*M'2*U'<X;Q'+4:JB9*K
M,/'MK1G7O'^R@A[#--'2-5'<[+P'G<@4)A;R-5Q6#\:X(H7)MV\E/89MHJ5O
MHKC9R5OK"-;WU6"X */,BG4,LT1+MT1QJW,G8=X'&R 3S"X=$.EX7MOKG=L'
MG6/X)5H:)HH[G<=0@Q&4,T+9A^>?R53XF8),6B%QI;&,8YA]IUKZWTY^=$^A
MG9(E5V3%HTR0)2QN\Y6_M0Z.X9Y8Z9X8[F_ Z@=A,B?33?PL(QOZ 8&O]X]W
MU@V$8U@D5EHDAON9?3+)]8N_X,E<5+KA T+WH^G5R+KBQ@.;$I:FB-4R1>-,
M*;-FVR[4\E3"A))9-YD.*#Y9MZ;&>%13SM()L5I.Z#;10FVW(\WBF^_!K9RX
M8A7G,2P0*RT0JV6!S.(45BW@">926<>B SIW7$%K'_F^ "&0";:25N)C."%6
M.B%6RPE-8QY%Y#)+X75J;[>X3N5> Q[7E*\T0*R6 ;J.A9J;CODK*.@%>(1X
MR1-[:G'!:M!C^!]6^A^&VY=](A<"$HGA-=PSPN.:XI4^B-7:-GHSR0.LV<HG
MGS,-KC;)Y] /8;+;X?_92O^=W,ZN3K9JW5S-'".MAMWS3J_79YV!L[+QEKZ(
MU=I)&L/HJL  WB:!>"&_"WM*<2D7G%"/=0'"RG ,[^.5WL?#K<LH%DF0;WC>
M1'QN/73 !2H;+![7%*PT/Q[N68J-W)LPS2W\=M_Z!AY;Q]<#<E^LYAT/:LI8
MVA\/-RM[W[-#?!)@M[&-^0-R[39E;<\.>@S_X[TZ&\/=ROMDYJ35J<3%JHX=
M\+#_R^B\.BDUDU]^@)P2WVS%;@]-BZ?%(?4H/YIURL^W)]R?N)D[4Q*)&82Z
MIST8\-3VT'A[H^4R/W=]EEK+.+]<"!X(93Z ]S,I]?[&_(/BZ'[X'U!+ P04
M    " #*.*I6WNE)6V8&  !1&@  &    'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;*U9;6_;-A#^*X17%"U@QR*IUR8QT"9[*;"M6=-LV+XQ$AT3D417I.QD
MOWY'V;%LB:+3+A\2Z^7N]-SIR.<A=;:6U;U:<*[10Y&7ZGRTT'KY;CI5Z8(7
M3)W()2_ASEQ6!=-P6MU-U;+B+&N<BGQ*/"^<%DR4H]E9<^VJFIW)6N>BY%<5
M4G51L.KQ \_E^GR$1T\7/HN[A387IK.S);OCUUS?+*\J.)ONHF2BX*42LD05
MGY^/WN-W%Y08A\;B3\'7:N\8F51NI;PW)Q^S\Y%G$/&<I]J$8/"SXA<\STTD
MP/%U&W2T>Z9QW#]^BOY3DSPD<\L4OY#Y7R+3B_-1/$(9G[,ZUY_E^A>^32@P
M\5*9J^8_6F]MO1%*:Z5EL74&!(4H-[_L85N(/0?L#SB0K0-YK@/=.M FT0VR
M)JU+IMGLK))K5!EKB&8.FMHTWI"-*,UKO-85W!7@IV<7LLS@I? ,P9&2N<B8
MAI,/+&=ERM&U":S0FYN2U9F .V_1!-U<7Z(WK]ZB5TB4Z,M"UHJ5F3J;:L!C
MHD[3[;,_;)Y-!I[]&ZM.$,5C1#Q"+>X7;O=+GN[<R:'[%*JP*P79E8(T\>A0
M*>JJXJ5&3"G(V9;.QM^W^YL!]TXM6<K/1S"B%*]6?#1[_0,.O5-;<B\4["!5
MNDN5NJ+/+IA:('AI*#4'_&LM5BR'W*U9;T*%32@S*ZQF-"2Q=S9=[:?3M_*I
M%R8[JP.<_@ZG[\0)'7+/-;O-.5(\K2NA!5=CQ%9,Y.;J!.:QB0+H-MR;T,$^
M[B D-.D MY@E )W8D0<[Y($3^57%ETQDB#\LS?!23;6E7O *1O6Q/@MZD' 4
M>5$'N,7*AP3MN,,=[M")^XO4+'\&Q+#W<!_#, P[&"UF 4XHM8.,=B"C(\4%
M&JOT8U-4T[U+(!8]1B77-JQ1#T08]_JW;P0E#^PXXQW.V(GS$Z!D6I1W*.=
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MO<X .51UEZDZ1N;E=6 A#5XNRF:*]S]0-@#GEU*:QXZ]8=0WRN@/4$L#!!0
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M\;43]649S;RQ3&]+)9ZNE:]4%:=9J0[I_T%7]#I=1K-176V-Q9/U#)J,5HI
MI>HV !T$[DM],BBZNK55=^JJ869=L^&19>Y& UU#,S]P.R7A7%=;2/%T)?T_
MNKJ3-Z5L6$R-R@PUUZ#,[C2(.>4[W3<+("T+6?5/S=NF-_^@.]+>^UO5L^O&
MLW53-?S0'>U2:! SN@67SG4$3+SJH:L'R?:Z#5TS"4VMODTHB2E7!O#[EC%Y
M>E ?:/Z3L?H'4$L#!!0    ( ,HXJE:]=J0$.P,  +4)   8    >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&ULK59M;]LV$/XKA%H,";!$MF3+=F8+2-P6#=!N
M0=.L0(=]H*6S180B7?)D=_OU.TJ*YA?&*-!\D4CJ[N'SW)W(FVZU>;0% ++O
MI51V%A2(ZZLPM%D!);>7>@V*OBRU*3G2U*Q"NS; \]JIE&'4ZR5AR84*TFF]
M=F?2J:Y0"@5WAMFJ++GYYP:DWLZ"?O"T\$FL"G0+83I=\Q7< SZL[PS-P@XE
M%R4H*[1B!I:SX+I_-9\X^]K@3P%;NS-F3LE"ZT<WN<UG0<\1 @D9.@1.KPW,
M04H'1#2^M9A!MZ5SW!T_H;^KM9.6!;<PU_*+R+&8!>. Y;#DE<1/>OL>6CU#
MAY=I:>LGV[:VO8!EE45=ML[$H!2J>?/O;1QV' C'[Q"U#M&AP^ 9A[AUB&NA
M#;-:UAN./)T:O67&61.:&]2QJ;U)C5 NB_=HZ*L@/TSG6N64$\@9C:R6(N=(
MDWND%R4++=-+^E12B10N=QM@'[2U[.Q!\2H79'O.+MC#_1MV]OJ<O69"L<^%
MKBQ7N9V&2 S=/F'6LKEIV$3/L(G91ZVPL.PML<KW_4-2ULF+GN3=1"<!/W)S
MR>+^KRSJ1;&'S_S'W:,3=.(NVG&-%S^#UX7U.*JW*M,EL+^N%Q8-%???ON@U
MZ ,_NOOAK^R:9S +"-B"V4"0_O*JG_1^\TE_(;"]0 RZ0 Q.H:>_T_DDJ8Y\
M(AO/I/9TA] FO4CB**'X;W;I>\R&DR@>=69[Q(8=L>')#/V!!1B6[:5&-*DY
M<X3/KWR4AR^9EQ<"VY.?=/*3DWEY4'052/$O'0$KN@):S8S.6SKC'P'Y0@*S
MD%5&H !O^IH-ACMY&4U&![D[MKF8C ?^S(TZZJ.3U#]KY/(@<\^5V.AX_R0:
M),,#FCXS.@CZ?J+CCNCX)-'Y$47&$8U85$UX43.EJ>04&BW)>44%B$"Y1J^6
M\3')07P@Q&-#!>.7,>ED3'Y6QE<ZZ:B:O+0GGK\\&D2'?[G/C!J4PQ2$.S=@
M"695-P:6JJ%2V-P6W6K7>US75^[!^@WU)$T+\3],T]#07; 2RC()2X+L78XH
MG*9I$IH)ZG5]SRXTTJU=#POJJ\ X _J^U!J?)FZ#KE-+_P-02P,$%     @
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M%R2.)[S>=S]@<%]S7N^ZPRW+Q*);&HCO'^J:?SF1OXEP^AV/Y?\ 4$L#!!0
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ML-]9(7+VH@W!#Q$##PP1 @R=<@_>JQ'?UH: 4U)(RW9<M:(K%U9X'A@]2CR
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M8[N"\6!F<<V5V9K6$>6E/D'/*:B-$C^#+H*<ABO:D$^'/\&Q))GLVC5R'?V
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ME71XL!P&B6F%"47-AF,)S3MQO@C.Y"</M1B:PD(Q3X1N-6]+27NQL:0WY70
M[L?>Z3R=AQ.\C<PN*9)H_4+N.'%\/#Q1(*$+&!N.\U%2'Z<'$T:7[A-!:L[F
M&X%-QK&<_2KBH20<P#K^UUAI:7@?QGC$,:IU;4/,)]YT!"GOC_5?#S&=X[@+
M6J/G0>R4\Y@*$/'\V*>H^>A#(FKF-GPNI=B!+/&;8O^T_R)['3]$#LOCYUQ
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M<%<K+9/W(HS-A2?F6]UUJV/I*H/'$Q]9VN9H]D$YQ^B2?\!2<S=FF3#\7AK
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MV#\_ZZF0W]1YDGPC[]BY3W@5R[#"OR$4V #?%]ZGS80=;/^QF?T+4$L#!!0
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MB1U)N%QFH!BB;Q(_/!*/#*5C\7WQ^PH"B2&2CCN%9/$;LLZG W.I8@TP>1D
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M$[?U?7R_O?Y7 R8L>4+/:0'6L#\=]X2I_RFH%TZO_>U\KAWN^OYU13C+#6_
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M%P;9P2 +O'M'@>5;06*]M&8/UFLSFC^$4(,UDY/:%^66++]*MJ/UQG)]+3V
MT"6\^]')EC-.,6BD94+LP*LEQ0'LN@?+?@&6PT>CJ7;P3I=8/K=/F-C +GMD
M=YV=!/PH[ 7DHQBR-,M/X.5#M'G R_\CVA@VC=#T/&CXYVKKR/)W\NVET'OD
M\<O(OG<N72L*7$7<' [M'4;KUW^,INF;$[S' ^_Q*?3?K=+_!H-G;_C\K3#<
MBHZP!%,!U0B5:;BGI=[!F=1\8SK'9N[\$KAN11T*]Q8+5%NT0Q7]DL%?8OL$
M#Z\@BZ>31;_[5^0^JTU3@E2M-7?HM1R,X_DB#>L(/E65+/ (PQ.N.JLE=189
M)YU.#NN-46U'3.%)>31)P^^&0R+;]0."8V!G.ZZ>8Y(+R&=PVVW)D&A@$2]F
M.:\SQKLJBDYUC?"9*)&K74C13QBF()2Q)/_M+\[R.%WDYW#FB:3G)[/["J;Q
M?)[R/HMGZ803=PH9[WDJ.U\"&TI!M44$U7<?^NX[JD%(NX?PJ7_I:TR.YH="
MNPM3TG'!.TW]*!ENAT%\U<^?)_5^BK/7G=0.&JS8-+V832*P_63L!3)MF$9;
M0SS;PK'F/Q.T7H'?*V/H4? .AK^G]4]02P,$%     @ RCBJ5LE+(6_A @
M:@8  !D   !X;"]W;W)K<VAE971S+W-H965T,34N>&ULC57;CM,P$/V544 (
MI+!)G/3"TE;:Y2*06&FUW!X0#VXR32P<.]CNMOOWC)TV+6A;\>+8XS/'9SR>
MR6RCS2_;(#K8ME+9>=0XUUTFB2T;;+F]T!TJVEEITW)'2U,GMC/(J^#4RH2E
MZ3AIN5#18A9LMV8QTVLGA<); W;=MMP\7*/4FWF417O#G:@;YPW)8M;Q&C^C
M^]K=&EHE TLE6E16: 4&5_/H*KN\+CP^ +X)W-BC.?A(EEK_\HN/U3Q*O2"4
M6#K/P.ESCV]02D]$,G[O.*/A2.]X/-^SOP^Q4RQ+;O&-EM]%Y9IY-(V@PA5?
M2W>G-Q]P%\_(\Y5:VC#"IL?F>03EVCK=[IQ)02M4_^7;W3T<.4S3$PYLY\""
M[OZ@H/(M=WPQ,WH#QJ.)S4]"J,&;Q GED_+9&=H5Y.<65V5IUEC!NRVEV:*=
M)8Y8_5Y2[ABN>P9V@B&'&ZU<8^&=JK#ZVS\A-8,DMI=TS<X2WG!S 7D6 TM9
M?H8O'T+, U]^@N^6/_"E1 M<51#BY=+"CZNE=88>Q<_'0NX9B\<9?:%<VHZ7
M.(^H$BR:>XP6SYYDX_3U&;W%H+<XQ_Y?*3G+\+B^?VEA;\"]H=14:]:!7H%K
M$%9:4LD*5<-SH<BBUY9NT+ZX!,I0V804O<42VR6:(5]^8 .U/SQ@_=57>$\]
MH*.*=H<SGT)>Q(Q-_(3%>98>9+6=U ^(!^PXGDY>09;%K!@/,(DUEP?,E$V!
M *,#H$:%AB!> J^HA(3/N^\%!Z\)&\-XS. 34H&#%'PII' /P.BH"8T9[7WA
M6T)V_6."@HT@GQ;P13O/_>]5%J,XSQD4TSAE*=%:"U*K^J5#TT*G3>A(63QY
MQ8A]3) 3/$^AR.-1D?K)*"[2%!Y[8,E1_;=HZM#E?#[7RO6M8+ .C?2J[Q\'
M>-^%*;6U4*065^2:7DQ&$9B^L_4+I[O039;:46\*TX9^!F@\@/976KO]PA\P
M_%X6?P!02P,$%     @ RCBJ5B0?O-)/"@  :QP  !D   !X;"]W;W)K<VAE
M971S+W-H965T,38N>&ULO5EM;^,V$OXK1+HI$D!Q)-F.G<T+D-U-[WI <4'2
MM, =[@,CT39O)=%+4G'<7W_/D)0L)4J:/1P.Z#:R-)SW>69&.M\H_=6LA+#L
MJ2PJ<[&WLG;]\?C89"M1<C-2:U'AR4+IDEO\U,MCL]:"Y^Y061RG<7QR7')9
M[5V>NWLW^O)<U;:0E;C1S-1ER?7VDRC4YF(OV6MNW,KERM*-X\OS-5^*.V'O
MUS<:OXY;+KDL166DJI@6BXN]J^3CIPG1.X+?I-B8SC4C2QZ4^DH_?LXO]F)2
M2!0BL\2!X\^C^"R*@AA!C6^!YUXKD@YVKQON/SG;8<L#-^*S*GZ7N5U=[,WW
M6"X6O"[LK=K\501[IL0O4X5Q_V<;3YM"8E8;J\IP&+]+6?F__"GXH7-@'K]R
M( T'4J>W%^2T_,(MOSS7:L,T48,;73A3W6DH)RL*RIW5>"IQSE[>695]7:DB
M%]K\^,,\369G[/I;+>WV_-B"/U$=9X'7)\\K?877F/VB*KLR[+K*1=X_?PR]
M6N721KE/Z9L,?^%ZQ,9)Q-(X';_!;]P:.W;\QJ_P\X:Q?UX]&*N1#_\:LM&S
MF RSH!KY:-8\$Q=[* (C]*/8N_SQA^0D/GM#P4FKX.0M[M\9C3=Y#6OZN@!V
MM^):'%&&Y^RS*E'UAKO"^;EB5VLM"XI"'#&[$NXYK[:!@V&?%-<Y4POV16J4
MF]*&\5RMK<@CQJM\\(SIJ,+X>JW5(Y$3*0F"V$Q45++L:D/<;PI>L0-Z3"S2
M^,Q1T5WW.SD[C-AF);,5XP6@QC @%EMJ7EG#K&(>"&";*->%V@IA(I:IRJ!Z
M'0FI6:GJJ'G,2E$^D&JPBH2^-''$?A<H4:VA9K'UHKQ5#*;#<YXI?&^U=*+]
MP[J2D'<0K+B]NS<[ VI4CM[Y@*P;>?L-JG[+'J 7S\40':QY%%I62U:OR6!Z
M"*@EE0^20S:-3N(XBN.8&0JTLRM398D .[7.V+JHH59Z"*VW#1%\N!"2=%]H
M53J>=?4(BT3?L):EJG6/+9/&U*"HUXHTQ%GM\!RD+://!3?(H>9<\(^W(HG2
M:5?MPT;/,>F)_ZJ:%TQ6&3J2$0S'2<>%U,:R' Z#',&1$PMI,A!N!0>*BZ6L
M*O+41MI5.+![+*J<GGT1F<N !H 2%TV88&55$X%5/KDAO*CI2/1.5F-4D?A&
M>H<P%<*@/EVD."*UW^3<<*3@8VN0M(YU:W %=L%@NB'+4N226X',1/EGPE%#
M,:@$Q9QVI/S!PR&R! XR)<H&2E2UTQ1L@G1NT.6LT&@^B-7#UH5XJ!JN+ -@
M@U6#V!$[C4YGTRB>GS3,-D)35C[\&X?(^JXIW*?Y4&J3IDDT1B9,3N,>+_[(
M9<$?"N'*?5';&C=#U3<V!%![G?^(,.YO-5R%6^G[(2Z EJ/_!U" %]*P&X@L
M ;NUE7 W4 9 -G*,V;7#%HPT%C?S&DGA+_\<Z-+N@2',@^":C!1/2$8#9C"&
M/$)L/#)1)7BD#XZ ^RM,32T>4J0A6>X$8>@!HNSRM"5M6@>(/.3("B1B9UY;
M6,&-(_;K((:R%81*%#RD0./0IRC8TQ=H-1257EV0O00W' YEZUK3E<NR8+#S
M V%1-P->>'8PD9-H,I]2,O^WB?Q"C,_I212GT_]E0@^8\ZM"8O8.9MWV+I[H
M6L#W!2?O4*\D6M83LN'.V9@#Z&:(QD)1IR63#R3AD*H-K#*''Q%MC1;:'0>=
M([V&MXBR\R^Y(!?(5;5V^C:J?$"WFL_&[F\\2=E?1"4T;"!ZG@.(),UOKF2:
M([-H?A*#/(FG[S7X TO&T6Q,8I(X2B:SW@@T> 3H9[=K,1B([_.!&\38W\.<
MX#0XB4]Q,8MFLWE "ASW=#<UW$7]S64.V9C$\./=E1\Q:(9@XRA.3ED:I2>S
M(=-Z\MRA7?OV#^]=WZ4Z%4]"9P@T.H?,O+6]L:8I)(!.KX]EA3*4#>VQ/RW9
MT+YR9![1.\8>*Q9<:O;(BUJT/=R+#]XFV<;*TN7L$!O@H>O2A#L%S[X>W668
M-E%FI<I%,6)?P#GH_5S%0I9NYL'J2VD&+BMDG-);GX&,V(6NO';#TEID<B&S
M0$:X[R<#1%&"SZ-":<F"L!<J\EZ#::TP+LM</#KT/L&"?1WV'1(HPF&RPL!$
MD8+N!==!-PFV=L4MHX)>UP^%S "S*!YDH_?S,$]2LZWYVH%FZ\T< +7MQ]JT
MO:8=LUOY3:\(()?7NF%$[>B1)A++X&BI6ER!,EGMT:CU"4T@[5Q$N=,#06]+
MXU)T0L,Z#=2X0"PH%*5 B>:A>SJM@_];I9X+;!>"D/W4<0'4! 4OR%TU>-%<
MHP5"&K*"8^CER[8@:.IUTNA$LQTA!$LWP]& 2;NI*ZN.S2'Y#Y8>"Q&!)'9C
MG#GTQ@.9OQXM"'(D=64(89KJ 8722Z+[T1T.T+A<(Z&W4A2Y\P-O@D!;$9*B
MU\8'PQ!4 NR)Q8+Z(/*,[L.?K;&=BFZB0RV_4K;9#.A6+A]ECLG4(U.NA*?P
M4JE*'6V'C%8=/SK+A>CK0Y,H^- L@=VN7VLD>H<:+ID#R^ (B,**]8?0:@B%
MVMQ[@82=K+8.]DL/^\+!?G^:<#;V;J6NU#I3]FXO:3LL5J2Z]%(_/F?XC-GU
M ([,3D?Q/CMB\W@TWV>S\>B$?LTFH_$^NPKYV0\RM3.?7VPZFH+X9)3@7QRN
M;E])M_%H0IPGHW2?):,I7:<DI%7JF<<=/*1G;+]S]6;W^W^^CGCG9!^_K7%W
MEK^^N[EY/KM3\#%*&J"'?Y7 2Y\WS>L#CX2NQFCF\>%.IGXM]8E:\B=98MOG
MRZ462PK$BT7N/?VX/WVVP_1NQ"3]J<Z?92"9D$2GZ6DT/X5&]RT]I5(KF@X/
M1VRWA-!;#M=#J!97@,[P.B.-F[58ZMYP%@4"WOJ@K=</Z=3M$ "V_NH;N0I;
MA8I?-]'ZSEV#[T[ZB:<=AN:['1[EZZ-@&S@IN?XJ;-"25//C]@&\&IKJX7MG
MIP-YV'G?06V=H"*\!N"8!9Z.'!#AY\(O:A[C(_0;' ZGD>V8"US46X-HE(KH
M];;#(^Y[6L%?2G&8^)H<GYL;]VJ<V 2@Z6"9WUII>0RPO/-3&T9O;JN:)F[F
M>4YV$#CTL6'LI17+!%P%DEX/$3F&O^W ,XD3X%X'PSQ !G2,@8Z$ALRAH0/!
M29_\%<CKO66]#BO&G?\Z$I:8N@* J64E_R $:#M7;SG)%*+2V4S\?-S@W OG
M:QJ[#.9;1KLVI6TS?%%/]8CDW@@U2X_L3*:^/W9TZBT]]/Z2WF4Q!<EZ0QL$
MVKC(#U]TK/NN7;>"OAY1].YZS17+2P) P3HT'B53O^ZDR9P<'H>=!_MS?$*/
M3WS0/K3.C3'@O[\G Q!$,Y!0]W_MU9MT+S&K\$FI,Q[YA<F\V)5&[*<P&;]#
MATF"QMIX\S45ACXS''<^ )5"+]UG+H*+NK+^6U![M_V2=N4_(.W(_6<XZ(1!
M%#N06.!H/)I-]WS%-3^L6KO/20_*6E6ZRY7 /J&) ,\7"B$//TA ^WWQ\C]0
M2P,$%     @ RCBJ5O/-0)$#!P  L@\  !D   !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&ULA5?;;N,V$/T5PBV*74#U+4Z<I$F 9-NB!=KNHML+BJ(/M#2R
MV:5(+4G9\=_WS%"6DS2;?;$IB7,Y<SD<7NU\^! W1$G=-];%Z]$FI?9R,HGE
MAAH=Q[XEAR^U#XU.> SK26P#Z4J$&CN93Z=GDT8;-[JYDG?OPLV5[Y(UCMX%
M%;NFT6%_1];OKD>ST>'%KV:]2?QB<G/5ZC6]I_1[^R[@:3)HJ4Q#+AKO5*#Z
M>G0[N[Q;\'[9\(>A77RP5HQDY?T'?OBQNAY-V2&R5";6H/&WI3=D+2N"&Q][
MG:/!) L^7!^T?R_8@66E([WQ]D]3I<WUZ'RD*JIU9].O?O<#]7A.65_I;91?
MM<M[3^<C578Q^:87A@>-<?E?W_=Q>"!P/OV$P+P7F(O?V9!X^:U.^N8J^)T*
MO!O:>"%011K.&<=)>9\"OAK(I9LWOFE,0I23TJY2;[Q+QJW)E8;BU23! N^;
ME+VVNZQM_@EM)^IG*-A$]9VKJ'HL/X%G@WOS@WMW\Q<5_JS#6)W,"C6?SD]>
MT'<RP#T1?2>?A1O_CU=]:V)I?>P"J;]O5S$%U,P_ST4A&UD\;X3[Z#*VNJ3K
M$1HE4MC2Z.:K+V9GTV]>@+ 8("Q>TOXRA.><?5'=\\Z^'*:?:*WMDW??!]^H
MA'95R<M_H7:$0MVK%2GCMMYNJ<)";74POHNJ,K'M$L4"+TO;55"EK-[%SO0V
M2ZM-@V4PD;]!-&U(^8"=8 ]5^BY$/-=JU6$#Q4>:M/1\1#.E#;@CMB !]LRX
M! + 0P<$;0"WA;0O%#6M]7O&6V3;P,;)YUWH_$0ACM6MV[,Y> &[O7?PPE9@
MM-6_; "P8*/T,=F]LA(EN@=]1H+X;_ ><6TUU 0J 03@E#5Z9:Q)>P;(T&$Z
M>FLJG1"O&E@17^B)"2]R0L#$O1.]:VJW(<>Z?(S*1/7!^9U#I$27J2A $["N
M],J2P.- ZL9W:/I2.\X0^#QZAPU[11'I8^M/7=XR(_:6#YNB(EUN$.Z2M7'D
M$5'C*Z4!KJH,9P'>&Y>/#^;AP4'V1%?_@N-$:W8??FZ-,'X&U7*2@H&IL?JQ
M!LB,F;6L/'([X$+@D6=P,0?R85P? XZ<0K'T O)"! [(CUA9594Y@K+/+309
M-B\J$?*@T1*##>X%[*+[Q 3KJ$29<O'B?:,_D'S\?,*=3Z#^:''F(L(2AR%>
M)G\>PL!9UXY??1+;HZ++XKD><X.BKS[OTUC]N3$PAQZOO ()4-#6<K-;0UL&
MIA-_W&@\Z(H^=I"$=G K=%%NDRWRV'"$*U/7J%*$*.U;RBGJ733,$.S24;;4
M(1@N>V:7BMP^J\((43!\WMS"^1(M:!INJ8&%!D=@ON[8WXB:C#47"53I!CJ4
MWFEN36B*E)(5O'W,$:T=_&3Q#2J37"Z45@MUL-NL)W;<$5E+YH<<!2Y=- ?B
MJ"OXRUT$V* -_TS0<RU+*)BD=*8S+L!C.E!\TF"@IJ'5[+XX.I%)JN!6@I^!
M,7&V\8T+$1$H>@=[Z.Q%(-!R[E2V=B!7)!P0@+WL F<*L6-5&N#!H!P1MIHY
M#\58$G&MQEP( 6$W@0X4=2P_B$F9YNH;XV31W%EO)1K'(RCS^A#H" DK48)\
M'QT^/408P6#.N)=JAU...;SN$A_JF)],TS5/98YZM00<0P>"=Y@Z!+5FVK68
M8*-Z)2<1CC"$)[Z^5'^1#NKMH+&'()*O O%<C->OU9=J45R<G?&'A3HK%N>R
M/,5R>7'!RS.U+.;+<UXNL5R<SIA_T<(U\]W)>;'$Q]]\XB.IQ_'8^TNUG!7+
MTW.X$/%@&CY?*SGR4$U)O9HOBN5B^KI7\C0(#SI.+9;%='90U&<<Y1:D+%[-
MB_EB^3HC/2:S +])#SS=#^0PO!0XZ!\>DZGZ6N>654.(>C?@;"-5CQIXFENF
M*WW,+FKP8GRJ]D@ TO[6]8D[RWF3 80$O 0!%<H'=;:BUX&DLU6+,:+33J:#
MW<9 'F([8^UQL\P==6W /3(IH8I+*3^4]NSD]$+=!:^KG48(WF-\@9^SY6PJ
M[3,[GTZ95'_!]>0O7$^*8:4.#N%HT,PPMSP.]$<81Q&3B>92"V:]!FT@""!6
MI%EP(3!\HK(/+F?8-)QQ;8*@2ISP%3,CWHFP'#5@SCT_;+7MJ!]F@,:MO[:&
MYS,=P7EJ'7S7RK2$EA@.#E5#>98L#I%"6U3$&0-'5'([JIC-6"MZUF,:E'3Q
MB-#)%*?E_.2#&#M+'3>J1E.IQE=DQ^J[1R<MG.F:-A-?%_/AQ)IE\X$39++A
MX>NAOEY^L(53F>>'!Q$NU'.3^.3!/:JAL);;HI"X2_E*-;P=+J2W^1YVW)YO
MLRC%-8XL%&X-T>EX>3I2(=\0\T/RK=S*,,7@CB?+#0YX"KP!WVOOT^&!#0S7
M])O_ %!+ P04    " #*.*I6=EM;,9(#   U"   &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6R55FUOXS8,_BN$-PP7P(L=VWE=$J#IW; !NU[1KCM@
MPSXH-AT+E26?)"?=OQ\E)VFR-;GMBR/)Y./G(2DR\YW2SZ9"M/!2"VD6065M
M,XLBDU=8,]-7#4IZ4RI=,TM;O8E,HY$5WJD641+'HZAF7 ;+N3^[U\NY:JW@
M$N\UF+:NF?YKA4+M%L$@.!P\\$UEW4&TG#=L@X]HGYI[3;OHB%+P&J7A2H+&
M<A'<#&:KS-E[@]\X[LS)&IR2M5+/;O-SL0AB1P@%YM8A,/K9XBT*X8"(QI<]
M9G#\I',\71_0?_3:2<N:&;Q5XC,O;+4()@$46+)6V >U^PGW>H8.+U?"^"?L
M.MLT#B!OC57UWID8U%QVO^QE'X<3A\DEAV3OD'C>W8<\R_?,LN5<JQUH9TUH
M;N&E>F\BQZ5+RJ/5]):3GUW>4=Y_4<; /6JX575-D7JLF,9Y9 G>&47Y'FK5
M0247H%+XJ*2M#'R0!1;G_A'1.G)+#MQ6R57 CTSW(1V$D,1)>@4O/6I-/5YZ
M >\#TY++3:?5BX0_;M;&:BJ-/]_2V\%E;\.YZS(S#<MQ$=!],*BW&"R_^V8P
MBG^X0C8[DLVNH?^_Q%R%>IOH17Q8,<-S8+* @HO68@&2;(6S;<@V[VR-M]TA
M/7(F\E8P9\D,E$K033?PCDNPE6H-(1G EQP;ZP$Z3U:K5EK3F\&OE48\JQV?
M</=(X*ZM43.K] SN#BR8M9JO6\O6 L$J^!VE98(;^!;>C=(P&4Q[;CF<AO%X
MW(/W*!7=G [DL[^FCNF6<#<(LJW71$J59\(,4 ,SEJA3P83NWO\C) 2>C,>0
M#<,DRUZI_2M Q&/0C\>];I$.>O"IU= H2YPY$Z^8U)O 8-YJ;CF:$'85SRO@
M,A=M@:=L@'I"_@RJ<5V-#%NY1>,H/3S>&(]W<O)DH"*EL$:4+@<.K(!2JYIR
M@XYJ0W'T_9$B\/5\4WZ='Y8E=55JN*TH")N^:OGW!QE]RBCNR\#Q/0!XVOBE
MY5LF2/U7F.UKRFG\;]36F+/6H//FN@N<GQQG)(^A/JO.7A^HUU"X#\VFJ[U/
MEX(.TW R'<(P3,<)/)W%?Y) ,AF?'E(*!N%P-((L36% RRR%41A/$WBK2T0G
MK9PJ?^,'EB&E=%FZKGX\/<[$FVX4O)IW Y4D;3B1%5B2:]P?#P/0W9#J-E8U
M?C"LE:4QXY<5S774SH#>EXK*=+]Q'SC^4UC^#5!+ P04    " #*.*I6.Q-6
M'E@#  !5!P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6R=56UOXS8,
M_BN$-PP;$-ANDGM!EP1(FAMVN"L6M-T&;-@'1:9CH;+D47+<_/M1<NS+;;UB
MVQ=;E,B'#TF16G26'EV%Z.&IUL8MD\K[YCK+G*RP%BZU#1H^*2W5PK-(A\PU
MA**(1K7.IGG^.JN%,LEJ$?=VM%K8UFME<$?@VKH6=-J@MMTRN4J&C3MUJ'S8
MR%:+1ASP'OW/S8Y8RD:40M5HG+(&",MELKZZWLR#?E3X16'G+M80(ME;^QB$
M]\4RR0,AU"A]0!#\.^(-:AV F,:?9\QD=!D,+]<#^@\Q=HYE+QS>6/VK*GRU
M3-XF4& I6NWO;/<CGN-Y%?"DU2Y^H>MU9ZPL6^=M?39F!K4R_5\\G?-P8? V
M_X+!]&PPC;Q[1Y'E5GBQ6I#M@((VHX5%##5:,SEE0E'N/?&I8CN_ND,M/!:P
M$^1/L%5.:NM:0K?(/,,'I4R>H38]U/0+4#.XM<97#MZ9 HO/[3.F-7*;#MPV
MTQ<!;P6E,+N:P#2?SE[ FXVQSB+>[%_%^D#".!'OAH/?UWOGB:4_GHN[AYT_
M#QO:YMHU0N(RX;YP2$=,5M]\=?4Z__X%TO.1]/PE]/]6H/\)!0]8-ZV##ZK>
M(^D3;+20CQVWR@1NTVTZ =L2W%0*2WCWA+(-G00_E:622"!, 0)J#+9@RZB[
ML8**(&P5<?]9<A/HA -.T%'9UK$/=JGMB>GL3X/_CV+/>N^-3.';I-]+OHOX
MAI,6,^N 401W<W%4SD9_O6(*#Q7"C:T;81C<>"3&5L9;)G<K',MPSPA,V<'Z
M0(@\6CQWFZ\&]\K %F4?!U^Y'-BV(7M4!4+!S06:C7D<F4/D%&HM2%:16("-
M% BA"Y^O\W3.#:MUG#VLKGCJ,0DE-)2(P9ML*7#DR3I"0(,4)NUG:0D*GH/S
M%;.&NF\R#$W&@04"0X]$/[R83@*Y!N/$TZ<4?HOY$/"!L\]!IK!IS2/2!';5
MW\I[+Q7K*J[L4-_)9>(ORAP8_;/,03A[2V$MI:6"\Z5/DZ@_E(<S&ITPZD M
MHM/YAC;AAJ;/=4]V,>IJI$,<Z ZD;8WOI]ZX.[X9ZWY4?E+O'QS.W4%Q[VLL
MV31/W[Q*@/HAW@O>-G%P[JWG,1R7%;][2$&!STMK_2 $!^-+NOH+4$L#!!0
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MTY):.VKG0/LKI>QVX1+T/XOT+U!+ P04    " #*.*I6DGD.@1X%  !?#@
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MP&$5^J(S(S1_71-@MJ$*G?0]7*&')\QH6=0<B* AI8,6>RC</URTA=DCM=\
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MIP/O7_1T]W"]?S2H2];4 ""P)M7XK,@#T#T1]QNK.D]^*V6)2OVRH;<+M;M
M\EHIN]\X \-KN/@)4$L#!!0    ( ,HXJE8QY#/@X (  %\&   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;(55VV[;, S]%<(KAA0P:L?.?4F )-VP
M 2L6M+L\#'M0;#H6*DNN)#?MOGZ4G;H)D&8/ED2)/#P417JZ4_K>Y(@6G@HA
MS<S+K2TG06"2' MFKE2)DDXRI0MF2=3;P)0:65H;%2*(PG 0%(Q+;SZM]]9Z
M/E65%5SB6H.IBH+IYR4*M9MY7>]EXY9O<^LV@OFT9%N\0_NC7&N2@A8EY05*
MPY4$C=G,6W0GRY[3KQ5^<MR9@S6X2#9*W3OA2SKS0D<(!2;6(3":'G&%0C@@
MHO&PQ_1:E\[P</V"_JF.G6+9,(,K)7[QU.8S;^1!BAFKA+U5N\^XCZ?O\!(E
M3#W"KM'MD<>D,E85>V.2"RZ;F3WM[^' 8!2^81#M#:*:=^.H9GG-+)M/M=J!
M=MJ$YA9UJ+4UD>/2)>7.:CKE9&?G:TWYU?89F$SAXT/%2[IQZX.D]]#YSC8"
MS>4TL.3)Z0?)'G79H$9OH,9PHZ3-#7R4*:;']@$Q;&E&+S27T5G &Z:O(.[Z
M$(51? 8O;L..:[SX/V'[L!9,VN/HX?=B8ZRF!_/G5.@-<N\TLBNBB2E9@C./
MJL2@?D1O_OY==Q!^.,.[U_+NG4.?WS6U RJ#,YD[Q?HL[FG61Q[P^&TDBNK2
M6$P=%9LC9$I0@7.YA0Z7M*,J0V;F<@*4NR2ODW>-"18;U&TFW1#!5[9YA8<+
MB/Q!?]S,[A2IZ'(E4N!%J=4C.BT#/7\T#NNQ"]^RC"=X@.$(9Y66W%8:"2<<
M]/?C2A5E98G"JW*W'];?BD*RNFJZ!<5 SK9T%X9(CB$>PEVUL<HR 6-_/(QI
M'!+>(DFJHA+,W42*='<)9TV[(0JL4-KRO\U&)_;#<7P)'4<DO(1SMWL! W\T
M"FD>^L.P#Z=>3G!0] 7J;=W:#"6FDK:I_W:W[9Z+IFF\JC>MES*TY=* P(Q,
MPZMAWP/=M+-&L*JL6\A&66I(]3*G/P!JIT#GF5+V17 .VG_*_!]02P,$%
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M]KQG+_#>"R/%4B&+)#1H"3Z7)&D'O[]S),P)"_OGD-R6=G28UBW+E:VX">.
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M\@#Y^992\7R3G\!7O[C,_P=02P,$%     @ RCBJ5K?ZPH+, @  =P@  !D
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M1>O_HXVY2MEO3VG/Q)'.68(3AS:]1K5")_KXH1MXGW< ]VK@WJ[LT661QJA
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M+JJRN:0O U1V CV?2VFV'7M;U=\:T1]02P,$%     @ RCBJ5NK5%45C @
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M84K7JQ>F8CE,*3:C ;T#FGW^-)Z$WX?\_B>R5^[CWGW\'GLV1]L-MP5>J9)
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MPFFJ6J8X\(+0 OA^Q[EZW.B1JAVA5S\!4$L#!!0    ( ,HXJE8/[;"3UP,
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M8B VO12]#X%V(V)MT7,+(1W$^+1%?Q&E"^N-!K0[C07-RTI@9M_&[207C\5
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MJLM*U5"\*,_[.5?Z]E ^KO0%#X0)T-\7G*OGAKE"-%?&^"]02P,$%     @
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MRMD3I5VE7]1\N5:N'"UR4CIS[L7USCDD+0&E82B:+4QDA(D@6W!'@](%DI:
MTC 4S=;%>.C0:PCG'^KBCO)&F+8RH6Z0%*T81ZM:UIQJ"Z%]W:$*!NJQ.]IV
M!0MGT6PZ"W<K&*B!AJ+9@A@+'?H]=(^FZR?U3O?H<-L%'1%#T>Q,&WL<^OTQ
MOETLFBN365$7J*)\24O97;FH:"F(/O64K#W[S.YJ29TB@)KCCF:+<!SMR@#J
MCJ%HM@S&'X=^@WS3*;!)L[X<7["ZE,Y\@_KECC;92G<T=IPC@5IA*)J=<&.&
M0Z^S:W_WU?.94<6S_0MV1]O'0T'X%RK;#9V*@/KECK9S!$S'NXJ 6F$HFJV(
M,<.AWTU^7*TH;QR"RGK&4MUF"WWGP-UF08WN@;E-NIDXSX1 K2X4S1;!F-W0
M[W:;"Z'.;(-Z6U!: DK#4#3[UI:QS%$ :1$B4+L,2DM :1B*9NMB/'7D]]0?
M6/FNNQ!'VQNM62DDKPO5'\11GRL<_H%Z2Q;N^P/7!0[043$4S1;#^.C(ZP=5
ME?KLK%+^L-ZI!37,H#0,1;,%,(8Y KWK'(%:8E!: DK#4#1;%^.;([]O!JQ2
MH+8ZVK_CK#9UE2E0;PU%L]4PWCKR>^L_UE2O47GQPJL_OG>2(6D)* U#T6PE
MC+V.)J#U"M1>@](24!J&HMFZ&!<>^5TX8+T"]=\=S;YO=#(.II/=>@7JP*%H
MMAK&@4=^E[MW&9P\D"PG=SG=O@Y^SXD2YZ >H/:\HUG](QX'H]E>_P UXU T
M6P]CQB._&6^6"*+K,JV7M#D@7FXCH.8<E): TC 4S5YJ:<QY#&K.8U!S#DI+
M0&D8BF;K8LQY_*/,N7^@WI(YS/EH.E:=9*=L@0Z+H6BV&L:=QWYW#ME&_$/U
MUB-RZ!%$>VJ 6G4HFJW&UOKP'WAOVS]6;SE@%Y##KB!WW'<?VX[5%L1X]-CO
MT:_:6TQM"_D/'32)?ESOG$/2$E :AJ+9PAB['H]!NSNH>0>E): T#$6S=3'F
M/3ZP>+SK(K5<,Y[]JRJ79.B.;M;TEZFJ;Y4Z>@Y6K\G>,3UV786Z\D^HMQB@
MCAV*9HMA''OL=^P+:XF(>;AE^QRK%DH6(I!<JQDT3ZGI!20D7]8YD=1]5O#<
M@9RZ.>^&!^-=U4!7F8/2,!3-5LTX^]CO[+N>TU:XR]VNH]YWZT^<V0=U\J"T
M!)2&H6BV2,;NQS/0_@/J^D%I"2@-0]'LQ_F,ZQ_Y5[&#]9_1_FKT4"^TVNT_
M_@GU%0.4AJ%HK1C#K6>@"\KO]</G0K66NI3M$\&;3S</N%_HQ[IW/K\*3Y/V
M,76#:9^:OR'\/BL%RNE*(8/C$Y5_WCZ(WKZ1K-)/6M\Q*5FA7ZXI4:(V&ZCO
M5XS)YS?- )O_#F#^/U!+ P04    " #*.*I63?TO8R$#  #&"P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970T,2YX;6S%5EUOVC 4_2M65E6MM#9?0&@+D8!V
M6Z550J7='J8]F.1"HB8QM0V4?[]K)Z0!I=$J4?4%;.?>XW..;YS;6S/^)"(
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M*P_Z-?(8^[,P7-B/IR(&PXP4X;<B_',B?!-X;16<@(?^M L^Z'HD>-""!^?
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M:&5E=#0W+GAM;*U5WV^;,!#^5RQ63:W4% ))NG8)4I-LVAZZ5>VZ/4Q[<.
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M>S,AVC'G %..EW@TWS"N2 IKA/1NQLA(EA-;N= BMT//B] X0MG;!*=<D"8
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #*.*I6!VFQ"QH$  "N(0
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MR,L'U1!4EP^:0-"D?- C!#V6#WJ"H*?R05,(FI8/DC'*."9(NL&:0&M!KH7
M:T&PA4!L0;*%P&Q!M(5 ;4&VA<!M0;B%0&Y!NH7 ;D&\A4!O1;V50&]%O95
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M'[_33U!+ 0(4 Q0    ( ,HXJE8'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ RCBJ5MURD]#N
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ RCBJ5IE<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " #*.*I6>N3M*_4%  #&'P  &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ RCBJ5M[I25MF!@  41H  !@              ("!. X  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ,HXJE:S+'I%!0,  %T*
M   8              " @=04  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " #*.*I6Z-9@%Y@$  #5$   &               @($/&
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ RCBJ5KUVI 0[
M P  M0D  !@              ("!W1P  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( ,HXJE;*U[:JXP8  %D=   8              "
M@4X@  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #*.*I6
MX(HE,%H(  #30P  &               @(%G)P  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ RCBJ5I4^WB=& P  -0<  !@
M     ("!]R\  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M ,HXJE9C]@P&)@@  ,04   8              " @7,S  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " #*.*I6;^)#-+<(  "S%@  &0
M            @('/.P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( ,HXJE;G-$#0C@4  .0,   9              " @;U$  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ RCBJ5BH5*9JW!@
MNA$  !D              ("!@DH  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " #*.*I6A&ANQ"X#   G!P  &0              @(%P
M40  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,HXJE;6
MZ%KL[P(  *H&   9              " @=54  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ RCBJ5LE+(6_A @  :@8  !D
M     ("!^U<  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,HXJE9X(KOO#@@  * 4   9              "
M@2MT  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ RCBJ
M5L&#SX>P @  . 8  !D              ("!<'P  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " #*.*I6DGD.@1X%  !?#@  &0
M        @(%7?P  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( ,HXJE8TT+(9-P,  !D'   9              " @:R$  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ RCBJ5C'D,^#@ @  7P8
M !D              ("!&H@  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " #*.*I6)*N!!>X"  !N!@  &0              @($QBP
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ,HXJE;EU(TA
MX00  )<,   9              " @5:.  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ RCBJ5GB7[FH" P  AP8  !D
M ("!;I,  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #*
M.*I6UN77Z8H#   ="   &0              @(&GE@  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( ,HXJE9XSSK]M@,   X1   9
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M970S,RYX;6Q02P$"% ,4    " #*.*I6ZM4516,"  #8!0  &0
M    @(&UK   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M ,HXJE9<I3O!> <  +)#   9              " @4^O  !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ RCBJ5C\[@*61 P  3@L  !D
M             ("!_K8  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    " #*.*I6#^VPD]<#  !A$P  &0              @('&N@  >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ,HXJE; <YVH9P(
M ,@%   9              " @=2^  !X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ RCBJ5JOIS)HM P  /@H  !D              ("!
M<L$  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #*.*I6
M54&8B9P'   :0   &0              @('6Q   >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( ,HXJE9-_2]C(0,  ,8+   9
M      " @:G,  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ RCBJ5EB;VP=? P  B X  !D              ("! =   'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " #*.*I6\CM7I)D#  "F#@
M&0              @(&7TP  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( ,HXJE8017&LMP(  'H&   9              " @6?7  !X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ RCBJ5BM*,%U[
M P  L0X  !D              ("!5=H  'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    " #*.*I61!E?6'8#  #G#   &0
M@($'W@  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( ,HX
MJE:T%CTRM@(   8'   9              " @;3A  !X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ RCBJ5KL\> \G P   PH  !D
M         ("!H>0  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
M    " #*.*I6-KS4WV,#  !##P  &0              @('_YP  >&PO=V]R
M:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( ,HXJE8=&]5AZ (  %$)
M   9              " @9GK  !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL
M4$L! A0#%     @ RCBJ5B-,*_LU P  2!,   T              ( !N.X
M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #*.*I6EXJ[',     3 @  "P
M            @ $8\@  7W)E;',O+G)E;'-02P$"% ,4    " #*.*I6!VFQ
M"QH$  "N(0  #P              @ $!\P  >&PO=V]R:V)O;VLN>&UL4$L!
M A0#%     @ RCBJ5CB#;R;$ 0  #1X  !H              ( !2/<  'AL
M+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ RCBJ5H"$^)W
M 0   !X  !,              ( !1/D  %M#;VYT96YT7U1Y<&5S72YX;6Q0
52P4&     #H .@#-#P  -?L

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>132</ContextCount>
  <ElementCount>215</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>39</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization and Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/OrganizationandBusiness</Role>
      <ShortName>Organization and Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Interim Unaudited Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/InterimUnauditedFinancialStatements</Role>
      <ShortName>Interim Unaudited Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Significant Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/SignificantTransactions</Role>
      <ShortName>Significant Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/BusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Prepaid Expenses and Other Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/PrepaidExpensesandOtherAssets</Role>
      <ShortName>Prepaid Expenses and Other Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/PropertyandEquipmentnet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/NetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Related Party Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/RelatedPartyDisclosures</Role>
      <ShortName>Related Party Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Interim Unaudited Financial Statements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies</Role>
      <ShortName>Interim Unaudited Financial Statements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Business Combinations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/BusinessCombinationsTables</Role>
      <ShortName>Business Combinations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/BusinessCombinations</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/FairValueMeasurement</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Prepaid Expenses and Other Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/PrepaidExpensesandOtherAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/PropertyandEquipmentnetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/PropertyandEquipmentnet</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/AccruedExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/StockholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Commitment and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/CommitmentandContingenciesTables</Role>
      <ShortName>Commitment and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/CommitmentandContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Net Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/NetLossPerCommonShareTables</Role>
      <ShortName>Net Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/NetLossPerCommonShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Significant Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/SignificantTransactionsDetails</Role>
      <ShortName>Significant Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/SignificantTransactions</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Business Combinations - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails</Role>
      <ShortName>Business Combinations - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Business Combinations - Reconciliation of Equity (Net Assets) Attributable to Noncontrolling Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails</Role>
      <ShortName>Business Combinations - Reconciliation of Equity (Net Assets) Attributable to Noncontrolling Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Fair Value Measurement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails</Role>
      <ShortName>Fair Value Measurement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Fair Value Measurement - Contractual Maturities of Available-for-sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Fair Value Measurement - Contractual Maturities of Available-for-sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Prepaid Expenses and Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Property and Equipment, net - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails</Role>
      <ShortName>Property and Equipment, net - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Property and Equipment, net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/PropertyandEquipmentnetNarrativeDetails</Role>
      <ShortName>Property and Equipment, net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/AccruedExpensesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Stockholders??? Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders??? Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Stockholders??? Equity - Share-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails</Role>
      <ShortName>Stockholders??? Equity - Share-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Stockholders??? Equity - Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders??? Equity - Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Stockholders??? Equity - Fair Value Assumptions for Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails</Role>
      <ShortName>Stockholders??? Equity - Fair Value Assumptions for Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Stockholders??? Equity - Fair Value Assumptions for ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails</Role>
      <ShortName>Stockholders??? Equity - Fair Value Assumptions for ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Stockholders??? Equity - Unrecognized Compensation Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails</Role>
      <ShortName>Stockholders??? Equity - Unrecognized Compensation Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Commitment and Contingencies - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Commitment and Contingencies - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Commitment and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails</Role>
      <ShortName>Commitment and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Net Loss Per Common Share - Calculation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails</Role>
      <ShortName>Net Loss Per Common Share - Calculation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Net Loss Per Common Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss Per Common Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="zntl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Related Party Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zentalis.com/role/RelatedPartyDisclosuresDetails</Role>
      <ShortName>Related Party Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.zentalis.com/role/RelatedPartyDisclosures</ParentRole>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrentAndNoncurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. zntl-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueFromRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. zntl-20230331.htm 4</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DueToRelatedPartiesCurrentAndNoncurrent -  zntl-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="zntl-20230331.htm">zntl-20230331.htm</File>
    <File>ex101-zntlxformofindemnifi.htm</File>
    <File>ex102-zntlxsublease_zental.htm</File>
    <File>zentalis10-qq12023ex311.htm</File>
    <File>zentalis10-qq12023ex312.htm</File>
    <File>zentalis10-qq12023ex321.htm</File>
    <File>zentalis10-qq12023ex322.htm</File>
    <File>zntl-20230331.xsd</File>
    <File>zntl-20230331_cal.xml</File>
    <File>zntl-20230331_def.xml</File>
    <File>zntl-20230331_lab.xml</File>
    <File>zntl-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>zntl-20230331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="492">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>71
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "zntl-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 492,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 132,
   "dts": {
    "calculationLink": {
     "local": [
      "zntl-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "zntl-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "zntl-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "zntl-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "zntl-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "zntl-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 339,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 6
   },
   "keyCustom": 15,
   "keyStandard": 200,
   "memberCustom": 8,
   "memberStandard": 26,
   "nsprefix": "zntl",
   "nsuri": "http://www.zentalis.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.zentalis.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Significant Transactions",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.zentalis.com/role/SignificantTransactions",
     "shortName": "Significant Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Business Combinations",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.zentalis.com/role/BusinessCombinations",
     "shortName": "Business Combinations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Fair Value Measurement",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.zentalis.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Prepaid Expenses and Other Assets",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.zentalis.com/role/PrepaidExpensesandOtherAssets",
     "shortName": "Prepaid Expenses and Other Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Property and Equipment, net",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.zentalis.com/role/PropertyandEquipmentnet",
     "shortName": "Property and Equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Accrued Expenses",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.zentalis.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Stockholders\u2019 Equity",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.zentalis.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Commitment and Contingencies",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.zentalis.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Net Loss Per Common Share",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.zentalis.com/role/NetLossPerCommonShare",
     "shortName": "Net Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Related Party Disclosures",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.zentalis.com/role/RelatedPartyDisclosures",
     "shortName": "Related Party Disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Interim Unaudited Financial Statements (Policies)",
     "menuCat": "Policies",
     "order": "20",
     "role": "http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies",
     "shortName": "Interim Unaudited Financial Statements (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "zntl:ReconciliationOfNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Business Combinations (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.zentalis.com/role/BusinessCombinationsTables",
     "shortName": "Business Combinations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "zntl:ReconciliationOfNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Fair Value Measurement (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.zentalis.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Prepaid Expenses and Other Assets (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsTables",
     "shortName": "Prepaid Expenses and Other Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Property and Equipment, net (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.zentalis.com/role/PropertyandEquipmentnetTables",
     "shortName": "Property and Equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.zentalis.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.zentalis.com/role/StockholdersEquityTables",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Commitment and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.zentalis.com/role/CommitmentandContingenciesTables",
     "shortName": "Commitment and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Net Loss Per Common Share (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.zentalis.com/role/NetLossPerCommonShareTables",
     "shortName": "Net Loss Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Significant Transactions (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.zentalis.com/role/SignificantTransactionsDetails",
     "shortName": "Significant Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i4df1e7317eb24fb4960e2db40e43b0ae_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i4817ffa176c043dcaa4bcc0e640d9ac8_D20171221-20171221",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Business Combinations - Narrative (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails",
     "shortName": "Business Combinations - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i4817ffa176c043dcaa4bcc0e640d9ac8_D20171221-20171221",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "ibc4b56c1868744f5b822318ab0a0bd57_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Business Combinations - Reconciliation of Equity (Net Assets) Attributable to Noncontrolling Interest (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails",
     "shortName": "Business Combinations - Reconciliation of Equity (Net Assets) Attributable to Noncontrolling Interest (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "zntl:ReconciliationOfNoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i6809bcb1666148168afab58d0ffe577e_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
     "shortName": "Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Fair Value Measurement - Narrative (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails",
     "shortName": "Fair Value Measurement - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Fair Value Measurement - Contractual Maturities of Available-for-sale Securities (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails",
     "shortName": "Fair Value Measurement - Contractual Maturities of Available-for-sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails",
     "shortName": "Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Prepaid Expenses and Other Assets (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails",
     "shortName": "Prepaid Expenses and Other Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Property and Equipment, net - Summary (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails",
     "shortName": "Property and Equipment, net - Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Property and Equipment, net - Narrative (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.zentalis.com/role/PropertyandEquipmentnetNarrativeDetails",
     "shortName": "Property and Equipment, net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "zntl:AccruedResearchAndDevelopmentCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.zentalis.com/role/AccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "zntl:AccruedResearchAndDevelopmentCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Stockholders\u2019 Equity - Narrative (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders\u2019 Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i037f9049a8294a5c99bf21de04775e11_D20230101-20230331",
      "decimals": null,
      "lang": "en-US",
      "name": "zntl:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Stockholders\u2019 Equity - Share-based Compensation (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails",
     "shortName": "Stockholders\u2019 Equity - Share-based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "icc1a500ef2574f02955ba6e37b2c81ac_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Stockholders\u2019 Equity - Share-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails",
     "shortName": "Stockholders\u2019 Equity - Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i037f9049a8294a5c99bf21de04775e11_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i037f9049a8294a5c99bf21de04775e11_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Stockholders\u2019 Equity - Fair Value Assumptions for Stock Options (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails",
     "shortName": "Stockholders\u2019 Equity - Fair Value Assumptions for Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i037f9049a8294a5c99bf21de04775e11_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i45742a89bf3246eb9070cc158debe73f_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Stockholders\u2019 Equity - Fair Value Assumptions for ESPP (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails",
     "shortName": "Stockholders\u2019 Equity - Fair Value Assumptions for ESPP (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i45742a89bf3246eb9070cc158debe73f_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "ia9df9a5968b2476b88207ca1aa4feb7a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Stockholders\u2019 Equity - Unrecognized Compensation Cost (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails",
     "shortName": "Stockholders\u2019 Equity - Unrecognized Compensation Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "ia9df9a5968b2476b88207ca1aa4feb7a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Commitment and Contingencies - Future Minimum Lease Payments (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails",
     "shortName": "Commitment and Contingencies - Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Commitment and Contingencies - Narrative (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails",
     "shortName": "Commitment and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3e95cef051ea47c385703716fa2a0497_I20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Net Loss Per Common Share - Calculation (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails",
     "shortName": "Net Loss Per Common Share - Calculation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Net Loss Per Common Share - Antidilutive Securities (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails",
     "shortName": "Net Loss Per Common Share - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i7c81d5274f084d8ca588db925f2f294d_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "zntl:ResearchAndDevelopmentExpenseReimbursements",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Related Party Disclosures (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails",
     "shortName": "Related Party Disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i4be5fa9930e7403c9c0f8ba0f46352fe_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i8fd115a5bb984e3b9b063c8e4aa9ff7a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "i3ceba3c1b5264b9e942aad44dfafc886_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Organization and Business",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.zentalis.com/role/OrganizationandBusiness",
     "shortName": "Organization and Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Interim Unaudited Financial Statements",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.zentalis.com/role/InterimUnauditedFinancialStatements",
     "shortName": "Interim Unaudited Financial Statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zntl-20230331.htm",
      "contextRef": "id5d00801af3d4ee59eee8a5043cc34a1_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 39,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.zentalis.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r451",
      "r527",
      "r559",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r183",
      "r344",
      "r345",
      "r348",
      "r349",
      "r376",
      "r451",
      "r520",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r183",
      "r344",
      "r345",
      "r348",
      "r349",
      "r376",
      "r451",
      "r520",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails",
      "http://www.zentalis.com/role/SignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r299",
      "r410",
      "r439",
      "r452",
      "r453",
      "r469",
      "r475",
      "r481",
      "r525",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r299",
      "r410",
      "r439",
      "r452",
      "r453",
      "r469",
      "r475",
      "r481",
      "r525",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r291",
      "r299",
      "r325",
      "r326",
      "r327",
      "r383",
      "r410",
      "r439",
      "r452",
      "r453",
      "r469",
      "r475",
      "r481",
      "r518",
      "r525",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r291",
      "r299",
      "r325",
      "r326",
      "r327",
      "r383",
      "r410",
      "r439",
      "r452",
      "r453",
      "r469",
      "r475",
      "r481",
      "r518",
      "r525",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails",
      "http://www.zentalis.com/role/SignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r8",
      "r480"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "(Accretion of discounts)/amortization of premiums on marketable securities, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r0",
      "r122",
      "r132"
     ],
     "calculation": {
      "http://www.zentalis.com/role/AccruedExpensesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.zentalis.com/role/AccruedExpensesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.zentalis.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      },
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "verboseLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/AccruedExpensesDetails",
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.zentalis.com/role/AccruedExpensesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued legal expenses"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r59",
      "r150"
     ],
     "calculation": {
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r158",
      "r433",
      "r444",
      "r445"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r18",
      "r21",
      "r102",
      "r369",
      "r440",
      "r441",
      "r495",
      "r496",
      "r497",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r3",
      "r480"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r502",
      "r503",
      "r504",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r83",
      "r84",
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails",
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per unit (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r33",
      "r57"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Operating lease right-of-use asset and fixed asset impairment"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r121",
      "r131",
      "r152",
      "r181",
      "r220",
      "r223",
      "r225",
      "r237",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r344",
      "r348",
      "r358",
      "r480",
      "r521",
      "r522",
      "r562"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r146",
      "r159",
      "r181",
      "r237",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r344",
      "r348",
      "r358",
      "r480",
      "r521",
      "r522",
      "r562"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total fair value of assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r228",
      "r245"
     ],
     "calculation": {
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r507",
      "r508",
      "r573"
     ],
     "calculation": {
      "http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r50",
      "r227",
      "r245",
      "r425"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Marketable securities, available-for-sale",
        "verboseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails",
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails",
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails",
      "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r341",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r88",
      "r89",
      "r341",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r90",
      "r91",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Cash payments to acquire interest"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r93",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accrued capital expenditures"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r35",
      "r148",
      "r455"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r30",
      "r35",
      "r39"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash reported in the Condensed Consolidated Statement of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r30",
      "r117"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r181",
      "r199",
      "r200",
      "r202",
      "r204",
      "r211",
      "r212",
      "r237",
      "r261",
      "r264",
      "r265",
      "r266",
      "r270",
      "r271",
      "r274",
      "r275",
      "r278",
      "r282",
      "r289",
      "r358",
      "r454",
      "r488",
      "r499",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "netLabel": "Commercial paper",
        "terseLabel": "Commercial paper",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r14",
      "r126",
      "r137"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r62",
      "r255",
      "r256",
      "r447",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]",
        "terseLabel": "Common Class B"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r502",
      "r503",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r2",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r2",
      "r480"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 250,000,000 shares authorized; 59,442,342 and 59,280,247 shares issued and outstanding at March\u00a031, 2023 and December 31, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r22",
      "r165",
      "r167",
      "r173",
      "r428",
      "r436"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Zentalis"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r97",
      "r98",
      "r111",
      "r165",
      "r167",
      "r172",
      "r427",
      "r435"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive loss attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r96",
      "r111",
      "r165",
      "r167",
      "r171",
      "r426",
      "r434"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r99",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r470",
      "r472",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r234",
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "terseLabel": "Gross unrealized loss position for more than one year"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r514"
     ],
     "calculation": {
      "http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Number of available-for-sale securities in unrealized loss position for more than one year"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r234",
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "terseLabel": "Gross unrealized loss position for less than one year"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "auth_ref": [
      "r514"
     ],
     "calculation": {
      "http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "terseLabel": "Number of available-for-sale securities in unrealized loss position for less than one year"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Components of Available-for-sale Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r232",
      "r246",
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Fair market value of available-for-sale securities in unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r233",
      "r247"
     ],
     "calculation": {
      "http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "totalLabel": "Number of available-for-sale securities in unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "terseLabel": "Gain on deconsolidation of Zentera, net of tax"
       }
      }
     },
     "localname": "DeconsolidationGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/SignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Summary of Prepaid Expenses and Other Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates": {
     "auth_ref": [
      "r86",
      "r555"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated.",
        "label": "Deferred Tax Liabilities, Investment in Noncontrolled Affiliates",
        "terseLabel": "Deferred tax liability, deconsolidation of Zentera"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/SignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r33",
      "r217"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.zentalis.com/role/PropertyandEquipmentnetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r76",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "terseLabel": "Share-based Compensation Expense by Type of Share-based Award"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r157",
      "r263",
      "r264",
      "r265",
      "r269",
      "r270",
      "r271",
      "r373",
      "r456",
      "r501"
     ],
     "calculation": {
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from Related Parties, Current",
        "terseLabel": "Zentera receivable"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r125",
      "r138",
      "r263",
      "r264",
      "r265",
      "r269",
      "r270",
      "r271",
      "r373",
      "r501"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r174",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r197",
      "r199",
      "r202",
      "r203",
      "r204",
      "r208",
      "r353",
      "r354",
      "r429",
      "r437",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share outstanding, basic (in dollars per share)",
        "verboseLabel": "Net loss per common share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r174",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r199",
      "r202",
      "r203",
      "r204",
      "r208",
      "r353",
      "r354",
      "r429",
      "r437",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share outstanding, diluted (in dollars per share)",
        "verboseLabel": "Net loss per common share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.zentalis.com/role/AccruedExpensesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued employee expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Remaining Weighted-Average Recognition Period (years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r554"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized expense, other than options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r554"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized expense, stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan",
        "verboseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails",
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails",
      "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "netLabel": "Outstanding stock options",
        "terseLabel": "Stock Options",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails",
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails",
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails",
      "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "EQUITY"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r67",
      "r143",
      "r168",
      "r169",
      "r170",
      "r184",
      "r185",
      "r186",
      "r188",
      "r194",
      "r196",
      "r210",
      "r239",
      "r290",
      "r331",
      "r332",
      "r333",
      "r337",
      "r338",
      "r352",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r369",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/SignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r54",
      "r221",
      "r490"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investment in Zentera Therapeutics"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.zentalis.com/role/SignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Significant Transactions"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/SignificantTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails",
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails",
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r115",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r272",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r356",
      "r380",
      "r381",
      "r382",
      "r467",
      "r468",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r272",
      "r292",
      "r297",
      "r356",
      "r380",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r272",
      "r292",
      "r297",
      "r356",
      "r381",
      "r467",
      "r468",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r272",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r380",
      "r381",
      "r382",
      "r467",
      "r468",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r229",
      "r230",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r248",
      "r250",
      "r251",
      "r273",
      "r287",
      "r350",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r464",
      "r510",
      "r511",
      "r512",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r151",
      "r252",
      "r424",
      "r466",
      "r480",
      "r516",
      "r517"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r53",
      "r129",
      "r231",
      "r431"
     ],
     "calculation": {
      "http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r220",
      "r222",
      "r224",
      "r226",
      "r463"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r23",
      "r33",
      "r54",
      "r127",
      "r139",
      "r218"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Loss on equity method investment",
        "negatedTerseLabel": "Loss on equity method investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r182",
      "r195",
      "r196",
      "r219",
      "r336",
      "r339",
      "r340",
      "r438"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Contractual Maturities of Available-for-sale Debt Securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Operating Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r368"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments:"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r368"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r368"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r368"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r368"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r558"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2023 (remaining)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r368"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r10",
      "r181",
      "r237",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r345",
      "r348",
      "r349",
      "r358",
      "r462",
      "r521",
      "r562",
      "r563"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r7",
      "r124",
      "r135",
      "r480",
      "r500",
      "r513",
      "r557"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES\u00a0AND\u00a0STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r147",
      "r181",
      "r237",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r345",
      "r348",
      "r349",
      "r358",
      "r480",
      "r521",
      "r562",
      "r563"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r17",
      "r123",
      "r134",
      "r181",
      "r237",
      "r261",
      "r264",
      "r265",
      "r266",
      "r270",
      "r271",
      "r358"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "periodEndLabel": "Noncontrolling interest at end of period",
        "periodStartLabel": "Noncontrolling interest at beginning of period",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails",
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInMinorityInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]"
       }
      }
     },
     "localname": "MovementInMinorityInterestRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r178"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r178"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r30",
      "r31",
      "r34"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r24",
      "r34",
      "r128",
      "r140",
      "r145",
      "r163",
      "r166",
      "r170",
      "r181",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r195",
      "r196",
      "r201",
      "r220",
      "r222",
      "r224",
      "r226",
      "r237",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r354",
      "r358",
      "r463",
      "r521"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss attributable to Zentalis",
        "totalLabel": "Net loss attributable to Zentalis"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r100",
      "r110",
      "r163",
      "r166",
      "r195",
      "r196",
      "r497"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to noncontrolling interests",
        "verboseLabel": "Net loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails",
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of\u00a0non-cash\u00a0investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r94",
      "r290",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other Income (Expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses [Abstract]",
        "terseLabel": "Operating Expenses"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r220",
      "r222",
      "r224",
      "r226",
      "r463"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.zentalis.com/role/AccruedExpensesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      },
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Less: current portion",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/AccruedExpensesDetails",
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability, net of current portion",
        "verboseLabel": "Long-term lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails",
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease\u00a0right-of-use\u00a0assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r367",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r40",
      "r41",
      "r46",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization and Business"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/OrganizationandBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "Other Assets Disclosure [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Assets"
       }
      }
     },
     "localname": "OtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r160",
      "r161",
      "r162"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r96",
      "r97",
      "r101",
      "r164",
      "r167"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.zentalis.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      },
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "verboseLabel": "Less long-term portion"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/AccruedExpensesDetails",
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r27",
      "r49",
      "r175"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r1",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r1",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r1",
      "r480"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March\u00a031, 2023 and December 31, 2022"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "totalLabel": "Total prepaid expenses and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r494"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "verboseLabel": "Total prepaid expenses and other assets, current"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "auth_ref": [
      "r120",
      "r130",
      "r492"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Noncurrent",
        "terseLabel": "Prepaid expenses and other assets",
        "verboseLabel": "Less long-term portion"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r458",
      "r465",
      "r515"
     ],
     "calculation": {
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r29",
      "r82"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under equity incentive plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r49",
      "r175",
      "r176"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r145",
      "r163",
      "r166",
      "r177",
      "r181",
      "r187",
      "r195",
      "r196",
      "r220",
      "r222",
      "r224",
      "r226",
      "r237",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r343",
      "r346",
      "r347",
      "r354",
      "r358",
      "r430",
      "r463",
      "r477",
      "r478",
      "r497",
      "r521"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Consolidated net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r61",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r58",
      "r149"
     ],
     "calculation": {
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Subtotal"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r60",
      "r136",
      "r432",
      "r480"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r298",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r142",
      "r372",
      "r373",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r298",
      "r372",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r370",
      "r371",
      "r373",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Disclosures"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r85",
      "r141",
      "r570"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r489",
      "r498",
      "r571",
      "r574"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash equivalents:"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r446",
      "r491",
      "r498"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "RSAs",
        "verboseLabel": "Unvested RSAs"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails",
      "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs",
        "verboseLabel": "Unvested RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails",
      "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r4",
      "r74",
      "r133",
      "r443",
      "r445",
      "r480"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r143",
      "r184",
      "r185",
      "r186",
      "r188",
      "r194",
      "r196",
      "r239",
      "r331",
      "r332",
      "r333",
      "r337",
      "r338",
      "r352",
      "r440",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Unit"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Loss Per Unit"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/SignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r56",
      "r145",
      "r181",
      "r237",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/SignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r300",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails",
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails",
      "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions, ESPP"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r64",
      "r65",
      "r66",
      "r68",
      "r69",
      "r70",
      "r71",
      "r72",
      "r73",
      "r74",
      "r154",
      "r155",
      "r156",
      "r211",
      "r274",
      "r275",
      "r276",
      "r278",
      "r282",
      "r287",
      "r289",
      "r469",
      "r488",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r344",
      "r345",
      "r348",
      "r349",
      "r391",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "verboseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails",
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationDetails",
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails",
      "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "ESPP maximum percent of compensation to contribute"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r77",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "terseLabel": "Non-option equity instruments, outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized to be issued under plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for future grants (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails",
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails",
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails",
      "http://www.zentalis.com/role/StockholdersEquityUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Average expected term (in years)",
        "verboseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforESPPDetails",
      "http://www.zentalis.com/role/StockholdersEquityFairValueAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "ESPP purchase price of common stock, percent of market price"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r40",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Interim Unaudited Financial Statements"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/InterimUnauditedFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r181",
      "r199",
      "r200",
      "r202",
      "r204",
      "r211",
      "r212",
      "r237",
      "r261",
      "r264",
      "r265",
      "r266",
      "r270",
      "r271",
      "r274",
      "r275",
      "r278",
      "r282",
      "r289",
      "r358",
      "r454",
      "r488",
      "r499",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r16",
      "r67",
      "r143",
      "r168",
      "r169",
      "r170",
      "r184",
      "r185",
      "r186",
      "r188",
      "r194",
      "r196",
      "r210",
      "r239",
      "r290",
      "r331",
      "r332",
      "r333",
      "r337",
      "r338",
      "r352",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r369",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r210",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r1",
      "r2",
      "r67",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r1",
      "r2",
      "r67",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedTerseLabel": "Cancellation of restricted stock awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r67",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Shares issued upon vesting of certain RSAs (in shares)",
        "verboseLabel": "Issuance of common stock in connection with restricted stock unit vesting (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r1",
      "r2",
      "r67",
      "r74",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock upon exercise of options, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r1",
      "r2",
      "r67",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Shares issued under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r1",
      "r2",
      "r67",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of common stock in connection with restricted stock unit vesting"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r67",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of options, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r47",
      "r480",
      "r500",
      "r513",
      "r557"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r94",
      "r95",
      "r109",
      "r143",
      "r144",
      "r169",
      "r184",
      "r185",
      "r186",
      "r188",
      "r194",
      "r239",
      "r290",
      "r331",
      "r332",
      "r333",
      "r337",
      "r338",
      "r352",
      "r359",
      "r360",
      "r364",
      "r369",
      "r441",
      "r442",
      "r500",
      "r513",
      "r557"
     ],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r75",
      "r180",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r290",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TradingSecuritiesDebt": {
     "auth_ref": [
      "r48",
      "r153",
      "r227",
      "r457"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Debt Securities, Trading",
        "terseLabel": "Debt securities fair market value"
       }
      }
     },
     "localname": "TradingSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r229",
      "r230",
      "r273",
      "r287",
      "r350",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r510",
      "r511",
      "r512",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Available-for-sale marketable securities:"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r460",
      "r470",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "US Government Agencies",
        "verboseLabel": "US Government Agencies"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r460",
      "r470",
      "r472",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "US Treasury",
        "verboseLabel": "US Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
      "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r43",
      "r44",
      "r45",
      "r213",
      "r214",
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r104",
      "r344",
      "r345",
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "VIE, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsReconciliationofEquityNetAssetsAttributabletoNoncontrollingInterestDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r198",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Common shares used in computing net loss per share, diluted (in shares)",
        "verboseLabel": "Weighted average number of common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r197",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Common shares used in computing net loss per share, basic (in shares)",
        "verboseLabel": "Weighted average number of common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "zntl_A2020IncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Incentive Award Plan",
        "label": "2020 Incentive Award Plan [Member]",
        "terseLabel": "The 2020 Plan"
       }
      }
     },
     "localname": "A2020IncentiveAwardPlanMember",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "zntl_A2022EmploymentInducementIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Employment Inducement Incentive Award Plan",
        "label": "2022 Employment Inducement Incentive Award Plan [Member]",
        "terseLabel": "2022 Inducement Plan"
       }
      }
     },
     "localname": "A2022EmploymentInducementIncentiveAwardPlanMember",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "zntl_AccruedGeneralAndAdministrativeCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/AccruedExpensesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued General And Administrative Costs, Current",
        "label": "Accrued General And Administrative Costs, Current",
        "terseLabel": "Accrued general and administrative expenses"
       }
      }
     },
     "localname": "AccruedGeneralAndAdministrativeCostsCurrent",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/AccruedExpensesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research And Development Costs, Current",
        "label": "Accrued Research And Development Costs, Current",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_EarningsPerShareDenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share, Denominator",
        "label": "Earnings Per Share, Denominator [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareDenominatorAbstract",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "zntl_EarningsPerShareNumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share, Numerator",
        "label": "Earnings Per Share, Numerator [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareNumeratorAbstract",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/NetLossPerCommonShareCalculationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "zntl_ForeignResearchAndDevelopmentCreditRefund": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Research and Development Credit Refund",
        "label": "Foreign Research and Development Credit Refund",
        "terseLabel": "Foreign R&amp;D credit refund"
       }
      }
     },
     "localname": "ForeignResearchAndDevelopmentCreditRefund",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Right-Of-Use Assets And Liabilities, Net",
        "label": "Increase (Decrease) In Operating Lease Right-Of-Use Assets And Liabilities, Net",
        "terseLabel": "Operating lease right-of-use assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_InvestmentAndOtherIncomeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment and Other Income (Expense)",
        "label": "Investment and Other Income (Expense)",
        "terseLabel": "Investment and other income, net"
       }
      }
     },
     "localname": "InvestmentAndOtherIncomeExpense",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_KalyraPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kalyra Pharmaceuticals, Inc.",
        "label": "Kalyra Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Kalyra Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "KalyraPharmaceuticalsIncMember",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "zntl_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "zntl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, Due After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_MasterServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master Services Agreement",
        "label": "Master Services Agreement [Member]",
        "terseLabel": "Master Services Agreement"
       }
      }
     },
     "localname": "MasterServicesAgreementMember",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "zntl_OfficeEquipmentAndFurnitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Equipment And Furniture",
        "label": "Office Equipment And Furniture [Member]",
        "terseLabel": "Office equipment and furniture"
       }
      }
     },
     "localname": "OfficeEquipmentAndFurnitureMember",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "zntl_OtherPrepaidExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Prepaid Expense",
        "label": "Other Prepaid Expense",
        "terseLabel": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpense",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_PrepaidResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Research And Development Costs",
        "label": "Prepaid Research And Development Costs",
        "terseLabel": "Prepaid research and development expenses"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentCosts",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_PrepaidSoftwareLicenseAndMaintenance": {
     "auth_ref": [],
     "calculation": {
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Software License And Maintenance",
        "label": "Prepaid Software License And Maintenance",
        "terseLabel": "Prepaid software licenses and maintenance"
       }
      }
     },
     "localname": "PrepaidSoftwareLicenseAndMaintenance",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_ReconciliationOfNoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation Of Noncontrolling Interest",
        "label": "Reconciliation Of Noncontrolling Interest [Table Text Block]",
        "terseLabel": "Reconciliation of Equity Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "ReconciliationOfNoncontrollingInterestTableTextBlock",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "zntl_ResearchAndDevelopmentExpenseReimbursements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Expense, Reimbursements",
        "label": "Research and Development Expense, Reimbursements",
        "terseLabel": "Contra-research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseReimbursements",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails",
      "http://www.zentalis.com/role/SignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Awards And Restricted Stock Units",
        "label": "Restricted Stock Awards And Restricted Stock Units [Member]",
        "terseLabel": "RSAs and RSUs"
       }
      }
     },
     "localname": "RestrictedStockAwardsAndRestrictedStockUnitsMember",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquitySharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Generally Expected Term",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Generally Expected Term",
        "terseLabel": "Generally expected vesting term of the option contract (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount",
        "terseLabel": "Maximum contribution amount"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Shares Authorized, Percent Threshold Used To Calculate Increase",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Shares Authorized, Percent Threshold Used To Calculate Increase",
        "terseLabel": "Percent of common stock outstanding used as threshold to calculate shares available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period",
        "terseLabel": "Offering period (in months)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "zntl_ZenteraTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zentera Therapeutics",
        "label": "Zentera Therapeutics [Member]",
        "terseLabel": "Zentera"
       }
      }
     },
     "localname": "ZenteraTherapeuticsMember",
     "nsuri": "http://www.zentalis.com/20230331",
     "presentation": [
      "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails",
      "http://www.zentalis.com/role/SignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269825-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r482": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r483": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r484": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r485": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r486": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r487": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>72
<FILENAME>0001725160-23-000113-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001725160-23-000113-xbrl.zip
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M63:25]MH_(Y?FV_7\AVO-G\R FU.98&ZG"L.I :M[4@FL<XW(Z%:KM"82:3
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M05^DW-.%9(1\Z5C;&)VKW-EM5$-+U>AVY3U1Q(TGMFB30*9G&#ET/7D[*-=
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ML X0C\T7OO;0G&?VAT<.)J\-Q:#Y%X@PE^B:'"[G(9@J9V2>/MU3# 02=%I
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MG<AM],LFR7"?10>GA_K6GF6PCP3U>G:+>]OT8O?.1VPQ= :+,(0V1S _,NF
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M PS&+0D^:L4:-!'(9$U4#IWZ/V,2'!(K3P,6SDRK 3129C,R+.=.XW@?TAO
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MS;"IS, YE\"HUS4:X7;2I5TC3-": A\\E_[/=7!1+'BD8A>\1P.&_V?:>^D
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M*(/$;+E)9\<8+9!:[%I9K+.,#I#S-%D_52HEGYL3Y:Y81GKTI!>$TQTMO<D
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MQJB6@C_L;CX!H1HOH\Z7.IP^VR%> K)NA)>VPQ,Z.4GYMKG^'AUK0M? &]L
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M1C!@JX[.45!*I=*(IDE:#T(BR/R?\@:H*18T.>UZ(*J&?\?U"?+\<JN4,><
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MKH6+=+DJ:I\ZI10JA0W+5JCQ*O!K]$[59:6F]TDE*=6VA]Q6-RQ E=9@MVY
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M=X<[!/3!Z]F*N2/&9!XES25/6=I<1>J2LBS6OD%]K.G8A7446M9(I1<)WSU
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M'^0X4FQV<LS$A CVMB8&_79[<'3PIM\;\#[K=X]8OW,8Q<F@V^Y$AT<'_^G
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M!;I0GMC1,-=+LS^:()K05)$TX2QQW(-XH8C&R'&?0!>P/)Y@^87T=BX3#:_
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M BE !PPH@9#EC-I,,,>-4#3+$F7 HEX! CWS&C0_6E%BB.5:FY0J9A$74B6
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M9BPC3B&NTHQ)X03%OOPJ(,(4LW09*B5]EQKT)].-AK98-OC'<:JXD8*"$<=
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M0]N-\*KJKI]GX6?KRW>P< :Z:^H8#64WRS21WS[VY,CD0VM^7SHU5O/ =_,
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M 4=F:QL??$)=/@RQ]$$%P0^=R7>OP3K]P<CG3VRJ_F@XJ72[EP^^UFII99B
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MWM+(M<>R_@%O@<WFI<XZ8Z:\4CIB2NP^4S%Z$J_O+Y_FE7/R>]Q:-9?\*)>
M]'HB >J"M23W116!7CT[!(09@!$03H>[[,G4'7(V*<-5)M24YQM4Z,:7[+J]
M)5>=? !_05_98'J5]*\I_<B4#D5-*^LWA/IZ3YX7[9LUW3T92\]#E: \X[7<
M<9.0[U%ODOY62&\1AV-')BV$%<=O7E2GK/3+ -.3X65*WOJD%(@*_*!+T&P
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M]GQGG&?N37^01[$]&@W:;CRRKA,/^A=9VSE&%>-F50!VN-RY+-B8O..(,0D
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MJ*D@_1K1P@+I-8'TY79:V&H1)96(.P;LS3J#'!$)?O!@*35$<X!TIIL&+_<
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M9KG$?X'# H=K"H<W.64937(Q:$4$XSQ8YY@T# ,@ @>DTOX"#\M9]QIA'UO
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MZ'X/E :NULO3T8'K@S).?"+GG]]LO(R#D:UFH')#5+QPHLGG&-.UH;*/JI'
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M>@*KGL"ZE. $.!4A4\4 ]5D45ADJD.RRYYY*5VN4+#_1S6G-:Y2UW$8B32E
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MJ)@<<> #D9$[8HW/Q"F;;=8J>*56UI0U-7FADN 3)\$EX,#GG+QP;QPXG;Q
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M1''N$,PVDL"U(33)8()6R35=M<6JL<O4I:.B>M'5Z1"^,FG\'A@I4$_+;-"
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M]=+<;+N[O?[[;OL3HO$DGGQ&*\8G&B6Q/#DBK74(/W1<=8P*!2HPM&RF^\"
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M@<*R,KGQ'S80#95V\GPZ%)\=X9:_8KA\:W_GAQ$%5NB8AFH&C*F6'CEJ $Q
M#1$U)#)8$%C!?'>IV.&Z%06198();5N1[QJQ;83<C3E8UVZX *\_1\Z-K%/A
M9J[Z8HLOC[&A]0:VU\'&5?PGS\(DY\H8EB2*KD3K6+G@HKM0DC?;%H>#-$<,
M_O)GM_8QD@UH(Y"I^#P-+)IGQ2S)E$N@>5ZV;!:OET5?^.Y\D@RI4T#;,,J4
MYH*?OQ\ :U?ALJ4#V*AA&O%!5]F%D>6\YZ<X2(;4_CP=<X3A@E'Z"<PWFPF$
M+@6'DWUUQ]0W?0RR/0;^(!Y#9BX:00_'@P3&N4RQ*=T >^G!%%FC86"YBIR*
MW8B":L^+.C>YOMKPM4=@(DQ!P36FDX*Y#U@FYY; L),^FRC81F$,0BL)!S-E
MDK&(1V*?V\?$:9:=%J;42:K<S8@!U37/.B][!^9\(-90OK_H_2?[G433K!@(
MVPM>8D_AB3*F[A\%R81%,^BHVA/L(5QV-D;::?1#$6LIMG2:T[++AH@Y'42,
M1S'DDWX:R6Z(-&NY_^6DYE]8-#$LJ!\[*/*,8T7BPN-T&\2K699,^O VH H&
M$IZ=E1?B$M^(;\-?()G@AW $9]2%&1D5JBMTK6IKEL3_]DQ@Q<$)W"2;[I7R
M_!A=OS_"M45)Q6M2ZE,QY3VY64>PKH:2#,PJ_!TH QM+OS8IMAMJH-9R(]+T
MT+54W0E\U0I8#/1M:*IGNIZG1[$1:R&JM?.2B'IQY[\)^L^2_$*-L2PNP=(D
MH#,E0Y8(O++!1XZ[W^ 'V&8=MER9)7P0T55@Q3T$6LJ!+S0Z<[;>1$F5R4CA
M<8R-LX#5X.=PI4IZKS'UXH)B&\11.J$6=GB'X2,0C@G(ODB(TRCEX@GQ5F34
M]&SML?12-D""F\V;\P%V@-%?[*\X'4R:[!9?70D.XF=R2+D1\*J +^_C-9(=
MV1ZSPN Q&WJU7<#BWNW*E1["VIM&:IS\Y)%ZS;/TU3;UZL&[$2 F# V-.;:J
M!QYZZCRXB' %5=NR33^P_<"UC3?O<*<6K,NNTM[[]'9M<Z[WJ<5#.W"Y'F@:
MO!5>BT$]$%@N=UV'N4)):RI(I5A<4-)J G=");-#43++L62VK94B7<#%SPW2
M!R*.UQ^TQJCB#%7S)5;1W.\MS7NWO7V7]_9U-[>W[ZV]>N?HFS//CEQ,/;$=
MRP]T!O<AC'TWL(%W>OJ]VIFU3^S6B_3,: ^NU?5,_SYH#Y;5]4WO\0$4[*YE
MK]PSZP[?.;;S-).U5AKV\6KS-ZH O 0_4%8LN7\5&]&LB7^FU,>G6?VJ=1V+
MGH1[X2\\<.GM<I:\WNL6/'H*M7XA?/0D2OT_Y1&C6K^?C)+A=%AJ\:JQF6J\
M"#.=1S"O$VW_'.:W"_\]^GJ-<^L9QU<'GPX'!T?1X 01RHQC:S[,!,]HI^=?
M9_O#8ZUW_O5G;[=WT=N],$]Q;I^.88Q_^B??>XAX%N_/YU'.?.WT__6U</C/
MB'WWIP?GI\G)$:S3.+TXW?ULGYX?)J='L$??3_33[R?:Z?<_+T[/>X/>\*OV
M_ZZ__N :BYS(XZK%L5C/-QPUB",@$M\*N&YKFA>"[N'ZW44$\_]1U.>U/5^$
M2-G/+9&^+)%>_ C,.&"NK:E@[_I J5&@,L>/53<V>,0]RXYU,'0]K;M84/H_
M<Z;!4V3Q;L72TAO_P/KNK5C:G!M_??.-[Y_O'QW_A/&,_2'<[-VO>N][KW]Z
M%%[M?_IX<3+<-T_.]Z\/=O\9HEC2X<I[@6^HM@G7W@H"765^B-YF30O"T&?,
M<$ LF5WG$<32)A+I5BR]-)%>_# LTXXT9JB<68%J::ZN>KH%4LIV_(ASYFM.
M#$1J=1?S)-O$TD9WT%Y1>NS(^&(S0H.HJ"(X]!#HO5].QK:'2W7=M4WN<!8;
MEFXR7]<Y#V,M\-PP9$Y['ZD6_A3<SI^"N_ G#)3JOUBD]'FYTWPJ]CQW&GXU
M3\_#G[WSP1#6I8/"?+W__9^D-SR%^1V#XKP'\]J[WC\_LU"$^@$P(\\UU<@'
M%F5%IJD&O@/FG6:'@1O:L8_<R>[:"W%:]<9X/<A*R_4UV])]PP(9[06A9P7
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MBRM14%,B<)^*(^E(.F$E&RSQ(O[U?"VO:A3T,&RA&\AG9PC:UV3+P980EX'
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MA\>$9\,";6X>^P#16%JA55NQ$.["=6[B,]_EE'?$C ^+"=.71S#=]6U&\ +
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M,4QT>[\<Y2D@A%UMLR"$]2?' -MC&6JX^1>>$4KWFB!]F?LEEG9T@<\<'%V
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M/MA%7/=4BYE,]0W/42/="V/.(L\+K#?O_([GVT_=R6G-@A);MK$JV^ NL\.
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M_DH036@P4]X/8"I7?##H*/O=W6Z'>N)^Z"<\5O9^@NBG@H0#:OV>R9[B0UY
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M8P$J0]^8=W#)!E-A1K :C\.5TN5 A68(&E<R!KF8CLY20H24TE>9H-Z5%_Y
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M)BBLNX@%,MB6\42DY>F6**L0<B&<3M(X1B\PU7+BPY99D^GH005I#1JNS)-
M6R%J^A6O"BE99C (9)QAFD^*]L,3,-\F)/"+W$T677*LMB6'KXA@[NPA9@^^
M<H1=BN'L'*UK_X^"OF]*7,C_[6/HDOZNF/@3Y'8\^ZVCQ##ELRE7WEK.JC_!
MRO>LCZ\QW:[1^(W;U=I^0SMPF0X3DH)O3:/KK/(SD4A7UDH(87G%1=UQD7-&
M\KE^WF25D2.V3C*%:S^#O>VS08PG)A0 65:-1@OEZ8TC\2[X'Q!PD4!$L4X@
M#4KHF D?.5G5XLP^[N[@ JA,[R.#=QQE++R0KNZBV$CI@6PO,(OTN=CZHDY8
M.I*1W?()PWAL$M(DKOK270[Z"D=!A8K*@..+08<&-2819AAF'PY5+*".FHZP
MC)\E2/&X3U5I-=%\^UMANV%XWDCLH_/ C1)[(A9;!H8+43I.Q[+9-B7N+.;F
M">V5IE0$#8KS.AZ1O/XVH0J#C1$V-]K4ZR9:8%+MHN5#S3E7B!;]WPO"!6AF
M9RZYX\O.X9<$S_!+08*@&R>DBLW9A)6 <5Y.P-"QW&S=M?DJ/WW[Z__DM-8J
M0-911@E<,%@BUF+L_7G\]\Z3+,K!([IU52W>4*RX5<UN2WH <@D<@+HUN]9+
MN8OI,'[KU,4V$EV+ 5W05E;25BII:RXALV*7,4M0(,^?&:I$2+*()8&),B-*
M@JYD+YJQ+!/LL9I)V "/*$@"Y0':Y,02&YJ*T ?(#KS"W/ ^<+V<$GUTXP_B
MV\*F+='?4)3AX[(B '^%.>,R7%'^8#ZUJJ) )B.QA#"#[DDA'!%\DC;OK(/)
M)3P;"8+/041$&">GA%E$Q^,7\Y:]<-H)5T/]F?*E<OWE+I4;<4<OA;AN;;G_
MU?I$:%PX(O/9B&<H01 D%;6JBT1L-I;42KI8&V..B/QEC3F:PB]LQOT"LC98
M0=1^J&MU-TK<3MW'BCD9#6?L@CPV7E@>WR4#8T$T%]!=8P9<9L)^\D$'A$(6
MI$)H=)0Q/YL)>VJ0@)"$Z0(?2G^FV33 <AKE[9>_=X79 IIQ"$,$: <DJ#!/
M,:,$^ ]:"043KPNKX%9G[W+)A1.KGU%<GM$$STB6HZ .7B(RL8:'E2-8( M%
MI%MB*$F+IG)E&N2=G'=.UOVB1H=LL &>1^FXO$T?:A@8#2\G_#>EPN;%<@#:
M.3 F+X&"<"4D=-$36UD-9*"UV,H[)4C7GPQ6 JLWO#8;?5)!O8*-+@@'\ZW*
M0XF%(YLVKB-EZD@Y.#S$\4V-;%Q1M8 V:S5 8\$%*;Q=0G-",0:J(G<T64'E
M@_+'C:EZ;3,5X S%U!P#3/8_RA2DVKM:QM/UVP>T;!J00%/%H##AML$,Z_;!
M=)S=O4[)=I:=DJ#H5=PD.WMYTR5B>7.^"KMKM?LW1GPZP52P48(_T[MZXV>F
M@1^T_6[2S^!*I.%L4OS8=.=\*KK;]=M_7/..:#BQAG>D]85RN_D0WV0X76^%
MWQ#M+8U^%/X5M(,*73 2T,J$-:$(<V(A=".1+8!+"X8G.4T9+_F6A@DR(O2W
M%S\\* JR"O8#I_CG%'BL+1+OM]D>5;:'N?G9'ENM\2FTQC;GOZ[LHHUW4$]+
M60P'?*/<U".1FUKJ?/IZ^&!NKP"_P<>OMZ3ES"ED):QW*36 ,]6S=:7CN185
M7E2P6CF?T!WJ@DV4%,T47? U7?S$M$JYAM7:0O(5YF],'#8=Q0G!D:/G(1'H
M0I1C+GS^X9?#O-/B0FZ47PJE)>>7\.]!O=*RGHHSYS1YJSH@HF!X$$IT[CS$
M $?YK:T7W_:^??C[ WQBE<^C1$+W=/49?03_-,4_;]C8&N#G,H&RFNI:!6]*
MA4._1>$PC4K-J R+2N$0HO;!H9L%G<3541VH*Q?+=(LR3&.;<_J([G6]V^(T
MEC/W'J<]MC,7IUGXV0U1&BRKO<.-X>5MK1,L_PE,)Q<09:ASXL$B/=V1'NY!
M >W:<1&%@"D42C#=<,/%_:M,'(':I*3!N4QM*>M!,BJFALT"I5C<#U_#39W[
M;1%>*9!KJ]_M?CC<'._,:X][S#MCL,''.!>QM$,>9P0T-U,.\@E/<Y:%%&<O
MA*^YR0Z7FI=D!=>]B+E3+0X'+C7!QE9-%\GAO\&&K&T3,9F,2P<RC%>(1 +<
MNXD_?$A'(WDKCY(\!QY:FA[2+J%[]N'HX-M"OM9<R+8F6@[@).G3UJR .F-9
M$"T%9O>\QP$+JWXF"!@(>VX"?ZFCD33Y!<7^U1@KA/)I=IE<8JT;#+GW$=8
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M]W1ND&HO*89??/<D.] M'[AS@E*+SG%+@M(CV^NO+^[C;DK<9ZU2JEH(M:X
MR)IHD1S7YM.5,'\U[(,':R2EA8HNTT=]?SJ=Y.1S76429=MA8G8-]2WCR3
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M(VG@T%D4888$HS#* $QPJM>Z)%,*3I<I8)(F: ZS9"BB<I6G@O($2S^A;E,
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M-ODOY6'R^/'C@^.G3Y\_>_DC[*R5>H!XV=\//Q["J>*M.[[=V\\0<!:G$//
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ML_3YBV^:[&YBTIIVS%?=,<<O)RJMNR+=>.^SQ2?>.]]/1,@?W79C:0VNB4;
M0]@/DRMES*]-NT,L'B\#)HQZ8VL!NP78O4"]"R7-)9CX8P,EXSY*_Q*A[;G3
MQ3+>6QR_ S4&]1N'I)F.;[*C?5;O+Z!R3X'CZ72R!4[[FF#J1,CUPH ]R;$B
M2&7=&6B8&FEX6 F87"'V3\+O'RPUR#4WV3N?J=OW37;E1.1U]P_-_+%AP<$-
MU:6/XN9]VS>RSAK3GC'>MW'TZ%E85JE=QZXQPH/4!/.9(/WTEK([7WYK"_(G
MGY/Y)A?D4,KI)@O2DBDQ_Y'<P_<L(3*>VZ\' <;24(6'3T'F%%O;KL5X]!
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MR/+,92LXJR%$J6 7SO-^OKW')),FOQ]^/.0X@/AK$N2(+I%C!O7DXBM47)&
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MTW=P'1*, V<?O^E6)/-A6KFZYR/]UC_JUE^&,J7__->O*7_#)[3CSU__RO&
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MIM,BN57:W@ '[UAVF(JFA$>;QO]6Q]][M'B888H@YTW'59)H)NBLKLK-AG-
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M"AK74 V\IYA2MK>]I7S#K<4*.U)RS0M5ZU), AQ:J-*'@!B"_<<(XW*&".W
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M4DQW![ W<IVVJ5(N40Z('S;U<8*1=49.O-"=5.0,3AYN=[>@^+TF3ETJC(U
M&5V!VNAH2[M>.?Z)"CL=SW>\5UZNJ?H-GBAJ!U&+-GRRO'7JU;"5-VN'<K;8
MQ% >K0?UB/4.TAIJV1[PIV%$.B'@8&MJGW4W3>I5><%%TL%W[!&4#(KTANW5
M?7W?E*571K84_I$?&1V1?5B2UJ]?9X;*2/)=9,PIIJ<5*=LVC9=F%4632V&W
M\O;'+T2OAUUU%_O0J4QQ_*4F8XB#;5A>FJF:9(5)7;1'2D,:A,S08KP[(7$"
M&X=T(Z2K2\ .I9;W"$9\;LJ0-,3S" <B]655..0]V?51L4/9=8)II'D0NZ_Y
MRYG6<9F?*Y#.!=H-I>GHF('SW)#@[53#[37W@^^!>5%+>85[SX.::GG]'GM=
M< 4P@LA]>UHP2=&-'L:^N28CUCN?BPPB42$(7'GR-"O"TI2E4'4&6AU>@HZO
MH6+4'G[$_5[A!+&$)\%V+IB#K$QM]ALLY4KE%$B3T)X-GM_G!N?K]U?0>;[_
M!9W[TN,.D"E=:K6P'')*Q<3K+8LJ]/8+.B$MYM)ZNV,761B<=!0MH6.*T7'W
MNFIAPZ[ 1EGE8$EIEWKE$ZHF-"UXI =P+Q&XA^%T*^)W(9;%%4S]8CMZO>&X
MCO1 33$#'7$*&<W3!KXJQ=-WE 7"=WO&I9M &&7.,4>9S^7380[A#[Q 7I])
MH@O;-D(G#IR"]F&BB-1G_\AW6Z+>@YYPU E _:\QJ+5W0TG_10/T,(Z+2^AJ
M,8E$1%CHU! 4VV>XNG/BIRO)%Y*-"!W=0IU&_%%_L 9/-!I2^T)')ZP8+($5
M1-DV4 J5FVPM3YQ9,90W&0S B ;(+Y7.597B;9 Z+OG!'9X>IC[E 9XS):36
MK5"U_9B42J$4B.,T4S6/& =7TF$O2:Q;+E&..@7#\PY/=IXW57E_A=.__0<.
MY0,<E?/['124E\)D,57D"/%$YI(('PLBZPI&";,Z,SPVV#<C6N 5E91)AU/V
MC]A#W:#D@*W]?O&+_Z!!>MV.:0S<O(*Q(F][281880/I>6=E=Z1H#3L/GY (
MFN ,+2LD.T_6KCDK%Z1P=9C\^G4Y'".5]8C0\:R%Z>FGY1^^E287?LRD2D9#
MZ=]NZNCOZ&D;3 P%5_[*$D(^5N2Z([H=DAOE_&?G(FJ$NX\;6..'!"2)BIN+
M;5D4A7 25R]^45;$[3C/-F@>?":0 Q*?JT3>%*8@P\6[=CNTFJJ,LKVA5((E
MS(X:TR+'.()C:-87D\>2?+XAOX]2.U( )8*T4%'V.N[X@/OG; P[&=9']!(&
M8[YJAPW6!)7,I<ALLE266.6T)T@L=AL@#='"X:Q$?"'C.GAR_7P]:V$!^]91
M8N*M&49 ;?J#/$H/2@+RNDD$C&KS=2HHF56:$/+JT:NFW."WZ;^.7J62/7%(
M/ED@_CLHSX]FM3 [411E2]UG8#=:<JH'*EE6)+)FIT]/'KJ-2%L$?DI*HU81
M)5$&RX7SJ^<X-NK!&M%&3BQVBA:8Z:.T=D<9$1-(S ?Y,*9U=[F\.Z(^V*,Q
MG^,1D=?S54DD!#+/=C))C87FNS.O5^055F-(."3U"K+H%IVFL^(@S";>,F0.
M/?4OE3>Y3Q1!EZAB( K1!64YB6 Y7@2RB+@/GW$LS(H-YTGESH2S2HB-; 7-
MR 41+W90*68Y'L7X4/!!1H[EP.JZ76]$:@'+=&O578"QF7N7J??4M9<2Y 8(
M9HBF2-J/1=?F2:F78&-G&8]52;C0MI#SA+T!NEN&S$#D-:GD(8).:3TG)R'/
MG$I54=:$+@*"&X:YTRD)SBC5@@DC01 $7C!RH!KE$-]7*FN'O([  F;'1!L^
M%OX4Q,L3H>]24+%R84R&S%V/ME58M%T11HHD?Z)1 (?DM7@?/IW,W+=T<#$E
MQ/6M2BS=$ML/ >:IH5EMS0!X OV>9;V@OYV+A(.83LJ$V\GK3=R@E:[/-+N.
MZU[/XWE&B$(1)^H\,YWEND'WV@+2Q!KK1\?=S:P<IO2Z/Q\[^-8!.>2Z5HJL
M'&JI<.TG3G5$A7BAY.>]8%90."SUG#1$7>I5UH$S??=I6E;F2O7XH1[<52;,
M5I8-GQ9$BGCPE9$ .3D1#*+%*"D2(YH%VJ1AY<VO(D]D-(@2CQ6321; 570/
MPM8*OK5;Y^IZ!.?4>K(2 =X@6:/@+_!8D9.X*>>?]F%CZ.C0G$5X6NO"GB)E
M@S/I.O2P-U0W)?K(D+L=.O)<Y\!+NY8]G'"5)-V5[A_)6/!Y/>2U:E2^AV;.
MVTK,#$3ZMP$*B;8]2%J$HULRAJE"8M!+UTKD #W^\!7Z/%#Z1ULTQ7B2TXJ8
M9NV@5_F(#2D>%*%&YAHR5GT/+4A!9X..2!]2[EVN"S0HJ *]W4BF,C!UFB=@
M!V-;MA[09/)!8;HOQ)8M'-?>283$.\PQ%@I'%_8)#I%]5<SV2H%%B);"+IWJ
M>Z&^]V*J[]T\A1:YL+D&M.(2I5UGELQ*QY.U7JPH* 1GL\)LY6[S&<",J>?#
M-DW+QA@2,2\"G3JIH*X@W5*[R2+\1GI) DY15-90#J C)-5$+R%O:;!:U1!Z
MXF$<===,;KR55'-06;U$+@Q)DQWFE[1;0845Z32D@XF9C#=G$,O"".%9IXY3
M:@'8FVP;R8L$=@HL>64K%9%MMJ:G/E9MT1SOPQCZG9M0!WID>!6E/) TH]-Q
MZR?@E#;!'8Z^)JAIQWH\J+TE0KN"OJ/7WAE#&K)V".<_=K4SC8M-3'V:7T?)
MP NZX3*0'BG&3E#D9'J@AE3!!'\L'4-#Y((3G<2M3Z%V-_E]":<[[SOKK_><
M=-.(XO$>Y_Z+T[S=^KP9<IF@<!N+;_=GS<BA3S-TRTWL5M*+HF-.!GF8[F60
MT:NANCQ[&>6+)#W<_]HTV[<YV]BX5.7:D5M8H.,8-$#+\+/R,TZP2$A+BAY.
M3+NKX>14V6/5F+ZJ;C2+RQ5;V^$JE5F/4$3O:_#PU>!(\GB3<;\SXQ[@051M
M@&!%JBT+Q,-EIR,4ZC7+%$ZNU#T=R:@XBAZ3Y\9F$*//TTT3<S\3TSUZY[A-
M4&"90 X:"D?8E+C5&HP[&5]JGPP47AP#VXR5H=\R&:MIAN]ZAD,Y8BB/X.4B
MJ!VLKRBQG2;L=MTE+C.@JW/N"D9'LO8Y.TV6**&<Y.UN??=@5@T^*$0^GM("
M#&CNHY.INEYA2O7"Z*]0&G!ILH94=P,'=%[E,^>UD>7KTXS>06*.@=PZIZ&C
M.;3CPY?*:O(_;G<VVF*9G9=,LL"%:#RBV 0R1Y,)$6M;_(Z#?(WTNJ?:V$\0
M_&TPX>JY*-B=J RGB;]MM\027E"&)C:;VNM' #X3\N]!/>I=5+,96H AUYC,
MB./>U7$%T)2A5KA4Z>@/52%8LK8*=5;6U&XP6H8*92J#Z_3\#<176*'7$1%
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MT YA5Y0)O-E:&)MZ7WK>DM^(9U!4-I W#?$CVV]%^4B5U\J,4VO0R 1%X9G
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M5:V6.#I&$&!*^5L5N9*)8>M7'35>'.3\"0-GU13I1;3:* 8[)?^C0<:H<7F
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M3^E\#6OFDIP^HOE)8*(T).%GE#T6A=9UM5'D!RV4L,18BP&MNXH(XT(QQ0+
MU*U\&D^@5AX HI1*.<HJS3)RNDU#AUD 21KJ7=?!WJXZ< <S@/58EK@0M%A?
M:.P5MO9EVUV*MJO#4M!>"L&I=%Q7OX3;]59-.I=OK'SSQ;E\\Y%#Q^=OO;>R
MN -&DD(HI<@G-!JN@V>62 ,*GB'X!G['!#/Y"#307:S3%$GZT#9'--_$Y1'L
M.FT4;*DK)JC<U$.BU5.5P%C%UI+@N(3S9AL%]9AN?^P$]=<F%=['X8'?,W)B
M.9JH3!M-=-5<UUTK9T"AKA+.RG)3'4&J)1"Z'*W/<;1'&/(!M )<MU?4P\>
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M/",S5;E1(B!^J2D^3 O)9=K_MS5RQ4H:"'M.^M%I=PWM;AHC!,*5/C]W])_
M6/_KE7J^.I=Z_H&3C$5PM4$@0]_&E/&QK$PJ\XT3:@(#K;L8=)K7Q[!D*Y$Z
MRZ\B]Y7 T9LL\YB+P)-KTAR2 Z.;6!\]-?U9(^: >?LX9(:C2F=-V&0B3X5M
M'(XS2+:%TR?\:NRD>X*9%P:)(OVQEYIT[31F7'\K#C,YV9<Q6+KT GO1L^-$
M.S<H)YFS$XFMXYE=UR:./+)ECNT/SD')FI7968Z2:)J_;MIFE<GE6;UB .A:
M6:\E\YAJ<Y$N&N75$P\( IZ/WQ=\@QQ16!!X]7U+F9*J3Y*D&E&H&'S3T[_&
MWFI,L?V0D;'!<83F-A])ABR.Z[OP?0/90L]*(5*2U ?TSY458](F^/NDT#5(
MU(Q9?C,^S*CVN=J6]8Y&9UTY(559PRS:>"WJKB$P(A;+Y983CC0*,"XB^5QM
M@J.#_!"(# H17]Q*HS\A*<*6H#^LHO!SK\&E@#$\WX36-A_'FKMG-OB[GV@3
MK9B7GKSDM#FDJ^K=<@PF55S>R#]'4^147.<;@*3]C:_$*'A,*=G+7(Y3EQ'K
M:)6*2V4[\!0V]-\XD.*(M:^J#S,]+L=L*\G,MU*13YB3)'U%#86< M!(Y.>P
M=?MUG4I8YKTUF1+O[&]/@P9C0<X9]V[<FNL<5P3FCW+;^:.)R*C>W2M%>@X5
M_K&N@I\*97Q9L4X\EB<*H>Y)DH-/149CPE<&W3^ECY&"7X&.KE[LEK\A763L
MR\M<XC'IWWS=*-F">R>Y@+;#Q*@I>5@O$D,U:A*",X5YMI9 >9#'Z5K7YFNQ
MQ[IYHS77G<C-+PJ4DY[%HT>^)Y]*PP_M">6C@#<\/8@>6;;-IU9$9%9B@6)?
M'BC9?7P=>F(4(QY;'F)!&#&E<+!X>1=@?RP%=Q]DJ@M1?AY["MQ_+084.H9)
M"93/6/&&7H83Y^(O]>K#LEQ]@*D8AT2J6_=1)E(HG54D\<&^WK)JJDW-R3Y4
MZUD6D/ C2>,CT9FL6'(D>&PCII8OAH9(<2Y,L42\5TXI2$/!?NQ65U!D9)7!
M0D"(4LV@+#SQ--7LV.FAT+.GKZ]6K:.%$(G%>[\.=;I@*RKPHEJ81PF!XG"A
M<"XFYX_3#Z11_<OBC]0%&KSUEV&E?O[\Q7/:;QLJ*57:>CE$T?@\\/=P'U,
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M/(#'\X,%V5ZJ2.+KSQ9O\M',!W(RB/SS\&#_538C.>4\BE]9UY.#R SIV_$
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M^?-FPGTPX6 DZ1!=$H&SL9\NJVT=SHCLB"+>GV <&V9S41)"2Y_X1/SR((I
M->;P".<J3A1A1&<U2_:/D/3:C-OLY:*J:L(A2&;V.\K0UJ+EP9>* '-Y?)?H
M@=1)A8,]^$!K#=A 4\[I!3LZX^$OG,RL$P/?*7QQ9\R^2!L=*4FF(=(,!>+3
M3LN]S$EM4CRW? @YBCFYDK"K>RBO5+.]_7Y=O0IQ?TDSU+7CY56B@^'DE3N0
M?/L8U3$-BTDSS  GM&@-)E<HN,JTK@!I3OJAM;>HX6K471[X?M0@\Y3VCYR
MY38F$<D1@2>%>TKR91+AU$S2%PV%$'^K>$ZPK,&2J6+8J;5%N]Q-*YQ+X\A1
MMM*4!UHC^1FM0-\JKS,K%%Y*79+&$ 1"QAHYNE C3>R<FN;+5(J;8>+:>='Z
M&MEDX]&U[[1"XZL,K5S>"2V[H?;E,[*%2%\("UC*2%822_A(,8QRWT8"72"S
M>]T1\T407@E5:OV1(UN7AXNAO5B7DB3CP,H-.I)@T[+'W."*TC(=@9308M;\
M*K<#"07RB;4AN76G2,X4QD1L;U.DCS%AMD^RN&OQC<12H8D&VG09@YP*9,\2
M[+21G2&JK/;%U(RA6;+G.M8<T?^]%E&F".%-*$^X:A()>8A*$:W"22I<$\0P
M%V(N5EL%F:GH2N5;.=[SI><>UBS"U.0V=\D)SEO87#K6VZVT8:;M3% \BX^/
M,=V =2YY ;_\A#4Y48ABZ0(SA]EZ3^1IN$H8N] 32T1%!+U(>.^J[%:T14V#
M@YLA4,^4U2N+FT;4I!B/O7_BNH>-7JVY#[?JZ&#3FNMQ_JBR2>R#^I-00I3H
MU\FEQ]#$;4'?OJ_;AKH@C)2*-O8VMOOKCLN7.MV'R\7[?4<=CM%QF%Q##-LD
MFYNM(9Q::%7FS<X_\X='!W&(L DHENJ$<4SK/)JC4HLAA1^<)A^"LU\)X8?F
MTX89:>+DBR+;$<W+W?;[8W(]YIW3=P ;O8OY(>*-?.U1HF\%)?HHWN4C",0E
M8!)9ZE[C57>@:F>M5J7F ;*R#_?$BU<RC?U 8>DC"4INU2V(QF4R)$);-#,T
M"K10X YZ\4I5LM5J-+80CK*^"ELN^=LIM7@_G$F'4T2CL3N$IY(YX+ZJEAEZ
M0_PXYQK1B1*\$4H<T"'DP&]V/VF8)@-+)E*<Z-D;_5]_BQA_,P%QI4L#H]*G
M>+M6C^<;RZQ?\&6I-*E)4W_HQ%9SA/\WR!,E3X.C?FP4;'/[XM4WA9S@K5\K
M 1@R#U>G+P78')O08R=13$YH2N)OU72<G0HD"!6SMTLVGUX8JB9;%BGB=O>8
MV8YJ7A.]R9/LBYXU\1];N=$W2]!':4[CC:V>].%%'H?.;) .4#W&KQB+R21Y
MKZO<3162/>P,,C347W]LMHBF&6DZU*0XQXM8@&F17]C_3LLU5<.,\.++"]N
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M+*AH2?]BGX ;C"8!>A3!UGD7Q/'Q0. \[0_=>.N20P6CT*$>UNXXJDG!?)>
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MK1:I8'#1)S#9)231L<1OBBL,'[$TY5P*+FPD)/?)]PR(1?O!<&\",Q;X*:S
MXG9I\%@%D=A"C L>!WT$Y:6Q&' J//OOK$1B*/?);A+P<1\2'U0F,9)[W2H?
M;V<U:/@C&D65:^$W]8&35YD:/&YZ=\VXL>@1\>@'2X>XZ3K$Z+7W0V.M^TJW
MWQ&!0<Q[-@-#XOPG$$BR)-(L30CV=YL^02?UAQ;]/MO\<.9$^6<'<J_.QKY=
M^OBJ0/[]QHU\J.[>Z.9KL"%7)EKN;UO?QJ#Z]Z3\4(Y^]]2$P#?]@OVN&1)4
MOT<GCZ6(]^*-;@X!A""9K![$!&P&A/P9DXA8;,V:,:*W.\H;]3A+ FK">I*0
M[_GOOX&KYQ6:!##7J,-K=&99U;%CZP@IJG&CT@(.?6UVZ?S:3R$M5Q0@\5:Q
MZ9"Z'FR^N*Z89F<I .803ZPP[YI_MB!I1AHU@)1[G//&$+ +MSTG=R,4>NMK
MZFN4V7PY)I3VVI:V^?9*+.=#B>7V+C8Z-G9Y),#;L1(9ZS3*N@R&"V$_R6)H
M7IO/;#WH^CF<UNCK>]T]0H1+H&H=_)R 4": D+M_"",^.E4JX:BR3M0PT61@
MW^TY72ZN*O*4VELZ7IR,FA;0^Q6R_?;/*=;AV1UPBH'<SF=C8"F51(!UGRWD
MZ?03\8"A>X]#S[20C9)$H[\"PLW<+L\QP>?&@=D#<"X"%0% X[@X2]U8P"4(
M-YA-&\_"$;@@K[#=EA\]L-=-A<1_&G<+O;@4S$,O4UIS-')>M5J?$[\\?]N0
MX&642V':U?;:Q@%X0'@Z)R:J@=XJR<-'Q*8D%30];(J0!GN3T@T-/]A Y)H<
M?%1T;#V:SBL*3HJ&V[Z80Y]SFXR=*>LTKLS,\7GARACA&./(6><]FR6K[KU,
MWTT(%]X0K.Z:8MZ , ?DC#>&7JTU>%A*(H5M'=3B7WG:K*81X-@@ABPP9-1Q
MV;'4MIL8+E3M-B]M91\[>$B?I6B,FX_!G>GD#4@D%W3SA@5?SC9ACMR,UGE-
M&QAMKI\B6%QV#+ SO^-IK5.'T4S71U39UI(VD>/;[AK']I9P2[^1*NZ<A;ID
MV)^8%U%TQC5-_XOS S"RV2]OWK;VEB1)_>SH)C!PW)6BMGY:P:3XR[5GL+!G
M552U+3-M=<HTVIU-]?).]\[5G'U^N*M;O0UW8G1DWQXA2*XG+1YSST/N1V)>
M1#63>4\1Y0]#D?K^R$[N*ONEA8G2:C$C4O#D*IJQV2;!-4*#[E40MU'P<\S#
MUQV5H+G&_&V0[I"T.NR%ABO/!_+8T1U%N-WD'!DWJ#"<BJL^7:#H(HO(?AUX
M**]R!IGV>_ZM*.A]Q[IP+:7BM-&\HJ".(LM4L%4XBYM>6B.?1)V?UPM"M:Z#
MOE7>NIC):NQNE^GI;'AV+DLCS>'HZI-"+*CX [ASS")*YWB0:%\RG-Z\<7KP
M^&I&#BT<O'/Z<,QY?[SX[:)-')5IRNF6S<$DB6?9:-*0_X&X.\3XQ/P@\.1_
MUEQ; #_0[E'8L S." ]%O)9PO)'I%C%8A6-2YC**%X*LT,9;'+QRO"E$GBOD
M-^AWE3U'0-@J/29[2B\HW/I<\KEM;!W.T Z!=@?K2S]TE<H\;CMY)&L_8TFS
M1B50V])1!3KZ4O%95;5'?!OIP55I #5V&&74D'Z&#0[AR0'8[-_$[2-0A/!>
M<O,7K04)>1K@ U\(H)HGMDP#S21BKAP$B$KM755LWO3^]L"TY4>]>7]&4V,=
MO>-1YHA"(MB7TZ\#0V_#3LB:8F(1R[#8R3@WE=NTG)0O&=)EO6H!4'7MGVMK
M<; F0DH\7HUBS-E@[!T2CSC%NLDE0;F$^V%J/YHGSNS-H-HO9M1GE-/$[F]L
M;3F A03-6\]_^\]7+XXF3^PX6LNR1#5;C7P&C%U)-/*(OD$C@B$-ISSX'(T;
M+1\ >_?H,8X4R3Q)'I4GEKWI.8 RN>,1DN9%O:)*-1Y[>)CZC+Y:<M)4XP)$
M1,S=)%&Z_Q/E<04<_#?]%>7\JGR0WXY]*5?C)0=QAUSJ'6H=7+L(B/H8+T>%
M<GNBVQG?+C_YSEYDMF#T"I@1"-5\D(=79'KO,HC^@%B%/&X\*\N@7H)*3!F
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MFFFL;1<WZRT78)IA/?>WE4W-+*J1@X*IKSQO(,7*$''G]@FB@EN3@(OMDC+
MRM4BG\H]V97AQ_>$IP&+%[ST56+'&!"W$,U9)UWR$.A, >9(V1LL4CEV&>&4
MP5,/8LEH=@@$0!VD%U[K)Z1A\6<JE!KL'Q0K\G+JLR/H1% 2MI=)'ZTH,Z;!
M<<L\ITYP1&G4N?'F!1.X35MHV$-EIL8ZW>:2(*Q"KVM.(A*& JPR9-S"6_ S
M*@PWV'IFD:5;$>%BYZEU""XO5D&8^N3:N!!*L;^$P5,?78SXN5TQM"M687%J
MW-7+IUJMI TV3.Q@%V KWK:12H44=6T"NJC+R:+UZ%A%,'?:$=92RRA^#\]S
M:7TF J*.,'BLKK<Q$B[D$= ;G%DW27HQ$6,8ZLEKBC_J]O#!G([<B!8#:A5(
M\K*UIU_'K)6X<A):R_!C#,VA9L]M)2B_R0TY^K W;*$/G,Z7)JB!M-!8,3W)
MLM.N6EUV+:GVBM(0))4@A'?H7=>.=DJTQGM+Q%.1SEP24 D=7<RZ"=^<KT0@
M[]Q>68==A1RTSX]L<Z1;\PX2 GOQ/K>H.F/[G.?OAFH0NRE70!*;I%Q: [I@
M<O11D 1)I OT.>#':_@U9?.QFW\O1F,KR1L 9JG4H\: Q8AH*)*28N0U>VM
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M2R9M9(W7I)".2&3+F@/]-@F8T"6W32SH3D%A'S9W4(@:/?.U4A0#H,IF^.3
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M:R!E[&:ZXQ=@1+ 02E+&<$A 6GW G=[EA%*5P@YV2HY2Q[PTU&9UM2;VDP=
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MSF<7C\XO9N<G\?F3R<GTA^CB["(ZN8@O)N?__>3\N]UJ./RG*E]]F97:DPF
M&/\4#*4Z:QR7XTO*(+W3W-[QZ!]DK-Y2W7@[HD%>,2S-G#]IEJW@+_>T87^%
MO)1+R':\T8Z3_\/A3?[9\>B%F4>8@/D' )K?F0Q"(C_IPP2[";8NZ>'-L'78
MW@##_KMH#MQR+US^Y;8S>WH.5=5P;NEOASZ[9X<WNX^.1[_A:??*9QH.P$7Z
MC2L&+C$)[( 7PEI/F#*,BMP1W^[5<.!T_$CSS4%%&)Z&V0N3C^3K  =5V&)N
M5PUH6=F?O$BL5S'Z6U27]MW&HS?'+X['U('Z'!VC5^Z7UF#:_^-O_D^((A+T
M58"V#?S9<K8P<9U21(9"]6;D<'+X3O9']CW/;1R%C2)O?$O=NP"_J!PUC!2D
M>P6>_$_[RT#^$(D>ZQGD:S%9&.-?3%2D"=:-HFJ!W)S)I9=0Q,;M* W>"#&Z
MF/A"9]&/$ YA 7FZS+V,(YFU_T!V8@>!YSGA&>K^KJ<Y_)4;=;  %+OV!#/Z
M!9$8V.2SY1;J$NZ;>Q)%;=P)>N@A&@+X 2\> 2\'=+Z0VL2YMG.!A%RE([S$
M3";F"(H8A\SUV_N%]VN>';UD[(/;2N'\O"5)W28+;YHBQ;, )P)\!8.?-EU.
MG&^''L6VBDRZI:CJ2#00?SU_-+:#[EZ5MCZ_\)C%RQWRH'$!]%S_^L/XD;I
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MYCD_?73?FX=&#(;J6-PJV#30<Q![$U3E/4<8;HP1HE[L,9=G?E=@^1$ #/#
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MKG$ 6^\FH+\&].P>T&.31\<7!/ZY*7KLR<7QDY/=H%.W*-;0>_N!V2T]ON-
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MP\$S)K(0F:%(__'Q!Q,3HA(,K/8&E'46O+,<9-8V)\>U%7;YT-%P_.</]8^
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M:2EB:CU<:P.R'DTJ8AO$K'%6FXFG=?AR*V'U/JQSVDCWH417B.-P?JF)UU9
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M9"])2-X)\#Y;D,)9S!A"4#WMGW=!_28)UU1_-VGGNUS;-J(>!&93]EE#2BA
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MW*0KJ?=&B5)2Y)E9X+K. $4>4V!DV@HK4:B@M)6MTT%[I,)7>>^'9\(NPNZ
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M]TJV/KMZ[!F_.^EZZXS?71354\:O<2BUYPF**YX@H0+GDP%MA3$BVEA4ZZ#
MX\WX;<::>RBG=<F*=;6:9S3D=?F!YQ%S+EV4N98&K]WF<TTU963HIAP*LU$E
M%-LU5-G]W=\P@?K0UL;$X(X#UNM:;)7)]&IY^J9AZQW>UTGP^K[CO1;"EJAM
MMDK3=I)5*LR'* O#F)*)(LEU(>P=WKS?)G3U13BO''TU#'$X(ODA43/,%E/,
MK\=O,2VFM7X\?>"WR7AZ_BW-IN&L_OURNKW'=#(>_O<"9Y>1'N&2YCQDT)&L
M1:6%@F@Y YZC<)9DH77KG/*NQW24S0W_.1G18VB,7VJ3L%]I!IPN3@>8F*(E
M2P')B%:5E!QXQQT(%4P]=LO,M(X/]3>Z_G>9HYHMO71.W)]6783[>QCIJF[#
MP&+TF04-4N5:2[20VQM] N.*X=X(&>/1-%7<>73?)]!#H%57L;;[=%"[;:2U
M;S ?%,]D\5@+OAE2@*)_0G!(__@8)49N;2<[3B>C^3Y!CI$V'=R+;#KUWPYG
M?_PR17PYGN.4/+ZK.V=B)27%#"#/""IR3>(/"<C?HQ\C^LB:GR_W-+;OD^7X
M*=6P)%]_XSS;,YTAOSD(#BG*1$9GU.!SHCTSJ,!E#+1O-N]%V-/8OD^=XZ?4
M(8IT[=WK7CHCG/81;*IIL('5:KQQ67\N9(?9,]^\V6+7@_H^68Z81#=GB=YW
MEG0D_57ZCPB&.6<<I.(LJ((6HLH6;'2.Z22-$ \D/-EK"N!1SXBC(<QQY@SJ
MDGTJ6H"/AM?+%P)H]Y,0@ZJ7)E+.^5'6_3P>6MR:1KB+>AY*&M8V8_J>1KA3
M&N%.-.DC'^L^.GXH_,VVN*P#@LF&9C=BA% ];B>XDSQ(J7WOQVA'P]N=T@B/
MCK:[J+;7-,(LG$,5)"2;R.IVGI/5;3.(D&K[RRQU\RYBCSV-<"==;YU&N(NB
M&AZ&?MU:@+$0>"J90$@!R@<+P6H-6&]EH2P!'T=WDZ,SXNZOAH;'&->[%6P#
MX_&U1]E)^!O::]Q'<AVV1S%!HG,9P0?T-=%"@:^M(Y)'-"6R)%RS:7WP]B@M
M]+>+P%JW1UF=QYP7>C4L!J<+A%+J8&JIBF0(5RY<:A=MXJJ!YKYZZ>':H^PD
M]DD+F37>2;_NTY(X1K('#(BB$JCL/(2@$Q3#>2(CPJNP553P8?2VN;?R[BVS
M0U7<V)!6^_.[-V_Z2%R^^IX^$Y8WCN]:HK+F*B:?M(TZ*L-=9-%&9HWEWIGD
MV/:)RE??>)31_\M(L]/.QYR6-]EJDG_@])5W(+E42NE I&Y=)_-[@C(.;!19
M"G+#DO29?#%O(!8,$(71Y(\IP77O-S/W']8C/)O<97X<(*-R)R)UE8O<44Y<
MD<J46G5/6E&S$SS$Z"1P^C*0W),UK0O/?4^E['-F')XVAPC [YN\,_ "M4S,
M@:UC4\YH<,PB9&><EYD')8ZF<M:V@_H^/8Z81,>><+PV:R>0U!'K]61F-2T#
MBOP[Q@T$;4O(EAN;]3'/DF\D]>MH9LG>).H@M[C3:#]JDS(: ;R6JU.."7!1
M>1#)Y1A,4.RAW$Q]7*E?^\R(HR',<:9^>2.]8K$6[D:L$?908W0(T:MB?+47
ML?6>\/A3OW:BQ:VI7[NHYZ&DSFPSIN^I7SNE?NU$DUY*<=U#QP^%OTD858MT
M0'0VTVY4;U<YLH6T,KI(6[14K;-E'PYO=TK].CK:[J+:KE._SIO*1JD]HB*+
MAY'MXP2#2#8V.&&E%LI*'UMW(GF\];]VTN\V'7]W4,[&2'/')YR_5ZME\F$\
M_-?7HOQI,ILW/>+<YD6=G''N/,)KAYQ"<8'<1$S"J\!"4$E;JWTLI60=UQUR
M;O/*@_<38%Y%5$4"K:6F+J\"O#<.7+9.9T:#E*UKYA^^G\#%-,7IIV'"]8#(
ME/^$LSFNUHK9^PEQ[+H:?YO,_R_.WUZH^6JEK0%SGA4I(F3C-:AL4K7P.2BM
M,DU^Q9GK+!6WRX$=X3K?EN<;5_6CH4N7=46;#_+B2:L_>CT_P>G[DS ^'WA.
M.:J</%@C' V7S+R( <&G(KB/6D77.J)VL,%^GSM'2:LN[?36 W^#T^$D_S*9
MGOVH?HX/@M/H%#JP*"VHQ!(Y3"H#]T*77(M#J0<SB=:.\/O,.1X"=7&RV:PU
M1^9%R90+)++607&GP=-D!RQ:!QETBO)[+Y[#4OLPRC[.PQ7#;;!H+>CH"RBC
M.1#L E(8+;4**K+6:2E'<;AR( [<>I*RBRX>2B1ZFS%]/TG9Z21E)YKT$9*^
MCXX?"G]YPJ)*%B!R]K5'H +'60%=G"8CA:-BX9OE[4XG*4='VUU4V^LE>EZR
M2597KY'51L,URR\S!UFP&$E*AJO6"0^/_1+]3KK>^A+]+HKJ(&9VK3''&2A9
M4&7!/8B8Z@%2('N$.P56<:%\="$VOQJT%LAWYC104 ?KSKIV+F_?_7X.CEZO
MG0Y@%)(?'C+YX2YSB#D'YD74R%IG#MP*Z#N+&BJL@\#)NB/GH"5'SQF(9,@W
M5[EZ1)%\<Z5]PNQ\\IWVDOO.G$;*V9@<W30?X#><OYK,9F]P2F([G8R7(GH^
MG@_S<+28#S_ANYK2N,QZW",9X!YO:9 )L._8KJ4!>$1M?"[)J:Q<H?\[9DP6
M(I@4$Y.#>[QOSVC2VF?__#F-%@3[%YHC=2XLYLNI\+K\'*;CX?A#!;B$=AG0
MRS'K% N#Q*LME:2I*5<6#*)3)0;MFC>@;(5][XC<?CB>GTX6X_D@ZX*6U>7?
ML@1*)@?!%@^,E:0L+SS:UIYJ$^#]K],'X>R-T%_O2N_B'O%%%'7/X:Q"J99'
MIFU69!G7RN8N<?"&=BFN7>"(7F;?_.YPTQ'T=8!R% P^H/*/YBQEOX'_^&7]
M Y;Q,MK4=0B.0?"6#+7H,GA6(D06/>WX5HK0.JNVP^$<_IRG?Y*V7?&;D:6#
MF,)Z9%>\F&WP=70,=!>V QWI' L9MB+IGIH\!.-P60B,YF<6I8#B7$) 5A-*
M:&N3.EE=FM\:/ C3[CJ$>:A$VT6!_1[/*,&%(TM)JJA A7K@'X4",L6%23ZG
MG%KGK!_1\4Q;O6U_U+*#T'L[:M%.2<&8 Y]5!J58C<U%76L0.EX\>BM:5U@_
MDJ.63EFPO[![/S9)$JWW)8#.61 ]-=F%PI)'54SVEBME?>LUX<B.3?IDQ!["
MWW@$TC2D_19'85Y#_-/YEQ?#675)%].]PM=W/+%!J'H7S-=OIV5;DO*EY!A5
M/9!212I2KI8)C11E<,>S]YV9EP]_/PWC64AGHS\+<M2+<TD8#4&ERH_$P'/C
MB(/!Y^BM9M@Z,GH7IGU7HQ<+?#^Y\A*::C\MIM-ZGK2L I%6WPR4L<)F[FB5
ME'72,5X[5R2P.BF%07"RWQH/?4MH_:]037ER?87J0B$-[9BZH-15%.EI)X3H
M!7["T>1CC8'5$DKC&2UNP].XF,Y6!Y4#15!B1$O+LR-[*_D +D@+.O@BD^!9
M7[^8>7/-VO6ECX02G<JZB[S)BQ#9!G',?OSRU6]6!60\9TDE#:($!DK4P@@R
M)BBEU.:D5H;8/#'R/D#["LEWNKITKZ)CB:AO-[YE],'&$JTD@1HK:P7XXLF@
M- 6<10PNT8QB[6WN;=$=/M[=&5-NV.:=:*P3%^Z*%;IR2K9!U%%<^B::PT2B
MN]+?+3390_C]T")PGE5!!<Z+FJLN$_AB(UA13.$L\Y*[]!@.&"X^'!MVD7GC
M)CC/2QF.AA70S^/Y</[E+*X@?+8RB@ ,:\P1DX7('0.+C&SUXB+;KN?L'0U5
MUK_]L,;P?70R:2K03H*X:[F])+/D7F='EK=)V8!BC-$.&#CPH@P&9*[]/9];
MX'SSUL/..ND@M7D#M+.IL0VX'BR'&\".RHC878W;T6,/'71L0-P$J;0U3FH!
MF*,$9>L)AG0>8DY,FVB*MSVY*<=G5G3,CUU$WY 7RP#0KV$VQ^E9]8S9\P]3
M7#K*Y]W+G#"^I #6*EO;KT8(/I<:]W&:UT),X=K)X8;PVJVO.9J VGWT,>E$
MF(T[\%UNF*NB>[_B_&227RZKHBP#?C=^BEC/Q%;I$RALUFC 15Y+,R[WS4*&
MD4[:Z&@Y8RVZ+>Z#\?$;(KUJL6&W@8I[$Z[S5*TMD#5LJ'L[FOY[[/:GU4FG
M*FGL[-Z!,(5(DX=;"$G86G_6@'<N@D<N!<O""K953LL1DN66?K['R)5=--':
M>ODOK&V'POL3^N<C+N;#-#O;;.OUY$SN.OAD$JCHZ_W!["$YVKQI'\XDC*TL
MEXVOZ+>G;$LE3)I+<->*S&<_KO_4)FQ__\O_!U!+ P04    " #*.*I6]S/$
MZ!\# @ DP0( %    'IN=&PM,C R,S S,S%?9S$N:G!G['L)/%5?O_=6"4EF
M0BA#E*1DR'B:D"0I0Q&G2:8X?QDSG%W&$*(0XF0FP\F<\61*A60.<3@R9#S'
M<&QG?+?_?>Z]_^%YGGN?]][W<^]]/W>S?*QSUE[K-_^^O[779GYCC@,\%_0-
M]0$6%A;@)OP#,$> L\ V%I:MW[]<VUFW;UT[=^S8SLJVDXUMJ[%S<'*PL^]B
M9V/;Q;5K%^=N^&+CV,/-M7O/UO];DVS=OG47_+N;G8U]]S]\,=\#O.S;_%FM
MM[-( =MX6;;SLC!; $D 8&%E^?4"_G*Q;-N^@W4G3-(N3GA !0],_O;MVV!B
M67?L@+\-@+\'=O"R\ATX?GHGO^DM-BDW >7'L>GLTF=*&@6O=!-E3MQ^$,BQ
M2TAXKXBH[$$Y^4.'5535U$]J:)X]IZ=O<-[PPE4S<PO+:]>M[MRUNV?OX.CD
M[N'IY>WST#<H."0T[$EX1-SS%_$)B2^3DC,RL[)S<O/RWY26E5=45KVKKFEJ
M;FG]T/;QT^>>WK[^@<%O0\,3A,D?4],SLS_G2"NK:^OD#6B3LL47"["=Y9^O
MO\H7+\S7-E@'.]BV^&+9YKTU@'<'ZX'C._E.F[+=<N.74G[,+G F-KVDD4/Z
MQ!6BX.T'W;N$9%0F9$E;K/W*V;^/L<#_*\[^A;%_Y6L8V+V=!5;>=EX  5"M
M/^!6=* P1M,&CF(J>V\@,0K\X4?BIH<L@VL9%SJQ/W<AMZTA8HYCVC %M*8(
M^:(]-S,BY(%_H&VO),;0(@>8 %&)SCX0?P\R8.C-@Y P(]CY0@.W".TA!==!
MOW.4"7AD,_8RSLMG1,QH;8N0?_T?;7NH$RC:<XP@$QCTDYQ1/7O57Y$)Q+D3
M<)3E.[3I/.<9-V0;Y@TM=KF'P8HP8 +96TNWW-(3N,SR-QJ;WH3))A_-E G8
M?@5_GK'4LA$.0?PP(AG0_4[#]W/<6+3GFIJG2/OB=N@@+ 1,]1QNPG^ ?VZ"
MW3Z6C',8 7"0$Z3+7YAQSB!B:>&Z\DR@6(@)4"['IQHW.*^JIY,0!ILG4C,B
M%,[^2909Q"K:D[&M.]3@.W2<4XLCF_ KTCZ9C'<C3&!VO=BK+'1EG<Y;CPR5
MP!3LDL\H/P;_>?17VP"1FQ;CJT0'&YE IE"IL_5[Q(K.+&Z="; QGEJ%TXX,
MQ)"DYR+2]C.!9^O+=']#)I NFF]!@UD],(^G0,^9P!G5*Z^\SID08*&9\_V6
MU3^P/<\XC19C F^M8!I_;A'=AESA).+I@8-,P,#H>CM!?XW!04'GS3AD1'Q]
M#ZL!^$>;PAQR)_@1DP4K^Q6" F 3"O[P@?IQZ'; GM.DKF[)U#15)A"[W((@
M"]<S@9YP!;7R.F<F((U_ BXH^<&*Y+-P0:\;C=N&K4J<@%;7P9>F>H+I'7^+
MO[_5O,9XX65\\0S6+<'U%.+9F<#'>A03V,8$OD8Y6C9.(F(0EIN80CO\T@M<
ML^0G5@'3&S,W3?4$@/]@8\'_WM2=4"&XE4O^EDS 9@%\U<_EOZ0 LX6,TZ$@
MW^?.,H&U?'CI:T__GGQGZPXQ 2ED!&)^F/LOMIM+"T?#EHAU0*RE*Z063M35
M@^=0EN-AN7--$0K2C1*(KPT'?0)445SS5B9/5/)E$W;4]Z*D:ZL<I;RBS_'I
M7T@PL+ 0^6BW?X7+X<ZT<[>> /N_*/./CO%E4&\"N<GG#WO>#9@S>#W-%/_!
M:=19 CIFQ5Y+3\ BE$7OKH]8&T6XA0GL/ET$.5OU^)_-M%$)9V4D/10?+>S<
M%R7P^.[3>-F[!OH \>/[%?8B7[;*+99W"%CH%TW2.4^1[L6^1CI;&2?4$EA3
MU^HU_3Y.UO8EL%J\:N0],,5;D/[@]>+NK$FIBMF]L(C99^M@0J3488%$X1@Q
M5EL"^8-K_K-$)OXBD?=CL$3DH-M<J&:K@><$<=&?6>>5UMH_+BW><_CAD,4I
M<S=?04KS&%NH/MLSO3^*Y'>V_GM/_52$ F#+VLB 39TF23GN)$<LLT*TQ+PY
M[!/$.#N(6R?),8*=LJU);+0P+#A/,*&S]U]P&^)%A(<(QG+'K"G$[#.>"!XH
M3R3)5L0Y7754>"C2$-$_FFDXO&^9]T2!_ .UN"Q[J8J?3^"U;__52#);Y\D$
M]N.XF, W17#-HP)6UR1VDQ5",1IAO\K,+IPB2?N".^@(,_?RWP5%<QMGJS+B
M6)1WWIRZUX!H0+"2NZ>G^^%6KO+SV6D&7OL/OPDTE .V&1]\C/T&8<^4]JO4
MCA@;7>Q['3WW967 +IDS[^[E3S*N6069AW8<D^$Y+<#=407'Z?W_GLR$S?<7
M@36(AL.8[2]P7-K68/6GC^J^MTV$KVFPM2'.H;U\!AD&.!Z81]L-)G!!!IN(
M&,_=4*]D JS:<M.17=#I+%)E7)KN,7LGR,^/7O"E#7$/_R.\A D<>9HTJ;HN
M^8?$^GWN*_D;:.=G R*))M/?"&ALC.<B^CJBBQB T?<_0.H!@P88)R MB0@&
MG\E0\62+;PG)_ML%L&D?Y>7;*D:7H1<3R A(Z?S>HK2$[@G&+?MW;!JT(K;-
M8GC1(OZGOM;I[$ 1N5M $6V%7!]S%2;PW"A))FZO)W*!YH^Q5]>_+"HYBN)S
M^:&*SC2UM;L?:_Z@+LZD'*QM=V%(5"X7=5ESMQ1'Q!RQ=EL^VCLS#:$199VT
MFFNT%R2E<&U+4I4I=!T1F5X7L4I^2-H(TY70::[FR)M'##>Z+O6R37<6%87O
M]OO^Z6D@EV_;P@A5:1ZYEPDX89Z@%;H+_>5>5P6B->>2XP<C+ BG"9SO[I2$
M6Y]G?P;<GSJ1_V!P[^:/;?LF8F93!5-U)2.24PU7K^=6%@\K!BANB X0JC^_
MRN_.RO3H&=3S2ND9M1E-2\8D-/"!7,Z292:/Q4R$3J"_82<CK^81<<27S;ZJ
M!ZD.-=(;\[<KI>SNR%&./9*7VUN$BTE>Q(0QV!EP_N'"NMZJA!Y/XL52,%P^
M#_0_Y!+8BWM-HCD4]U-7,[4?;.L.Y9RJOIU^"6$TFTL/WM00H%BCEMZ-SI.T
MYF@)CQGE6.=%<46-Z@9%C,K=N V/P*G2&*-ZDW8F,!QSGB3<B!R.(8="%1GT
M M/>.D3.SP9!DE?\3NM%41MR^#;.=X.U(S>>9&F#;Y177O.;0O8,@2Z:8M=N
M)M#TDPD$(ZC"#)&V9MQMQO"*;N\T@PEX?_-FK"Y:GRC[2)]VJWIE.2<KD':6
MVJ:J(^;::6-32=W$)N-,VR(PI5$:5[U-3:>?%B[$&2W4NZ;@[%W#XAA-DL0D
M)M"\S_\D$P@)H><R 8Y$LB".C"$G+%>A1E;HF=Y=,_>'<& 7SFLY177>S-1V
M413]Y97C&-G09E-2*;QHL>!"45''2.F0S=A'."+T_=UTO5@G#3O4.H[&N046
MQI%$RYA-_; /**KP03@))M1O-"%6E*R9P'O<FK25.5$D6&/./,Q;J8_N+9>_
M,'LY?TB/_DGR&:+<+NP)@]/?FYZCJSR+<.DK-PJ0OD@T>5K^Y+0+Q07FQ(.$
M\@\J&QY].?2%X[BA/*L^P7L1-P$CEJ9Y%&2#((;2(QDBO<W((<EAA@$Y;%B[
M-A4_E((+('?<L1_"^=7>PZ<(4G!Z/DQ@:&R]KV:L$XE+6I,<'HR(C/ZDD&N?
M86N+C*J1C$,KU$(3=Q0,V4E*M*/]]!>W^6*G09?"-FO30WOIRR,[6+\8+)_+
MI*XO2O+I'J'Q0C94OCD*N/!>6U4I0E?:ZJ<N>\\$,;-))H[,!/R/J7X9/+\S
M?=_.:8L3I>U4S)CRZ^^(T_(%T:P?R ES(T[UVM2D+N4K%1-E]<^[-W74%D>N
MKL:,JS<O[[%B=('EZN_!O31-ZLX4XJB2MOTXCMNG9L2DS[['@SIO%"Z5(+V[
MB@<5,;^8;JO!*?]RVVD9"_5F1"A%J1GW6/*MXF"(O]9K!TI:?9Z5DV67_1WQ
M*G+VO,^#R8W!W8\OQAW_8!-^9QZ94VZZSII3^_ AG@&DV<D%J ^BZRK!Z-P?
M7<V9$^+6Y/N0WL' ^TO@_7+2>J1S'*LD,47/1VE*]'4?^[:I^ZR885[:@O5#
M+>'T4_Z3Y(92DN1[)19T?YKV6^&:W,>,0U";+1$1?K\W-A.I)^/NF#B'>#=M
MN/CC$R!R '%\O^6BB^"+TI$/WP?0:18-=-\-]5"W=EU7HX(%?.I">??1U)B4
M.GN2-/E1*;U619S[ C$L= :ZI182H++!771#L:ZXRB)R7^\EE:H5UP'UE/;R
MZ]=E6;]];KB&E:/#H&_"#':"SVA>L.D'[&6<#!X\='J=!IL+DHQ<8 +E 1E=
M]W1[5QZ^PU=)JM^P'%6QM+FH]>+&#:Q76LUB;WJCB4"ZK*S8==6<&.OY/IH_
M23S8ZA6N]!R2=QW).MNP5YEV2E,<WTJ7HUYI5+DEFTN^61,X-SV4U(F+DU*^
ML'>[2..X93YC<+ 7W8D04L7M\5<UUOX)5N #R[OV^-QSV=/'=53\MES0I=7Q
ME78#+AS99OPECQ>A[U:,%?U81O4 \FY/0HWS2A6Z#4DN^I$2'4%!&MMUU'AX
MK5<989)_\3\"V1';&;MJ\R'G:WUHCEE-]1#M0Q-<B-.EI+$H%.CG\39I\GQY
MM5UUT,?JI@^[(_>UN3U=&-_YN4=7Y;LCLJ1J,6I""?!)&])5Q$3H'L65=:L4
M&;(]0;?2LWFJWU556:RN[.>/][05\=$0I 3I6?:YH"V=\;D@Y@Q8CG5U&/M>
M#R9.#>9O=F:-^,NAAI'O#<BW) 1 CA&(LV4[0:"!^UIK;+FSC*@E.?8)*_76
MN^L7.$#PL<:MIX.1- GZ\W4,#"0:C]:9DLP]F "[CU8SG&]97#W"WA+7.^)N
M^-1,;5RL2<C!V8>J),OL?L*2VI6V^9*E G?3(6ME;71DN;37&DSL<%9]89Y1
MZ[HTFN+[<V;E/.T:/5TEP!<<<FY#EI63-0,A]?&<J'S:N8CU[ YUS8#^#*/,
MH65JUY0-TE:\Z-%.C+!B(%N-CVC;>THB3=#(-N5#S6"CC2Y!:8^/[-HW;<_,
M$;R3;_#TF$FB8;)UGG']AV6EHR4=1BH(^?VN]!,9.1J>61AUUU2L'2[I2F=*
M9(QB,<:VN+.^9H12 F62^$U@9Y ,0PBJ%H"5<VDLT SI"A/0[\L 2B'0NI=F
M=J^JFAQ*&) +?FK?$:%LO8.%[(3N0'+=9@*!PZS(L 8V<V0(DO@<4!&[O+-@
MRZ /<%<S 4GDV@C=GFJ^P25HMK(N/DK^.<P$4C\5)']VUK-_@Z\OVI"],VX"
M'2X*K:5>\[]3 <'U+)</IO6*CUC31II2-:.IIB1D;=25H*'H89BM;JDV7WG0
MNCHBW7M:BK_^H<D'SG F,)Z#$$)SV?Y$\Q&%(U5!,9K H) 12N@2N=+J8";Y
MI6*QW)F$P3URE=6K@F<*758J99Y&T$TSWN2PI5VZ9+V<ZQ*>G>1W\L/QF&8_
M9SS8UNLLF2"A00_1-B3EDNM)@\W6"M@]\PVR1/QC;:Z[>-YU:GC&8)V.;'FI
MB*H1RS[ECQL/V$7>NM[<K'2-;W1J@I+&Y3V0(W($5(N-[<CIF":&,#0Y0;5Q
M1U;U#"CQS[H9.MY[VR64<:/02W_Z/)_/#@V/..-B#@!=:7IYY5L]QIKA16/<
MB^V<3BLPLE[!X5&QFY:D9)!E#N3".99#T2IP#G8,(7EE"S]*KS9F'(G:$0O'
M"%T5U>V+MH:H0X,+=:Z.1I/3!;A*?#A#RA\)A>0YUU@&UQD30!Y&>X-H#VJ
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MS[;ER\0!G_(3+*,"I^-%9!G"C+/3-EV%>1D1$WM_>\K- HSXWC818/CB6=/
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M:ZAT2'RLP)U,@!V$(X2,2RKQ555/M'G7LBN+8J3B$^[&W9G*X :^<.XZ2KS
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MN^K'$@W0%9Y^)FB!"6*"G'6MUV,(V,T#"^CUG7')L5P,2X@+,DV!=+J?8XT
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M"F-H?2;P;ASM G[[-!/T?7TGRF>S9D7Y<CL7S+!B)4?HEGCMS@:U8,@$37E
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MFP[8ZR:[N;596@]-(7^XYD<%^&N[A1=FG*\T.4$06P*NZ^1VPQ='O]AK@2M
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MF<!@$=#$*39('%J^B)ZA];(XF0;H:Y$\]>H)BAE ++?%!&ENGQS=$+'R,1%
M#=FI)32_9W@64??7=T(C=NJQ0:&)X)VR(;-?GNT9?@<=#O[JZIZW4R-UY1>E
M0IVKPHB.\B9T+)$?[ZBDVW"Q1P?J,JY,P2^V8.<"0M<W3^)R1T>! 4TCF83%
ME4/Y8\0H$?/XZ3VL6X]C32L$MC,/L(CO.01IQ(3.P$\:_"SLE>;[(Z,U6,!E
M!#?SQDZ[ZRF:E/+=%DRKH-Q)A9,]8U-1NRGX,(_2DL25YK3V8=>TV3ZES_HL
MGZ=BS0W'Z1+JPY_=VK\*7;N^83;1'$,%4)^)$CZ2L!;\/N5:I2Y*3".:(+4/
MM@51WR E=W*B2>=9WACQQAQ65?W0M?*$<_&$TXE?-?3*CIB#^S!+= X;*V&#
M\.TL5;3G$"<W+^4R63!JK@G8]&BG^@C%;SYS?756-,%K DSHHME2A?'!+%7@
MK"PP25[9,=?PD:74"V,)*/E=Z5/&B9I7LH9L3M].[4QRQY8(!D6/+D;KQY'#
M]K<D!##?E&;XD586&RCK+?@]!;72"]T,;7Q/J1=I2OP5@1A9XG^(+ME1TU_:
M[*FL+$"8*]SM9[BV07MCA22E;0K^['S@$1ITC>["!J%3&7#UF.<5_LF++*8
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M4%BY7I.!50L0(>!ZM>?KV@12C86%2\FU4RG?4P8(YO&G*M:V/;16PE8K\VI
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MDVP#V3-'L^XL/AD&%QQ]52B;YE!2\?B7R/AK9RZ;N/T=.//^1$TM&E"&</U
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M3"['2:7C7.]R "D2KBX*FEVG::B^<QGL\CQ>CL_0:=>L#Q=4T=,L<8/=?SW
MT\.I!;>+ 6>TN,@F D1$DND7;Q,NZQ'BO(7&2OAW8[#[\]6-XW;GR\VII4WY
M%UH(!_E$[T]X62CJWQ+[L! $6:9U>V] /IA'S<%VH*38H/IL $HRX0["T<^Q
M^..DNB[0+9*G@G(_/3RT=M*Q;'DXHRK^1&QF:<_@ T".Q>U#<6IA:9=1:N)K
MR*?4YKZ?*K$J^ [9 0^ S_D5*R\$!DYZN>Q[GWCW;)C')7UD @0%MT5/O(!Q
MP\AA@Z&"=OV. THXCV\EB= ]\PFY,")!?_7&D#6,QPON%[@O^N9 V6KK*6=9
MX_1L'SLNTOO]'6V\]$76:F&"4U:M&@7#$.XRI&)":GD1.!;_BL!LFFBCI,'5
M7A]-+H8T=LPURU+QU8<HU5F1?KF:;6]3$$I3QOD0Z;;[M1UDDY$U$BR\FHN$
M$9#T,^]7Q8BZ8$8"O)QK)?K5H@8:N*V7R3Q&_HZE83S;_94%U/3;WIMOVZDE
MC%!]#AY;8)W]G."059VX0IL$/,&-QO;U9=:ID5IG"YW%75TW0W7 E+)\K)Z[
MNVPYX:676D[)>T'5,T^O'/<?MI*V\#EZ0I3%+4=YAN3Q(?/$P6&]2XO?/U6K
MJ86_)"G=;K<ROFQSSVM[+LVM+#_ ,>WP.>Y(--)61'MQ_K4.UF8#/%H_2YM7
M:$6!6:,_^@\=[G 2224[75CQ7K*Y;NDC>73=.&67=_Y3;*EPAO*MN!=I!"NR
MU8$GBF]ES(=+IBL2"%6T;STL$*O-;A^ ?5E'8EKH4<-H"9ZYHP#&*K6>X%Y3
M^XH:6;B\+%N68F39+6-QE^)A=V[[@>[]2DYJO!9^N>ZH6SX5W_8(KWE^Y("@
MO$@(=2L-7@Q$X6;3WA)N+ 2D1"8A>"[U5P?EV*4K/+NE[EMN'?0PT<9@-5XN
M<5<JPEN,(%;ER_S DK@!']_;ZSUF84V5'(SWSI?TN\BIF@,;K%^7[^O%66)S
MECZGI*SF9%0WP1S*E02.19M*\)^V4)1U+A<5S9W[8"M5KH?TYT3K=BU+J#U,
M GA[ND1,1P90;ZC$12E_^_ZN*DC!I*R\ST-)B3!_<^2@B_DO[8*=B8;2S[HO
MZD]IPW\4L*$,N0$M0;(2 KY9FE$>AE-2I=.USS58YX2_Z1T7MCDR\2YS6'G9
MN/V4I5;D*\$R<^W%7<**P@AF:@T>TKGIQY--<,;M3F=QGZ,$\VUS(:S!-V>2
MW\+7 /,]J@@S"XVA_I=E@;GODBZ)X-VC)Q=G'2V_AEEU9SONEM$=]&&#1M@@
MDL=#RDR#G;QX<TV^2Z924;II[ZUN+85\N'@,H?ZZ4Z:-A)&+!W8R;$PZ^774
M-E.-YBG;X*>;6/>*OWF!JT)'M3K=!A!LQHN\H-B%O9FO9&&U7ZD3X3TEDKIL
MD%ZP/);5RY?^]MQ6R\:>,^;G+\B9^R0>>K$15=4#E]>]VG.Q@?M(UJO?<Z7=
M/Q\'M %F\8KWE+H[L79U4WLDA:U6!"^69)[9@>[.[G-WJ("&\L@S%!9^OB.I
M.9.WAW4(T#2GL"KL=^1F+91YN6R&/5^H5*CR?]2B>$DS7_J83G,EY7M-G.MU
M+,H<,[IL+_EK;P#K:.;.7WL#U$)%V:";T"A"<QZ);P^<#=K+XK]Q0XM@7IYC
M7;/4^6S+1J@%]7Q.E@.]UI<H3WDE?.<X;J;OO:I D4:1AD!!P;%K\2^BF0T\
ML=E1K]]^2>X]G>8R'/=_<KC>KS_A4>0>9IK.052OCG+I%Q08@#36'NOWE.%O
MV9&<VWHOV%#,]VJID%/*;6$#F8=F\LT*:9<_.1' %/CKJ+>N>(H5&Q1>/#>G
M8.V2ABKURGLR%EJN8?OYHLU^^ZZ4+6OW$C7)^/R+C $V*"0 .A&ECJ9<@D5L
MXN-0!])Y,#&9:J5&-I'NSXU%(PK.*6(<K';R25=F7VQ?G5:]+J,\S93'M0#9
M8"/1^)FLE7VO<$2_S0SOK#X?CFEKO;_\>.^NE3/Q5_MN]$(!?E,^W[K(Y^=W
MF_-3NK\QK9*AT7;X+,XM+_K^\"- S9_;Y>G_ONM>(:8Y,I\"U?VCCQ^OU;3%
M?^+,<^X/FWI]HG0Q0GWPFS^.QR7L':AQ0#BQ=#6(3 ZG7-KE.DG!+^0]81UA
M@VS%6E!#L&(ZJQ]3U)7 DC H@$00FS<E!V(KDZR8[RR?91^1/;:2\'GD^=)X
M!8NR<",1U<&AF:B#KFP0GP\TDJ5#,2_-0VI2HZAZV0AX7:JUHNA52;DKO:S/
M<SJYB+IUV#/D%Z#QK!8^'?&=+Q8LRE"G\)#B2R>A^US?S:+V4:;R[>:M0S\M
M23Y76']U\T59=Z;A?EYX>S4G=6\_!!B3H'PNXJ_SWP METKZ"QSZ7]%A#]5F
M';\4"+@<5"<4&-^1Z7'G.7?<*/U[>5@/URL#9[*OI9H"4I@9SDFZC&N4P2@\
MZ0BKFP.&OFLM@[ [K(Y5%.>*RR R:Z!L9<W&<QB)ESNEX^''6I!02 -^M.Y;
MI\J%5UN0;/; R/J8 J0:X)4_7\F9H,00><Q=#0YO'\+=C(6Y@N&(Y1?E(5>K
M#'L4;/S<SO08'8QC$,]3/9>(E-Z/F_A&!7<C4ZK020Z9_Y9?X]2D\0HEV#_=
M_>V#DGOB/ E=(M"/E<T\96LYTJ30T><?^.1A!MT$->0+XV(<Q]H@[DQS6'&S
M. _"?'.Y>;7'2TC#MQR;<5)L?4_TY_IQNFM^BOY#H\*!*Q-2_B0,(-O%D,;S
MN9> @<O(E6) E$0,KN90+]LJ/$FP;P7"ZBWO@E+7:7A(>]<RLF8D9ZS$CQ_5
MN#K7.Z=^#!%W.%T/R'B#O!"O_OXXML'V;.#>]XHRMQ\:3R.7L!@($];1#'G(
MJ:'>L+8.9@')RJ6O@/4S$21B=$N8/E(0=Z,=^WE)0(]V*N6C]N?/JR?=ET([
M'[]X]EYP)^X*\)A^;AAQ8F(F@N'HSMUD3U:"Z?8J35*WB8?'J:!=YT^F["UX
M)'%!^38F:/36K;1=;!!"MXVV4&OY46<K![KN_?"UDIG%QQ-= @V>%)R1E&P$
M">C^ELX&"<]O[]&^+1KG]B(LFWHX!TPS3(17+)L.]!I*W$YH+5-LWP:]QQH@
M%NV(HCL"D#J6%#4V0"H_"Q'86&9WL*]DS$@_X<J[09$Q63,WRL4FW=-)OC:?
M1TKNCKE"?T$18=PL6>0=G2W=I<R+,XUH0D!\=*U31*E"()?/'NUIFW:9VL0Q
M=ZGY@]L*;UI="I=9TWWZZ3X2S7Q3B@X&[Z\5 LRA6T?GT^0:X]#T7]![:_/W
M5(L[+-FC?2,?@=8NT]UL[CI&'Y/5+=+<<69+0#OMZA<&A)I+PD=IJ8DDDX*V
MDG#A/IC=0PBO2SV39<66N.E>&;.]L6]U'Z.=;NJ_?S3N=WTX?,.@$4\Y=W+P
M&S0LP"%3BQ*>R]>0L!,!K8\*PB&V^+B;-C&@D*<>)2Y?:[A>I2\>O?%0:/E3
MY+:'C\4"T008B\>"TDZSCJ'%]E8;%R $C:BY'Q?1]@#L&C7G->8M8L8WQ/YM
M$PWA %/3:H6(]_O*##L;[4Z:PO7BQ:N-)V&[ ?,=%+[0;VA1('A^[J:-.\Q.
MXW &7&K0+RWP27E%LL7775D*_I:MBC=#C5=?[/R,%X%.//&#258;4]T9>I-\
MW'.U$D!RKJWUX1 29E='[M"-L5(F=JHPMV"DX\T-Z_GR+\SH?=8^Y64NI$3G
MKVW[3,%VS$@VR.$-YX?>MB!NV<WBGCOA.E@_AR?9(#6DN(J2S[OFSXPPRQ8[
MCAS$^]>@3$4]Q72N9Z/KC!B.5#]25VAAK1CR2'>U$;D#5K=>>VS NP;6['3Q
M?6]6225=XBS<3SBYW4YK71XZ/%JWVU2/Z_&XP)R$!Y# XCY8T#2Q$@;F]X9&
ME%4FU&&B#>J[1Q;\,J5%TACW$<&(@Z6KJJ_*DIT,X_JKC"OGY:ZO11L<B%'>
MTHOJ@A6K-W:%H4MF&F&2B'0R^"'2(!NI"_>7[5'MVF;K8F%N A>H<S.?-S:?
MLMSU<&W+ \_[8I=NNFGEQG&B+=-.CLK7Y'Y_X1+P[%8.L+41NK?$)"HU;5NM
M"/UR-C,WM^OU)XHL!]R3]5XU7#8K7IR^EF)<?R<.&3Y$D5L:>P/@:5_Q@.ZX
M%.7: ,T%V6N<!8RIH?<ZZQ+;CQOGS]T;V=8[46DQME6B0N8F)3Q*[)5E[:,7
M?*G5.^F_(,KK6*<I7]7!@JK8<Z2N!TB#MXCR^DI1QJ%PI<OC+*KG^7M$UU\H
M.?W8BC[EBP;"I=78(CX5OV&Y].DT/(,_JMJ18LPX0>;C9QSO@UVD!B7$($^0
M2)1E)\#OI5K-<]I]&S[>&_-)N&15BU2WA>W]U;=]PQW/'CJ=OMQV9.M,'S-8
MU1W-XF*#<,A=_5@&%XFIV5AYG?4,P<DXC(/@<.] ^_NKQ])&C/T+$T_:?KJA
M5:186-@(HN],0\!97(Z!)/"#RO70DAI-FO&74DDOLZ+:Q+6S@+!.W!V](J.I
MMB\V\"CUD:R4LS*B]T:;!V903:-UO8N$(UNG5T+0[S&-T&%Z2Z5R#FDEQMQZ
M ..5Y:P!C36(J5;7>?\6\?#;)^LQW($:(T!\G$P^S)R\(4OLC 9D/J#W O:<
MU*&N RJF?C5%S-0USS2CN/N08LK8UX@M;FH95\;&&KR8>05V$L,R_9 UP9W)
MU3E>!QT-5^OP9XZ\X(OO8@@\?OV#10\C[Z8WLG@K;-6;3B!>$SLINNWD9I79
ME=?H.[65@PZ<.KIENE71MYOPPFPJN*.DV!O&AY[(J,R,>P' SE+5X[V7T V9
MN_M\UG+J'$DSO<O$2_U*A3=%R@4E*LPOD.E&F!*#_1=)U_R/W&^9/WIDZZ2[
M#8L+/<D7A>'^[KD;H)/'4\E\[QEJ?2@QQ,6URQ0_FOU<2BIUQ, K\(U\3;)G
MX9#EL'TK?;^T&Q#IGS\5)#:Q$@RE1+&ZI4YS$@R& "6=Z"F).[$(O3-"@[Y3
MFR-.>V@RNLJ\"57(6FQ5/.V_N ]"S0G6+G_Z3N2I'QVJ680>AA*0A$.D-] J
M4R,@.&\K;X5\A+*RVCYQ.?[WF6+7L^FG*NZ_?8GWY9W8TK6\MU$W?(]Y7LGM
M='I\H.T0L!S-/,^9YS ;5/=+B0EP!!*M<VH.(Z)F(HJXP5#JFZ3T/ZG<,U9R
MX5[^C@K1XQ5I7$8%NOM:N?>2KW;E/D+]^,^CI:UD]<5 NC7R,E#J3T[8#?W(
M<[A7U?D;/=_Y10V5;V62KM3R3"BLVTDD\OIN-Z*S!$S[1(IGN-ES2(&_)QOD
MZ>XQ^=6IX9K% ,&3L3>55M;/VH&N;PZ9P$1)U!.'9Z[M'C1W0=%(6AT+M^^(
MNEU<%=*UI.VH@ ZML[A.T,^QB%("M8,L089*O];5EW.]$BX^HC4EO5CK*RJF
MIY5SHAQN->N**#Q^[F!A,$@9+43UG+2IPFKKM='!&MVP,XPCS$0DA#)#>TL%
M/T"[= ERZH9M6(:@1Z]K&676,V\^=9!'1L+-O9LKSLXYQ\74[[!DI(2BF-<\
MFF+'!\CQ!:,G4M%EOLF4A8_6N&B?.!%Z?4K:UZ2%];TFWG(IY/G#5[XT<"\V
M<I\9>9[4.LFST%=3XJSTM;"D.V>FF/C"BC#3Y&U!P%",<#_FPKL3AYUH6&I+
MM(^GT!P!]Q&W%1I5LJ\D/U*ZO+K"QE@_*-5(1N5$2V7/\4C"B7#/]-?':GDY
M=N.&NJXDC.^AE$<BI2G1;)#EEVJ7'+2[B^@"UN71R*AUQ@<_?^5KNBUW"8F+
MOF('+_=&I=B'QTYQ)UV=*O+S'8/A'MVOC6@5LIB78_!+L+A$22OQT)+UI>T4
M/"T$N)=O1.Z*D!)RP7K[>Q86+*LNG7V^ZRNL^&*6>]NGUD1J9>6[W?O$-[PF
M,0P!:=I#9BRL+FVP"1]*&$\@80071 C>2KS9CO=HSV1NZA5K"4*'IWQ&13N'
M/T''3D5./W4Q3^;U]+=Y.S#/6JZ,4"CM2GV#&^5[B*9PBNT'>!%.BBA%00&3
M E87"T+9&:R*"<&2;:'U 3-1F62:MJ'=<'UYS+U;;T:7S:U>717[X//I])F[
M.Z<3EJYSS!C*S&:#;L/"1&I/ 1F4<G-*5YC'=/RH*]B]N,;(7Z:SZ9G[].,7
MH_H[TT2G#P8\4M Z>2\<"[V3D7XAOQ1+MZK:&/+8XXH<T4,U(#FE<0A*">V&
M!H[$)U#HI-P&G#"K0VI[#TIRCC 3Y:%U+LB1;!16]0%SQ= C.UK)_#9U5,)L
M+X_*T\^\'>([;(E[&3]VZ8ZQNNVXF>]? 9)PRH+9 -)'-@1N[EN6ZGN_@ #+
MD+DZWJ[H57UR=DEL7\KU \EF[<JNX?="\[/2+@^ZE&8Q\'OO.F_816]:T)(Y
M<T%1/> BWE*2)C@2P_,=PM<Z&6>NQ'?^J>M)BY3RU)[G>AY.Y6F&V8\K#A@N
M/"H(4."'+BEPE.+&S$';KX0&X.-9THQCU92NT&\*LR4+';K&,),/Y]-,WSX4
M$1O[:OI9-$#AP.GM#[?Q1DZ^ZYF:R@,'NIO79C2U=3V=S8I>D/D7CE@K01UF
M*%):FG';[ "G9KO]7Y VI!JC=OJ=)*P+%38TMG%?,6_ZW-$BG6'^_0[[5>3W
M/X3Q_>C'A9(IZ^64M,3MAY(A1EL*]S<YJN:S00>7#(!D0R9\.0$P5L3/9'*J
MR. 1#.L0?F_'P:OV"Q?E&?=_ &K?V]Z+'=F?\;?!0Y@ZS+OR.AL(%V!VGM(4
M-]#$ZN_[EL&]YZBQZW6E,JL!K51'<P)/\5Y-&NX(!<P0\+I$\6OT#*UDU*I4
M5260B 1\F??77G--V#[AVLH^U>Q3*L<CYP;]DCKX34<R5N^>PN5!2:I%;%!F
M (;%XX$&HG]W.4,#"EV,;-J#M"T6F%8[2W,8[2LZ-N\Y<CL#Z1]K)2C;='8#
MV;FS:?A0AE(! #&MK:7DTH)= WQS_;;W)6R#P1,6UZ]J5V[<US0!?QXAW7N@
MW,XQ8.>'$-+EXA=6B.53:CS$'0A(@XA%CS/*P3=51Z+B0T7XLB'JR^[W'3*M
ME7MGK]L?N&BT Y;#!OVII'CL;4Z-G!I(6Y;J25V#5&]XTN*8T2QI(.7D(%*;
M''=XH<7N -4BU(=3%:KJ19CTO.I)=5M'.Z8M9=KXNE64"4:==V@N%FW,AC=
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M=G^? J.LA9/BV2MK=UQ.W!W0/[9JK- LN[OCA#QQ ?8O(DU3M3Q]-[K^>![
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M?1L"A#R!C=0W!_B!Z%*N(YJ%^=]/^$@?C4DF&FR"FP=_WYK,E0\XG+HD@W:
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M,WL!XT5NBY:=BF]2-)F?N;0;WZ]NOZ*HGPPF+N BUL''?9@@+L!4J[:?=T+
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MNR^V'8QAG]/HUS_O\.O!F:!.R Z_'C^$)&XXZLV(A3&L-CF8H-/#AIM)"8R
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M^5F+#9S1^^(<MGXZ[^'F?MR6(>)&/U*&?J:A2NA@+56BM5X;_Z6SV>A'VH.
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M5;![-*E(*%619;U.^T7K'O+.),2"J7JX70@H\(CD;D)IF5#OKX-,_5B!XTX
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MP?PC'T_>>(@]$,J*)$F:1P']/. @P-=.X*KC),E$)L']TE%1E2,K'U8/UVK
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MI(#AI(J4)W;$L/GS:G"\<D^Z^/*H2: 02HTSOO%F?(7'&$B^IH*A@FPWI7L
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M'<2ZINKY!ZJ>1/T\;96A?Q)&)78:G+<!VB8_'33"L/TDCFQ4C2P=9.-5V";
MM>D!<&9*KS+IC\M(,.WEN@ MF7G)2C!%_0YSK.Z 4#^NV,UQ0,5BI4"[F+/C
M*>*-"FVMNQ#Q6P4,6]A,6[;0*[ZM!.@3BX6QEKS_%!TDU7/-:$AH9?R?@2U5
M!5S9A5 4J)@CZ=6P8Q26<7^5Q5>SO$=S$J8A]Y2B>2=M<W.B_VP44:.L..E/
MYD]RU_X^S)_[D[NK_P<>RNBG#72='VP_K[#$';M$Y6,DK2LJNJEFVD\1Z0N[
M7[O?<FR90;^T9VNUD"H'G!9:YV>S_CQ5V>9RLU\"KS*RIN_W7OR9=4R:=_IH
M4?ZV>$U#FO\DU5#F<OM?\;T_.0_QSQ=PA,8(4P'JZW?[_7Z;QY^NH4C/2W\7
ML\Z,#HI$:]!!.7F,-?@AVV'*_?5W*,#?H3AO7E(4O6]+=V K)N.'H0I><:1\
M&MZP^?7C=MIR):4<\A<Z=$1Z:B;]WU/BOPC6;0X_'J?\N/)ND>_P#I(:4\IF
M=*0V33SWP$^)/%*#>AO?9'GC$)2AOPIU7YJBV= 2Z:!3 '0AG@Z2C/^\>&I
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M380VN(D?<;1?6\:Z_!E!Y[T/GX*S;*]770[%?^? KBT% O.G@TA7Z2"TZ2G
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ML+!UNAR;M1O8]E7?S%2H4246BXF+(Y:')H(_N!G7NC"\8B-- FBO.DYR#IL
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M="@=.OOD^QFU?[;Q?W I%<Q066%[H23W3W30:A%ZPU^645%^47M;#HX^:;P
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M""<3\JWN+3"^&T$S@OZ)<X$J\)J==O$*G+:9/(:..5;"BMU$*]"9$3+*P81
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M@W"[T!P:=BCO-Z;WZ&I9_\)(UV:*N=>9[ P"-GY9=;JD PT>FZ()RNJ!VN0
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MAV>KR!+VV=_COMN-Z%=J?7#Z$?'^!@I?]^TO\"MLR QF6+ *GDPLW0T/3,L
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M';;:6M2'TU-E;'6#-(<FW#7&KELC8!-99O3^S<W3Y):KS=9:6M4!ZY8.:/W
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MZ,XV'QV#\7 RH?)RSDO'Z/9RWXORU_P4?%5YHW_<6HQB^>__T)=POVO'0,6
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M3K@VN'9=940J[BL/9Z_2FSM:.UZE]U/4GV+'D^!B7N*[2.HT&8849;*$Y"%
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MB6+PP2[UPK@DVE'M>(4CRCMM\;=V[B4=$VPJ.VQYX0/@^IALVDX:<(*U9X[
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MX=::2.Z:ZYH59E>K_:P"O-T6B(ZQ8<TOG9;\'%RD.*2<7#S-'M5OE=0XQ_=
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M,/M\Q,%]7T8D5]?Z?-K:,U&[6&2(DPGX?$'S*,OI6R$8R4:@/P('QP$L:UX
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MD8 MA68@R0A)U0L4&W$&DEYMC3N1%)HQ['XLKEWK"V^2+A@#[>1!,N"3*\1
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M$2; _MOH5D*B?N=RAI @K/3-Q^,>?6I%6%P"98Z:1W.!WX<W=9+UZ)(84DQ
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MC,EG4P:?Q&3D.0XEN)I^KW^EZ&=.OK,X+FL=?*)GY"5]?!19!2'>GS3994S
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MPEF4LC4ZDM#U9H2S:OAL"?=I]OYH;>RQE]F'579R0%)T@9W$!U0C<N1XZ[9
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M(UCT0M_J]%ZV['LW.)Y!-2@CY/96?9AT,0BJ#62'6MM04Z6#UU,K6.3N2D!
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M_S[HO)[_AGG8OR#_GP#YX[28F0J892Y/GLLS>BKE6;XVUW;=U):F#]$*^0M
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M4S)GW<WA;5+4B?M:RK#%':6-[>^2'INKBX[5M>%B5>5B:J$12X)&TZ77TZ)
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MQS8O88PW9 5QT@1YL1.O4;97B((NTV$(HMEXKPS6M@-KWJB!?1F#&]8/:,4
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M[1Y?E5:3* MT_<@O0TE%[=</F8H[#4PII#3T0$=1&TW2L(QF3=3*9B.[)K0
MT7(D*'-FL91G(:*4?Z[3Z8LLC:Q4&(>_D?2<'1U<,&+L6&@V4?Z[T\WYOF!Y
M)-BBG,:;7 L.G\(:IC(5LY]Y:;##MR:Q@[>ED;-EUE?UN;R\OM?^G7S<1**T
M[$Y)L.R<M!(M J,O.2\QJFN.S1VSM4-I/9Y\;^J0!T-Z^H++W6$[B?(]R:<]
M+7>R?YJX5M8YG0=)_W*B!Z&4!X(AX/">A>V7Z<=-[S+.JD+.YJ.=\?E%I37T
M ZF8$6:+5'N5]+W&?@X_)3.;AS/=?CC@^'!8W7GZ>2  S^2NQ9A75%?2#FS'
M3F=GNB>+6F2,/'BSE$NJV\WS->MUH(^QJVKHXQ?\XCTZ=FJ+-Z;G=318H$83
M3#D*%D,Q)"VNU'[BI-"E4>-,>Q0)=7]2:R:##6XF4NT5J0;=$;X%*]&/@M]-
MH",V));CR2K'2(UHY[K*LH')!"VQ343 D=KDD0/&DDTBGSX5-MR[_!W#OY<-
M8748(B:-N-WLV*+7Y0"KJZRG,=)YRVFF1;'%L07NVUH8HD!#VP;Q<U&FC66Q
MG+'@'G^$O8\X][NG-W[7=UO*G8!RHYPQ7ZRSD!W7:+R=GVRLM(:?^>65CYDC
ME^3J/!Z?/5^T[\THFWVX"S]>X^OXU2?'%;\@X1C<1'*ZXF"=>#'@T@05/0&!
MDE<D ; 1-2#Z: T50UQ>AE^M2N;T7)RB.WK<E[<2<(Z^O*P>_U3HRZ)3?C=#
M,#[G]Q;:$=2#M&;FP6H[G18-9 [I._5"!Z55?78E!^W<4#/LR (YMTVWG_#O
M);R]-?6LJ[P,Y)>Q%SV1'[P;**!#7)GZ [X8\"RL$ [+/9^I\'2=OG1SWC)&
MU,/F]D<Q'6^E?2ZIG-:*[4K+XI=+W*EB;6!>QG5F:]#N:1;H=CEM?_Q.E0-:
M%!NPP86HRKQ;?/7>H9D.S%J 7]JN;FSH0YP"<I/)M2^ )DGN#BFW"VA&<S&<
M%)I,?2QJJ.7ZIP#X3OU[56R>8+<'VG$[.B8MC]3A6!MN<C\0N7K9A6-6[:D]
M)PW;J"8P*\T5<@$(>L_0IG:'RAHK4)>C=F(0/H5G\=*F8=&CG2HJLN$* 7&F
M;7X#N^2#$D&[%LK_'ZRB3<SX<Q5L2? WJ)CFRE,XN!PLXMYC/^JV#2= ?BP)
MV#O_4IF*1!SXA@O$GSGZQ!VSI,8"*4C1]C!;3=FN]<K[XF.X4L6[;I1/G\D?
M&!HYF3N'[W=/6@,UKVR'+%/APDIGU,R4L^8E8002N:I1#R;IKK^K#X+PH7A)
MO,\_L3U)E*_/>/6].;/YVCF7K^8<I_<$6+=024L&$^A(-*@<O9MQO;?.R)L-
M\3KV]:V;<KVC7_5^<NZ"O(RA&$_O4^Y<T//A;F&+W60(M\5F]7)V=^=68O24
M>5!"325A_A%?3.D2<>QG&49!Z:<[+&4LP/,[?>[=VB8>2L"287B,,% LI=/$
M/%5&'<)E7<SA+>%M6>S;HY:BL?)"5O"3XJZ'^E<G7$2FQD\!L>3N"&SR*NK(
M</"Q6;2;H9UI!<^/HG1;@:DP[4+U_7"]>D.]X90;=H>"I9INEBC-?;MF/GT3
MJYZ4A%5_7+'U&HB3:S%_=UCO^;VL8(M#JY]_Z3685^)^!HE0A39R*@ ]*K%9
M]V= VTT@A6("J(#-ASRS7&6NW\[.#WCYK?_*VQ?<8<K/; 1.23]]QQPB'41I
MT,UM&4;1>K6*ZRK'RTV=^[^7CXD6V\M^?.8"^MHAON_:J/"]1\9EE(Y8V;[E
MGUTJ176)FH;[_9^+NG;+<S'GUN:NP@_^.#9J9<W[(B@)_;#N(@L$V0XB>2:M
M;D7LHW@?BJZX>UK^5@K4W^*G_Q75_BN]QM;M5B7:0>,6K5O:8)X+2>YFK_-7
MZQ5@V#=VU<K]7N.(\:7:L\$B:!M@F,P"A55*@XTA7$&4G(:*.NW4: ^L_XF/
M'>499?N>+-//X>4#&]^G3!U60U,G-UX "&^ZHB5#AY:=&\O.*RLX&@+++9<>
MM'6Z7)>P6/,,AK\K25DJ-]$[GID@:>+Z_AFXK+7]T/[3@-ZNQ;J#NF8?-O,=
M10KN'KVH_F%&$9:N'MMOBBCP\L!]V;H?P#^1-^D4V:[X^<*#GR_='[;KU2.^
M91;VV0<TY/: A:'W$4I2?/C@PT#@V]'9]$-4YUS1,@EX5P-E>_K,@9AIQ+W=
MRR=@G0\OMXZ]M?";+"&6X*5/#BS7G2MC.)4/%JOXLT#WK)&1!-?&.VD7]QQ^
M9B"^1^\<1_%H(ERV]PH*G-QN9&P/(; GVB70Y^S8>!6I(@[IG>PD=M;![>'<
MMR)I,]?5HJ3D9&)]=U_&;B,T&1T"YX;HN+) _)J3!:XTN2I[H8_E-?U+,1]T
MTGPT>\\\3YCZ%.JB-AP"AR C*(81="4WM$3#H7';!7V9 :VM"U;S5^)KRHP/
M3M,OBO'67WUU;U>'\@-=BV>N<$F($SE(W'=)HZ5!H;]\;9_YT/#M]$.WI=_*
M?I3J=I_.>;/L[";GG&!\J$SC<+)"OL)0':KLF9-AD5%T7C97@X>\\\_<;G&=
MAC3KY9FR5._&HBNIC?W>K\54B#4WV(*]2;1;<?( 7T%Q[)1"5"9P(\MM>.M9
MVG2B/C:O?GX,L%[6<QD0>87#:H8E#1HC<EU.F^&EE/,&H1.9#9(-.YE>D'.^
MI@^]N!?2)3&7!HJD[IED^R58C+]Z6'A*QM[*>!1V2'QK?_2ZQP-[*_.**_TQ
M=5LE!>.FVL,NOJF+@;=/$S6S#-\<,K8^7+EIWFLJ1R_0SO"90WAL% -!$RLC
M_;>HT">^:!'+J]MOB@O< C\$JHOGQKDZNF ]R,@P8:7C'*[?U3T*:+"E7Q,8
MZ7G_FHW?5?PUN\SUG(S7$& X_5B\]Q&I$3DK#FCS.]B>(ZG =K0\/L6W?L[G
MC#TL+66L6BZ] 570G_T,XI%B-(91BLU\&6BA= /1VM&1LKU>O51#6M+)7H"7
MQN*:YNX.*=# &TWN.F()H1Z!(N\3+@2LJ'XW.3 5%+A.4U(L>;P'V]MX_(/R
M9&+B>O+,4TRGQ^1AJ8#@RWEJEQ?9[CW@\!]=[N>A#*$LYE4BGK1!9X&RAT7F
MT"(H*$5-"!!<[6X,E@UI3)=1.U!IG=3ZJB:ISO1PODR<QT-:BFR\6>:#!*-C
M[8?>QW^V@/_>[>*+;D]#ZC%)Z+4:2GTE#G,ZB7BF18L%@KJP^9;1U<+80<24
M'4E*;K- :Z$H<>HO)F>66J-RK$Z+M B-%(8Z0P-?!IYZ3Q)U^E&\&S!.:\BV
MUX9CI;=KZ7C!>U/$,TO[P/ ;=94'"5;0B4AODQQ BTBQQ13.5L+Y)>WJ]<&2
M6F-&+3TG L1N-*N>JXP>PQ[?[SCZ^=:1([5!4P;>:'=*&DYGHE:+V)5.4H+J
M,H)8H+U'AK1*GM:L/(&<H:7S\<V.ZP).9'1$NFHRFH-G(?8"C.]+KQ6)<*K>
MH.+@0?FPY/M9IZT$OGW+L&02H)^\&%J;BQ:3T! 6B,@"43'H1KM,%LB!!?+8
MB5A".](SZE91S:3-X.7UA:'ZN.BHZ4-1W]1?5L34]'KE)M>JT/F2P'+,(1SU
M:I?+QA-:1,3Z"@_C<@75/MN-NGD;<"HT#B"7+/GA^DJ8W=/&GCCW4)O1_*?1
MM5MS=/RK[Z2TK@H<((/=Z&Y4$T):,$4Q6!:(2PROQL>0HELPC@;2H1L6C&;_
MH(+I7^B9<'(9\U$%^X8-S"#=0IQYK=9J\N,[M1%*^BI $5L,3V%1</X&%2!'
M+5(EUP/*KX79!\1<0B]"==4.SDM+1,KQ*06]"QX6[E2GA7"9R7$H'!!78 BJ
MTIO'3_;5.5#@4=JI$7&8UK/*E/':( =R3EG_.GAQ2==.GW2ULL*CVIIPBB=?
M ])??:?YV:%]=/-H$_7F;"<UE>0ADRK'AH7EPWE;B9?9&H2TG0-3;^3KG[4!
M:DW[99+['GMT*1CU2%YKH'&W>\8;21<%2'7'HT5J.9 \(X5S]&R-FK;P51:(
MD,CDK%=8.DYWTVG)ASPFT\V\A)$NS;WG\Y$GW%._)]3HL(4C2.>]/*XP<F+Y
MBF9"ZT>A&3U]"M?%33OA=Z\H,JK(#IN'BY5+'Q]F45;VHO%''*C)!>3 :1I[
M:N]15UK/!E Z6G;"'>C6\P]&FWV7&B=>KK:THI@!]UD@\^JON70%=E(KLUXR
M4D+9Q+]QWZ34XZ)09ZC@*\.^?#QSRN0;3@\W)!)W%_CYJHZ::,K<@#1':_G%
MHOT+K8A+A.-U'8+]UVRVU*!J.ILQ26!-H)_)Q0Y_7.@V&(;)MJQ0W");O^H8
M'!X3F%(6R,F+V;QZIS9FR=[E-62'Y-Z-K83<;_WU&B/RNYB&\)PTF*;PK,*U
MA,D/?)\Y!SQFL]KE_A%E"%B!HXN\H)^.\!L%.89O[_^8<'M42J<SE^OUR_8=
M4&:DL^4K-W%_&]7H#NK%*:/6!VB\;!^Q%5M3'GSV=MS"9%=)ZV"E'<=N@7VO
M*B0LH:ZSWK7=7]I@BNO%RG#VN$)N-27A*'4YFD4(RJ@(>:N-J4![4VA_BGK@
M$0L4L:*R/N2<WCISS>-S9ZS0"=[#"[K\/3,N74^W]QC<[#IE8J:&]Z_R[+3-
MVVJ:'&8(;?/%0:DP8^9>FWEI :IFP/$[O.QD2%%S1[IWJ>*06L8BX4ZU_I7+
M/1^),Y7],O<ZD?I\-!,FI] [U+E!G*M-!S121]<&A1CPK>U2%>L-[N4(D0VQ
MK!Q2(X?I]V3"*\=M(NY!BB)<^,HR>AXIN4ZS\6534@7.=#EC%I?3]BV%6L+&
M$!//!8'NC8TJH%<-LR;N4 X\=9F<=:BGWJFAR<%=/L;UT^7]0ORYYW#*WUZH
M?.9<?H]5Y/H%BR)1+^*$&=H[KY95& *3ER%.%!(/4HAR,"3;[98;_UQ["8QB
M_/[S;?4NS5*#*<_54MF76$@=*!G>;ZU\>1K(6Z4/7R%8W2\NVM16O11\A]G!
MGOFK;*Y"=7S0"%3@6QN4^J<>U&,R5-IZH>99QP=D1(N.Q)6PA+Z?T$BMH,H%
M86W:!<JZ.:2]LF=/XER&&'0BVH=A%&%Y"G6!NDYPQPFOKT0AWB.S\$?MJ>OX
M0<WNCRH5W].][ME$(6 K;S^K[JZ&UI34Y>6>( G.=(MY83N*FN+!7"@V5G^F
M4-($Y04<3&%1IO[IDH!R(4K:PHMO46<W<_*[1!0+9'QZE5;5/A, /_7( D'7
M1N.U($9T191E7\4*)^IZ>8QI/34B#'*<LJ#<S<,U,Q3^=.^+\UJO62!W'L=C
M<8;& I1J/:M*7?UA>-%L86[*/>?4ER5!:W8KQ,];-[:ZR'R #MV4*A;"%,:+
M106+ \-6@!=YR:))!TS]V'"HC6(G9%99-^@TD)6L)Q0D9&/;^.OR,[,WFUD?
ME32B-]YH,+GB?+V($7C2(<UN(:1/8^6X4/^MJXG&U)*P:U'Z1:XU*/.8G-%N
M$5*B?LKA%VW>(G4;?1T\F1]L]YJ9;3=&^W2=NH73K*H9\2/EKO?8YBEF1D\H
M_GVC^->_OJ@JL)?M0=29O1UWJRK=JL12ZX34/GP\,DE*+?BS9TB)!N9$5@T+
MI'TG2_Q7ZY6YW[TE]!LT&'Q#P3S(.!N/6;D$_$_9OJU;FQ;* SXCI8.PHQQY
M>(A3<,JX55.>#42CY3#UZTG:UW=)$>\X0FP74")4#VU8:)VZ\<_$;'PW4P^>
M>0=@@9)3XXXE_:S)Q76\VQ*]2S;2<CDAY?AVVQ@QY8=;K]X:,PB.9($:$ZDN
M.]SZA]C.S!;,, 53WS/$6: +F' HU8*#!1*R@]/X3[) O^;ACTZC*4+W6* 9
M1O!T<, ->";T[[1&C./0_>B>+#*&(8)G@9I[62"!/7PLD'[V)AL;19K&L$ 9
M-'K*?W%D(\:E U#&-G8\A"FCK<9$MRV[S/B);!]E@;AA^(PU18 ==O<]0-,T
MT7_G](\KY@-"?^"V6"!P=<:;@5V)_\$EFY=CPJ4E>E23'X/Y7/UO'?_6[G57
M^#Y?*3>O H67Q\U@9]:;FB:"?BP@^4ACAO2C;>/!@.92L)J81^4GJ^P:G8V@
MNJS[<9W<*>*/GNPZW7W3YX?+W+9BR9.N,NN1<!F*\B/Y$7^HQ=>'$/U;H997
M]>MM'E>1MF?9B"PPHMS1@[1ZTA6]3E-@1B94+!RU9X'B0]CI5$D4=.U24HF%
M2M;<=ID26K@>?8E]POF\/UH2_JU0KO7Z'V49!OM)/]G_*Y'XNH)=AS.CE7@O
M_*TH[8$_2^46_+O"#-4(,&PPY1:0O;!]Y#]B\(]/69T="R2;D\L"V2>P3]U?
M[J'70EI5<D>OSZDQG[C/,5RC<7O65.9(JWPAS.J2U?P/?UT*/YJW^"Q:\?W)
M?UGGX6]OY#R&_FS&6 SE8=:DP"B8]=[7$4N![.#-%+?8@--FFC&+&4LKP 5-
MDS<.=+TEN!/=*R&,@=-Q6/Q^JM;!H6<X IAA<N>Z45<VPH"%":E;^(3S"HT8
M/EL/ZWU;@WQ)D^)%FAX(\XU.S%'1A#:1I>+NU%M*@<O"G);@!SLE^B!TDUEP
M!Q,">.T4[83\7M 7Y9/% KGN8)?@]WZ]R$V9\C(%OONOV&Y'T_@()4PN*S<Z
M##@Z&?245M$=X8>+3IW*B/0]ZTPT$>R>6/BL:1(D%9W_DB<IE:#WZN>MJ?#P
MWTT\B2?=C2DEQ$V*75LLXP9B(B-D'$SSC)J \[B.*PU+P"7;[Q9VBS LA"0?
M\US,-=[7W"Y5GG9IV'_AJ,B^%X)-1+8'=^_>ZY91Q@RA:2.NT!C'*3&2RCOR
M19K$M(4E4]5)*Y7)JK*J.).H:;\'EVX8=N.WD*=I<*'@+VA!1%T Q2-C/^I.
M#^3X6V"A<5LMS&\@$:\.][C>=%>D644_ ^FW]]FXV]'J1+?4OBF'!\_-SW&G
M9_Q.@I[Y 1:3FXM9$]UA_B>!1_U7 &^?[%' G]C\2!"),6P)A;M$\Q#%Y3!+
M#[1J(4ZH'S]$+2P.O.W9WUK-MF@QP)2-7KB1/F9IEC2Y+LK(BHIFD5(W?KMK
MNMK'V_FVG<T;=67#>F,R;S4%:6Y@$* D(!XZS@9CST(8RE1L!$2FV-:]0:Z:
MVAU7>&+=5*'9.B!4*];H EV%J(17:<WR<M](CF[IR2CO$&VYTU416*CV!/KQ
M-7J_%E_X,-N>N/LO>(%R*C^YI>^AGJ16QJ (F!<Z;6X;M1B9GG.UF!2%5\T9
MB=E(G182((,'LL@EN^=N(A<:Q3X"4#S!*[1OLED?9.<^<_6Q7G5Q+#.N^U%,
MCNWH5KY(TV)*NI['@R))0XDG9TO(.(:P3^,FNAP>VR )5-+6NAQ,:#W4Y B5
MXJ?Y^F\44G*MQL[SCK\]^OBTZE3@E$"+7*EFR#<N2=%]9,"8+22NRFKJ@T'&
M(^;AWOL(39@X@+WYN8+N _/(G948_F%_N])2WHK_W.RJ#F%O@W/O84'ETG!L
M)'HB7?\8#=I:9+VQ0+%/9X$.U)VG\5T%L'E(#Z; /:WS>7,=CALOFO)Y/D8A
M-M[H?G<367(,X)(]$1^QY;:0034I62J)2&WXK>W=V)V"";@T4KF;V=J=Q#Z@
MGRO"QN3^6XR=M(Y51AU&QW^I=Q(!>B0=S[Y:*>!\$:#0G,K0EQV<+*46#O';
M&_B08\T)VU,57*@WD!&"\?TJL?8 M>6E\:$SYF2\9<P+ U_27G9:Y;6/V4/B
M62<=0MX&/LT84L>6IM."L>/\@VM=YU41(!T!(R<_A,C ]]"7S3>T'2V>.U]R
M I]!XR^C[WH=8ERB&L4R#";.^U'@_$ $C'H0(XUQ%NU;'82<+2&YFP9ZG1HX
MP7.EZ?JW3+AE.WC$)+O=W[+;E"X5_-W^[! ;#:;KJP-NDT':Z-#MX:AAV_[[
MZ[S'R*U57E+;^GY68Q6F-\+?>BJDV\W<K'8F'GX^N]AKN&NVQH@A#"6;ETR
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M>64/8QTN/-\[!/1X8CK'BXV+[4SH8VYEO0&5M-5N>2/O(/<=UN@,G3KQ9>Y
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M-F<L0$(0$FJ^-V?B)(T@T:8X1 GCJ5(2\<CI,.-\=U/C\U.E,+81K7XK872
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M9SP,")=!"(F*-7-$&8<9"BED,HP3C-,D24.G\*,^4DQMU]+496OR ZV7>A"
M; -1ZMQ!CVT@RJ-^TS'"J-= V?'0X/ /S%%UE$^M *@U +4*-VT-TG,101[C
M?*X!TE<$3R\9QHW-N0:F@ZB;JQKKG1_M,9?W<EG,GV3MW*3MN4_JCGZ?!2I)
MN<@B*"4.(,X$AXR&>E.(4R931J,@29S*[ISN:VIVU8ZH/C/]G,/;CN(\H3@P
MD>T"N),/Z :8': V5+7$-X,G![* RU^*M9,]C9UF[9+*1U*M77S%C6"*O#R2
ME$3*C_JC:9VCLS!4(4XA2SB%F >)WK4%%*8H)4E ,H*(U2GPY:ZF9F!M,[3H
MR:"?<[SWL<#V/)?X16Q@*G$'RYHD['$XQQ&ZE0X_Z']MN<&B@U&HP5[1EAD<
MWNCK$;?B4HK"Q),9H\?XZ#3QQL4O9LNA:4B/N>:CVZ78AB$;IM(T57E=&_O'
M!'4LUD);2Y5I]*F..9YE2N_B&$$PR B'.$8F!"/"$"&F9"9"%H=.@1>#2CLU
M>FJ5K:-$YXVZ9LGFW?RQS<:POJ"=M_I7.T)'JVC8;\'.KIK," ],IZV>=2;;
M=F#;[+9'4U'DN6Y U@R\40_4JH&WWV7.YX7?XNTC#(4W9\@A91W9LW($V _=
M-,?HM-\2]44N3"E4O24IGQN[*B4L8&8AR9!0$"=I8#)'*!C1)$ IRWB J,NZ
M<MC%U!:#1D)0B=C30>D(D':D?!T\ S.I(S+.-'A:>4_<=:2#40GGM(+[+''F
MR9[6IQY)8\K>?I\7LR3E$2%$P"!-8XA%G$&6*@X3E* TE!'!J9/O8;?QJ4UG
M(UNSC3+B.4[D'=@L[:J>8 QM!MGBX&Z]'%'8E['1;7I<V^"(4@=+^;%G^AY+
M+XLR7W.SBK]?:AOAFQ[[HJFG%R@5ATI(F$9Z6X=9S"&).8=([^K2C!%.F5,R
MV7.=36WZ=F4U<1&/C;2NI]!GX+4]AO8#VN#GT+MXM8)>KO#8XZ3Y,B+>CIK/
M=#7R6?-EI0\/FRW>Z>DBM!? L!?>P/GZ85U9$G_.5T6Q#6_XL[8H7DFURJ6Y
MB,%QDO @"*", P9Q0%)((R9@C).,TD0F-"!.Z>%\2#4U)JID[88$&6E=W8Z\
M#)<=88T^" ,SFU7$5D<M<'3 ;@"K=#.7<1Y]H'QB[<M?RHM,X_I6^83QP _+
M:^/N$2%OEZ6),*FKO7V1CZN\K$YO:+DN9C'E2O(4:\K%"&(I34+H(((JXQ0E
M2D;*+AKL4D=3(]5:UDTUPHVTH!;7/H#D++KG"=,G9@-S8%^XG.)-;+#H%7YR
MMN'1HE%LU.L&IU@][\=ZV]+1+CG-0AFE(9(Q1%&H#32,"22I_F>(.$(2*1XQ
MI^09MAU/C2Y^KL+H*]>9HF,)'$;37V>6G1P'/001CK,,LBC.(!9(_Y1HDYGP
M$+,@D F+Z>Q)YFSUDB/1%6! +BK*^4-E:&T=S >"O9_!ZP/*E[=IAS-2+^$S
MD!UZLML7-34O@7')FKSXOML*\?=EN9A]D$4AY:='F5.SY'R05$_JIG#P\]WJ
ME33I/-^LY:W2W/M72?-W^L.<)21D,F#:BE0FUWM$,DB3)(942JJ".*(")39K
M17\1IK9JF!)V6G?=E1T_70'^>:8:!]*!.:N6_P9L- "5"C=@H\0-N%N!5[)*
M%GP#M"J@T@4898#19O!A$"N]FS/^RE5"FY<=CAU9_C&'Q7JIN1[1>M$Q[9B5
M) JB**Q6DRM:'F5=N5[S=H7QT%+?C%^/N>3S.K^K?%S(JJ[)4MP^F"W/W^NY
MA,( !5E(H8@DAY@+#HED%$8BS7B41*$( K<,7Y<[G=IZTI49T*4 M".L:X(N
M"\SMS%_?2 YN^F[%U6S4"ESA>6N#9X]<6_8 ><NM9='ER+FT[$$XS)WE\&[/
MH%;C\,;V'=XZ#IFOGK>/="LT;4+$\KGQIWM=^>W6P6,R-PYULQ"E2B!BPBVP
MN>1" K(P$A"S) EEDD72,?)U,%&GQG>FJ%XG -:(O>\;?6/J'QG9S1^:9(?5
M@XZALL,-OQV)3F-0!Z;>KL]S5\VNX[/)47*F3-\V"K?]&FJ-ZR#=&] H[3$^
M=_"!\17$.YR@XT;Z#@[X03CP\#WV3.#8QB++_$GW<-PI^^.J#A@2E4A%E:BD
M^_?7JZ(IPO)%\M6WI;E:W+94O_2IO)?YW3U=MI$<F"(>IIS $&E#&Q.)($M"
M!;E( BE2B;AP6K->3).I+6GF>K>5O2X=9;;**R,U*+788/5X/G'^Q#X4N]7M
M'V+X1US\C@;\;/3?E*3]OAL!= ,,!)N26%L4_%</?/$!\Y4-],7T&#?CZ$L/
MUT%6TQ<7Z+IHA29V)L AXU@0*.)(02P8@I2'!$8I8VF*PBSC3H=.N\U/;6WJ
M>.KW"C[: \]N:>@/R<!\[8!&[\B%08*-]AI_D>B%\T%&)Y[J-V7/GE@W"VWQ
M19J>A"DT\VY><+HP1]>S#$=QQ&4"$TP%Q 'GD*(00\F30&4""10[E33M+\K4
MJ,!<@8 ?\DI4K8EC0>DKAL2.-,8!>@+WF>4*L/;B;*./.?6H-:JNT/S1TO6P
M>J*P*P09E>ZN!VR?&CVTV#>K8U-I\9,R26;?+5:_%;>L*'/*K<\PSS0QH7FW
M+?5I3@]-?N1*4O!K*ZO'A=X&$F])_,YT-7*NOLM*'Z;DLWBGWY>]F4QF/U'<
M+L7;^MAE^WFS@,=IJNWZ&)F[991$D 1(F_E9@B55,DU"Z6('7.QQ:LO]=@EJ
M)75;\"]#;,<@7H$;F$:VF%7"5O?'K;B#<(DU.)X(Y7)_H[**M?K[U&+_8M_8
MFELA3&!EQ6&?\BH_NZF<*#".>2#U?H)@ K%,0T@3GL L(51%.(TPX6ZQ-<<[
MFAJ;-,$BC; W=6UM#2EH!7:-KCF![WE.\8G:P%32'[ >\37GT;@BON9$PR/'
MUYQ7[S"^YL+S_4R.3=+U]\O'=5E\D$]R$391_PDEBG.4P2!&B6:%"$'S&Y/V
M%Z6$QC2-G&*>S_0U-6*H9 .AFVUQ#DL[J\(30@.3P#:8Q>1^,X+>@ :P 7(H
M6&#BR8PXU].H!H2%RONF@\TK7HLHU.G83N8@+V8D(&$8,PQ1E"C-&0F!-,T2
M*%$81EQB(A.G#$H]Y9@:L[@64@ _S)>@J%YR/-OL.W"V1RB##\?@IRNG"RNT
MN2_/55;P6(+J2C"'+:YP48HIE%>PA<JRP()U<U>Z2YF&&PL!8:%BA2,81+&V
ML1B)8);&>DL6,)XB$1!&G-(3'^EC:ES8JVZ)/:!ZH0FX4I QFD(<*;T <2(@
M9TF8T21&2F&W2.0K(1TIZ/CKY\_7@V>W"%P)R-";U=W/R[]I>D9]WUY!G1Y>
MQE_G4,63GC1''NUY'FY<9H[4H3 U0]I:%#5?Z]_GY@+JC:S_?W.::Y+_A4F:
M0#WE(VV%1A1F-(PA142P6)NFL;(ZV?(GTM1(N-+(1"ITBK/,F^(LILK-CW]T
M/&&_?M LC^!''8JAS^BK4; LD3/,H;TW.'V=ZE\OT+C'_MX /+@7\-?R%3%G
M!UZ1AW$'K_;C#AI?QT_KLBCITG@(?UQ7]@7&,0E)H(DX2K1Q%B0<4JDB&&&%
M5,I2'" G7O8NX>1HNI83K+:"7G$TX'T\+0\-7G*4ACY.N#YDK-%2_[#54_-^
MI:GG.+$A!L%G>)A7^<:/"AL"WJ/!8(-TU#-!-RWN;Y?"_)^I$O5$%\8#K$H+
MSSG%Q/BKQD%$( YY!@E7 <1Q0)00,:*)4XF,TUU-C;8KKRWC<%']T!&V5Z[]
M,Q#;$; ?X 9FTMZ8N>?GO@B'K^S<ISL:-S?W184/,G-??J-G9D=#17?ZW>KS
MQ1%/PB3D, UCO4]/I=0,D00P8S*+D*2IWJH[I6_LMCXU4JB$ T:Z7BRPBYS=
MQ.^-Q\!SW1X*]V1^QU3VE;%OI^UQT_(=4^L@]][1AWIN_OB]%.N%*<%E3O9>
M/;]>T**X,YG]9D2@,..Q@I%*L%[810"IDAB2F'%&XD31*'/:QIWN:VJ3N!6U
M*I57'3!KX[X2%_Q:">PXJ\_!;+F[\@/>T/ND_KBY;W4N(^)KTW*FIW&W'Y=5
M/MA(6+S2-U_:3@+YO82@KU?+<KY<K]:=5/+F2.OSJIB;'8J),#$!LR'Z63]Y
M7]2[E$^J_7LQ2T(4"$E"2 BB$ >Q@ S1P&3S9 AG)$N%T[YB8'FG1F&U@&8B
M'J:'[F2/-D5RUML:$>92 #PV.@']/%B8ZCEU3HBE!,_G(KU>Y#.QH\\)#?[
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MDL08)5F06>>&/-G-U*S)1E"'9(6G$3Q/1?YP&9AP&AE!5\C+)HX+4 [)'+T
M-E(.QV/ ><K8>!&&LXD:3[\]7G[&BQKLI&6\_'0_V^ZC+%_3XOYSOGJ:"RE>
M/?]22/%^V=137WZ[Y>7\J:+=&4$)H910F 3:M-,;P!AF08)@Q.-(X42)B"4N
M5IU]UU.SY[3D@&O1P6,C.V#/0+5R [H1W,W4<Q@+.R-O&(0'9EL#KI$:?.Z
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M#D,W#RS/^(_I]_IX>AQJ_&_:\? _$'96O&=P!UYWV^^Z$;>"LQ*XKO<[Q#&
M T"^ZEY;]#AN_6M[" [J8#N\VC>UA)*Z'5$GK[BCWZNX"?W_K_4OYV4QHRQ@
M-$LS&"I.((XCO1V(<0#C4,5!R%.214Y!5Y<ZG-I:T,H+YG6ZE=)([)K X0+&
M=ESC$[F!B68#6I.CIA*VHAO]$VCD]9G\P X9;_D++G0W<@H".^4/LPA8ON<G
M3]N=_%Z^TG+_;98HEC+, X@#J1E%TPO,.!509H%F$Q3B0#E5 3_9T]2HQ%QQ
MUUE"](K[>O7PL%K6^=T<+R].(FMY:>$#KZ$O*X[DP#-R@DK0 ;/@'8 Q4!J\
M;3\OF@?O0-U+B? .7^AQ'%E9,;NVS2Q*E$*,8)B)(#')/0BD4F4P#94@F:!!
M:!?(<ZJ#J9%!;7?O[W <#KJ.@6AQ8G@E- //^QJ5O7W*E: XG/)="<Y(IWEN
M(+F=V)U!X.S)W+'WQCN!.R/USDG;N>=Z[I_F!5^L3#FH3ZI.E$$+XZ+^8!JO
M\__EN1Z\*B5@\>IY^\QG^ERE_?^-YF*[A$N%5$2HYCU*J:D4(B$)1 H3)>,4
MQ9H&$7/:;OF5;VHL6HD+F9$7=)7:''&P9W"G>ZT*27>>K;1RW,5Y'FG+3=_+
MC=_0>\2-9MO!>74XD%WUS&AV'VQ4K$=3&XA5PO=!S,2!AL'7AM2S=./N7X>!
M]F"[.U W_9:-K_Q>BO5B1Y9N/U7BDD^/1JQM'<';HE@_U+^K/O4ME\28)1&2
M G**.,0D#""-(J17#2HH#P0CF57,TC#B36[1:+0SO+,M)-H1WVUA\#R6=NO"
MRXW0P,M"=W!.<OT-J/0#C8(WQX=QT!5AF 'PM"!X%F[4]6 88/>7@X%ZZ5L6
M8%,=X_6"%L5<S4W$A,GD:MS*UW3Q,RU-&.SS&UK*/;[ B$18H!BFQ/B$)YF
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M&&">01PA 5F2))"2C,0B%BR-D9NM/*X"TS.VOTCS%9B-4&L;P-;JZP@.:FW
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M^]MY[?%050G:1D\ 6H*?]>@T!Q51> -,_N+JL3>25U=?H/DM<BXD=#"$=GN
M*P=F8 +9CLG7>DP:KY':J\!K=:!3*/BK!G30P]C5?TZI>*3:S\E'!PKZ.>6A
M_H[.\TJ 3LH[<Q!K/$?>S)_F0B[%%UK*F;8SDH2S!)* Z=T"5Q$D,DFA%)*0
M)&:)"JRJA8XF\=3HKY41B$9(\#R7"\?<U,./,Q>*A9PS*&B@QSE.!"0I9C!.
M<1QCS)*4.KKZ3VJDQ_'N_P<9:[L5;%+C-^+=XJGLY&>3D]\ HW6]C'93U-:W
MDM4WT:H.C.XCAIWY&J:Q8M"NEG=: 6F^X'>.3O/6<=]T/3N>J(V#(T(H384)
M(T:QR=$3<D@9$=#4  JC(,MBY&1.'.UE:B; EZ^WCG<0Q\'+3*(1JM$*4XF;
M$DI1$, XSA+=L\8.16YK]-7PC;.N_M*&2/E"TFX%O!J=@5>M Q]__SZV9R'P
MEI+H6!\CYR$ZH^9A\J%S#_<]*UH]RKQ\-M'"Y>U2;#QW/VPR;3$5)/^ONV]K
M<AO7SGT_OX)5J4IFJH0<D@ )(*E*58\O.T[L<<?V[%,[^T&%JUMGJR4?4NV9
MWK_^ "0E43<*H$ VG8<9=[=$8*T/Q(<%8%T23@B "FE@DPZ9/1E#UMM6I DS
M#)!(OZ.C:UU.C4>W$L^B2N;J@*?E8/Z^;Y(S!_!=#WU"0CKX&=#-:/8X#W(%
M*-CQT-4.1SXM<@7@]/#(^<E^%/0GM5(%6YJF[^3C8E6=@V\6WU7CG]>LG#FC
M6G/) "<YLN=!##"$$> XCX5.,8&YE[N_4Z]3(Z)&Z&K*L .Q^SGVND'OQD'!
M 1V8AMI8'DJ\J_$6WJSQ BD0%;GU.2H;><%P3$A^#_>]_[Z3TKQMY2OSX\?B
MR_KWU5PAF4/,<I E, >(, AXK#404F,$1<QSY>2_V]''U/BFN>]MY)Q%5E*#
M8V1E];T+/P74]3K\)IC&N1'W0ZC'O?A%#&ZX&C]M<^3;\8M*G5Z07_YJ?W?6
M]:K:1[UBWQ8;MJR3XYD]EBJ^*YL5XNW3YJE0VRP$<T(02[7&()>IV0:E4 /.
M! >0I 1E*54T<\K4WEN"J9'#/EMD<TM>-))7F6)T)7MU<UXE<>B=L=-_I-SL
ME4'Q'YAUFF2WS1UZ(_XV:>>G]C#4*D1;'<*ZU_:"+Z#3K5__H[OB]H+GG(-N
MOX9Z.P^UBE@;(ZLJ;7U7EFI3SE.,!<FU!$BQ!""I;4;.! *$!549S6(HO,H/
M=77F17>CU1+ZUA1';[9;M0?[NJJ;SBJQO?U\+J/M>O83!L/!3WT.JLI7N-7U
MYN^Z<>OC^W,5D'!.0)>[&ML;Z*K29]R"KC_COW]ZM?YN6G&+H3OY_H3>V$JN
MH#%P%[7M9<0?MC2:Z7Y6@;;!?OX+-Z13>U@OS1.E/7C<//>JN)9RLVP)B !B
MB .4)!D@-)6 Q8@@DF>YLKE"W->M,&)-<X53E3X]<J;=/DQ)EN:*Y1K@E.0
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M1IFS%]783LK+7^AA=/TG6SX7[/Z!%8]FG)XV"\&6I3'UME&E0DL.N0 9R2A
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MY]L=.0ZY4[G36.3NK]\<CWS/BH]%Q3MU:>5[550A?_,,0QDSPD".;!HVP6/
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M)R8 2W .%,:8,9@A*'3/*K)]_*Q&JQLKFD"45OW8W@5B_9RL;D-H8"9I"3>
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MO:KR:>74ZX_THXWJ)N=AO93O'K\5Z^_5@<BVXF\62YBCS 9 R1P@G@G ,-=
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M:33+NZ?-P[JP%MJ],B_O:O/%#&YIK[/MSOO+^A5;BDH5(W=A.7>>9B2E&FH
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M3)'.&*,^.]=;!9J:'?;YZ?&1%<_6#FM4V,9?U^X<]2;WKL?QV<U#Y[;;'7-
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M)0--U5VSHT[+8V6.I^#)YY>F6QO?]^:G?_M?V[^8_]F<1?_VO_X_4$L#!!0
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M?6!2&94UQG8 N;/V?O#H./?92*PC@Z-:O6<+#&NZ8U(B92Y!,F- F2S!>1N
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M3K1&AJFY(CJ UU_G\_S[].QLXD(PS)-4BBI^,VK)<ZWK#:\K'D.T[+'"NV,
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M?%9M*\Y2906S]ZF65 ;E; U%-;AB$Y!3Z 32F>V:WX \0LZX%V=/@J-6RNC
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MNABOI7+:MT^D#<M3;Y,9A]L97:&C ]=B5QZI#L:^>@MWJ\EXNU;MQ*!VP8L
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M[AHCPY*,(:4 .M9!IH5)$HN/H(P4+M:9N_N-[#\D CEA+M3P>9N1?;H6>NK
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M#.>)S*I7X: ,1?,UT<UM1C/!'\V_#ES4D0SFUT2V<$ES'C+HB!*4IHL0+6?
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M<+7.4!B?V2BR%,9"DIZT%WH#L6" *(QV@BO!=3<+P@XGZUDZ[T?B^/S=%H-
M=?0]^X2KN+R 1HLBE2EU0PBYK;5NX"%&)X'3/P-)*EG3>NG%Q(T6EV:X&MZK
MZ2'4SW4:LRA7MXUIF9@#6[FAG-'@F$7(SC@O,P]*=#,"ZE"BGGD74S=&ZV1
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M?V)8S:)1RF:=09+^(,MG%+%&*A#2)Z:=*\*V?MOB^--.&Y6,A[F'*OE,\NS
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M>F5N=&%L+FAT;5!+ 0(4 Q0    ( ,HXJE83KUI,7@@  -TI   ;
M      "  3B(  !Z96YT86QI<S$P+7%Q,3(P,C-E>#,Q,2YH=&U02P$"% ,4
M    " #*.*I65!8Y_D<(  "X*@  &P              @ '/D   >F5N=&%L
M:7,Q,"UQ<3$R,#(S97@S,3(N:'1M4$L! A0#%     @ RCBJ5H2X^:4E!0
MO!4  !L              ( !3YD  'IE;G1A;&ES,3 M<7$Q,C R,V5X,S(Q
M+FAT;5!+ 0(4 Q0    ( ,HXJE8%YJR]'P4  !D4   ;              "
M :V>  !Z96YT86QI<S$P+7%Q,3(P,C-E>#,R,BYH=&U02P$"% ,4    " #*
M.*I6')Z4OF2= @"(SQ8 $0              @ $%I   >FYT;"TR,#(S,#,S
M,2YH=&U02P$"% ,4    " #*.*I6DH.C9 H,  "4@   $0
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3!@     -  T B ,  %>;!@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
